<extract createDate="2022-03-31">
	<manufacturerList>
		<manufacturer id="AAP">A A Pharma Inc.</manufacturer>
		<manufacturer id="ABB">Abbott Laboratories Limited</manufacturer>
		<manufacturer id="ABD">Abbott Diabetes Care</manufacturer>
		<manufacturer id="ABH">Manufacturer name not currently available</manufacturer>
		<manufacturer id="ABI">Abiogen Pharma</manufacturer>
		<manufacturer id="ABP">Manufacturer name not currently available</manufacturer>
		<manufacturer id="ABT">Albert Pharma Inc - &quot; DO NOT USE &quot;</manufacturer>
		<manufacturer id="ABV">AbbVie Corporation</manufacturer>
		<manufacturer id="ACC">Accel Pharma Inc.</manufacturer>
		<manufacturer id="ACH">Accord Healthcare Inc.</manufacturer>
		<manufacturer id="ACO">Acon Laboratories Incorporated</manufacturer>
		<manufacturer id="ACP">Accelera Pharma Canada, Inc.</manufacturer>
		<manufacturer id="ACT">Actelion Pharmaceutiques Canada Inc.</manufacturer>
		<manufacturer id="ACV">Actavis Pharma Company</manufacturer>
		<manufacturer id="ADC">Ascensia Diabetes Care Canada Inc.</manufacturer>
		<manufacturer id="ADI">Adria Laboratories of Canada Ltd.</manufacturer>
		<manufacturer id="ADR">Manufacturer name not currently available</manufacturer>
		<manufacturer id="AEZ">AEterna Zentaris Inc.</manufacturer>
		<manufacturer id="AGI">Agila Specialties Pvt. Ltd.</manufacturer>
		<manufacturer id="AGN">Agnes Pharmaceutical Products Inc.</manufacturer>
		<manufacturer id="AGO">Agouron Pharmaceuticals Canada Inc.</manufacturer>
		<manufacturer id="AGP">Actavis Group PTC ehf</manufacturer>
		<manufacturer id="AHA">Manufacturer name not currently available</manufacturer>
		<manufacturer id="AJC">Agila-Jamp Canada Inc.</manufacturer>
		<manufacturer id="AKC">Akcea Therapeutics, Inc.</manufacturer>
		<manufacturer id="AKN">Akorn Pharmaceuticals Canada Inc. - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="AKO">Manufacturer name not currently available</manufacturer>
		<manufacturer id="ALA">Altana Pharma Inc.</manufacturer>
		<manufacturer id="ALB">Albert Pharma Inc. - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="ALC">Alcon Canada Inc.</manufacturer>
		<manufacturer id="ALE">Alexion Pharmaceuticals Inc.</manufacturer>
		<manufacturer id="ALG">Alexion Pharma GMBH</manufacturer>
		<manufacturer id="ALH">Altius Healthcare Inc.</manufacturer>
		<manufacturer id="ALK">ALK-Abello A/S</manufacturer>
		<manufacturer id="ALL">Allergan Inc.</manufacturer>
		<manufacturer id="ALM">Almirall Limited</manufacturer>
		<manufacturer id="ALN">Alnylam Netherlands B.V.</manufacturer>
		<manufacturer id="ALR">AllerPharma Inc.</manufacturer>
		<manufacturer id="ALT">Altimed Pharmaceutical Company</manufacturer>
		<manufacturer id="ALV">Alveda Pharmaceuticals Inc.</manufacturer>
		<manufacturer id="ALZ">ALZA Canada</manufacturer>
		<manufacturer id="AMA">Amada (Nutritional Products)</manufacturer>
		<manufacturer id="AMC">Allmedicus Co., Ltd.</manufacturer>
		<manufacturer id="AMD">Amdipharm Limited</manufacturer>
		<manufacturer id="AMG">Amgen Canada Inc.</manufacturer>
		<manufacturer id="AMT">Amicus Therapeutics UK Ltd., Buckinghamshire</manufacturer>
		<manufacturer id="ANC">Manufacturer name not currently available</manufacturer>
		<manufacturer id="ANG">Angita Pharma Inc.</manufacturer>
		<manufacturer id="APC">Acerus Pharmaceuticals Corporation</manufacturer>
		<manufacturer id="APO">ApoPharma Inc.</manufacturer>
		<manufacturer id="APP">APP Pharmaceuticals LLC</manufacturer>
		<manufacturer id="APU">Atnahs Pharma UK Limited</manufacturer>
		<manufacturer id="APX">Apotex Inc.</manufacturer>
		<manufacturer id="ARA">ARA Pharmaceuticals Inc.</manufacturer>
		<manufacturer id="ARZ">Aralez Pharmaceuticals Canada Inc.</manufacturer>
		<manufacturer id="ASC">Actavis Specialty Pharmaceuticals Co.</manufacturer>
		<manufacturer id="ASE">Astellas Pharma Canada Inc.</manufacturer>
		<manufacturer id="ASI">Aspen Pharmacare Canada Inc.</manufacturer>
		<manufacturer id="ASN">Aspen Pharma Trading Limited</manufacturer>
		<manufacturer id="ASP">Aspri Pharma Canada Inc.</manufacturer>
		<manufacturer id="AST">Astra Pharma Inc.</manufacturer>
		<manufacturer id="ASZ">Astra Zeneca - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="ATO">Aton Pharma Inc.</manufacturer>
		<manufacturer id="AUR">Auro Pharma Inc.</manufacturer>
		<manufacturer id="AUT">Auto Control Medical</manufacturer>
		<manufacturer id="AVE">Aventis Pharma</manufacturer>
		<manufacturer id="AVN">Aventis Pasteur Limited (S8)</manufacturer>
		<manufacturer id="AVP">Avir Pharma Inc.</manufacturer>
		<manufacturer id="AVR">Advanced Vision Research, Inc. (S8)</manufacturer>
		<manufacturer id="AXC">Axcan Pharma Inc.</manufacturer>
		<manufacturer id="AXX">Axxess Pharma Inc.</manufacturer>
		<manufacturer id="AYE">Ayerst Laboratories, Division of Ayerst, McKenna &amp; Harrison</manufacturer>
		<manufacturer id="AZC">AstraZeneca</manufacturer>
		<manufacturer id="AZU">AstraZeneca USA</manufacturer>
		<manufacturer id="BAC">Baxter Corporation - Clintec Nutrition Division (S8)</manufacturer>
		<manufacturer id="BAH">Bayer Inc., Health Care Division</manufacturer>
		<manufacturer id="BAK">Baker Cummins Inc</manufacturer>
		<manufacturer id="BAL">Bayer Healthcare LLC Subsidiary of Bayer Corporation</manufacturer>
		<manufacturer id="BAR">Barr Laboratories Inc.</manufacturer>
		<manufacturer id="BAU">Bausch &amp; Lomb Canada Inc. - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="BAX">Baxter Corporation</manufacturer>
		<manufacturer id="BAY">Bayer Inc., Consumer Care Division</manufacturer>
		<manufacturer id="BCA">Manufacturer name not currently available</manufacturer>
		<manufacturer id="BCI">Baker Cummins Inc. - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="BDH">Manufacturer name not currently available</manufacturer>
		<manufacturer id="BED">BD Consumer Healthcare</manufacturer>
		<manufacturer id="BEE">Manufacturer name not currently available</manufacturer>
		<manufacturer id="BER">Berlex Canada Inc. - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="BEX">Berlex Canada Inc</manufacturer>
		<manufacturer id="BFI">Axcan Pharma Inc.</manufacturer>
		<manufacturer id="BGP">BGP Pharma ULC</manufacturer>
		<manufacturer id="BHC">Bausch Health Canada Inc.</manufacturer>
		<manufacturer id="BIC">Biocodex SA</manufacturer>
		<manufacturer id="BIG">Biogen Idec Canada Inc.</manufacturer>
		<manufacturer id="BII">Biomed 2002 Inc.</manufacturer>
		<manufacturer id="BIM">BioMarin International Ltd.</manufacturer>
		<manufacturer id="BIN">Bionime Corporation</manufacturer>
		<manufacturer id="BIO">Biovail Pharmaceuticals Canada</manufacturer>
		<manufacturer id="BIS">Biosyent Pharma Inc.</manufacturer>
		<manufacturer id="BJH">Draxis Health Inc.</manufacturer>
		<manufacturer id="BLI">Bausch &amp; Lomb Inc.</manufacturer>
		<manufacturer id="BMN">Biomarin International Limited</manufacturer>
		<manufacturer id="BMP">Biomed Pharma</manufacturer>
		<manufacturer id="BMS">Bristol-Myers Squibb Canada Inc. - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="BNQ">Bioniche Pharma (Canada) Ltd. (S8)</manufacturer>
		<manufacturer id="BNT">BioNTech Manufacturing GmbH</manufacturer>
		<manufacturer id="BNY">Manufacturer name not currently available</manufacturer>
		<manufacturer id="BOE">Boehringer-Ingelheim (Canada) Ltd./Ltee</manufacturer>
		<manufacturer id="BOM">Boehringer - Mannheim Canada</manufacturer>
		<manufacturer id="BOP">Boots Pharmaceuticals - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="BQU">Bristol Myers Squibb Canada Inc</manufacturer>
		<manufacturer id="BRA">B. Braun Medical Inc. (S8)</manufacturer>
		<manufacturer id="BRD">Bard Pharmaceuticals (1990) Inc.</manufacturer>
		<manufacturer id="BRI">Bristol-Myers Squibb Canada Inc. Nutritional Div. Ottawa</manufacturer>
		<manufacturer id="BSH">Bausch &amp; Lomb Canada Inc</manufacturer>
		<manufacturer id="BSS">Bauch &amp; Lomb Surgical Inc. (S8)</manufacturer>
		<manufacturer id="BWE">Burroughs Wellcome Inc.</manufacturer>
		<manufacturer id="BYK">Byk Canada Inc.</manufacturer>
		<manufacturer id="CAM">Ajinomoto Cambrooke, Inc.</manufacturer>
		<manufacturer id="CBS">Manufacturer name not currently available</manufacturer>
		<manufacturer id="CBV">CIBA Vision</manufacturer>
		<manufacturer id="CCI">Clement Clark International Ltd.</manufacturer>
		<manufacturer id="CCP">CellChem Pharmaceuticals Inc.</manufacturer>
		<manufacturer id="CDC">Church &amp; Dwight Canada Corp., Inc.</manufacturer>
		<manufacturer id="CDI">Concordia Laboratories Inc.</manufacturer>
		<manufacturer id="CDM">Canderm Pharmacal Ltd./Ltee - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="CDX">Canderm Pharmacal Ltd</manufacturer>
		<manufacturer id="CEH">Celltrion Healthcare Co. Ltd.</manufacturer>
		<manufacturer id="CEL">Celgene Inc.</manufacturer>
		<manufacturer id="CEN">Centocor Ortho Biotech Inc</manufacturer>
		<manufacturer id="CEP">Cephalon Inc.</manufacturer>
		<manufacturer id="CGP">Manufacturer name not currently available</manufacturer>
		<manufacturer id="CGS">Ciba-Geigy Self Medication Products</manufacturer>
		<manufacturer id="CHE">Cheplapharm Arzneimittel GmbH</manufacturer>
		<manufacturer id="CHU">Church and Dwight Canada Corp.</manufacturer>
		<manufacturer id="CIB">Ciba Pharmaceuticals, Division of Ciba-Geigy Canada Ltd.</manufacturer>
		<manufacturer id="CIL">Chilcott Laboratories-Division of Warner-Lambert Canada Inc.</manufacturer>
		<manufacturer id="CIP">Cipher Pharmaceuticals Inc.</manufacturer>
		<manufacturer id="CLI">Clinigen Healthcare Ltd.</manufacturer>
		<manufacturer id="CLK">Clark Laboratory - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="CLT">Clintec (Non-Formulary) - &quot; DO NOT USE&quot;</manufacturer>
		<manufacturer id="CMA">Cosmair Canada Inc.</manufacturer>
		<manufacturer id="CMH">Manufacturer name not currently available</manufacturer>
		<manufacturer id="CMP">Can-Med Pharma Inc.</manufacturer>
		<manufacturer id="CNG">Manufacturer name not currently available</manufacturer>
		<manufacturer id="CNN">Connaught Novo Nordisk Canada Inc. - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="COB">Cobalt Pharmaceuticals Company</manufacturer>
		<manufacturer id="COL">Columbia Laboratories</manufacturer>
		<manufacturer id="CON">Pasteur Merieux Connaught Canada</manufacturer>
		<manufacturer id="COP">Covis Pharma GmbH</manufacturer>
		<manufacturer id="COV">Covis Pharma B.V.</manufacturer>
		<manufacturer id="CPL">Clay-Park Labs Inc.</manufacturer>
		<manufacturer id="CRY">Crystaal Corp.</manufacturer>
		<manufacturer id="CTS">Custom Pharmaceuticals - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="CUB">Cubist Pharmaceuticals</manufacturer>
		<manufacturer id="CUV">Chauvin Pharmaceuticals Limited (S8)</manufacturer>
		<manufacturer id="CYI">Cytex Pharmaceutical Co.</manufacturer>
		<manufacturer id="DBL">David Bull Laboratories - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="DBU">David Bull Laboratories (Canada) Inc.</manufacturer>
		<manufacturer id="DCL">DC Labs</manufacturer>
		<manufacturer id="DDC">Ddrops Company</manufacturer>
		<manufacturer id="DER">Dermik Laboratories Canada Inc.</manufacturer>
		<manufacturer id="DES">Desbergers Limited</manufacturer>
		<manufacturer id="DKT">Dioptic Laboratories, Division of Akorn Pharmaceuticals Cana</manufacturer>
		<manufacturer id="DLU">L. P. Dey (S8)</manufacturer>
		<manufacturer id="DME">Dupont Merck Pharma (Endo Canada Division) - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="DPC">Dominion Pharmacal</manufacturer>
		<manufacturer id="DPL">DPT Laboratories - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="DPM">Dupont Merck Pharma - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="DPT">Dermtek Pharmaceuticals Ltd.</manufacturer>
		<manufacturer id="DPY">Manufacturer Name currently not available</manufacturer>
		<manufacturer id="DRR">Dr. Reddy&apos;s Laboratories Inc.</manufacturer>
		<manufacturer id="DTC">Drug Trading Company Ltd. - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="DUI">Duchesnay Inc.</manufacturer>
		<manufacturer id="DUP">Du Pont Pharma</manufacturer>
		<manufacturer id="EAT">Manufacturer name not currently available</manufacturer>
		<manufacturer id="ECL">ECL Pharma Group Ltd.</manufacturer>
		<manufacturer id="EDM">Endo Canada Division Du Pont Merck Pharma</manufacturer>
		<manufacturer id="EDO">Endo Pharmaceuticals Inc.</manufacturer>
		<manufacturer id="EFM">Manufacturer name not currently available</manufacturer>
		<manufacturer id="EHS">Entra Health Systems.</manufacturer>
		<manufacturer id="EIS">Eisai Limited</manufacturer>
		<manufacturer id="ELA">Elan Pharmaceuticals, Inc.</manufacturer>
		<manufacturer id="ELD">Manufacturer name not currently available</manufacturer>
		<manufacturer id="ELN">Elan Pharma International Ltd.</manufacturer>
		<manufacturer id="ELV">Elvium Life Sciences</manufacturer>
		<manufacturer id="EMS">EMD Serono Canada Inc.</manufacturer>
		<manufacturer id="ENZ">Enzon Inc. (S8)</manufacturer>
		<manufacturer id="EPI">Endo Par Innovation Company, LLC</manufacturer>
		<manufacturer id="ERF">Erfa Canada Inc.</manufacturer>
		<manufacturer id="ETH">Ethypharm Inc.</manufacturer>
		<manufacturer id="EUG">Euro Generics</manufacturer>
		<manufacturer id="EUR">Euro-Pharm International Canada</manufacturer>
		<manufacturer id="EVL">Endo Ventures Ltd.</manufacturer>
		<manufacturer id="EVM">Evans Medical Ltd.</manufacturer>
		<manufacturer id="FAB">Fabrigen Inc.</manufacturer>
		<manufacturer id="FAM">Famy Care Ltd</manufacturer>
		<manufacturer id="FAU">Faulding Canada Inc.</manufacturer>
		<manufacturer id="FEI">Ferring Inc.</manufacturer>
		<manufacturer id="FIC">Manufacturer name not currently available</manufacturer>
		<manufacturer id="FIS">Fisons Corporation Limited</manufacturer>
		<manufacturer id="FKC">Fresenius Kabi Canada Ltd.</manufacturer>
		<manufacturer id="FLI">Boots Pharmaceuticals Ltd.</manufacturer>
		<manufacturer id="FOU">Fournier Pharma Inc.</manufacturer>
		<manufacturer id="FRS">Merck Frosst Canada &amp; Cie, Merck Frosst Canada &amp; Co.</manufacturer>
		<manufacturer id="FUJ">Fujisawa Canada Inc.</manufacturer>
		<manufacturer id="GAC">Galderma Canada Inc</manufacturer>
		<manufacturer id="GAL">Galderma - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="GCC">Manufacturer name not currently available</manufacturer>
		<manufacturer id="GCH">GlaxoSmithKline Consumer Healthcare Inc.</manufacturer>
		<manufacturer id="GEB">Manufacturer name not currently available</manufacturer>
		<manufacturer id="GED">GenDerm Canada Inc. - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="GEI">Geigy Pharmaceuticals,Division of Ciba-Geigy Canada Ltd.</manufacturer>
		<manufacturer id="GEM">Genmed, A Division of Pfizer Canada Inc.</manufacturer>
		<manufacturer id="GEN">Genpharm Inc.</manufacturer>
		<manufacturer id="GET">Genentech Inc. - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="GEZ">Genzyme - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="GIL">Gilead Sciences Canada, Inc.</manufacturer>
		<manufacturer id="GLA">Glaxo Canada Inc.</manufacturer>
		<manufacturer id="GLC">Glenwood Laboratories Canada Ltd. - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="GLD">Glades, Division of Stiefel Canada Inc. - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="GLE">Glenwood Laboratories Canada Ltd</manufacturer>
		<manufacturer id="GLP">Glenmark Pharmaceuticals Canada Inc.</manufacturer>
		<manufacturer id="GLW">Glaxo Wellcome Inc.</manufacturer>
		<manufacturer id="GMP">Generic Medical Partners Inc.</manufacturer>
		<manufacturer id="GPB">G Pohl Boskamp GMBH &amp; Co KG, hohenlockstedt</manufacturer>
		<manufacturer id="GPM">Manufacturer name not currently available</manufacturer>
		<manufacturer id="GRA">Graceway Pharmaceuticals</manufacturer>
		<manufacturer id="GRI">Grifols Therapeutics Inc.</manufacturer>
		<manufacturer id="GSK">GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care</manufacturer>
		<manufacturer id="GSS">GlaxoSmithKline Shire Biochem</manufacturer>
		<manufacturer id="GWP">GW Pharma Limited</manufacturer>
		<manufacturer id="GZM">Genzyme Canada Inc.</manufacturer>
		<manufacturer id="HCI">Les Lab Charton, Division of Herdt &amp; Charton - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="HCM">Healthcomm International Inc. (S8)</manufacturer>
		<manufacturer id="HEA">Healthpoint Canada</manufacturer>
		<manufacturer id="HER">Manufacturer name not currently available</manufacturer>
		<manufacturer id="HEY">HEYL Chemisch-pharmazeutische Fabrik GmbH &amp; Co. KG</manufacturer>
		<manufacturer id="HIL">Hill Dermaceuticals Inc.</manufacturer>
		<manufacturer id="HJS">H.J. Sutton Industries Ltd.</manufacturer>
		<manufacturer id="HLL">Hollister Stier Laboratories LLC</manufacturer>
		<manufacturer id="HLR">Hoffmann-La Roche Limited</manufacturer>
		<manufacturer id="HLS">HLS Therapeutics Inc.</manufacturer>
		<manufacturer id="HLZ">Manufacturer name not currently available</manufacturer>
		<manufacturer id="HMR">Hoechst Marion Roussel Canada Inc.</manufacturer>
		<manufacturer id="HOE">Hoechst Canada Inc.,Pharmaceutical Div.(Hoechst-Roussel Cana</manufacturer>
		<manufacturer id="HOL">Manufacturer name not currently available</manufacturer>
		<manufacturer id="HOM">Home Diagnostics Inc</manufacturer>
		<manufacturer id="HOP">Hope Pharmaceuticals Ltd.</manufacturer>
		<manufacturer id="HOR">Frank W. Horner Inc.</manufacturer>
		<manufacturer id="HOS">Hospira Healthcare Corporation.</manufacturer>
		<manufacturer id="HPI">Horizon Pharma Ireland Ltd.</manufacturer>
		<manufacturer id="HRA">HRA Pharma Rare Diseases</manufacturer>
		<manufacturer id="HRU">Hoechst-Roussel Canada Inc.</manufacturer>
		<manufacturer id="ICI">Manufacturer name not currently available</manufacturer>
		<manufacturer id="ICN">ICN Canada Limited</manufacturer>
		<manufacturer id="IDB">ID Biomedical Corporation of Quebec.</manufacturer>
		<manufacturer id="IDL">Ideal Life Inc.</manufacturer>
		<manufacturer id="IGN">Ignite Pharma Inc.</manufacturer>
		<manufacturer id="IMM">Immunotech Research Ltd.</manufacturer>
		<manufacturer id="IMU">Immunex Corporation</manufacturer>
		<manufacturer id="IND">Indivior UK Limited</manufacturer>
		<manufacturer id="INF">Interfalk Canada Inc. - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="INK">Manufacturer name not currently available</manufacturer>
		<manufacturer id="INP">Intercept Pharmaceuticals Inc.</manufacturer>
		<manufacturer id="INR">Manufacturer name not currently available</manufacturer>
		<manufacturer id="INS">InspiRx Inc.</manufacturer>
		<manufacturer id="INT">InterMune Canada, Inc.</manufacturer>
		<manufacturer id="IOB">Iolab Canada Inc.</manufacturer>
		<manufacturer id="IOL">Manufacturer name not currently available</manufacturer>
		<manufacturer id="IPB">Ipsen Biopharmaceuticals Canada Inc.</manufacturer>
		<manufacturer id="IPC">Insight Pharmaceuticals Corporation</manufacturer>
		<manufacturer id="IPL">Insight Pharmaceuticals, LLC</manufacturer>
		<manufacturer id="IPS">Ipsen Limited</manufacturer>
		<manufacturer id="ISE">I-Sens, Inc.</manufacturer>
		<manufacturer id="IVA">Ivax Laboratories Incorporated</manufacturer>
		<manufacturer id="JAC">Jacobus Pharmaceutical Company Inc.</manufacturer>
		<manufacturer id="JAJ">Johnson &amp; Johnson Inc</manufacturer>
		<manufacturer id="JAM">Jamieson Laboratories Ltd.</manufacturer>
		<manufacturer id="JAN">Janssen Inc.</manufacturer>
		<manufacturer id="JAS">Manufacturer name not currently available</manufacturer>
		<manufacturer id="JAZ">Jazz Pharmaceuticals Canada Inc.</manufacturer>
		<manufacturer id="JFO">Chiron Canada ULC (S8)</manufacturer>
		<manufacturer id="JHP">JHP Pharmaceuticals LLC</manufacturer>
		<manufacturer id="JNO">Janssen-Ortho Inc.</manufacturer>
		<manufacturer id="JOU">Jouveinal Inc.</manufacturer>
		<manufacturer id="JPC">Jamp Pharma Corporation</manufacturer>
		<manufacturer id="JUN">Juno Pharmaceuticals Corp.</manufacturer>
		<manufacturer id="KAL">Kaleo Inc.</manufacturer>
		<manufacturer id="KAP">Kabi Pharmacia</manufacturer>
		<manufacturer id="KEY">Key Pharmaceuticals,Div.of Schering Canada Inc.</manufacturer>
		<manufacturer id="KGW">Manufacturer name not currently available</manufacturer>
		<manufacturer id="KNL">Knoll Pharma Inc. - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="KNO">Knoll Pharma Inc.</manufacturer>
		<manufacturer id="KNR">Kenral Inc.,Division of The Upjohn Company of Canada</manufacturer>
		<manufacturer id="KNT">Knight Therapeutics Inc.</manufacturer>
		<manufacturer id="KUC">Kremers-Urban (Canada) - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="KUR">Manufacturer name not currently available</manufacturer>
		<manufacturer id="KVR">KVR Pharmaceuticals</manufacturer>
		<manufacturer id="KYK">Kyowa Kirin Limited</manufacturer>
		<manufacturer id="LAA">Laboratoire Atlas Inc.</manufacturer>
		<manufacturer id="LAB">Labopharm Inc.</manufacturer>
		<manufacturer id="LAF">Laboratoires Fournier S.A.</manufacturer>
		<manufacturer id="LAT">Laboratoires Trianon Inc.</manufacturer>
		<manufacturer id="LBI">Leadiant Biosciences, Inc.</manufacturer>
		<manufacturer id="LBT">Laboratoires Thea</manufacturer>
		<manufacturer id="LDA">Leda Health Innovations Inc.</manufacturer>
		<manufacturer id="LEA">Lee-Adams Lab.</manufacturer>
		<manufacturer id="LED">Lederle Division-of Cyanamid Canada Inc.</manufacturer>
		<manufacturer id="LEO">Leo Pharma Inc.</manufacturer>
		<manufacturer id="LIF">Lifescan Canada Ltd.</manufacturer>
		<manufacturer id="LIL">Eli Lilly Canada Inc.</manufacturer>
		<manufacturer id="LIN">Linepharma International Limited</manufacturer>
		<manufacturer id="LIO">LIOH Inc.</manufacturer>
		<manufacturer id="LIP">The Liposome Company Inc. (S8)</manufacturer>
		<manufacturer id="LON">Linson Pharma Inc.</manufacturer>
		<manufacturer id="LUI">Luitpold Pharmaceuticals Inc.</manufacturer>
		<manufacturer id="LUN">Lundbeck Inc.</manufacturer>
		<manufacturer id="LUP">Lupin Pharma Canada Limited</manufacturer>
		<manufacturer id="LYP">Manufacturer name not currently available</manufacturer>
		<manufacturer id="MAB">Meda AB</manufacturer>
		<manufacturer id="MAL">Mallinckrodt Canada ULC</manufacturer>
		<manufacturer id="MAN">Paul Maney Labs., Division of Canapharm Ind. Inc.</manufacturer>
		<manufacturer id="MAR">Marcan Pharmaceuticals Inc.</manufacturer>
		<manufacturer id="MAT">Mantra Pharma Inc.</manufacturer>
		<manufacturer id="MAY">Mayne Pharma (Canada) Inc.</manufacturer>
		<manufacturer id="MCL">McNeil Consumer Products Co.</manufacturer>
		<manufacturer id="MCN">Manufacturer name not currently available</manufacturer>
		<manufacturer id="MDA">Manufacturer name not currently available</manufacturer>
		<manufacturer id="MDF">Medfhar Inc.</manufacturer>
		<manufacturer id="MDI">MDA Inc.</manufacturer>
		<manufacturer id="MDK">Medunik Canada</manufacturer>
		<manufacturer id="MDO">Manufacturer name not currently available</manufacturer>
		<manufacturer id="MDP">Manufacturer name not currently available</manufacturer>
		<manufacturer id="MDX">Medexus Inc.</manufacturer>
		<manufacturer id="MEA">Meta Pharmaceuticals Inc.</manufacturer>
		<manufacturer id="MEC">Medicis Canada Ltd.</manufacturer>
		<manufacturer id="MED">Medisense Canada Inc.</manufacturer>
		<manufacturer id="MEF">Medical Futures Inc.</manufacturer>
		<manufacturer id="MEH">MediHub International Inc., Ajax</manufacturer>
		<manufacturer id="MEI">Medican Pharma</manufacturer>
		<manufacturer id="MEK">Merck Canada Inc.</manufacturer>
		<manufacturer id="MEL">MeliaPharm Inc.</manufacturer>
		<manufacturer id="MEM">Medical Mart Supplies - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="MEP">MedTech Products Inc.</manufacturer>
		<manufacturer id="MER">Merrell Dow Pharmaceuticals (Canada) Inc.</manufacturer>
		<manufacturer id="MET">Medican Technologies Inc.</manufacturer>
		<manufacturer id="MEU">Merus Labs Inc.</manufacturer>
		<manufacturer id="MEV">Meda Valeant Pharma Canada Inc.</manufacturer>
		<manufacturer id="MEZ">Merz Pharmaceutical Gmbh</manufacturer>
		<manufacturer id="MFC">Merck Frosst Canada Ltd.</manufacturer>
		<manufacturer id="MFS">Merck Frosst/Schering Pharma GP</manufacturer>
		<manufacturer id="MGI">MGI Pharma Inc.</manufacturer>
		<manufacturer id="MIB">Mitsubishi-Tanabe Pharma Corporation</manufacturer>
		<manufacturer id="MIN">Mint Pharmaceuticals Inc.</manufacturer>
		<manufacturer id="MIP">Miles Canada Inc Pharmaceutical Division - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="MIS">Miles Canada Inc.Diagnostic Division - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="MIT">Miles Canada Inc., Pharmaceuticals Division</manufacturer>
		<manufacturer id="MJN">Mead Johnson Nutritionals</manufacturer>
		<manufacturer id="MJO">Manufacturer name not currently available</manufacturer>
		<manufacturer id="MJS">Mead Johnson Canada</manufacturer>
		<manufacturer id="MMH">3M Pharmaceuticals, Division 3M Canada Inc.</manufacturer>
		<manufacturer id="MMT">MM Therapeutics Inc.</manufacturer>
		<manufacturer id="MMZ">Medical Mart Supplies Ltd</manufacturer>
		<manufacturer id="MOD">Moderna Therapeutics Inc.</manufacturer>
		<manufacturer id="MOG">Med-O-Gen Medical Inc.</manufacturer>
		<manufacturer id="MPC">Mission Pharmacal Company</manufacturer>
		<manufacturer id="MPH">Mayne Pharma (Canada) Inc. (S8)</manufacturer>
		<manufacturer id="MPU">Merit Pharmaceuticals - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="MRR">Marion Merrell Dow Canada</manufacturer>
		<manufacturer id="MSD">Merck Sharp &amp; Dohme Canada, Division of Merck Frosst Canada</manufacturer>
		<manufacturer id="MYL">Mylan Pharmaceuticals ULC</manufacturer>
		<manufacturer id="MYS">Mylan Specialty LP</manufacturer>
		<manufacturer id="NAM">Manufacturer name not currently available</manufacturer>
		<manufacturer id="NAT">Natco Pharma (Canada) Inc.</manufacturer>
		<manufacturer id="NDA">Nadeau Laboratory Ltd.</manufacturer>
		<manufacturer id="NEO">Manufacturer name not currently available</manufacturer>
		<manufacturer id="NEP">Nephro-Tech, Inc. (S8)</manufacturer>
		<manufacturer id="NES">Nestle Health Science</manufacturer>
		<manufacturer id="NGP">Next Generation Pharma Inc.</manufacturer>
		<manufacturer id="NOA">Novartis Vaccines And Diagnostics Inc.</manufacturer>
		<manufacturer id="NOB">Nova Biomedical Corporation.</manufacturer>
		<manufacturer id="NON">Novartis Nutrition Corporation</manufacturer>
		<manufacturer id="NOO">Novo Nordisk Canada Inc</manufacturer>
		<manufacturer id="NOP">Novopharm Ltd.</manufacturer>
		<manufacturer id="NOV">Novartis Pharma Canada Inc.</manufacturer>
		<manufacturer id="NOW">Manufacturer name not currently available</manufacturer>
		<manufacturer id="NPI">Nutravite Pharmaceuticals Inc.</manufacturer>
		<manufacturer id="NPS">NPS Pharma Holding Limited.</manufacturer>
		<manufacturer id="NRA">Nora Pharma</manufacturer>
		<manufacturer id="NRD">Nordic Laboratories Inc., Marion Merrell Dow (Canada) Inc.</manufacturer>
		<manufacturer id="NSA">Nestle Enterprises S.A.</manufacturer>
		<manufacturer id="NTP">NT Pharma Canada Ltd</manufacturer>
		<manufacturer id="NUT">Nutricia North America</manufacturer>
		<manufacturer id="NVV">Novavax Inc.</manufacturer>
		<manufacturer id="NXP">Nu-Pharm Inc.</manufacturer>
		<manufacturer id="NYC">Nycomed Canada Inc.</manufacturer>
		<manufacturer id="OCI">Organon Canada Inc.</manufacturer>
		<manufacturer id="OCU">Manufacturer name not currently available</manufacturer>
		<manufacturer id="ODN">Odan Laboratories Ltd.</manufacturer>
		<manufacturer id="OGN">Organon Teknika Canada Inc</manufacturer>
		<manufacturer id="OGS">Organon Sanofi-Synthelabo Canada</manufacturer>
		<manufacturer id="OMC">Ortho McNeil</manufacturer>
		<manufacturer id="OMG">Omega Laboratories Ltd.</manufacturer>
		<manufacturer id="OPI">OptimaPharma, a Division of Taro Pharmaceuticals Inc.</manufacturer>
		<manufacturer id="OPS">OPI S.A.</manufacturer>
		<manufacturer id="OPT">Optimer Pharmaceuticals Canada Inc.</manufacturer>
		<manufacturer id="ORC">Orchid Healthcare</manufacturer>
		<manufacturer id="ORG">Organon Canada Ltd./Ltee</manufacturer>
		<manufacturer id="ORI">Orimed Pharma</manufacturer>
		<manufacturer id="ORP">Orphan Medical Inc. (S8)</manufacturer>
		<manufacturer id="ORT">Manufacturer name not currently available</manufacturer>
		<manufacturer id="ORY">Oryx Pharmaceuticals Inc.</manufacturer>
		<manufacturer id="OTK">Organon Teknika Inc. - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="OTS">Otsuka Pharmaceutical Co. Ltd.</manufacturer>
		<manufacturer id="OVA">Ovation Pharmaceuticals Inc.</manufacturer>
		<manufacturer id="PAL">Paladin Labs Inc.</manufacturer>
		<manufacturer id="PAP">PAR Pharmaceutical</manufacturer>
		<manufacturer id="PAR">Patriot, A Division of Janssen Inc.</manufacturer>
		<manufacturer id="PAT">Pathogenesis Canada Ltd.</manufacturer>
		<manufacturer id="PBN">Pharmalab (1982) Inc. (S8)</manufacturer>
		<manufacturer id="PCO">Manufacturer name not currently available</manufacturer>
		<manufacturer id="PDA">Parke-Davis,Division Warner-Lambert Canada Inc.</manufacturer>
		<manufacturer id="PDL">Pro Doc Laboratories - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="PED">Pediapharm Licensing Inc.</manufacturer>
		<manufacturer id="PEN">Pendopharm, Division of Pharmascience Inc.</manufacturer>
		<manufacturer id="PER">Perrigo International</manufacturer>
		<manufacturer id="PFC">Pfizer Consumer Healthcare</manufacturer>
		<manufacturer id="PFD">Pierre Fabre Dermo-Cosmetique Canada Inc.</manufacturer>
		<manufacturer id="PFI">Pfizer Canada Inc.</manufacturer>
		<manufacturer id="PFP">Purdue Pharma</manufacturer>
		<manufacturer id="PFR">Purdue Frederick Inc.</manufacturer>
		<manufacturer id="PGI">Proctor &amp; Gamble Inc.</manufacturer>
		<manufacturer id="PGO">PanGeo Pharma (Canada) Inc.</manufacturer>
		<manufacturer id="PGP">Proctor &amp; Gamble Pharmaceuticals Canada, Inc.</manufacturer>
		<manufacturer id="PHA">Pharmacia Canada Inc.</manufacturer>
		<manufacturer id="PHB">Phebra Canada</manufacturer>
		<manufacturer id="PHC">Pharmacosmos A/S</manufacturer>
		<manufacturer id="PHD">Manufacturer name not currently available</manufacturer>
		<manufacturer id="PHE">Pharmel Inc.</manufacturer>
		<manufacturer id="PHI">Pharmetics (2011) Inc.</manufacturer>
		<manufacturer id="PHO">Pharmaco Canada Inc. - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="PHP">Pharmapar Inc.</manufacturer>
		<manufacturer id="PHR">Pharmaco Canada Inc</manufacturer>
		<manufacturer id="PHS">Pharma Stulln Inc.</manufacturer>
		<manufacturer id="PMJ">Pharmacia &amp; Upjohn</manufacturer>
		<manufacturer id="PMS">Pharmascience Inc.</manufacturer>
		<manufacturer id="PMT">Pharmetics Inc. (S8)</manufacturer>
		<manufacturer id="PMV">Pharmavite Lab. - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="POU">Manufacturer name not currently available</manufacturer>
		<manufacturer id="PPC">Pharmaceutical Partners of Canada</manufacturer>
		<manufacturer id="PRD">Pro Doc Limitee</manufacturer>
		<manufacturer id="PRE">Prempharm Inc.</manufacturer>
		<manufacturer id="PRO">Proval Pharma Inc.</manufacturer>
		<manufacturer id="PRZ">Pharmaris Canada Inc.</manufacturer>
		<manufacturer id="PVR">Pharmavite Corporation</manufacturer>
		<manufacturer id="PWC">Manufacturer name not currently available</manufacturer>
		<manufacturer id="QHP">Quality Home Products, a division of H.J. Sutton Ind. Ltd.</manufacturer>
		<manufacturer id="QUO">Questcor Operations Ltd.</manufacturer>
		<manufacturer id="QVS">Quest Vitamins, Division of Pangeo Health Brands Inc. (S8)</manufacturer>
		<manufacturer id="RAI">Ratiopharm Inc. (DO NOT USE)</manufacturer>
		<manufacturer id="RAN">Ranbaxy Pharmaceuticals Canada Inc.</manufacturer>
		<manufacturer id="RBP">RB Pharmaceuticals Ltd.</manufacturer>
		<manufacturer id="RBT">Roberts Pharmaceutical of Canada Inc.</manufacturer>
		<manufacturer id="RCA">Reed &amp; Carnrick,Division of Block Drug Company (Canada) Ltd.</manufacturer>
		<manufacturer id="RCH">Roche Diabetes Care GmbH</manufacturer>
		<manufacturer id="RDC">Reddy-Cheminor Inc.</manufacturer>
		<manufacturer id="REK">Rekah Pharmaceuticals Industry Ltd.</manufacturer>
		<manufacturer id="RHO">Rhoxalpharma Inc.</manufacturer>
		<manufacturer id="RHP">Rhodiapharm Inc.</manufacturer>
		<manufacturer id="RIA">Laboratoire Riva Inc.</manufacturer>
		<manufacturer id="RIC">Richmond Pharmaceuticals Inc.</manufacturer>
		<manufacturer id="RIK">Manufacturer name not currently available</manufacturer>
		<manufacturer id="RIP">Richmond Pharmaceuticals Inc.</manufacturer>
		<manufacturer id="RIV">Rivex Pharma Inc.</manufacturer>
		<manufacturer id="ROB">Manufacturer name not currently available</manufacturer>
		<manufacturer id="ROC">Manufacturer Name currently not available</manufacturer>
		<manufacturer id="ROD">Roche Diagnostics, a division of Hoffmann-La Roche Limited</manufacturer>
		<manufacturer id="ROG">Rougier Pharma, Division of Ratiopharm Inc.</manufacturer>
		<manufacturer id="ROM">Romark Laboratories</manufacturer>
		<manufacturer id="ROP">Roberts Pharmaceutical - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="ROR">Rhone-Poulenc Rorer Consumer Inc. - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="ROS">Ross Laboratories-Abbott (Nutritional Products)</manufacturer>
		<manufacturer id="ROU">Roussel Canada Inc.(Hoechst-Roussel Canada Inc.)</manufacturer>
		<manufacturer id="ROY">C. A. Roy Limited - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="RPH">Ratiopharm Inc.</manufacturer>
		<manufacturer id="RPP">Rhone-Poulenc Rorer-Ethical Division</manufacturer>
		<manufacturer id="RPR">Rhone-Poulenc Rorer Consumer Inc.</manufacturer>
		<manufacturer id="RRD">Respironics Respiratory Drug Delivery (UK) Ltd.</manufacturer>
		<manufacturer id="SAB">Sabex Inc. - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="SAC">Sanofi-Aventis Canada Inc.</manufacturer>
		<manufacturer id="SAE">Savient Pharmaceuticals Inc.</manufacturer>
		<manufacturer id="SAF">Sanofi Pasteur Limited.</manufacturer>
		<manufacturer id="SAG">Sanofi Genzyme</manufacturer>
		<manufacturer id="SAI">Sanis Health Inc.</manufacturer>
		<manufacturer id="SAL">Salix Pharmaceuticals Inc.</manufacturer>
		<manufacturer id="SAM">Samsung Bioepis Co. Ltd</manufacturer>
		<manufacturer id="SAN">Sandoz Canada Inc. - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="SAO">Sanofi Canada Inc.</manufacturer>
		<manufacturer id="SAS">Sanofi - Synthelabo Canada Inc.</manufacturer>
		<manufacturer id="SAT">Santen Inc.</manufacturer>
		<manufacturer id="SAV">Sanofi Aventis Pharma</manufacturer>
		<manufacturer id="SAW">Sanofi Winthrop - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="SBI">Shire BioChem Inc.</manufacturer>
		<manufacturer id="SBP">STIEFFEL BCD PHARMA</manufacturer>
		<manufacturer id="SCC">Manufacturer name not currently available</manufacturer>
		<manufacturer id="SCE">Schein Pharmaceutical</manufacturer>
		<manufacturer id="SCH">Schering Canada Inc.</manufacturer>
		<manufacturer id="SCJ">Manufacturer name not currently available</manufacturer>
		<manufacturer id="SCK">Manufacturer name not currently available</manufacturer>
		<manufacturer id="SCP">Schering-Plough Canada Inc.</manufacturer>
		<manufacturer id="SDM">Shoppers Drug Mart</manufacturer>
		<manufacturer id="SDR">Stanley Pharmaceuticals Ltd.</manufacturer>
		<manufacturer id="SDZ">Sandoz Canada Inc.</manufacturer>
		<manufacturer id="SEA">Searle Canada Inc.</manufacturer>
		<manufacturer id="SEF">Seaford Pharmaceuticals Inc</manufacturer>
		<manufacturer id="SEG">Seattle Generics Inc.</manufacturer>
		<manufacturer id="SEP">Sepracor Pharmaceuticals Inc.</manufacturer>
		<manufacturer id="SEQ">Seqirus PTY LTD.</manufacturer>
		<manufacturer id="SER">Manufacturer name not currently available</manufacturer>
		<manufacturer id="SET">Septa Pharmaceuticals Inc.</manufacturer>
		<manufacturer id="SEV">Servier Canada Inc.</manufacturer>
		<manufacturer id="SHE">Shenzhen Techdow Pharmaceutical Co., Ltd.</manufacturer>
		<manufacturer id="SHG">Shire Human Genetic Therapies Inc.</manufacturer>
		<manufacturer id="SHI">Shire Pharma Canada ULC</manufacturer>
		<manufacturer id="SHL">SHS International Ltd.</manufacturer>
		<manufacturer id="SHM">Sherwood Inc.</manufacturer>
		<manufacturer id="SHS">SHS North America</manufacturer>
		<manufacturer id="SIG">Sigma-Tau Pharmaceutical Inc.</manufacturer>
		<manufacturer id="SIL">Sabex 2002 Inc</manufacturer>
		<manufacturer id="SIV">Sivem Pharmaceuticals ULC</manufacturer>
		<manufacturer id="SKB">SmithKline Beecham Consumer Healthcare.</manufacturer>
		<manufacturer id="SKF">Seaford Pharmaceuticals Inc. (S8)</manufacturer>
		<manufacturer id="SKY">Skymed Corporation</manufacturer>
		<manufacturer id="SLL">Manufacturer name not currently available</manufacturer>
		<manufacturer id="SLO">Solvay Kingswood Inc. - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="SLP">Searchlight Pharma Inc.</manufacturer>
		<manufacturer id="SMJ">Smith Kline Beecham Pharma Inc</manufacturer>
		<manufacturer id="SNE">Smith &amp; Nephew Inc.</manufacturer>
		<manufacturer id="SOL">Solvay Kingswood Inc. - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="SOR">Sorres Pharma Inc.</manufacturer>
		<manufacturer id="SOT">Shire Orphan Therapies Inc.</manufacturer>
		<manufacturer id="SPC">Sun Pharma</manufacturer>
		<manufacturer id="SPG">Sun Pharma Global FZE</manufacturer>
		<manufacturer id="SPH">Solvay Pharma Inc.</manufacturer>
		<manufacturer id="SPI">Shire Pharmaceuticals Ireland Limited.</manufacturer>
		<manufacturer id="SQI">Squire Pharmaceuticals Inc.</manufacturer>
		<manufacturer id="SQU">Manufacturer name not currently available</manufacturer>
		<manufacturer id="SRO">Serono Canada Inc.</manufacturer>
		<manufacturer id="STA">Stason Pharmaceuticals Inc., Irvine</manufacturer>
		<manufacturer id="STE">Sterimax Inc.</manufacturer>
		<manufacturer id="STH">Sterling Health</manufacturer>
		<manufacturer id="STI">Stiefel Canada Inc.</manufacturer>
		<manufacturer id="STL">Stallergenes Canada Inc.</manufacturer>
		<manufacturer id="STN">Sterinova Inc.</manufacturer>
		<manufacturer id="STR">Strides Pharma Canada Inc.</manufacturer>
		<manufacturer id="STW">Manufacturer name not currently available</manufacturer>
		<manufacturer id="SUN">Sun Pharmaceutical Inc</manufacturer>
		<manufacturer id="SUO">Sunovion Pharmaceuticals Canada Inc.</manufacturer>
		<manufacturer id="SUP">Supplements Aromatik Inc.</manufacturer>
		<manufacturer id="SWE">Swedish Orphan BioVitrum</manufacturer>
		<manufacturer id="SWS">Swiss Herbal Remedies Ltd.</manufacturer>
		<manufacturer id="SYN">Syntex Inc.</manufacturer>
		<manufacturer id="SYP">SynCare Pharmaceutical Inc.</manufacturer>
		<manufacturer id="TAH">Taiho Pharma Canada Inc.</manufacturer>
		<manufacturer id="TAI">Taidoc Technology Corporation</manufacturer>
		<manufacturer id="TAK">Takeda Canada Inc.</manufacturer>
		<manufacturer id="TAN">Tanta Pharmaceutical Co.</manufacturer>
		<manufacturer id="TAP">TAP Pharmaceuticals</manufacturer>
		<manufacturer id="TAR">Taro Pharmaceuticals Inc.</manufacturer>
		<manufacturer id="TBP">Teva Branded Pharmaceutical Products R&amp;D Inc.</manufacturer>
		<manufacturer id="TCD">Trans Canaderm Inc.</manufacturer>
		<manufacturer id="TCH">Technilab Inc.</manufacturer>
		<manufacturer id="TCI">Teligent Canada Inc.</manufacturer>
		<manufacturer id="TEI">Teva Canada Innovation.</manufacturer>
		<manufacturer id="TEL">Teligent OU</manufacturer>
		<manufacturer id="TEP">Teligent Pharma Inc.</manufacturer>
		<manufacturer id="TER">Therasense Canada Inc.</manufacturer>
		<manufacturer id="TEV">Teva Canada Limited</manufacturer>
		<manufacturer id="TEW">Teva Women&apos;s Health Inc.</manufacturer>
		<manufacturer id="THE">Theramed Corporation</manufacturer>
		<manufacturer id="THO">Thrombogenics NV</manufacturer>
		<manufacturer id="THR">Thermor Ltd.</manufacturer>
		<manufacturer id="TIC">Tican Pharmaceuticals Ltd.</manufacturer>
		<manufacturer id="TIL">Tillomed Laboratories Ltd.</manufacturer>
		<manufacturer id="TKJ">TEVA Pharmaceutical Industries Ltd.</manufacturer>
		<manufacturer id="TLI">Laboratory Trianon Inc. - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="TMI">Trudell Medical International</manufacturer>
		<manufacturer id="TMP">3M Pharmaceuticals/3M Canada Inc. - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="TOL">Tolmar International Ltd.</manufacturer>
		<manufacturer id="TPA">Takeda Pharmaceuticals America Inc.</manufacturer>
		<manufacturer id="TPG">Tillotts Pharma GMBH:</manufacturer>
		<manufacturer id="TPH">TaroPharma, a Division of Taro Pharmaceuticals Inc.</manufacturer>
		<manufacturer id="TRA">Manufacturer name not currently available</manufacturer>
		<manufacturer id="TRE">Tremblay Harrison Inc.</manufacturer>
		<manufacturer id="TRI">Trillium Health Care Products Inc.</manufacturer>
		<manufacturer id="TRO">Trophic Canada Ltd.</manufacturer>
		<manufacturer id="TRS">TerSera Therapeutics LLC</manufacturer>
		<manufacturer id="TRT">Triton Pharma Inc.</manufacturer>
		<manufacturer id="UCB">UCB Canada Inc.</manufacturer>
		<manufacturer id="UJC">Upjohn Canada ULC</manufacturer>
		<manufacturer id="UME">Unimed Canada Inc.</manufacturer>
		<manufacturer id="UNV">Univar Ltd.</manufacturer>
		<manufacturer id="UPJ">The Upjohn Company of Canada</manufacturer>
		<manufacturer id="UPS">Manufacturer name not currently available</manufacturer>
		<manufacturer id="USV">Manufacturer name not currently available</manufacturer>
		<manufacturer id="UTC">United Therapeutics Corporation (S8)</manufacturer>
		<manufacturer id="VAE">Valeo Pharma Inc.</manufacturer>
		<manufacturer id="VAL">Valeant Canada Ltd.</manufacturer>
		<manufacturer id="VAN">Vanc Pharmaceuticals Inc.</manufacturer>
		<manufacturer id="VER">Vertex Pharmaceuticals (Canada) Inc.</manufacturer>
		<manufacturer id="VET">Verity Pharmaceuticals Inc.</manufacturer>
		<manufacturer id="VHL">Vita Health Products Inc. (S8)</manufacturer>
		<manufacturer id="VIA">Viatris</manufacturer>
		<manufacturer id="VIF">Vifor Fresenius Medical Care Renal Pharma Ltd.</manufacturer>
		<manufacturer id="VIH">ViiV Healthcare ULC</manufacturer>
		<manufacturer id="VIP">Vita Health Products Inc.</manufacturer>
		<manufacturer id="VIT">Vitaflo USA, LLC</manufacturer>
		<manufacturer id="VIU">Vivus Inc.</manufacturer>
		<manufacturer id="VIV">Viva Pharmaceuticals</manufacturer>
		<manufacturer id="VLH">Lundbeck Canada Inc.</manufacturer>
		<manufacturer id="VPI">VPI Pharmaceuticals Inc.</manufacturer>
		<manufacturer id="VRO">Virco Pharmaceutical (Canada) Inc.</manufacturer>
		<manufacturer id="WAB">Waymar Pharmaceuticals Inc.</manufacturer>
		<manufacturer id="WAM">Manufacturer name not currently available</manufacturer>
		<manufacturer id="WAP">Wampole</manufacturer>
		<manufacturer id="WAR">Warner Chilcott Canada Co.</manufacturer>
		<manufacturer id="WAT">Watson Laboratories Inc.</manufacturer>
		<manufacturer id="WAY">Wyeth Pharmaceuticals</manufacturer>
		<manufacturer id="WBP">Manufacturer name not currently available</manufacturer>
		<manufacturer id="WCC">Women&apos;s Capital Corporation</manufacturer>
		<manufacturer id="WEL">WellSpring Pharmaceutical Canada Corp.</manufacturer>
		<manufacturer id="WHB">Whitehall-Robins Inc</manufacturer>
		<manufacturer id="WHH">Manufacturer name not currently available</manufacturer>
		<manufacturer id="WIN">Winthrop Laboratories</manufacturer>
		<manufacturer id="WLA">Warner-Lambert - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="WLN">Manufacturer name not currently available</manufacturer>
		<manufacturer id="WNP">WN Pharmaceuticals Ltd.</manufacturer>
		<manufacturer id="WOC">Wockhardt UK Ltd. (S8)</manufacturer>
		<manufacturer id="WRI">Whitehall-Robins Inc. - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="WSD">Manufacturer name not currently available</manufacturer>
		<manufacturer id="WSQ">Westwood Squibb Pharmaceuticals</manufacturer>
		<manufacturer id="WTR">Westcan Pharmaceuticals - &quot;DO NOT USE&quot;</manufacturer>
		<manufacturer id="WYA">Wyeth-Ayerst Canada Inc.</manufacturer>
		<manufacturer id="WYE">Wyeth Ltd.</manufacturer>
		<manufacturer id="XED">Xediton Pharmaceuticals Inc.</manufacturer>
		<manufacturer id="XEN">Xenex Laboratories Inc.</manufacturer>
		<manufacturer id="XXX">Manufacturer cannot be identified</manufacturer>
		<manufacturer id="YNO">Baxter AG (S8)</manufacturer>
		<manufacturer id="YYY">Manufacturer for Gov&apos;t Pharmacy Items</manufacturer>
		<manufacturer id="ZEN">Zeneca Pharma Inc.</manufacturer>
		<manufacturer id="ZIL">Zila Pharmaceuticals Inc.</manufacturer>
		<manufacturer id="ZOG">Zogenix, Inc.</manufacturer>
		<manufacturer id="ZYN">Zymcan Pharmaceuticals Inc.</manufacturer>
	</manufacturerList>
	<formulary edition="4322" updateVer="A" formularyDate="2022-03-31" createDate="2022-03-31">
		<pcg2 id="040000000">
			<name>ANTIHISTAMINES</name>
			<pcg6>
				<genericName id="00005">
					<name>CETIRIZINE HYDROCHLORIDE</name>
					<pcgGroup>
						<pcg9 id="040000086">
							<itemNumber>0001</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02223554" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Reactine</name>
								<manufacturerId>MCL</manufacturerId>
								<listingDate>2007-12-19</listingDate>
							</drug>
							<drug id="02231603" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Cetirizine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.4083</individualPrice>
								<listingDate>2007-12-19</listingDate>
							</drug>
							<drug id="02315955" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Extra Strength Allergy Relief</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3938</individualPrice>
								<listingDate>2009-11-13</listingDate>
							</drug>
							<drug id="02427133" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mar-Cetirizine</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.4083</individualPrice>
								<listingDate>2014-10-29</listingDate>
							</drug>
							<drug id="02451778" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Jamp-Cetirizine</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.4083</individualPrice>
								<listingDate>2016-08-30</listingDate>
							</drug>
							<drug id="02496461" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Nat-Cetirizine</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>.4083</individualPrice>
								<listingDate>2020-05-29</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="040000087">
							<itemNumber>0002</itemNumber>
							<strength>20mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="01900978" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Reactine</name>
								<manufacturerId>MCL</manufacturerId>
								<listingDate>2008-12-23</listingDate>
							</drug>
							<drug id="02315963" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>PMS-Cetirizine</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.7535</individualPrice>
								<listingDate>2008-12-23</listingDate>
							</drug>
							<drug id="02427141" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mar-Cetirizine</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.7535</individualPrice>
								<listingDate>2014-10-29</listingDate>
							</drug>
							<drug id="02453363" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Cetirizine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.7535</individualPrice>
								<listingDate>2016-06-29</listingDate>
							</drug>
							<drug id="02466171" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Jamp-Cetirizine</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.7535</individualPrice>
								<listingDate>2017-10-30</listingDate>
							</drug>
							<drug id="02491125" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mint-Cetirizine</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.7535</individualPrice>
								<listingDate>2020-02-28</listingDate>
							</drug>
							<drug id="02496488" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Nat-Cetirizine</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>.7535</individualPrice>
								<listingDate>2020-05-29</listingDate>
							</drug>
							<drug id="02512025" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>M-Cetirizine</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.7535</individualPrice>
								<listingDate>2021-11-30</listingDate>
							</drug>
							<drug id="02515695" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Cetirizine</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.7535</individualPrice>
								<listingDate>2021-07-30</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00015">
					<name>LORATADINE</name>
					<pcgGroup>
						<pcg9 id="040000061">
							<itemNumber>0003</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00782696" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Claritin</name>
								<manufacturerId>SCP</manufacturerId>
								<listingDate>2007-12-19</listingDate>
							</drug>
							<drug id="02243880" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Apo-Loratadine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.6267</individualPrice>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.6267</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00003">
					<name>PROMETHAZINE HCL</name>
					<pcgGroup>
						<pcg9 id="040000022">
							<itemNumber>0004</itemNumber>
							<strength>2mg/mL</strength>
							<dosageForm>O/L</dosageForm>
							<drug id="00583979" notABenefit="Y" sec3="Y">
								<name>PMS-Promethazine</name>
								<manufacturerId>PMS</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="01937693" notABenefit="Y" sec3="Y">
								<name>Phenergan</name>
								<manufacturerId>RPR</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
			</pcg6>
		</pcg2>
		<pcg2 id="080000000">
			<name>ANTI-INFECTIVE AGENTS</name>
			<pcg6 id="080800000">
				<name>ANTHELMINTICS</name>
				<genericName id="00021">
					<name>MEBENDAZOLE</name>
					<pcgGroup>
						<pcg9 id="080800013">
							<itemNumber>0005</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00556734" sec3="Y">
								<name>Vermox</name>
								<manufacturerId>JAN</manufacturerId>
								<individualPrice>8.5000</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>8.5000</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="081204000">
				<name>ANTIBIOTICS ANTIFUNGALS</name>
				<genericName id="00023">
					<name>AMPHOTERICIN B</name>
					<pcgGroup>
						<pcg9 id="081204001">
							<itemNumber>0006</itemNumber>
							<dosageForm>Inj Pd-50mg Pk</dosageForm>
							<drug id="00029149" sec3="Y">
								<name>Fungizone</name>
								<manufacturerId>CHE</manufacturerId>
								<individualPrice>88.7500</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>88.7500</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01604">
					<name>CASPOFUNGIN ACETATE</name>
					<pcgGroup>
						<pcg9 id="081204027">
							<itemNumber>0007</itemNumber>
							<strength>50mg/Vial</strength>
							<dosageForm>Inj-Vial Pk</dosageForm>
							<drug id="02244265" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Cancidas</name>
								<manufacturerId>FRS</manufacturerId>
								<listingDate>2017-08-30</listingDate>
							</drug>
							<drug id="02460947" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Caspofungin for Injection</name>
								<manufacturerId>MDI</manufacturerId>
								<individualPrice>188.7000</individualPrice>
								<listingDate>2017-08-30</listingDate>
								<amountMOHLTCPays>188.7000</amountMOHLTCPays>
							</drug>
							<drug id="02486989" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Caspofungin for Injection</name>
								<manufacturerId>FKC</manufacturerId>
								<individualPrice>222.5000</individualPrice>
								<listingDate>2020-05-29</listingDate>
								<amountMOHLTCPays>222.5000</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00032">
					<name>FLUCONAZOLE</name>
					<pcgGroup lccId="00001">
						<pcg9 id="081204025">
							<itemNumber>0008</itemNumber>
							<strength>10mg/mL</strength>
							<dosageForm>O/L</dosageForm>
							<drug id="02024152" sec3="Y" sec12="Y">
								<name>Diflucan P.O.S.</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>1.2796</individualPrice>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>1.2796</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="528">For patients who are unable to swallow or tolerate solid oral dosage forms.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
					<pcgGroup lccId="00002">
						<pcg9 id="081204023">
							<itemNumber>0009</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>2.5808</dailyCost>
							<drug id="00891800" notABenefit="Y" sec3="Y">
								<name>Diflucan</name>
								<manufacturerId>PFI</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02236978" sec3="Y">
								<name>Teva-Fluconazole</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>1.2904</individualPrice>
								<dailyCost>2.5808</dailyCost>
								<listingDate>2003-04-16</listingDate>
								<amountMOHLTCPays>1.2904</amountMOHLTCPays>
							</drug>
							<drug id="02237370" sec3="Y">
								<name>Apo-Fluconazole</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.2904</individualPrice>
								<dailyCost>2.5808</dailyCost>
								<listingDate>1999-09-15</listingDate>
								<amountMOHLTCPays>1.2904</amountMOHLTCPays>
							</drug>
							<drug id="02245292" sec3="Y">
								<name>Mylan-Fluconazole</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>1.2904</individualPrice>
								<dailyCost>2.5808</dailyCost>
								<listingDate>2003-04-16</listingDate>
								<amountMOHLTCPays>1.2904</amountMOHLTCPays>
							</drug>
							<drug id="02245643" sec3="Y">
								<name>PMS-Fluconazole</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>1.2904</individualPrice>
								<dailyCost>2.5808</dailyCost>
								<listingDate>2003-01-30</listingDate>
								<amountMOHLTCPays>1.2904</amountMOHLTCPays>
							</drug>
							<drug id="02249294" notABenefit="Y" sec3="Y">
								<name>Taro-Fluconazole</name>
								<manufacturerId>TAR</manufacturerId>
								<listingDate>2004-12-21</listingDate>
							</drug>
							<drug id="02281260" sec3="Y">
								<name>ACT Fluconazole</name>
								<manufacturerId>ACV</manufacturerId>
								<individualPrice>1.2904</individualPrice>
								<dailyCost>2.5808</dailyCost>
								<listingDate>2008-01-15</listingDate>
								<amountMOHLTCPays>1.2904</amountMOHLTCPays>
							</drug>
							<drug id="02517396" sec3="Y">
								<name>Fluconazole</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>1.2904</individualPrice>
								<dailyCost>2.5808</dailyCost>
								<listingDate>2022-03-31</listingDate>
								<amountMOHLTCPays>1.2904</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081204024">
							<itemNumber>0010</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>2.2891</dailyCost>
							<drug id="00891819" notABenefit="Y" sec3="Y">
								<name>Diflucan</name>
								<manufacturerId>PFI</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02236979" sec3="Y">
								<name>Teva-Fluconazole</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>2.2891</individualPrice>
								<dailyCost>2.2891</dailyCost>
								<listingDate>2003-04-16</listingDate>
								<amountMOHLTCPays>2.2891</amountMOHLTCPays>
							</drug>
							<drug id="02237371" sec3="Y">
								<name>Apo-Fluconazole</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>2.2891</individualPrice>
								<dailyCost>2.2891</dailyCost>
								<listingDate>1999-09-15</listingDate>
								<amountMOHLTCPays>2.2891</amountMOHLTCPays>
							</drug>
							<drug id="02245293" sec3="Y">
								<name>Mylan-Fluconazole</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>2.2891</individualPrice>
								<dailyCost>2.2891</dailyCost>
								<listingDate>2003-04-16</listingDate>
								<amountMOHLTCPays>2.2891</amountMOHLTCPays>
							</drug>
							<drug id="02245644" sec3="Y">
								<name>PMS-Fluconazole</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>2.2891</individualPrice>
								<dailyCost>2.2891</dailyCost>
								<listingDate>2003-01-30</listingDate>
								<amountMOHLTCPays>2.2891</amountMOHLTCPays>
							</drug>
							<drug id="02249308" notABenefit="Y" sec3="Y">
								<name>Taro-Fluconazole</name>
								<manufacturerId>TAR</manufacturerId>
								<listingDate>2004-12-21</listingDate>
							</drug>
							<drug id="02281279" sec3="Y">
								<name>ACT Fluconazole</name>
								<manufacturerId>ACV</manufacturerId>
								<individualPrice>2.2891</individualPrice>
								<dailyCost>2.2891</dailyCost>
								<listingDate>2008-01-15</listingDate>
								<amountMOHLTCPays>2.2891</amountMOHLTCPays>
							</drug>
							<drug id="02517418" sec3="Y">
								<name>Fluconazole</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>2.2891</individualPrice>
								<dailyCost>2.2891</dailyCost>
								<listingDate>2022-03-31</listingDate>
								<amountMOHLTCPays>2.2891</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00031">
					<name>ITRACONAZOLE</name>
					<pcgGroup>
						<pcg9 id="081204040">
							<itemNumber>0011</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02047454" sec3="Y">
								<name>Sporanox</name>
								<manufacturerId>JAN</manufacturerId>
								<individualPrice>5.4880</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>3.9270</amountMOHLTCPays>
							</drug>
							<drug id="02462559" sec3="Y">
								<name>Mint-Itraconazole</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>3.9270</individualPrice>
								<listingDate>2017-07-31</listingDate>
								<amountMOHLTCPays>3.9270</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
					<pcgGroup lccId="00327">
						<pcg9 id="081204043">
							<itemNumber>0012</itemNumber>
							<strength>10mg/mL</strength>
							<dosageForm>Oral Sol</dosageForm>
							<drug id="02231347" sec3="Y" sec12="Y">
								<name>Sporanox</name>
								<manufacturerId>JAN</manufacturerId>
								<individualPrice>1.0236</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.4111</amountMOHLTCPays>
							</drug>
							<drug id="02484315" sec3="Y" sec12="Y">
								<name>Jamp Itraconazole Oral Solution</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.4111</individualPrice>
								<listingDate>2020-04-30</listingDate>
								<amountMOHLTCPays>.4111</amountMOHLTCPays>
							</drug>
							<drug id="02495988" sec3="Y" sec12="Y">
								<name>Odan-Itraconazole</name>
								<manufacturerId>ODN</manufacturerId>
								<individualPrice>.4111</individualPrice>
								<listingDate>2020-08-28</listingDate>
								<amountMOHLTCPays>.4111</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="570">For patients who are unable to swallow or tolerate solid oral dosage forms.
</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00027">
					<name>KETOCONAZOLE</name>
					<pcgGroup>
						<pcg9 id="081204010">
							<itemNumber>0013</itemNumber>
							<strength>200mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.9393</dailyCost>
							<drug id="00633836" notABenefit="Y" sec3="Y">
								<name>Nizoral</name>
								<manufacturerId>JAN</manufacturerId>
								<note>A low pH is necessary for absorption. Antacids, anticholinergics/antispasmodics, H2-blockers, and omeprazole may decrease absorption. Ketoconazole is a potent inhibitor of hepatic oxidation of drugs and may cause significant elevation of blood levels of astemizole, cisapride, cyclosporine, terfenadine, theophylline and warfarin. Potentially fatal arrhythmias (torsade de pointes) can occur with the combination of ketoconazole and astemizole, cisapride or terfenadine. Insulin requirements may be reduced. Hepatotoxicity occurs in approximately 1 in 1500 patients treated with ketoconazole for onychomycosis; female gender, pre-existing disease, alcoholism and greater than 2 weeks of therapy are pre-disposing factors.</note>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02231061" sec3="Y">
								<name>Teva-Ketoconazole</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.9393</individualPrice>
								<dailyCost>.9393</dailyCost>
								<note>A low pH is necessary for absorption. Antacids, anticholinergics/antispasmodics, H2-blockers, and omeprazole may decrease absorption. Ketoconazole is a potent inhibitor of hepatic oxidation of drugs and may cause significant elevation of blood levels of astemizole, cisapride, cyclosporine, terfenadine, theophylline and warfarin. Potentially fatal arrhythmias (torsade de pointes) can occur with the combination of ketoconazole and astemizole, cisapride or terfenadine. Insulin requirements may be reduced. Hepatotoxicity occurs in approximately 1 in 1500 patients treated with ketoconazole for onychomycosis; female gender, pre-existing disease, alcoholism and greater than 2 weeks of therapy are pre-disposing factors.</note>
								<listingDate>2000-01-17</listingDate>
								<amountMOHLTCPays>.9393</amountMOHLTCPays>
							</drug>
							<drug id="02237235" sec3="Y">
								<name>Apo-Ketoconazole</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.9393</individualPrice>
								<dailyCost>.9393</dailyCost>
								<note>A low pH is necessary for absorption. Antacids, anticholinergics/antispasmodics, H2-blockers, and omeprazole may decrease absorption. Ketoconazole is a potent inhibitor of hepatic oxidation of drugs and may cause significant elevation of blood levels of astemizole, cisapride, cyclosporine, terfenadine, theophylline and warfarin. Potentially fatal arrhythmias (torsade de pointes) can occur with the combination of ketoconazole and astemizole, cisapride or terfenadine. Insulin requirements may be reduced. Hepatotoxicity occurs in approximately 1 in 1500 patients treated with ketoconazole for onychomycosis; female gender, pre-existing disease, alcoholism and greater than 2 weeks of therapy are pre-disposing factors.</note>
								<listingDate>1999-09-15</listingDate>
								<amountMOHLTCPays>.9393</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00025">
					<name>NYSTATIN</name>
					<pcgGroup>
						<pcg9 id="081204006">
							<itemNumber>0014</itemNumber>
							<strength>100000U/mL</strength>
							<dosageForm>O/L</dosageForm>
							<dailyCost>.2072</dailyCost>
							<drug id="00248169" notABenefit="Y" sec3="Y">
								<name>Mycostatin</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02194201" sec3="Y">
								<name>Ratio-Nystatin</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>.0518</individualPrice>
								<dailyCost>.2072</dailyCost>
								<listingDate>1997-10-31</listingDate>
								<amountMOHLTCPays>.0518</amountMOHLTCPays>
							</drug>
							<drug id="02433443" sec3="Y">
								<name>Jamp-Nystatin Oral Suspension USP</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.0518</individualPrice>
								<dailyCost>.2072</dailyCost>
								<listingDate>2021-11-30</listingDate>
								<amountMOHLTCPays>.0518</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01704">
					<name>POSACONAZOLE</name>
					<pcgGroup>
						<pcg9 id="081204038">
							<itemNumber>0015</itemNumber>
							<strength>100mg</strength>
							<dosageForm>DR Tab</dosageForm>
							<drug id="02424622" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Posanol</name>
								<manufacturerId>MEK</manufacturerId>
								<individualPrice>51.4244</individualPrice>
								<listingDate>2021-01-29</listingDate>
								<amountMOHLTCPays>42.6030</amountMOHLTCPays>
							</drug>
							<drug id="02496259" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Sandoz Posaconazole</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>42.6030</individualPrice>
								<listingDate>2021-01-29</listingDate>
								<amountMOHLTCPays>42.6030</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00030">
					<name>TERBINAFINE HCL</name>
					<pcgGroup>
						<pcg9 id="081204016">
							<itemNumber>0016</itemNumber>
							<strength>250mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02031116" notABenefit="Y" sec3="Y">
								<name>Lamisil</name>
								<manufacturerId>NOV</manufacturerId>
								<listingDate>2007-12-19</listingDate>
							</drug>
							<drug id="02239893" sec3="Y">
								<name>Apo-Terbinafine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.7714</individualPrice>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.7714</amountMOHLTCPays>
							</drug>
							<drug id="02240346" sec3="Y">
								<name>Teva-Terbinafine</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.7714</individualPrice>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.7714</amountMOHLTCPays>
							</drug>
							<drug id="02254727" sec3="Y">
								<name>Co Terbinafine</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.7714</individualPrice>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.7714</amountMOHLTCPays>
							</drug>
							<drug id="02294273" sec3="Y">
								<name>PMS-Terbinafine</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.7714</individualPrice>
								<listingDate>2009-09-30</listingDate>
								<amountMOHLTCPays>.7714</amountMOHLTCPays>
							</drug>
							<drug id="02320134" sec3="Y">
								<name>Auro-Terbinafine</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.7714</individualPrice>
								<listingDate>2011-09-15</listingDate>
								<amountMOHLTCPays>.7714</amountMOHLTCPays>
							</drug>
							<drug id="02353121" sec3="Y">
								<name>Terbinafine</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.7714</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.7714</amountMOHLTCPays>
							</drug>
							<drug id="02385279" sec3="Y">
								<name>Terbinafine</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.7714</individualPrice>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.7714</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01634">
					<name>VORICONAZOLE</name>
					<pcgGroup lccId="00165">
						<pcg9 id="081204029">
							<itemNumber>0017</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02256460" sec3="Y" sec12="Y">
								<name>Vfend</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>13.5635</individualPrice>
								<listingDate>2005-09-27</listingDate>
								<amountMOHLTCPays>6.7818</amountMOHLTCPays>
							</drug>
							<drug id="02396866" sec3="Y" sec12="Y">
								<name>Teva-Voriconazole</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>6.7818</individualPrice>
								<listingDate>2014-05-29</listingDate>
								<amountMOHLTCPays>6.7818</amountMOHLTCPays>
							</drug>
							<drug id="02399245" sec3="Y" sec12="Y">
								<name>Sandoz Voriconazole</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>6.7818</individualPrice>
								<listingDate>2014-05-29</listingDate>
								<amountMOHLTCPays>6.7818</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081204030">
							<itemNumber>0018</itemNumber>
							<strength>200mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02256479" sec3="Y" sec12="Y">
								<name>Vfend</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>54.2323</individualPrice>
								<listingDate>2005-09-27</listingDate>
								<amountMOHLTCPays>26.4807</amountMOHLTCPays>
							</drug>
							<drug id="02396874" sec3="Y" sec12="Y">
								<name>Teva-Voriconazole</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>26.4807</individualPrice>
								<listingDate>2014-05-29</listingDate>
								<amountMOHLTCPays>26.4807</amountMOHLTCPays>
							</drug>
							<drug id="02399253" sec3="Y" sec12="Y">
								<name>Sandoz Voriconazole</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>26.4807</individualPrice>
								<listingDate>2014-05-29</listingDate>
								<amountMOHLTCPays>26.4807</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="399">Outpatient continuation of treatment for documented invasive aspergillosis in patients who have demonstrated a clinical response to either oral or parenteral voriconazole.
* The first prescription must be written by a physician based at the hospital where the patient was hospitalized.
Note: Limited to 3 months of reimbursement.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="081207000">
				<name>ANTIBIOTICS CARBAPENEMS</name>
				<genericName id="01375">
					<name>MEROPENEM</name>
					<pcgGroup>
						<pcg9 id="081207003">
							<itemNumber>0019</itemNumber>
							<strength>1g/Vial</strength>
							<dosageForm>Pd for Inj Sol</dosageForm>
							<drug id="02218496" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Merrem</name>
								<manufacturerId>PFI</manufacturerId>
								<listingDate>2021-04-30</listingDate>
							</drug>
							<drug id="02378795" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Meropenem for Injection</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>47.9900</individualPrice>
								<listingDate>2021-10-29</listingDate>
								<amountMOHLTCPays>47.9900</amountMOHLTCPays>
							</drug>
							<drug id="02421526" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Taro-Meropenem</name>
								<manufacturerId>SPC</manufacturerId>
								<individualPrice>47.9900</individualPrice>
								<listingDate>2021-04-30</listingDate>
								<amountMOHLTCPays>47.9900</amountMOHLTCPays>
							</drug>
							<drug id="02493349" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Meropenem for Injection</name>
								<manufacturerId>STE</manufacturerId>
								<individualPrice>47.9900</individualPrice>
								<listingDate>2021-09-30</listingDate>
								<amountMOHLTCPays>47.9900</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081207002">
							<itemNumber>0020</itemNumber>
							<strength>500mg/Vial</strength>
							<dosageForm>Pd for Inj Sol</dosageForm>
							<drug id="02218488" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Merrem</name>
								<manufacturerId>PFI</manufacturerId>
								<listingDate>2021-04-30</listingDate>
							</drug>
							<drug id="02378787" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Meropenem for Injection</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>23.9950</individualPrice>
								<listingDate>2021-10-29</listingDate>
								<amountMOHLTCPays>23.9950</amountMOHLTCPays>
							</drug>
							<drug id="02421518" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Taro-Meropenem</name>
								<manufacturerId>SPC</manufacturerId>
								<individualPrice>23.9950</individualPrice>
								<listingDate>2021-04-30</listingDate>
								<amountMOHLTCPays>23.9950</amountMOHLTCPays>
							</drug>
							<drug id="02493330" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Meropenem for Injection</name>
								<manufacturerId>STE</manufacturerId>
								<individualPrice>23.9950</individualPrice>
								<listingDate>2021-09-30</listingDate>
								<amountMOHLTCPays>23.9950</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="081212000">
				<name>ANTIBIOTICS ERYTHROMYCINS</name>
				<note>Erythromycin alone is not adequate for the treatment of H. influenzae infections. It lacks consistently reliable activity against this organism. Erythromycin is a potent inhibitor of hepatic oxidation of some drugs and may cause significant elevation of blood levels of astemizole, carbamazepine, cyclosporine, digoxin, dihydropyridines, terfenadine, theophylline and warfarin. Potentially fatal arrhythmias (torsade de pointes) can occur with the combination of erythromycin and astemizole or terfenadine.</note>
				<genericName id="00040">
					<name>AZITHROMYCIN</name>
					<pcgGroup>
						<pcg9 id="081212025">
							<itemNumber>0021</itemNumber>
							<strength>100mg/5mL</strength>
							<dosageForm>O/L-15mL Pk</dosageForm>
							<drug id="02223716" sec3="Y">
								<name>Zithromax</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>17.6415</individualPrice>
								<listingDate>1997-08-28</listingDate>
								<amountMOHLTCPays>8.8208</amountMOHLTCPays>
							</drug>
							<drug id="02332388" sec3="Y">
								<name>Sandoz Azithromycin</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>8.8208</individualPrice>
								<listingDate>2010-04-23</listingDate>
								<amountMOHLTCPays>8.8208</amountMOHLTCPays>
							</drug>
							<drug id="02482363" sec3="Y">
								<name>Auro-Azithromycin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>8.8208</individualPrice>
								<listingDate>2020-04-30</listingDate>
								<amountMOHLTCPays>8.8208</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081212026">
							<itemNumber>0022</itemNumber>
							<strength>200mg/5mL</strength>
							<dosageForm>O/L-15mL Pk</dosageForm>
							<drug id="02223724" sec3="Y">
								<name>Zithromax</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>24.9885</individualPrice>
								<listingDate>1997-08-28</listingDate>
								<amountMOHLTCPays>12.4943</amountMOHLTCPays>
							</drug>
							<drug id="02332396" sec3="Y">
								<name>Sandoz Azithromycin</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>12.4943</individualPrice>
								<listingDate>2010-04-23</listingDate>
								<amountMOHLTCPays>12.4943</amountMOHLTCPays>
							</drug>
							<drug id="02482371" sec3="Y">
								<name>Auro-Azithromycin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>12.4943</individualPrice>
								<listingDate>2020-04-30</listingDate>
								<amountMOHLTCPays>12.4943</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081212036">
							<itemNumber>0023</itemNumber>
							<strength>200mg/5mL</strength>
							<dosageForm>O/L-22.5mL Pk</dosageForm>
							<drug id="09857315" sec3="Y">
								<name>Zithromax</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>37.4828</individualPrice>
								<listingDate>2009-03-02</listingDate>
								<amountMOHLTCPays>18.7425</amountMOHLTCPays>
							</drug>
							<drug id="09857351" sec3="Y">
								<name>Sandoz Azithromycin</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>18.7425</individualPrice>
								<listingDate>2010-04-23</listingDate>
								<amountMOHLTCPays>18.7425</amountMOHLTCPays>
							</drug>
							<drug id="09857636" sec3="Y">
								<name>Auro-Azithromycin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>18.7425</individualPrice>
								<listingDate>2020-04-30</listingDate>
								<amountMOHLTCPays>18.7425</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081212041">
							<itemNumber>0024</itemNumber>
							<strength>200mg/5mL</strength>
							<dosageForm>O/L-37.5mL Pk</dosageForm>
							<note>Zithromax 200mg/5mL oral solution is not commercially available in the 37.5mL pack size and it is only shown in this interchangeable category to facilitate the interchangeability designation with Auro-Azithromycin 200mg/5mL - 37.5mL pack.</note>
							<drug id="09857637" notABenefit="Y" sec3="Y">
								<name>Zithromax</name>
								<manufacturerId>PFI</manufacturerId>
								<listingDate>2020-05-29</listingDate>
							</drug>
							<drug id="09857638" sec3="Y">
								<name>Auro-Azithromycin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>31.2375</individualPrice>
								<listingDate>2020-05-29</listingDate>
								<amountMOHLTCPays>31.2375</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081212029">
							<itemNumber>0025</itemNumber>
							<strength>250mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02212021" sec3="Y">
								<name>Zithromax</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>5.4382</individualPrice>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>.9410</amountMOHLTCPays>
							</drug>
							<drug id="02247423" sec3="Y">
								<name>Apo-Azithromycin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.9410</individualPrice>
								<listingDate>2006-01-24</listingDate>
								<amountMOHLTCPays>.9410</amountMOHLTCPays>
							</drug>
							<drug id="02261634" sec3="Y">
								<name>PMS-Azithromycin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.9410</individualPrice>
								<listingDate>2006-03-01</listingDate>
								<amountMOHLTCPays>.9410</amountMOHLTCPays>
							</drug>
							<drug id="02265826" sec3="Y">
								<name>Sandoz Azithromycin</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.9410</individualPrice>
								<listingDate>2006-01-24</listingDate>
								<amountMOHLTCPays>.9410</amountMOHLTCPays>
							</drug>
							<drug id="02267845" sec3="Y">
								<name>Novo-Azithromycin</name>
								<manufacturerId>NOP</manufacturerId>
								<individualPrice>.9410</individualPrice>
								<listingDate>2006-01-24</listingDate>
								<amountMOHLTCPays>.9410</amountMOHLTCPays>
							</drug>
							<drug id="02275309" sec3="Y">
								<name>Riva-Azithromycin</name>
								<manufacturerId>RIA</manufacturerId>
								<individualPrice>.9410</individualPrice>
								<listingDate>2021-08-31</listingDate>
								<amountMOHLTCPays>.9410</amountMOHLTCPays>
							</drug>
							<drug id="02330881" sec3="Y">
								<name>Azithromycin</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.9410</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.9410</amountMOHLTCPays>
							</drug>
							<drug id="02415542" sec3="Y">
								<name>Apo-Azithromycin Z</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.9410</individualPrice>
								<listingDate>2014-01-30</listingDate>
								<amountMOHLTCPays>.9410</amountMOHLTCPays>
							</drug>
							<drug id="02442434" sec3="Y">
								<name>Azithromycin</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.9410</individualPrice>
								<listingDate>2020-04-30</listingDate>
								<amountMOHLTCPays>.9410</amountMOHLTCPays>
							</drug>
							<drug id="02452308" sec3="Y">
								<name>Jamp-Azithromycin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.9410</individualPrice>
								<listingDate>2016-11-30</listingDate>
								<amountMOHLTCPays>.9410</amountMOHLTCPays>
							</drug>
							<drug id="02452324" sec3="Y">
								<name>Mar-Azithromycin</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.9410</individualPrice>
								<listingDate>2016-11-30</listingDate>
								<amountMOHLTCPays>.9410</amountMOHLTCPays>
							</drug>
							<drug id="02479680" sec3="Y">
								<name>NRA-Azithromycin</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.9410</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.9410</amountMOHLTCPays>
							</drug>
							<drug id="02480700" sec3="Y">
								<name>AG-Azithromycin</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.9410</individualPrice>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>.9410</amountMOHLTCPays>
							</drug>
							<drug id="02502038" sec3="Y">
								<name>M-Azithromycin</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.9410</individualPrice>
								<listingDate>2021-08-31</listingDate>
								<amountMOHLTCPays>.9410</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
					<pcgGroup lccId="00313">
						<pcg9 id="081212028">
							<itemNumber>0026</itemNumber>
							<strength>600mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02231143" notABenefit="Y" sec3="Y">
								<name>Zithromax</name>
								<manufacturerId>PFI</manufacturerId>
								<listingDate>1998-12-31</listingDate>
							</drug>
							<drug id="02261642" sec3="Y" sec12="Y">
								<name>PMS-Azithromycin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>10.6652</individualPrice>
								<listingDate>2011-10-25</listingDate>
								<amountMOHLTCPays>10.6652</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="549">For the prevention of disseminated Mycobacterium avium complex (MAC) disease in persons with advanced HIV infections.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00039">
					<name>CLARITHROMYCIN</name>
					<pcgGroup>
						<pcg9 id="081212032">
							<itemNumber>0027</itemNumber>
							<strength>500mg</strength>
							<dosageForm>ER Tab</dosageForm>
							<dailyCost>2.5144</dailyCost>
							<drug id="02244756" sec3="Y">
								<name>Biaxin XL</name>
								<manufacturerId>BGP</manufacturerId>
								<individualPrice>2.5672</individualPrice>
								<dailyCost>5.1344</dailyCost>
								<listingDate>2003-01-30</listingDate>
								<amountMOHLTCPays>1.2572</amountMOHLTCPays>
							</drug>
							<drug id="02403196" sec3="Y">
								<name>Act Clarithromycin XL</name>
								<manufacturerId>ACV</manufacturerId>
								<individualPrice>1.2572</individualPrice>
								<dailyCost>2.5144</dailyCost>
								<listingDate>2014-12-18</listingDate>
								<amountMOHLTCPays>1.2572</amountMOHLTCPays>
							</drug>
							<drug id="02413345" sec3="Y">
								<name>Apo-Clarithromycin XL</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.2572</individualPrice>
								<dailyCost>2.5144</dailyCost>
								<listingDate>2014-10-29</listingDate>
								<amountMOHLTCPays>1.2572</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081212030">
							<itemNumber>0028</itemNumber>
							<strength>125mg/5mL</strength>
							<dosageForm>Ped Gran</dosageForm>
							<dailyCost>2.0470</dailyCost>
							<drug id="02146908" sec3="Y">
								<name>Biaxin</name>
								<manufacturerId>BGP</manufacturerId>
								<individualPrice>.3029</individualPrice>
								<dailyCost>3.0290</dailyCost>
								<listingDate>1997-08-28</listingDate>
								<amountMOHLTCPays>.2047</amountMOHLTCPays>
							</drug>
							<drug id="02390442" sec3="Y">
								<name>Taro-Clarithromycin</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>.2047</individualPrice>
								<dailyCost>2.0470</dailyCost>
								<listingDate>2013-01-29</listingDate>
								<amountMOHLTCPays>.2047</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081212031">
							<itemNumber>0029</itemNumber>
							<strength>250mg/5mL</strength>
							<dosageForm>Susp</dosageForm>
							<dailyCost>3.9980</dailyCost>
							<drug id="02244641" sec3="Y">
								<name>Biaxin</name>
								<manufacturerId>BGP</manufacturerId>
								<individualPrice>.5944</individualPrice>
								<dailyCost>5.9440</dailyCost>
								<listingDate>2003-01-30</listingDate>
								<amountMOHLTCPays>.3998</amountMOHLTCPays>
							</drug>
							<drug id="02390450" sec3="Y">
								<name>Taro-Clarithromycin</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>.3998</individualPrice>
								<dailyCost>3.9980</dailyCost>
								<listingDate>2013-01-29</listingDate>
								<amountMOHLTCPays>.3998</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081212020">
							<itemNumber>0030</itemNumber>
							<strength>250mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.8244</dailyCost>
							<drug id="01984853" sec3="Y">
								<name>Biaxin BID</name>
								<manufacturerId>BGP</manufacturerId>
								<individualPrice>1.6833</individualPrice>
								<dailyCost>3.3666</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.4122</amountMOHLTCPays>
							</drug>
							<drug id="02247573" sec3="Y">
								<name>PMS-Clarithromycin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.4122</individualPrice>
								<dailyCost>.8244</dailyCost>
								<listingDate>2007-10-03</listingDate>
								<amountMOHLTCPays>.4122</amountMOHLTCPays>
							</drug>
							<drug id="02248804" sec3="Y">
								<name>Teva-Clarithromycin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.4122</individualPrice>
								<dailyCost>.8244</dailyCost>
								<listingDate>2012-12-21</listingDate>
								<amountMOHLTCPays>.4122</amountMOHLTCPays>
							</drug>
							<drug id="02266539" sec3="Y">
								<name>Sandoz Clarithromycin</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.4122</individualPrice>
								<dailyCost>.8244</dailyCost>
								<listingDate>2008-08-28</listingDate>
								<amountMOHLTCPays>.4122</amountMOHLTCPays>
							</drug>
							<drug id="02274744" sec3="Y">
								<name>Apo-Clarithromycin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.4122</individualPrice>
								<dailyCost>.8244</dailyCost>
								<listingDate>2007-09-04</listingDate>
								<amountMOHLTCPays>.4122</amountMOHLTCPays>
							</drug>
							<drug id="02361426" sec3="Y">
								<name>Ran-Clarithromycin</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.4122</individualPrice>
								<dailyCost>.8244</dailyCost>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.4122</amountMOHLTCPays>
							</drug>
							<drug id="02442469" sec3="Y">
								<name>Clarithromycin</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.4122</individualPrice>
								<dailyCost>.8244</dailyCost>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.4122</amountMOHLTCPays>
							</drug>
							<drug id="02466120" sec3="Y">
								<name>Clarithromycin</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.4122</individualPrice>
								<dailyCost>.8244</dailyCost>
								<listingDate>2020-04-30</listingDate>
								<amountMOHLTCPays>.4122</amountMOHLTCPays>
							</drug>
							<drug id="02471388" sec3="Y">
								<name>M-Clarithromycin</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.4122</individualPrice>
								<dailyCost>.8244</dailyCost>
								<listingDate>2021-10-29</listingDate>
								<amountMOHLTCPays>.4122</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081212024">
							<itemNumber>0031</itemNumber>
							<strength>500mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02126710" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Biaxin BID</name>
								<manufacturerId>BGP</manufacturerId>
								<listingDate>2007-10-03</listingDate>
							</drug>
							<drug id="02247574" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>PMS-Clarithromycin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>2.2009</individualPrice>
								<listingDate>2007-10-03</listingDate>
							</drug>
							<drug id="02248805" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Teva-Clarithromycin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>2.2009</individualPrice>
								<listingDate>2013-01-29</listingDate>
							</drug>
							<drug id="02266547" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Sandoz Clarithromycin</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>2.2009</individualPrice>
								<listingDate>2008-08-28</listingDate>
							</drug>
							<drug id="02274752" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Clarithromycin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>2.2009</individualPrice>
								<listingDate>2007-10-03</listingDate>
							</drug>
							<drug id="02346532" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Riva-Clarithromycin</name>
								<manufacturerId>RIA</manufacturerId>
								<individualPrice>2.2009</individualPrice>
								<listingDate>2021-08-31</listingDate>
							</drug>
							<drug id="02361434" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Ran-Clarithromycin</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>2.2009</individualPrice>
								<listingDate>2011-08-04</listingDate>
							</drug>
							<drug id="02442485" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Clarithromycin</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>2.2009</individualPrice>
								<listingDate>2020-06-30</listingDate>
							</drug>
							<drug id="02466139" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Clarithromycin</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>2.2009</individualPrice>
								<listingDate>2021-05-31</listingDate>
							</drug>
							<drug id="02471396" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>M-Clarithromycin</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>2.2009</individualPrice>
								<listingDate>2021-10-29</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00033">
					<name>ERYTHROMYCIN BASE</name>
					<pcgGroup>
						<pcg9 id="081212001">
							<itemNumber>0032</itemNumber>
							<strength>250mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.7460</dailyCost>
							<drug id="00244635" notABenefit="Y" sec3="Y">
								<name>Erythromid</name>
								<manufacturerId>ABB</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00682020" sec3="Y">
								<name>Erythro-Base</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.1865</individualPrice>
								<dailyCost>.7460</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1865</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00036">
					<name>ERYTHROMYCIN ESTOLATE</name>
					<pcgGroup>
						<pcg9 id="081212007">
							<itemNumber>0033</itemNumber>
							<strength>50mg/mL</strength>
							<dosageForm>O/L</dosageForm>
							<dailyCost>1.4260</dailyCost>
							<drug id="00210641" notABenefit="Y" sec3="Y">
								<name>Ilosone</name>
								<manufacturerId>LIL</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00262595" sec3="Y">
								<name>Novo-Rythro Estolate</name>
								<manufacturerId>NOP</manufacturerId>
								<individualPrice>.0713</individualPrice>
								<dailyCost>1.4260</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0713</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00034">
					<name>ERYTHROMYCIN ETHYLSUCCINATE</name>
					<pcgGroup>
						<pcg9 id="081212002">
							<itemNumber>0034</itemNumber>
							<strength>40mg/mL</strength>
							<dosageForm>O/L</dosageForm>
							<dailyCost>1.0035</dailyCost>
							<drug id="00000299" notABenefit="Y" sec3="Y">
								<name>EES-200</name>
								<manufacturerId>ABB</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00605859" sec3="Y">
								<name>Novo-Rythro Ethyl Succinate</name>
								<manufacturerId>NOP</manufacturerId>
								<individualPrice>.0669</individualPrice>
								<dailyCost>1.0035</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0669</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081212009">
							<itemNumber>0035</itemNumber>
							<strength>80mg/mL</strength>
							<dosageForm>O/L</dosageForm>
							<dailyCost>1.5195</dailyCost>
							<drug id="00453617" notABenefit="Y" sec3="Y">
								<name>EES-400</name>
								<manufacturerId>ABB</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00652318" sec3="Y">
								<name>Novo-Rythro Ethyl Succinate</name>
								<manufacturerId>NOP</manufacturerId>
								<individualPrice>.1013</individualPrice>
								<dailyCost>1.5195</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1013</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="081216000">
				<name>ANTIBIOTICS PENICILLINS</name>
				<genericName id="00050">
					<name>AMOXICILLIN</name>
					<note>The activity of amoxicillin is essentially identical to ampicillin. However, amoxicillin is more completely absorbed and causes diarrhea less frequently than ampicillin. The only situation where amoxicillin should not be used to replace oral ampicillin is Shigellosis.</note>
					<pcgGroup>
						<pcg9 id="081216036">
							<itemNumber>0036</itemNumber>
							<strength>250mg</strength>
							<dosageForm>Cap</dosageForm>
							<dailyCost>.2016</dailyCost>
							<drug id="00406724" sec3="Y">
								<name>Novamoxin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.0672</individualPrice>
								<dailyCost>.2016</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0672</amountMOHLTCPays>
							</drug>
							<drug id="00628115" sec3="Y">
								<name>Apo-Amoxi</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0672</individualPrice>
								<dailyCost>.2016</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0672</amountMOHLTCPays>
							</drug>
							<drug id="02041294" notABenefit="Y" sec3="Y">
								<name>Amoxil</name>
								<manufacturerId>WAY</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02352710" sec3="Y">
								<name>Amoxicillin</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.0672</individualPrice>
								<dailyCost>.2016</dailyCost>
								<listingDate>2020-08-28</listingDate>
								<amountMOHLTCPays>.0672</amountMOHLTCPays>
							</drug>
							<drug id="02388073" sec3="Y">
								<name>Auro-Amoxicillin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.0672</individualPrice>
								<dailyCost>.2016</dailyCost>
								<listingDate>2012-12-21</listingDate>
								<amountMOHLTCPays>.0672</amountMOHLTCPays>
							</drug>
							<drug id="02433060" sec3="Y">
								<name>Jamp-Amoxicillin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.0672</individualPrice>
								<dailyCost>.2016</dailyCost>
								<listingDate>2019-03-28</listingDate>
								<amountMOHLTCPays>.0672</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081216039">
							<itemNumber>0037</itemNumber>
							<strength>500mg</strength>
							<dosageForm>Cap</dosageForm>
							<dailyCost>.3924</dailyCost>
							<drug id="00406716" sec3="Y">
								<name>Novamoxin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1308</individualPrice>
								<dailyCost>.3924</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1308</amountMOHLTCPays>
							</drug>
							<drug id="00628123" sec3="Y">
								<name>Apo-Amoxi</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1308</individualPrice>
								<dailyCost>.3924</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1308</amountMOHLTCPays>
							</drug>
							<drug id="02041308" notABenefit="Y" sec3="Y">
								<name>Amoxil</name>
								<manufacturerId>WAY</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02230244" sec3="Y">
								<name>PMS-Amoxicillin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3417</individualPrice>
								<dailyCost>1.0251</dailyCost>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.1308</amountMOHLTCPays>
							</drug>
							<drug id="02352729" sec3="Y">
								<name>Amoxicillin</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.1308</individualPrice>
								<dailyCost>.3924</dailyCost>
								<listingDate>2020-08-28</listingDate>
								<amountMOHLTCPays>.1308</amountMOHLTCPays>
							</drug>
							<drug id="02388081" sec3="Y">
								<name>Auro-Amoxicillin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.1308</individualPrice>
								<dailyCost>.3924</dailyCost>
								<listingDate>2012-12-21</listingDate>
								<amountMOHLTCPays>.1308</amountMOHLTCPays>
							</drug>
							<drug id="02401509" sec3="Y">
								<name>Amoxicillin</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.1308</individualPrice>
								<dailyCost>.3924</dailyCost>
								<listingDate>2020-12-18</listingDate>
								<amountMOHLTCPays>.1308</amountMOHLTCPays>
							</drug>
							<drug id="02433079" sec3="Y">
								<name>Jamp-Amoxicillin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1308</individualPrice>
								<dailyCost>.3924</dailyCost>
								<listingDate>2019-03-28</listingDate>
								<amountMOHLTCPays>.1308</amountMOHLTCPays>
							</drug>
							<drug id="02477726" sec3="Y">
								<name>AG-Amoxicillin</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.1308</individualPrice>
								<dailyCost>.3924</dailyCost>
								<listingDate>2020-12-18</listingDate>
								<amountMOHLTCPays>.1308</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081216090">
							<itemNumber>0038</itemNumber>
							<strength>125mg</strength>
							<dosageForm>Chew Tab</dosageForm>
							<drug id="02036347" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Novamoxin Chewable</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.5099</individualPrice>
								<listingDate>2008-11-04</listingDate>
							</drug>
							<drug id="02041685" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Amoxil Chewable</name>
								<manufacturerId>AYE</manufacturerId>
								<listingDate>2008-11-04</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="081216091">
							<itemNumber>0039</itemNumber>
							<strength>250mg</strength>
							<dosageForm>Chew Tab</dosageForm>
							<drug id="02036355" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Novamoxin Chewable</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.7512</individualPrice>
								<listingDate>2008-11-04</listingDate>
							</drug>
							<drug id="02041286" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Amoxil Chewable</name>
								<manufacturerId>AYE</manufacturerId>
								<listingDate>2008-11-04</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="081216038">
							<itemNumber>0040</itemNumber>
							<strength>25mg/mL</strength>
							<dosageForm>O/L</dosageForm>
							<dailyCost>.5295</dailyCost>
							<drug id="00452149" dinStatus="E" sec3="Y">
								<name>Novamoxin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.0353</individualPrice>
								<dailyCost>.5295</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0353</amountMOHLTCPays>
							</drug>
							<drug id="00628131" sec3="Y">
								<name>Apo-Amoxi</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0353</individualPrice>
								<dailyCost>.5295</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0353</amountMOHLTCPays>
							</drug>
							<drug id="01934171" dinStatus="E" sec3="Y">
								<name>Novamoxin (Sugar Reduced)</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.0353</individualPrice>
								<dailyCost>.5295</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0353</amountMOHLTCPays>
							</drug>
							<drug id="02041316" notABenefit="Y" sec3="Y">
								<name>Amoxil</name>
								<manufacturerId>WAY</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="081216037">
							<itemNumber>0041</itemNumber>
							<strength>50mg/mL</strength>
							<dosageForm>O/L</dosageForm>
							<dailyCost>.8100</dailyCost>
							<drug id="00452130" sec3="Y">
								<name>Novamoxin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.0540</individualPrice>
								<dailyCost>.8100</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0540</amountMOHLTCPays>
							</drug>
							<drug id="00628158" sec3="Y">
								<name>Apo-Amoxi</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0540</individualPrice>
								<dailyCost>.8100</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0540</amountMOHLTCPays>
							</drug>
							<drug id="01934163" sec3="Y">
								<name>Novamoxin (Sugar Reduced)</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.0540</individualPrice>
								<dailyCost>.8100</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0540</amountMOHLTCPays>
							</drug>
							<drug id="02042592" notABenefit="Y" sec3="Y">
								<name>Amoxil</name>
								<manufacturerId>WAY</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02352753" sec3="Y">
								<name>Amoxicillin</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.0540</individualPrice>
								<dailyCost>.8100</dailyCost>
								<listingDate>2020-08-28</listingDate>
								<amountMOHLTCPays>.0540</amountMOHLTCPays>
							</drug>
							<drug id="02352788" sec3="Y">
								<name>Amoxicillin (Sugar Reduced)</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.0540</individualPrice>
								<dailyCost>.8100</dailyCost>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>.0540</amountMOHLTCPays>
							</drug>
							<drug id="02401541" sec3="Y">
								<name>Amoxicillin</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.0540</individualPrice>
								<dailyCost>.8100</dailyCost>
								<listingDate>2020-08-28</listingDate>
								<amountMOHLTCPays>.0540</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00054">
					<name>AMOXICILLIN &amp; CLAVULANIC ACID</name>
					<note>Amoxicillin/clavulanic acid is not recommended as first line treatment for acute otitis media and sinusitis. Antibiotic resistance (H. influenzae, M. catarrhalis) due to B-lactamase production has caused only a minority of treatment failures with amoxicillin. Amoxicillin/clavulanic acid is first line treatment for infected bites of cat, dog or human.</note>
					<pcgGroup>
						<pcg9 id="081216054">
							<itemNumber>0042</itemNumber>
							<strength>25mg &amp; 6.25mg/mL</strength>
							<dosageForm>O/L</dosageForm>
							<dailyCost>1.4970</dailyCost>
							<drug id="01916882" sec3="Y">
								<name>Clavulin</name>
								<manufacturerId>GSK</manufacturerId>
								<individualPrice>.0998</individualPrice>
								<dailyCost>1.4970</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0998</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081216053">
							<itemNumber>0043</itemNumber>
							<strength>50mg &amp; 12.5mg/mL</strength>
							<dosageForm>O/L</dosageForm>
							<dailyCost>3.2595</dailyCost>
							<drug id="01916874" sec3="Y">
								<name>Clavulin</name>
								<manufacturerId>GSK</manufacturerId>
								<individualPrice>.2173</individualPrice>
								<dailyCost>3.2595</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2173</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081216081">
							<itemNumber>0044</itemNumber>
							<strength>200mg &amp; 28.5mg/5mL</strength>
							<dosageForm>Susp</dosageForm>
							<drug id="02238831" sec3="Y">
								<name>Clavulin (BID)</name>
								<manufacturerId>GSK</manufacturerId>
								<individualPrice>.1559</individualPrice>
								<listingDate>2000-01-17</listingDate>
								<amountMOHLTCPays>.1559</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081216082">
							<itemNumber>0045</itemNumber>
							<strength>400mg &amp; 57mg/5mL</strength>
							<dosageForm>Susp</dosageForm>
							<drug id="02238830" sec3="Y">
								<name>Clavulin (BID)</name>
								<manufacturerId>GSK</manufacturerId>
								<individualPrice>.3039</individualPrice>
								<listingDate>2000-01-17</listingDate>
								<amountMOHLTCPays>.3039</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081216052">
							<itemNumber>0046</itemNumber>
							<strength>250mg &amp; 125mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>1.4802</dailyCost>
							<drug id="01916866" notABenefit="Y" sec3="Y">
								<name>Clavulin</name>
								<manufacturerId>GSK</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02243350" sec3="Y">
								<name>Apo-Amoxi Clav</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.4934</individualPrice>
								<dailyCost>1.4802</dailyCost>
								<listingDate>2001-10-11</listingDate>
								<amountMOHLTCPays>.4934</amountMOHLTCPays>
							</drug>
							<drug id="02508249" sec3="Y">
								<name>Jamp Amoxi Clav</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.4934</individualPrice>
								<dailyCost>1.4802</dailyCost>
								<listingDate>2022-02-28</listingDate>
								<amountMOHLTCPays>.4934</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081216051">
							<itemNumber>0047</itemNumber>
							<strength>500mg &amp; 125mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>1.1334</dailyCost>
							<drug id="01916858" sec3="Y">
								<name>Clavulin</name>
								<manufacturerId>GSK</manufacturerId>
								<individualPrice>1.6060</individualPrice>
								<dailyCost>4.8180</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3778</amountMOHLTCPays>
							</drug>
							<drug id="02243351" sec3="Y">
								<name>Apo-Amoxi Clav</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3778</individualPrice>
								<dailyCost>1.1334</dailyCost>
								<listingDate>2001-10-11</listingDate>
								<amountMOHLTCPays>.3778</amountMOHLTCPays>
							</drug>
							<drug id="02482576" sec3="Y">
								<name>Sandoz Amoxi-Clav Tablets</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.3778</individualPrice>
								<dailyCost>1.1334</dailyCost>
								<listingDate>2019-04-30</listingDate>
								<amountMOHLTCPays>.3778</amountMOHLTCPays>
							</drug>
							<drug id="02508257" sec3="Y">
								<name>Jamp Amoxi Clav</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.3778</individualPrice>
								<dailyCost>1.1334</dailyCost>
								<listingDate>2022-02-28</listingDate>
								<amountMOHLTCPays>.3778</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081216080">
							<itemNumber>0048</itemNumber>
							<strength>875mg &amp; 125mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02238829" sec3="Y">
								<name>Clavulin (BID)</name>
								<manufacturerId>GSK</manufacturerId>
								<individualPrice>2.3415</individualPrice>
								<listingDate>2000-01-17</listingDate>
								<amountMOHLTCPays>.5551</amountMOHLTCPays>
							</drug>
							<drug id="02245623" sec3="Y">
								<name>Apo-Amoxi Clav</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.5551</individualPrice>
								<listingDate>2003-09-04</listingDate>
								<amountMOHLTCPays>.5551</amountMOHLTCPays>
							</drug>
							<drug id="02482584" sec3="Y">
								<name>Sandoz Amoxi-Clav Tablets</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.5551</individualPrice>
								<listingDate>2019-04-30</listingDate>
								<amountMOHLTCPays>.5551</amountMOHLTCPays>
							</drug>
							<drug id="02508265" sec3="Y">
								<name>Jamp Amoxi Clav</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.5551</individualPrice>
								<listingDate>2022-02-28</listingDate>
								<amountMOHLTCPays>.5551</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00042">
					<name>AMPICILLIN</name>
					<note>Use with caution in urinary tract infections as even E. coli is resistant in approximately 20% of cases.</note>
					<pcgGroup>
						<pcg9 id="081216002">
							<itemNumber>0049</itemNumber>
							<strength>250mg</strength>
							<dosageForm>Cap</dosageForm>
							<dailyCost>1.6892</dailyCost>
							<drug id="00002003" notABenefit="Y" sec3="Y">
								<name>Penbritin</name>
								<manufacturerId>AYE</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00020877" sec3="Y">
								<name>Novo-Ampicillin</name>
								<manufacturerId>NOP</manufacturerId>
								<individualPrice>.4223</individualPrice>
								<dailyCost>1.6892</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.4223</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081216001">
							<itemNumber>0050</itemNumber>
							<strength>500mg</strength>
							<dosageForm>Cap</dosageForm>
							<dailyCost>3.2024</dailyCost>
							<drug id="00002011" notABenefit="Y" sec3="Y">
								<name>Penbritin</name>
								<manufacturerId>AYE</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00020885" sec3="Y">
								<name>Novo-Ampicillin</name>
								<manufacturerId>NOP</manufacturerId>
								<individualPrice>.8006</individualPrice>
								<dailyCost>3.2024</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.8006</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00043">
					<name>CLOXACILLIN</name>
					<pcgGroup>
						<pcg9 id="081216008">
							<itemNumber>0051</itemNumber>
							<strength>250mg</strength>
							<dosageForm>Cap</dosageForm>
							<dailyCost>.9516</dailyCost>
							<drug id="00002046" notABenefit="Y" sec3="Y">
								<name>Orbenin</name>
								<manufacturerId>AYE</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00337765" sec3="Y">
								<name>Teva-Cloxacillin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2379</individualPrice>
								<dailyCost>.9516</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2379</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081216007">
							<itemNumber>0052</itemNumber>
							<strength>500mg</strength>
							<dosageForm>Cap</dosageForm>
							<dailyCost>1.7976</dailyCost>
							<drug id="00002054" notABenefit="Y" sec3="Y">
								<name>Orbenin</name>
								<manufacturerId>AYE</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00337773" sec3="Y">
								<name>Teva-Cloxacillin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.4494</individualPrice>
								<dailyCost>1.7976</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.4494</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081216009">
							<itemNumber>0053</itemNumber>
							<strength>25mg/mL</strength>
							<dosageForm>O/L</dosageForm>
							<dailyCost>2.4240</dailyCost>
							<drug id="00337757" sec3="Y">
								<name>Teva-Cloxacillin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.0606</individualPrice>
								<dailyCost>2.4240</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0606</amountMOHLTCPays>
							</drug>
							<drug id="02042975" notABenefit="Y" sec3="Y">
								<name>Orbenin</name>
								<manufacturerId>WAY</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00049">
					<name>PENICILLIN V (POTASSIUM)</name>
					<pcgGroup>
						<pcg9 id="081216035">
							<itemNumber>0054</itemNumber>
							<strength>25mg/mL</strength>
							<dosageForm>O/L</dosageForm>
							<dailyCost>1.0700</dailyCost>
							<drug id="00018635" notABenefit="Y" sec3="Y">
								<name>Nadopen-V</name>
								<manufacturerId>NDA</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00642223" sec3="Y">
								<name>Apo-Pen V-K</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0535</individualPrice>
								<dailyCost>1.0700</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0535</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081216034">
							<itemNumber>0055</itemNumber>
							<strength>300mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.7492</dailyCost>
							<drug id="00248843" notABenefit="Y" sec3="Y">
								<name>PVF-K 500</name>
								<manufacturerId>FRS</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00642215" sec3="Y">
								<name>PEN V-K</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.1873</individualPrice>
								<dailyCost>.7492</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1873</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01429">
					<name>PIPERACILLIN SODIUM &amp; TAZOBACTAM SODIUM</name>
					<pcgGroup>
						<pcg9 id="081216101">
							<itemNumber>0056</itemNumber>
							<strength>2g &amp; 250mg</strength>
							<dosageForm>Inj Pd-2.25g Vial Pk</dosageForm>
							<drug id="02170817" sec3b="Y" sec3="Y">
								<name>Tazocin</name>
								<manufacturerId>PFI</manufacturerId>
								<listingDate>2008-12-03</listingDate>
							</drug>
							<drug id="02308444" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Piperacillin &amp; Tazobactam for Injection</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>10.1300</individualPrice>
								<listingDate>2008-12-03</listingDate>
								<amountMOHLTCPays>10.1300</amountMOHLTCPays>
							</drug>
							<drug id="02362619" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Piperacillin &amp; Tazobactam for Injection</name>
								<manufacturerId>STE</manufacturerId>
								<individualPrice>10.1300</individualPrice>
								<listingDate>2016-06-29</listingDate>
								<amountMOHLTCPays>10.1300</amountMOHLTCPays>
							</drug>
							<drug id="02401312" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Piperacillin and Tazobactam for Inj</name>
								<manufacturerId>TEL</manufacturerId>
								<individualPrice>10.1300</individualPrice>
								<listingDate>2018-11-29</listingDate>
								<amountMOHLTCPays>10.1300</amountMOHLTCPays>
							</drug>
							<drug id="02402068" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Piperacillin &amp; Tazobactam For Injection</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>10.1300</individualPrice>
								<listingDate>2021-08-31</listingDate>
								<amountMOHLTCPays>10.1300</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081216097">
							<itemNumber>0057</itemNumber>
							<strength>3g &amp; 375mg</strength>
							<dosageForm>Inj Pd-3.375g Vial Pk</dosageForm>
							<drug id="02170795" sec3b="Y" sec3="Y">
								<name>Tazocin</name>
								<manufacturerId>WYE</manufacturerId>
								<listingDate>2008-12-03</listingDate>
							</drug>
							<drug id="02308452" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Piperacillin &amp; Tazobactam for Injection</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>15.2000</individualPrice>
								<listingDate>2008-12-03</listingDate>
								<amountMOHLTCPays>15.2000</amountMOHLTCPays>
							</drug>
							<drug id="02362627" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Piperacillin &amp; Tazobactam for Injection</name>
								<manufacturerId>STE</manufacturerId>
								<individualPrice>15.2000</individualPrice>
								<listingDate>2016-06-29</listingDate>
								<amountMOHLTCPays>15.2000</amountMOHLTCPays>
							</drug>
							<drug id="02370166" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Piperacillin/Tazobactam powder for Inj.</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>15.2000</individualPrice>
								<listingDate>2012-07-27</listingDate>
								<amountMOHLTCPays>15.2000</amountMOHLTCPays>
							</drug>
							<drug id="02391538" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Piperacillin &amp; Tazobactam for Injection</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>15.2000</individualPrice>
								<listingDate>2012-12-21</listingDate>
								<amountMOHLTCPays>15.2000</amountMOHLTCPays>
							</drug>
							<drug id="02401320" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Piperacillin and Tazobactam for Inj</name>
								<manufacturerId>TEL</manufacturerId>
								<individualPrice>15.2000</individualPrice>
								<listingDate>2018-11-29</listingDate>
								<amountMOHLTCPays>15.2000</amountMOHLTCPays>
							</drug>
							<drug id="02402076" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Piperacillin &amp; Tazobactam For Injection</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>15.2000</individualPrice>
								<listingDate>2021-08-31</listingDate>
								<amountMOHLTCPays>15.2000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081216102">
							<itemNumber>0058</itemNumber>
							<strength>4g &amp; 500mg</strength>
							<dosageForm>Inj Pd-4.5g Vial Pk</dosageForm>
							<drug id="02170809" sec3b="Y" sec3="Y">
								<name>Tazocin</name>
								<manufacturerId>WYE</manufacturerId>
								<listingDate>2008-12-03</listingDate>
							</drug>
							<drug id="02308460" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Piperacillin &amp; Tazobactam for Injection</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>20.2700</individualPrice>
								<listingDate>2008-12-03</listingDate>
								<amountMOHLTCPays>20.2700</amountMOHLTCPays>
							</drug>
							<drug id="02362635" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Piperacillin &amp; Tazobactam for Injection</name>
								<manufacturerId>STE</manufacturerId>
								<individualPrice>20.2700</individualPrice>
								<listingDate>2016-06-29</listingDate>
								<amountMOHLTCPays>20.2700</amountMOHLTCPays>
							</drug>
							<drug id="02370174" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Piperacillin/Tazobactam powder for Inj.</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>20.2700</individualPrice>
								<listingDate>2012-07-27</listingDate>
								<amountMOHLTCPays>20.2700</amountMOHLTCPays>
							</drug>
							<drug id="02401339" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Piperacillin and Tazobactam for Inj</name>
								<manufacturerId>TEL</manufacturerId>
								<individualPrice>20.2700</individualPrice>
								<listingDate>2018-11-29</listingDate>
								<amountMOHLTCPays>20.2700</amountMOHLTCPays>
							</drug>
							<drug id="02402084" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Piperacillin &amp; Tazobactam For Injection</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>20.2700</individualPrice>
								<listingDate>2021-08-31</listingDate>
								<amountMOHLTCPays>20.2700</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="081224000">
				<name>ANTIBIOTICS TETRACYCLINES</name>
				<genericName id="01347">
					<name>DOXYCYCLINE</name>
					<pcgGroup>
						<pcg9 id="081224027">
							<itemNumber>0059</itemNumber>
							<strength>40mg</strength>
							<dosageForm>MR Cap</dosageForm>
							<drug id="02375885" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apprilon</name>
								<manufacturerId>GAC</manufacturerId>
								<listingDate>2021-07-30</listingDate>
							</drug>
							<drug id="02512645" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Doxycycline MR</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>2.4277</individualPrice>
								<listingDate>2021-07-30</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00062">
					<name>DOXYCYCLINE HYCLATE</name>
					<pcgGroup>
						<pcg9 id="081224015">
							<itemNumber>0060</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00578452" notABenefit="Y" sec3="Y">
								<name>Vibra-Tabs</name>
								<manufacturerId>PFI</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00874256" sec3="Y">
								<name>Apo-Doxy-Tabs</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.5860</individualPrice>
								<listingDate>2009-05-20</listingDate>
								<amountMOHLTCPays>.5860</amountMOHLTCPays>
							</drug>
							<drug id="02158574" sec3="Y">
								<name>Teva-Doxycycline</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.5860</individualPrice>
								<listingDate>2010-12-14</listingDate>
								<amountMOHLTCPays>.5860</amountMOHLTCPays>
							</drug>
							<drug id="02351242" sec3="Y">
								<name>Doxycycline Tablets</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.5860</individualPrice>
								<listingDate>2011-09-15</listingDate>
								<amountMOHLTCPays>.5860</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00063">
					<name>MINOCYCLINE HCL</name>
					<pcgGroup>
						<pcg9 id="081224021">
							<itemNumber>0061</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02084090" sec3="Y">
								<name>Minocycline</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.1101</individualPrice>
								<listingDate>2008-01-15</listingDate>
								<amountMOHLTCPays>.1101</amountMOHLTCPays>
							</drug>
							<drug id="02108143" sec3="Y">
								<name>Teva-Minocycline</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1101</individualPrice>
								<listingDate>2008-11-04</listingDate>
								<amountMOHLTCPays>.1101</amountMOHLTCPays>
							</drug>
							<drug id="02173514" notABenefit="Y" sec3="Y">
								<name>Minocin</name>
								<manufacturerId>STI</manufacturerId>
								<listingDate>2008-01-15</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="081224022">
							<itemNumber>0062</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02084104" sec3="Y">
								<name>Minocycline</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.2125</individualPrice>
								<listingDate>2008-01-15</listingDate>
								<amountMOHLTCPays>.2125</amountMOHLTCPays>
							</drug>
							<drug id="02108151" sec3="Y">
								<name>Teva-Minocycline</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2125</individualPrice>
								<listingDate>2008-11-04</listingDate>
								<amountMOHLTCPays>.2125</amountMOHLTCPays>
							</drug>
							<drug id="02173506" notABenefit="Y" sec3="Y">
								<name>Minocin</name>
								<manufacturerId>STI</manufacturerId>
								<listingDate>2008-01-15</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00060">
					<name>TETRACYCLINE</name>
					<note>Tetracycline use during tooth development (last half of pregnancy and up to age 8) may cause permanent tooth discoloration or enamel hypoplasia. These reactions are more common during long-term use. Tetracyclines should not be used in these groups unless other antibiotics are unlikely to be effective or are contraindicated.</note>
					<pcgGroup>
						<pcg9 id="081224002">
							<itemNumber>0063</itemNumber>
							<strength>250mg</strength>
							<dosageForm>Cap</dosageForm>
							<dailyCost>.2680</dailyCost>
							<drug id="00024422" notABenefit="Y" sec3="Y">
								<name>Tetracyn</name>
								<manufacturerId>PFI</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00580929" sec3="Y">
								<name>Tetracycline</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.0670</individualPrice>
								<dailyCost>.2680</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0670</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01697">
					<name>TIGECYCLINE</name>
					<pcgGroup>
						<pcg9 id="081224020">
							<itemNumber>0064</itemNumber>
							<strength>50mg/Vial</strength>
							<dosageForm>Pd for Inj-5mLVial Pk (Preservative-Free)</dosageForm>
							<drug id="02285401" sec3="Y">
								<name>Tygacil</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>83.4740</individualPrice>
								<listingDate>2014-11-27</listingDate>
								<amountMOHLTCPays>83.4740</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="081228000">
				<name>ANTIBIOTICS OTHER ANTIBIOTICS</name>
				<genericName id="00076">
					<name>CEFADROXIL</name>
					<pcgGroup>
						<pcg9 id="081228036">
							<itemNumber>0065</itemNumber>
							<strength>500mg</strength>
							<dosageForm>Cap</dosageForm>
							<dailyCost>1.6842</dailyCost>
							<drug id="00507245" notABenefit="Y" sec3="Y">
								<name>Duricef</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02235134" sec3="Y">
								<name>Teva-Cefadroxil</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.8421</individualPrice>
								<dailyCost>1.6842</dailyCost>
								<listingDate>2000-01-17</listingDate>
								<amountMOHLTCPays>.8421</amountMOHLTCPays>
							</drug>
							<drug id="02240774" sec3="Y">
								<name>Apo-Cefadroxil</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.8421</individualPrice>
								<dailyCost>1.6842</dailyCost>
								<listingDate>2000-04-17</listingDate>
								<amountMOHLTCPays>.8421</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00074">
					<name>CEFAZOLIN SODIUM</name>
					<pcgGroup>
						<pcg9 id="081228112">
							<itemNumber>0066</itemNumber>
							<strength>500mg/Vial</strength>
							<dosageForm>Inj Pd-Vial Pk</dosageForm>
							<drug id="02108119" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Cefazolin for Injection</name>
								<manufacturerId>TEV</manufacturerId>
								<listingDate>2022-01-31</listingDate>
							</drug>
							<drug id="02437104" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Cefazolin for Injection</name>
								<manufacturerId>STE</manufacturerId>
								<individualPrice>4.0000</individualPrice>
								<listingDate>2022-01-31</listingDate>
								<amountMOHLTCPays>4.0000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081228103">
							<itemNumber>0067</itemNumber>
							<strength>1g/Vial</strength>
							<dosageForm>Inj Pd-Vial Pk</dosageForm>
							<drug id="02108127" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Cefazolin for Injection</name>
								<manufacturerId>TEV</manufacturerId>
								<listingDate>2010-06-14</listingDate>
							</drug>
							<drug id="02297205" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Cefazolin for Injection</name>
								<manufacturerId>ORC</manufacturerId>
								<individualPrice>6.0000</individualPrice>
								<listingDate>2010-06-14</listingDate>
								<amountMOHLTCPays>6.0000</amountMOHLTCPays>
							</drug>
							<drug id="02437112" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Cefazolin for Injection</name>
								<manufacturerId>STE</manufacturerId>
								<individualPrice>6.0000</individualPrice>
								<listingDate>2022-01-31</listingDate>
								<amountMOHLTCPays>6.0000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081228122">
							<itemNumber>0068</itemNumber>
							<strength>10g/Vial</strength>
							<dosageForm>Inj Pd-Vial Pk</dosageForm>
							<drug id="02108135" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Cefazolin for Injection</name>
								<manufacturerId>TEV</manufacturerId>
								<listingDate>2010-06-14</listingDate>
							</drug>
							<drug id="02297213" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Cefazolin for Injection</name>
								<manufacturerId>ORC</manufacturerId>
								<individualPrice>56.0000</individualPrice>
								<listingDate>2010-06-14</listingDate>
								<amountMOHLTCPays>56.0000</amountMOHLTCPays>
							</drug>
							<drug id="02437120" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Cefazolin for Injection</name>
								<manufacturerId>STE</manufacturerId>
								<individualPrice>56.0000</individualPrice>
								<listingDate>2022-01-31</listingDate>
								<amountMOHLTCPays>56.0000</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00084">
					<name>CEFIXIME</name>
					<pcgGroup>
						<pcg9 id="081228054">
							<itemNumber>0069</itemNumber>
							<strength>20mg/mL</strength>
							<dosageForm>Oral Susp</dosageForm>
							<drug id="00868965" sec3="Y">
								<name>Suprax</name>
								<manufacturerId>ODN</manufacturerId>
								<individualPrice>.3899</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3899</amountMOHLTCPays>
							</drug>
							<drug id="02468689" sec3="Y">
								<name>Auro-Cefixime</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.3899</individualPrice>
								<listingDate>2019-11-29</listingDate>
								<amountMOHLTCPays>.3899</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081228056">
							<itemNumber>0070</itemNumber>
							<strength>400mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>2.7172</dailyCost>
							<drug id="00868981" sec3="Y">
								<name>Suprax</name>
								<manufacturerId>ODN</manufacturerId>
								<individualPrice>2.7172</individualPrice>
								<dailyCost>2.7172</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>2.7172</amountMOHLTCPays>
							</drug>
							<drug id="02432773" sec3="Y">
								<name>Auro-Cefixime</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>2.7172</individualPrice>
								<dailyCost>2.7172</dailyCost>
								<listingDate>2014-12-18</listingDate>
								<amountMOHLTCPays>2.7172</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00095">
					<name>CEFOXITIN SODIUM</name>
					<pcgGroup>
						<pcg9 id="081228119">
							<itemNumber>0071</itemNumber>
							<strength>1g/Vial</strength>
							<dosageForm>Inj Pd-Vial Pk</dosageForm>
							<drug id="00663697" sec3b="Y" sec3="Y">
								<name>Mefoxin</name>
								<manufacturerId>MSD</manufacturerId>
								<listingDate>2008-06-27</listingDate>
							</drug>
							<drug id="02128187" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Cefoxitin for Injection USP</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>10.6000</individualPrice>
								<listingDate>2012-04-24</listingDate>
								<amountMOHLTCPays>10.6000</amountMOHLTCPays>
							</drug>
							<drug id="02291711" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Cefoxitin for Injection</name>
								<manufacturerId>ORC</manufacturerId>
								<individualPrice>10.6000</individualPrice>
								<listingDate>2008-06-27</listingDate>
								<amountMOHLTCPays>10.6000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081228120">
							<itemNumber>0072</itemNumber>
							<strength>2g/Vial</strength>
							<dosageForm>Inj Pd-Vial Pk</dosageForm>
							<drug id="00663700" sec3b="Y" sec3="Y">
								<name>Mefoxin</name>
								<manufacturerId>MSD</manufacturerId>
								<listingDate>2008-06-27</listingDate>
							</drug>
							<drug id="02128195" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Cefoxitin for Injection USP</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>21.2500</individualPrice>
								<listingDate>2012-04-24</listingDate>
								<amountMOHLTCPays>21.2500</amountMOHLTCPays>
							</drug>
							<drug id="02291738" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Cefoxitin for Injection</name>
								<manufacturerId>ORC</manufacturerId>
								<individualPrice>21.2500</individualPrice>
								<listingDate>2008-06-27</listingDate>
								<amountMOHLTCPays>21.2500</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00099">
					<name>CEFPROZIL</name>
					<pcgGroup>
						<pcg9 id="081228123">
							<itemNumber>0073</itemNumber>
							<strength>125mg/5mL</strength>
							<dosageForm>Oral Susp-100mL Pk</dosageForm>
							<drug id="09857356" sec3="Y">
								<name>Ran-Cefprozil</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>16.4900</individualPrice>
								<listingDate>2010-06-14</listingDate>
								<amountMOHLTCPays>16.4900</amountMOHLTCPays>
							</drug>
							<drug id="09857358" notABenefit="Y" sec3="Y">
								<name>Cefzil</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>2010-06-14</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="081228124">
							<itemNumber>0074</itemNumber>
							<strength>250mg/5mL</strength>
							<dosageForm>Oral Susp-100mL Pk</dosageForm>
							<drug id="09857359" notABenefit="Y" sec3="Y">
								<name>Cefzil</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>2010-06-14</listingDate>
							</drug>
							<drug id="09857365" sec3="Y">
								<name>Ran-Cefprozil</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>32.9400</individualPrice>
								<listingDate>2010-06-14</listingDate>
								<amountMOHLTCPays>32.9400</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081228083">
							<itemNumber>0075</itemNumber>
							<strength>125mg/5mL</strength>
							<dosageForm>Oral Susp-75mL Pk</dosageForm>
							<drug id="02163675" notABenefit="Y" sec3="Y">
								<name>Cefzil</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>1996-12-19</listingDate>
							</drug>
							<drug id="02329204" sec3="Y">
								<name>Ran-Cefprozil</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>12.3675</individualPrice>
								<listingDate>2010-06-14</listingDate>
								<amountMOHLTCPays>12.3675</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081228084">
							<itemNumber>0076</itemNumber>
							<strength>250mg/5mL</strength>
							<dosageForm>Oral Susp-75mL Pk</dosageForm>
							<drug id="02163683" notABenefit="Y" sec3="Y">
								<name>Cefzil</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>1996-12-19</listingDate>
							</drug>
							<drug id="02293579" sec3="Y">
								<name>Ran-Cefprozil</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>24.7050</individualPrice>
								<listingDate>2007-09-04</listingDate>
								<amountMOHLTCPays>24.7050</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081228085">
							<itemNumber>0077</itemNumber>
							<strength>250mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02163659" notABenefit="Y" sec3="Y">
								<name>Cefzil</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>1996-12-19</listingDate>
							</drug>
							<drug id="02293528" sec3="Y">
								<name>Ran-Cefprozil</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>1.7374</individualPrice>
								<listingDate>2007-06-06</listingDate>
								<amountMOHLTCPays>1.7374</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081228086">
							<itemNumber>0078</itemNumber>
							<strength>500mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02163667" notABenefit="Y" sec3="Y">
								<name>Cefzil</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>1996-12-19</listingDate>
							</drug>
							<drug id="02293005" sec3="Y">
								<name>Apo-Cefprozil</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.8494</individualPrice>
								<listingDate>2007-06-06</listingDate>
								<amountMOHLTCPays>.8494</amountMOHLTCPays>
							</drug>
							<drug id="02293536" sec3="Y">
								<name>Ran-Cefprozil</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.8494</individualPrice>
								<listingDate>2007-06-06</listingDate>
								<amountMOHLTCPays>.8494</amountMOHLTCPays>
							</drug>
							<drug id="02302187" sec3="Y">
								<name>Sandoz Cefprozil</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.8494</individualPrice>
								<listingDate>2008-03-25</listingDate>
								<amountMOHLTCPays>.8494</amountMOHLTCPays>
							</drug>
							<drug id="02347253" sec3="Y">
								<name>Auro-Cefprozil</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.8494</individualPrice>
								<listingDate>2012-04-24</listingDate>
								<amountMOHLTCPays>.8494</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00078">
					<name>CEFTRIAXONE DISODIUM</name>
					<pcgGroup>
						<pcg9 id="081228043">
							<itemNumber>0079</itemNumber>
							<strength>0.25g/Vial</strength>
							<dosageForm>Inj Pd-1 Vial Pk</dosageForm>
							<drug id="00657387" notABenefit="Y" sec3="Y">
								<name>Rocephin</name>
								<manufacturerId>HLR</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02250276" sec3="Y">
								<name>Ceftriaxone Sodium for Injection, BP</name>
								<manufacturerId>MAY</manufacturerId>
								<individualPrice>3.9501</individualPrice>
								<listingDate>2007-09-04</listingDate>
								<amountMOHLTCPays>3.9501</amountMOHLTCPays>
							</drug>
							<drug id="02292866" sec3="Y">
								<name>Ceftriaxone for Injection USP</name>
								<manufacturerId>ORC</manufacturerId>
								<individualPrice>3.9501</individualPrice>
								<listingDate>2008-08-28</listingDate>
								<amountMOHLTCPays>3.9501</amountMOHLTCPays>
							</drug>
							<drug id="02325594" sec3="Y">
								<name>Ceftriaxone Sodium For Injection BP</name>
								<manufacturerId>STE</manufacturerId>
								<individualPrice>3.9501</individualPrice>
								<listingDate>2016-03-30</listingDate>
								<amountMOHLTCPays>3.9501</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081228045">
							<itemNumber>0080</itemNumber>
							<strength>1g/Vial</strength>
							<dosageForm>Inj Pd-1 Vial Pk</dosageForm>
							<drug id="00657417" notABenefit="Y" sec3="Y">
								<name>Rocephin</name>
								<manufacturerId>HLR</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02250292" sec3="Y">
								<name>Ceftriaxone Sodium for Injection, BP</name>
								<manufacturerId>MAY</manufacturerId>
								<individualPrice>12.4950</individualPrice>
								<listingDate>2007-09-04</listingDate>
								<amountMOHLTCPays>12.4950</amountMOHLTCPays>
							</drug>
							<drug id="02287633" sec3="Y">
								<name>Ceftriaxone Sodium for Injection</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>12.4950</individualPrice>
								<listingDate>2008-03-25</listingDate>
								<amountMOHLTCPays>12.4950</amountMOHLTCPays>
							</drug>
							<drug id="02292270" sec3="Y">
								<name>Ceftriaxone</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>12.4950</individualPrice>
								<listingDate>2007-05-04</listingDate>
								<amountMOHLTCPays>12.4950</amountMOHLTCPays>
							</drug>
							<drug id="02292874" sec3="Y">
								<name>Ceftriaxone for Injection USP</name>
								<manufacturerId>ORC</manufacturerId>
								<individualPrice>12.4950</individualPrice>
								<listingDate>2008-01-15</listingDate>
								<amountMOHLTCPays>12.4950</amountMOHLTCPays>
							</drug>
							<drug id="02325616" sec3="Y">
								<name>Ceftriaxone Sodium For Injection BP</name>
								<manufacturerId>STE</manufacturerId>
								<individualPrice>12.4950</individualPrice>
								<listingDate>2016-03-30</listingDate>
								<amountMOHLTCPays>12.4950</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081228046">
							<itemNumber>0081</itemNumber>
							<strength>2g/Vial</strength>
							<dosageForm>Inj Pd-1 Vial Pk</dosageForm>
							<drug id="00657409" notABenefit="Y" sec3="Y">
								<name>Rocephin</name>
								<manufacturerId>HLR</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02292289" sec3="Y">
								<name>Ceftriaxone</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>24.1395</individualPrice>
								<listingDate>2007-05-04</listingDate>
								<amountMOHLTCPays>24.1395</amountMOHLTCPays>
							</drug>
							<drug id="02292882" sec3="Y">
								<name>Ceftriaxone for Injection USP</name>
								<manufacturerId>ORC</manufacturerId>
								<individualPrice>24.1395</individualPrice>
								<listingDate>2008-01-15</listingDate>
								<amountMOHLTCPays>24.1395</amountMOHLTCPays>
							</drug>
							<drug id="02325624" sec3="Y">
								<name>Ceftriaxone Sodium For Injection BP</name>
								<manufacturerId>STE</manufacturerId>
								<individualPrice>24.1395</individualPrice>
								<listingDate>2016-03-30</listingDate>
								<amountMOHLTCPays>24.1395</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081228121">
							<itemNumber>0082</itemNumber>
							<strength>10g/Vial</strength>
							<dosageForm>Inj Pd-1 Vial Pk</dosageForm>
							<drug id="00851957" sec3b="Y" sec3="Y">
								<name>Rocephin</name>
								<manufacturerId>HLR</manufacturerId>
								<listingDate>2008-08-28</listingDate>
							</drug>
							<drug id="02292904" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Ceftriaxone for Injection USP</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>214.2000</individualPrice>
								<listingDate>2008-08-28</listingDate>
								<amountMOHLTCPays>214.2000</amountMOHLTCPays>
							</drug>
							<drug id="02325632" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Ceftriaxone Sodium For Injection BP</name>
								<manufacturerId>STE</manufacturerId>
								<individualPrice>214.2000</individualPrice>
								<listingDate>2016-03-30</listingDate>
								<amountMOHLTCPays>214.2000</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00088">
					<name>CEFUROXIME AXETIL</name>
					<pcgGroup>
						<pcg9 id="081228079">
							<itemNumber>0083</itemNumber>
							<strength>125mg/5mL</strength>
							<dosageForm>Susp</dosageForm>
							<drug id="02212307" sec3="Y">
								<name>Ceftin</name>
								<manufacturerId>GSK</manufacturerId>
								<individualPrice>.1791</individualPrice>
								<listingDate>1998-10-21</listingDate>
								<amountMOHLTCPays>.1791</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081228064">
							<itemNumber>0084</itemNumber>
							<strength>250mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>1.6776</dailyCost>
							<drug id="02212277" notABenefit="Y" sec3="Y">
								<name>Ceftin</name>
								<manufacturerId>GSK</manufacturerId>
								<listingDate>1998-10-21</listingDate>
							</drug>
							<drug id="02244393" sec3="Y">
								<name>Apo-Cefuroxime</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.8388</individualPrice>
								<dailyCost>1.6776</dailyCost>
								<listingDate>2002-04-04</listingDate>
								<amountMOHLTCPays>.8388</amountMOHLTCPays>
							</drug>
							<drug id="02344823" sec3="Y">
								<name>Auro-Cefuroxime</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.8388</individualPrice>
								<dailyCost>1.6776</dailyCost>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.8388</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081228065">
							<itemNumber>0085</itemNumber>
							<strength>500mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>2.8674</dailyCost>
							<drug id="02212285" notABenefit="Y" sec3="Y">
								<name>Ceftin</name>
								<manufacturerId>GSK</manufacturerId>
								<listingDate>1998-10-21</listingDate>
							</drug>
							<drug id="02244394" sec3="Y">
								<name>Apo-Cefuroxime</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.4337</individualPrice>
								<dailyCost>2.8674</dailyCost>
								<listingDate>2002-04-04</listingDate>
								<amountMOHLTCPays>1.4337</amountMOHLTCPays>
							</drug>
							<drug id="02344831" sec3="Y">
								<name>Auro-Cefuroxime</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>1.4337</individualPrice>
								<dailyCost>2.8674</dailyCost>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>1.4337</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00065">
					<name>CEPHALEXIN MONOHYDRATE</name>
					<pcgGroup>
						<pcg9 id="081228001">
							<itemNumber>0086</itemNumber>
							<strength>250mg</strength>
							<dosageForm>Cap</dosageForm>
							<dailyCost>1.4812</dailyCost>
							<drug id="00253154" notABenefit="Y" sec3="Y">
								<name>Ceporex</name>
								<manufacturerId>GLA</manufacturerId>
								<listingDate>2006-06-15</listingDate>
							</drug>
							<drug id="00342084" sec3="Y">
								<name>Teva-Cephalexin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3703</individualPrice>
								<dailyCost>1.4812</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3703</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081228029">
							<itemNumber>0087</itemNumber>
							<strength>500mg</strength>
							<dosageForm>Cap</dosageForm>
							<dailyCost>2.9008</dailyCost>
							<drug id="00253146" notABenefit="Y" sec3="Y">
								<name>Ceporex</name>
								<manufacturerId>GLA</manufacturerId>
								<listingDate>2006-06-15</listingDate>
							</drug>
							<drug id="00342114" sec3="Y">
								<name>Teva-Cephalexin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.7252</individualPrice>
								<dailyCost>2.9008</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.7252</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081228003">
							<itemNumber>0088</itemNumber>
							<strength>25mg/mL</strength>
							<dosageForm>Pd for Oral Susp</dosageForm>
							<dailyCost>4.3860</dailyCost>
							<drug id="00015547" notABenefit="Y" sec3="Y">
								<name>Keflex</name>
								<manufacturerId>PHE</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00342106" sec3="Y">
								<name>Teva-Cephalexin 125</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2193</individualPrice>
								<dailyCost>4.3860</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2193</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081228002">
							<itemNumber>0089</itemNumber>
							<strength>50mg/mL</strength>
							<dosageForm>Pd for Oral Susp</dosageForm>
							<dailyCost>7.3500</dailyCost>
							<drug id="00035645" notABenefit="Y" sec3="Y">
								<name>Keflex</name>
								<manufacturerId>PHE</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00342092" sec3="Y">
								<name>Teva-Cephalexin 250</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3675</individualPrice>
								<dailyCost>7.3500</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3675</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081228034">
							<itemNumber>0090</itemNumber>
							<strength>250mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.3464</dailyCost>
							<drug id="00403628" notABenefit="Y" sec3="Y">
								<name>Keflex</name>
								<manufacturerId>PHE</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00583413" sec3="Y">
								<name>Teva-Cephalexin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.0866</individualPrice>
								<dailyCost>.3464</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0866</amountMOHLTCPays>
							</drug>
							<drug id="00768723" sec3="Y">
								<name>Apo-Cephalex</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0866</individualPrice>
								<dailyCost>.3464</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0866</amountMOHLTCPays>
							</drug>
							<drug id="02177781" notABenefit="Y" sec3="Y">
								<name>PMS-Cephalexin</name>
								<manufacturerId>PMS</manufacturerId>
								<listingDate>1998-12-31</listingDate>
							</drug>
							<drug id="02470578" sec3="Y">
								<name>Auro-Cephalexin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.0866</individualPrice>
								<dailyCost>.3464</dailyCost>
								<listingDate>2018-10-31</listingDate>
								<amountMOHLTCPays>.0866</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081228028">
							<itemNumber>0091</itemNumber>
							<strength>500mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.6924</dailyCost>
							<drug id="00244392" notABenefit="Y" sec3="Y">
								<name>Keflex</name>
								<manufacturerId>PHE</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00583421" sec3="Y">
								<name>Teva-Cephalexin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1731</individualPrice>
								<dailyCost>.6924</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1731</amountMOHLTCPays>
							</drug>
							<drug id="00768715" sec3="Y">
								<name>Apo-Cephalex</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1731</individualPrice>
								<dailyCost>.6924</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1731</amountMOHLTCPays>
							</drug>
							<drug id="02177803" notABenefit="Y" sec3="Y">
								<name>PMS-Cephalexin</name>
								<manufacturerId>PMS</manufacturerId>
								<listingDate>1998-12-31</listingDate>
							</drug>
							<drug id="02470586" sec3="Y">
								<name>Auro-Cephalexin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.1731</individualPrice>
								<dailyCost>.6924</dailyCost>
								<listingDate>2018-10-31</listingDate>
								<amountMOHLTCPays>.1731</amountMOHLTCPays>
							</drug>
							<drug id="02495651" sec3="Y">
								<name>Cephalexin</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.1731</individualPrice>
								<dailyCost>.6924</dailyCost>
								<listingDate>2020-12-18</listingDate>
								<amountMOHLTCPays>.1731</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00067">
					<name>CLINDAMYCIN HCL</name>
					<pcgGroup>
						<pcg9 id="081228006">
							<itemNumber>0092</itemNumber>
							<strength>150mg</strength>
							<dosageForm>Cap</dosageForm>
							<dailyCost>1.7736</dailyCost>
							<drug id="00030570" sec3="Y">
								<name>Dalacin C</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>1.4504</individualPrice>
								<dailyCost>11.6032</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2217</amountMOHLTCPays>
							</drug>
							<drug id="02241709" sec3="Y">
								<name>Teva-Clindamycin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2217</individualPrice>
								<dailyCost>1.7736</dailyCost>
								<listingDate>2000-11-30</listingDate>
								<amountMOHLTCPays>.2217</amountMOHLTCPays>
							</drug>
							<drug id="02245232" sec3="Y">
								<name>Apo-Clindamycin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2217</individualPrice>
								<dailyCost>1.7736</dailyCost>
								<listingDate>2002-07-29</listingDate>
								<amountMOHLTCPays>.2217</amountMOHLTCPays>
							</drug>
							<drug id="02436906" sec3="Y">
								<name>Auro-Clindamycin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2217</individualPrice>
								<dailyCost>1.7736</dailyCost>
								<listingDate>2015-05-28</listingDate>
								<amountMOHLTCPays>.2217</amountMOHLTCPays>
							</drug>
							<drug id="02468476" sec3="Y">
								<name>Riva-Clindamycin</name>
								<manufacturerId>RIA</manufacturerId>
								<individualPrice>.2217</individualPrice>
								<dailyCost>1.7736</dailyCost>
								<listingDate>2021-09-30</listingDate>
								<amountMOHLTCPays>.2217</amountMOHLTCPays>
							</drug>
							<drug id="02479923" sec3="Y">
								<name>M-Clindamycin</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.2217</individualPrice>
								<dailyCost>1.7736</dailyCost>
								<listingDate>2021-09-30</listingDate>
								<amountMOHLTCPays>.2217</amountMOHLTCPays>
							</drug>
							<drug id="02483734" sec3="Y">
								<name>Jamp-Clindamycin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2217</individualPrice>
								<dailyCost>1.7736</dailyCost>
								<listingDate>2019-10-31</listingDate>
								<amountMOHLTCPays>.2217</amountMOHLTCPays>
							</drug>
							<drug id="02493748" sec3="Y">
								<name>NRA-Clindamycin</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.2217</individualPrice>
								<dailyCost>1.7736</dailyCost>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>.2217</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081228088">
							<itemNumber>0093</itemNumber>
							<strength>300mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02182866" sec3="Y">
								<name>Dalacin C</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>2.9008</individualPrice>
								<listingDate>1996-12-19</listingDate>
								<amountMOHLTCPays>.4434</amountMOHLTCPays>
							</drug>
							<drug id="02241710" sec3="Y">
								<name>Teva-Clindamycin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.4434</individualPrice>
								<listingDate>2000-11-30</listingDate>
								<amountMOHLTCPays>.4434</amountMOHLTCPays>
							</drug>
							<drug id="02245233" sec3="Y">
								<name>Apo-Clindamycin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.4434</individualPrice>
								<listingDate>2002-07-29</listingDate>
								<amountMOHLTCPays>.4434</amountMOHLTCPays>
							</drug>
							<drug id="02436914" sec3="Y">
								<name>Auro-Clindamycin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.4434</individualPrice>
								<listingDate>2015-05-28</listingDate>
								<amountMOHLTCPays>.4434</amountMOHLTCPays>
							</drug>
							<drug id="02468484" sec3="Y">
								<name>Riva-Clindamycin</name>
								<manufacturerId>RIA</manufacturerId>
								<individualPrice>.4434</individualPrice>
								<listingDate>2021-08-31</listingDate>
								<amountMOHLTCPays>.4434</amountMOHLTCPays>
							</drug>
							<drug id="02479931" sec3="Y">
								<name>M-Clindamycin</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.4434</individualPrice>
								<listingDate>2021-09-30</listingDate>
								<amountMOHLTCPays>.4434</amountMOHLTCPays>
							</drug>
							<drug id="02483742" sec3="Y">
								<name>Jamp-Clindamycin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.4434</individualPrice>
								<listingDate>2019-10-31</listingDate>
								<amountMOHLTCPays>.4434</amountMOHLTCPays>
							</drug>
							<drug id="02493756" sec3="Y">
								<name>NRA-Clindamycin</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.4434</individualPrice>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>.4434</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00068">
					<name>CLINDAMYCIN PALMITATE</name>
					<pcgGroup>
						<pcg9 id="081228007">
							<itemNumber>0094</itemNumber>
							<strength>15mg/mL</strength>
							<dosageForm>Pd for Oral Susp</dosageForm>
							<drug id="00225851" sec3="Y">
								<name>Dalacin C Flavoured Granules</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>.3152</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3152</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00069">
					<name>CLINDAMYCIN PHOSPHATE</name>
					<pcgGroup>
						<pcg9 id="081228008">
							<itemNumber>0095</itemNumber>
							<strength>300mg/2mL</strength>
							<dosageForm>Inj Sol-2mL Pk</dosageForm>
							<drug id="00260436" sec3="Y">
								<name>Dalacin C</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>8.8938</individualPrice>
								<note>Clindamycin is well absorbed by the oral route, therefore stepdown therapy from IV to oral is possible.</note>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>8.8938</amountMOHLTCPays>
							</drug>
							<drug id="02230540" notABenefit="Y" sec3="Y">
								<name>Clindamycin Phosphate Injection USP</name>
								<manufacturerId>SDZ</manufacturerId>
								<note>Clindamycin is well absorbed by the oral route, therefore stepdown therapy from IV to oral is possible.
</note>
								<listingDate>2001-03-07</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01791">
					<name>DAPTOMYCIN</name>
					<pcgGroup>
						<pcg9 id="081228125">
							<itemNumber>0096</itemNumber>
							<strength>500mg/Vial</strength>
							<dosageForm>Pd for Inj Sol-Vial Pk</dosageForm>
							<drug id="02299909" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Cubicin</name>
								<manufacturerId>SUO</manufacturerId>
								<listingDate>2020-11-30</listingDate>
							</drug>
							<drug id="02490463" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Daptomycin for Injection</name>
								<manufacturerId>DRR</manufacturerId>
								<individualPrice>162.3500</individualPrice>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>162.3500</amountMOHLTCPays>
							</drug>
							<drug id="02490838" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Daptomycin for Injection</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>162.3500</individualPrice>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>162.3500</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="02011">
					<name>RIFAXIMIN</name>
					<pcgGroup lccId="00264">
						<pcg9 id="081228164">
							<itemNumber>0097</itemNumber>
							<strength>550mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02410702" sec3="Y" sec12="Y">
								<name>Zaxine</name>
								<manufacturerId>SAL</manufacturerId>
								<individualPrice>8.3030</individualPrice>
								<listingDate>2016-06-29</listingDate>
								<amountMOHLTCPays>8.3030</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="475">For reducing the risk of overt hepatic encephalopathy (HE) recurrence (i.e., 2 or more episodes) in patients who are unable to achieve adequate control of HE recurrence with maximal tolerated dose of lactulose alone. Rifaximin should be used in combination with a maximal tolerated dose of lactulose. For patients not maintained on lactulose, the nature of the patient&apos;s intolerance to lactulose should be documented.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00668">
					<name>TOBRAMYCIN</name>
					<pcgGroup lccId="00265">
						<pcg9 id="081228163">
							<itemNumber>0098</itemNumber>
							<strength>28mg</strength>
							<dosageForm>Inh Pd-Cap</dosageForm>
							<drug id="02365154" sec3="Y" sec12="Y">
								<name>TOBI Podhaler</name>
								<manufacturerId>BGP</manufacturerId>
								<individualPrice>14.2080</individualPrice>
								<listingDate>2016-06-29</listingDate>
								<amountMOHLTCPays>14.2080</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="472">For the management of cystic fibrosis patients with chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infections.
Tobramycin is administered in alternating periods of 28 days. After 28 days of therapy, patients should stop therapy for the next 28 days, and then resume therapy for the next 28 day on / 28 day off cycle.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
					<pcgGroup>
						<pcg9 id="081228094">
							<itemNumber>0099</itemNumber>
							<strength>300mg/5mL</strength>
							<dosageForm>Inh Sol-5mL Pk</dosageForm>
							<note>For the management of cystic fibrosis patients with chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infections.
Tobramycin is administered in alternating periods of 28 days. After 28 days of therapy, patients should stop therapy for the next 28 days, and then resume therapy for the next 28 day on / 28 day off cycle.</note>
							<drug id="02239630" sec3="Y">
								<name>TOBI</name>
								<manufacturerId>BGP</manufacturerId>
								<individualPrice>56.8319</individualPrice>
								<listingDate>2006-10-23</listingDate>
								<amountMOHLTCPays>27.3815</amountMOHLTCPays>
							</drug>
							<drug id="02389622" sec3="Y">
								<name>Teva-Tobramycin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>27.3815</individualPrice>
								<listingDate>2016-03-30</listingDate>
								<amountMOHLTCPays>27.3815</amountMOHLTCPays>
							</drug>
							<drug id="02443368" sec3="Y">
								<name>Tobramycin Inhalation Solution</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>27.3815</individualPrice>
								<listingDate>2016-04-29</listingDate>
								<amountMOHLTCPays>27.3815</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00075">
					<name>TOBRAMYCIN SULFATE</name>
					<note>The prescriber should be aware that tobramycin injection products may be preservative-free or preservative-containing. If applicable, the prescriber should choose the most appropriate formulation (preservative-free or preservative containing) for use in the specific clinical situation in which the product was prescribed.</note>
					<pcgGroup>
						<pcg9 id="081228035">
							<itemNumber>0100</itemNumber>
							<strength>80mg/2mL</strength>
							<dosageForm>Inj Sol-2mL Pk</dosageForm>
							<drug id="00325449" notABenefit="Y" sec3="Y">
								<name>Nebcin</name>
								<manufacturerId>LIL</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02241210" sec3="Y">
								<name>Tobramycin</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>4.5000</individualPrice>
								<listingDate>2002-04-04</listingDate>
								<amountMOHLTCPays>4.5000</amountMOHLTCPays>
							</drug>
							<drug id="02382814" sec3="Y">
								<name>Tobramycin Injection USP</name>
								<manufacturerId>AGI</manufacturerId>
								<individualPrice>4.5000</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>4.5000</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00094">
					<name>VANCOMYCIN HCL</name>
					<pcgGroup lccId="00322">
						<pcg9 id="081228075">
							<itemNumber>0101</itemNumber>
							<strength>125mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00800430" sec3="Y" sec12="Y">
								<name>Vancocin</name>
								<manufacturerId>SLP</manufacturerId>
								<individualPrice>5.3485</individualPrice>
								<listingDate>2016-12-22</listingDate>
								<amountMOHLTCPays>5.1800</amountMOHLTCPays>
							</drug>
							<drug id="02407744" sec3="Y" sec12="Y">
								<name>Jamp-Vancomycin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>5.1800</individualPrice>
								<listingDate>2016-12-22</listingDate>
								<amountMOHLTCPays>5.1800</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="557">For the treatment of initial episodes of Clostridium difficile infection; mild cases, if no response or intolerance to an adequate trial of oral metronidazole*:
*As defined by the Association of Medical Microbiology and Infectious Disease Canada treatment practice guidelines for Clostridium difficile infection, 2018.
Notes:
- Metronidazole 500mg orally three times daily for 10-14 days can be used in patients with mild diarrhea.
- Discontinue antibiotics for other indications if possible.
- Higher doses of vancomycin have not been shown to be beneficial.
- There is no evidence to support combination therapy with metronidazole or fidaxomicin.
Maximum funded dose: Vancomycin 125mg four times daily, up to 14 days
Maximum funded quantity: 56 capsules</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 14 days</lccNote>
						<lccNote seq="003" reasonForUseId="558">For the treatment of initial episodes of Clostridium difficile infection; moderate or severe, uncomplicated cases*:
*As defined by the Association of Medical Microbiology and Infectious Disease Canada treatment practice guidelines for Clostridium difficile infection, 2018.
Notes:
- Metronidazole 500mg orally three times daily for 10-14 days can be used in patients with mild diarrhea.
- For mild to moderate cases, treatment should only be continued beyond 7 days if diarrhea persists, up to a maximum of 14 days.
- Severe, uncomplicated cases should be treated for 10-14 days. There is no evidence to support treatment durations beyond 14 days.
- Higher doses of vancomycin have not been shown to be beneficial.
- There is no evidence to support combination therapy with metronidazole or fidaxomicin.
Maximum funded dose: Vancomycin 125mg four times daily, up to 14 days
Maximum funded quantity: 56 capsules</lccNote>
						<lccNote seq="004" type="R">LU Authorization Period: 14 days</lccNote>
						<lccNote seq="005" reasonForUseId="559">For the treatment of recurrent Clostridium difficile infection (CDI), first recurrence, mild to moderate* or severe, uncomplicated* cases:
*As defined by the Association of Medical Microbiology and Infectious Disease Canada treatment practice guidelines for Clostridium difficile infection, 2018.
Notes:
- Recurrent CDI is defined as the reoccurrence of CDI within 8 weeks following the onset of a previous episode which resolved with treatment.
- Treatment should only be continued for 14 days.
- Higher doses or longer treatment duration with vancomycin have not been shown to be beneficial.
- There is no evidence to support combination therapy with metronidazole or fidaxomicin.
Maximum funded dose: Vancomycin 125mg four times daily, up to 14 days
Maximum funded quantity: 56 capsules</lccNote>
						<lccNote seq="006" type="R">LU Authorization Period: 14 days</lccNote>
						<lccNote seq="007" reasonForUseId="560">For the treatment of recurrent Clostridium difficile infection (CDI), second or subsequent recurrences, mild to moderate* or severe, uncomplicated* cases:
*As defined by the Association of Medical Microbiology and Infectious Disease Canada treatment practice guidelines for Clostridium difficile infection, 2018.
Notes:
- Recurrent CDI is defined as the reoccurrence of CDI within 8 weeks following the onset of a previous episode which resolved with treatment.
- There is no evidence to support combination therapy with metronidazole or fidaxomicin.
Funded dose: Vancomycin 125mg four times daily for 10-14 days, followed by vancomycin taper.
Maximum funded quantity: 114 capsules</lccNote>
						<lccNote seq="008" type="R">LU Authorization Period: 13 Weeks</lccNote>
					</pcgGroup>
					<pcgGroup>
						<pcg9 id="081228074">
							<itemNumber>0102</itemNumber>
							<strength>250mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00788716" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Vancocin</name>
								<manufacturerId>SLP</manufacturerId>
								<individualPrice>10.6875</individualPrice>
								<listingDate>2016-12-22</listingDate>
								<amountMOHLTCPays>10.3600</amountMOHLTCPays>
							</drug>
							<drug id="02407752" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Jamp-Vancomycin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>10.3600</individualPrice>
								<listingDate>2016-12-22</listingDate>
								<amountMOHLTCPays>10.3600</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="081600000">
				<name>ANTITUBERCULAR AGENTS</name>
				<genericName id="00100">
					<name>ETHAMBUTOL HCL</name>
					<pcgGroup>
						<pcg9 id="081600004">
							<itemNumber>0103</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00127957" notABenefit="Y" sec3="Y">
								<name>Myambutol</name>
								<manufacturerId>LED</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00247960" sec3="Y">
								<name>Etibi</name>
								<manufacturerId>VAL</manufacturerId>
								<individualPrice>.2331</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2331</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081600003">
							<itemNumber>0104</itemNumber>
							<strength>400mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00247979" sec3="Y">
								<name>Etibi</name>
								<manufacturerId>VAL</manufacturerId>
								<individualPrice>.6995</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.6995</amountMOHLTCPays>
							</drug>
							<drug id="02170078" notABenefit="Y" sec3="Y">
								<name>Myambutol</name>
								<manufacturerId>WAY</manufacturerId>
								<listingDate>1997-02-04</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00107">
					<name>RIFABUTIN</name>
					<pcgGroup lccId="00005">
						<pcg9 id="081600018">
							<itemNumber>0105</itemNumber>
							<strength>150mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02063786" sec3="Y" sec12="Y">
								<name>Mycobutin</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>5.7207</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>5.7207</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" type="R">For the prevention of Mycobacterium Avium Intracellular (MAI) in:</lccNote>
						<lccNote seq="002" reasonForUseId="103">Patients with a CD4+ cell count less than 200/mm3 with an AIDS-defining diagnosis;</lccNote>
						<lccNote seq="003" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="004" reasonForUseId="104">Patients with a CD4+ cell count less than 100/mm3 without an AIDS-defining diagnosis.</lccNote>
						<lccNote seq="005" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00102">
					<name>RIFAMPIN</name>
					<note>Except when used for prophylaxis in contacts of H. influenzae or N. meningitidis, rifampin should not be used as monotherapy, as bacterial resistance will develop quickly.</note>
					<pcgGroup>
						<pcg9 id="081600009">
							<itemNumber>0106</itemNumber>
							<strength>150mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00393444" sec3="Y">
								<name>Rofact</name>
								<manufacturerId>VAL</manufacturerId>
								<individualPrice>.7536</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.7536</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081600008">
							<itemNumber>0107</itemNumber>
							<strength>300mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00343617" sec3="Y">
								<name>Rofact</name>
								<manufacturerId>VAL</manufacturerId>
								<individualPrice>1.1862</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>1.1862</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="081800000">
				<name>ANTIVIRALS</name>
				<genericName id="01567">
					<name>ABACAVIR &amp; LAMIVUDINE &amp; ZIDOVUDINE</name>
					<pcgGroup>
						<pcg9 id="081800065">
							<itemNumber>0108</itemNumber>
							<strength>300mg &amp; 150mg &amp; 300mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02244757" sec3="Y">
								<name>Trizivir</name>
								<manufacturerId>VIH</manufacturerId>
								<individualPrice>19.0426</individualPrice>
								<listingDate>2003-01-30</listingDate>
								<amountMOHLTCPays>13.6425</amountMOHLTCPays>
							</drug>
							<drug id="02416255" sec3="Y">
								<name>Apo-Abacavir-Lamivudine-Zidovudine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>13.6425</individualPrice>
								<listingDate>2016-01-28</listingDate>
								<amountMOHLTCPays>13.6425</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01426">
					<name>ABACAVIR SULFATE</name>
					<pcgGroup>
						<pcg9 id="081800054">
							<itemNumber>0109</itemNumber>
							<strength>20mg/mL</strength>
							<dosageForm>O/L</dosageForm>
							<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02240358" sec3="Y">
								<name>Ziagen</name>
								<manufacturerId>VIH</manufacturerId>
								<individualPrice>.5283</individualPrice>
								<listingDate>2000-01-17</listingDate>
								<amountMOHLTCPays>.5283</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081800053">
							<itemNumber>0110</itemNumber>
							<strength>300mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02240357" sec3="Y">
								<name>Ziagen</name>
								<manufacturerId>VIH</manufacturerId>
								<individualPrice>7.9434</individualPrice>
								<listingDate>2000-01-17</listingDate>
								<amountMOHLTCPays>3.4828</amountMOHLTCPays>
							</drug>
							<drug id="02396769" sec3="Y">
								<name>Apo-Abacavir</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>3.4828</individualPrice>
								<listingDate>2016-05-31</listingDate>
								<amountMOHLTCPays>3.4828</amountMOHLTCPays>
							</drug>
							<drug id="02480956" sec3="Y">
								<name>Mint-Abacavir</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>3.4828</individualPrice>
								<listingDate>2019-05-31</listingDate>
								<amountMOHLTCPays>3.4828</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01678">
					<name>ABACAVIR SULFATE &amp; LAMIVUDINE</name>
					<pcgGroup>
						<pcg9 id="081800094">
							<itemNumber>0111</itemNumber>
							<strength>600mg &amp; 300mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02269341" sec3="Y">
								<name>Kivexa</name>
								<manufacturerId>VIH</manufacturerId>
								<individualPrice>25.9296</individualPrice>
								<listingDate>2006-06-15</listingDate>
								<amountMOHLTCPays>5.9875</amountMOHLTCPays>
							</drug>
							<drug id="02399539" sec3="Y">
								<name>Apo-Abacavir-Lamivudine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>5.9875</individualPrice>
								<listingDate>2016-05-31</listingDate>
								<amountMOHLTCPays>5.9875</amountMOHLTCPays>
							</drug>
							<drug id="02416662" sec3="Y">
								<name>Teva-Abacavir-Lamivudine</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>5.9875</individualPrice>
								<listingDate>2016-05-31</listingDate>
								<amountMOHLTCPays>5.9875</amountMOHLTCPays>
							</drug>
							<drug id="02450682" sec3="Y">
								<name>Mylan-Abacavir-Lamivudine</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>5.9875</individualPrice>
								<listingDate>2016-05-31</listingDate>
								<amountMOHLTCPays>5.9875</amountMOHLTCPays>
							</drug>
							<drug id="02454513" sec3="Y">
								<name>Auro-Abacavir/Lamivudine</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>5.9875</individualPrice>
								<listingDate>2016-12-22</listingDate>
								<amountMOHLTCPays>5.9875</amountMOHLTCPays>
							</drug>
							<drug id="02458381" sec3="Y">
								<name>PMS-Abacavir-Lamivudine</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>5.9875</individualPrice>
								<listingDate>2016-12-22</listingDate>
								<amountMOHLTCPays>5.9875</amountMOHLTCPays>
							</drug>
							<drug id="02497654" sec3="Y">
								<name>Jamp Abacavir/Lamivudine</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>5.9875</individualPrice>
								<listingDate>2022-03-31</listingDate>
								<amountMOHLTCPays>5.9875</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00109">
					<name>ACYCLOVIR</name>
					<pcgGroup>
						<pcg9 id="081800019">
							<itemNumber>0112</itemNumber>
							<strength>200mg/5mL</strength>
							<dosageForm>Oral Susp</dosageForm>
							<drug id="00886157" sec3="Y">
								<name>Zovirax</name>
								<manufacturerId>GLW</manufacturerId>
								<individualPrice>.2674</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2674</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081800100">
							<itemNumber>0113</itemNumber>
							<strength>200mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00634506" notABenefit="Y" sec3="Y">
								<name>Zovirax</name>
								<manufacturerId>GSK</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02207621" sec3="Y">
								<name>Apo-Acyclovir</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.6397</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.6397</amountMOHLTCPays>
							</drug>
							<drug id="02242784" sec3="Y">
								<name>Mylan-Acyclovir</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.6397</individualPrice>
								<listingDate>2001-06-07</listingDate>
								<amountMOHLTCPays>.6397</amountMOHLTCPays>
							</drug>
							<drug id="02285959" sec3="Y">
								<name>Teva-Acyclovir</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.6397</individualPrice>
								<listingDate>2008-01-15</listingDate>
								<amountMOHLTCPays>.6397</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081800101">
							<itemNumber>0114</itemNumber>
							<strength>400mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="01911627" notABenefit="Y" sec3="Y">
								<name>Zovirax</name>
								<manufacturerId>GSK</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02207648" sec3="Y">
								<name>Apo-Acyclovir</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.2700</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>1.2700</amountMOHLTCPays>
							</drug>
							<drug id="02242463" sec3="Y">
								<name>Mylan-Acyclovir</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>1.2700</individualPrice>
								<listingDate>2001-06-07</listingDate>
								<amountMOHLTCPays>1.2700</amountMOHLTCPays>
							</drug>
							<drug id="02285967" sec3="Y">
								<name>Teva-Acyclovir</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>1.2700</individualPrice>
								<listingDate>2008-01-15</listingDate>
								<amountMOHLTCPays>1.2700</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081800002">
							<itemNumber>0115</itemNumber>
							<strength>800mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="01911635" sec3="Y">
								<name>Zovirax</name>
								<manufacturerId>GSK</manufacturerId>
								<individualPrice>5.0692</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>1.2673</amountMOHLTCPays>
							</drug>
							<drug id="02207656" sec3="Y">
								<name>Apo-Acyclovir</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.2673</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>1.2673</amountMOHLTCPays>
							</drug>
							<drug id="02242464" sec3="Y">
								<name>Mylan-Acyclovir</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>1.2673</individualPrice>
								<listingDate>2001-03-07</listingDate>
								<amountMOHLTCPays>1.2673</amountMOHLTCPays>
							</drug>
							<drug id="02285975" sec3="Y">
								<name>Teva-Acyclovir</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>1.2673</individualPrice>
								<listingDate>2007-01-02</listingDate>
								<amountMOHLTCPays>1.2673</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01734">
					<name>ADEFOVIR DIPIVOXIL</name>
					<pcgGroup>
						<pcg9 id="081800105">
							<itemNumber>0116</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02247823" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Hepsera</name>
								<manufacturerId>GIL</manufacturerId>
								<listingDate>2014-04-30</listingDate>
							</drug>
							<drug id="02420333" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>AA-Adefovir</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>20.4400</individualPrice>
								<listingDate>2014-04-30</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01614">
					<name>ATAZANAVIR SULFATE</name>
					<pcgGroup>
						<pcg9 id="081800080">
							<itemNumber>0117</itemNumber>
							<strength>150mg</strength>
							<dosageForm>Cap</dosageForm>
							<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02248610" sec3="Y">
								<name>Reyataz</name>
								<manufacturerId>BQU</manufacturerId>
								<individualPrice>11.6950</individualPrice>
								<listingDate>2004-11-04</listingDate>
								<amountMOHLTCPays>5.6771</amountMOHLTCPays>
							</drug>
							<drug id="02443791" sec3="Y">
								<name>Teva-Atazanavir</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>5.6771</individualPrice>
								<listingDate>2017-06-29</listingDate>
								<amountMOHLTCPays>5.6771</amountMOHLTCPays>
							</drug>
							<drug id="02456877" sec3="Y">
								<name>Mylan-Atazanavir</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>5.6771</individualPrice>
								<listingDate>2017-06-29</listingDate>
								<amountMOHLTCPays>5.6771</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081800081">
							<itemNumber>0118</itemNumber>
							<strength>200mg</strength>
							<dosageForm>Cap</dosageForm>
							<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02248611" sec3="Y">
								<name>Reyataz</name>
								<manufacturerId>BQU</manufacturerId>
								<individualPrice>11.7633</individualPrice>
								<listingDate>2004-11-04</listingDate>
								<amountMOHLTCPays>5.7104</amountMOHLTCPays>
							</drug>
							<drug id="02443813" sec3="Y">
								<name>Teva-Atazanavir</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>5.7104</individualPrice>
								<listingDate>2017-06-29</listingDate>
								<amountMOHLTCPays>5.7104</amountMOHLTCPays>
							</drug>
							<drug id="02456885" sec3="Y">
								<name>Mylan-Atazanavir</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>5.7104</individualPrice>
								<listingDate>2017-06-29</listingDate>
								<amountMOHLTCPays>5.7104</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081800388">
							<itemNumber>0119</itemNumber>
							<strength>300mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02294176" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Reyataz</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>2017-06-29</listingDate>
							</drug>
							<drug id="02443821" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Teva-Atazanavir</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>19.0681</individualPrice>
								<listingDate>2017-06-29</listingDate>
							</drug>
							<drug id="02456893" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mylan-Atazanavir</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>19.0681</individualPrice>
								<listingDate>2017-06-29</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="02095">
					<name>BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE</name>
					<pcgGroup>
						<pcg9 id="081800393">
							<itemNumber>0120</itemNumber>
							<strength>50mg &amp; 200mg &amp; 25mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>As a complete regimen for the treatment of HIV-1 infection in adults with no known substitutions associated with resistance to the individual components of Biktarvy.
For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.
</note>
							<drug id="02478579" sec3="Y" sec6="Y">
								<name>Biktarvy</name>
								<manufacturerId>GIL</manufacturerId>
								<individualPrice>39.2227</individualPrice>
								<listingDate>2019-07-31</listingDate>
								<amountMOHLTCPays>39.2227</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="02172">
					<name>CABOTEGRAVIR</name>
					<pcgGroup>
						<pcg9 id="081800407">
							<itemNumber>0121</itemNumber>
							<strength>30mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>In combination with rilpivirine tablets, as a complete regimen for short-term treatment of Human Immunodeficiency Virus-Type 1 (HIV-1) infection in adult patients who are virologically stable and suppressed (defined as HIV-1 ribonucleic acid [RNA] level [viral load] of less than 50 copies/mL) as:
- An oral lead-in to assess tolerability of cabotegravir prior to initiating Cabenuva (cabotegravir/rilpivirine) injections;
- Oral bridging therapy for missed Cabenuva injections;
The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02497204" sec3="Y" sec6="Y">
								<name>Vocabria</name>
								<manufacturerId>VIH</manufacturerId>
								<individualPrice>27.0460</individualPrice>
								<listingDate>2021-11-30</listingDate>
								<amountMOHLTCPays>27.0460</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="02174">
					<name>CABOTEGRAVIR &amp; RILPIVIRINE</name>
					<pcgGroup>
						<pcg9 id="081800405">
							<itemNumber>0122</itemNumber>
							<strength>200mg/mL &amp; 300mg/mL</strength>
							<dosageForm>Inj Sol-2mL Kit</dosageForm>
							<note>As a complete regimen for the treatment of Human Immunodeficiency Virus-Type 1 (HIV-1) infection in adult patients to replace the current antiretroviral regimen in patients who are virologically stable and suppressed (virologic suppression is defined as HIV-1 ribonucleic acid [RNA] level [viral load] of less than 50 copies/mL);
Response to treatment with Cabenuva, defined as ongoing virologic suppression (as defined above), should be assessed every 6 months;
Treatment should be discontinued if there is evidence of:
- Sustained loss of virologic suppression (as defined above); OR
- Development of resistance to, adverse events leading to lack of tolerability of, and/or lack of adherence to either component of the drug regimen;
The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02497220" sec3="Y" sec6="Y">
								<name>Cabenuva</name>
								<manufacturerId>VIH</manufacturerId>
								<individualPrice>1233.5700</individualPrice>
								<listingDate>2021-11-30</listingDate>
								<amountMOHLTCPays>1233.5700</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081800406">
							<itemNumber>0123</itemNumber>
							<strength>200mg/mL &amp; 300mg/mL</strength>
							<dosageForm>Inj Sol-3mL Kit</dosageForm>
							<note>As a complete regimen for the treatment of Human Immunodeficiency Virus-Type 1 (HIV-1) infection in adult patients to replace the current antiretroviral regimen in patients who are virologically stable and suppressed (virologic suppression is defined as HIV-1 ribonucleic acid [RNA] level [viral load] of less than 50 copies/mL);
Response to treatment with Cabenuva, defined as ongoing virologic suppression (as defined above), should be assessed every 6 months;
Treatment should be discontinued if there is evidence of:
- Sustained loss of virologic suppression (as defined above); OR
- Development of resistance to, adverse events leading to lack of tolerability of, and/or lack of adherence to either component of the drug regimen;
The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02497247" sec3="Y" sec6="Y">
								<name>Cabenuva</name>
								<manufacturerId>VIH</manufacturerId>
								<individualPrice>2467.1300</individualPrice>
								<listingDate>2021-11-30</listingDate>
								<amountMOHLTCPays>2467.1300</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01918">
					<name>COBICISTAT &amp; ELVITEGRAVIR &amp; EMTRICITABINE &amp; TENOFOVIR DISOPROXIL FUMARATE</name>
					<pcgGroup>
						<pcg9 id="081800361">
							<itemNumber>0124</itemNumber>
							<strength>150mg &amp; 150mg &amp; 200mg &amp; 300mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>As a complete regimen for antiretroviral treatment-naive HIV-1 infected patients in whom efavirenz is not indicated.
For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02397137" sec3="Y">
								<name>Stribild</name>
								<manufacturerId>GIL</manufacturerId>
								<individualPrice>48.0177</individualPrice>
								<listingDate>2013-07-30</listingDate>
								<amountMOHLTCPays>48.0177</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01702">
					<name>DARUNAVIR</name>
					<pcgGroup>
						<pcg9 id="081800340">
							<itemNumber>0125</itemNumber>
							<strength>75mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism. For the treatment of HIV infection in treatment-experienced pediatric patients in combination with ritonavir and an appropriate background regimen, who are resistant to two other protease inhibitors.</note>
							<drug id="02338432" sec3="Y" sec6="Y">
								<name>Prezista</name>
								<manufacturerId>JAN</manufacturerId>
								<individualPrice>1.8930</individualPrice>
								<listingDate>2010-09-09</listingDate>
								<amountMOHLTCPays>1.8930</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081800358">
							<itemNumber>0126</itemNumber>
							<strength>150mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism. For the treatment of HIV infection in treatment-experienced pediatric patients in combination with ritonavir and an appropriate background regimen, who are resistant to two other protease inhibitors.</note>
							<drug id="02369753" sec3="Y" sec6="Y">
								<name>Prezista</name>
								<manufacturerId>JAN</manufacturerId>
								<individualPrice>4.0080</individualPrice>
								<listingDate>2012-12-21</listingDate>
								<amountMOHLTCPays>4.0080</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081800337">
							<itemNumber>0127</itemNumber>
							<strength>600mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>In combination with ritonavir, as part of a HIV treatment regimen for
treatment-experienced adult and pediatric patients who have demonstrated failure to at least 2 Protease Inhibitors.
For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02324024" sec3="Y" sec6="Y">
								<name>Prezista</name>
								<manufacturerId>JAN</manufacturerId>
								<individualPrice>17.7030</individualPrice>
								<listingDate>2010-03-02</listingDate>
								<amountMOHLTCPays>8.5940</amountMOHLTCPays>
							</drug>
							<drug id="02486121" sec3="Y" sec6="Y">
								<name>Auro-Darunavir</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>8.5940</individualPrice>
								<listingDate>2020-05-29</listingDate>
								<amountMOHLTCPays>8.5940</amountMOHLTCPays>
							</drug>
							<drug id="02487241" sec3="Y" sec6="Y">
								<name>Apo-Darunavir</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>8.5940</individualPrice>
								<listingDate>2020-03-31</listingDate>
								<amountMOHLTCPays>8.5940</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081800360">
							<itemNumber>0128</itemNumber>
							<strength>800mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>In combination with ritonavir, as part of a HIV treatment regimen for treatment-naive adult patients.
For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02393050" sec3="Y">
								<name>Prezista</name>
								<manufacturerId>JAN</manufacturerId>
								<individualPrice>23.3180</individualPrice>
								<listingDate>2013-07-30</listingDate>
								<amountMOHLTCPays>11.6590</amountMOHLTCPays>
							</drug>
							<drug id="02486148" sec3="Y">
								<name>Auro-Darunavir</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>11.6590</individualPrice>
								<listingDate>2020-05-29</listingDate>
								<amountMOHLTCPays>11.6590</amountMOHLTCPays>
							</drug>
							<drug id="02487268" sec3="Y">
								<name>Apo-Darunavir</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>11.6590</individualPrice>
								<listingDate>2020-03-31</listingDate>
								<amountMOHLTCPays>11.6590</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="02010">
					<name>DARUNAVIR &amp; COBICISTAT</name>
					<pcgGroup>
						<pcg9 id="081800377">
							<itemNumber>0129</itemNumber>
							<strength>800mg &amp; 150mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>For treatment of human immunodeficiency virus (HIV) infection in treatment-naive and treatment-experienced patients without darunavir (DRV) resistance-associated mutations (RAMS).
For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02426501" sec3="Y">
								<name>Prezcobix</name>
								<manufacturerId>JAN</manufacturerId>
								<individualPrice>25.1870</individualPrice>
								<listingDate>2016-06-29</listingDate>
								<amountMOHLTCPays>25.1870</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01391">
					<name>DELAVIRDINE MESYLATE</name>
					<pcgGroup>
						<pcg9 id="081800043">
							<itemNumber>0130</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02238348" sec3="Y">
								<name>Rescriptor</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>.7609</individualPrice>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>.7609</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01234">
					<name>DIDANOSINE</name>
					<pcgGroup>
						<pcg9 id="081800072">
							<itemNumber>0131</itemNumber>
							<strength>125mg</strength>
							<dosageForm>Enteric Coated Cap</dosageForm>
							<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02244596" sec3="Y">
								<name>Videx EC</name>
								<manufacturerId>BQU</manufacturerId>
								<individualPrice>4.2950</individualPrice>
								<listingDate>2006-10-23</listingDate>
								<amountMOHLTCPays>4.2950</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081800073">
							<itemNumber>0132</itemNumber>
							<strength>200mg</strength>
							<dosageForm>Enteric Coated Cap</dosageForm>
							<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02244597" sec3="Y">
								<name>Videx EC</name>
								<manufacturerId>BQU</manufacturerId>
								<individualPrice>6.8716</individualPrice>
								<listingDate>2006-10-23</listingDate>
								<amountMOHLTCPays>6.8716</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081800074">
							<itemNumber>0133</itemNumber>
							<strength>250mg</strength>
							<dosageForm>Enteric Coated Cap</dosageForm>
							<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02244598" sec3="Y">
								<name>Videx EC</name>
								<manufacturerId>BQU</manufacturerId>
								<individualPrice>8.5150</individualPrice>
								<listingDate>2006-10-23</listingDate>
								<amountMOHLTCPays>8.5150</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081800075">
							<itemNumber>0134</itemNumber>
							<strength>400mg</strength>
							<dosageForm>Enteric Coated Cap</dosageForm>
							<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02244599" sec3="Y">
								<name>Videx EC</name>
								<manufacturerId>BQU</manufacturerId>
								<individualPrice>13.7717</individualPrice>
								<listingDate>2006-10-23</listingDate>
								<amountMOHLTCPays>13.7717</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01973">
					<name>DOLUTEGRAVIR</name>
					<pcgGroup>
						<pcg9 id="081800373">
							<itemNumber>0135</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>For the treatment of HIV in both treatment-naive and treatment-experienced adults and children 12 years of age and older weighing at least 40kg, in combination with other antiretrovirals.
For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02414945" sec3="Y" sec6="Y">
								<name>Tivicay</name>
								<manufacturerId>VIH</manufacturerId>
								<individualPrice>20.6501</individualPrice>
								<listingDate>2015-04-30</listingDate>
								<amountMOHLTCPays>20.6501</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01974">
					<name>DOLUTEGRAVIR &amp; ABACAVIR &amp; LAMIVUDINE</name>
					<pcgGroup>
						<pcg9 id="081800374">
							<itemNumber>0136</itemNumber>
							<strength>50mg &amp; 600mg &amp; 300mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>For the treatment of HIV in both treatment-naive and treatment-experienced adults.
For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02430932" sec3="Y" sec6="Y">
								<name>Triumeq</name>
								<manufacturerId>VIH</manufacturerId>
								<individualPrice>45.7490</individualPrice>
								<listingDate>2015-05-28</listingDate>
								<amountMOHLTCPays>45.7490</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="02081">
					<name>DOLUTEGRAVIR &amp; RILPIVIRINE</name>
					<pcgGroup>
						<pcg9 id="081800392">
							<itemNumber>0137</itemNumber>
							<strength>50mg &amp; 25mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>As a complete regimen to replace the current antiretroviral (cARV) regimen for the treatment of human immunodeficiency virus (HIV-1) infection in adults who are virologically stable and suppressed (HIV-1 RNA less than 50 copies per mL).
For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02475774" sec3="Y" sec6="Y">
								<name>Juluca</name>
								<manufacturerId>VIH</manufacturerId>
								<individualPrice>35.9137</individualPrice>
								<listingDate>2019-04-30</listingDate>
								<amountMOHLTCPays>35.9137</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="02119">
					<name>DOLUTEGRAVIR SODIUM/LAMIVUDINE</name>
					<pcgGroup>
						<pcg9 id="081800397">
							<itemNumber>0138</itemNumber>
							<strength>50mg &amp; 300mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>- As a complete regimen for the treatment of Human Immunodeficiency Virus-Type 1 (HIV-1) infection in adults and adolescents 12 years of age and older and weighing at least 40 kg.
- The patient must be naive to any antiretroviral therapy (ART) and have an HIV-1 viral load less than or equal to 500,000 copies/mL.
- For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02491753" sec3="Y" sec6="Y">
								<name>Dovato</name>
								<manufacturerId>VIH</manufacturerId>
								<individualPrice>31.3532</individualPrice>
								<listingDate>2020-01-31</listingDate>
								<amountMOHLTCPays>31.3532</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="02108">
					<name>DORAVIRINE</name>
					<pcgGroup>
						<pcg9 id="081800396">
							<itemNumber>0139</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>In combination with other antiretroviral medicinal products, for the treatment of adults infected with HIV-1 without past or present evidence of viral resistance to DOR.
For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02481545" sec3="Y" sec6="Y">
								<name>Pifeltro</name>
								<manufacturerId>MEK</manufacturerId>
								<individualPrice>16.6500</individualPrice>
								<listingDate>2019-10-31</listingDate>
								<amountMOHLTCPays>16.6500</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="02109">
					<name>DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE</name>
					<pcgGroup>
						<pcg9 id="081800395">
							<itemNumber>0140</itemNumber>
							<strength>100mg &amp; 300mg &amp; 300mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>As a complete regimen for the treatment of HIV-1 infection in adults without past or present evidence of viral resistance to DOR, 3TC, or tenofovir.
For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02482592" sec3="Y" sec6="Y">
								<name>Delstrigo</name>
								<manufacturerId>MEK</manufacturerId>
								<individualPrice>28.7900</individualPrice>
								<listingDate>2019-10-31</listingDate>
								<amountMOHLTCPays>28.7900</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01416">
					<name>EFAVIRENZ</name>
					<pcgGroup>
						<pcg9 id="081800050">
							<itemNumber>0141</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Cap</dosageForm>
							<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02239886" sec3="Y">
								<name>Sustiva</name>
								<manufacturerId>BQU</manufacturerId>
								<individualPrice>1.3050</individualPrice>
								<listingDate>1999-09-15</listingDate>
								<amountMOHLTCPays>1.3050</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081800052">
							<itemNumber>0142</itemNumber>
							<strength>200mg</strength>
							<dosageForm>Cap</dosageForm>
							<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02239888" sec3="Y">
								<name>Sustiva</name>
								<manufacturerId>BQU</manufacturerId>
								<individualPrice>5.2228</individualPrice>
								<listingDate>1999-09-15</listingDate>
								<amountMOHLTCPays>5.2228</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081800076">
							<itemNumber>0143</itemNumber>
							<strength>600mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02246045" sec3="Y">
								<name>Sustiva</name>
								<manufacturerId>BQU</manufacturerId>
								<individualPrice>15.6683</individualPrice>
								<listingDate>2003-09-04</listingDate>
								<amountMOHLTCPays>3.8030</amountMOHLTCPays>
							</drug>
							<drug id="02381524" sec3="Y">
								<name>Mylan-Efavirenz</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>3.8030</individualPrice>
								<listingDate>2013-09-27</listingDate>
								<amountMOHLTCPays>3.8030</amountMOHLTCPays>
							</drug>
							<drug id="02389762" sec3="Y">
								<name>Teva-Efavirenz</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>3.8030</individualPrice>
								<listingDate>2013-09-27</listingDate>
								<amountMOHLTCPays>3.8030</amountMOHLTCPays>
							</drug>
							<drug id="02418428" sec3="Y">
								<name>Auro-Efavirenz</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>3.8030</individualPrice>
								<listingDate>2014-05-29</listingDate>
								<amountMOHLTCPays>3.8030</amountMOHLTCPays>
							</drug>
							<drug id="02458233" sec3="Y">
								<name>Jamp-Efavirenz</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>3.8030</individualPrice>
								<listingDate>2019-08-30</listingDate>
								<amountMOHLTCPays>3.8030</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01732">
					<name>EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE</name>
					<pcgGroup>
						<pcg9 id="081800103">
							<itemNumber>0144</itemNumber>
							<strength>600mg/300mg/200mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02300699" sec3="Y">
								<name>Atripla</name>
								<manufacturerId>BQU</manufacturerId>
								<individualPrice>45.3200</individualPrice>
								<listingDate>2008-08-28</listingDate>
								<amountMOHLTCPays>11.3300</amountMOHLTCPays>
							</drug>
							<drug id="02393549" sec3="Y">
								<name>Teva-Efavirenz/Emtricitabine/Tenofovir</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>11.3300</individualPrice>
								<listingDate>2017-09-28</listingDate>
								<amountMOHLTCPays>11.3300</amountMOHLTCPays>
							</drug>
							<drug id="02461412" sec3="Y">
								<name>Mylan-Efavirenz/Emtricitabine/Tenofovir</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>11.3300</individualPrice>
								<listingDate>2017-09-28</listingDate>
								<amountMOHLTCPays>11.3300</amountMOHLTCPays>
							</drug>
							<drug id="02468247" sec3="Y">
								<name>Apo-Efavirenz-Emtricitabine-Tenofovir</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>11.3300</individualPrice>
								<listingDate>2018-10-31</listingDate>
								<amountMOHLTCPays>11.3300</amountMOHLTCPays>
							</drug>
							<drug id="02478404" sec3="Y">
								<name>Auro-Efavirenz-Emtricitabine-Tenofovir</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>11.3300</individualPrice>
								<listingDate>2020-05-29</listingDate>
								<amountMOHLTCPays>11.3300</amountMOHLTCPays>
							</drug>
							<drug id="02484676" sec3="Y">
								<name>Sandoz Efavirenz/Emtricitabine/Tenofovir</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>11.3300</individualPrice>
								<listingDate>2020-01-31</listingDate>
								<amountMOHLTCPays>11.3300</amountMOHLTCPays>
							</drug>
							<drug id="02487284" sec3="Y">
								<name>PMS-Efavirenz-Emtricitabine-Tenofovir</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>11.3300</individualPrice>
								<listingDate>2020-02-28</listingDate>
								<amountMOHLTCPays>11.3300</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="02027">
					<name>ELBASVIR &amp; GRAZOPREVIR</name>
					<pcgGroup lccId="00279">
						<pcg9 id="081800381">
							<itemNumber>0145</itemNumber>
							<strength>50mg &amp; 100mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02451131" sec3="Y" sec12="Y">
								<name>Zepatier</name>
								<manufacturerId>MEK</manufacturerId>
								<individualPrice>666.9400</individualPrice>
								<listingDate>2017-02-28</listingDate>
								<amountMOHLTCPays>666.9400</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="489">For treatment-naive or treatment-experienced (1) adult patients with chronic hepatitis C (CHC) infection who meet all the following criteria:
(i) Treatment is prescribed by a hepatologist, gastroenterologist, infectious disease specialist or other prescriber experienced in treating chronic hepatitis C; AND
(ii) Laboratory confirmed hepatitis C genotype 1 or genotype 4; AND
(iii) Established chronicity of HCV infection either by two laboratory confirmed quantitative HCV RNA values taken at least 6 months apart;
OR
One recent laboratory confirmed quantitative HCV RNA within the past 6 months and clinical features establishing a duration of HCV infection longer than 6 months (e.g. presence of fibrosis, presence of non-liver manifestations of HCV, prolonged ALT elevation greater than 6 months without another cause, HCV antibody positivity greater than 6 months), or risk factors for HCV acquisition greater than 6 months (e.g. injection drug use).
Treatment regimens for Zepatier (elbasvir-grazoprevir) for genotype 1:
I. Treatment-naive with or without compensated cirrhosis (2)
Approved duration: 12 weeks
Note: As approved by Health Canada, 8 weeks may be considered in treatment-naive genotype 1b patients without significant fibrosis or cirrhosis as determined by liver biopsy (i.e., Metavir F0-F2) or by non-invasive tests.
II. Treatment-experienced genotype 1b patients and genotype 1a relapsers, with or without compensated cirrhosis (2)
Approved duration: 12 weeks
Treatment regimens for Zepatier (elbasvir-grazoprevir) for genotype 4:
I. Treatment-naive patients, treatment-experienced relapsers, with or without compensated cirrhosis (2)
Approved duration: 12 weeks
Retreatment for failure or re-infection in patients who have received an adequate prior course of direct-acting antiviral will be considered on a case-by-case basis through the Exceptional Access Program.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 12 Weeks.</lccNote>
						<lccNote seq="003" reasonForUseId="490">For treatment-naive or treatment-experienced (1) adult patients with chronic hepatitis C (CHC) infection who meet all the following criteria:
(i) Treatment is prescribed by a hepatologist, gastroenterologist, infectious disease specialist or other prescriber experienced in treating chronic hepatitis C; AND
(ii) Laboratory confirmed hepatitis C genotype 1 or genotype 4 AND
(iii) Established chronicity of HCV infection either by two laboratory confirmed quantitative HCV RNA values taken at least 6 months apart;
OR
One recent laboratory confirmed quantitative HCV RNA within the past 6 months and clinical features establishing a duration of HCV infection longer than 6 months (e.g. presence of fibrosis, presence of non-liver manifestations of HCV, prolonged ALT elevation greater than 6 months without another cause, HCV antibody positivity greater than 6 months), or risk factors for HCV acquisition greater than 6 months (e.g. injection drug use).
Treatment-experienced genotype 1a or genotype 4 who have had on-treatment virologic failures (3)
Approved regimen: 16 weeks in combination with ribavirin (Ibavyr)
Retreatment is not funded. Retreatment for failure or re-infection in patients who have received an adequate prior course of direct-acting antiviral will be considered on a case-by-case basis through the Exceptional Access Program.</lccNote>
						<lccNote seq="004" type="R">LU Authorization Period: 16 Weeks.</lccNote>
						<lccNote seq="005" type="N">1. Treatment-experienced for patients with genotype 1 is defined as patients who have been previously treated with a pegylated interferon + ribavirin regimen or a protease inhibitor + pegylated interferon + ribavirin regimen and have not experienced adequate response.
Treatment-experienced for patients with genotype 4 is defined as patients who have been previously treated with a pegylated interferon + ribavirin regimen and have not experienced adequate response.
2. Treatment may be considered for patients with compensated cirrhosis (Child-Turcotte-Pugh A [i.e. Score 5 to 6])
3. On-treatment virologic failures are patients who have had a null response, partial response, virologic breakthrough or rebound, or intolerance to prior treatment.
4. Combination therapy with Sovaldi (sofosbuvir) will not be considered for funding for any genotypes.
5. Health care professionals are advised to refer to the product monograph and prescribing guidelines for appropriate use of the selected drug, including use in special populations.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="02035">
					<name>ELVITEGRAVIR &amp; COBICISTAT &amp; EMTRICITABINE &amp; TENOFOVIR ALAFENAMIDE</name>
					<pcgGroup>
						<pcg9 id="081800387">
							<itemNumber>0146</itemNumber>
							<strength>150mg &amp; 150mg &amp; 200mg &amp; 10mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>As a complete regimen for the treatment of HIV-1 infection in adult and pediatric patients 12 years of age and older (and weighing greater than or equal to 35kg) and with no known mutations associated with resistance to the individual components of Genvoya.
For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02449498" sec3="Y" sec6="Y">
								<name>Genvoya</name>
								<manufacturerId>GIL</manufacturerId>
								<individualPrice>45.1440</individualPrice>
								<listingDate>2017-04-27</listingDate>
								<amountMOHLTCPays>45.1440</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="02056">
					<name>EMTRICITABINE &amp; RILPIVIRINE HCL &amp; TENOFOVIR ALAFENAMIDE HEMIFUMARATE</name>
					<pcgGroup>
						<pcg9 id="081800390">
							<itemNumber>0147</itemNumber>
							<strength>200mg &amp; 25mg &amp; 25mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>As a complete regimen for the treatment of adults infected with HIV-1 with no known mutations associated with resistance to the non-nucleoside reverse-transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine (FTC), and with a viral load less than or equal to 100,000 copies/mL.
For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02461463" sec3="Y" sec6="Y">
								<name>Odefsey</name>
								<manufacturerId>GIL</manufacturerId>
								<individualPrice>42.3670</individualPrice>
								<listingDate>2018-08-30</listingDate>
								<amountMOHLTCPays>42.3670</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01889">
					<name>EMTRICITABINE &amp; RILPIVIRINE HCL &amp; TENOFOVIR DISOPROXIL</name>
					<pcgGroup>
						<pcg9 id="081800357">
							<itemNumber>0148</itemNumber>
							<strength>200mg &amp; 25mg &amp; 300mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>For the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment naive adult patients, or to replace the three components given as dual or triple therapy for patients stabilized on appropriate doses.
For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02374129" sec3="Y">
								<name>Complera</name>
								<manufacturerId>GIL</manufacturerId>
								<individualPrice>44.8643</individualPrice>
								<listingDate>2012-09-28</listingDate>
								<amountMOHLTCPays>44.8643</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01710">
					<name>EMTRICITABINE &amp; TENOFOVIR DISOPROXIL FUMARATE</name>
					<pcgGroup>
						<pcg9 id="081800099">
							<itemNumber>0149</itemNumber>
							<strength>200mg &amp; 300mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>Prescribers should be informed and stay current with a drug&apos;s official indications in accordance with Health Canada&apos;s approved product monograph.
</note>
							<drug id="02274906" sec3="Y">
								<name>Truvada</name>
								<manufacturerId>GIL</manufacturerId>
								<individualPrice>29.2140</individualPrice>
								<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.
For use as pre-exposure prophylaxis (PrEP) of HIV-1 in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 infection in adults at high risk for infection, in accordance with Health Canada&apos;s approved product monograph. Approval for the Facilitated Access to HIV/AIDS Drug Products mechanism is not required.</note>
								<listingDate>2007-09-04</listingDate>
								<amountMOHLTCPays>7.3035</amountMOHLTCPays>
							</drug>
							<drug id="02399059" sec3="Y">
								<name>Teva-Emtricitabine/Tenofovir</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>7.3035</individualPrice>
								<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.
For use as pre-exposure prophylaxis (PrEP) of HIV-1 in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 infection in adults at high risk for infection, in accordance with Health Canada&apos;s approved product monograph. Approval for the Facilitated Access to HIV/AIDS Drug Products mechanism is not required.</note>
								<listingDate>2017-09-28</listingDate>
								<amountMOHLTCPays>7.3035</amountMOHLTCPays>
							</drug>
							<drug id="02443902" sec3="Y">
								<name>Mylan-Emtricitabine/Tenofovir Disoproxil</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>7.3035</individualPrice>
								<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.
For use as pre-exposure prophylaxis (PrEP) of HIV-1 in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 infection in adults at high risk for infection, in accordance with Health Canada&apos;s approved product monograph. Approval for the Facilitated Access to HIV/AIDS Drug Products mechanism is not required.</note>
								<listingDate>2017-09-28</listingDate>
								<amountMOHLTCPays>7.3035</amountMOHLTCPays>
							</drug>
							<drug id="02452006" sec3="Y">
								<name>Apo-Emtricitabine-Tenofovir</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>7.3035</individualPrice>
								<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.
For use as pre-exposure prophylaxis (PrEP) of HIV-1 in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 infection in adults at high risk for infection, in accordance with Health Canada&apos;s approved product monograph. Approval for the Facilitated Access to HIV/AIDS Drug Products mechanism is not required.</note>
								<listingDate>2017-08-30</listingDate>
								<amountMOHLTCPays>7.3035</amountMOHLTCPays>
							</drug>
							<drug id="02461110" sec3="Y">
								<name>PMS-Emtricitabine/Tenofovir</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>7.3035</individualPrice>
								<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.
For use as pre-exposure prophylaxis (PrEP) of HIV-1 in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 infection in adults at high risk for infection, in accordance with Health Canada&apos;s approved product monograph. Approval for the Facilitated Access to HIV/AIDS Drug Products mechanism is not required.</note>
								<listingDate>2019-11-29</listingDate>
								<amountMOHLTCPays>7.3035</amountMOHLTCPays>
							</drug>
							<drug id="02487012" sec3="Y">
								<name>Jamp-Emtricitabine/Tenofovir Disoproxil</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>7.3035</individualPrice>
								<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.
For use as pre-exposure prophylaxis (PrEP) of HIV-1 in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 infection in adults at high risk for infection, in accordance with Health Canada&apos;s approved product monograph. Approval for the Facilitated Access to HIV/AIDS Drug Products mechanism is not required.</note>
								<listingDate>2019-10-31</listingDate>
								<amountMOHLTCPays>7.3035</amountMOHLTCPays>
							</drug>
							<drug id="02496356" sec3="Y">
								<name>AG-Emtricitabine &amp; Tenofovir Disoproxil</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>7.3035</individualPrice>
								<listingDate>2021-01-29</listingDate>
								<amountMOHLTCPays>7.3035</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01735">
					<name>ENTECAVIR</name>
					<pcgGroup lccId="00295">
						<pcg9 id="081800106">
							<itemNumber>0150</itemNumber>
							<strength>0.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02282224" sec3="Y" sec12="Y">
								<name>Baraclude</name>
								<manufacturerId>BQU</manufacturerId>
								<individualPrice>22.6600</individualPrice>
								<listingDate>2013-01-29</listingDate>
								<amountMOHLTCPays>4.4000</amountMOHLTCPays>
							</drug>
							<drug id="02396955" sec3="Y" sec12="Y">
								<name>Apo-Entecavir</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>5.5000</individualPrice>
								<listingDate>2013-01-29</listingDate>
								<amountMOHLTCPays>4.4000</amountMOHLTCPays>
							</drug>
							<drug id="02430576" sec3="Y" sec12="Y">
								<name>PMS-Entecavir</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>5.5000</individualPrice>
								<listingDate>2014-10-29</listingDate>
								<amountMOHLTCPays>4.4000</amountMOHLTCPays>
							</drug>
							<drug id="02448777" sec3="Y" sec12="Y">
								<name>Auro-Entecavir</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>5.5000</individualPrice>
								<listingDate>2016-03-30</listingDate>
								<amountMOHLTCPays>4.4000</amountMOHLTCPays>
							</drug>
							<drug id="02453797" sec3="Y" sec12="Y">
								<name>Entecavir Tablets</name>
								<manufacturerId>STR</manufacturerId>
								<individualPrice>5.5000</individualPrice>
								<listingDate>2021-01-29</listingDate>
								<amountMOHLTCPays>4.4000</amountMOHLTCPays>
							</drug>
							<drug id="02467232" sec3="Y" sec12="Y">
								<name>Jamp-Entecavir</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>5.5000</individualPrice>
								<listingDate>2018-08-30</listingDate>
								<amountMOHLTCPays>4.4000</amountMOHLTCPays>
							</drug>
							<drug id="02479907" sec3="Y" sec12="Y">
								<name>Accel-Entecavir</name>
								<manufacturerId>ACC</manufacturerId>
								<individualPrice>4.4000</individualPrice>
								<listingDate>2022-01-31</listingDate>
								<amountMOHLTCPays>4.4000</amountMOHLTCPays>
							</drug>
							<drug id="02485907" sec3="Y" sec12="Y">
								<name>Mint-Entecavir</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>5.5000</individualPrice>
								<listingDate>2020-03-31</listingDate>
								<amountMOHLTCPays>4.4000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="505">Confirmed chronic Hepatitis B infection in persons with
- HBV DNA greater than or equal to 1000 IU/mL
AND
- ALT levels greater than ULN
OR
- Evidence of fibrosis
or
- Documented evidence of cirrhosis</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="003" reasonForUseId="506">For patients with chronic Hepatitis B infection who have a contraindication, intolerance or inadequate response to one or more of the following: lamivudine, tenofovir, adefovir or telbivudine.</lccNote>
						<lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="005" reasonForUseId="507">Patients with chronic Hepatitis B infection currently receiving treatment with entecavir and requires treatment continuation.</lccNote>
						<lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="007" reasonForUseId="508">Patients with chronic Hepatitis B infection who are scheduled to undergo chemotherapy or significant immunosuppressive treatment.</lccNote>
						<lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="01747">
					<name>ETRAVIRINE</name>
					<pcgGroup>
						<pcg9 id="081800104">
							<itemNumber>0151</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>For use in combination with an optimized regimen, for the treatment of HIV-1
infection in treatment-experienced adult patients who have failed prior anti-retroviral therapies and have HIV-1 strains resistant to multiple antiretroviral agents, including protease inhibitors (PIs) and other non-nucleoside reverse transcriptase inhibitors (NNRTIs).
For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02306778" sec3="Y">
								<name>Intelence</name>
								<manufacturerId>JAN</manufacturerId>
								<individualPrice>6.5710</individualPrice>
								<listingDate>2009-01-30</listingDate>
								<amountMOHLTCPays>6.5710</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081800354">
							<itemNumber>0152</itemNumber>
							<strength>200mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>Note: For use in combination with an optimized regimen, for the treatment of HIV-1
infection in treatment-experienced adult patients who have failed prior anti-retroviral therapies and have HIV-1 strains resistant to multiple antiretroviral agents, including protease inhibitors (PIs) and other non-nucleoside reverse transcriptase inhibitors (NNRTIs).
For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02375931" sec3="Y">
								<name>Intelence</name>
								<manufacturerId>JAN</manufacturerId>
								<individualPrice>12.6195</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>12.6195</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00114">
					<name>FAMCICLOVIR</name>
					<pcgGroup>
						<pcg9 id="081800028">
							<itemNumber>0153</itemNumber>
							<strength>125mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02229110" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Famvir</name>
								<manufacturerId>APU</manufacturerId>
								<listingDate>2007-09-04</listingDate>
							</drug>
							<drug id="02278081" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>PMS-Famciclovir</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>2.0240</individualPrice>
								<listingDate>2007-10-03</listingDate>
								<amountMOHLTCPays>2.0240</amountMOHLTCPays>
							</drug>
							<drug id="02278634" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Sandoz Famciclovir</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>2.0240</individualPrice>
								<listingDate>2007-09-04</listingDate>
								<amountMOHLTCPays>2.0240</amountMOHLTCPays>
							</drug>
							<drug id="02292025" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Apo-Famciclovir</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>2.0240</individualPrice>
								<listingDate>2007-09-04</listingDate>
								<amountMOHLTCPays>2.0240</amountMOHLTCPays>
							</drug>
							<drug id="02305682" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Co Famciclovir</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>2.0240</individualPrice>
								<listingDate>2008-12-23</listingDate>
								<amountMOHLTCPays>2.0240</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081800029">
							<itemNumber>0154</itemNumber>
							<strength>250mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02229129" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Famvir</name>
								<manufacturerId>APU</manufacturerId>
								<listingDate>2007-09-04</listingDate>
							</drug>
							<drug id="02278103" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>PMS-Famciclovir</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>2.7200</individualPrice>
								<listingDate>2007-10-03</listingDate>
								<amountMOHLTCPays>2.7200</amountMOHLTCPays>
							</drug>
							<drug id="02278642" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Sandoz Famciclovir</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>2.7200</individualPrice>
								<listingDate>2007-09-04</listingDate>
								<amountMOHLTCPays>2.7200</amountMOHLTCPays>
							</drug>
							<drug id="02292041" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Apo-Famciclovir</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>2.7200</individualPrice>
								<listingDate>2007-09-04</listingDate>
								<amountMOHLTCPays>2.7200</amountMOHLTCPays>
							</drug>
							<drug id="02305690" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Co Famciclovir</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>2.7200</individualPrice>
								<listingDate>2008-12-23</listingDate>
								<amountMOHLTCPays>2.7200</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
					<pcgGroup lccId="00008">
						<pcg9 id="081800011">
							<itemNumber>0155</itemNumber>
							<strength>500mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02177102" sec3="Y" sec12="Y">
								<name>Famvir</name>
								<manufacturerId>APU</manufacturerId>
								<individualPrice>7.7438</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>1.3436</amountMOHLTCPays>
							</drug>
							<drug id="02278111" sec3="Y" sec12="Y">
								<name>PMS-Famciclovir</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>1.3436</individualPrice>
								<listingDate>2007-03-09</listingDate>
								<amountMOHLTCPays>1.3436</amountMOHLTCPays>
							</drug>
							<drug id="02278650" sec3="Y" sec12="Y">
								<name>Sandoz Famciclovir</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>1.3436</individualPrice>
								<listingDate>2007-01-02</listingDate>
								<amountMOHLTCPays>1.3436</amountMOHLTCPays>
							</drug>
							<drug id="02292068" sec3="Y" sec12="Y">
								<name>Apo-Famciclovir</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.3436</individualPrice>
								<listingDate>2007-04-02</listingDate>
								<amountMOHLTCPays>1.3436</amountMOHLTCPays>
							</drug>
							<drug id="02305704" sec3="Y" sec12="Y">
								<name>Co Famciclovir</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>1.3436</individualPrice>
								<listingDate>2008-12-23</listingDate>
								<amountMOHLTCPays>1.3436</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="147">Herpes zoster in patients 50 years of age or older, up to 72 hours* after appearance of lesions. Dose: 500mg 3 times/day for 7 days.</lccNote>
						<lccNote seq="002" type="R">*The patient must begin treatment within the time frame specified for the product to be reimbursed. There is no benefit from the therapy begun after this time frame.</lccNote>
						<lccNote seq="003" type="W">Network will limit supply to 7 days and 21 tablets.</lccNote>
						<lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="01636">
					<name>FOSAMPRENAVIR CALCIUM</name>
					<pcgGroup>
						<pcg9 id="081800107">
							<itemNumber>0156</itemNumber>
							<strength>50mg/mL</strength>
							<dosageForm>Oral Susp</dosageForm>
							<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02261553" sec3="Y">
								<name>Telzir</name>
								<manufacturerId>VIH</manufacturerId>
								<individualPrice>.6535</individualPrice>
								<listingDate>2009-01-30</listingDate>
								<amountMOHLTCPays>.6535</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081800093">
							<itemNumber>0157</itemNumber>
							<strength>700mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02261545" sec3="Y">
								<name>Telzir</name>
								<manufacturerId>VIH</manufacturerId>
								<individualPrice>9.4389</individualPrice>
								<listingDate>2006-01-12</listingDate>
								<amountMOHLTCPays>9.4389</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00108">
					<name>GANCICLOVIR SODIUM</name>
					<pcgGroup>
						<pcg9 id="081800001">
							<itemNumber>0158</itemNumber>
							<strength>500mg/Vial</strength>
							<dosageForm>Pd Inj-10mL Pk</dosageForm>
							<drug id="02162695" sec3="Y">
								<name>Cytovene</name>
								<manufacturerId>CHE</manufacturerId>
								<individualPrice>44.5480</individualPrice>
								<listingDate>2007-01-02</listingDate>
								<amountMOHLTCPays>44.5480</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="02074">
					<name>GLECAPREVIR &amp; PIBRENTASVIR</name>
					<pcgGroup lccId="00314">
						<pcg9 id="081800391">
							<itemNumber>0159</itemNumber>
							<strength>100mg &amp; 40mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02467550" sec3="Y" sec12="Y">
								<name>Maviret</name>
								<manufacturerId>ABV</manufacturerId>
								<individualPrice>238.0952</individualPrice>
								<listingDate>2019-02-28</listingDate>
								<amountMOHLTCPays>238.0952</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="550">For treatment-naive or treatment-experienced (1) adult patients with chronic hepatitis C (CHC) infection who meet all the following criteria:
(i) Treatment is prescribed by a hepatologist, gastroenterologist, infectious disease specialist or other prescriber experienced in treating chronic hepatitis C.
(ii) Laboratory confirmed hepatitis C genotype 1, 2, 3, 4, 5, or 6;
(iii) Established chronicity of HCV infection either by two laboratory confirmed quantitative HCV RNA values taken at least 6 months apart;
OR
One recent laboratory confirmed quantitative HCV RNA within the past 6 months and clinical features establishing a duration of HCV infection longer than 6 months (e.g. presence of fibrosis, presence of non-liver manifestations of HCV, prolonged ALT elevation greater than 6 months without another cause, HCV antibody positivity greater than 6 months), or risk factors for HCV acquisition greater than 6 months (e.g. injection drug use).
Exclusion criteria:
- Patients with genotype 1 who have relapsed but are treatment experienced on both an NS3/4A protease inhibitor and an NS5A inhibitor
- For use in combination with other hepatitis C antiviral agents
- Patients with decompensated cirrhosis or severe hepatic impairment (Child-Pugh C)
Retreatment is not funded. Retreatment for re-infection in patients who have received an adequate prior course of Maviret will be considered on a case-by-case basis through the Exceptional Access Program.
Treatment regimens for Maviret:
I. Treatment-naive, non-cirrhotic genotype 1, 2, 3, 4, 5, or 6.
Approved duration: 8 weeks
II. Treatment-naive genotype 1, 2, 3, 4, 5, or 6 with compensated cirrhosis.
Approved duration: 8 weeks
III. Treatment-experienced, non-cirrhotic genotype 1, 2, 4, 5, or 6 who have failed peginterferon/ribavirin and/or sofosbuvir ONLY.
Approved duration: 8 weeks
Notes:
(1) Treatment-experienced definitions vary by the genotype being treated. Health care professionals are advised to refer to the Maviret product monograph and prescribing guidelines for appropriate use of the drug product, including use in special populations.
(2) NS3/4A Pls include simeprevir, boceprevir, and telepravir.
(3) NS5A inhibitors include daclatasvir and ledipasvir.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 8 Weeks</lccNote>
						<lccNote seq="003" reasonForUseId="551">For treatment-naive or treatment-experienced (1) adult patients with chronic hepatitis C (CHC) infection who meet all the following criteria:
(i) Treatment is prescribed by a hepatologist, gastroenterologist, infectious disease specialist or other prescriber experienced in treating chronic hepatitis C;
(ii) Laboratory confirmed hepatitis C genotype 1, 2, 4, 5, or 6;
(iii) Established chronicity of HCV infection either by two laboratory confirmed quantitative HCV RNA values taken at least 6 months apart;
OR
One recent laboratory confirmed quantitative HCV RNA within the past 6 months and clinical features establishing a duration of HCV infection longer than 6 months (e.g. presence of fibrosis, presence of non-liver manifestations of HCV, prolonged ALT elevation greater than 6 months without another cause, HCV antibody positivity greater than 6 months), or risk factors for HCV acquisition greater than 6 months (e.g. injection drug use).
Exclusion criteria:
- Patients with genotype 1 who have relapsed but are treatment experienced on both an NS3/4A protease inhibitor and an NS5A inhibitor
- For use in combination with other hepatitis C antiviral agents
- Patients with decompensated cirrhosis or severe hepatic impairment (Child-Pugh C)
Retreatment is not funded. Retreatment for re-infection in patients who have received an adequate prior course of Maviret will be considered on a case-by-case basis through the Exceptional Access Program.
Treatment regimens for Maviret:
I. Treatment-experienced, genotype 1, 2, 4, 5, or 6 with compensated cirrhosis who have failed peginterferon/ribavirin and/or sofosbuvir ONLY.
Approved duration: 12 weeks
II. Treatment-experienced genotype 1 non-cirrhotic or compensated cirrhosis who have failed an NS3/4A protease inhibitor (2) but are NS5A inhibitor naive.
Approved duration: 12 weeks
Notes:
(1) Treatment-experienced definitions vary by the genotype being treated. Health care professionals are advised to refer to the Maviret product monograph and prescribing guidelines for appropriate use of the drug product, including use in special populations.
(2) NS3/4A PIs include simeprevir, boceprevir, and telepravir.
(3) NS5A inhibitors include daclatasvir and ledipasvir.</lccNote>
						<lccNote seq="004" type="R">LU Authorization Period: 12 Weeks.</lccNote>
						<lccNote seq="005" reasonForUseId="552">For treatment-naive or treatment-experienced (1) adult patients with chronic hepatitis C (CHC) infection who meet all the following criteria:
(i) Treatment is prescribed by a hepatologist, gastroenterologist, infectious disease specialist or other prescriber experienced in treating chronic hepatitis C;
(ii) Laboratory confirmed hepatitis C genotype 1 or 3;
(iii) Established chronicity of HCV infection either by two laboratory confirmed quantitative HCV RNA values taken at least 6 months apart;
OR
One recent laboratory confirmed quantitative HCV RNA within the past 6 months and clinical features establishing a duration of HCV infection longer than 6 months (e.g. presence of fibrosis, presence of non-liver manifestations of HCV, prolonged ALT elevation greater than 6 months without another cause, HCV antibody positivity greater than 6 months), or risk factors for HCV acquisition greater than 6 months (e.g. injection drug use).
Exclusion criteria:
- Patients with genotype 1 who have relapsed but are treatment experienced on both an NS3/4A protease inhibitor and an NS5A inhibitor
- For use in combination with other hepatitis C antiviral agents
- Patients with decompensated cirrhosis or severe hepatic impairment (Child-Pugh C)
Retreatment is not funded. Retreatment for re-infection in patients who have received an adequate prior course of Maviret will be considered on a case-by-case basis through the Exceptional Access Program.
Treatment regimens for Maviret:
I. Treatment-experienced genotype 1 non-cirrhotic or compensated cirrhosis who have failed an NS5A inhibitor (3) but is NS3/4A protease inhibitor naive.
Approved duration: 16 weeks
II. Treatment-experienced genotype 3 non-cirrhotic or compensated cirrhosis who have failed peginterferon/ribavirin and/or sofosbuvir ONLY.
Approved duration: 16 weeks
Notes:
(1) Treatment-experienced definitions vary by the genotype being treated. Health care professionals are advised to refer to the Maviret product monograph and prescribing guidelines for appropriate use of the drug product, including use in special populations.
(2) NS3/4A PIs include simeprevir, boceprevir, and telepravir.
(3) NS5A inhibitors include daclatasvir and ledipasvir.</lccNote>
						<lccNote seq="006" type="R">LU Authorization Period: 16 Weeks.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00111">
					<name>LAMIVUDINE</name>
					<pcgGroup>
						<pcg9 id="081800005">
							<itemNumber>0160</itemNumber>
							<strength>10mg/mL</strength>
							<dosageForm>O/L</dosageForm>
							<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism. Reimbursement will not be provided for the treatment of hepatitis.</note>
							<drug id="02192691" sec3="Y">
								<name>3TC</name>
								<manufacturerId>VIH</manufacturerId>
								<individualPrice>.3670</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3670</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
					<pcgGroup lccId="00296">
						<pcg9 id="081800048">
							<itemNumber>0161</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02239193" sec3="Y" sec12="Y">
								<name>Heptovir</name>
								<manufacturerId>GSK</manufacturerId>
								<individualPrice>5.2307</individualPrice>
								<listingDate>2012-11-27</listingDate>
								<amountMOHLTCPays>2.6154</amountMOHLTCPays>
							</drug>
							<drug id="02393239" sec3="Y" sec12="Y">
								<name>Apo-Lamivudine HBV</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>2.6154</individualPrice>
								<listingDate>2012-11-27</listingDate>
								<amountMOHLTCPays>2.6154</amountMOHLTCPays>
							</drug>
							<drug id="02512467" sec3="Y" sec12="Y">
								<name>Jamp Lamivudine HBV</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>2.6154</individualPrice>
								<listingDate>2021-09-30</listingDate>
								<amountMOHLTCPays>2.6154</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="502">Confirmed chronic Hepatitis B infection in persons with
- HBV DNA greater than or equal to 1000 IU/mL
AND
- ALT levels greater than ULN
OR
- Evidence of fibrosis
or
- Documented evidence of cirrhosis</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="003" reasonForUseId="503">Patients with chronic Hepatitis B infection currently receiving treatment with lamivudine and requires treatment continuation.</lccNote>
						<lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="005" reasonForUseId="504">Patients with chronic Hepatitis B infection who are scheduled to undergo chemotherapy or significant immunosuppressive treatment.</lccNote>
						<lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
					<pcgGroup>
						<pcg9 id="081800004">
							<itemNumber>0162</itemNumber>
							<strength>150mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism. Reimbursement will not be provided for the treatment of hepatitis.</note>
							<drug id="02192683" sec3="Y">
								<name>3TC</name>
								<manufacturerId>VIH</manufacturerId>
								<individualPrice>5.6833</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>2.7323</amountMOHLTCPays>
							</drug>
							<drug id="02369052" sec3="Y">
								<name>Apo-Lamivudine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>2.7323</individualPrice>
								<listingDate>2012-07-27</listingDate>
								<amountMOHLTCPays>2.7323</amountMOHLTCPays>
							</drug>
							<drug id="02507110" sec3="Y">
								<name>Jamp Lamivudine</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>2.7323</individualPrice>
								<listingDate>2021-04-30</listingDate>
								<amountMOHLTCPays>2.7323</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081800078">
							<itemNumber>0163</itemNumber>
							<strength>300mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism. Reimbursement will not be provided for the treatment of hepatitis</note>
							<drug id="02247825" sec3="Y">
								<name>3TC</name>
								<manufacturerId>VIH</manufacturerId>
								<individualPrice>11.4102</individualPrice>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>5.4857</amountMOHLTCPays>
							</drug>
							<drug id="02369060" sec3="Y">
								<name>Apo-Lamivudine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>5.4857</individualPrice>
								<listingDate>2012-07-27</listingDate>
								<amountMOHLTCPays>5.4857</amountMOHLTCPays>
							</drug>
							<drug id="02507129" sec3="Y">
								<name>Jamp Lamivudine</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>5.4857</individualPrice>
								<listingDate>2021-04-30</listingDate>
								<amountMOHLTCPays>5.4857</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01404">
					<name>LAMIVUDINE &amp; ZIDOVUDINE</name>
					<pcgGroup>
						<pcg9 id="081800049">
							<itemNumber>0164</itemNumber>
							<strength>150mg &amp; 300mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02239213" sec3="Y">
								<name>Combivir</name>
								<manufacturerId>VIH</manufacturerId>
								<individualPrice>12.1140</individualPrice>
								<listingDate>1999-09-15</listingDate>
								<amountMOHLTCPays>5.2206</amountMOHLTCPays>
							</drug>
							<drug id="02375540" sec3="Y">
								<name>Apo-Lamivudine-Zidovudine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>5.2206</individualPrice>
								<listingDate>2012-07-27</listingDate>
								<amountMOHLTCPays>5.2206</amountMOHLTCPays>
							</drug>
							<drug id="02414414" sec3="Y">
								<name>Auro-Lamivudine/Zidovudine</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>5.2206</individualPrice>
								<listingDate>2014-05-29</listingDate>
								<amountMOHLTCPays>5.2206</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01968">
					<name>LEDIPASVIR &amp; SOFOSBUVIR</name>
					<pcgGroup lccId="00276">
						<pcg9 id="081800370">
							<itemNumber>0165</itemNumber>
							<strength>90mg &amp; 400mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02432226" sec3="Y" sec12="Y">
								<name>Harvoni</name>
								<manufacturerId>GIL</manufacturerId>
								<individualPrice>797.6190</individualPrice>
								<listingDate>2017-02-28</listingDate>
								<amountMOHLTCPays>797.6190</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="482">For treatment-naive or treatment-experienced (1) adult patients with chronic hepatitis C (CHC) infection who meet all the following criteria:
(i) Treatment is prescribed by a hepatologist, gastroenterologist, infectious disease specialist or other prescriber experienced in treating chronic hepatitis C; AND
(ii) Laboratory confirmed hepatitis C genotype 1; AND
(iii) Established chronicity of HCV infection either by two laboratory confirmed quantitative HCV RNA values taken at least 6 months apart;
OR
One recent laboratory confirmed quantitative HCV RNA within the past 6 months and clinical features establishing a duration of HCV infection longer than 6 months (e.g. presence of fibrosis, presence of non-liver manifestations of HCV, prolonged ALT elevation greater than 6 months without another cause, HCV antibody positivity greater than 6 months), or risk factors for HCV acquisition greater than 6 months (e.g. injection drug use).
Treatment regimens:
- Treatment-naive, non-cirrhotic, recent quantitative hepatitis C viral load less than 6 M IU/mL
Approved duration: 8 weeks
Retreatment is not funded. Retreatment for failure or re-infection in patients who have received an adequate prior course of direct-acting antiviral will be considered on a case-by-case basis through the Exceptional Access Program.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 8 Weeks</lccNote>
						<lccNote seq="003" reasonForUseId="483">For treatment-naive or treatment-experienced (1) adult patients with chronic hepatitis C (CHC) infection who meet all the following criteria:
(i) Treatment is prescribed by a hepatologist, gastroenterologist, infectious disease specialist or other prescriber experienced in treating chronic hepatitis C; AND
(ii) Laboratory confirmed hepatitis C genotype 1; AND
(iii) Established chronicity of HCV infection either by two laboratory confirmed quantitative HCV RNA values taken at least 6 months apart;
OR
One recent laboratory confirmed quantitative HCV RNA within the past 6 months and clinical features establishing a duration of HCV infection longer than 6 months (e.g. presence of fibrosis, presence of non-liver manifestations of HCV, prolonged ALT elevation greater than 6 months without another cause, HCV antibody positivity greater than 6 months), or risk factors for HCV acquisition greater than 6 months (e.g. injection drug use).
Treatment regimens:
I. Treatment-naive, without cirrhosis, viral load greater than or equal to 6 M IU/mL; or treatment-naive with cirrhosis; or treatment-experienced without cirrhosis
Approved duration: 12 weeks
II. Treatment-naive or treatment-experienced with decompensated cirrhosis (2)
Approved regimen: 12 weeks in combination with ribavirin (Ibavyr)
III. Treatment-naive or treatment-experienced liver transplant recipients without cirrhosis or with compensated cirrhosis (2)
Approved regimen: 12 weeks in combination with ribavirin (Ibavyr)
Retreatment is not funded. Retreatment for failure or re-infection in patients who have received an adequate prior course of direct-acting antiviral will be considered on a case-by-case basis through the Exceptional Access Program.</lccNote>
						<lccNote seq="004" type="R">LU Authorization Period: 12 Weeks.</lccNote>
						<lccNote seq="005" reasonForUseId="484">For treatment-naive or treatment-experienced (1) adult patients with chronic hepatitis C (CHC) infection who meet all the following criteria:
(i) Treatment is prescribed by a hepatologist, gastroenterologist, infectious disease specialist or other prescriber experienced in treating chronic hepatitis C; AND
(ii) Laboratory confirmed hepatitis C genotype 1; AND
(iii) Established chronicity of HCV infection either by two laboratory confirmed quantitative HCV RNA values taken at least 6 months apart;
OR
One recent laboratory confirmed quantitative HCV RNA within the past 6 months and clinical features establishing a duration of HCV infection longer than 6 months (e.g. presence of fibrosis, presence of non-liver manifestations of HCV, prolonged ALT elevation greater than 6 months without another cause, HCV antibody positivity greater than 6 months), or risk factors for HCV acquisition greater than 6 months (e.g. injection drug use).
Treatment regimen:
- Treatment-experienced, cirrhotic:
Approved duration: 24 weeks
Retreatment is not funded. Retreatment for failure or re-infection in patients who have received an adequate prior course of direct-acting antiviral will be considered on a case-by-case basis through the Exceptional Access Program.</lccNote>
						<lccNote seq="006" type="R">LU Authorization Period: 24 Weeks.</lccNote>
						<lccNote seq="007" type="N">1. Treatment-experienced are those who failed prior therapy with an interferon-based regimen, including regimens containing an HCV protease inhibitor.
2. Compensated cirrhosis (Child-Turcotte-Pugh A [i.e. Scores 5 to 6]) and decompensated cirrhosis (Child-Turcotte-Pugh B or C [i.e. Score 7 or above]) may be considered.
3. Health care professionals are advised to refer to the product monograph and prescribing guidelines for appropriate use of the drug product, including use in special populations.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="01511">
					<name>LOPINAVIR &amp; RITONAVIR</name>
					<pcgGroup>
						<pcg9 id="081800061">
							<itemNumber>0166</itemNumber>
							<strength>80mg/mL &amp; 20mg/mL</strength>
							<dosageForm>O/L</dosageForm>
							<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02243644" sec3="Y">
								<name>Kaletra</name>
								<manufacturerId>ABV</manufacturerId>
								<individualPrice>2.3688</individualPrice>
								<listingDate>2001-10-11</listingDate>
								<amountMOHLTCPays>2.3688</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081800110">
							<itemNumber>0167</itemNumber>
							<strength>100mg &amp; 25mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02312301" sec3="Y">
								<name>Kaletra</name>
								<manufacturerId>ABV</manufacturerId>
								<individualPrice>2.9317</individualPrice>
								<listingDate>2009-04-01</listingDate>
								<amountMOHLTCPays>2.9317</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081800098">
							<itemNumber>0168</itemNumber>
							<strength>200mg &amp; 50mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02285533" sec3="Y">
								<name>Kaletra</name>
								<manufacturerId>ABV</manufacturerId>
								<individualPrice>5.8633</individualPrice>
								<listingDate>2007-09-04</listingDate>
								<amountMOHLTCPays>5.8633</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01751">
					<name>MARAVIROC</name>
					<pcgGroup>
						<pcg9 id="081800111">
							<itemNumber>0169</itemNumber>
							<strength>150mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>For use in combination with an optimized regimen for the treatment of HIV-1 infection in treatment experienced adult patients with:
CCR5 tropic virus only; AND who have one of the following:
- Documented resistance to at least one drug in each of the major classes of anti-retrovirals: protease inhibitors (PIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and nucleoside reverse transcriptase inhibitors (NRTIs);
OR
- Documented class resistance to ONE of the major classes of anti-retrovirals: PIs, NNRTIs and NRTIs precluding treatment with that antiretroviral class;
OR
- Experienced serious class-effect intolerance to at least one major class of anti-retrovirals: PIs, NNRTIs or NRTIs precluding treatment with that antiretroviral class.
For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.
</note>
							<drug id="02299844" sec3="Y">
								<name>Celsentri</name>
								<manufacturerId>VIH</manufacturerId>
								<individualPrice>18.4158</individualPrice>
								<listingDate>2014-04-30</listingDate>
								<amountMOHLTCPays>18.4158</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081800112">
							<itemNumber>0170</itemNumber>
							<strength>300mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>For use in combination with an optimized regimen for the treatment of HIV-1 infection in treatment experienced adult patients with:
CCR5 tropic virus only; AND who have one of the following:
- Documented resistance to at least one drug in each of the major classes of anti-retrovirals: protease inhibitors (PIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and nucleoside reverse transcriptase inhibitors (NRTIs);
OR
- Documented class resistance to ONE of the major classes of anti-retrovirals: PIs, NNRTIs and NRTIs precluding treatment with that antiretroviral class;
OR
- Experienced serious class-effect intolerance to at least one major class of anti-retrovirals: PIs, NNRTIs or NRTIs precluding treatment with that antiretroviral class.
For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.
</note>
							<drug id="02299852" sec3="Y">
								<name>Celsentri</name>
								<manufacturerId>VIH</manufacturerId>
								<individualPrice>18.4158</individualPrice>
								<listingDate>2014-04-30</listingDate>
								<amountMOHLTCPays>18.4158</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01390">
					<name>NELFINAVIR MESYLATE</name>
					<pcgGroup>
						<pcg9 id="081800042">
							<itemNumber>0171</itemNumber>
							<strength>250mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02238617" sec3="Y">
								<name>Viracept</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>2.1814</individualPrice>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>2.1814</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081800086">
							<itemNumber>0172</itemNumber>
							<strength>625mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02248761" sec3="Y">
								<name>Viracept</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>5.4642</individualPrice>
								<listingDate>2005-05-25</listingDate>
								<amountMOHLTCPays>5.4642</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01393">
					<name>NEVIRAPINE</name>
					<pcgGroup>
						<pcg9 id="081800356">
							<itemNumber>0173</itemNumber>
							<strength>400mg</strength>
							<dosageForm>ER Tab</dosageForm>
							<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02367289" sec3="Y">
								<name>Viramune XR</name>
								<manufacturerId>BOE</manufacturerId>
								<individualPrice>2.6420</individualPrice>
								<listingDate>2012-07-27</listingDate>
								<amountMOHLTCPays>1.8519</amountMOHLTCPays>
							</drug>
							<drug id="02427931" sec3="Y">
								<name>Apo-Nevirapine XR</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.8519</individualPrice>
								<listingDate>2016-01-28</listingDate>
								<amountMOHLTCPays>1.8519</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081800044">
							<itemNumber>0174</itemNumber>
							<strength>200mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02238748" notABenefit="Y" sec3="Y">
								<name>Viramune</name>
								<manufacturerId>BOE</manufacturerId>
								<listingDate>1999-04-15</listingDate>
							</drug>
							<drug id="02318601" sec3="Y">
								<name>Auro-Nevirapine</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>1.2346</individualPrice>
								<listingDate>2011-05-19</listingDate>
								<amountMOHLTCPays>1.2346</amountMOHLTCPays>
							</drug>
							<drug id="02352893" sec3="Y">
								<name>Teva-Nevirapine</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>1.2346</individualPrice>
								<listingDate>2011-05-19</listingDate>
								<amountMOHLTCPays>1.2346</amountMOHLTCPays>
							</drug>
							<drug id="02387727" sec3="Y">
								<name>Mylan-Nevirapine</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>1.2346</individualPrice>
								<listingDate>2012-08-27</listingDate>
								<amountMOHLTCPays>1.2346</amountMOHLTCPays>
							</drug>
							<drug id="02405776" sec3="Y">
								<name>Jamp Nevirapine</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>1.2346</individualPrice>
								<listingDate>2013-07-30</listingDate>
								<amountMOHLTCPays>1.2346</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01554">
					<name>OSELTAMIVIR PHOSPHATE</name>
					<pcgGroup lccId="00143">
						<pcg9 id="081800341">
							<itemNumber>0175</itemNumber>
							<strength>30mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02304848" sec3="Y" sec12="Y">
								<name>Tamiflu</name>
								<manufacturerId>HLR</manufacturerId>
								<individualPrice>2.1150</individualPrice>
								<listingDate>2011-03-15</listingDate>
								<amountMOHLTCPays>.5243</amountMOHLTCPays>
							</drug>
							<drug id="02472635" sec3="Y" sec12="Y">
								<name>Nat-Oseltamivir</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>.5243</individualPrice>
								<listingDate>2018-05-31</listingDate>
								<amountMOHLTCPays>.5243</amountMOHLTCPays>
							</drug>
							<drug id="02497352" sec3="Y" sec12="Y">
								<name>Mar-Oseltamivir</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.5243</individualPrice>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>.5243</amountMOHLTCPays>
							</drug>
							<drug id="02497409" sec3="Y" sec12="Y">
								<name>Jamp Oseltamivir</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.5243</individualPrice>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.5243</amountMOHLTCPays>
							</drug>
							<drug id="02497441" sec3="Y" sec12="Y">
								<name>Mint-Oseltamivir</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.5243</individualPrice>
								<listingDate>2020-08-28</listingDate>
								<amountMOHLTCPays>.5243</amountMOHLTCPays>
							</drug>
							<drug id="02504006" sec3="Y" sec12="Y">
								<name>Oseltamivir Phosphate Capsules</name>
								<manufacturerId>STR</manufacturerId>
								<individualPrice>.5243</individualPrice>
								<listingDate>2021-01-29</listingDate>
								<amountMOHLTCPays>.5243</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081800342">
							<itemNumber>0176</itemNumber>
							<strength>45mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02304856" sec3="Y" sec12="Y">
								<name>Tamiflu</name>
								<manufacturerId>HLR</manufacturerId>
								<individualPrice>3.2540</individualPrice>
								<listingDate>2011-03-15</listingDate>
								<amountMOHLTCPays>.8068</amountMOHLTCPays>
							</drug>
							<drug id="02472643" sec3="Y" sec12="Y">
								<name>Nat-Oseltamivir</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>.8068</individualPrice>
								<listingDate>2018-05-31</listingDate>
								<amountMOHLTCPays>.8068</amountMOHLTCPays>
							</drug>
							<drug id="02497360" sec3="Y" sec12="Y">
								<name>Mar-Oseltamivir</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.8068</individualPrice>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>.8068</amountMOHLTCPays>
							</drug>
							<drug id="02504014" sec3="Y" sec12="Y">
								<name>Oseltamivir Phosphate Capsules</name>
								<manufacturerId>STR</manufacturerId>
								<individualPrice>.8068</individualPrice>
								<listingDate>2021-01-29</listingDate>
								<amountMOHLTCPays>.8068</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081800064">
							<itemNumber>0177</itemNumber>
							<strength>75mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02241472" sec3="Y" sec12="Y">
								<name>Tamiflu</name>
								<manufacturerId>HLR</manufacturerId>
								<individualPrice>4.1940</individualPrice>
								<listingDate>2003-04-16</listingDate>
								<amountMOHLTCPays>1.0393</amountMOHLTCPays>
							</drug>
							<drug id="02457989" sec3="Y" sec12="Y">
								<name>Nat-Oseltamivir</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>1.0393</individualPrice>
								<listingDate>2016-11-30</listingDate>
								<amountMOHLTCPays>1.0393</amountMOHLTCPays>
							</drug>
							<drug id="02497379" sec3="Y" sec12="Y">
								<name>Mar-Oseltamivir</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>1.0393</individualPrice>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>1.0393</amountMOHLTCPays>
							</drug>
							<drug id="02497425" sec3="Y" sec12="Y">
								<name>Jamp Oseltamivir</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>1.0393</individualPrice>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>1.0393</amountMOHLTCPays>
							</drug>
							<drug id="02497476" sec3="Y" sec12="Y">
								<name>Mint-Oseltamivir</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>1.0393</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>1.0393</amountMOHLTCPays>
							</drug>
							<drug id="02504022" sec3="Y" sec12="Y">
								<name>Oseltamivir Phosphate Capsules</name>
								<manufacturerId>STR</manufacturerId>
								<individualPrice>1.0393</individualPrice>
								<listingDate>2021-01-29</listingDate>
								<amountMOHLTCPays>1.0393</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="371">For the prophylaxis (max: 75mg daily) of institutionalized individuals during confirmed* outbreaks of Influenza A or Influenza B.</lccNote>
						<lccNote seq="002" type="N">Network will limit supply to 6 weeks.</lccNote>
						<lccNote seq="003" type="R">*The outbreak must be confirmed by Public Health.</lccNote>
						<lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="005" reasonForUseId="372">For the treatment (max: 75mg bid) of institutionalized individuals during confirmed* outbreaks due to: Influenza B or, Influenza A (as an alternative to amantadine) or, Influenza A where new cases have developed despite amantadine prophylaxis.</lccNote>
						<lccNote seq="006" type="N">Network will limit supply to 5 days.</lccNote>
						<lccNote seq="007" type="R">*The outbreak must be confirmed by Public Health.</lccNote>
						<lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
					<pcgGroup>
						<pcg9 id="081800403">
							<itemNumber>0178</itemNumber>
							<strength>6mg/mL</strength>
							<dosageForm>O/L</dosageForm>
							<drug id="02381842" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Tamiflu</name>
								<manufacturerId>HLR</manufacturerId>
								<listingDate>2020-08-28</listingDate>
							</drug>
							<drug id="02499894" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Nat-Oseltamivir</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>.2811</individualPrice>
								<listingDate>2020-08-28</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01723">
					<name>RALTEGRAVIR POTASSIUM</name>
					<pcgGroup>
						<pcg9 id="081800102">
							<itemNumber>0179</itemNumber>
							<strength>400mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>For use as part of an optimized regimen for the treatment of HIV/AIDS in adult patients.
For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02301881" sec3="Y" sec6="Y">
								<name>Isentress</name>
								<manufacturerId>MFC</manufacturerId>
								<individualPrice>14.0301</individualPrice>
								<listingDate>2010-04-23</listingDate>
								<amountMOHLTCPays>14.0301</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081800394">
							<itemNumber>0180</itemNumber>
							<strength>600mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>For use as part of an optimized regimen for the treatment of HIV/AIDS in adult patients.
For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.
</note>
							<drug id="02465337" sec3="Y" sec6="Y">
								<name>Isentress HD</name>
								<manufacturerId>MEK</manufacturerId>
								<individualPrice>14.0301</individualPrice>
								<listingDate>2019-07-31</listingDate>
								<amountMOHLTCPays>14.0301</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01970">
					<name>RIBAVIRIN</name>
					<pcgGroup lccId="00282">
						<pcg9 id="081800376">
							<itemNumber>0181</itemNumber>
							<strength>200mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02439212" sec3="Y" sec12="Y">
								<name>Ibavyr</name>
								<manufacturerId>PEN</manufacturerId>
								<individualPrice>7.2500</individualPrice>
								<listingDate>2017-02-28</listingDate>
								<amountMOHLTCPays>7.2500</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081800371">
							<itemNumber>0182</itemNumber>
							<strength>400mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02425890" sec3="Y" sec12="Y">
								<name>Ibavyr</name>
								<manufacturerId>PEN</manufacturerId>
								<individualPrice>14.5000</individualPrice>
								<listingDate>2017-02-28</listingDate>
								<amountMOHLTCPays>14.5000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081800372">
							<itemNumber>0183</itemNumber>
							<strength>600mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02425904" sec3="Y" sec12="Y">
								<name>Ibavyr</name>
								<manufacturerId>PEN</manufacturerId>
								<individualPrice>21.7500</individualPrice>
								<listingDate>2017-02-28</listingDate>
								<amountMOHLTCPays>21.7500</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="494">For use within a Ministry-approved and funded combination therapy regimen for the treatment of chronic hepatitis C according to specific eligibility criteria.
The regimen for the use of ribavirin must comply with the Ontario Drug Benefit Program&apos;s criteria for funding of the hepatitis C regimen in which it is being administered and use of ribavirin outside of an approved hepatitis C funded regimen will not be reimbursed.
Note: Treatment must be prescribed by a hepatologist, gastroenterologist, infectious disease specialist or other prescriber experienced in treating chronic hepatitis C.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: Upto a maximum of 24 weeks.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="01888">
					<name>RILPIVIRINE HYDROCHLORIDE</name>
					<pcgGroup>
						<pcg9 id="081800355">
							<itemNumber>0184</itemNumber>
							<strength>25mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>For use in combination with other antiretroviral therapies, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment naive adult patients.
For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02370603" sec3="Y">
								<name>Edurant</name>
								<manufacturerId>JAN</manufacturerId>
								<individualPrice>16.2870</individualPrice>
								<listingDate>2012-07-27</listingDate>
								<amountMOHLTCPays>16.2870</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00113">
					<name>RITONAVIR</name>
					<pcgGroup>
						<pcg9 id="081800350">
							<itemNumber>0185</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02357593" sec3="Y">
								<name>Norvir</name>
								<manufacturerId>ABB</manufacturerId>
								<individualPrice>1.5660</individualPrice>
								<listingDate>2012-02-29</listingDate>
								<amountMOHLTCPays>1.5660</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01967">
					<name>SOFOSBUVIR</name>
					<pcgGroup lccId="00277">
						<pcg9 id="081800369">
							<itemNumber>0186</itemNumber>
							<strength>400mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02418355" sec3="Y" sec12="Y">
								<name>Sovaldi</name>
								<manufacturerId>GIL</manufacturerId>
								<individualPrice>654.7619</individualPrice>
								<listingDate>2017-02-28</listingDate>
								<amountMOHLTCPays>654.7619</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="485">In combination with ribavirin (Ibavyr) for treatment-naive or treatment-experienced (1) adult patients with chronic hepatitis C (CHC) infection who meet all the following criteria:
(i) Treatment is prescribed by a hepatologist, gastroenterologist, infectious disease specialist or other prescriber experienced in treating chronic hepatitis C; AND
(ii) Laboratory confirmed hepatitis C genotype 2; AND
(iii) Established chronicity of HCV infection either by two laboratory confirmed quantitative HCV RNA values taken at least 6 months apart;
OR
One recent laboratory confirmed quantitative HCV RNA within the past 6 months and clinical features establishing a duration of HCV infection longer than 6 months (e.g. presence of fibrosis, presence of non-liver manifestations of HCV, prolonged ALT elevation greater than 6 months without another cause, HCV antibody positivity greater than 6 months), or risk factors for HCV acquisition greater than 6 months (e.g. injection drug use).
For patients who meet the eligibility criteria for sofosbuvir (Sovaldi), clinicians are encouraged to choose sofosbuvir/velpatasvir (Epclusa) as the preferred therapeutic option over sofosbuvir with ribavirin regimens for treatment of genotype 2 or 3 patients only. This recommendation is based on evidence that Epclusa offers advantages in some patient populations, including potentially higher SVR rates and a shorter course of therapy for genotype 3 infections.
Treatment regimens for sofosbuvir (Sovaldi) for genotype 2:
- Treatment-naive or treatment-experienced genotype 2
Approved regimen: 12 weeks in combination with ribavirin (Ibavyr)
Retreatment is not funded. Retreatment for failure or re-infection in patients who have received an adequate prior course of direct-acting antiviral will be considered on a case-by-case basis through the Exceptional Access Program.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 12 Weeks.</lccNote>
						<lccNote seq="005" reasonForUseId="487">In combination with ribavirin (Ibavyr) for treatment-naive or treatment-experienced (1) adult patients with chronic hepatitis C (CHC) infection who meet all the following criteria:
(i) Treatment is prescribed by a hepatologist, gastroenterologist, infectious disease specialist or other prescriber experienced in treating chronic hepatitis C; AND
(ii) Laboratory confirmed hepatitis C genotype 3; AND
(iii) Established chronicity of HCV infection either by two laboratory confirmed quantitative HCV RNA values taken at least 6 months apart;
OR
One recent laboratory confirmed quantitative HCV RNA within the past 6 months and clinical features establishing a duration of HCV infection longer than 6 months (e.g. presence of fibrosis, presence of non-liver manifestations of HCV, prolonged ALT elevation greater than 6 months without another cause, HCV antibody positivity greater than 6 months), or risk factors for HCV acquisition greater than 6 months (e.g. injection drug use).
For patients who meet the eligibility criteria for sofosbuvir (Sovaldi), clinicians are encouraged to choose sofosbuvir/velpatasvir (Epclusa) as the preferred therapeutic option over sofosbuvir with ribavirin regimens for treatment of genotype 2 or 3 patients only. This recommendation is based on evidence that Epclusa offers advantages in some patient populations, including potentially higher SVR rates and a shorter course of therapy for genotype 3 infections.
Treatment regimens for sofosbuvir (Sovaldi) for genotype 3:
- Treatment-naive or treatment-experienced without cirrhosis, or with compensated cirrhosis (2), or with decompensated cirrhosis (2), or post-liver transplant
Approved regimen: 24 weeks in combination with ribavirin (Ibavyr).
Retreatment is not funded. Retreatment for failure or re-infection in patients who have received an adequate prior course of direct-acting antiviral will be considered on a case-by-case basis through the Exceptional Access Program.</lccNote>
						<lccNote seq="006" type="R">LU Authorization Period: 24 Weeks.</lccNote>
						<lccNote seq="007" type="N">1. Treatment-experienced are those who failed prior therapy with an interferon-based regimen, including regimens containing an HCV protease inhibitor.
2. Compensated cirrhosis (Child-Turcotte-Pugh A [i.e. Score 5 to 6]) and decompensated cirrhosis (Child-Turcotte-Pugh B or C [i.e. Score 7 or above]) may be considered.
3. Combination therapy with Zepatier (elbasvir/grazoprevir) will not be considered for funding.
4. Health care professionals are advised to refer to the product monograph and prescribing guidelines for appropriate use of the drug product, including use in special populations.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="02028">
					<name>SOFOSBUVIR &amp; VELPATASVIR</name>
					<pcgGroup lccId="00278">
						<pcg9 id="081800382">
							<itemNumber>0187</itemNumber>
							<strength>400mg &amp; 100mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02456370" sec3="Y" sec12="Y">
								<name>Epclusa</name>
								<manufacturerId>GIL</manufacturerId>
								<individualPrice>714.2857</individualPrice>
								<listingDate>2017-02-28</listingDate>
								<amountMOHLTCPays>714.2857</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="488">For treatment-naive or treatment-experienced (1) adult patients with chronic hepatitis C (CHC) infection who meet all the following criteria:
(i) Treatment is prescribed by a hepatologist, gastroenterologist, infectious disease specialist or other prescriber experienced in treating chronic hepatitis C; AND
(ii) Laboratory confirmed hepatitis C genotype 1, 2, 3, 4, 5, 6 or mixed genotypes; AND
(iii) Established chronicity of HCV infection either by two laboratory confirmed quantitative HCV RNA values taken at least 6 months apart;
OR
One recent laboratory confirmed quantitative HCV RNA within the past 6 months and clinical features establishing a duration of HCV infection longer than 6 months (e.g. presence of fibrosis, presence of non-liver manifestations of HCV, prolonged ALT elevation greater than 6 months without another cause, HCV antibody positivity greater than 6 months), or risk factors for HCV acquisition greater than 6 months (e.g. injection drug use).
Treatment regimens for Epclusa (sofosbuvir-velpatasvir):
I. Treatment-naive or treatment-experienced (1) non-cirrhotic or compensated cirrhosis (2)
Approved duration: 12 weeks
II. Treatment-naive or treatment-experienced patients with decompensated cirrhosis (2)
Approved regimen: 12 weeks in combination with ribavirin (Ibavyr)
Retreatment is not funded. Retreatment for failure or re-infection in patients who have received an adequate prior course of direct-acting antiviral will be considered on a case-by-case basis through the Exceptional Access Program.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 12 Weeks.</lccNote>
						<lccNote seq="003" type="N">1. Treatment-experienced are those who failed prior therapy with an interferon-based regimen, including regimens containing an HCV protease inhibitor.
2. Compensated cirrhosis (Child-Turcotte-Pugh A [i.e. Scores 5 to 6]) and decompensated cirrhosis (Child-Turcotte-Pugh B or C [i.e. Score 7 or above]) may be considered.
3. Health care professionals are advised to refer to the product monograph and prescribing guidelines for appropriate use of the drug product, including use in special populations.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="02046">
					<name>SOFOSBUVIR &amp; VELPATASVIR &amp; VOXILAPREVIR</name>
					<pcgGroup lccId="00298">
						<pcg9 id="081800389">
							<itemNumber>0188</itemNumber>
							<strength>400mg &amp; 100mg &amp; 100mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02467542" sec3="Y" sec12="Y">
								<name>Vosevi</name>
								<manufacturerId>GIL</manufacturerId>
								<individualPrice>714.2857</individualPrice>
								<listingDate>2018-02-28</listingDate>
								<amountMOHLTCPays>714.2857</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="524">For treatment-experienced (1) adult patients with chronic hepatitis C (CHC) infection who meet all the following criteria:
(i) Treatment is prescribed by a hepatologist, gastroenterologist, infectious disease specialist or other prescriber experienced in treating chronic hepatitis C; AND
(ii) Laboratory confirmed hepatitis C genotype 1, 2, 3, 4, 5, 6 or mixed genotypes; AND
(iii) Established chronicity of HCV infection either by two laboratory confirmed quantitative HCV RNA values taken at least 6 months apart;
OR
One recent laboratory confirmed quantitative HCV RNA within the past 6 months and clinical features establishing a duration of HCV infection longer than 6 months (e.g. presence of fibrosis, presence of non-liver manifestations of HCV, prolonged ALT elevation greater than 6 months without another cause, HCV antibody positivity greater than 6 months), or risk factors for HCV acquisition greater than 6 months (e.g. injection drug use).
Treatment regimen for Vosevi (sofosbuvir-velpatasvir-voxilaprevir):
Treatment-experienced, non-cirrhotic or compensated cirrhosis (2)
Approved duration: 12 weeks
Retreatment is not funded. Retreatment for failure or re-infection in patients who have received an adequate prior course of Vosevi will be considered on a case-by-case basis through the Exceptional Access Program.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 12 Weeks.</lccNote>
						<lccNote seq="003" type="N">1. Treatment-experienced are those who failed prior therapy with a HCV regimen containing:
i. NS5A inhibitor* for genotype 1, 2, 3, 4, 5, or 6; OR
ii. Sofosbuvir (Sovaldi) without an NS5A inhibitor for genotype 1, 2, 3, or 4
*NS5A inhibitors include: daclatasvir (Daklinza), elbasvir (as part of Zepatier), ledipasvir (as part of Harvoni), ombitasvir (as part of Holkira Pak), velpatasvir (as part of Epclusa), pibrentasvir (as part of Maviret)
2. Compensated cirrhosis (Child-Turcotte-Pugh A [i.e. Scores 5 to 6]) may be considered.
3. Health care professionals are advised to refer to the product monograph and prescribing guidelines for appropriate use of the drug product, including use in special populations.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00112">
					<name>STAVUDINE</name>
					<pcgGroup>
						<pcg9 id="081800017">
							<itemNumber>0189</itemNumber>
							<strength>15mg</strength>
							<dosageForm>Cap</dosageForm>
							<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02216086" sec3="Y">
								<name>Zerit</name>
								<manufacturerId>BQU</manufacturerId>
								<individualPrice>5.2358</individualPrice>
								<listingDate>1996-12-19</listingDate>
								<amountMOHLTCPays>5.2358</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081800006">
							<itemNumber>0190</itemNumber>
							<strength>20mg</strength>
							<dosageForm>Cap</dosageForm>
							<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02216094" sec3="Y">
								<name>Zerit</name>
								<manufacturerId>BQU</manufacturerId>
								<individualPrice>5.4450</individualPrice>
								<listingDate>1996-12-19</listingDate>
								<amountMOHLTCPays>5.4450</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081800007">
							<itemNumber>0191</itemNumber>
							<strength>30mg</strength>
							<dosageForm>Cap</dosageForm>
							<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02216108" sec3="Y">
								<name>Zerit</name>
								<manufacturerId>BQU</manufacturerId>
								<individualPrice>5.6791</individualPrice>
								<listingDate>1996-12-19</listingDate>
								<amountMOHLTCPays>5.6791</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081800008">
							<itemNumber>0192</itemNumber>
							<strength>40mg</strength>
							<dosageForm>Cap</dosageForm>
							<note>For the treatment of HIV/AIDS. The prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</note>
							<drug id="02216116" sec3="Y">
								<name>Zerit</name>
								<manufacturerId>BQU</manufacturerId>
								<individualPrice>5.8883</individualPrice>
								<listingDate>1996-12-19</listingDate>
								<amountMOHLTCPays>5.8883</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01619">
					<name>TENOFOVIR DISOPROXIL</name>
					<pcgGroup lccId="00297">
						<pcg9 id="081800083">
							<itemNumber>0193</itemNumber>
							<strength>300mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02247128" sec3="Y" sec12="Y">
								<name>Viread</name>
								<manufacturerId>GIL</manufacturerId>
								<individualPrice>19.5537</individualPrice>
								<listingDate>2007-01-02</listingDate>
								<amountMOHLTCPays>4.8884</amountMOHLTCPays>
							</drug>
							<drug id="02403889" sec3="Y" sec12="Y">
								<name>Teva-Tenofovir</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>4.8884</individualPrice>
								<listingDate>2017-09-28</listingDate>
								<amountMOHLTCPays>4.8884</amountMOHLTCPays>
							</drug>
							<drug id="02451980" sec3="Y" sec12="Y">
								<name>Apo-Tenofovir</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>4.8884</individualPrice>
								<listingDate>2017-09-28</listingDate>
								<amountMOHLTCPays>4.8884</amountMOHLTCPays>
							</drug>
							<drug id="02452634" sec3="Y" sec12="Y">
								<name>Mylan-Tenofovir Disoproxil</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>4.8884</individualPrice>
								<listingDate>2017-09-28</listingDate>
								<amountMOHLTCPays>4.8884</amountMOHLTCPays>
							</drug>
							<drug id="02453940" sec3="Y" sec12="Y">
								<name>PMS-Tenofovir</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>4.8884</individualPrice>
								<listingDate>2018-06-29</listingDate>
								<amountMOHLTCPays>4.8884</amountMOHLTCPays>
							</drug>
							<drug id="02460173" sec3="Y" sec12="Y">
								<name>Auro-Tenofovir</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>4.8884</individualPrice>
								<listingDate>2017-09-28</listingDate>
								<amountMOHLTCPays>4.8884</amountMOHLTCPays>
							</drug>
							<drug id="02472511" sec3="Y" sec12="Y">
								<name>Nat-Tenofovir</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>4.8884</individualPrice>
								<listingDate>2018-07-31</listingDate>
								<amountMOHLTCPays>4.8884</amountMOHLTCPays>
							</drug>
							<drug id="02479087" sec3="Y" sec12="Y">
								<name>Jamp-Tenofovir</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>4.8884</individualPrice>
								<listingDate>2019-02-28</listingDate>
								<amountMOHLTCPays>4.8884</amountMOHLTCPays>
							</drug>
							<drug id="02512327" sec3="Y" sec12="Y">
								<name>Tenofovir</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>4.8884</individualPrice>
								<listingDate>2021-10-29</listingDate>
								<amountMOHLTCPays>4.8884</amountMOHLTCPays>
							</drug>
							<drug id="02512939" sec3="Y" sec12="Y">
								<name>Mint-Tenofovir</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>4.8884</individualPrice>
								<listingDate>2021-11-30</listingDate>
								<amountMOHLTCPays>4.8884</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="517">Confirmed chronic Hepatitis B infection in persons with
- HBV DNA greater than or equal to 1000 IU/mL
AND
- ALT levels greater than ULN
OR
- Evidence of fibrosis
OR
- Documented evidence of cirrhosis</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="003" reasonForUseId="518">For patients with chronic Hepatitis B infection who have a contraindication, intolerance or inadequate response to one or more of the following: lamivudine, entecavir, adefovir or telbivudine.</lccNote>
						<lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="005" reasonForUseId="519">Patient is pregnant (2nd trimester or later) with HBV DNA greater than 1,000,000 IU/mL.</lccNote>
						<lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="007" reasonForUseId="520">Patients with chronic Hepatitis B infection currently receiving treatment with tenofovir and requires treatment continuation.</lccNote>
						<lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="009" reasonForUseId="521">Patients with chronic Hepatitis B infection who are scheduled to undergo chemotherapy or significant immunosuppressive treatment.</lccNote>
						<lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="011" reasonForUseId="522">For the treatment of HIV/AIDS, the prescriber must be approved for the Facilitated Access to HIV/AIDS Drug Products mechanism.</lccNote>
						<lccNote seq="012" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00115">
					<name>VALACYCLOVIR</name>
					<pcgGroup>
						<pcg9 id="081800012">
							<itemNumber>0194</itemNumber>
							<strength>500mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02219492" sec3="Y">
								<name>Valtrex</name>
								<manufacturerId>GSK</manufacturerId>
								<individualPrice>3.6710</individualPrice>
								<listingDate>1996-12-19</listingDate>
								<amountMOHLTCPays>.6198</amountMOHLTCPays>
							</drug>
							<drug id="02295822" sec3="Y">
								<name>Apo-Valacyclovir</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.6198</individualPrice>
								<listingDate>2008-08-28</listingDate>
								<amountMOHLTCPays>.6198</amountMOHLTCPays>
							</drug>
							<drug id="02298457" sec3="Y">
								<name>PMS-Valacyclovir</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.6198</individualPrice>
								<listingDate>2008-08-28</listingDate>
								<amountMOHLTCPays>.6198</amountMOHLTCPays>
							</drug>
							<drug id="02331748" sec3="Y">
								<name>Co Valacyclovir</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.6198</individualPrice>
								<listingDate>2010-10-28</listingDate>
								<amountMOHLTCPays>.6198</amountMOHLTCPays>
							</drug>
							<drug id="02347091" sec3="Y">
								<name>Sandoz Valacyclovir</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.6198</individualPrice>
								<listingDate>2015-09-30</listingDate>
								<amountMOHLTCPays>.6198</amountMOHLTCPays>
							</drug>
							<drug id="02351579" sec3="Y">
								<name>Mylan-Valacyclovir</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.6198</individualPrice>
								<listingDate>2010-07-20</listingDate>
								<amountMOHLTCPays>.6198</amountMOHLTCPays>
							</drug>
							<drug id="02357534" sec3="Y">
								<name>Teva-Valacyclovir</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.6198</individualPrice>
								<listingDate>2012-11-27</listingDate>
								<amountMOHLTCPays>.6198</amountMOHLTCPays>
							</drug>
							<drug id="02405040" sec3="Y">
								<name>Auro-Valacyclovir</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.6198</individualPrice>
								<listingDate>2013-07-30</listingDate>
								<amountMOHLTCPays>.6198</amountMOHLTCPays>
							</drug>
							<drug id="02440598" sec3="Y">
								<name>Jamp Valacyclovir</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.6198</individualPrice>
								<listingDate>2021-07-30</listingDate>
								<amountMOHLTCPays>.6198</amountMOHLTCPays>
							</drug>
							<drug id="02441454" sec3="Y">
								<name>Jamp-Valacyclovir</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.6198</individualPrice>
								<listingDate>2015-12-22</listingDate>
								<amountMOHLTCPays>.6198</amountMOHLTCPays>
							</drug>
							<drug id="02442000" sec3="Y">
								<name>Valacyclovir</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.6198</individualPrice>
								<listingDate>2020-08-28</listingDate>
								<amountMOHLTCPays>.6198</amountMOHLTCPays>
							</drug>
							<drug id="02454645" sec3="Y">
								<name>Valacyclovir</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.6198</individualPrice>
								<listingDate>2016-11-30</listingDate>
								<amountMOHLTCPays>.6198</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="081800339">
							<itemNumber>0195</itemNumber>
							<strength>1000mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02246559" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Valtrex</name>
								<manufacturerId>GSK</manufacturerId>
								<listingDate>2010-07-20</listingDate>
							</drug>
							<drug id="02351560" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mylan-Valacyclovir</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>5.8537</individualPrice>
								<listingDate>2010-07-20</listingDate>
							</drug>
							<drug id="02354705" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Valacyclovir</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>5.8537</individualPrice>
								<listingDate>2010-10-28</listingDate>
							</drug>
							<drug id="02381230" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>PMS-Valacyclovir</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>5.8537</individualPrice>
								<listingDate>2012-05-29</listingDate>
							</drug>
							<drug id="02405059" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Auro-Valacyclovir</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>5.8537</individualPrice>
								<listingDate>2020-12-18</listingDate>
							</drug>
							<drug id="02519585" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Valacyclovir</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>5.8537</individualPrice>
								<listingDate>2021-12-17</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01581">
					<name>VALGANCICLOVIR</name>
					<pcgGroup lccId="00328">
						<pcg9 id="081800108">
							<itemNumber>0196</itemNumber>
							<strength>50mg/mL</strength>
							<dosageForm>Pd for Oral Sol-100mL Pk</dosageForm>
							<drug id="02306085" sec3="Y" sec12="Y">
								<name>Valcyte</name>
								<manufacturerId>HLR</manufacturerId>
								<individualPrice>274.5200</individualPrice>
								<listingDate>2020-02-28</listingDate>
								<amountMOHLTCPays>274.5200</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="571">For those unable to swallow or tolerate solid oral dosage form AND
For the treatment of Cytomegalovirus (CMV) retinitis in patients with HIV/AIDS.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="003" reasonForUseId="572">For those unable to swallow or tolerate solid oral dosage form AND
For the prevention of Cytomegalovirus (CMV) in solid organ transplant patients (not lung or heart-lung).</lccNote>
						<lccNote seq="004" type="R">LU Authorization Period: Up to 6 months</lccNote>
						<lccNote seq="005" reasonForUseId="573">For those unable to swallow or tolerate solid oral dosage form AND
For the prevention of Cytomegalovirus (CMV) in lung or heart-lung transplant patients.</lccNote>
						<lccNote seq="006" type="R">LU Authorization Period: Up to 12 months</lccNote>
					</pcgGroup>
					<pcgGroup lccId="00145">
						<pcg9 id="081800066">
							<itemNumber>0197</itemNumber>
							<strength>450mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02245777" sec3="Y" sec12="Y">
								<name>Valcyte</name>
								<manufacturerId>HLR</manufacturerId>
								<individualPrice>24.7087</individualPrice>
								<listingDate>2003-04-16</listingDate>
								<amountMOHLTCPays>5.8553</amountMOHLTCPays>
							</drug>
							<drug id="02413825" sec3="Y" sec12="Y">
								<name>Teva-Valganciclovir</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>5.8553</individualPrice>
								<listingDate>2015-01-28</listingDate>
								<amountMOHLTCPays>5.8553</amountMOHLTCPays>
							</drug>
							<drug id="02435179" sec3="Y" sec12="Y">
								<name>Auro-Valganciclovir</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>5.8553</individualPrice>
								<listingDate>2015-11-26</listingDate>
								<amountMOHLTCPays>5.8553</amountMOHLTCPays>
							</drug>
							<drug id="02495457" sec3="Y" sec12="Y">
								<name>Mint-Valganciclovir</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>5.8553</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>5.8553</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="374">For the treatment of CMV retinitis in patients with HIV/AIDS.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="003" reasonForUseId="568">For the prevention of Cytomegalovirus (CMV) in solid organ transplant patients (not lung or heart-lung).</lccNote>
						<lccNote seq="004" type="R">LU Authorization Period: Up to 6 months</lccNote>
						<lccNote seq="005" reasonForUseId="569">For the prevention of Cytomegalovirus (CMV) in lung or heart-lung transplant patients.</lccNote>
						<lccNote seq="006" type="R">LU Authorization Period: Up to 12 months</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="01749">
					<name>ZANAMIVIR</name>
					<pcgGroup lccId="00203">
						<pcg9 id="081800109">
							<itemNumber>0198</itemNumber>
							<strength>5mg</strength>
							<dosageForm>Pd Inh-5 Rotadisks Pk</dosageForm>
							<drug id="02240863" sec3="Y" sec12="Y">
								<name>Relenza</name>
								<manufacturerId>GSK</manufacturerId>
								<individualPrice>39.5900</individualPrice>
								<listingDate>2010-03-02</listingDate>
								<amountMOHLTCPays>39.5900</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" type="R">For the treatment or prophylaxis of institutionalized individuals during confirmed outbreaks due to influenza A or Influenza B when the predominant circulating strain is resistant to oseltamivir or for the prophylaxis of influenza A, where new cases have developed despite amantadine prophylaxis.
The outbreak must be confirmed by Public Health.</lccNote>
						<lccNote seq="002" reasonForUseId="414">For treatment: 2 inhalations of 5mg (10mg) bid for 5 days,</lccNote>
						<lccNote seq="003" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="004" reasonForUseId="415">For prophylaxis: 2 inhalations of 5mg (10mg) once daily for 10 days.</lccNote>
						<lccNote seq="005" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00144">
					<name>ZIDOVUDINE</name>
					<pcgGroup>
						<pcg9 id="081800031">
							<itemNumber>0199</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="01902660" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Retrovir</name>
								<manufacturerId>VIH</manufacturerId>
								<listingDate>2009-06-23</listingDate>
							</drug>
							<drug id="01946323" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Zidovudine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.3977</individualPrice>
								<listingDate>2009-06-23</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="082000000">
				<name>PLASMODICIDES (ANTIMALARIALS)</name>
				<genericName id="01672">
					<name>ATOVAQUONE &amp; PROGUANIL HCL</name>
					<pcgGroup>
						<pcg9 id="082000010">
							<itemNumber>0200</itemNumber>
							<strength>250mg &amp; 100mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02238151" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Malarone</name>
								<manufacturerId>GSK</manufacturerId>
								<individualPrice>5.2767</individualPrice>
								<listingDate>2012-04-24</listingDate>
								<amountMOHLTCPays>4.1308</amountMOHLTCPays>
							</drug>
							<drug id="02380927" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Teva-Atovaquone Proguanil</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>4.1308</individualPrice>
								<listingDate>2012-04-24</listingDate>
								<amountMOHLTCPays>4.1308</amountMOHLTCPays>
							</drug>
							<drug id="02402165" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Mylan-Atovaquone/Proguanil</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>4.1308</individualPrice>
								<listingDate>2014-01-30</listingDate>
								<amountMOHLTCPays>4.1308</amountMOHLTCPays>
							</drug>
							<drug id="02421429" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Atovaquone Proguanil</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>4.1308</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>4.1308</amountMOHLTCPays>
							</drug>
							<drug id="02466783" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Atovaquone and Proguanil Hydrochloride</name>
								<manufacturerId>GLP</manufacturerId>
								<individualPrice>4.1308</individualPrice>
								<listingDate>2018-02-28</listingDate>
								<amountMOHLTCPays>4.1308</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00117">
					<name>CHLOROQUINE PHOSPHATE</name>
					<pcgGroup>
						<pcg9 id="082000001">
							<itemNumber>0201</itemNumber>
							<strength>250mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00021261" sec3="Y">
								<name>Teva-Chloroquine</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3208</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3208</amountMOHLTCPays>
							</drug>
							<drug id="02017539" notABenefit="Y" sec3="Y">
								<name>Aralen</name>
								<manufacturerId>SAO</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00118">
					<name>HYDROXYCHLOROQUINE SULFATE</name>
					<pcgGroup>
						<pcg9 id="082000002">
							<itemNumber>0202</itemNumber>
							<strength>200mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02017709" sec3="Y">
								<name>Plaquenil</name>
								<manufacturerId>SAV</manufacturerId>
								<individualPrice>.6302</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1576</amountMOHLTCPays>
							</drug>
							<drug id="02246691" sec3="Y">
								<name>Apo-Hydroxyquine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1576</individualPrice>
								<listingDate>2003-09-04</listingDate>
								<amountMOHLTCPays>.1576</amountMOHLTCPays>
							</drug>
							<drug id="02424991" sec3="Y">
								<name>Mint-Hydroxychloroquine</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.1576</individualPrice>
								<listingDate>2016-04-29</listingDate>
								<amountMOHLTCPays>.1576</amountMOHLTCPays>
							</drug>
							<drug id="02491427" sec3="Y">
								<name>Jamp-Hydroxychloroquine</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1576</individualPrice>
								<listingDate>2020-04-07</listingDate>
								<amountMOHLTCPays>.1576</amountMOHLTCPays>
							</drug>
							<drug id="02511886" sec3="Y">
								<name>NRA-Hydroxychloroquine</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.1576</individualPrice>
								<listingDate>2021-12-17</listingDate>
								<amountMOHLTCPays>.1576</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00147">
					<name>MEFLOQUINE HCL</name>
					<pcgGroup>
						<pcg9 id="082000011">
							<itemNumber>0203</itemNumber>
							<strength>250mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02018055" sec3b="Y" sec3="Y">
								<name>Lariam</name>
								<manufacturerId>HLR</manufacturerId>
								<listingDate>2007-06-06</listingDate>
							</drug>
							<drug id="02244366" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Mefloquine</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>3.6950</individualPrice>
								<listingDate>2007-06-06</listingDate>
								<amountMOHLTCPays>3.6950</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="082400000">
				<name>SULFONAMIDES</name>
				<genericName id="00126">
					<name>SULFASALAZINE</name>
					<pcgGroup>
						<pcg9 id="082400006">
							<itemNumber>0204</itemNumber>
							<strength>500mg</strength>
							<dosageForm>Ent Tab</dosageForm>
							<drug id="00598488" sec3="Y">
								<name>PMS-Sulfasalazine-E.C.</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3863</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3863</amountMOHLTCPays>
							</drug>
							<drug id="02064472" sec3="Y">
								<name>Salazopyrin EN-TABS 500 MG</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>.5331</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3863</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="082400005">
							<itemNumber>0205</itemNumber>
							<strength>500mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00598461" sec3="Y">
								<name>PMS-Sulfasalazine</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2533</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2533</amountMOHLTCPays>
							</drug>
							<drug id="02064480" sec3="Y">
								<name>Salazopyrin</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>.3495</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2533</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="082600000">
				<name>SULFONES</name>
				<genericName id="00129">
					<name>DAPSONE</name>
					<pcgGroup>
						<pcg9 id="082600002">
							<itemNumber>0206</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.7031</dailyCost>
							<drug id="02041510" sec3="Y">
								<name>Dapsone</name>
								<manufacturerId>JAC</manufacturerId>
								<individualPrice>1.4061</individualPrice>
								<dailyCost>1.4061</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.7031</amountMOHLTCPays>
							</drug>
							<drug id="02481227" sec3="Y">
								<name>Mar-Dapsone</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.7031</individualPrice>
								<dailyCost>.7031</dailyCost>
								<listingDate>2019-05-31</listingDate>
								<amountMOHLTCPays>.7031</amountMOHLTCPays>
							</drug>
							<drug id="02489058" sec3="Y">
								<name>Riva-Dapsone</name>
								<manufacturerId>RIA</manufacturerId>
								<individualPrice>.7031</individualPrice>
								<dailyCost>.7031</dailyCost>
								<listingDate>2020-03-31</listingDate>
								<amountMOHLTCPays>.7031</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="083000000">
				<name>ANTIPROTOZOALS</name>
				<genericName id="00146">
					<name>ATOVAQUONE</name>
					<pcgGroup>
						<pcg9 id="083000001">
							<itemNumber>0207</itemNumber>
							<strength>750mg/5mL</strength>
							<dosageForm>O/L</dosageForm>
							<drug id="02217422" sec3="Y">
								<name>Mepron</name>
								<manufacturerId>GSK</manufacturerId>
								<individualPrice>3.0289</individualPrice>
								<listingDate>1997-04-10</listingDate>
								<amountMOHLTCPays>3.0289</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="083200000">
				<name>TRICHOMONACIDES</name>
				<genericName id="00029">
					<name>METRONIDAZOLE</name>
					<pcgGroup>
						<pcg9 id="083200002">
							<itemNumber>0208</itemNumber>
							<strength>500mg</strength>
							<dosageForm>Cap</dosageForm>
							<dailyCost>.8217</dailyCost>
							<drug id="00783137" sec3="Y">
								<name>PMS-Metronidazole</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2739</individualPrice>
								<dailyCost>.8217</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2739</amountMOHLTCPays>
							</drug>
							<drug id="01926853" sec3="Y">
								<name>Flagyl</name>
								<manufacturerId>ODN</manufacturerId>
								<individualPrice>.2739</individualPrice>
								<dailyCost>.8217</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2739</amountMOHLTCPays>
							</drug>
							<drug id="02248562" sec3="Y">
								<name>Apo-Metronidazole</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2739</individualPrice>
								<dailyCost>.8217</dailyCost>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.2739</amountMOHLTCPays>
							</drug>
							<drug id="02470284" sec3="Y">
								<name>Auro-Metronidazole</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2739</individualPrice>
								<dailyCost>.8217</dailyCost>
								<listingDate>2018-07-31</listingDate>
								<amountMOHLTCPays>.2739</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="083200001">
							<itemNumber>0209</itemNumber>
							<strength>250mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.1905</dailyCost>
							<drug id="00545066" sec3="Y">
								<name>Metronidazole</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.0635</individualPrice>
								<dailyCost>.1905</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0635</amountMOHLTCPays>
							</drug>
							<drug id="01926896" notABenefit="Y" sec3="Y">
								<name>Flagyl</name>
								<manufacturerId>RPP</manufacturerId>
								<listingDate>2001-02-28</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="083600000">
				<name>URINARY ANTI-INFECTIVES</name>
				<genericName id="01472">
					<name>FOSFOMYCIN TROMETHAMINE</name>
					<pcgGroup>
						<pcg9 id="083600019">
							<itemNumber>0210</itemNumber>
							<dosageForm>Sachet-3g Pk</dosageForm>
							<note>The recommended dosage for women over 18 years with acute uncomplicated urinary tract infections (acute cystitis) is one sachet containing the equivalent of 3 grams of fosfomycin.
A single dose of fosfomycin should be used to treat an episode of acute cystitis.</note>
							<drug id="02240335" sec3="Y">
								<name>Monurol</name>
								<manufacturerId>PAL</manufacturerId>
								<individualPrice>20.6200</individualPrice>
								<listingDate>2015-07-29</listingDate>
								<amountMOHLTCPays>14.0250</amountMOHLTCPays>
							</drug>
							<drug id="02473801" sec3="Y">
								<name>Jamp-Fosfomycin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>14.0250</individualPrice>
								<listingDate>2018-11-29</listingDate>
								<amountMOHLTCPays>14.0250</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00133">
					<name>NITROFURANTOIN</name>
					<note>Nitrofurantoin macrocrystals may be better tolerated. Avoid use of nitrofurantoin during the last 6 weeks of pregnancy. Use with caution in patients with renal impairment.</note>
					<pcgGroup>
						<pcg9 id="083600013">
							<itemNumber>0211</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Cap</dosageForm>
							<dailyCost>1.3008</dailyCost>
							<drug id="01997637" notABenefit="Y" sec3="Y">
								<name>Macrodantin</name>
								<manufacturerId>PGP</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02231015" sec3="Y">
								<name>Teva-Nitrofurantoin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3252</individualPrice>
								<dailyCost>1.3008</dailyCost>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.3252</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="083600012">
							<itemNumber>0212</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Cap</dosageForm>
							<dailyCost>2.4440</dailyCost>
							<drug id="01997645" notABenefit="Y" sec3="Y">
								<name>Macrodantin</name>
								<manufacturerId>PGP</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02231016" sec3="Y">
								<name>Teva-Nitrofurantoin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.6110</individualPrice>
								<dailyCost>2.4440</dailyCost>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.6110</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="083600015">
							<itemNumber>0213</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.6812</dailyCost>
							<drug id="00017086" notABenefit="Y" sec3="Y">
								<name>Nifuran</name>
								<manufacturerId>MAN</manufacturerId>
								<listingDate>2006-06-15</listingDate>
							</drug>
							<drug id="00319511" sec3="Y">
								<name>Nitrofurantoin</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.1703</individualPrice>
								<dailyCost>.6812</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1703</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="083600008">
							<itemNumber>0214</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.9088</dailyCost>
							<drug id="00017094" notABenefit="Y" sec3="Y">
								<name>Nifuran</name>
								<manufacturerId>MAN</manufacturerId>
								<listingDate>2006-06-15</listingDate>
							</drug>
							<drug id="00312738" sec3="Y">
								<name>Nitrofurantoin</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.2272</individualPrice>
								<dailyCost>.9088</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2272</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00135">
					<name>NITROFURANTOIN MONO/MICRO CRYSTALS</name>
					<pcgGroup>
						<pcg9 id="083600018">
							<itemNumber>0215</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02063662" dinStatus="E" sec3="Y">
								<name>MacroBID</name>
								<manufacturerId>WAR</manufacturerId>
								<individualPrice>.5974</individualPrice>
								<listingDate>1996-12-19</listingDate>
								<amountMOHLTCPays>.5974</amountMOHLTCPays>
							</drug>
							<drug id="02455676" sec3="Y">
								<name>PMS-Nitrofurantoin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.5974</individualPrice>
								<listingDate>2018-07-31</listingDate>
								<amountMOHLTCPays>.5974</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="084000000">
				<name>MISCELLANEOUS ANTI-INFECTIVES</name>
				<genericName id="01616">
					<name>CEFEPIME</name>
					<pcgGroup>
						<pcg9 id="084000065">
							<itemNumber>0216</itemNumber>
							<strength>1g</strength>
							<dosageForm>Inj Pd-Vial Pk</dosageForm>
							<drug id="02163632" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Maxipime</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>2009-05-20</listingDate>
							</drug>
							<drug id="02319020" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Cefepime for Injection</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>12.9360</individualPrice>
								<listingDate>2009-05-20</listingDate>
							</drug>
							<drug id="02467496" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Cefepime</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>15.1003</individualPrice>
								<listingDate>2018-08-30</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="084000072">
							<itemNumber>0217</itemNumber>
							<strength>2g</strength>
							<dosageForm>Inj Pd-Vial Pk</dosageForm>
							<drug id="02163640" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Maxipime</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>2009-05-20</listingDate>
							</drug>
							<drug id="02319039" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Cefepime for Injection</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>30.1963</individualPrice>
								<listingDate>2009-05-20</listingDate>
							</drug>
							<drug id="02467518" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Cefepime</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>30.2000</individualPrice>
								<listingDate>2018-08-30</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00141">
					<name>CIPROFLOXACIN</name>
					<note>Ciprofloxacin is not intended for the treatment of asymptomatic bacteriuria in the absence of risk factors. Avoid use in pregnancy and children &lt; 18 years of age. Ciprofloxacin inhibits theophylline clearance and also affects phenytoin kinetics. Theophylline doses should be decreased and blood levels of phenytoin or theophylline monitored when either of these drugs is used concomitantly with ciprofloxacin.</note>
					<pcgGroup lccId="00307">
						<pcg9 id="084000050">
							<itemNumber>0218</itemNumber>
							<strength>10g/100mL</strength>
							<dosageForm>Oral Susp</dosageForm>
							<dailyCost>5.7560</dailyCost>
							<drug id="02237514" sec3="Y" sec12="Y">
								<name>Cipro</name>
								<manufacturerId>BAY</manufacturerId>
								<individualPrice>.5756</individualPrice>
								<dailyCost>5.7560</dailyCost>
								<listingDate>2001-03-07</listingDate>
								<amountMOHLTCPays>.5756</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="533">For patients who are unable to swallow or tolerate solid oral dosage forms.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
					<pcgGroup>
						<pcg9 id="084000014">
							<itemNumber>0219</itemNumber>
							<strength>250mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.8908</dailyCost>
							<drug id="02155958" sec3="Y">
								<name>Cipro</name>
								<manufacturerId>BAY</manufacturerId>
								<individualPrice>2.4989</individualPrice>
								<dailyCost>4.9978</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.4454</amountMOHLTCPays>
							</drug>
							<drug id="02161737" sec3="Y">
								<name>Teva-Ciprofloxacin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.4454</individualPrice>
								<dailyCost>.8908</dailyCost>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.4454</amountMOHLTCPays>
							</drug>
							<drug id="02229521" sec3="Y">
								<name>Apo-Ciproflox</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.4454</individualPrice>
								<dailyCost>.8908</dailyCost>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.4454</amountMOHLTCPays>
							</drug>
							<drug id="02246825" sec3="Y">
								<name>Ratio-Ciprofloxacin</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>.4454</individualPrice>
								<dailyCost>.8908</dailyCost>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.4454</amountMOHLTCPays>
							</drug>
							<drug id="02247339" sec3="Y">
								<name>Co Ciprofloxacin</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.4454</individualPrice>
								<dailyCost>.8908</dailyCost>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.4454</amountMOHLTCPays>
							</drug>
							<drug id="02248437" sec3="Y">
								<name>PMS-Ciprofloxacin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.4454</individualPrice>
								<dailyCost>.8908</dailyCost>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.4454</amountMOHLTCPays>
							</drug>
							<drug id="02248756" sec3="Y">
								<name>Sandoz Ciprofloxacin</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.4454</individualPrice>
								<dailyCost>.8908</dailyCost>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.4454</amountMOHLTCPays>
							</drug>
							<drug id="02303728" sec3="Y">
								<name>Ran-Ciproflox</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.4454</individualPrice>
								<dailyCost>.8908</dailyCost>
								<listingDate>2008-03-25</listingDate>
								<amountMOHLTCPays>.4454</amountMOHLTCPays>
							</drug>
							<drug id="02353318" sec3="Y">
								<name>Ciprofloxacin</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.4454</individualPrice>
								<dailyCost>.8908</dailyCost>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.4454</amountMOHLTCPays>
							</drug>
							<drug id="02379627" sec3="Y">
								<name>Septa-Ciprofloxacin</name>
								<manufacturerId>SET</manufacturerId>
								<individualPrice>.4454</individualPrice>
								<dailyCost>.8908</dailyCost>
								<listingDate>2012-06-26</listingDate>
								<amountMOHLTCPays>.4454</amountMOHLTCPays>
							</drug>
							<drug id="02379686" sec3="Y">
								<name>Mar-Ciprofloxacin</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.4454</individualPrice>
								<dailyCost>.8908</dailyCost>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.4454</amountMOHLTCPays>
							</drug>
							<drug id="02380358" sec3="Y">
								<name>Jamp-Ciprofloxacin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.4454</individualPrice>
								<dailyCost>.8908</dailyCost>
								<listingDate>2012-09-28</listingDate>
								<amountMOHLTCPays>.4454</amountMOHLTCPays>
							</drug>
							<drug id="02381907" sec3="Y">
								<name>Auro-Ciprofloxacin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.4454</individualPrice>
								<dailyCost>.8908</dailyCost>
								<listingDate>2012-08-27</listingDate>
								<amountMOHLTCPays>.4454</amountMOHLTCPays>
							</drug>
							<drug id="02386119" sec3="Y">
								<name>Ciprofloxacin</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.4454</individualPrice>
								<dailyCost>.8908</dailyCost>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.4454</amountMOHLTCPays>
							</drug>
							<drug id="02423553" sec3="Y">
								<name>Mint-Ciproflox</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.4454</individualPrice>
								<dailyCost>.8908</dailyCost>
								<listingDate>2014-07-30</listingDate>
								<amountMOHLTCPays>.4454</amountMOHLTCPays>
							</drug>
							<drug id="02426978" dinStatus="E" sec3="Y">
								<name>Van-Ciprofloxacin</name>
								<manufacturerId>VAN</manufacturerId>
								<individualPrice>.4454</individualPrice>
								<dailyCost>.8908</dailyCost>
								<listingDate>2015-07-29</listingDate>
								<amountMOHLTCPays>.4454</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="084000015">
							<itemNumber>0220</itemNumber>
							<strength>500mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>1.0050</dailyCost>
							<drug id="02155966" sec3="Y">
								<name>Cipro</name>
								<manufacturerId>BAY</manufacturerId>
								<individualPrice>2.8194</individualPrice>
								<dailyCost>5.6388</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.5025</amountMOHLTCPays>
							</drug>
							<drug id="02229522" sec3="Y">
								<name>Apo-Ciproflox</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.5025</individualPrice>
								<dailyCost>1.0050</dailyCost>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.5025</amountMOHLTCPays>
							</drug>
							<drug id="02246826" sec3="Y">
								<name>Ratio-Ciprofloxacin</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>.5025</individualPrice>
								<dailyCost>1.0050</dailyCost>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.5025</amountMOHLTCPays>
							</drug>
							<drug id="02247340" sec3="Y">
								<name>Co Ciprofloxacin</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.5025</individualPrice>
								<dailyCost>1.0050</dailyCost>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.5025</amountMOHLTCPays>
							</drug>
							<drug id="02248438" sec3="Y">
								<name>PMS-Ciprofloxacin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.5025</individualPrice>
								<dailyCost>1.0050</dailyCost>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.5025</amountMOHLTCPays>
							</drug>
							<drug id="02248757" sec3="Y">
								<name>Sandoz Ciprofloxacin</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.5025</individualPrice>
								<dailyCost>1.0050</dailyCost>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.5025</amountMOHLTCPays>
							</drug>
							<drug id="02303736" sec3="Y">
								<name>Ran-Ciproflox</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.5025</individualPrice>
								<dailyCost>1.0050</dailyCost>
								<listingDate>2008-03-25</listingDate>
								<amountMOHLTCPays>.5025</amountMOHLTCPays>
							</drug>
							<drug id="02353326" sec3="Y">
								<name>Ciprofloxacin</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.5025</individualPrice>
								<dailyCost>1.0050</dailyCost>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.5025</amountMOHLTCPays>
							</drug>
							<drug id="02379635" sec3="Y">
								<name>Septa-Ciprofloxacin</name>
								<manufacturerId>SET</manufacturerId>
								<individualPrice>.5025</individualPrice>
								<dailyCost>1.0050</dailyCost>
								<listingDate>2012-06-26</listingDate>
								<amountMOHLTCPays>.5025</amountMOHLTCPays>
							</drug>
							<drug id="02379694" sec3="Y">
								<name>Mar-Ciprofloxacin</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.5025</individualPrice>
								<dailyCost>1.0050</dailyCost>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.5025</amountMOHLTCPays>
							</drug>
							<drug id="02380366" sec3="Y">
								<name>Jamp-Ciprofloxacin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.5025</individualPrice>
								<dailyCost>1.0050</dailyCost>
								<listingDate>2012-09-28</listingDate>
								<amountMOHLTCPays>.5025</amountMOHLTCPays>
							</drug>
							<drug id="02381923" sec3="Y">
								<name>Auro-Ciprofloxacin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.5025</individualPrice>
								<dailyCost>1.0050</dailyCost>
								<listingDate>2012-08-27</listingDate>
								<amountMOHLTCPays>.5025</amountMOHLTCPays>
							</drug>
							<drug id="02386127" sec3="Y">
								<name>Ciprofloxacin</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.5025</individualPrice>
								<dailyCost>1.0050</dailyCost>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.5025</amountMOHLTCPays>
							</drug>
							<drug id="02423561" sec3="Y">
								<name>Mint-Ciproflox</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.5025</individualPrice>
								<dailyCost>1.0050</dailyCost>
								<listingDate>2014-07-30</listingDate>
								<amountMOHLTCPays>.5025</amountMOHLTCPays>
							</drug>
							<drug id="02427001" dinStatus="E" sec3="Y">
								<name>Van-Ciprofloxacin</name>
								<manufacturerId>VAN</manufacturerId>
								<individualPrice>.5025</individualPrice>
								<dailyCost>1.0050</dailyCost>
								<listingDate>2015-07-29</listingDate>
								<amountMOHLTCPays>.5025</amountMOHLTCPays>
							</drug>
							<drug id="02492008" sec3="Y">
								<name>NRA-Ciprofloxacin</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.5025</individualPrice>
								<dailyCost>1.0050</dailyCost>
								<listingDate>2021-02-26</listingDate>
								<amountMOHLTCPays>.5025</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="084000016">
							<itemNumber>0221</itemNumber>
							<strength>750mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>1.8402</dailyCost>
							<drug id="02155974" sec3="Y">
								<name>Cipro</name>
								<manufacturerId>BAY</manufacturerId>
								<individualPrice>5.1630</individualPrice>
								<dailyCost>10.3260</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.9201</amountMOHLTCPays>
							</drug>
							<drug id="02229523" sec3="Y">
								<name>Apo-Ciproflox</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.9201</individualPrice>
								<dailyCost>1.8402</dailyCost>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.9201</amountMOHLTCPays>
							</drug>
							<drug id="02246827" sec3="Y">
								<name>Ratio-Ciprofloxacin</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>.9201</individualPrice>
								<dailyCost>1.8402</dailyCost>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.9201</amountMOHLTCPays>
							</drug>
							<drug id="02247341" sec3="Y">
								<name>Co Ciprofloxacin</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.9201</individualPrice>
								<dailyCost>1.8402</dailyCost>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.9201</amountMOHLTCPays>
							</drug>
							<drug id="02248439" sec3="Y">
								<name>PMS-Ciprofloxacin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.9201</individualPrice>
								<dailyCost>1.8402</dailyCost>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.9201</amountMOHLTCPays>
							</drug>
							<drug id="02248758" sec3="Y">
								<name>Sandoz Ciprofloxacin</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.9201</individualPrice>
								<dailyCost>1.8402</dailyCost>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.9201</amountMOHLTCPays>
							</drug>
							<drug id="02303744" sec3="Y">
								<name>Ran-Ciproflox</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.9201</individualPrice>
								<dailyCost>1.8402</dailyCost>
								<listingDate>2008-03-25</listingDate>
								<amountMOHLTCPays>.9201</amountMOHLTCPays>
							</drug>
							<drug id="02379643" sec3="Y">
								<name>Septa-Ciprofloxacin</name>
								<manufacturerId>SET</manufacturerId>
								<individualPrice>.9201</individualPrice>
								<dailyCost>1.8402</dailyCost>
								<listingDate>2012-06-26</listingDate>
								<amountMOHLTCPays>.9201</amountMOHLTCPays>
							</drug>
							<drug id="02379708" sec3="Y">
								<name>Mar-Ciprofloxacin</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.9201</individualPrice>
								<dailyCost>1.8402</dailyCost>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.9201</amountMOHLTCPays>
							</drug>
							<drug id="02380374" sec3="Y">
								<name>Jamp-Ciprofloxacin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.9201</individualPrice>
								<dailyCost>1.8402</dailyCost>
								<listingDate>2012-09-28</listingDate>
								<amountMOHLTCPays>.9201</amountMOHLTCPays>
							</drug>
							<drug id="02381931" sec3="Y">
								<name>Auro-Ciprofloxacin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.9201</individualPrice>
								<dailyCost>1.8402</dailyCost>
								<listingDate>2012-08-27</listingDate>
								<amountMOHLTCPays>.9201</amountMOHLTCPays>
							</drug>
							<drug id="02423588" sec3="Y">
								<name>Mint-Ciproflox</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.9201</individualPrice>
								<dailyCost>1.8402</dailyCost>
								<listingDate>2014-07-30</listingDate>
								<amountMOHLTCPays>.9201</amountMOHLTCPays>
							</drug>
							<drug id="02427028" dinStatus="E" sec3="Y">
								<name>Van-Ciprofloxacin</name>
								<manufacturerId>VAN</manufacturerId>
								<individualPrice>.9201</individualPrice>
								<dailyCost>1.8402</dailyCost>
								<listingDate>2015-07-29</listingDate>
								<amountMOHLTCPays>.9201</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01629">
					<name>CIPROFLOXACIN HCL &amp; CIPROFLOXACIN BASE</name>
					<pcgGroup lccId="00161">
						<pcg9 id="084000066">
							<itemNumber>0222</itemNumber>
							<strength>500mg</strength>
							<dosageForm>ER Tab</dosageForm>
							<drug id="02247916" sec3="Y" sec12="Y">
								<name>Cipro XL</name>
								<manufacturerId>BAY</manufacturerId>
								<individualPrice>3.1120</individualPrice>
								<listingDate>2005-02-22</listingDate>
								<amountMOHLTCPays>2.3110</amountMOHLTCPays>
							</drug>
							<drug id="02416433" sec3="Y" sec12="Y">
								<name>PMS-Ciprofloxacin XL</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>2.3110</individualPrice>
								<listingDate>2014-03-27</listingDate>
								<amountMOHLTCPays>2.3110</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="394">For patients with uncomplicated urinary tract infections (acute cystitis) who have failure, intolerance or hypersensitivity to all formulary antibiotic alternatives that are listed as General Benefits.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
					<pcgGroup lccId="00162">
						<pcg9 id="084000067">
							<itemNumber>0223</itemNumber>
							<strength>1000mg</strength>
							<dosageForm>ER Tab</dosageForm>
							<drug id="02251787" sec3="Y" sec12="Y">
								<name>Cipro XL</name>
								<manufacturerId>BAY</manufacturerId>
								<individualPrice>3.1120</individualPrice>
								<listingDate>2005-02-22</listingDate>
								<amountMOHLTCPays>3.1120</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="395">For patients with complicated urinary tract infections or acute uncomplicated pyelonephritis who have failure, intolerance or hypersensitivity to all formulary antibiotic alternatives that are listed as General Benefits.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="01773">
					<name>ERTAPENEM</name>
					<pcgGroup>
						<pcg9 id="084000077">
							<itemNumber>0224</itemNumber>
							<strength>1g/Vial</strength>
							<dosageForm>Inj Pd-Vial Pk</dosageForm>
							<drug id="02247437" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Invanz</name>
								<manufacturerId>MFC</manufacturerId>
								<listingDate>2021-03-29</listingDate>
							</drug>
							<drug id="02492148" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Ertapenem for Injection</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>52.2650</individualPrice>
								<listingDate>2021-11-30</listingDate>
								<amountMOHLTCPays>52.2650</amountMOHLTCPays>
							</drug>
							<drug id="02511150" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Ertapenem for Injection</name>
								<manufacturerId>DRR</manufacturerId>
								<individualPrice>52.2650</individualPrice>
								<listingDate>2021-03-29</listingDate>
								<amountMOHLTCPays>52.2650</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01381">
					<name>LEVOFLOXACIN</name>
					<pcgGroup>
						<pcg9 id="084000051">
							<itemNumber>0225</itemNumber>
							<strength>250mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02236841" notABenefit="Y" sec3="Y">
								<name>Levaquin</name>
								<manufacturerId>JAN</manufacturerId>
								<listingDate>1999-09-15</listingDate>
							</drug>
							<drug id="02248262" sec3="Y">
								<name>Novo-Levofloxacin</name>
								<manufacturerId>NOP</manufacturerId>
								<individualPrice>1.2038</individualPrice>
								<listingDate>2005-01-25</listingDate>
								<amountMOHLTCPays>1.2038</amountMOHLTCPays>
							</drug>
							<drug id="02284707" sec3="Y">
								<name>Apo-Levofloxacin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.2038</individualPrice>
								<listingDate>2009-09-30</listingDate>
								<amountMOHLTCPays>1.2038</amountMOHLTCPays>
							</drug>
							<drug id="02298635" sec3="Y">
								<name>Sandoz Levofloxacin</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>1.2038</individualPrice>
								<listingDate>2009-09-30</listingDate>
								<amountMOHLTCPays>1.2038</amountMOHLTCPays>
							</drug>
							<drug id="02315424" sec3="Y">
								<name>Act Levofloxacin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>1.2038</individualPrice>
								<listingDate>2009-09-30</listingDate>
								<amountMOHLTCPays>1.2038</amountMOHLTCPays>
							</drug>
							<drug id="02492725" sec3="Y">
								<name>Riva-Levofloxacin</name>
								<manufacturerId>RIA</manufacturerId>
								<individualPrice>1.2038</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>1.2038</amountMOHLTCPays>
							</drug>
							<drug id="02505797" sec3="Y">
								<name>Mint-Levofloxacin</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>1.2038</individualPrice>
								<listingDate>2021-10-29</listingDate>
								<amountMOHLTCPays>1.2038</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="084000049">
							<itemNumber>0226</itemNumber>
							<strength>500mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02236842" notABenefit="Y" sec3="Y">
								<name>Levaquin</name>
								<manufacturerId>JAN</manufacturerId>
								<listingDate>1999-09-15</listingDate>
							</drug>
							<drug id="02248263" sec3="Y">
								<name>Novo-Levofloxacin</name>
								<manufacturerId>NOP</manufacturerId>
								<individualPrice>1.3718</individualPrice>
								<listingDate>2005-01-25</listingDate>
								<amountMOHLTCPays>1.3718</amountMOHLTCPays>
							</drug>
							<drug id="02284715" sec3="Y">
								<name>Apo-Levofloxacin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.3718</individualPrice>
								<listingDate>2009-09-30</listingDate>
								<amountMOHLTCPays>1.3718</amountMOHLTCPays>
							</drug>
							<drug id="02298643" sec3="Y">
								<name>Sandoz Levofloxacin</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>1.3718</individualPrice>
								<listingDate>2009-09-30</listingDate>
								<amountMOHLTCPays>1.3718</amountMOHLTCPays>
							</drug>
							<drug id="02315432" sec3="Y">
								<name>Act Levofloxacin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>1.3718</individualPrice>
								<listingDate>2009-09-30</listingDate>
								<amountMOHLTCPays>1.3718</amountMOHLTCPays>
							</drug>
							<drug id="02492733" sec3="Y">
								<name>Riva-Levofloxacin</name>
								<manufacturerId>RIA</manufacturerId>
								<individualPrice>1.3718</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>1.3718</amountMOHLTCPays>
							</drug>
							<drug id="02505819" sec3="Y">
								<name>Mint-Levofloxacin</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>1.3718</individualPrice>
								<listingDate>2021-10-29</listingDate>
								<amountMOHLTCPays>1.3718</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="084000075">
							<itemNumber>0227</itemNumber>
							<strength>750mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02246804" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Levaquin</name>
								<manufacturerId>JAN</manufacturerId>
								<listingDate>2009-09-30</listingDate>
							</drug>
							<drug id="02285649" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Novo-Levofloxacin</name>
								<manufacturerId>NOP</manufacturerId>
								<individualPrice>6.5484</individualPrice>
								<listingDate>2009-09-30</listingDate>
							</drug>
							<drug id="02298651" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Sandoz Levofloxacin</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>6.5484</individualPrice>
								<listingDate>2009-11-13</listingDate>
							</drug>
							<drug id="02315440" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Act Levofloxacin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>6.5484</individualPrice>
								<listingDate>2009-09-30</listingDate>
							</drug>
							<drug id="02325942" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Levofloxacin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>6.5484</individualPrice>
								<listingDate>2009-09-30</listingDate>
							</drug>
							<drug id="02492741" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Riva-Levofloxacin</name>
								<manufacturerId>RIA</manufacturerId>
								<individualPrice>6.5484</individualPrice>
								<listingDate>2020-08-28</listingDate>
							</drug>
							<drug id="02505800" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mint-Levofloxacin</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>6.5484</individualPrice>
								<listingDate>2021-11-30</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01514">
					<name>LINEZOLID</name>
					<pcgGroup>
						<pcg9 id="084000068">
							<itemNumber>0228</itemNumber>
							<strength>2mg/mL</strength>
							<dosageForm>Inj-300mL Pk</dosageForm>
							<drug id="02243685" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Zyvoxam</name>
								<manufacturerId>PFI</manufacturerId>
								<listingDate>2014-10-29</listingDate>
							</drug>
							<drug id="02481278" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Linezolid Injection</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>88.7400</individualPrice>
								<listingDate>2020-05-29</listingDate>
								<amountMOHLTCPays>88.7400</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
					<pcgGroup lccId="00014">
						<pcg9 id="084000054">
							<itemNumber>0229</itemNumber>
							<strength>600mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02243684" notABenefit="Y" sec3="Y">
								<name>Zyvoxam</name>
								<manufacturerId>PFI</manufacturerId>
								<listingDate>2003-01-30</listingDate>
							</drug>
							<drug id="02422689" sec3="Y" sec12="Y">
								<name>Sandoz Linezolid</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>38.6083</individualPrice>
								<listingDate>2014-10-29</listingDate>
								<amountMOHLTCPays>38.6083</amountMOHLTCPays>
							</drug>
							<drug id="02426552" sec3="Y" sec12="Y">
								<name>Apo-Linezolid</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>38.6083</individualPrice>
								<listingDate>2014-10-29</listingDate>
								<amountMOHLTCPays>38.6083</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" type="R">For the treatment of patients with:</lccNote>
						<lccNote seq="002" reasonForUseId="362">Methicillin-resistant Staphylococcus species (MRSA, MRSE) infections* in patients who are intolerant or have failed vancomycin therapy, or have contraindications to venous access.</lccNote>
						<lccNote seq="003" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="004" reasonForUseId="363">Vancomycin resistant Enterococcus species (VRE) infections* in patients switching from IV linezolid.</lccNote>
						<lccNote seq="005" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="006" reasonForUseId="364">Step-down therapy for the treatment of methicillin-resistant Staphylococcus species or vancomycin resistant Enterococcus species (VRE) infections* after parenteral therapy or hospital/ emergency department discharge.</lccNote>
						<lccNote seq="007" type="R">* Infections must be documented and culture proven. Not approved for colonization (e.g. nares, urine, etc). Maximum 28 days supply.</lccNote>
						<lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="01516">
					<name>MOXIFLOXACIN HYDROCHLORIDE</name>
					<pcgGroup>
						<pcg9 id="084000053">
							<itemNumber>0230</itemNumber>
							<strength>400mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02242965" sec3="Y">
								<name>Avelox</name>
								<manufacturerId>BAY</manufacturerId>
								<individualPrice>6.0920</individualPrice>
								<listingDate>2001-06-07</listingDate>
								<amountMOHLTCPays>1.5230</amountMOHLTCPays>
							</drug>
							<drug id="02375702" sec3="Y">
								<name>Teva-Moxifloxacin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>1.5230</individualPrice>
								<listingDate>2016-01-28</listingDate>
								<amountMOHLTCPays>1.5230</amountMOHLTCPays>
							</drug>
							<drug id="02383381" sec3="Y">
								<name>Sandoz Moxifloxacin</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>1.5230</individualPrice>
								<listingDate>2018-01-31</listingDate>
								<amountMOHLTCPays>1.5230</amountMOHLTCPays>
							</drug>
							<drug id="02404923" sec3="Y">
								<name>Apo-Moxifloxacin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.5230</individualPrice>
								<listingDate>2016-03-30</listingDate>
								<amountMOHLTCPays>1.5230</amountMOHLTCPays>
							</drug>
							<drug id="02432242" sec3="Y">
								<name>Auro-Moxifloxacin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>1.5230</individualPrice>
								<listingDate>2016-01-28</listingDate>
								<amountMOHLTCPays>1.5230</amountMOHLTCPays>
							</drug>
							<drug id="02443929" sec3="Y">
								<name>Jamp-Moxifloxacin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>1.5230</individualPrice>
								<listingDate>2015-12-22</listingDate>
								<amountMOHLTCPays>1.5230</amountMOHLTCPays>
							</drug>
							<drug id="02447053" sec3="Y">
								<name>Mar-Moxifloxacin</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>1.5230</individualPrice>
								<listingDate>2016-01-28</listingDate>
								<amountMOHLTCPays>1.5230</amountMOHLTCPays>
							</drug>
							<drug id="02447061" sec3="Y">
								<name>Jamp-Moxifloxacin Tablets</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>1.5230</individualPrice>
								<listingDate>2016-03-30</listingDate>
								<amountMOHLTCPays>1.5230</amountMOHLTCPays>
							</drug>
							<drug id="02457814" sec3="Y">
								<name>Med-Moxifloxacin</name>
								<manufacturerId>GMP</manufacturerId>
								<individualPrice>1.5230</individualPrice>
								<listingDate>2017-02-28</listingDate>
								<amountMOHLTCPays>1.5230</amountMOHLTCPays>
							</drug>
							<drug id="02472791" sec3="Y">
								<name>M-Moxifloxacin</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>1.5230</individualPrice>
								<listingDate>2019-03-28</listingDate>
								<amountMOHLTCPays>1.5230</amountMOHLTCPays>
							</drug>
							<drug id="02478137" sec3="Y">
								<name>AG-Moxifloxacin</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>1.5230</individualPrice>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>1.5230</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00138">
					<name>NORFLOXACIN</name>
					<pcgGroup>
						<pcg9 id="084000010">
							<itemNumber>0231</itemNumber>
							<strength>400mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>3.7172</dailyCost>
							<drug id="00643025" notABenefit="Y" sec3="Y">
								<name>Noroxin</name>
								<manufacturerId>MSD</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02229524" sec3="Y">
								<name>Norfloxacin</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>1.8586</individualPrice>
								<dailyCost>3.7172</dailyCost>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>1.8586</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00136">
					<name>SULFAMETHOXAZOLE &amp; TRIMETHOPRIM</name>
					<note>Avoid using sulfamethoxazole/trimethoprim during the last 6 weeks of pregnancy.</note>
					<pcgGroup>
						<pcg9 id="084000002">
							<itemNumber>0232</itemNumber>
							<strength>40mg &amp; 8mg/mL</strength>
							<dosageForm>O/L</dosageForm>
							<dailyCost>1.0260</dailyCost>
							<drug id="00270644" notABenefit="Y" sec3="Y">
								<name>Septra</name>
								<manufacturerId>BWE</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00272485" notABenefit="Y" sec3="Y">
								<name>Bactrim Sugar Free</name>
								<manufacturerId>HLR</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00726540" sec3="Y">
								<name>Teva-Trimel</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1026</individualPrice>
								<dailyCost>1.0260</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1026</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="084000001">
							<itemNumber>0233</itemNumber>
							<strength>400mg &amp; 80mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.4308</dailyCost>
							<drug id="00270636" notABenefit="Y" sec3="Y">
								<name>Septra</name>
								<manufacturerId>BWE</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00272469" notABenefit="Y" sec3="Y">
								<name>Bactrim</name>
								<manufacturerId>HLR</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00445274" sec3="Y">
								<name>Sulfatrim</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.1077</individualPrice>
								<dailyCost>.4308</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1077</amountMOHLTCPays>
							</drug>
							<drug id="00510637" sec3="Y">
								<name>Teva-Trimel</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1077</individualPrice>
								<dailyCost>.4308</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1077</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="084000003">
							<itemNumber>0234</itemNumber>
							<strength>800mg &amp; 160mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.4148</dailyCost>
							<drug id="00368040" notABenefit="Y" sec3="Y">
								<name>Septra DS</name>
								<manufacturerId>BWE</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00371823" notABenefit="Y" sec3="Y">
								<name>Bactrim-DS</name>
								<manufacturerId>HLR</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00445282" sec3="Y">
								<name>Sulfatrim-DS</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.2074</individualPrice>
								<dailyCost>.4148</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2074</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00137">
					<name>TRIMETHOPRIM</name>
					<pcgGroup>
						<pcg9 id="084000007">
							<itemNumber>0235</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.5234</dailyCost>
							<drug id="00675229" notABenefit="Y" sec3="Y">
								<name>Proloprim</name>
								<manufacturerId>BWE</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02243116" sec3="Y">
								<name>Trimethoprim</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.2617</individualPrice>
								<dailyCost>.5234</dailyCost>
								<listingDate>2001-06-07</listingDate>
								<amountMOHLTCPays>.2617</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="084000009">
							<itemNumber>0236</itemNumber>
							<strength>200mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.5378</dailyCost>
							<drug id="00677590" notABenefit="Y" sec3="Y">
								<name>Proloprim</name>
								<manufacturerId>BWE</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02243117" sec3="Y">
								<name>Trimethoprim</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.5378</individualPrice>
								<dailyCost>.5378</dailyCost>
								<listingDate>2001-06-07</listingDate>
								<amountMOHLTCPays>.5378</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
			</pcg6>
		</pcg2>
		<pcg2 id="100000000">
			<name>ANTINEOPLASTIC AGENTS</name>
			<pcg6>
				<genericName id="01891">
					<name>ABIRATERONE ACETATE</name>
					<pcgGroup>
						<pcg9 id="100000210">
							<itemNumber>0237</itemNumber>
							<strength>250mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02371065" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Zytiga</name>
								<manufacturerId>JAN</manufacturerId>
								<individualPrice>31.4150</individualPrice>
								<listingDate>2021-03-29</listingDate>
								<amountMOHLTCPays>26.0313</amountMOHLTCPays>
							</drug>
							<drug id="02477114" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Reddy-Abiraterone</name>
								<manufacturerId>DRR</manufacturerId>
								<individualPrice>26.0313</individualPrice>
								<listingDate>2021-03-29</listingDate>
								<amountMOHLTCPays>26.0313</amountMOHLTCPays>
							</drug>
							<drug id="02486393" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Sandoz Abiraterone</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>26.0313</individualPrice>
								<listingDate>2021-03-29</listingDate>
								<amountMOHLTCPays>26.0313</amountMOHLTCPays>
							</drug>
							<drug id="02491397" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Apo-Abiraterone Film Coated Tablets</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>26.0313</individualPrice>
								<listingDate>2021-03-29</listingDate>
								<amountMOHLTCPays>26.0313</amountMOHLTCPays>
							</drug>
							<drug id="02492601" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>PMS-Abiraterone</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>26.0313</individualPrice>
								<listingDate>2021-03-29</listingDate>
								<amountMOHLTCPays>26.0313</amountMOHLTCPays>
							</drug>
							<drug id="02494132" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Nat-Abiraterone</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>26.0313</individualPrice>
								<listingDate>2021-03-29</listingDate>
								<amountMOHLTCPays>26.0313</amountMOHLTCPays>
							</drug>
							<drug id="02502305" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Jamp Abiraterone</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>26.0313</individualPrice>
								<listingDate>2021-03-29</listingDate>
								<amountMOHLTCPays>26.0313</amountMOHLTCPays>
							</drug>
							<drug id="02503980" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Mar-Abiraterone</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>26.0313</individualPrice>
								<listingDate>2021-03-29</listingDate>
								<amountMOHLTCPays>26.0313</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000258">
							<itemNumber>0238</itemNumber>
							<strength>500mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02457113" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Zytiga</name>
								<manufacturerId>JAN</manufacturerId>
								<individualPrice>62.8300</individualPrice>
								<listingDate>2021-03-29</listingDate>
								<amountMOHLTCPays>52.0625</amountMOHLTCPays>
							</drug>
							<drug id="02491400" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Apo-Abiraterone Film Coated Tablets</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>52.0625</individualPrice>
								<listingDate>2021-03-29</listingDate>
								<amountMOHLTCPays>52.0625</amountMOHLTCPays>
							</drug>
							<drug id="02501503" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>PMS-Abiraterone</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>52.0625</individualPrice>
								<listingDate>2021-03-29</listingDate>
								<amountMOHLTCPays>52.0625</amountMOHLTCPays>
							</drug>
							<drug id="02503999" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Mar-Abiraterone</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>52.0625</individualPrice>
								<listingDate>2021-03-29</listingDate>
								<amountMOHLTCPays>52.0625</amountMOHLTCPays>
							</drug>
							<drug id="02521644" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Sandoz Abiraterone</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>52.0625</individualPrice>
								<listingDate>2022-03-31</listingDate>
								<amountMOHLTCPays>52.0625</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00202">
					<name>ALTRETAMINE</name>
					<pcgGroup>
						<pcg9 id="100000095">
							<itemNumber>0239</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02126230" sec3="Y">
								<name>Hexalen</name>
								<manufacturerId>LIL</manufacturerId>
								<individualPrice>3.3600</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>3.3600</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00208">
					<name>ANASTROZOLE</name>
					<pcgGroup>
						<pcg9 id="100000109">
							<itemNumber>0240</itemNumber>
							<strength>1mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02224135" sec3="Y">
								<name>Arimidex</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>5.4750</individualPrice>
								<listingDate>1996-12-19</listingDate>
								<amountMOHLTCPays>.9522</amountMOHLTCPays>
							</drug>
							<drug id="02320738" sec3="Y">
								<name>PMS-Anastrozole</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.9522</individualPrice>
								<listingDate>2012-12-21</listingDate>
								<amountMOHLTCPays>.9522</amountMOHLTCPays>
							</drug>
							<drug id="02328690" sec3="Y">
								<name>Ran-Anastrozole</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.9522</individualPrice>
								<listingDate>2012-12-21</listingDate>
								<amountMOHLTCPays>.9522</amountMOHLTCPays>
							</drug>
							<drug id="02338467" sec3="Y">
								<name>Sandoz Anastrozole</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.9522</individualPrice>
								<listingDate>2012-09-28</listingDate>
								<amountMOHLTCPays>.9522</amountMOHLTCPays>
							</drug>
							<drug id="02339080" sec3="Y">
								<name>Jamp-Anastrozole</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.9522</individualPrice>
								<listingDate>2013-01-29</listingDate>
								<amountMOHLTCPays>.9522</amountMOHLTCPays>
							</drug>
							<drug id="02351218" sec3="Y">
								<name>Anastrozole</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.9522</individualPrice>
								<listingDate>2012-12-21</listingDate>
								<amountMOHLTCPays>.9522</amountMOHLTCPays>
							</drug>
							<drug id="02365650" sec3="Y">
								<name>Taro-Anastrozole</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>.9522</individualPrice>
								<listingDate>2013-01-29</listingDate>
								<amountMOHLTCPays>.9522</amountMOHLTCPays>
							</drug>
							<drug id="02374420" sec3="Y">
								<name>Apo-Anastrozole</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.9522</individualPrice>
								<listingDate>2012-12-21</listingDate>
								<amountMOHLTCPays>.9522</amountMOHLTCPays>
							</drug>
							<drug id="02379104" sec3="Y">
								<name>Med-Anastrozole</name>
								<manufacturerId>GMP</manufacturerId>
								<individualPrice>.9522</individualPrice>
								<listingDate>2012-12-21</listingDate>
								<amountMOHLTCPays>.9522</amountMOHLTCPays>
							</drug>
							<drug id="02379562" sec3="Y">
								<name>Mar-Anastrozole</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.9522</individualPrice>
								<listingDate>2013-01-29</listingDate>
								<amountMOHLTCPays>.9522</amountMOHLTCPays>
							</drug>
							<drug id="02392259" sec3="Y">
								<name>Riva-Anastrozole</name>
								<manufacturerId>RIA</manufacturerId>
								<individualPrice>.9522</individualPrice>
								<listingDate>2021-08-31</listingDate>
								<amountMOHLTCPays>.9522</amountMOHLTCPays>
							</drug>
							<drug id="02393573" sec3="Y">
								<name>Mint-Anastrozole</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.9522</individualPrice>
								<listingDate>2013-01-29</listingDate>
								<amountMOHLTCPays>.9522</amountMOHLTCPays>
							</drug>
							<drug id="02394898" sec3="Y">
								<name>Co Anastrozole</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.9522</individualPrice>
								<listingDate>2012-12-21</listingDate>
								<amountMOHLTCPays>.9522</amountMOHLTCPays>
							</drug>
							<drug id="02417855" sec3="Y">
								<name>Nat-Anastrozole</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>.9522</individualPrice>
								<listingDate>2015-04-30</listingDate>
								<amountMOHLTCPays>.9522</amountMOHLTCPays>
							</drug>
							<drug id="02427818" dinStatus="E" sec3="Y">
								<name>Van-Anastrozole</name>
								<manufacturerId>VAN</manufacturerId>
								<individualPrice>.9522</individualPrice>
								<listingDate>2015-08-26</listingDate>
								<amountMOHLTCPays>.9522</amountMOHLTCPays>
							</drug>
							<drug id="02442736" sec3="Y">
								<name>Anastrozole</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.9522</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.9522</amountMOHLTCPays>
							</drug>
							<drug id="02458799" sec3="Y">
								<name>CCP-Anastrozole</name>
								<manufacturerId>CCP</manufacturerId>
								<individualPrice>.9522</individualPrice>
								<listingDate>2017-12-21</listingDate>
								<amountMOHLTCPays>.9522</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00207">
					<name>BICALUTAMIDE</name>
					<pcgGroup>
						<pcg9 id="100000108">
							<itemNumber>0241</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02184478" sec3="Y">
								<name>Casodex</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>7.0500</individualPrice>
								<listingDate>1996-12-19</listingDate>
								<amountMOHLTCPays>1.2690</amountMOHLTCPays>
							</drug>
							<drug id="02270226" sec3="Y">
								<name>Teva-Bicalutamide</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>1.2690</individualPrice>
								<listingDate>2006-04-04</listingDate>
								<amountMOHLTCPays>1.2690</amountMOHLTCPays>
							</drug>
							<drug id="02274337" sec3="Y">
								<name>Co Bicalutamide</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>1.2690</individualPrice>
								<listingDate>2006-04-04</listingDate>
								<amountMOHLTCPays>1.2690</amountMOHLTCPays>
							</drug>
							<drug id="02275589" sec3="Y">
								<name>PMS-Bicalutamide</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>1.2690</individualPrice>
								<listingDate>2006-04-04</listingDate>
								<amountMOHLTCPays>1.2690</amountMOHLTCPays>
							</drug>
							<drug id="02296063" sec3="Y">
								<name>Apo-Bicalutamide</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.2690</individualPrice>
								<listingDate>2008-01-15</listingDate>
								<amountMOHLTCPays>1.2690</amountMOHLTCPays>
							</drug>
							<drug id="02325985" sec3="Y">
								<name>Bicalutamide Tablets</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>1.2690</individualPrice>
								<listingDate>2010-07-20</listingDate>
								<amountMOHLTCPays>1.2690</amountMOHLTCPays>
							</drug>
							<drug id="02357216" sec3="Y">
								<name>Jamp-Bicalutamide</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>1.2690</individualPrice>
								<listingDate>2011-03-15</listingDate>
								<amountMOHLTCPays>1.2690</amountMOHLTCPays>
							</drug>
							<drug id="02371324" sec3="Y">
								<name>Ran-Bicalutamide</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>1.2690</individualPrice>
								<listingDate>2011-12-15</listingDate>
								<amountMOHLTCPays>1.2690</amountMOHLTCPays>
							</drug>
							<drug id="02428709" dinStatus="E" sec3="Y">
								<name>Van-Bicalutamide</name>
								<manufacturerId>VAN</manufacturerId>
								<individualPrice>1.2690</individualPrice>
								<listingDate>2015-08-26</listingDate>
								<amountMOHLTCPays>1.2690</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00187">
					<name>BUSERELIN ACETATE</name>
					<pcgGroup>
						<pcg9 id="100000111">
							<itemNumber>0242</itemNumber>
							<strength>6.3mg</strength>
							<dosageForm>Implant Kit</dosageForm>
							<drug id="02228955" sec3="Y">
								<name>Suprefact Depot 2 Months</name>
								<manufacturerId>CHE</manufacturerId>
								<individualPrice>827.8500</individualPrice>
								<listingDate>1997-04-10</listingDate>
								<amountMOHLTCPays>827.8500</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000151">
							<itemNumber>0243</itemNumber>
							<strength>9.45mg</strength>
							<dosageForm>Implant Kit</dosageForm>
							<drug id="02240749" sec3="Y">
								<name>Suprefact Depot 3 Months</name>
								<manufacturerId>CHE</manufacturerId>
								<individualPrice>1226.7600</individualPrice>
								<listingDate>2000-11-30</listingDate>
								<amountMOHLTCPays>1226.7600</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000075">
							<itemNumber>0244</itemNumber>
							<strength>1mg/mL</strength>
							<dosageForm>Inj Sol-5.5mL Pk</dosageForm>
							<drug id="02225166" sec3="Y">
								<name>Suprefact</name>
								<manufacturerId>CHE</manufacturerId>
								<individualPrice>67.0300</individualPrice>
								<listingDate>1999-01-08</listingDate>
								<amountMOHLTCPays>67.0300</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000076">
							<itemNumber>0245</itemNumber>
							<strength>1mg/mL</strength>
							<dosageForm>Nas Sp-10mL Pk</dosageForm>
							<drug id="02225158" sec3="Y">
								<name>Suprefact</name>
								<manufacturerId>CHE</manufacturerId>
								<individualPrice>85.5300</individualPrice>
								<listingDate>1999-01-08</listingDate>
								<amountMOHLTCPays>85.5300</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00157">
					<name>BUSULFAN</name>
					<pcgGroup>
						<pcg9 id="100000005">
							<itemNumber>0246</itemNumber>
							<strength>2mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00004618" sec3="Y">
								<name>Myleran</name>
								<manufacturerId>ASN</manufacturerId>
								<individualPrice>1.8040</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>1.8040</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01399">
					<name>CAPECITABINE</name>
					<pcgGroup>
						<pcg9 id="100000136">
							<itemNumber>0247</itemNumber>
							<strength>150mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02238453" sec3="Y">
								<name>Xeloda</name>
								<manufacturerId>HLR</manufacturerId>
								<individualPrice>1.9478</individualPrice>
								<listingDate>2001-06-07</listingDate>
								<amountMOHLTCPays>.4575</amountMOHLTCPays>
							</drug>
							<drug id="02400022" sec3="Y">
								<name>Teva-Capecitabine</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.4575</individualPrice>
								<listingDate>2013-10-31</listingDate>
								<amountMOHLTCPays>.4575</amountMOHLTCPays>
							</drug>
							<drug id="02421917" sec3="Y">
								<name>Sandoz Capecitabine</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.4575</individualPrice>
								<listingDate>2014-12-18</listingDate>
								<amountMOHLTCPays>.4575</amountMOHLTCPays>
							</drug>
							<drug id="02426757" sec3="Y">
								<name>Ach-Capecitabine</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.4575</individualPrice>
								<listingDate>2015-02-26</listingDate>
								<amountMOHLTCPays>.4575</amountMOHLTCPays>
							</drug>
							<drug id="02457490" sec3="Y">
								<name>Taro-Capecitabine</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>.4575</individualPrice>
								<listingDate>2017-10-30</listingDate>
								<amountMOHLTCPays>.4575</amountMOHLTCPays>
							</drug>
							<drug id="02514982" sec3="Y">
								<name>Capecitabine</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.4575</individualPrice>
								<listingDate>2021-12-17</listingDate>
								<amountMOHLTCPays>.4575</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000137">
							<itemNumber>0248</itemNumber>
							<strength>500mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02238454" sec3="Y">
								<name>Xeloda</name>
								<manufacturerId>HLR</manufacturerId>
								<individualPrice>6.4933</individualPrice>
								<listingDate>2001-06-07</listingDate>
								<amountMOHLTCPays>1.5250</amountMOHLTCPays>
							</drug>
							<drug id="02400030" sec3="Y">
								<name>Teva-Capecitabine</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>1.5250</individualPrice>
								<listingDate>2013-10-31</listingDate>
								<amountMOHLTCPays>1.5250</amountMOHLTCPays>
							</drug>
							<drug id="02421925" sec3="Y">
								<name>Sandoz Capecitabine</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>1.5250</individualPrice>
								<listingDate>2014-12-18</listingDate>
								<amountMOHLTCPays>1.5250</amountMOHLTCPays>
							</drug>
							<drug id="02426765" sec3="Y">
								<name>Ach-Capecitabine</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>1.5250</individualPrice>
								<listingDate>2015-02-26</listingDate>
								<amountMOHLTCPays>1.5250</amountMOHLTCPays>
							</drug>
							<drug id="02457504" sec3="Y">
								<name>Taro-Capecitabine</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>1.5250</individualPrice>
								<listingDate>2017-10-30</listingDate>
								<amountMOHLTCPays>1.5250</amountMOHLTCPays>
							</drug>
							<drug id="02508028" sec3="Y">
								<name>Mint-Capecitabine</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>1.5250</individualPrice>
								<listingDate>2021-12-17</listingDate>
								<amountMOHLTCPays>1.5250</amountMOHLTCPays>
							</drug>
							<drug id="02514990" sec3="Y">
								<name>Capecitabine</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>1.5250</individualPrice>
								<listingDate>2021-12-17</listingDate>
								<amountMOHLTCPays>1.5250</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00158">
					<name>CHLORAMBUCIL</name>
					<pcgGroup>
						<pcg9 id="100000006">
							<itemNumber>0249</itemNumber>
							<strength>2mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00004626" sec3="Y">
								<name>Leukeran</name>
								<manufacturerId>ASN</manufacturerId>
								<individualPrice>1.6960</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>1.6960</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00159">
					<name>CYCLOPHOSPHAMIDE</name>
					<pcgGroup>
						<pcg9 id="100000008">
							<itemNumber>0250</itemNumber>
							<strength>25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02241795" sec3="Y">
								<name>Procytox</name>
								<manufacturerId>BAX</manufacturerId>
								<individualPrice>.3545</individualPrice>
								<listingDate>2005-05-25</listingDate>
								<amountMOHLTCPays>.3545</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000007">
							<itemNumber>0251</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00344885" notABenefit="Y" sec3="Y">
								<name>Cytoxan</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02241796" sec3="Y">
								<name>Procytox</name>
								<manufacturerId>BAX</manufacturerId>
								<individualPrice>.4773</individualPrice>
								<listingDate>2005-05-25</listingDate>
								<amountMOHLTCPays>.4773</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00180">
					<name>CYPROTERONE ACETATE</name>
					<pcgGroup>
						<pcg9 id="100000057">
							<itemNumber>0252</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00704431" sec3="Y">
								<name>Androcur</name>
								<manufacturerId>BAY</manufacturerId>
								<individualPrice>1.4085</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>1.4000</amountMOHLTCPays>
							</drug>
							<drug id="02245898" sec3="Y">
								<name>Cyproterone</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>1.4085</individualPrice>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>1.4000</amountMOHLTCPays>
							</drug>
							<drug id="02390760" sec3="Y">
								<name>Med-Cyproterone</name>
								<manufacturerId>GMP</manufacturerId>
								<individualPrice>1.4000</individualPrice>
								<listingDate>2013-11-28</listingDate>
								<amountMOHLTCPays>1.4000</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01716">
					<name>DASATINIB</name>
					<pcgGroup>
						<pcg9 id="100000192">
							<itemNumber>0253</itemNumber>
							<strength>20mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02293129" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Sprycel</name>
								<manufacturerId>BQU</manufacturerId>
								<individualPrice>38.6850</individualPrice>
								<listingDate>2020-01-31</listingDate>
								<amountMOHLTCPays>32.8823</amountMOHLTCPays>
							</drug>
							<drug id="02470705" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Apo-Dasatinib</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>32.8823</individualPrice>
								<listingDate>2020-01-31</listingDate>
								<amountMOHLTCPays>32.8823</amountMOHLTCPays>
							</drug>
							<drug id="02478307" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Teva-Dasatinib</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>32.8823</individualPrice>
								<listingDate>2021-04-30</listingDate>
								<amountMOHLTCPays>32.8823</amountMOHLTCPays>
							</drug>
							<drug id="02499282" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Taro-Dasatinib</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>32.8823</individualPrice>
								<listingDate>2021-03-29</listingDate>
								<amountMOHLTCPays>32.8823</amountMOHLTCPays>
							</drug>
							<drug id="02514737" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Reddy-Dasatinib</name>
								<manufacturerId>DRR</manufacturerId>
								<individualPrice>32.8823</individualPrice>
								<listingDate>2021-06-30</listingDate>
								<amountMOHLTCPays>32.8823</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000193">
							<itemNumber>0254</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02293137" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Sprycel</name>
								<manufacturerId>BQU</manufacturerId>
								<individualPrice>77.8567</individualPrice>
								<listingDate>2020-01-31</listingDate>
								<amountMOHLTCPays>66.1783</amountMOHLTCPays>
							</drug>
							<drug id="02470713" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Apo-Dasatinib</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>66.1782</individualPrice>
								<listingDate>2020-01-31</listingDate>
								<amountMOHLTCPays>66.1782</amountMOHLTCPays>
							</drug>
							<drug id="02478315" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Teva-Dasatinib</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>66.1782</individualPrice>
								<listingDate>2021-04-30</listingDate>
								<amountMOHLTCPays>66.1782</amountMOHLTCPays>
							</drug>
							<drug id="02499304" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Taro-Dasatinib</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>66.1783</individualPrice>
								<listingDate>2021-03-29</listingDate>
								<amountMOHLTCPays>66.1783</amountMOHLTCPays>
							</drug>
							<drug id="02514745" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Reddy-Dasatinib</name>
								<manufacturerId>DRR</manufacturerId>
								<individualPrice>66.1782</individualPrice>
								<listingDate>2021-06-30</listingDate>
								<amountMOHLTCPays>66.1782</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000194">
							<itemNumber>0255</itemNumber>
							<strength>70mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02293145" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Sprycel</name>
								<manufacturerId>BQU</manufacturerId>
								<individualPrice>85.8042</individualPrice>
								<listingDate>2020-01-31</listingDate>
								<amountMOHLTCPays>72.9337</amountMOHLTCPays>
							</drug>
							<drug id="02478323" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Teva-Dasatinib</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>72.9336</individualPrice>
								<listingDate>2021-04-30</listingDate>
								<amountMOHLTCPays>72.9336</amountMOHLTCPays>
							</drug>
							<drug id="02481499" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Apo-Dasatinib</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>72.9336</individualPrice>
								<listingDate>2020-01-31</listingDate>
								<amountMOHLTCPays>72.9336</amountMOHLTCPays>
							</drug>
							<drug id="02499312" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Taro-Dasatinib</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>72.9337</individualPrice>
								<listingDate>2021-03-29</listingDate>
								<amountMOHLTCPays>72.9337</amountMOHLTCPays>
							</drug>
							<drug id="02514753" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Reddy-Dasatinib</name>
								<manufacturerId>DRR</manufacturerId>
								<individualPrice>72.9336</individualPrice>
								<listingDate>2021-06-30</listingDate>
								<amountMOHLTCPays>72.9336</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000301">
							<itemNumber>0256</itemNumber>
							<strength>80mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02360810" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Sprycel</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>2020-01-31</listingDate>
							</drug>
							<drug id="02478331" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Teva-Dasatinib</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>117.3255</individualPrice>
								<listingDate>2021-04-30</listingDate>
							</drug>
							<drug id="02481502" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Dasatinib</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>117.3255</individualPrice>
								<listingDate>2020-01-31</listingDate>
							</drug>
							<drug id="02499320" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Taro-Dasatinib</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>117.3257</individualPrice>
								<listingDate>2021-03-29</listingDate>
							</drug>
							<drug id="02514761" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Reddy-Dasatinib</name>
								<manufacturerId>DRR</manufacturerId>
								<individualPrice>117.3255</individualPrice>
								<listingDate>2021-06-30</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="100000207">
							<itemNumber>0257</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02320193" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Sprycel</name>
								<manufacturerId>BQU</manufacturerId>
								<individualPrice>155.6083</individualPrice>
								<listingDate>2020-01-31</listingDate>
								<amountMOHLTCPays>132.2671</amountMOHLTCPays>
							</drug>
							<drug id="02470721" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Apo-Dasatinib</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>132.2671</individualPrice>
								<listingDate>2020-01-31</listingDate>
								<amountMOHLTCPays>132.2671</amountMOHLTCPays>
							</drug>
							<drug id="02478358" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Teva-Dasatinib</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>132.2671</individualPrice>
								<listingDate>2021-04-30</listingDate>
								<amountMOHLTCPays>132.2671</amountMOHLTCPays>
							</drug>
							<drug id="02499339" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Taro-Dasatinib</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>132.2670</individualPrice>
								<listingDate>2021-03-29</listingDate>
								<amountMOHLTCPays>132.2670</amountMOHLTCPays>
							</drug>
							<drug id="02514788" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Reddy-Dasatinib</name>
								<manufacturerId>DRR</manufacturerId>
								<individualPrice>132.2670</individualPrice>
								<listingDate>2021-06-30</listingDate>
								<amountMOHLTCPays>132.2670</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000322">
							<itemNumber>0258</itemNumber>
							<strength>140mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02360829" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Sprycel</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>2021-03-29</listingDate>
							</drug>
							<drug id="02499347" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Taro-Dasatinib</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>141.8806</individualPrice>
								<listingDate>2021-03-29</listingDate>
							</drug>
							<drug id="02514796" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Reddy-Dasatinib</name>
								<manufacturerId>DRR</manufacturerId>
								<individualPrice>141.8806</individualPrice>
								<listingDate>2021-06-30</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00161">
					<name>DAUNORUBICIN</name>
					<pcgGroup>
						<pcg9 id="100000014">
							<itemNumber>0259</itemNumber>
							<dosageForm>Inj Pd-20mg Pk</dosageForm>
							<drug id="01926683" sec3="Y">
								<name>Cerubidine</name>
								<manufacturerId>ERF</manufacturerId>
								<individualPrice>91.0000</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>91.0000</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01793">
					<name>DEGARELIX ACETATE</name>
					<pcgGroup>
						<pcg9 id="100000198">
							<itemNumber>0260</itemNumber>
							<strength>80mg</strength>
							<dosageForm>Pd for Inj-Vial Pk</dosageForm>
							<drug id="02337029" sec3="Y">
								<name>Firmagon</name>
								<manufacturerId>FEI</manufacturerId>
								<individualPrice>274.1760</individualPrice>
								<listingDate>2011-03-15</listingDate>
								<amountMOHLTCPays>274.1760</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000199">
							<itemNumber>0261</itemNumber>
							<strength>120mg</strength>
							<dosageForm>Pd for Inj-Vial Pk</dosageForm>
							<drug id="02337037" sec3="Y">
								<name>Firmagon</name>
								<manufacturerId>FEI</manufacturerId>
								<individualPrice>370.9440</individualPrice>
								<listingDate>2011-03-15</listingDate>
								<amountMOHLTCPays>370.9440</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01677">
					<name>ERLOTINIB</name>
					<pcgGroup>
						<pcg9 id="100000204">
							<itemNumber>0262</itemNumber>
							<strength>25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02269007" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Tarceva</name>
								<manufacturerId>HLR</manufacturerId>
								<listingDate>2015-02-26</listingDate>
							</drug>
							<drug id="02377691" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Teva-Erlotinib</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>11.8666</individualPrice>
								<listingDate>2015-02-26</listingDate>
								<amountMOHLTCPays>11.8666</amountMOHLTCPays>
							</drug>
							<drug id="02461862" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Apo-Erlotinib</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>11.8667</individualPrice>
								<listingDate>2017-10-30</listingDate>
								<amountMOHLTCPays>11.8667</amountMOHLTCPays>
							</drug>
							<drug id="02483912" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Nat-Erlotinib</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>11.8667</individualPrice>
								<listingDate>2019-03-28</listingDate>
								<amountMOHLTCPays>11.8667</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000183">
							<itemNumber>0263</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02269015" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Tarceva</name>
								<manufacturerId>HLR</manufacturerId>
								<listingDate>2015-02-26</listingDate>
							</drug>
							<drug id="02377705" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Teva-Erlotinib</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>47.4666</individualPrice>
								<listingDate>2015-02-26</listingDate>
								<amountMOHLTCPays>47.4666</amountMOHLTCPays>
							</drug>
							<drug id="02454386" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>PMS-Erlotinib</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>47.4667</individualPrice>
								<listingDate>2016-09-29</listingDate>
								<amountMOHLTCPays>47.4667</amountMOHLTCPays>
							</drug>
							<drug id="02461870" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Apo-Erlotinib</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>47.4667</individualPrice>
								<listingDate>2017-10-30</listingDate>
								<amountMOHLTCPays>47.4667</amountMOHLTCPays>
							</drug>
							<drug id="02483920" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Nat-Erlotinib</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>47.4667</individualPrice>
								<listingDate>2019-03-28</listingDate>
								<amountMOHLTCPays>47.4667</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000184">
							<itemNumber>0264</itemNumber>
							<strength>150mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02269023" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Tarceva</name>
								<manufacturerId>HLR</manufacturerId>
								<listingDate>2015-02-26</listingDate>
							</drug>
							<drug id="02377713" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Teva-Erlotinib</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>71.2000</individualPrice>
								<listingDate>2015-02-26</listingDate>
								<amountMOHLTCPays>71.2000</amountMOHLTCPays>
							</drug>
							<drug id="02454394" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>PMS-Erlotinib</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>71.2000</individualPrice>
								<listingDate>2016-09-29</listingDate>
								<amountMOHLTCPays>71.2000</amountMOHLTCPays>
							</drug>
							<drug id="02461889" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Apo-Erlotinib</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>71.2000</individualPrice>
								<listingDate>2017-10-30</listingDate>
								<amountMOHLTCPays>71.2000</amountMOHLTCPays>
							</drug>
							<drug id="02483939" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Nat-Erlotinib</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>71.2000</individualPrice>
								<listingDate>2019-03-28</listingDate>
								<amountMOHLTCPays>71.2000</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00174">
					<name>ESTRAMUSTINE PHOSPHATE DISODIUM</name>
					<pcgGroup>
						<pcg9 id="100000046">
							<itemNumber>0265</itemNumber>
							<strength>140mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02063794" sec3="Y">
								<name>Emcyt</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>4.9309</individualPrice>
								<listingDate>2006-10-23</listingDate>
								<amountMOHLTCPays>4.9309</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00185">
					<name>ETOPOSIDE</name>
					<pcgGroup>
						<pcg9 id="100000072">
							<itemNumber>0266</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00616192" sec3="Y">
								<name>Vepesid</name>
								<manufacturerId>CHE</manufacturerId>
								<individualPrice>41.5875</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>41.5875</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01794">
					<name>EVEROLIMUS</name>
					<pcgGroup>
						<pcg9 id="100000225">
							<itemNumber>0267</itemNumber>
							<strength>2.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02369257" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Afinitor</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>202.6540</individualPrice>
								<listingDate>2020-02-28</listingDate>
								<amountMOHLTCPays>172.2559</amountMOHLTCPays>
							</drug>
							<drug id="02463229" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Teva-Everolimus</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>172.2559</individualPrice>
								<listingDate>2020-02-28</listingDate>
								<amountMOHLTCPays>172.2559</amountMOHLTCPays>
							</drug>
							<drug id="02492911" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Sandoz Everolimus</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>172.2559</individualPrice>
								<listingDate>2020-12-18</listingDate>
								<amountMOHLTCPays>172.2559</amountMOHLTCPays>
							</drug>
							<drug id="02504677" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>PMS-Everolimus</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>172.2559</individualPrice>
								<listingDate>2021-11-30</listingDate>
								<amountMOHLTCPays>172.2559</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000208">
							<itemNumber>0268</itemNumber>
							<strength>5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02339501" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Afinitor</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>202.6540</individualPrice>
								<listingDate>2020-02-28</listingDate>
								<amountMOHLTCPays>172.2559</amountMOHLTCPays>
							</drug>
							<drug id="02463237" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Teva-Everolimus</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>172.2559</individualPrice>
								<listingDate>2020-02-28</listingDate>
								<amountMOHLTCPays>172.2559</amountMOHLTCPays>
							</drug>
							<drug id="02492938" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Sandoz Everolimus</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>172.2559</individualPrice>
								<listingDate>2020-12-18</listingDate>
								<amountMOHLTCPays>172.2559</amountMOHLTCPays>
							</drug>
							<drug id="02504685" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>PMS-Everolimus</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>172.2559</individualPrice>
								<listingDate>2021-11-30</listingDate>
								<amountMOHLTCPays>172.2559</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000200">
							<itemNumber>0269</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02339528" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Afinitor</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>202.6540</individualPrice>
								<listingDate>2020-02-28</listingDate>
								<amountMOHLTCPays>172.2559</amountMOHLTCPays>
							</drug>
							<drug id="02463253" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Teva-Everolimus</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>172.2559</individualPrice>
								<listingDate>2020-02-28</listingDate>
								<amountMOHLTCPays>172.2559</amountMOHLTCPays>
							</drug>
							<drug id="02492946" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Sandoz Everolimus</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>172.2559</individualPrice>
								<listingDate>2020-12-18</listingDate>
								<amountMOHLTCPays>172.2559</amountMOHLTCPays>
							</drug>
							<drug id="02504693" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>PMS-Everolimus</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>172.2559</individualPrice>
								<listingDate>2021-11-30</listingDate>
								<amountMOHLTCPays>172.2559</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01507">
					<name>EXEMESTANE</name>
					<pcgGroup>
						<pcg9 id="100000162">
							<itemNumber>0270</itemNumber>
							<strength>25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02242705" sec3="Y">
								<name>Aromasin</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>5.7533</individualPrice>
								<listingDate>2002-07-29</listingDate>
								<amountMOHLTCPays>1.3263</amountMOHLTCPays>
							</drug>
							<drug id="02390183" sec3="Y">
								<name>Co Exemestane</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>1.3263</individualPrice>
								<listingDate>2012-10-30</listingDate>
								<amountMOHLTCPays>1.3263</amountMOHLTCPays>
							</drug>
							<drug id="02407841" sec3="Y">
								<name>Med-Exemestane</name>
								<manufacturerId>GMP</manufacturerId>
								<individualPrice>1.3263</individualPrice>
								<listingDate>2014-01-30</listingDate>
								<amountMOHLTCPays>1.3263</amountMOHLTCPays>
							</drug>
							<drug id="02408473" sec3="Y">
								<name>Teva-Exemestane</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>1.3263</individualPrice>
								<listingDate>2014-03-27</listingDate>
								<amountMOHLTCPays>1.3263</amountMOHLTCPays>
							</drug>
							<drug id="02419726" sec3="Y">
								<name>Apo-Exemestane</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.3263</individualPrice>
								<listingDate>2014-04-30</listingDate>
								<amountMOHLTCPays>1.3263</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01583">
					<name>FLUDARABINE PHOSPHATE</name>
					<pcgGroup lccId="00151">
						<pcg9 id="100000171">
							<itemNumber>0271</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02246226" sec3="Y" sec12="Y">
								<name>Fludara</name>
								<manufacturerId>GZM</manufacturerId>
								<individualPrice>40.0760</individualPrice>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>40.0760</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="424">For the first-line treatment of chronic lymphocytic leukemia (CLL) in combination with rituximab (with or without cyclophosphamide).</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: Indefinite.</lccNote>
						<lccNote seq="003" reasonForUseId="379">For second line therapy of patients with chronic lymphocytic leukemia (CLL) who have failed or are intolerant to chlorambucil.</lccNote>
						<lccNote seq="004" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="02064">
					<name>FLUOROURACIL &amp; SALICYLIC ACID</name>
					<pcgGroup>
						<pcg9 id="100000288">
							<itemNumber>0272</itemNumber>
							<strength>0.5% w/w &amp; 10% w/w</strength>
							<dosageForm>Top Sol</dosageForm>
							<drug id="02428946" sec3="Y">
								<name>Actikerall</name>
								<manufacturerId>CIP</manufacturerId>
								<individualPrice>1.7381</individualPrice>
								<listingDate>2018-10-31</listingDate>
								<amountMOHLTCPays>1.7381</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00177">
					<name>FLUTAMIDE</name>
					<pcgGroup>
						<pcg9 id="100000050">
							<itemNumber>0273</itemNumber>
							<strength>250mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00637726" notABenefit="Y" sec3="Y">
								<name>Euflex</name>
								<manufacturerId>SCH</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02238560" sec3="Y">
								<name>Flutamide</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>1.8255</individualPrice>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>1.8255</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="02077">
					<name>FULVESTRANT</name>
					<pcgGroup>
						<pcg9 id="100000291">
							<itemNumber>0274</itemNumber>
							<strength>50mg/mL</strength>
							<dosageForm>Inj Sol</dosageForm>
							<drug id="02248624" sec3="Y">
								<name>Faslodex</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>116.5790</individualPrice>
								<listingDate>2019-03-28</listingDate>
								<amountMOHLTCPays>58.2895</amountMOHLTCPays>
							</drug>
							<drug id="02460130" sec3="Y">
								<name>Teva-Fulvestrant Injection</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>58.2895</individualPrice>
								<listingDate>2019-03-28</listingDate>
								<amountMOHLTCPays>58.2895</amountMOHLTCPays>
							</drug>
							<drug id="02483610" sec3="Y">
								<name>Fulvestrant Injection</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>58.2895</individualPrice>
								<listingDate>2019-04-30</listingDate>
								<amountMOHLTCPays>58.2895</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01631">
					<name>GEFITINIB</name>
					<pcgGroup>
						<pcg9 id="100000178">
							<itemNumber>0275</itemNumber>
							<strength>250mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02248676" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Iressa</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>73.3000</individualPrice>
								<listingDate>2017-10-30</listingDate>
								<amountMOHLTCPays>62.3050</amountMOHLTCPays>
							</drug>
							<drug id="02468050" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Apo-Gefitinib</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>62.3050</individualPrice>
								<listingDate>2017-10-30</listingDate>
								<amountMOHLTCPays>62.3050</amountMOHLTCPays>
							</drug>
							<drug id="02487748" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Sandoz Gefitinib</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>62.3050</individualPrice>
								<listingDate>2019-08-30</listingDate>
								<amountMOHLTCPays>62.3050</amountMOHLTCPays>
							</drug>
							<drug id="02491796" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Nat-Gefitinib</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>62.3050</individualPrice>
								<listingDate>2019-10-31</listingDate>
								<amountMOHLTCPays>62.3050</amountMOHLTCPays>
							</drug>
							<drug id="02500663" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Jamp-Gefitinib</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>62.3050</individualPrice>
								<listingDate>2021-01-29</listingDate>
								<amountMOHLTCPays>62.3050</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00182">
					<name>GOSERELIN ACETATE</name>
					<pcgGroup>
						<pcg9 id="100000069">
							<itemNumber>0276</itemNumber>
							<strength>3.6mg</strength>
							<dosageForm>Depot Inj</dosageForm>
							<drug id="02049325" sec3="Y">
								<name>Zoladex</name>
								<manufacturerId>TRS</manufacturerId>
								<individualPrice>422.6778</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>422.6778</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000110">
							<itemNumber>0277</itemNumber>
							<strength>10.8mg</strength>
							<dosageForm>Depot Inj</dosageForm>
							<drug id="02225905" sec3="Y">
								<name>Zoladex LA</name>
								<manufacturerId>TRS</manufacturerId>
								<individualPrice>1204.7322</individualPrice>
								<listingDate>1996-12-19</listingDate>
								<amountMOHLTCPays>1204.7322</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00184">
					<name>HYDROXYUREA</name>
					<pcgGroup>
						<pcg9 id="100000071">
							<itemNumber>0278</itemNumber>
							<strength>500mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00465283" sec3="Y">
								<name>Hydrea</name>
								<manufacturerId>BQU</manufacturerId>
								<individualPrice>1.0203</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>1.0203</amountMOHLTCPays>
							</drug>
							<drug id="02242920" sec3="Y">
								<name>Mylan-Hydroxyurea</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>1.0203</individualPrice>
								<listingDate>2002-07-29</listingDate>
								<amountMOHLTCPays>1.0203</amountMOHLTCPays>
							</drug>
							<drug id="02247937" sec3="Y">
								<name>Apo-Hydroxyurea</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.0203</individualPrice>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>1.0203</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01534">
					<name>IMATINIB MESYLATE</name>
					<note>It is recommended that Pharmacists inform their patients when a different brand of imatinib is dispensed to support appropriate monitoring.
In patients with CML, regular response monitoring is recommended, particularly when therapy is modified,to detect any changes in response so that actions may be implemented as appropriate.
</note>
					<pcgGroup>
						<pcg9 id="100000180">
							<itemNumber>0279</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>These products must be prescribed based on the following criteria:
1) For treatment of Philadelphia chromosome-positive Chronic Myelogenous Leukemia (CML) in chronic phase.
The initial dose is 400mg/day. The dose may be increased up to a maximum of 800mg/day in patients who do not have an adequate hematologic response at 3 months or cytogenetic response at 1 year; or if there has been loss of a previously achieved hematologic and/or cytogenetic response.
Note: The ministry will only reimburse, in a patient&apos;s lifetime, any two (2) of the oral Tyrosine Kinase Inhibitors (TKIs)* used for chronic phase CML.
(* TKIs: Imatinib, Nilotinib, or Dasatinib).
2) For treatment of Philadelphia chromosome-positive Chronic Myelogenous Leukemia (CML) in blast phase or accelerated phase.
The initial dose is 600mg/day. The dose may be increased to a maximum of 800mg/day in patients who do not have an adequate hematologic response at 3 months or cytogenetic response at 1 year; or loss of a previously achieved hematologic and/or cytogenetic response.</note>
							<drug id="02253275" sec3="Y">
								<name>Gleevec</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>29.7475</individualPrice>
								<listingDate>2007-01-02</listingDate>
								<amountMOHLTCPays>5.2079</amountMOHLTCPays>
							</drug>
							<drug id="02355337" sec3="Y">
								<name>Apo-Imatinib</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>5.2079</individualPrice>
								<listingDate>2013-05-31</listingDate>
								<amountMOHLTCPays>5.2079</amountMOHLTCPays>
							</drug>
							<drug id="02397285" sec3="Y">
								<name>Nat-Imatinib</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>5.2079</individualPrice>
								<listingDate>2014-06-26</listingDate>
								<amountMOHLTCPays>5.2079</amountMOHLTCPays>
							</drug>
							<drug id="02399806" sec3="Y">
								<name>Teva-Imatinib</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>5.2079</individualPrice>
								<listingDate>2013-05-31</listingDate>
								<amountMOHLTCPays>5.2079</amountMOHLTCPays>
							</drug>
							<drug id="02431114" sec3="Y">
								<name>PMS-Imatinib</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>5.2079</individualPrice>
								<listingDate>2015-07-29</listingDate>
								<amountMOHLTCPays>5.2079</amountMOHLTCPays>
							</drug>
							<drug id="02490986" sec3="Y">
								<name>Ach-Imatinib</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>5.2079</individualPrice>
								<listingDate>2021-01-29</listingDate>
								<amountMOHLTCPays>5.2079</amountMOHLTCPays>
							</drug>
							<drug id="02492334" sec3="Y">
								<name>Mint-Imatinib</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>5.2079</individualPrice>
								<listingDate>2020-08-28</listingDate>
								<amountMOHLTCPays>5.2079</amountMOHLTCPays>
							</drug>
							<drug id="02495066" sec3="Y">
								<name>Jamp Imatinib</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>5.2079</individualPrice>
								<listingDate>2021-06-30</listingDate>
								<amountMOHLTCPays>5.2079</amountMOHLTCPays>
							</drug>
							<drug id="02504596" sec3="Y">
								<name>Imatinib</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>5.2079</individualPrice>
								<listingDate>2021-05-31</listingDate>
								<amountMOHLTCPays>5.2079</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000177">
							<itemNumber>0280</itemNumber>
							<strength>400mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>These products must be prescribed based on the following criteria:
1) For treatment of Philadelphia chromosome-positive Chronic Myelogenous Leukemia (CML) in chronic phase.
The initial dose is 400mg/day. The dose may be increased up to a maximum of 800mg/day in patients who do not have an adequate hematologic response at 3 months or cytogenetic response at 1 year; or if there has been loss of a previously achieved hematologic and/or cytogenetic response.
Note: The ministry will only reimburse, in a patient&apos;s lifetime, any two (2) of the oral Tyrosine Kinase Inhibitors (TKIs)* used for chronic phase CML.
(* TKIs: Imatinib, Nilotinib, or Dasatinib).
2) For treatment of Philadelphia chromosome-positive Chronic Myelogenous Leukemia (CML) in blast phase or accelerated phase.
The initial dose is 600mg/day. The dose may be increased to a maximum of 800mg/day in patients who do not have an adequate hematologic response at 3 months or cytogenetic response at 1 year; or loss of a previously achieved hematologic and/or cytogenetic response.</note>
							<drug id="02253283" sec3="Y">
								<name>Gleevec</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>118.9900</individualPrice>
								<listingDate>2007-01-02</listingDate>
								<amountMOHLTCPays>20.8314</amountMOHLTCPays>
							</drug>
							<drug id="02355345" sec3="Y">
								<name>Apo-Imatinib</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>20.8314</individualPrice>
								<listingDate>2013-05-31</listingDate>
								<amountMOHLTCPays>20.8314</amountMOHLTCPays>
							</drug>
							<drug id="02397293" sec3="Y">
								<name>Nat-Imatinib</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>20.8314</individualPrice>
								<listingDate>2014-06-26</listingDate>
								<amountMOHLTCPays>20.8314</amountMOHLTCPays>
							</drug>
							<drug id="02399814" sec3="Y">
								<name>Teva-Imatinib</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>20.8314</individualPrice>
								<listingDate>2013-05-31</listingDate>
								<amountMOHLTCPays>20.8314</amountMOHLTCPays>
							</drug>
							<drug id="02431122" sec3="Y">
								<name>PMS-Imatinib</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>20.8314</individualPrice>
								<listingDate>2015-07-29</listingDate>
								<amountMOHLTCPays>20.8314</amountMOHLTCPays>
							</drug>
							<drug id="02490994" sec3="Y">
								<name>Ach-Imatinib</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>20.8314</individualPrice>
								<listingDate>2021-01-29</listingDate>
								<amountMOHLTCPays>20.8314</amountMOHLTCPays>
							</drug>
							<drug id="02492342" sec3="Y">
								<name>Mint-Imatinib</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>20.8314</individualPrice>
								<listingDate>2020-08-28</listingDate>
								<amountMOHLTCPays>20.8314</amountMOHLTCPays>
							</drug>
							<drug id="02495074" sec3="Y">
								<name>Jamp Imatinib</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>20.8314</individualPrice>
								<listingDate>2021-06-30</listingDate>
								<amountMOHLTCPays>20.8314</amountMOHLTCPays>
							</drug>
							<drug id="02504618" sec3="Y">
								<name>Imatinib</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>20.8314</individualPrice>
								<listingDate>2021-05-31</listingDate>
								<amountMOHLTCPays>20.8314</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01334">
					<name>LETROZOLE</name>
					<pcgGroup>
						<pcg9 id="100000116">
							<itemNumber>0281</itemNumber>
							<strength>2.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02231384" sec3="Y">
								<name>Femara</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>7.6350</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>1.3780</amountMOHLTCPays>
							</drug>
							<drug id="02309114" sec3="Y">
								<name>PMS-Letrozole</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>1.3780</individualPrice>
								<listingDate>2010-07-20</listingDate>
								<amountMOHLTCPays>1.3780</amountMOHLTCPays>
							</drug>
							<drug id="02322315" sec3="Y">
								<name>Med-Letrozole</name>
								<manufacturerId>GMP</manufacturerId>
								<individualPrice>1.3780</individualPrice>
								<listingDate>2010-07-20</listingDate>
								<amountMOHLTCPays>1.3780</amountMOHLTCPays>
							</drug>
							<drug id="02338459" sec3="Y">
								<name>Letrozole Tablets USP</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>1.3780</individualPrice>
								<listingDate>2010-07-20</listingDate>
								<amountMOHLTCPays>1.3780</amountMOHLTCPays>
							</drug>
							<drug id="02343657" sec3="Y">
								<name>Teva-Letrozole</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>1.3780</individualPrice>
								<listingDate>2013-06-27</listingDate>
								<amountMOHLTCPays>1.3780</amountMOHLTCPays>
							</drug>
							<drug id="02344815" sec3="Y">
								<name>Sandoz Letrozole</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>1.3780</individualPrice>
								<listingDate>2010-06-14</listingDate>
								<amountMOHLTCPays>1.3780</amountMOHLTCPays>
							</drug>
							<drug id="02348969" sec3="Y">
								<name>Letrozole</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>1.3780</individualPrice>
								<listingDate>2010-07-20</listingDate>
								<amountMOHLTCPays>1.3780</amountMOHLTCPays>
							</drug>
							<drug id="02358514" sec3="Y">
								<name>Apo-Letrozole</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.3780</individualPrice>
								<listingDate>2011-05-19</listingDate>
								<amountMOHLTCPays>1.3780</amountMOHLTCPays>
							</drug>
							<drug id="02372282" sec3="Y">
								<name>Ran-Letrozole</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>1.3780</individualPrice>
								<listingDate>2011-12-15</listingDate>
								<amountMOHLTCPays>1.3780</amountMOHLTCPays>
							</drug>
							<drug id="02373009" sec3="Y">
								<name>Jamp-Letrozole</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>1.3780</individualPrice>
								<listingDate>2012-08-27</listingDate>
								<amountMOHLTCPays>1.3780</amountMOHLTCPays>
							</drug>
							<drug id="02373424" sec3="Y">
								<name>Mar-Letrozole</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>1.3780</individualPrice>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>1.3780</amountMOHLTCPays>
							</drug>
							<drug id="02378213" sec3="Y">
								<name>Zinda-Letrozole</name>
								<manufacturerId>STA</manufacturerId>
								<individualPrice>1.3780</individualPrice>
								<listingDate>2014-01-03</listingDate>
								<amountMOHLTCPays>1.3780</amountMOHLTCPays>
							</drug>
							<drug id="02398656" sec3="Y">
								<name>Riva-Letrozole</name>
								<manufacturerId>RIA</manufacturerId>
								<individualPrice>1.3780</individualPrice>
								<listingDate>2021-08-31</listingDate>
								<amountMOHLTCPays>1.3780</amountMOHLTCPays>
							</drug>
							<drug id="02421585" sec3="Y">
								<name>Nat-Letrozole</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>1.3780</individualPrice>
								<listingDate>2015-04-30</listingDate>
								<amountMOHLTCPays>1.3780</amountMOHLTCPays>
							</drug>
							<drug id="02428156" dinStatus="E" sec3="Y">
								<name>Van-Letrozole</name>
								<manufacturerId>VAN</manufacturerId>
								<individualPrice>1.3780</individualPrice>
								<listingDate>2015-08-26</listingDate>
								<amountMOHLTCPays>1.3780</amountMOHLTCPays>
							</drug>
							<drug id="02459884" sec3="Y">
								<name>CCP-Letrozole</name>
								<manufacturerId>CCP</manufacturerId>
								<individualPrice>1.3780</individualPrice>
								<listingDate>2018-01-31</listingDate>
								<amountMOHLTCPays>1.3780</amountMOHLTCPays>
							</drug>
							<drug id="02504472" sec3="Y">
								<name>Letrozole</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>1.3780</individualPrice>
								<listingDate>2021-05-31</listingDate>
								<amountMOHLTCPays>1.3780</amountMOHLTCPays>
							</drug>
							<drug id="02508109" sec3="Y">
								<name>Mint-Letrozole</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>1.3780</individualPrice>
								<listingDate>2021-10-29</listingDate>
								<amountMOHLTCPays>1.3780</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00178">
					<name>LEUPROLIDE ACETATE</name>
					<pcgGroup>
						<pcg9 id="100000084">
							<itemNumber>0282</itemNumber>
							<strength>3.75mg</strength>
							<dosageForm>Inj-Kit</dosageForm>
							<drug id="00884502" sec3="Y">
								<name>Lupron Depot PDS</name>
								<manufacturerId>ABB</manufacturerId>
								<individualPrice>370.6000</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>370.6000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000066">
							<itemNumber>0283</itemNumber>
							<strength>7.5mg</strength>
							<dosageForm>Inj-Kit</dosageForm>
							<drug id="00836273" sec3="Y">
								<name>Lupron Depot PDS</name>
								<manufacturerId>ABB</manufacturerId>
								<individualPrice>387.9700</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>387.9700</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000148">
							<itemNumber>0284</itemNumber>
							<strength>11.25mg</strength>
							<dosageForm>Inj-Kit</dosageForm>
							<drug id="02239834" sec3="Y">
								<name>Lupron Depot PDS</name>
								<manufacturerId>ABB</manufacturerId>
								<individualPrice>1104.3000</individualPrice>
								<listingDate>2000-07-17</listingDate>
								<amountMOHLTCPays>1104.3000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000113">
							<itemNumber>0285</itemNumber>
							<strength>22.5mg</strength>
							<dosageForm>Inj-Kit</dosageForm>
							<drug id="02230248" sec3="Y">
								<name>Lupron Depot PDS</name>
								<manufacturerId>ABB</manufacturerId>
								<individualPrice>1071.0000</individualPrice>
								<listingDate>1997-08-28</listingDate>
								<amountMOHLTCPays>1071.0000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000146">
							<itemNumber>0286</itemNumber>
							<strength>30mg</strength>
							<dosageForm>Inj-Kit</dosageForm>
							<drug id="02239833" sec3="Y">
								<name>Lupron Depot PDS</name>
								<manufacturerId>ABB</manufacturerId>
								<individualPrice>1428.0000</individualPrice>
								<listingDate>2000-04-17</listingDate>
								<amountMOHLTCPays>1428.0000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000310">
							<itemNumber>0287</itemNumber>
							<strength>3.75mg/Vial</strength>
							<dosageForm>Pd for Inj - Vial Pk</dosageForm>
							<drug id="02429977" sec3="Y">
								<name>Zeulide Depot</name>
								<manufacturerId>VET</manufacturerId>
								<individualPrice>304.0000</individualPrice>
								<listingDate>2020-05-29</listingDate>
								<amountMOHLTCPays>304.0000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000311">
							<itemNumber>0288</itemNumber>
							<strength>22.5mg/Vial</strength>
							<dosageForm>Pd for Inj - Vial Pk</dosageForm>
							<drug id="02462699" sec3="Y">
								<name>Zeulide Depot</name>
								<manufacturerId>VET</manufacturerId>
								<individualPrice>873.0000</individualPrice>
								<listingDate>2020-05-29</listingDate>
								<amountMOHLTCPays>873.0000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000172">
							<itemNumber>0289</itemNumber>
							<strength>7.5mg</strength>
							<dosageForm>Pd Susp Inj-Pref Syr Kit</dosageForm>
							<drug id="02248239" sec3="Y">
								<name>Eligard</name>
								<manufacturerId>TOL</manufacturerId>
								<individualPrice>310.7200</individualPrice>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>310.7200</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000173">
							<itemNumber>0290</itemNumber>
							<strength>22.5mg</strength>
							<dosageForm>Pd Susp Inj-Pref Syr Kit</dosageForm>
							<drug id="02248240" sec3="Y">
								<name>Eligard</name>
								<manufacturerId>TOL</manufacturerId>
								<individualPrice>891.0000</individualPrice>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>891.0000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000176">
							<itemNumber>0291</itemNumber>
							<strength>30mg</strength>
							<dosageForm>Pd Susp Inj-Pref Syr Kit</dosageForm>
							<drug id="02248999" sec3="Y">
								<name>Eligard</name>
								<manufacturerId>TOL</manufacturerId>
								<individualPrice>1285.2000</individualPrice>
								<listingDate>2005-05-25</listingDate>
								<amountMOHLTCPays>1285.2000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000181">
							<itemNumber>0292</itemNumber>
							<strength>45mg</strength>
							<dosageForm>Pd Susp Inj-Pref Syr Kit</dosageForm>
							<drug id="02268892" sec3="Y">
								<name>Eligard</name>
								<manufacturerId>TOL</manufacturerId>
								<individualPrice>1565.1900</individualPrice>
								<listingDate>2006-06-15</listingDate>
								<amountMOHLTCPays>1565.1900</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00172">
					<name>LOMUSTINE (CCNU)</name>
					<pcgGroup>
						<pcg9 id="100000044">
							<itemNumber>0293</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00360430" sec3="Y">
								<name>CeeNU</name>
								<manufacturerId>BQU</manufacturerId>
								<individualPrice>7.8900</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>7.8900</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000043">
							<itemNumber>0294</itemNumber>
							<strength>40mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00360422" sec3="Y">
								<name>CeeNU</name>
								<manufacturerId>BQU</manufacturerId>
								<individualPrice>13.6025</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>13.6025</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000042">
							<itemNumber>0295</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00360414" sec3="Y">
								<name>CeeNU</name>
								<manufacturerId>BQU</manufacturerId>
								<individualPrice>22.4550</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>22.4550</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00173">
					<name>MEGESTROL ACETATE</name>
					<pcgGroup>
						<pcg9 id="100000045">
							<itemNumber>0296</itemNumber>
							<strength>40mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00386391" notABenefit="Y" sec3="Y">
								<name>Megace</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02195917" sec3="Y">
								<name>Megestrol</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>1.3340</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>1.3340</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000063">
							<itemNumber>0297</itemNumber>
							<strength>160mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00731323" notABenefit="Y" sec3="Y">
								<name>Megace</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02195925" sec3="Y">
								<name>Megestrol</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>5.8151</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>5.8151</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00163">
					<name>MELPHALAN</name>
					<pcgGroup>
						<pcg9 id="100000017">
							<itemNumber>0298</itemNumber>
							<strength>2mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00004715" sec3="Y">
								<name>Alkeran</name>
								<manufacturerId>ASN</manufacturerId>
								<individualPrice>1.9200</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>1.9200</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00164">
					<name>MERCAPTOPURINE</name>
					<pcgGroup>
						<pcg9 id="100000018">
							<itemNumber>0299</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00004723" sec3="Y">
								<name>Purinethol</name>
								<manufacturerId>NOP</manufacturerId>
								<individualPrice>2.8610</individualPrice>
								<note>Decrease dose of mercaptopurine to 25-33% of initial dose if allopurinol used concomitantly.
</note>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>2.8610</amountMOHLTCPays>
							</drug>
							<drug id="02415275" sec3="Y">
								<name>Mercaptopurine Tablets USP</name>
								<manufacturerId>STE</manufacturerId>
								<individualPrice>2.8610</individualPrice>
								<note>Decrease dose of mercaptopurine to 25-33% of initial dose if allopurinol used concomitantly.</note>
								<listingDate>2014-03-27</listingDate>
								<amountMOHLTCPays>2.8610</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00179">
					<name>METHOTREXATE</name>
					<pcgGroup>
						<pcg9 id="100000292">
							<itemNumber>0300</itemNumber>
							<strength>15mg/0.3mL</strength>
							<dosageForm>Inj Sol-0.3mL Pref Syr</dosageForm>
							<drug id="02454858" sec3="Y">
								<name>Metoject Subcutaneous</name>
								<manufacturerId>MDX</manufacturerId>
								<individualPrice>24.5700</individualPrice>
								<listingDate>2019-04-30</listingDate>
								<amountMOHLTCPays>24.5700</amountMOHLTCPays>
							</drug>
							<drug id="02491311" sec3="Y">
								<name>Methotrexate Subcutaneous</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>24.5700</individualPrice>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>24.5700</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000054">
							<itemNumber>0301</itemNumber>
							<strength>20mg/2mL</strength>
							<dosageForm>Inj Sol-2mL Pk</dosageForm>
							<drug id="02182947" sec3="Y">
								<name>Methotrexate Sodium</name>
								<manufacturerId>MAY</manufacturerId>
								<individualPrice>12.5000</individualPrice>
								<listingDate>2002-04-04</listingDate>
								<amountMOHLTCPays>12.5000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000032">
							<itemNumber>0302</itemNumber>
							<strength>50mg/2mL</strength>
							<dosageForm>Inj Sol-2mL Pk</dosageForm>
							<drug id="02170671" notABenefit="Y" sec3="Y">
								<name>Methotrexate</name>
								<manufacturerId>WAY</manufacturerId>
								<listingDate>1998-03-17</listingDate>
							</drug>
							<drug id="02182777" sec3="Y">
								<name>Methotrexate</name>
								<manufacturerId>MAY</manufacturerId>
								<individualPrice>8.9200</individualPrice>
								<listingDate>2005-10-06</listingDate>
								<amountMOHLTCPays>8.9200</amountMOHLTCPays>
							</drug>
							<drug id="02464365" sec3="Y">
								<name>Methotrexate Injection BP</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>8.9200</individualPrice>
								<listingDate>2021-02-26</listingDate>
								<amountMOHLTCPays>8.9200</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000302">
							<itemNumber>0303</itemNumber>
							<strength>10mg/0.2mL</strength>
							<dosageForm>Inj Sol-Pref Syr</dosageForm>
							<drug id="02454831" sec3="Y">
								<name>Metoject Subcutaneous</name>
								<manufacturerId>MDX</manufacturerId>
								<individualPrice>29.6400</individualPrice>
								<listingDate>2020-02-28</listingDate>
								<amountMOHLTCPays>29.6400</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000303">
							<itemNumber>0304</itemNumber>
							<strength>12.5mg/0.25mL</strength>
							<dosageForm>Inj Sol-Pref Syr</dosageForm>
							<drug id="02454750" sec3="Y">
								<name>Metoject Subcutaneous</name>
								<manufacturerId>MDX</manufacturerId>
								<individualPrice>31.2000</individualPrice>
								<listingDate>2020-02-28</listingDate>
								<amountMOHLTCPays>31.2000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000275">
							<itemNumber>0305</itemNumber>
							<strength>17.5mg/0.35mL</strength>
							<dosageForm>Inj Sol-Pref Syr</dosageForm>
							<drug id="02454769" sec3="Y">
								<name>Metoject Subcutaneous</name>
								<manufacturerId>MDX</manufacturerId>
								<individualPrice>24.0000</individualPrice>
								<listingDate>2018-02-28</listingDate>
								<amountMOHLTCPays>24.0000</amountMOHLTCPays>
							</drug>
							<drug id="02491338" sec3="Y">
								<name>Methotrexate Subcutaneous</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>24.0000</individualPrice>
								<listingDate>2020-05-29</listingDate>
								<amountMOHLTCPays>24.0000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000276">
							<itemNumber>0306</itemNumber>
							<strength>20mg/0.4mL</strength>
							<dosageForm>Inj Sol-Pref Syr</dosageForm>
							<drug id="02454866" sec3="Y">
								<name>Metoject Subcutaneous</name>
								<manufacturerId>MDX</manufacturerId>
								<individualPrice>26.2500</individualPrice>
								<listingDate>2018-02-28</listingDate>
								<amountMOHLTCPays>26.2500</amountMOHLTCPays>
							</drug>
							<drug id="02491346" sec3="Y">
								<name>Methotrexate Subcutaneous</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>26.2500</individualPrice>
								<listingDate>2020-05-29</listingDate>
								<amountMOHLTCPays>26.2500</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000277">
							<itemNumber>0307</itemNumber>
							<strength>22.5mg/0.45mL</strength>
							<dosageForm>Inj Sol-Pref Syr</dosageForm>
							<drug id="02454777" sec3="Y">
								<name>Metoject Subcutaneous</name>
								<manufacturerId>MDX</manufacturerId>
								<individualPrice>26.2500</individualPrice>
								<listingDate>2018-02-28</listingDate>
								<amountMOHLTCPays>26.2500</amountMOHLTCPays>
							</drug>
							<drug id="02491354" sec3="Y">
								<name>Methotrexate Subcutaneous</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>26.2500</individualPrice>
								<listingDate>2020-05-29</listingDate>
								<amountMOHLTCPays>26.2500</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000278">
							<itemNumber>0308</itemNumber>
							<strength>25mg/0.5mL</strength>
							<dosageForm>Inj Sol-Pref Syr</dosageForm>
							<drug id="02454874" sec3="Y">
								<name>Metoject Subcutaneous</name>
								<manufacturerId>MDX</manufacturerId>
								<individualPrice>29.2500</individualPrice>
								<listingDate>2018-02-28</listingDate>
								<amountMOHLTCPays>29.2500</amountMOHLTCPays>
							</drug>
							<drug id="02491362" sec3="Y">
								<name>Methotrexate Subcutaneous</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>29.2500</individualPrice>
								<listingDate>2020-05-29</listingDate>
								<amountMOHLTCPays>29.2500</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000001">
							<itemNumber>0309</itemNumber>
							<strength>2.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02170698" sec3="Y">
								<name>PMS-Methotrexate</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.5027</individualPrice>
								<listingDate>1997-02-04</listingDate>
								<amountMOHLTCPays>.5027</amountMOHLTCPays>
							</drug>
							<drug id="02182963" sec3="Y">
								<name>Apo-Methotrexate</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.5027</individualPrice>
								<listingDate>2001-10-11</listingDate>
								<amountMOHLTCPays>.5027</amountMOHLTCPays>
							</drug>
							<drug id="02509067" sec3="Y">
								<name>Ach-Methotrexate</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.5027</individualPrice>
								<listingDate>2021-12-17</listingDate>
								<amountMOHLTCPays>.5027</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00193">
					<name>MITOTANE</name>
					<pcgGroup>
						<pcg9 id="100000086">
							<itemNumber>0310</itemNumber>
							<strength>500mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00463221" sec3="Y">
								<name>Lysodren</name>
								<manufacturerId>HRA</manufacturerId>
								<individualPrice>9.7900</individualPrice>
								<listingDate>2021-11-30</listingDate>
								<amountMOHLTCPays>9.7900</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00186">
					<name>NILUTAMIDE</name>
					<pcgGroup>
						<pcg9 id="100000073">
							<itemNumber>0311</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02221861" sec3="Y">
								<name>Anandron</name>
								<manufacturerId>CHE</manufacturerId>
								<individualPrice>2.4100</individualPrice>
								<listingDate>1999-01-06</listingDate>
								<amountMOHLTCPays>2.4100</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00165">
					<name>PROCARBAZINE HCL</name>
					<pcgGroup>
						<pcg9 id="100000021">
							<itemNumber>0312</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00012750" sec3="Y">
								<name>Matulane</name>
								<manufacturerId>LBI</manufacturerId>
								<individualPrice>61.1031</individualPrice>
								<note>Procarbazine inhibits monoamine oxidase. Avoid alcohol and foods with high tyramine content (e.g. aged cheese, red wine, yogurt, etc.)</note>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>61.1031</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01618">
					<name>RITUXIMAB</name>
					<pcgGroup lccId="00330">
						<pcg9 id="100000304">
							<itemNumber>0313</itemNumber>
							<strength>100mg/10mL</strength>
							<dosageForm>Inj Sol-10mL Vial Pk</dosageForm>
							<drug id="02478382" sec3="Y" sec12="Y">
								<name>Truxima</name>
								<manufacturerId>CEH</manufacturerId>
								<individualPrice>297.0000</individualPrice>
								<listingDate>2020-03-31</listingDate>
								<amountMOHLTCPays>297.0000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000305">
							<itemNumber>0314</itemNumber>
							<strength>500mg/50mL</strength>
							<dosageForm>Inj Sol-50mL Vial Pk</dosageForm>
							<drug id="02478390" sec3="Y" sec12="Y">
								<name>Truxima</name>
								<manufacturerId>CEH</manufacturerId>
								<individualPrice>1485.0000</individualPrice>
								<listingDate>2020-03-31</listingDate>
								<amountMOHLTCPays>1485.0000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="575">For the treatment of adults with severe active rheumatoid arthritis (RA) (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or anti-CCP positive, and radiographic evidence of rheumatoid arthritis) who meet ALL the following criteria.
1. Patient has experienced failure to respond, documented intolerance, or contraindication to optimal use of one of the following disease modifying, anti-rheumatic (DMARD) regimens:
A. i) Methotrexate (20mg/week) for at least 3 months, AND
ii) Leflunomide (20mg/day) for at least 3 months, in addition to
iii) An adequate trial of at least one combination of DMARDs for 3 months;
OR
B. i) Methotrexate (20mg/week) for at least 3 months, AND
ii) Leflunomide in combination with methotrexate for at least 3 months; OR
C. i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months.
(Hydroxychloroquine is based by weight up to 400mg per day.)
2. Patient has experienced failure to respond, documented intolerance, or contraindication to an adequate trial of at least ONE anti-TNF agent (e.g., adalimumab, etanercept, infliximab, golimumab, certolizumab pegol).
3. Patient is not using rituximab in a maintenance setting.
4. Patient is not using a treatment course of rituximab earlier than 6 months after the completion of a prior course of rituximab.
5. Rituximab is not used in combination with another biologic to treat the patient&apos;s RA.
6. Treatment must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.
One course of treatment is 1000mg followed two weeks later by the second 1000mg dose.
</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 3 Months</lccNote>
						<lccNote seq="003" reasonForUseId="576">For the re-treatment of patients with severe active rheumatoid arthritis (RA) (greater than or equal to 5 swollen joints, and rheumatoid factor positive and/or anti-CCP positive, and radiographic evidence of rheumatoid arthritis) who meet ALL the following criteria:
1. Patient has met the initiation criteria for rituximab in accordance with RFU 575;
2. Patient has experienced loss of effect after having responded to the prior treatment course of rituximab (Response is defined as a 20% reduction in the swollen joint count compared to the joint count prior to the first, pre-treatment course evaluated at 3 to 4 months following the administered course AND improvement in 2 swollen joints); AND
3. Patient is not using rituximab in a maintenance setting; AND
4. Patient is not using a treatment course of rituximab earlier than 6 months after the completion of a prior course of rituximab; AND
5. Rituximab is not used in combination with another biologic to treat the patient&apos;s RA.
6. Treatment must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.
One course of re-treatment is 1000mg followed two weeks later by the second 1000mg dose.
</lccNote>
						<lccNote seq="004" type="R">LU Authorization Period: 3 Months</lccNote>
						<lccNote seq="005" reasonForUseId="587">Rituximab is used in combination with glucocorticoids for the induction of remission in patients with severely active Granulomatosis with Polyangiitis [(GPA), also known as Wegener&apos;s Granulomatosis (WG)] OR microscopic polyangiitis (MPA), for patients who meet all of the following criteria:
1. The patient must have severe active disease that is life- or organ-threatening as supported by laboratory and/or imaging reports.
AND
2. There is a positive serum assay for either proteinase 3-ANCA (anti-neutrophil cytoplasmic autoantibodies) or myeloperoxidase-ANCA.
AND
3. Cyclophosphamide cannot be used by the Patient for ONE of the following reasons:
a. The patient has failed a minimum of six IV pulses of cyclophosphamide; OR
b. The patient has failed three months of oral cyclophosphamide therapy; OR
c. The patient has a severe intolerance or an allergy to cyclophosphamide; OR
d. Cyclophosphamide is contraindicated; OR
e. The patient has received a cumulative lifetime dose of at least 25g of cyclophosphamide; OR
f. The patient wishes to preserve ovarian/testicular function for fertility.
4. The request is from a prescriber experienced in the diagnosis and management of GPA, MPA, and vasculitis.
Exclusion criteria:
The patient should not have received a course of rituximab in the prior 6 months.
The recommended dosing regimen for the initial treatment would be a once weekly infusion dosed at 375 milligrams per square metre x 4 weeks.
Case-by-case considerations for patients not meeting the LU criteria may be considered through the Exceptional Access Program.</lccNote>
						<lccNote seq="006" type="R">LU Authorization Period: 1 month (1 treatment course)</lccNote>
						<lccNote seq="007" reasonForUseId="588">Rituximab (Truxima) treatment will be used for patients with severely active Granulomatosis with Polyangiitis [(GPA), also known as Wegener&apos;s Granulomatosis (WG)] OR microscopic polyangiitis (MPA) who have achieved disease remission. Patient must meet all of the following criteria:
1. The patient must have severe active disease that is life- or organ-threatening as supported by laboratory and/or imaging reports.
2. There is a positive serum assay for either proteinase 3-ANCA (anti-neutrophil cytoplasmic autoantibodies) or myeloperoxidase-ANCA. A copy of the laboratory report must be provided.
3. Stabilization of the condition with induction doses of cyclophosphamide (injectable or oral doses are acceptable) and a glucocorticoid as combination over 4 to 6 months until disease remission prior to initiation of rituximab.
4. The request is from a prescriber experienced in the diagnosis and management of GPA, MPA, and vasculitis.
Exclusion criteria:
The patient should not have received a dose of rituximab in the prior 6 months. Doses of rituximab administered at intervals more frequently than every 6 months are not funded.
The recommended dosing regimen: A fixed dose regimen of Rituximab of 500mg IV every 6 months.
Case-by-case considerations for patients not meeting the LU criteria may be considered through the Exceptional Access Program.</lccNote>
						<lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
					<pcgGroup lccId="00337">
						<pcg9 id="100000315">
							<itemNumber>0315</itemNumber>
							<strength>10mg/mL</strength>
							<dosageForm>Inj Sol-Vial (Preservative-Free)</dosageForm>
							<drug id="02495724" sec3="Y" sec12="Y">
								<name>Ruxience</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>29.7000</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>29.7000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="583">For the treatment of adults with severe active rheumatoid arthritis (RA) (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or anti-CCP postive, and radiographic evidence of rheumatoid arthritis) who meet ALL the following criteria.
1. Patient has experienced failure to respond, documented intolerance, or contraindication to optimal use of one of the following disease modifying, anti-rheumatic (DMARD) regimens:
A) i) Methotrexate (20mg/week) for at least 3 months, AND
ii) Leflunomide (20mg/day) for at least 3 months, in addition to
iii) An adequate trial of at least one combination of DMARDs for 3 months;
OR
B) i) Methotrexate (20mg/week) for at least 3 months, AND
ii) Leflunomide in combination with methotrexate for at least 3 months; OR
C) i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months.
(Hydroxychloroquine is based by weight up to 400mg per day.)
2. Patient has experienced failure to respond, documented intolerance, or contraindication to an adequate trial of at least ONE anti-TNF agent (e.g., adalimumab, etanercept, infliximab, golimumab, certolizumab pegol).
3. Patient is not using rituximab in a maintenance setting.
4. Patient is not using a treatment course of rituximab earlier than 6 months after the completion of a prior course of rituximab.
5. Rituximab is not used in combination with another biologic to treat the patient&apos;s RA.
6. Treatment must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.
One course of treatment is 1000mg followed two weeks later by the second 1000mg dose.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 3 Months</lccNote>
						<lccNote seq="003" reasonForUseId="584">For the re-treatment of patients with severe active rheumatoid arthritis (RA) (greater than or equal to 5 swollen joints, and rheumatoid factor positive and/or anti-CCP positive, and radiographic evidence of rheumatoid arthritis) who meet ALL the following criteria:
1. Patient has met the initiation criteria for rituximab in accordance with RFU 583;
2. Patient has experienced loss of effect after having responded to the prior treatment course of rituximab (Response is defined as a 20% reduction in the swollen joint count compared to the joint count prior to the first, pre-treatment course evaluated at 3 to 4 months following the administered course AND improvement in 2 swollen joints); AND
3. Patient is not using rituximab in a maintenance setting; AND
4. Patient is not using a treatment course of rituximab earlier than 6 months after the completion of a prior course of rituximab; AND
5. Rituximab is not used in combination with another biologic to treat the patient&apos;s RA.
6. Treatment must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.
One course of re-treatment is 1000mg followed two weeks later by the second 1000mg dose.</lccNote>
						<lccNote seq="004" type="R">LU Authorization Period: 3 Months</lccNote>
						<lccNote seq="005" reasonForUseId="585">Rituximab is used in combination with glucocorticoids for the induction of remission in patients with severely active Granulomatosis with Polyangiitis [(GPA), also known as Wegener&apos;s Granulomatosis (WG)] OR microscopic polyangiitis (MPA), for patients who meet all of the following criteria:
1. The patient must have severe active disease that is life- or organ-threatening as supported by laboratory and/or imaging reports.
AND
2. There is a positive serum assay for either proteinase 3-ANCA (anti-neutrophil cytoplasmic autoantibodies) or myeloperoxidase-ANCA.
AND
3. Cyclophosphamide cannot be used by the patient for one of the following reasons:
a. The patient has failed a minimum of six IV pulses of cyclophosphamide; OR
b. The patient has failed three months of oral cyclophosphamide therapy; OR
c. The patient has a severe intolerance or an allergy to cyclophosphamide; OR
d. Cyclophosphamide is contraindicated; OR
e. The patient has received a cumulative lifetime dose of at least 25g of cyclophosphamide; OR
f. The patient wishes to preserve ovarian/testicular function for fertility.
4. The request is from a prescriber experienced in the diagnosis and management of GPA, MPA, and vasculitis.
Exclusion criteria:
The patient should not have received a course of rituximab in the prior 6 months.
The recommended dosing regimen for the initial treatment would be a once weekly infusion dosed at 375 milligrams per square metre x 4 weeks.
Case-by-case considerations for patients not meeting the LU criteria may be considered through the Exceptional Access Program.
</lccNote>
						<lccNote seq="006" type="R">LU Authorization Period: 1 month (1 treatment course)</lccNote>
						<lccNote seq="007" reasonForUseId="586">Rituximab (Ruxience) treatment will be used for patients with severely active Granulomatosis with Polyangiitis [(GPA), also known as Wegener&apos;s Granulomatosis (WG)] OR microscopic polyangiitis (MPA) who have achieved disease remission. Patient must meet all of the following criteria:
1. The patient must have severe active disease that is life- or organ-threatening as supported by laboratory and/or imaging reports.
2. There is a positive serum assay for either proteinase 3-ANCA (anti-neutrophil cytoplasmic autoantibodies) or myeloperoxidase-ANCA. A copy of the laboratory report must be provided.
3. Stabilization of the condition with induction doses of cyclophosphamide (injectable or oral doses are acceptable) and a glucocorticoid as combination over 4 to 6 months until disease remission prior to initiation of rituximab.
4. The request is from a prescriber experienced in the diagnosis and management of GPA, MPA, and vasculitis.
Exclusion criteria:
The patient should not have received a dose of rituximab in the prior 6 months. Doses of rituximab administered at intervals more frequently than every 6 months are not funded.
The recommended dosing regimen: A fixed dose regimen of Rituximab of 500mg IV every 6 months.
Case-by-case considerations for patients not meeting the LU criteria may be considered through the Exceptional Access Program.</lccNote>
						<lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
					<pcgGroup lccId="00338">
						<pcg9 id="100000316">
							<itemNumber>0316</itemNumber>
							<strength>10mg/mL</strength>
							<dosageForm>Inj Sol-Vial (Preservative-Free)</dosageForm>
							<drug id="02498316" sec3="Y" sec12="Y">
								<name>Riximyo</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>29.7000</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>29.7000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="581">For the treatment of adults with severe active rheumatoid arthritis (RA) (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or anti-CCP postive, and radiographic evidence of rheumatoid arthritis) who meet ALL the following criteria.
1. Patient has experienced failure to respond, documented intolerance, or contraindication to optimal use of one of the following disease modifying, anti-rheumatic (DMARD) regimens:
A) i) Methotrexate (20mg/week) for at least 3 months, AND
ii) Leflunomide (20mg/day) for at least 3 months, in addition to
iii) An adequate trial of at least one combination of DMARDs for 3 months;
OR
B) i) Methotrexate (20mg/week) for at least 3 months, AND
ii) Leflunomide in combination with methotrexate for at least 3 months; OR
C) i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine 400mg/day) for at least 3 months.
(Hydroxychloroquine is based by weight up to 400mg per day.)
2. Patient has experienced failure to respond, documented intolerance, or contraindication to an adequate trial of at least ONE anti-TNF agent (e.g., adalimumab, etanercept, infliximab, golimumab, certolizumab pegol).
3. Patient is not using rituximab in a maintenance setting.
4. Patient is not using a treatment course of rituximab earlier than 6 months after the completion of a prior course of rituximab.
5. Rituximab is not used in combination with another biologic to treat the patient&apos;s RA.
6. Treatment must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.
One course of treatment is 1000mg followed two weeks later by the second 1000mg dose.
</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 3 Months</lccNote>
						<lccNote seq="003" reasonForUseId="582">For the re-treatment of patients with severe active rheumatoid arthritis (RA) (greater than or equal to 5 swollen joints, and rheumatoid factor positive and/or anti-CCP positive, and radiographic evidence of rheumatoid arthritis) who meet ALL the following criteria:
1. Patient has met the initiation criteria for rituximab in accordance with RFU 581;
2. Patient has experienced loss of effect after having responded to the prior treatment course of rituximab (Response is defined as a 20% reduction in the swollen joint count compared to the joint count prior to the first, pre-treatment course evaluated at 3 to 4 months following the administered course AND improvement in 2 swollen joints); AND
3. Patient is not using rituximab in a maintenance setting; AND
4. Patient is not using a treatment course of rituximab earlier than 6 months after the completion of a prior course of rituximab; AND
5. Rituximab is not used in combination with another biologic to treat the patient&apos;s RA.
6. Treatment must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.
One course of re-treatment is 1000mg followed two weeks later by the second 1000mg dose.</lccNote>
						<lccNote seq="004" type="R">LU Authorization Period: 3 Months</lccNote>
						<lccNote seq="005" reasonForUseId="616">Rituximab is used in combination with glucocorticoids for the induction of remission in patients with severely active Granulomatosis with Polyangiitis [(GPA), also known as Wegener&apos;s Granulomatosis (WG)] OR microscopic polyangiitis (MPA), for patients who meet all of the following criteria:
1. The patient must have severe active disease that is life- or organ-threatening as supported by laboratory and/or imaging reports.
AND
2. There is a positive serum assay for either proteinase 3-ANCA (anti-neutrophil cytoplasmic autoantibodies) or myeloperoxidase-ANCA.
AND
3. Cyclophosphamide cannot be used by the patient for one of the following reasons:
a. The patient has failed a minimum of six IV pulses of cyclophosphamide; OR
b. The patient has failed three months of oral cyclophosphamide therapy; OR
c. The patient has a severe intolerance or an allergy to cyclophosphamide; OR
d. Cyclophosphamide is contraindicated; OR
e. The patient has received a cumulative lifetime dose of at least 25g of cyclophosphamide; OR
f. The patient wishes to preserve ovarian/testicular function for fertility.
4. The request is from a prescriber experienced in the diagnosis and management of GPA, MPA, and vasculitis.
Exclusion criteria:
The patient should not have received a course of rituximab in the prior 6 months.
The recommended dosing regimen for the initial treatment would be a once weekly infusion dosed at 375 milligrams per square metre x 4 weeks.
Case-by-case considerations for patients not meeting the LU criteria may be considered through the Exceptional Access Program.</lccNote>
						<lccNote seq="006" type="R">LU Authorization Period: 1 month (1 treatment course)</lccNote>
						<lccNote seq="007" reasonForUseId="617">Rituximab (Riximyo) treatment will be used for patients with severely active Granulomatosis with Polyangiitis [(GPA), also known as Wegener&apos;s Granulomatosis (WG)] OR microscopic polyangiitis (MPA) who have achieved disease remission. Patient must meet all of the following criteria:
1. The patient must have severe active disease that is life- or organ-threatening as supported by laboratory and/or imaging reports.
2. There is a positive serum assay for either proteinase 3-ANCA (anti-neutrophil cytoplasmic autoantibodies) or myeloperoxidase-ANCA. A copy of the laboratory report must be provided.
3. Stabilization of the condition with induction doses of cyclophosphamide (injectable or oral doses are acceptable) and a glucocorticoid as combination over 4 to 6 months until disease remission prior to initiation of rituximab.
4. The request is from a prescriber experienced in the diagnosis and management of GPA, MPA, and vasculitis.
Exclusion criteria:
The patient should not have received a dose of rituximab in the prior 6 months. Doses of rituximab administered at intervals more frequently than every 6 months are not funded.
The recommended dosing regimen: A fixed dose regimen of Rituximab of 500mg IV every 6 months.
Case-by-case considerations for patients not meeting the LU criteria may be considered through the Exceptional Access Program.</lccNote>
						<lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
					<pcgGroup lccId="00350">
						<pcg9 id="100000343">
							<itemNumber>0317</itemNumber>
							<strength>10mg/mL</strength>
							<dosageForm>Inj Sol-Vial (Preservative-Free)</dosageForm>
							<drug id="02513447" sec3="Y" sec12="Y">
								<name>Riabni</name>
								<manufacturerId>AMG</manufacturerId>
								<individualPrice>29.7000</individualPrice>
								<listingDate>2022-01-31</listingDate>
								<amountMOHLTCPays>29.7000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="621">For the treatment of adult patients with severe active rheumatoid arthritis (RA) (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or anti-CCP positive, and radiographic evidence of rheumatoid arthritis) who meet ALL the following criteria.
1. Patient has experienced failure to respond, documented intolerance, or contraindication to optimal use of one of the following disease modifying, anti-rheumatic (DMARD) regimens:
A. i) Methotrexate (20mg/week) for at least 3 months, AND
ii) Leflunomide (20mg/day) for at least 3 months, in addition to
iii) An adequate trial of at least one combination of DMARDs for 3 months;
OR
B. i) Methotrexate (20mg/week) for at least 3 months, AND
ii) Leflunomide in combination with methotrexate for at least 3 months; OR
C. i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months.
(Hydroxychloroquine is based by weight up to 400mg per day.)
2. Patient has experienced failure to respond, documented intolerance, or contraindication to an adequate trial of at least ONE anti-TNF agent (e.g., adalimumab, etanercept, infliximab, golimumab, certolizumab pegol).
3. Patient is not using rituximab in a maintenance setting.
4. Patient is not using a treatment course of rituximab earlier than 6 months after the completion of a prior course of rituximab.
5. Rituximab is not used in combination with another biologic to treat the patient&apos;s RA.
6. Treatment must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.
One course of treatment is 1000mg followed two weeks later by the second 1000mg dose.
</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 3 Months</lccNote>
						<lccNote seq="003" reasonForUseId="622">For the re-treatment of patients with severe active rheumatoid arthritis (RA) (greater than or equal to 5 swollen joints, and rheumatoid factor positive and/or anti-CCP positive, and radiographic evidence of rheumatoid arthritis) who meet ALL the following criteria:
1. Patient has met the initiation criteria for rituximab in accordance with RFU 621;
2. Patient has experienced loss of effect after having responded to the prior treatment course of rituximab (Response is defined as a 20% reduction in the swollen joint count compared to the joint count prior to the first, pre-treatment course evaluated at 3 to 4 months following the administered course AND improvement in 2 swollen joints); AND
3. Patient is not using rituximab in a maintenance setting; AND
4. Patient is not using a treatment course of rituximab earlier than 6 months after the completion of a prior course of rituximab; AND
5. Rituximab is not used in combination with another biologic to treat the patient&apos;s RA.
6. Treatment must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.
One course of re-treatment is 1000mg followed two weeks later by the second 1000mg dose.</lccNote>
						<lccNote seq="004" type="R">LU Authorization Period: 3 Months</lccNote>
						<lccNote seq="005" reasonForUseId="623">Rituximab is used in combination with glucocorticoids for the induction of remission in patients with severely active Granulomatosis with Polyangiitis [(GPA), also known as Wegener&apos;s Granulomatosis (WG)] OR microscopic polyangiitis (MPA), for patients who meet all of the following criteria:
1. The patient must have severe active disease that is life- or organ-threatening as supported by laboratory and/or imaging reports.
AND
2. There is a positive serum assay for either proteinase 3-ANCA (anti-neutrophil cytoplasmic autoantibodies) or myeloperoxidase-ANCA.
AND
3. Cyclophosphamide cannot be used by the patient for ONE of the following reasons:
a. The patient has failed a minimum of six IV pulses of cyclophosphamide; OR
b. The patient has failed three months of oral cyclophosphamide therapy; OR
c. The patient has a severe intolerance or an allergy to cyclophosphamide; OR
d. Cyclophosphamide is contraindicated; OR
e. The patient has received a cumulative lifetime dose of at least 25g of cyclophosphamide; OR
f. The patient wishes to preserve ovarian/testicular function for fertility.
4. The request is from a prescriber experienced in the diagnosis and management of GPA, MPA, and vasculitis.
Exclusion criteria:
The patient should not have received a course of rituximab in the prior 6 months.
The recommended dosing regimen for the initial treatment would be a once weekly infusion dosed at 375 milligrams per square metre x 4 weeks.
Case-by-case considerations for patients not meeting the LU criteria may be considered through the Exceptional Access Program.</lccNote>
						<lccNote seq="006" type="R">LU Authorization Period: 1 month (1 treatment course)</lccNote>
						<lccNote seq="007" reasonForUseId="624">Rituximab (Riabni) treatment will be used for patients with severely active Granulomatosis with Polyangiitis [(GPA), also known as Wegener&apos;s Granulomatosis (WG)] OR microscopic polyangiitis (MPA) who have achieved disease remission. Patient must meet all of the following criteria:
1. The patient must have severe active disease that is life- or organ-threatening as supported by laboratory and/or imaging reports.
2. There is a positive serum assay for either proteinase 3-ANCA (anti-neutrophil cytoplasmic autoantibodies) or myeloperoxidase-ANCA. A copy of the laboratory report must be provided.
3. Stabilization of the condition with induction doses of cyclophosphamide (injectable or oral doses are acceptable) and a glucocorticoid as combination over 4 to 6 months until disease remission prior to initiation of rituximab.
4. The request is from a prescriber experienced in the diagnosis and management of GPA, MPA, and vasculitis.
Exclusion criteria:
The patient should not have received a dose of rituximab in the prior 6 months. Doses of rituximab administered at intervals more frequently than every 6 months are not funded.
The recommended dosing regimen: A fixed dose regimen of Rituximab of 500mg IV every 6 months.
Case-by-case considerations for patients not meeting the LU criteria may be considered through the Exceptional Access Program.</lccNote>
						<lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00171">
					<name>TAMOXIFEN CITRATE</name>
					<pcgGroup>
						<pcg9 id="100000040">
							<itemNumber>0318</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00812404" sec3="Y">
								<name>Apo-Tamox</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1750</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1750</amountMOHLTCPays>
							</drug>
							<drug id="00851965" sec3="Y">
								<name>Teva-Tamoxifen</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1750</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1750</amountMOHLTCPays>
							</drug>
							<drug id="01926624" notABenefit="Y" sec3="Y">
								<name>Tamofen</name>
								<manufacturerId>SAV</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02048477" notABenefit="Y" sec3="Y">
								<name>Nolvadex</name>
								<manufacturerId>AZC</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="100000056">
							<itemNumber>0319</itemNumber>
							<strength>20mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00812390" sec3="Y">
								<name>Apo-Tamox</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3500</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3500</amountMOHLTCPays>
							</drug>
							<drug id="00851973" sec3="Y">
								<name>Teva-Tamoxifen</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3500</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3500</amountMOHLTCPays>
							</drug>
							<drug id="01926632" notABenefit="Y" sec3="Y">
								<name>Tamofen</name>
								<manufacturerId>SAV</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02048485" sec3="Y">
								<name>Nolvadex D</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>.3867</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3500</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01449">
					<name>TEMOZOLOMIDE</name>
					<pcgGroup>
						<pcg9 id="100000156">
							<itemNumber>0320</itemNumber>
							<strength>5mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02241093" sec3="Y">
								<name>Temodal</name>
								<manufacturerId>MEK</manufacturerId>
								<individualPrice>8.0340</individualPrice>
								<listingDate>2000-07-17</listingDate>
								<amountMOHLTCPays>3.9000</amountMOHLTCPays>
							</drug>
							<drug id="02441160" sec3="Y">
								<name>Act Temozolomide</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>3.9000</individualPrice>
								<listingDate>2016-01-28</listingDate>
								<amountMOHLTCPays>3.9000</amountMOHLTCPays>
							</drug>
							<drug id="02443473" sec3="Y">
								<name>Taro-Temozolomide</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>3.9000</individualPrice>
								<listingDate>2015-11-26</listingDate>
								<amountMOHLTCPays>3.9000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000157">
							<itemNumber>0321</itemNumber>
							<strength>20mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02241094" sec3="Y">
								<name>Temodal</name>
								<manufacturerId>MEK</manufacturerId>
								<individualPrice>32.1360</individualPrice>
								<listingDate>2000-07-17</listingDate>
								<amountMOHLTCPays>15.6000</amountMOHLTCPays>
							</drug>
							<drug id="02395274" sec3="Y">
								<name>Act Temozolomide</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>15.6000</individualPrice>
								<listingDate>2013-05-31</listingDate>
								<amountMOHLTCPays>15.6000</amountMOHLTCPays>
							</drug>
							<drug id="02443481" sec3="Y">
								<name>Taro-Temozolomide</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>15.6000</individualPrice>
								<listingDate>2015-11-26</listingDate>
								<amountMOHLTCPays>15.6000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000158">
							<itemNumber>0322</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02241095" sec3="Y">
								<name>Temodal</name>
								<manufacturerId>MEK</manufacturerId>
								<individualPrice>160.6862</individualPrice>
								<listingDate>2000-07-17</listingDate>
								<amountMOHLTCPays>78.0030</amountMOHLTCPays>
							</drug>
							<drug id="02395282" sec3="Y">
								<name>Act Temozolomide</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>78.0030</individualPrice>
								<listingDate>2013-05-31</listingDate>
								<amountMOHLTCPays>78.0030</amountMOHLTCPays>
							</drug>
							<drug id="02443511" sec3="Y">
								<name>Taro-Temozolomide</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>78.0030</individualPrice>
								<listingDate>2015-11-26</listingDate>
								<amountMOHLTCPays>78.0030</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000196">
							<itemNumber>0323</itemNumber>
							<strength>140mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02312794" sec3="Y">
								<name>Temodal</name>
								<manufacturerId>MEK</manufacturerId>
								<individualPrice>224.9623</individualPrice>
								<listingDate>2011-09-15</listingDate>
								<amountMOHLTCPays>109.2050</amountMOHLTCPays>
							</drug>
							<drug id="02395290" sec3="Y">
								<name>Act Temozolomide</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>109.2050</individualPrice>
								<listingDate>2013-05-31</listingDate>
								<amountMOHLTCPays>109.2050</amountMOHLTCPays>
							</drug>
							<drug id="02443538" sec3="Y">
								<name>Taro-Temozolomide</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>109.2050</individualPrice>
								<listingDate>2015-11-26</listingDate>
								<amountMOHLTCPays>109.2050</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000159">
							<itemNumber>0324</itemNumber>
							<strength>250mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02241096" sec3="Y">
								<name>Temodal</name>
								<manufacturerId>MEK</manufacturerId>
								<individualPrice>401.7041</individualPrice>
								<listingDate>2000-07-17</listingDate>
								<amountMOHLTCPays>195.0020</amountMOHLTCPays>
							</drug>
							<drug id="02395312" sec3="Y">
								<name>Act Temozolomide</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>195.0020</individualPrice>
								<listingDate>2013-05-31</listingDate>
								<amountMOHLTCPays>195.0020</amountMOHLTCPays>
							</drug>
							<drug id="02443554" sec3="Y">
								<name>Taro-Temozolomide</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>195.0020</individualPrice>
								<listingDate>2015-11-26</listingDate>
								<amountMOHLTCPays>195.0020</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00166">
					<name>THIOGUANINE</name>
					<pcgGroup>
						<pcg9 id="100000023">
							<itemNumber>0325</itemNumber>
							<strength>40mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00282081" sec3="Y">
								<name>Lanvis</name>
								<manufacturerId>ASN</manufacturerId>
								<individualPrice>5.1120</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>5.1120</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01690">
					<name>TRIPTORELIN PAMOATE</name>
					<pcgGroup>
						<pcg9 id="100000188">
							<itemNumber>0326</itemNumber>
							<strength>3.75mg/Vial</strength>
							<dosageForm>Inj Pd with Sterile Water-Vial Pk</dosageForm>
							<drug id="09857199" sec3="Y">
								<name>Trelstar (1 Month)</name>
								<manufacturerId>KNT</manufacturerId>
								<individualPrice>346.3100</individualPrice>
								<listingDate>2007-01-02</listingDate>
								<amountMOHLTCPays>346.3100</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000189">
							<itemNumber>0327</itemNumber>
							<strength>11.25mg/Vial</strength>
							<dosageForm>Inj Pd with Sterile Water-Vial Pk</dosageForm>
							<drug id="09857200" sec3="Y">
								<name>Trelstar LA (3 Month)</name>
								<manufacturerId>KNT</manufacturerId>
								<individualPrice>1038.9700</individualPrice>
								<listingDate>2007-01-02</listingDate>
								<amountMOHLTCPays>1038.9700</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000186">
							<itemNumber>0328</itemNumber>
							<strength>3.75mg/Vial</strength>
							<dosageForm>Inj Pd-Vial Pk</dosageForm>
							<drug id="02240000" sec3="Y">
								<name>Trelstar (1 Month)</name>
								<manufacturerId>KNT</manufacturerId>
								<individualPrice>346.3100</individualPrice>
								<listingDate>2007-01-02</listingDate>
								<amountMOHLTCPays>346.3100</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000187">
							<itemNumber>0329</itemNumber>
							<strength>11.25mg/Vial</strength>
							<dosageForm>Inj Pd-Vial Pk</dosageForm>
							<drug id="02243856" sec3="Y">
								<name>Trelstar LA (3 Month)</name>
								<manufacturerId>KNT</manufacturerId>
								<individualPrice>1038.9700</individualPrice>
								<listingDate>2007-01-02</listingDate>
								<amountMOHLTCPays>1038.9700</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="100000240">
							<itemNumber>0330</itemNumber>
							<strength>22.5mg/Vial</strength>
							<dosageForm>SR Inj Pd with Sterile Water-Vial Pk</dosageForm>
							<drug id="02412322" sec3="Y">
								<name>Trelstar</name>
								<manufacturerId>KNT</manufacturerId>
								<individualPrice>1659.9000</individualPrice>
								<listingDate>2014-10-29</listingDate>
								<amountMOHLTCPays>1659.9000</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00176">
					<name>VINCRISTINE SULFATE</name>
					<pcgGroup>
						<pcg9 id="100000049">
							<itemNumber>0331</itemNumber>
							<strength>1mg/mL</strength>
							<dosageForm>Inj Sol</dosageForm>
							<drug id="00611182" notABenefit="Y" sec3="Y">
								<name>Oncovin</name>
								<manufacturerId>LIL</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02143305" sec3="Y">
								<name>Vincristine Sulfate</name>
								<manufacturerId>NOP</manufacturerId>
								<individualPrice>30.6000</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>30.6000</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
			</pcg6>
		</pcg2>
		<pcg2 id="120000000">
			<name>AUTONOMIC AGENTS</name>
			<pcg6 id="120400000">
				<name>PARASYMPATHOMIMETIC (CHOLINERGIC) AGENTS</name>
				<genericName id="00210">
					<name>BETHANECHOL CHLORIDE</name>
					<pcgGroup>
						<pcg9 id="120400002">
							<itemNumber>0332</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="01947958" sec3="Y">
								<name>Duvoid</name>
								<manufacturerId>PAL</manufacturerId>
								<individualPrice>.4028</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.4028</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="120400001">
							<itemNumber>0333</itemNumber>
							<strength>25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="01947931" sec3="Y">
								<name>Duvoid</name>
								<manufacturerId>PAL</manufacturerId>
								<individualPrice>.6523</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.6523</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="120400015">
							<itemNumber>0334</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="01947923" sec3="Y">
								<name>Duvoid</name>
								<manufacturerId>PAL</manufacturerId>
								<individualPrice>.8590</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.8590</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00211">
					<name>CARBACHOL</name>
					<pcgGroup>
						<pcg9 id="120400005">
							<itemNumber>0335</itemNumber>
							<strength>2mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00885568" sec3="Y">
								<name>Carbachol</name>
								<manufacturerId>GLA</manufacturerId>
								<individualPrice>.3727</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3727</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01333">
					<name>DONEPEZIL HCL</name>
					<pcgGroup>
						<pcg9 id="120400033">
							<itemNumber>0336</itemNumber>
							<strength>5mg</strength>
							<dosageForm>Orally Disintegrating Tab</dosageForm>
							<drug id="02269457" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Aricept RDT</name>
								<manufacturerId>PFI</manufacturerId>
								<listingDate>2014-02-27</listingDate>
							</drug>
							<drug id="02367688" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Sandoz Donepezil ODT</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>3.6176</individualPrice>
								<listingDate>2014-05-29</listingDate>
							</drug>
							<drug id="02397617" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Co Donepezil ODT</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>3.6176</individualPrice>
								<listingDate>2014-02-27</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="120400034">
							<itemNumber>0337</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Orally Disintegrating Tab</dosageForm>
							<drug id="02269465" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Aricept RDT</name>
								<manufacturerId>PFI</manufacturerId>
								<listingDate>2014-02-27</listingDate>
							</drug>
							<drug id="02367696" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Sandoz Donepezil ODT</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>3.6176</individualPrice>
								<listingDate>2014-05-29</listingDate>
							</drug>
							<drug id="02397625" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Co Donepezil ODT</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>3.6176</individualPrice>
								<listingDate>2014-02-27</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
					<pcgGroup lccId="00026">
						<pcg9 id="120400017">
							<itemNumber>0338</itemNumber>
							<strength>5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02232043" sec3="Y" sec12="Y">
								<name>Aricept</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>5.1856</individualPrice>
								<listingDate>1999-06-01</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02322331" sec3="Y" sec12="Y">
								<name>PMS-Donepezil</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2014-02-27</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02328666" sec3="Y" sec12="Y">
								<name>Sandoz Donepezil</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2014-03-27</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02340607" sec3="Y" sec12="Y">
								<name>Teva-Donepezil</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2014-02-27</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02362260" sec3="Y" sec12="Y">
								<name>Apo-Donepezil</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2014-02-27</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02381508" sec3="Y" sec12="Y">
								<name>Ran-Donepezil</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2014-02-27</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02397595" sec3="Y" sec12="Y">
								<name>Co Donepezil</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2014-02-27</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02400561" sec3="Y" sec12="Y">
								<name>Auro-Donepezil</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2014-03-27</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02402092" sec3="Y" sec12="Y">
								<name>Mar-Donepezil</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2014-02-27</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02402645" sec3="Y" sec12="Y">
								<name>Donepezil Hydrochloride Tablets</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2014-05-29</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02404419" sec3="Y" sec12="Y">
								<name>Jamp-Donepezil</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2014-02-27</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02408600" sec3="Y" sec12="Y">
								<name>Mint-Donepezil</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2019-09-30</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02412853" sec3="Y" sec12="Y">
								<name>Bio-Donepezil</name>
								<manufacturerId>BMP</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2016-04-29</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02416948" sec3="Y" sec12="Y">
								<name>Jamp-Donepezil Tablets</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2014-12-18</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02426846" sec3="Y" sec12="Y">
								<name>Donepezil</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2018-05-31</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02426943" dinStatus="E" sec3="Y" sec12="Y">
								<name>Van-Donepezil</name>
								<manufacturerId>VAN</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2015-07-29</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02428482" sec3="Y" sec12="Y">
								<name>Septa-Donepezil</name>
								<manufacturerId>SET</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2014-12-18</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02432684" sec3="Y" sec12="Y">
								<name>AG-Donepezil</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2021-09-30</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02439557" sec3="Y" sec12="Y">
								<name>Nat-Donepezil</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2015-10-29</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02467453" sec3="Y" sec12="Y">
								<name>M-Donepezil</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2021-10-29</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02475278" sec3="Y" sec12="Y">
								<name>Donepezil</name>
								<manufacturerId>RIA</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2021-08-31</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="120400018">
							<itemNumber>0339</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02232044" sec3="Y" sec12="Y">
								<name>Aricept</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>5.1856</individualPrice>
								<listingDate>1999-06-01</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02322358" sec3="Y" sec12="Y">
								<name>PMS-Donepezil</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2014-02-27</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02328682" sec3="Y" sec12="Y">
								<name>Sandoz Donepezil</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2014-03-27</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02340615" sec3="Y" sec12="Y">
								<name>Teva-Donepezil</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2014-02-27</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02362279" sec3="Y" sec12="Y">
								<name>Apo-Donepezil</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2014-02-27</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02381516" sec3="Y" sec12="Y">
								<name>Ran-Donepezil</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2014-02-27</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02397609" sec3="Y" sec12="Y">
								<name>Co Donepezil</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2014-02-27</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02400588" sec3="Y" sec12="Y">
								<name>Auro-Donepezil</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2014-02-27</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02402106" sec3="Y" sec12="Y">
								<name>Mar-Donepezil</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2014-02-27</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02402653" sec3="Y" sec12="Y">
								<name>Donepezil Hydrochloride Tablets</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2014-05-29</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02404427" sec3="Y" sec12="Y">
								<name>Jamp-Donepezil</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2014-02-27</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02408619" sec3="Y" sec12="Y">
								<name>Mint-Donepezil</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2019-09-30</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02412861" sec3="Y" sec12="Y">
								<name>Bio-Donepezil</name>
								<manufacturerId>BMP</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2016-04-29</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02416956" sec3="Y" sec12="Y">
								<name>Jamp-Donepezil Tablets</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2014-12-18</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02426854" sec3="Y" sec12="Y">
								<name>Donepezil</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2018-05-31</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02426951" dinStatus="E" sec3="Y" sec12="Y">
								<name>Van-Donepezil</name>
								<manufacturerId>VAN</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2015-07-29</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02428490" sec3="Y" sec12="Y">
								<name>Septa-Donepezil</name>
								<manufacturerId>SET</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2014-12-18</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02432692" sec3="Y" sec12="Y">
								<name>AG-Donepezil</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2021-09-30</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02439565" sec3="Y" sec12="Y">
								<name>Nat-Donepezil</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2015-10-29</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02467461" sec3="Y" sec12="Y">
								<name>M-Donepezil</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2021-10-29</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
							<drug id="02475286" sec3="Y" sec12="Y">
								<name>Donepezil</name>
								<manufacturerId>RIA</manufacturerId>
								<individualPrice>.4586</individualPrice>
								<listingDate>2021-08-31</listingDate>
								<amountMOHLTCPays>.4586</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="347">Initial Trial: For patients with mild to moderate Alzheimer&apos;s Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="003" reasonForUseId="348">Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.</lccNote>
						<lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="01540">
					<name>GALANTAMINE HYDROBROMIDE</name>
					<pcgGroup lccId="00027">
						<pcg9 id="120400031">
							<itemNumber>0340</itemNumber>
							<strength>8mg</strength>
							<dosageForm>ER Cap</dosageForm>
							<drug id="02266717" notABenefit="Y" sec3="Y">
								<name>Reminyl ER</name>
								<manufacturerId>JAN</manufacturerId>
								<listingDate>2006-01-12</listingDate>
							</drug>
							<drug id="02316943" sec3="Y" sec12="Y">
								<name>Pat-Galantamine ER</name>
								<manufacturerId>PAR</manufacturerId>
								<individualPrice>1.2465</individualPrice>
								<listingDate>2011-05-19</listingDate>
								<amountMOHLTCPays>1.2465</amountMOHLTCPays>
							</drug>
							<drug id="02339439" sec3="Y" sec12="Y">
								<name>Mylan-Galantamine ER</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>1.2465</individualPrice>
								<listingDate>2011-03-15</listingDate>
								<amountMOHLTCPays>1.2465</amountMOHLTCPays>
							</drug>
							<drug id="02398370" sec3="Y" sec12="Y">
								<name>PMS-Galantamine ER</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>1.2465</individualPrice>
								<listingDate>2013-08-29</listingDate>
								<amountMOHLTCPays>1.2465</amountMOHLTCPays>
							</drug>
							<drug id="02425157" sec3="Y" sec12="Y">
								<name>Auro-Galantamine ER</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>1.2465</individualPrice>
								<listingDate>2014-09-25</listingDate>
								<amountMOHLTCPays>1.2465</amountMOHLTCPays>
							</drug>
							<drug id="02443015" sec3="Y" sec12="Y">
								<name>Galantamine ER</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>1.2465</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>1.2465</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="120400029">
							<itemNumber>0341</itemNumber>
							<strength>16mg</strength>
							<dosageForm>ER Cap</dosageForm>
							<drug id="02266725" notABenefit="Y" sec3="Y">
								<name>Reminyl ER</name>
								<manufacturerId>JAN</manufacturerId>
								<listingDate>2006-01-12</listingDate>
							</drug>
							<drug id="02316951" sec3="Y" sec12="Y">
								<name>Pat-Galantamine ER</name>
								<manufacturerId>PAR</manufacturerId>
								<individualPrice>1.2465</individualPrice>
								<listingDate>2011-05-19</listingDate>
								<amountMOHLTCPays>1.2465</amountMOHLTCPays>
							</drug>
							<drug id="02339447" sec3="Y" sec12="Y">
								<name>Mylan-Galantamine ER</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>1.2465</individualPrice>
								<listingDate>2011-03-15</listingDate>
								<amountMOHLTCPays>1.2465</amountMOHLTCPays>
							</drug>
							<drug id="02398389" sec3="Y" sec12="Y">
								<name>PMS-Galantamine ER</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>1.2465</individualPrice>
								<listingDate>2013-08-29</listingDate>
								<amountMOHLTCPays>1.2465</amountMOHLTCPays>
							</drug>
							<drug id="02425165" sec3="Y" sec12="Y">
								<name>Auro-Galantamine ER</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>1.2465</individualPrice>
								<listingDate>2014-09-25</listingDate>
								<amountMOHLTCPays>1.2465</amountMOHLTCPays>
							</drug>
							<drug id="02443023" sec3="Y" sec12="Y">
								<name>Galantamine ER</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>1.2465</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>1.2465</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="120400030">
							<itemNumber>0342</itemNumber>
							<strength>24mg</strength>
							<dosageForm>ER Cap</dosageForm>
							<drug id="02266733" notABenefit="Y" sec3="Y">
								<name>Reminyl ER</name>
								<manufacturerId>JAN</manufacturerId>
								<listingDate>2006-01-12</listingDate>
							</drug>
							<drug id="02316978" sec3="Y" sec12="Y">
								<name>Pat-Galantamine ER</name>
								<manufacturerId>PAR</manufacturerId>
								<individualPrice>1.2465</individualPrice>
								<listingDate>2011-05-19</listingDate>
								<amountMOHLTCPays>1.2465</amountMOHLTCPays>
							</drug>
							<drug id="02339455" sec3="Y" sec12="Y">
								<name>Mylan-Galantamine ER</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>1.2465</individualPrice>
								<listingDate>2011-03-15</listingDate>
								<amountMOHLTCPays>1.2465</amountMOHLTCPays>
							</drug>
							<drug id="02398397" sec3="Y" sec12="Y">
								<name>PMS-Galantamine ER</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>1.2465</individualPrice>
								<listingDate>2013-08-29</listingDate>
								<amountMOHLTCPays>1.2465</amountMOHLTCPays>
							</drug>
							<drug id="02425173" sec3="Y" sec12="Y">
								<name>Auro-Galantamine ER</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>1.2465</individualPrice>
								<listingDate>2014-09-25</listingDate>
								<amountMOHLTCPays>1.2465</amountMOHLTCPays>
							</drug>
							<drug id="02443031" sec3="Y" sec12="Y">
								<name>Galantamine ER</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>1.2465</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>1.2465</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="347">Initial Trial: For patients with mild to moderate Alzheimer&apos;s Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="003" reasonForUseId="348">Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.</lccNote>
						<lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00702">
					<name>PILOCARPINE HCL</name>
					<pcgGroup>
						<pcg9 id="120400032">
							<itemNumber>0343</itemNumber>
							<strength>5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02216345" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Salagen</name>
								<manufacturerId>AMD</manufacturerId>
								<listingDate>2013-05-31</listingDate>
							</drug>
							<drug id="02496119" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>M-Pilocarpine</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>1.1708</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>1.1708</amountMOHLTCPays>
							</drug>
							<drug id="02509571" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Jamp Pilocarpine</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>1.1708</individualPrice>
								<listingDate>2021-05-31</listingDate>
								<amountMOHLTCPays>1.1708</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00214">
					<name>PYRIDOSTIGMINE BROMIDE</name>
					<pcgGroup>
						<pcg9 id="120400011">
							<itemNumber>0344</itemNumber>
							<strength>180mg</strength>
							<dosageForm>LA Tab</dosageForm>
							<drug id="00869953" sec3="Y">
								<name>Mestinon</name>
								<manufacturerId>VAL</manufacturerId>
								<individualPrice>1.1920</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>1.1920</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="120400010">
							<itemNumber>0345</itemNumber>
							<strength>60mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00869961" sec3="Y">
								<name>Mestinon</name>
								<manufacturerId>VAL</manufacturerId>
								<individualPrice>.5345</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.4009</amountMOHLTCPays>
							</drug>
							<drug id="02495643" sec3="Y">
								<name>Riva-Pyridostigmine</name>
								<manufacturerId>RIA</manufacturerId>
								<individualPrice>.4009</individualPrice>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>.4009</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01491">
					<name>RIVASTIGMINE</name>
					<pcgGroup lccId="00028">
						<pcg9 id="120400019">
							<itemNumber>0346</itemNumber>
							<strength>1.5mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02242115" sec3="Y" sec12="Y">
								<name>Exelon</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>2.8500</individualPrice>
								<listingDate>2001-03-07</listingDate>
								<amountMOHLTCPays>.6514</amountMOHLTCPays>
							</drug>
							<drug id="02306034" sec3="Y" sec12="Y">
								<name>PMS-Rivastigmine</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.6515</individualPrice>
								<listingDate>2009-11-13</listingDate>
								<amountMOHLTCPays>.6514</amountMOHLTCPays>
							</drug>
							<drug id="02324563" sec3="Y" sec12="Y">
								<name>Sandoz Rivastigmine</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.6514</individualPrice>
								<listingDate>2009-11-19</listingDate>
								<amountMOHLTCPays>.6514</amountMOHLTCPays>
							</drug>
							<drug id="02336715" sec3="Y" sec12="Y">
								<name>Apo-Rivastigmine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.6515</individualPrice>
								<listingDate>2010-03-02</listingDate>
								<amountMOHLTCPays>.6514</amountMOHLTCPays>
							</drug>
							<drug id="02401614" sec3="Y" sec12="Y">
								<name>Med-Rivastigmine</name>
								<manufacturerId>GMP</manufacturerId>
								<individualPrice>.6514</individualPrice>
								<listingDate>2014-01-30</listingDate>
								<amountMOHLTCPays>.6514</amountMOHLTCPays>
							</drug>
							<drug id="02406985" sec3="Y" sec12="Y">
								<name>Mint-Rivastigmine</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.6515</individualPrice>
								<listingDate>2013-09-27</listingDate>
								<amountMOHLTCPays>.6514</amountMOHLTCPays>
							</drug>
							<drug id="02485362" sec3="Y" sec12="Y">
								<name>Jamp Rivastigmine</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.6514</individualPrice>
								<listingDate>2020-01-31</listingDate>
								<amountMOHLTCPays>.6514</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="120400020">
							<itemNumber>0347</itemNumber>
							<strength>3mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02242116" sec3="Y" sec12="Y">
								<name>Exelon</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>2.8500</individualPrice>
								<listingDate>2001-03-07</listingDate>
								<amountMOHLTCPays>.6514</amountMOHLTCPays>
							</drug>
							<drug id="02306042" dinStatus="E" sec3="Y" sec12="Y">
								<name>PMS-Rivastigmine</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.6515</individualPrice>
								<listingDate>2009-11-13</listingDate>
								<amountMOHLTCPays>.6514</amountMOHLTCPays>
							</drug>
							<drug id="02324571" sec3="Y" sec12="Y">
								<name>Sandoz Rivastigmine</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.6514</individualPrice>
								<listingDate>2009-11-19</listingDate>
								<amountMOHLTCPays>.6514</amountMOHLTCPays>
							</drug>
							<drug id="02336723" sec3="Y" sec12="Y">
								<name>Apo-Rivastigmine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.6515</individualPrice>
								<listingDate>2010-03-02</listingDate>
								<amountMOHLTCPays>.6514</amountMOHLTCPays>
							</drug>
							<drug id="02401622" sec3="Y" sec12="Y">
								<name>Med-Rivastigmine</name>
								<manufacturerId>GMP</manufacturerId>
								<individualPrice>.6514</individualPrice>
								<listingDate>2014-01-30</listingDate>
								<amountMOHLTCPays>.6514</amountMOHLTCPays>
							</drug>
							<drug id="02406993" sec3="Y" sec12="Y">
								<name>Mint-Rivastigmine</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.6515</individualPrice>
								<listingDate>2013-09-27</listingDate>
								<amountMOHLTCPays>.6514</amountMOHLTCPays>
							</drug>
							<drug id="02485370" sec3="Y" sec12="Y">
								<name>Jamp Rivastigmine</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.6514</individualPrice>
								<listingDate>2020-01-31</listingDate>
								<amountMOHLTCPays>.6514</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="120400021">
							<itemNumber>0348</itemNumber>
							<strength>4.5mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02242117" sec3="Y" sec12="Y">
								<name>Exelon</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>2.8500</individualPrice>
								<listingDate>2001-03-07</listingDate>
								<amountMOHLTCPays>.6514</amountMOHLTCPays>
							</drug>
							<drug id="02306050" sec3="Y" sec12="Y">
								<name>PMS-Rivastigmine</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.6515</individualPrice>
								<listingDate>2009-11-13</listingDate>
								<amountMOHLTCPays>.6514</amountMOHLTCPays>
							</drug>
							<drug id="02324598" sec3="Y" sec12="Y">
								<name>Sandoz Rivastigmine</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.6514</individualPrice>
								<listingDate>2009-11-19</listingDate>
								<amountMOHLTCPays>.6514</amountMOHLTCPays>
							</drug>
							<drug id="02336731" sec3="Y" sec12="Y">
								<name>Apo-Rivastigmine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.6515</individualPrice>
								<listingDate>2010-03-02</listingDate>
								<amountMOHLTCPays>.6514</amountMOHLTCPays>
							</drug>
							<drug id="02401630" sec3="Y" sec12="Y">
								<name>Med-Rivastigmine</name>
								<manufacturerId>GMP</manufacturerId>
								<individualPrice>.6514</individualPrice>
								<listingDate>2014-01-30</listingDate>
								<amountMOHLTCPays>.6514</amountMOHLTCPays>
							</drug>
							<drug id="02407000" sec3="Y" sec12="Y">
								<name>Mint-Rivastigmine</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.6515</individualPrice>
								<listingDate>2013-09-27</listingDate>
								<amountMOHLTCPays>.6514</amountMOHLTCPays>
							</drug>
							<drug id="02485389" sec3="Y" sec12="Y">
								<name>Jamp Rivastigmine</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.6514</individualPrice>
								<listingDate>2020-01-31</listingDate>
								<amountMOHLTCPays>.6514</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="120400022">
							<itemNumber>0349</itemNumber>
							<strength>6mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02242118" sec3="Y" sec12="Y">
								<name>Exelon</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>2.8500</individualPrice>
								<listingDate>2001-03-07</listingDate>
								<amountMOHLTCPays>.6514</amountMOHLTCPays>
							</drug>
							<drug id="02324601" sec3="Y" sec12="Y">
								<name>Sandoz Rivastigmine</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.6514</individualPrice>
								<listingDate>2009-11-19</listingDate>
								<amountMOHLTCPays>.6514</amountMOHLTCPays>
							</drug>
							<drug id="02336758" sec3="Y" sec12="Y">
								<name>Apo-Rivastigmine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.6515</individualPrice>
								<listingDate>2010-03-02</listingDate>
								<amountMOHLTCPays>.6514</amountMOHLTCPays>
							</drug>
							<drug id="02401649" sec3="Y" sec12="Y">
								<name>Med-Rivastigmine</name>
								<manufacturerId>GMP</manufacturerId>
								<individualPrice>.6514</individualPrice>
								<listingDate>2014-01-30</listingDate>
								<amountMOHLTCPays>.6514</amountMOHLTCPays>
							</drug>
							<drug id="02407019" sec3="Y" sec12="Y">
								<name>Mint-Rivastigmine</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.6515</individualPrice>
								<listingDate>2013-09-27</listingDate>
								<amountMOHLTCPays>.6514</amountMOHLTCPays>
							</drug>
							<drug id="02485397" sec3="Y" sec12="Y">
								<name>Jamp Rivastigmine</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.6514</individualPrice>
								<listingDate>2020-01-31</listingDate>
								<amountMOHLTCPays>.6514</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="347">Initial Trial: For patients with mild to moderate Alzheimer&apos;s Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
Network note: Maximum duration 3 months.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="003" reasonForUseId="348">Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.</lccNote>
						<lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
					<pcgGroup>
						<pcg9 id="120400035">
							<itemNumber>0350</itemNumber>
							<strength>9mg/5 Sq Cm</strength>
							<dosageForm>Trans Patch</dosageForm>
							<drug id="02302845" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Exelon Patch 5</name>
								<manufacturerId>NOV</manufacturerId>
								<listingDate>2017-01-31</listingDate>
							</drug>
							<drug id="02423413" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mylan-Rivastigmine Patch 5</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>3.9773</individualPrice>
								<listingDate>2017-01-31</listingDate>
							</drug>
							<drug id="02426293" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Sandoz Rivastigmine Patch 5</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>3.9773</individualPrice>
								<listingDate>2017-01-31</listingDate>
							</drug>
							<drug id="02479540" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Rivastigmine Patch 5</name>
								<manufacturerId>STR</manufacturerId>
								<individualPrice>3.9773</individualPrice>
								<listingDate>2021-03-29</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="120400036">
							<itemNumber>0351</itemNumber>
							<strength>18mg/10 Sq Cm</strength>
							<dosageForm>Trans Patch</dosageForm>
							<drug id="02302853" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Exelon Patch 10</name>
								<manufacturerId>NOV</manufacturerId>
								<listingDate>2017-01-31</listingDate>
							</drug>
							<drug id="02423421" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mylan-Rivastigmine Patch 10</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>3.9773</individualPrice>
								<listingDate>2017-01-31</listingDate>
							</drug>
							<drug id="02426307" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Sandoz Rivastigmine Patch 10</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>3.9773</individualPrice>
								<listingDate>2017-01-31</listingDate>
							</drug>
							<drug id="02479559" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Rivastigmine Patch 10</name>
								<manufacturerId>STR</manufacturerId>
								<individualPrice>3.9773</individualPrice>
								<listingDate>2021-03-29</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="120400037">
							<itemNumber>0352</itemNumber>
							<strength>13.3mg/24hr</strength>
							<dosageForm>Transdermal Patch</dosageForm>
							<drug id="02432803" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Exelon Patch 15</name>
								<manufacturerId>NOV</manufacturerId>
								<listingDate>2021-03-29</listingDate>
							</drug>
							<drug id="02479567" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Rivastigmine Patch 15</name>
								<manufacturerId>STR</manufacturerId>
								<individualPrice>3.9773</individualPrice>
								<listingDate>2021-03-29</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="120800000">
				<name>PARASYMPATHOLYTIC (CHOLINERGIC BLOCKING) AGENTS</name>
				<genericName id="01952">
					<name>ACLIDINIUM BROMIDE</name>
					<pcgGroup>
						<pcg9 id="120800071">
							<itemNumber>0353</itemNumber>
							<strength>400mcg/actuation</strength>
							<dosageForm>Pd Inh-60 Dose Pk</dosageForm>
							<drug id="02409720" sec3="Y">
								<name>Tudorza Genuair</name>
								<manufacturerId>ALM</manufacturerId>
								<individualPrice>53.1000</individualPrice>
								<listingDate>2014-08-28</listingDate>
								<amountMOHLTCPays>53.1000</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00215">
					<name>BENZTROPINE MESYLATE</name>
					<pcgGroup>
						<pcg9 id="120800072">
							<itemNumber>0354</itemNumber>
							<strength>1mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00706531" sec3="Y">
								<name>PDP-Benztropine</name>
								<manufacturerId>PEN</manufacturerId>
								<individualPrice>.0522</individualPrice>
								<listingDate>2018-08-30</listingDate>
								<amountMOHLTCPays>.0522</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00223">
					<name>ETHOPROPAZINE HCL</name>
					<pcgGroup>
						<pcg9 id="120800021">
							<itemNumber>0355</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="01927744" sec3="Y">
								<name>Parsitan</name>
								<manufacturerId>ERF</manufacturerId>
								<individualPrice>.3000</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3000</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00226">
					<name>FLAVOXATE HCL</name>
					<pcgGroup>
						<pcg9 id="120800038">
							<itemNumber>0356</itemNumber>
							<strength>200mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00728179" notABenefit="Y" sec3="Y">
								<name>Urispas</name>
								<manufacturerId>PAL</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02244842" notABenefit="Y" sec3="Y">
								<name>Apo-Flavoxate</name>
								<manufacturerId>APX</manufacturerId>
								<listingDate>2002-07-29</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01921">
					<name>GLYCOPYRRONIUM BROMIDE</name>
					<pcgGroup>
						<pcg9 id="120800070">
							<itemNumber>0357</itemNumber>
							<strength>50mcg</strength>
							<dosageForm>Inh Pd-Cap</dosageForm>
							<drug id="02394936" sec3="Y">
								<name>Seebri Breezhaler</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>1.7700</individualPrice>
								<note>The dose of Seebri Breezhaler should not exceed 50mcg per day.</note>
								<listingDate>2013-08-29</listingDate>
								<amountMOHLTCPays>1.7700</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00218">
					<name>HYOSCINE BUTYLBROMIDE</name>
					<pcgGroup lccId="00336">
						<pcg9 id="120800009">
							<itemNumber>0358</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00363812" sec3="Y" sec12="Y">
								<name>Buscopan</name>
								<manufacturerId>SAC</manufacturerId>
								<individualPrice>.3615</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>.2711</amountMOHLTCPays>
							</drug>
							<drug id="02512335" sec3="Y" sec12="Y">
								<name>Accel-Hyoscine</name>
								<manufacturerId>ACC</manufacturerId>
								<individualPrice>.2711</individualPrice>
								<listingDate>2021-11-30</listingDate>
								<amountMOHLTCPays>.2711</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="481">For the management of patients receiving palliative care*.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="003" type="N">*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00227">
					<name>IPRATROPIUM BROMIDE</name>
					<pcgGroup lccId="00030">
						<pcg9 id="120800039">
							<itemNumber>0359</itemNumber>
							<strength>250mcg/mL</strength>
							<dosageForm>Inh Sol-20mL Pk</dosageForm>
							<drug id="00731439" notABenefit="Y" sec3="Y">
								<name>Atrovent</name>
								<manufacturerId>BOE</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02126222" sec3="Y" sec12="Y">
								<name>Apo-Ipravent Inhalation Solution</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>6.3140</individualPrice>
								<listingDate>2000-11-30</listingDate>
								<amountMOHLTCPays>6.3140</amountMOHLTCPays>
							</drug>
							<drug id="02210479" sec3="Y" sec12="Y">
								<name>Novo-Ipramide</name>
								<manufacturerId>NOP</manufacturerId>
								<individualPrice>6.3140</individualPrice>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>6.3140</amountMOHLTCPays>
							</drug>
							<drug id="02231136" sec3="Y" sec12="Y">
								<name>PMS-Ipratropium</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>6.3140</individualPrice>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>6.3140</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" type="R">For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.</lccNote>
						<lccNote seq="002" reasonForUseId="256">Patients who have a tracheostomy;</lccNote>
						<lccNote seq="003" type="R">LU Authorization Period: Indefinite.</lccNote>
						<lccNote seq="004" reasonForUseId="257">Patients with cystic fibrosis in whom nebulizer therapy is indicated;</lccNote>
						<lccNote seq="005" type="R">LU Authorization Period: Indefinite.</lccNote>
						<lccNote seq="006" reasonForUseId="258">Patients with severe mental or physical disabilities;</lccNote>
						<lccNote seq="007" type="R">LU Authorization Period: Indefinite.</lccNote>
						<lccNote seq="008" reasonForUseId="259">Patients who have previously used nebulizer therapy within the last 12 month period.</lccNote>
						<lccNote seq="009" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
					<pcgGroup lccId="00031">
						<pcg9 id="120800047">
							<itemNumber>0360</itemNumber>
							<strength>125mcg/mL</strength>
							<dosageForm>Inh Sol-2mL UDV Pk</dosageForm>
							<drug id="02026759" notABenefit="Y" sec3="Y">
								<name>Atrovent UDV</name>
								<manufacturerId>BOE</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02231135" sec3="Y" sec12="Y">
								<name>PMS-Ipratropium</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>1.1505</individualPrice>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>1.1505</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="120800046">
							<itemNumber>0361</itemNumber>
							<strength>250mcg/mL</strength>
							<dosageForm>Inh Sol-2mL UDV Pk</dosageForm>
							<drug id="01950681" notABenefit="Y" sec3="Y">
								<name>Atrovent UDV</name>
								<manufacturerId>BOE</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02097168" sec3="Y" sec12="Y">
								<name>Ratio-Ipratropium UDV</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>1.3180</individualPrice>
								<listingDate>1996-12-19</listingDate>
								<amountMOHLTCPays>1.3180</amountMOHLTCPays>
							</drug>
							<drug id="02216221" sec3="Y" sec12="Y">
								<name>Teva-Ipratropium Sterinebs</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>1.3180</individualPrice>
								<listingDate>1999-09-15</listingDate>
								<amountMOHLTCPays>1.3180</amountMOHLTCPays>
							</drug>
							<drug id="02231245" sec3="Y" sec12="Y">
								<name>PMS-Ipratropium</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>1.3180</individualPrice>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>1.3180</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" type="R">For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.</lccNote>
						<lccNote seq="002" reasonForUseId="265">Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy;</lccNote>
						<lccNote seq="003" type="R">LU Authorization Period: Indefinite.</lccNote>
						<lccNote seq="004" reasonForUseId="266">Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;.</lccNote>
						<lccNote seq="005" type="R">LU Authorization Period: Indefinite.</lccNote>
						<lccNote seq="006" reasonForUseId="267">Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities;</lccNote>
						<lccNote seq="007" type="R">LU Authorization Period: Indefinite.</lccNote>
						<lccNote seq="008" reasonForUseId="268">Patients who have previously used nebulizer therapy within the last 12 month period.</lccNote>
						<lccNote seq="009" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
					<pcgGroup>
						<pcg9 id="120800056">
							<itemNumber>0362</itemNumber>
							<strength>20mcg/Metered Dose</strength>
							<dosageForm>Inh-200 Dose Pk</dosageForm>
							<drug id="02247686" sec3="Y">
								<name>Atrovent HFA</name>
								<manufacturerId>BOE</manufacturerId>
								<individualPrice>20.2459</individualPrice>
								<listingDate>2004-11-04</listingDate>
								<amountMOHLTCPays>20.2459</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01365">
					<name>IPRATROPIUM BROMIDE/SALBUTAMOL</name>
					<pcgGroup lccId="00029">
						<pcg9 id="120800050">
							<itemNumber>0363</itemNumber>
							<strength>500mcg/2.5mg/2.5mL</strength>
							<dosageForm>Inh Sol-2.5mL Amp Pk</dosageForm>
							<drug id="02231675" notABenefit="Y" sec3="Y">
								<name>Combivent UDV</name>
								<manufacturerId>BOE</manufacturerId>
								<listingDate>1998-12-31</listingDate>
							</drug>
							<drug id="02272695" sec3="Y" sec12="Y">
								<name>Teva-Combo Sterinebs</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.8066</individualPrice>
								<listingDate>2006-01-24</listingDate>
								<amountMOHLTCPays>.8066</amountMOHLTCPays>
							</drug>
							<drug id="02483394" sec3="Y" sec12="Y">
								<name>Ipratropium Bromide and Salbutamol Sulph</name>
								<manufacturerId>MDI</manufacturerId>
								<individualPrice>.8066</individualPrice>
								<listingDate>2019-12-20</listingDate>
								<amountMOHLTCPays>.8066</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" type="R">For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.</lccNote>
						<lccNote seq="002" reasonForUseId="256">Patients who have a tracheostomy;</lccNote>
						<lccNote seq="003" type="R">LU Authorization Period: Indefinite.</lccNote>
						<lccNote seq="004" reasonForUseId="257">Patients with cystic fibrosis in whom nebulizer therapy is indicated;</lccNote>
						<lccNote seq="005" type="R">LU Authorization Period: Indefinite.</lccNote>
						<lccNote seq="006" reasonForUseId="258">Patients with severe mental or physical disabilities;</lccNote>
						<lccNote seq="007" type="R">LU Authorization Period: Indefinite.</lccNote>
						<lccNote seq="008" reasonForUseId="259">Patients who have previously used nebulizer therapy within the last 12 month period.</lccNote>
						<lccNote seq="009" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00225">
					<name>OXYBUTYNIN CHLORIDE</name>
					<pcgGroup>
						<pcg9 id="120800034">
							<itemNumber>0364</itemNumber>
							<strength>1mg/mL</strength>
							<dosageForm>O/L</dosageForm>
							<drug id="01924753" notABenefit="Y" sec3="Y">
								<name>Ditropan</name>
								<manufacturerId>JNO</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02223376" sec3="Y">
								<name>PMS-Oxybutynin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.0970</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.0970</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="120800033">
							<itemNumber>0365</itemNumber>
							<strength>5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="01924761" notABenefit="Y" sec3="Y">
								<name>Ditropan</name>
								<manufacturerId>PGP</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02163543" sec3="Y">
								<name>Apo-Oxybutynin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0986</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0986</amountMOHLTCPays>
							</drug>
							<drug id="02230394" sec3="Y">
								<name>Novo-Oxybutynin</name>
								<manufacturerId>NOP</manufacturerId>
								<individualPrice>.0986</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.0986</amountMOHLTCPays>
							</drug>
							<drug id="02240550" sec3="Y">
								<name>PMS-Oxybutynin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.0986</individualPrice>
								<listingDate>2000-07-17</listingDate>
								<amountMOHLTCPays>.0986</amountMOHLTCPays>
							</drug>
							<drug id="02350238" sec3="Y">
								<name>Oxybutynin</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.0986</individualPrice>
								<listingDate>2011-10-25</listingDate>
								<amountMOHLTCPays>.0986</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00220">
					<name>PROCYCLIDINE HCL</name>
					<pcgGroup>
						<pcg9 id="120800037">
							<itemNumber>0366</itemNumber>
							<strength>2.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00649392" sec3="Y">
								<name>Pdp-Procyclidine</name>
								<manufacturerId>PEN</manufacturerId>
								<individualPrice>.0577</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0577</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00230">
					<name>SCOPOLAMINE HYDROBROMIDE</name>
					<pcgGroup lccId="00287">
						<pcg9 id="120800043">
							<itemNumber>0367</itemNumber>
							<strength>0.4mg/mL</strength>
							<dosageForm>Inj Sol (Preservative Free)</dosageForm>
							<drug id="00541869" notABenefit="Y" sec3="Y">
								<name>Scopolamine Hydrobromide Injection</name>
								<manufacturerId>HOS</manufacturerId>
								<listingDate>2011-05-19</listingDate>
							</drug>
							<drug id="02242810" sec3="Y" sec12="Y">
								<name>Scopolamine Hydrobromide Injection</name>
								<manufacturerId>OMG</manufacturerId>
								<individualPrice>5.5500</individualPrice>
								<listingDate>2011-05-19</listingDate>
								<amountMOHLTCPays>5.5500</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="120800065">
							<itemNumber>0368</itemNumber>
							<strength>0.6mg/mL</strength>
							<dosageForm>Inj Sol (Preservative Free)</dosageForm>
							<drug id="00541877" notABenefit="Y" sec3="Y">
								<name>Scopolamine Hydrobromide Injection</name>
								<manufacturerId>HOS</manufacturerId>
								<listingDate>2011-05-19</listingDate>
							</drug>
							<drug id="02242811" sec3="Y" sec12="Y">
								<name>Scopolamine Hydrobromide Injection</name>
								<manufacturerId>OMG</manufacturerId>
								<individualPrice>6.0000</individualPrice>
								<listingDate>2011-05-19</listingDate>
								<amountMOHLTCPays>6.0000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="481">For the management of patients receiving palliative care*.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="003" type="N">*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00222">
					<name>TRIHEXYPHENIDYL HCL</name>
					<pcgGroup>
						<pcg9 id="120800018">
							<itemNumber>0369</itemNumber>
							<strength>2mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00015040" notABenefit="Y" sec3="Y">
								<name>Artane</name>
								<manufacturerId>LED</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00545058" sec3="Y">
								<name>Trihexyphenidyl</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.0376</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0376</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="120800017">
							<itemNumber>0370</itemNumber>
							<strength>5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00015059" notABenefit="Y" sec3="Y">
								<name>Artane</name>
								<manufacturerId>LED</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00545074" sec3="Y">
								<name>Trihexyphenidyl</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.0681</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0681</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00818">
					<name>TRIMEBUTINE MALEATE</name>
					<pcgGroup>
						<pcg9 id="120800062">
							<itemNumber>0371</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00587869" sec3b="Y" sec3="Y">
								<name>Modulon</name>
								<manufacturerId>BFI</manufacturerId>
								<listingDate>2008-01-15</listingDate>
							</drug>
							<drug id="02245663" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Trimebutine</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.2690</individualPrice>
								<listingDate>2008-01-15</listingDate>
								<amountMOHLTCPays>.2690</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="120800061">
							<itemNumber>0372</itemNumber>
							<strength>200mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00803499" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Modulon</name>
								<manufacturerId>BFI</manufacturerId>
								<listingDate>2008-01-15</listingDate>
							</drug>
							<drug id="02245664" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Trimebutine</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.6275</individualPrice>
								<listingDate>2008-01-15</listingDate>
								<amountMOHLTCPays>.6275</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="120808000">
				<name>PARASYMPATHOLYTIC (CHOLINERGIC BLOCKING) AGENTS ANTIMUSCARINICS/ANTISPASMODICS</name>
				<genericName id="00217">
					<name>GLYCOPYRROLATE</name>
					<pcgGroup lccId="00288">
						<pcg9 id="120808010">
							<itemNumber>0373</itemNumber>
							<strength>0.2mg/mL</strength>
							<dosageForm>Inj Sol (Preservative Free)</dosageForm>
							<drug id="02039508" sec3="Y" sec12="Y">
								<name>Sandoz Glycopyrrolate</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>3.9750</individualPrice>
								<listingDate>2017-07-31</listingDate>
								<amountMOHLTCPays>3.9750</amountMOHLTCPays>
							</drug>
							<drug id="02043610" notABenefit="Y" sec3="Y">
								<name>Robinul</name>
								<manufacturerId>WYA</manufacturerId>
								<listingDate>2015-03-31</listingDate>
							</drug>
							<drug id="02382857" sec3="Y" sec12="Y">
								<name>Glycopyrrolate Injection</name>
								<manufacturerId>OMG</manufacturerId>
								<individualPrice>3.9750</individualPrice>
								<listingDate>2015-03-31</listingDate>
								<amountMOHLTCPays>3.9750</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="481">For the management of patients receiving palliative care*.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="003" type="N">*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00218">
					<name>HYOSCINE BUTYLBROMIDE</name>
					<pcgGroup lccId="00286">
						<pcg9 id="120808006">
							<itemNumber>0374</itemNumber>
							<strength>20mg/mL</strength>
							<dosageForm>Inj Sol</dosageForm>
							<drug id="00363839" sec3="Y" sec12="Y">
								<name>Buscopan</name>
								<manufacturerId>SAC</manufacturerId>
								<individualPrice>4.8350</individualPrice>
								<listingDate>2017-06-29</listingDate>
								<amountMOHLTCPays>4.8350</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="481">For the management of patients receiving palliative care*.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="003" type="N">*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="01592">
					<name>TIOTROPIUM BROMIDE MONOHYDRATE</name>
					<pcgGroup>
						<pcg9 id="120808009">
							<itemNumber>0375</itemNumber>
							<strength>18mcg</strength>
							<dosageForm>Inh Cap</dosageForm>
							<drug id="02246793" sec3="Y">
								<name>Spiriva</name>
								<manufacturerId>BOE</manufacturerId>
								<individualPrice>1.8087</individualPrice>
								<note>Each Spiriva 18mcg Capsule contains 18mcg of tiotropium, equivalent to 22.5mcg of tiotropium bromide monohydrate.</note>
								<listingDate>2003-09-04</listingDate>
								<amountMOHLTCPays>1.8087</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="120808013">
							<itemNumber>0376</itemNumber>
							<strength>2.5mcg/Actuation</strength>
							<dosageForm>Inh Sol-60 Actuation Pk</dosageForm>
							<drug id="02435381" sec3="Y">
								<name>Spiriva Respimat</name>
								<manufacturerId>BOE</manufacturerId>
								<individualPrice>54.2607</individualPrice>
								<note>Each actuation of Spiriva Respimat contains 2.5mcg of tiotropium, supplied as tiotropium bromide monohydrate.</note>
								<listingDate>2016-03-30</listingDate>
								<amountMOHLTCPays>54.2607</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01997">
					<name>TIOTROPIUM BROMIDE MONOHYDRATE &amp; OLODATEROL HYDROCHLORIDE</name>
					<pcgGroup lccId="00263">
						<pcg9 id="120808012">
							<itemNumber>0377</itemNumber>
							<strength>2.5mcg &amp; 2.5mcg/Actuation</strength>
							<dosageForm>Inh Sol-60 Actuation Pk</dosageForm>
							<drug id="02441888" sec3="Y" sec12="Y">
								<name>Inspiolto Respimat</name>
								<manufacturerId>BOE</manufacturerId>
								<individualPrice>63.6712</individualPrice>
								<note>Each actuation of Inspiotto Respimat contains 2.5mcg of tiotropium, supplied as tiotropium bromide monohydrate, and 2.5mcg of olodaterol, supplied as olodaterol hydrochloride.</note>
								<listingDate>2016-03-30</listingDate>
								<amountMOHLTCPays>63.6712</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="459">For the long-term treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD-see notes below) who have had an inadequate response to a long-acting bronchodilator (i.e., long-acting beta-2 agonist (LABA), or long-acting muscarinic antagonist (LAMA)).</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: Indefinite.</lccNote>
						<lccNote seq="003" type="N">COPD disease severity is based on spirometry, symptoms and disability (see classification tables below).
Classification
COPD Stages - Symptoms and disability:
Mild: Shortness of breath from COPD when hurrying on the level or walking up a slight hill.
Moderate: Shortness of breath from COPD causing the patient to stop after walking approximately 100m (or after a few minutes) on the level
Severe: Shortness of breath from COPD resulting in the patient being too breathless to leave the house, breathless when dressing or undressing (MRC 5), or the presence of chronic respiratory failure or clinical signs of right heart failure
Classification by impairment of lung function:
COPD stage and spirometry (post bronchodilator) FEV1 predicted:
Mild: Greater than or equal to 80 percent
Moderate: 50 to 79 percent
Severe: 30 to 49 percent
Very severe: Less than 30 percent
</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="01993">
					<name>UMECLIDINIUM</name>
					<pcgGroup>
						<pcg9 id="120808011">
							<itemNumber>0378</itemNumber>
							<strength>62.5mcg</strength>
							<dosageForm>Blister Pd Inh-30 Dose Pk</dosageForm>
							<drug id="02423596" sec3="Y">
								<name>Incruse Ellipta</name>
								<manufacturerId>GSK</manufacturerId>
								<individualPrice>50.0000</individualPrice>
								<listingDate>2016-02-25</listingDate>
								<amountMOHLTCPays>50.0000</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="121200000">
				<name>SYMPATHOMIMETIC (ADRENERGIC) AGENTS</name>
				<genericName id="01994">
					<name>ACLIDINIUM BROMIDE &amp; FORMOTEROL FUMARATE DIHYDRATE</name>
					<pcgGroup lccId="00261">
						<pcg9 id="121200110">
							<itemNumber>0379</itemNumber>
							<strength>400mcg &amp; 12mcg</strength>
							<dosageForm>Metered Dose Pd Inh-60 Dose Pk</dosageForm>
							<drug id="02439530" sec3="Y" sec12="Y">
								<name>Duaklir Genuair</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>60.0000</individualPrice>
								<listingDate>2016-02-25</listingDate>
								<amountMOHLTCPays>60.0000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="459">For the long-term treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD-see notes below) who have had an inadequate response to a long-acting bronchodilator (i.e., long-acting beta-2 agonist (LABA), or long-acting muscarinic antagonist (LAMA)).</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: Indefinite.</lccNote>
						<lccNote seq="003" type="N">COPD disease severity is based on spirometry, symptoms and disability (see classification tables below).
Classification
COPD Stages - Symptoms and disability:
Mild: Shortness of breath from COPD when hurrying on the level or walking up a slight hill.
Moderate: Shortness of breath from COPD causing the patient to stop after walking approximately 100m (or after a few minutes) on the level
Severe: Shortness of breath from COPD resulting in the patient being too breathless to leave the house, breathless when dressing or undressing (MRC 5), or the presence of chronic respiratory failure or clinical signs of right heart failure
Classification by impairment of lung function:
COPD stage and spirometry (post bronchodilator) FEV1 predicted:
Mild: Greater than or equal to 80 percent
Moderate: 50 to 79 percent
Severe: 30 to 49 percent
Very severe: Less than 30 percent
</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="01568">
					<name>BUDESONIDE &amp; FORMOTEROL FUMARATE DIHYDRATE</name>
					<pcgGroup lccId="00032">
						<pcg9 id="121200087">
							<itemNumber>0380</itemNumber>
							<strength>100mcg/6mcg</strength>
							<dosageForm>Pd Inh-120 Dose Pk</dosageForm>
							<drug id="02245385" sec3="Y" sec12="Y">
								<name>Symbicort 100 Turbuhaler</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>69.5400</individualPrice>
								<listingDate>2003-01-30</listingDate>
								<amountMOHLTCPays>69.5400</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="121200088">
							<itemNumber>0381</itemNumber>
							<strength>200mcg/6mcg</strength>
							<dosageForm>Pd Inh-120 Dose Pk</dosageForm>
							<drug id="02245386" sec3="Y" sec12="Y">
								<name>Symbicort 200 Turbuhaler</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>90.3600</individualPrice>
								<listingDate>2003-01-30</listingDate>
								<amountMOHLTCPays>90.3600</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="330">For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00236">
					<name>EPINEPHRINE HCL</name>
					<pcgGroup>
						<pcg9 id="121200005">
							<itemNumber>0382</itemNumber>
							<strength>30mg/30mL</strength>
							<dosageForm>Inj Sol-30mL Pk</dosageForm>
							<drug id="00155357" sec3="Y">
								<name>Adrenalin</name>
								<manufacturerId>ERF</manufacturerId>
								<individualPrice>22.2300</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>22.2300</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="02104">
					<name>FLUTICASONE FUROATE &amp; UMECLIDINIUM BROMIDE &amp; VILANTEROL TRIFENATATE</name>
					<pcgGroup lccId="00321">
						<pcg9 id="121200114">
							<itemNumber>0383</itemNumber>
							<strength>100mcg &amp; 62.5mcg &amp; 25mcg</strength>
							<dosageForm>Pd Inh-30 Dose Pk</dosageForm>
							<drug id="02474522" sec3="Y" sec12="Y">
								<name>Trelegy Ellipta</name>
								<manufacturerId>GSK</manufacturerId>
								<individualPrice>136.1700</individualPrice>
								<note>Prescribers should be informed and stay current with a drug&apos;s official indications in accordance with Health Canada&apos;s approved product monograph.</note>
								<listingDate>2019-09-30</listingDate>
								<amountMOHLTCPays>136.1700</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="567">For the long-term, once daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema and to reduce exacerbations of COPD in patients with a history of exacerbations in patients who require a combination of an inhaled corticosteroid (ICS), long-acting muscarinic antagonist (LAMA), and a long-acting beta2-adrenergic agonist (LABA).</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="01969">
					<name>FLUTICASONE FUROATE &amp; VILANTEROL</name>
					<pcgGroup lccId="00249">
						<pcg9 id="121200107">
							<itemNumber>0384</itemNumber>
							<strength>100mcg &amp; 25mcg</strength>
							<dosageForm>Blister Pd Inh-30 Dose Pk</dosageForm>
							<drug id="02408872" sec3="Y" sec12="Y">
								<name>Breo Ellipta</name>
								<manufacturerId>GSK</manufacturerId>
								<individualPrice>88.8700</individualPrice>
								<listingDate>2015-03-31</listingDate>
								<amountMOHLTCPays>88.8700</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="330">For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: Indefinite.</lccNote>
						<lccNote seq="003" reasonForUseId="456">For the long-term treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD-see notes below) who have a history of exacerbations and have had an inadequate response to a long-acting bronchodilator (i.e., long-acting beta-2 agonist (LABA), or long-acting muscarinic antagonist (LAMA)).
</lccNote>
						<lccNote seq="004" type="R">LU Authorization Period: Indefinite.</lccNote>
						<lccNote seq="005" type="N">COPD disease severity is based on spirometry, symptoms and disability (see classification below).
Classification
COPD Stages - Symptoms and disability:
Mild: Shortness of breath from COPD when hurrying on the level or walking up a slight hill
Moderate: Shortness of breath from COPD causing the patient to stop after walking approximately 100m (or after a few minutes) on the level
Severe: Shortness of breath from COPD resulting in the patient being too breathless to leave the house, breathless when dressing or undressing (MRC 5), or the presence of chronic respiratory failure or clinical signs of right heart failure
Classification by impairment of lung function:
COPD stage and spirometry (post bronchodilator) FEV1 predicted:
Mild: Greater than or equal to 80 percent
Moderate: 50 to 79 percent
Severe: 30 to 49 percent
Very severe: Less than 30 percent</lccNote>
					</pcgGroup>
					<pcgGroup lccId="00268">
						<pcg9 id="121200111">
							<itemNumber>0385</itemNumber>
							<strength>200mcg &amp; 25mcg</strength>
							<dosageForm>Blister Pd Inh-30 Dose Pk</dosageForm>
							<drug id="02444186" sec3="Y" sec12="Y">
								<name>Breo Ellipta</name>
								<manufacturerId>GSK</manufacturerId>
								<individualPrice>138.2400</individualPrice>
								<listingDate>2016-08-30</listingDate>
								<amountMOHLTCPays>138.2400</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="330">For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="01345">
					<name>FORMOTEROL FUMARATE</name>
					<pcgGroup lccId="00036">
						<pcg9 id="121200075">
							<itemNumber>0386</itemNumber>
							<strength>12mcg/Cap</strength>
							<dosageForm>Inh Pd-Device Pk</dosageForm>
							<drug id="02230898" sec3="Y" sec12="Y">
								<name>Foradil</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>55.1700</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>55.1700</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="132">For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms.</lccNote>
						<lccNote seq="002" type="N">This drug is not for relief of acute symptoms.</lccNote>
						<lccNote seq="003" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="01396">
					<name>FORMOTEROL FUMARATE DIHYDRATE</name>
					<pcgGroup lccId="00037">
						<pcg9 id="121200082">
							<itemNumber>0387</itemNumber>
							<strength>6mcg/Metered Dose</strength>
							<dosageForm>Pd Inh-60 Dose Pk</dosageForm>
							<drug id="02237225" sec3="Y" sec12="Y">
								<name>Oxeze Turbuhaler</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>33.6500</individualPrice>
								<listingDate>2001-03-07</listingDate>
								<amountMOHLTCPays>33.6500</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="121200078">
							<itemNumber>0388</itemNumber>
							<strength>12mcg/Metered Dose</strength>
							<dosageForm>Pd Inh-60 Dose Pk</dosageForm>
							<drug id="02237224" sec3="Y" sec12="Y">
								<name>Oxeze Turbuhaler</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>44.8000</individualPrice>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>44.8000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="132">For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms.</lccNote>
						<lccNote seq="002" type="N">This drug is not for relief of acute symptoms.</lccNote>
						<lccNote seq="003" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="01914">
					<name>INDACATEROL</name>
					<pcgGroup lccId="00231">
						<pcg9 id="121200104">
							<itemNumber>0389</itemNumber>
							<strength>75mcg</strength>
							<dosageForm>Inh Pd-Cap</dosageForm>
							<drug id="02376938" sec3="Y" sec12="Y">
								<name>Onbrez Breezhaler</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>1.5500</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>1.5500</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="443">For patients with moderate to severe COPD with persistent respiratory symptoms despite an adequate trial of, or an intolerance to, a regularly scheduled short-acting bronchodilator AND a long-acting anticholinergic.
Note: The dose of Onbrez Breezhaler should not exceed 75mcg per day.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="01975">
					<name>INDACATEROL &amp; GLYCOPYRRONIUM</name>
					<pcgGroup lccId="00252">
						<pcg9 id="121200108">
							<itemNumber>0390</itemNumber>
							<strength>110mcg &amp; 50mcg</strength>
							<dosageForm>Inh Pd-Cap</dosageForm>
							<drug id="02418282" sec3="Y" sec12="Y">
								<name>Ultibro Breezhaler</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>2.5830</individualPrice>
								<listingDate>2015-05-28</listingDate>
								<amountMOHLTCPays>2.5830</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="459">For the long-term treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD-see notes below) who have had an inadequate response to a long-acting bronchodilator (i.e., long-acting beta-2 agonist (LABA), or long-acting muscarinic antagonist (LAMA)).</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: Indefinite.</lccNote>
						<lccNote seq="003" type="N">COPD disease severity is based on spirometry, symptoms and disability (see classification tables below).
Classification
COPD Stages - Symptoms and disability:
Mild: Shortness of breath from COPD when hurrying on the level or walking up a slight hill.
Moderate: Shortness of breath from COPD causing the patient to stop after walking approximately 100m (or after a few minutes) on the level
Severe: Shortness of breath from COPD resulting in the patient being too breathless to leave the house, breathless when dressing or undressing (MRC 5), or the presence of chronic respiratory failure or clinical signs of right heart failure
Classification by impairment of lung function:
COPD stage and spirometry (post bronchodilator) FEV1 predicted:
Mild: Greater than or equal to 80 percent
Moderate: 50 to 79 percent
Severe: 30 to 49 percent
Very severe: Less than 30 percent
</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="01876">
					<name>MOMETASONE FUROATE &amp; FORMOTEROL FUMARATE DIHYDRATE</name>
					<pcgGroup lccId="00220">
						<pcg9 id="121200095">
							<itemNumber>0391</itemNumber>
							<strength>100mcg &amp; 5mcg</strength>
							<dosageForm>Metered Dose Inh-120 Dose Pk</dosageForm>
							<drug id="02361752" sec3="Y" sec12="Y">
								<name>Zenhale</name>
								<manufacturerId>OCI</manufacturerId>
								<individualPrice>107.6400</individualPrice>
								<listingDate>2012-02-29</listingDate>
								<amountMOHLTCPays>107.6400</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="121200096">
							<itemNumber>0392</itemNumber>
							<strength>200mcg &amp; 5mcg</strength>
							<dosageForm>Metered Dose Inh-120 Dose Pk</dosageForm>
							<drug id="02361760" sec3="Y" sec12="Y">
								<name>Zenhale</name>
								<manufacturerId>OCI</manufacturerId>
								<individualPrice>130.4300</individualPrice>
								<listingDate>2012-02-29</listingDate>
								<amountMOHLTCPays>130.4300</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="330">For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00241">
					<name>ORCIPRENALINE SULFATE</name>
					<pcgGroup>
						<pcg9 id="121200016">
							<itemNumber>0393</itemNumber>
							<strength>2mg/mL</strength>
							<dosageForm>O/L</dosageForm>
							<drug id="00249920" notABenefit="Y" sec3="Y">
								<name>Alupent</name>
								<manufacturerId>BOE</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02236783" sec3="Y">
								<name>Orciprenaline</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.0574</individualPrice>
								<listingDate>2001-03-07</listingDate>
								<amountMOHLTCPays>.0574</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00239">
					<name>SALBUTAMOL</name>
					<pcgGroup lccId="00040">
						<pcg9 id="121200048">
							<itemNumber>0394</itemNumber>
							<strength>1mg/mL</strength>
							<dosageForm>Inh Sol- 2.5mL Pk</dosageForm>
							<drug id="01926934" sec3="Y" sec12="Y">
								<name>Teva-Salbutamol Sterinebs P.F.</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3617</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3617</amountMOHLTCPays>
							</drug>
							<drug id="02208229" sec3="Y" sec12="Y">
								<name>PMS-Salbutamol</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3617</individualPrice>
								<listingDate>1997-04-10</listingDate>
								<amountMOHLTCPays>.3617</amountMOHLTCPays>
							</drug>
							<drug id="02213419" sec3="Y" sec12="Y">
								<name>Ventolin Nebules P.F.</name>
								<manufacturerId>GSK</manufacturerId>
								<individualPrice>.6270</individualPrice>
								<listingDate>1998-10-21</listingDate>
								<amountMOHLTCPays>.3617</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" type="R">For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.</lccNote>
						<lccNote seq="002" reasonForUseId="265">Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy;</lccNote>
						<lccNote seq="003" type="R">LU Authorization Period: Indefinite.</lccNote>
						<lccNote seq="004" reasonForUseId="266">Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;.</lccNote>
						<lccNote seq="005" type="R">LU Authorization Period: Indefinite.</lccNote>
						<lccNote seq="006" reasonForUseId="267">Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities;</lccNote>
						<lccNote seq="007" type="R">LU Authorization Period: Indefinite.</lccNote>
						<lccNote seq="008" reasonForUseId="268">Patients who have previously used nebulizer therapy within the last 12 month period.</lccNote>
						<lccNote seq="009" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
					<pcgGroup lccId="00041">
						<pcg9 id="121200070">
							<itemNumber>0395</itemNumber>
							<strength>2mg/mL</strength>
							<dosageForm>Inh Sol- 2.5mL Pk</dosageForm>
							<drug id="02173360" sec3="Y" sec12="Y">
								<name>Teva-Salbutamol Sterinebs P.F.</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.6871</individualPrice>
								<listingDate>1997-04-10</listingDate>
								<amountMOHLTCPays>.6750</amountMOHLTCPays>
							</drug>
							<drug id="02208237" sec3="Y" sec12="Y">
								<name>PMS-Salbutamol</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.6750</individualPrice>
								<listingDate>1997-04-10</listingDate>
								<amountMOHLTCPays>.6750</amountMOHLTCPays>
							</drug>
							<drug id="02213427" sec3="Y" sec12="Y">
								<name>Ventolin Nebules P.F.</name>
								<manufacturerId>GSK</manufacturerId>
								<individualPrice>.7360</individualPrice>
								<listingDate>2006-06-15</listingDate>
								<amountMOHLTCPays>.6750</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" type="R">For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.</lccNote>
						<lccNote seq="002" reasonForUseId="265">Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy;</lccNote>
						<lccNote seq="003" type="R">LU Authorization Period: Indefinite.</lccNote>
						<lccNote seq="004" reasonForUseId="266">Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;.</lccNote>
						<lccNote seq="005" type="R">LU Authorization Period: Indefinite.</lccNote>
						<lccNote seq="006" reasonForUseId="267">Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities;</lccNote>
						<lccNote seq="007" type="R">LU Authorization Period: Indefinite.</lccNote>
						<lccNote seq="008" reasonForUseId="268">Patients who have previously used nebulizer therapy within the last 12 month period.</lccNote>
						<lccNote seq="009" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
					<pcgGroup lccId="00042">
						<pcg9 id="121200025">
							<itemNumber>0396</itemNumber>
							<strength>5mg/mL</strength>
							<dosageForm>Inh Sol-10mL Pk</dosageForm>
							<drug id="02213486" sec3="Y" sec12="Y">
								<name>Ventolin</name>
								<manufacturerId>GSK</manufacturerId>
								<individualPrice>2.5000</individualPrice>
								<listingDate>1998-04-03</listingDate>
								<amountMOHLTCPays>2.5000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" type="R">For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.</lccNote>
						<lccNote seq="002" reasonForUseId="256">Patients who have a tracheostomy;</lccNote>
						<lccNote seq="003" type="R">LU Authorization Period: Indefinite.</lccNote>
						<lccNote seq="004" reasonForUseId="257">Patients with cystic fibrosis in whom nebulizer therapy is indicated;</lccNote>
						<lccNote seq="005" type="R">LU Authorization Period: Indefinite.</lccNote>
						<lccNote seq="006" reasonForUseId="258">Patients with severe mental or physical disabilities;</lccNote>
						<lccNote seq="007" type="R">LU Authorization Period: Indefinite.</lccNote>
						<lccNote seq="008" reasonForUseId="259">Patients who have previously used nebulizer therapy within the last 12 month period.</lccNote>
						<lccNote seq="009" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
					<pcgGroup>
						<pcg9 id="121200012">
							<itemNumber>0397</itemNumber>
							<strength>100mcg/Metered Dose</strength>
							<dosageForm>Inh-200 dose Pk</dosageForm>
							<drug id="00790419" notABenefit="Y" sec3="Y">
								<name>Apo-Salvent</name>
								<manufacturerId>APX</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00851841" notABenefit="Y" sec3="Y">
								<name>Ratio-Salbutamol Inhaler</name>
								<manufacturerId>RPH</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00874086" notABenefit="Y" sec3="Y">
								<name>Novo-Salmol</name>
								<manufacturerId>NOP</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02213478" notABenefit="Y" sec3="Y">
								<name>Ventolin</name>
								<manufacturerId>GLW</manufacturerId>
								<listingDate>1997-07-12</listingDate>
							</drug>
							<drug id="02232570" sec3="Y">
								<name>Airomir HFA</name>
								<manufacturerId>GRA</manufacturerId>
								<individualPrice>5.8400</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>5.0000</amountMOHLTCPays>
							</drug>
							<drug id="02241497" sec3="Y">
								<name>Ventolin HFA</name>
								<manufacturerId>GSK</manufacturerId>
								<individualPrice>6.0000</individualPrice>
								<listingDate>2009-11-13</listingDate>
								<amountMOHLTCPays>5.0000</amountMOHLTCPays>
							</drug>
							<drug id="02245669" sec3="Y">
								<name>Apo-Salbutamol HFA</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>5.0000</individualPrice>
								<listingDate>2003-01-01</listingDate>
								<amountMOHLTCPays>5.0000</amountMOHLTCPays>
							</drug>
							<drug id="02326450" sec3="Y">
								<name>Novo-Salbutamol HFA</name>
								<manufacturerId>NOP</manufacturerId>
								<individualPrice>5.0000</individualPrice>
								<listingDate>2011-05-19</listingDate>
								<amountMOHLTCPays>5.0000</amountMOHLTCPays>
							</drug>
							<drug id="02419858" sec3="Y">
								<name>Salbutamol HFA</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>5.0000</individualPrice>
								<listingDate>2020-04-07</listingDate>
								<amountMOHLTCPays>5.0000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="121200013">
							<itemNumber>0398</itemNumber>
							<strength>2mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="01961039" notABenefit="Y" sec3="Y">
								<name>Ventolin</name>
								<manufacturerId>GLA</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02146843" sec3="Y">
								<name>Apo-Salvent</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1274</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1274</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="121200021">
							<itemNumber>0399</itemNumber>
							<strength>4mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="01932691" notABenefit="Y" sec3="Y">
								<name>Ventolin</name>
								<manufacturerId>GLA</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02146851" sec3="Y">
								<name>Apo-Salvent</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2134</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2134</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00254">
					<name>SALMETEROL XINAFOATE</name>
					<pcgGroup lccId="00043">
						<pcg9 id="121200077">
							<itemNumber>0400</itemNumber>
							<strength>50mcg</strength>
							<dosageForm>Pd Inh-60 Dose Pk</dosageForm>
							<drug id="02231129" sec3="Y" sec12="Y">
								<name>SereVent Diskus</name>
								<manufacturerId>GSK</manufacturerId>
								<individualPrice>63.9900</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>63.9900</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="132">For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms.</lccNote>
						<lccNote seq="002" type="N">This drug is not for relief of acute symptoms.</lccNote>
						<lccNote seq="003" type="R">LU Authorization Period: Indefinite.</lccNote>
						<lccNote seq="004" reasonForUseId="391">For patients with moderate to severe COPD with persistent respiratory symptoms despite an adequate trial of, or an intolerance to, a regularly scheduled short-acting bronchodilator AND a long-acting anticholinergic.</lccNote>
						<lccNote seq="005" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="01460">
					<name>SALMETEROL XINAFOATE &amp; FLUTICASONE PROPIONATE</name>
					<pcgGroup lccId="00044">
						<pcg9 id="121200085">
							<itemNumber>0401</itemNumber>
							<strength>25/125mcg/Metered Dose</strength>
							<dosageForm>Inh-120 Dose Pk</dosageForm>
							<drug id="02245126" sec3="Y" sec12="Y">
								<name>Advair 125</name>
								<manufacturerId>GSK</manufacturerId>
								<individualPrice>109.2700</individualPrice>
								<listingDate>2003-01-30</listingDate>
								<amountMOHLTCPays>109.2700</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="121200086">
							<itemNumber>0402</itemNumber>
							<strength>25/250mcg/Metered Dose</strength>
							<dosageForm>Inh-120 Dose Pk</dosageForm>
							<drug id="02245127" sec3="Y" sec12="Y">
								<name>Advair 250</name>
								<manufacturerId>GSK</manufacturerId>
								<individualPrice>155.1300</individualPrice>
								<listingDate>2003-01-30</listingDate>
								<amountMOHLTCPays>155.1300</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="121200083">
							<itemNumber>0403</itemNumber>
							<strength>50/100mcg</strength>
							<dosageForm>Inh-60 Dose Pk</dosageForm>
							<drug id="02240835" sec3="Y" sec12="Y">
								<name>Advair Diskus</name>
								<manufacturerId>GSK</manufacturerId>
								<individualPrice>91.2800</individualPrice>
								<listingDate>2001-10-11</listingDate>
								<amountMOHLTCPays>42.4050</amountMOHLTCPays>
							</drug>
							<drug id="02494507" sec3="Y" sec12="Y">
								<name>PMS-FluticasonePropionateSalmeterol DPI</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>42.4050</individualPrice>
								<listingDate>2020-04-30</listingDate>
								<amountMOHLTCPays>42.4050</amountMOHLTCPays>
							</drug>
							<drug id="02495597" sec3="Y" sec12="Y">
								<name>Wixela Inhub</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>42.4050</individualPrice>
								<listingDate>2020-04-30</listingDate>
								<amountMOHLTCPays>42.4050</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="121200080">
							<itemNumber>0404</itemNumber>
							<strength>50/250mcg</strength>
							<dosageForm>Inh-60 Dose Pk</dosageForm>
							<drug id="02240836" sec3="Y" sec12="Y">
								<name>Advair Diskus</name>
								<manufacturerId>GSK</manufacturerId>
								<individualPrice>109.2700</individualPrice>
								<listingDate>2000-07-17</listingDate>
								<amountMOHLTCPays>50.7600</amountMOHLTCPays>
							</drug>
							<drug id="02494515" sec3="Y" sec12="Y">
								<name>PMS-FluticasonePropionateSalmeterol DPI</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>50.7600</individualPrice>
								<listingDate>2020-04-30</listingDate>
								<amountMOHLTCPays>50.7600</amountMOHLTCPays>
							</drug>
							<drug id="02495600" sec3="Y" sec12="Y">
								<name>Wixela Inhub</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>50.7600</individualPrice>
								<listingDate>2020-03-31</listingDate>
								<amountMOHLTCPays>50.7600</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="121200081">
							<itemNumber>0405</itemNumber>
							<strength>50/500mcg</strength>
							<dosageForm>Inh-60 Dose Pk</dosageForm>
							<drug id="02240837" sec3="Y" sec12="Y">
								<name>Advair Diskus</name>
								<manufacturerId>GSK</manufacturerId>
								<individualPrice>155.1300</individualPrice>
								<listingDate>2000-07-17</listingDate>
								<amountMOHLTCPays>72.0600</amountMOHLTCPays>
							</drug>
							<drug id="02494523" sec3="Y" sec12="Y">
								<name>PMS-FluticasonePropionateSalmeterol DPI</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>72.0600</individualPrice>
								<listingDate>2020-04-30</listingDate>
								<amountMOHLTCPays>72.0600</amountMOHLTCPays>
							</drug>
							<drug id="02495619" sec3="Y" sec12="Y">
								<name>Wixela Inhub</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>72.0600</individualPrice>
								<listingDate>2020-03-31</listingDate>
								<amountMOHLTCPays>72.0600</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="330">For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00245">
					<name>TERBUTALINE SULFATE</name>
					<pcgGroup>
						<pcg9 id="121200047">
							<itemNumber>0406</itemNumber>
							<strength>0.5mg/Dose</strength>
							<dosageForm>Inh-100 Dose Pk</dosageForm>
							<drug id="00786616" sec3="Y">
								<name>Bricanyl Turbuhaler</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>8.4900</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>8.4900</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="121200120">
							<itemNumber>0407</itemNumber>
							<strength>0.5mg/Dose</strength>
							<dosageForm>Inh-120 Dose Pk</dosageForm>
							<drug id="09858138" sec3="Y">
								<name>Bricanyl Turbuhaler</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>10.1880</individualPrice>
								<listingDate>2021-10-29</listingDate>
								<amountMOHLTCPays>10.1880</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01978">
					<name>UMECLIDINIUM &amp; VILANTEROL</name>
					<pcgGroup lccId="00255">
						<pcg9 id="121200109">
							<itemNumber>0408</itemNumber>
							<strength>62.5mcg &amp; 25mcg</strength>
							<dosageForm>Blister Pd Inh-30 Dose Pk</dosageForm>
							<drug id="02418401" sec3="Y" sec12="Y">
								<name>Anoro Ellipta</name>
								<manufacturerId>GSK</manufacturerId>
								<individualPrice>87.5500</individualPrice>
								<listingDate>2015-06-29</listingDate>
								<amountMOHLTCPays>87.5500</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="459">For the long-term treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD-see notes below) who have had an inadequate response to a long-acting bronchodilator (i.e., long-acting beta-2 agonist (LABA), or long-acting muscarinic antagonist (LAMA)).</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: Indefinite.</lccNote>
						<lccNote seq="003" type="N">COPD disease severity is based on spirometry, symptoms and disability (see classification tables below).
Classification
COPD Stages - Symptoms and disability:
Mild: Shortness of breath from COPD when hurrying on the level or walking up a slight hill.
Moderate: Shortness of breath from COPD causing the patient to stop after walking approximately 100m (or after a few minutes) on the level
Severe: Shortness of breath from COPD resulting in the patient being too breathless to leave the house, breathless when dressing or undressing (MRC 5), or the presence of chronic respiratory failure or clinical signs of right heart failure
Classification by impairment of lung function:
COPD stage and spirometry (post bronchodilator) FEV1 predicted:
Mild: Greater than or equal to 80 percent
Moderate: 50 to 79 percent
Severe: 30 to 49 percent
Very severe: Less than 30 percent
</lccNote>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="122000000">
				<name>SKELETAL MUSCLE RELAXANTS</name>
				<note>Muscle relaxants, other than baclofen and dantrolene sodium, are not indicated for spasticity due to cerebral palsy, multiple sclerosis, spinal cord injury, etc.</note>
				<genericName id="00271">
					<name>BACLOFEN</name>
					<pcgGroup>
						<pcg9 id="122000023">
							<itemNumber>0409</itemNumber>
							<strength>2mg/mL</strength>
							<dosageForm>Inj Sol (Preservative-Free)</dosageForm>
							<drug id="02131064" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Lioresal Intrathecal</name>
								<manufacturerId>NOV</manufacturerId>
								<listingDate>2015-08-26</listingDate>
							</drug>
							<drug id="02413647" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Baclofen Intrathecal</name>
								<manufacturerId>STE</manufacturerId>
								<individualPrice>35.4500</individualPrice>
								<listingDate>2015-08-26</listingDate>
								<amountMOHLTCPays>35.4500</amountMOHLTCPays>
							</drug>
							<drug id="02457075" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Baclofen Injection</name>
								<manufacturerId>TEL</manufacturerId>
								<individualPrice>35.4500</individualPrice>
								<listingDate>2019-02-28</listingDate>
								<amountMOHLTCPays>35.4500</amountMOHLTCPays>
							</drug>
							<drug id="02485516" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Baclofen Intrathecal</name>
								<manufacturerId>AVP</manufacturerId>
								<individualPrice>35.4500</individualPrice>
								<listingDate>2021-09-30</listingDate>
								<amountMOHLTCPays>35.4500</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="122000024">
							<itemNumber>0410</itemNumber>
							<strength>0.05mg/mL</strength>
							<dosageForm>Inj Sol-1mL Pk (Preservative-Free)</dosageForm>
							<drug id="02131048" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Lioresal Intrathecal</name>
								<manufacturerId>NOV</manufacturerId>
								<listingDate>2015-08-26</listingDate>
							</drug>
							<drug id="02413620" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Baclofen Injection</name>
								<manufacturerId>STE</manufacturerId>
								<individualPrice>11.2500</individualPrice>
								<listingDate>2015-08-26</listingDate>
								<amountMOHLTCPays>11.2500</amountMOHLTCPays>
							</drug>
							<drug id="02457059" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Baclofen Injection</name>
								<manufacturerId>TEL</manufacturerId>
								<individualPrice>11.2500</individualPrice>
								<listingDate>2019-02-28</listingDate>
								<amountMOHLTCPays>11.2500</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="122000022">
							<itemNumber>0411</itemNumber>
							<strength>0.5mg/mL</strength>
							<dosageForm>Inj Sol-20mL Pk (Preservative-Free)</dosageForm>
							<drug id="02131056" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Lioresal Intrathecal</name>
								<manufacturerId>NOV</manufacturerId>
								<listingDate>2015-08-26</listingDate>
							</drug>
							<drug id="02413639" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Baclofen Intrathecal</name>
								<manufacturerId>STE</manufacturerId>
								<individualPrice>177.2500</individualPrice>
								<listingDate>2015-08-26</listingDate>
								<amountMOHLTCPays>177.2500</amountMOHLTCPays>
							</drug>
							<drug id="02457067" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Baclofen Injection</name>
								<manufacturerId>TEL</manufacturerId>
								<individualPrice>177.2500</individualPrice>
								<listingDate>2019-02-28</listingDate>
								<amountMOHLTCPays>177.2500</amountMOHLTCPays>
							</drug>
							<drug id="02485508" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Baclofen Intrathecal</name>
								<manufacturerId>AVP</manufacturerId>
								<individualPrice>177.2500</individualPrice>
								<listingDate>2021-09-30</listingDate>
								<amountMOHLTCPays>177.2500</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="122000003">
							<itemNumber>0412</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00455881" sec3="Y">
								<name>Lioresal</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>.8795</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1595</amountMOHLTCPays>
							</drug>
							<drug id="02063735" sec3="Y">
								<name>PMS-Baclofen</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1595</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1595</amountMOHLTCPays>
							</drug>
							<drug id="02088398" sec3="Y">
								<name>Mylan-Baclofen</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.1595</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1595</amountMOHLTCPays>
							</drug>
							<drug id="02139332" sec3="Y">
								<name>Apo-Baclofen</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1595</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1595</amountMOHLTCPays>
							</drug>
							<drug id="02236507" sec3="Y">
								<name>Ratio-Baclofen</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>.1595</individualPrice>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>.1595</amountMOHLTCPays>
							</drug>
							<drug id="02287021" sec3="Y">
								<name>Baclofen</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.1595</individualPrice>
								<listingDate>2011-09-15</listingDate>
								<amountMOHLTCPays>.1595</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="122000006">
							<itemNumber>0413</itemNumber>
							<strength>20mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00636576" sec3="Y">
								<name>Lioresal DS</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>1.7122</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3104</amountMOHLTCPays>
							</drug>
							<drug id="02063743" sec3="Y">
								<name>PMS-Baclofen</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3104</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3104</amountMOHLTCPays>
							</drug>
							<drug id="02088401" sec3="Y">
								<name>Mylan-Baclofen</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.3104</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3104</amountMOHLTCPays>
							</drug>
							<drug id="02139391" sec3="Y">
								<name>Apo-Baclofen</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3104</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3104</amountMOHLTCPays>
							</drug>
							<drug id="02236508" sec3="Y">
								<name>Ratio-Baclofen</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>.3104</individualPrice>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>.3104</amountMOHLTCPays>
							</drug>
							<drug id="02287048" sec3="Y">
								<name>Baclofen</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.3104</individualPrice>
								<listingDate>2011-09-15</listingDate>
								<amountMOHLTCPays>.3104</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00272">
					<name>CYCLOBENZAPRINE HCL</name>
					<pcgGroup>
						<pcg9 id="122000005">
							<itemNumber>0414</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00782742" notABenefit="Y" sec3="Y">
								<name>Flexeril</name>
								<manufacturerId>FRS</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02080052" notABenefit="Y" sec3="Y">
								<name>Teva-Cyclobenzaprine HCL</name>
								<manufacturerId>TEV</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02177145" notABenefit="Y" sec3="Y">
								<name>Apo-Cyclobenzaprine</name>
								<manufacturerId>APX</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02212048" notABenefit="Y" sec3="Y">
								<name>PMS-Cyclobenzaprine</name>
								<manufacturerId>PMS</manufacturerId>
								<listingDate>1996-12-19</listingDate>
							</drug>
							<drug id="02236506" notABenefit="Y" sec3="Y">
								<name>Ratio-Cyclobenzaprine</name>
								<manufacturerId>RPH</manufacturerId>
								<listingDate>1999-09-15</listingDate>
							</drug>
							<drug id="02287064" notABenefit="Y" sec3="Y">
								<name>Cyclobenzaprine</name>
								<manufacturerId>SAI</manufacturerId>
								<listingDate>2011-08-04</listingDate>
							</drug>
							<drug id="02348853" notABenefit="Y" sec3="Y">
								<name>Auro-Cyclobenzaprine</name>
								<manufacturerId>AUR</manufacturerId>
								<listingDate>2011-12-15</listingDate>
							</drug>
							<drug id="02357127" notABenefit="Y" sec3="Y">
								<name>Jamp-Cyclobenzaprine</name>
								<manufacturerId>JPC</manufacturerId>
								<listingDate>2012-11-27</listingDate>
							</drug>
							<drug id="02424584" notABenefit="Y" sec3="Y">
								<name>Cyclobenzaprine</name>
								<manufacturerId>SIV</manufacturerId>
								<listingDate>2020-08-28</listingDate>
							</drug>
							<drug id="02485419" notABenefit="Y" sec3="Y">
								<name>AG-Cyclobenzaprine</name>
								<manufacturerId>ANG</manufacturerId>
								<listingDate>2020-12-18</listingDate>
							</drug>
							<drug id="02495422" notABenefit="Y" sec3="Y">
								<name>Flexeril</name>
								<manufacturerId>ORI</manufacturerId>
								<listingDate>2020-06-30</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00270">
					<name>DANTROLENE SODIUM</name>
					<pcgGroup>
						<pcg9 id="122000002">
							<itemNumber>0415</itemNumber>
							<strength>25mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="01997602" sec3="Y">
								<name>Dantrium Capsules</name>
								<manufacturerId>EPI</manufacturerId>
								<individualPrice>.5484</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.5484</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00273">
					<name>ORPHENADRINE CITRATE</name>
					<pcgGroup>
						<pcg9 id="122000007">
							<itemNumber>0416</itemNumber>
							<strength>60mg/2mL</strength>
							<dosageForm>Inj Sol-2mL Pk</dosageForm>
							<drug id="01966162" notABenefit="Y" sec3="Y">
								<name>Norflex</name>
								<manufacturerId>MMH</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02229731" notABenefit="Y" sec3="Y">
								<name>Orphenadrine</name>
								<manufacturerId>CYI</manufacturerId>
								<listingDate>1998-12-31</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01453">
					<name>TIZANIDINE HCL</name>
					<pcgGroup>
						<pcg9 id="122000025">
							<itemNumber>0417</itemNumber>
							<strength>4mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02239170" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Zanaflex</name>
								<manufacturerId>ELA</manufacturerId>
								<listingDate>2007-06-06</listingDate>
							</drug>
							<drug id="02259893" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Tizanidine</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.7694</individualPrice>
								<listingDate>2007-06-06</listingDate>
								<amountMOHLTCPays>.7694</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
			</pcg6>
		</pcg2>
		<pcg2 id="200000000">
			<name>BLOOD FORMATION AND COAGULATION</name>
			<pcg6 id="200400000">
				<name>ANTIANEMIA DRUGS</name>
				<genericName id="02193">
					<name>FERRIC DERISOMALTOSE</name>
					<pcgGroup lccId="00357">
						<pcg9 id="200400027">
							<itemNumber>0418</itemNumber>
							<strength>100mg elemental iron/mL</strength>
							<dosageForm>Inj Sol (Preservative-Free)</dosageForm>
							<drug id="02477777" sec3="Y" sec12="Y">
								<name>Monoferric</name>
								<manufacturerId>PHC</manufacturerId>
								<individualPrice>45.0000</individualPrice>
								<listingDate>2021-02-26</listingDate>
								<amountMOHLTCPays>45.0000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="610">For the treatment of patients with Iron Deficiency Anemia (IDA) who meet ALL the following criteria:
- Patient has documented diagnosis of IDA confirmed by laboratory testing results (e.g. hemoglobin, ferritin); AND
- Patient&apos;s IDA has experienced a failure to respond, documented intolerance, or contraindication to an adequate trial (i.e. at least 4 weeks) of at least one oral iron therapy; AND
- Patient does not have hemochromatosis or other iron storage disorders; AND
- Monoferric is administered in a setting where appropriate monitoring and management of hypersensitivity reactions can be provided to the Patient.
</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00282">
					<name>FERROUS FUMARATE</name>
					<pcgGroup>
						<pcg9 id="200400013">
							<itemNumber>0419</itemNumber>
							<strength>300mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="01923420" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Palafer</name>
								<manufacturerId>GSK</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02237556" chronicUseMed="Y" sec3="Y">
								<name>Euro-Fer</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.1057</individualPrice>
								<listingDate>2006-07-19</listingDate>
								<amountMOHLTCPays>.1057</amountMOHLTCPays>
							</drug>
							<drug id="80024232" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Fer</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1057</individualPrice>
								<listingDate>2016-01-28</listingDate>
								<amountMOHLTCPays>.1057</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="200400003">
							<itemNumber>0420</itemNumber>
							<strength>60mg/mL</strength>
							<dosageForm>O/L</dosageForm>
							<drug id="01923439" sec3="Y">
								<name>Palafer</name>
								<manufacturerId>GSK</manufacturerId>
								<individualPrice>.0900</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0900</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00283">
					<name>FERROUS GLUCONATE</name>
					<pcgGroup>
						<pcg9 id="200400004" suppliedBy="L">
							<itemNumber>0421</itemNumber>
							<strength>300mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00031097" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Ferrous Gluconate</name>
								<manufacturerId>JPC</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00545031" selfMed="Y" chronicUseMed="Y" sec3="Y">
								<name>Ferrous Gluconate 300mg</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.0360</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0360</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00284">
					<name>FERROUS SULFATE</name>
					<pcgGroup>
						<pcg9 id="200400007">
							<itemNumber>0422</itemNumber>
							<strength>75mg/mL</strength>
							<dosageForm>O/L</dosageForm>
							<drug id="00762954" sec3="Y">
								<name>Fer-In-Sol</name>
								<manufacturerId>MJS</manufacturerId>
								<individualPrice>.2436</individualPrice>
								<listingDate>1997-01-03</listingDate>
								<amountMOHLTCPays>.2436</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01544">
					<name>IRON SUCROSE</name>
					<pcgGroup>
						<pcg9 id="200400023">
							<itemNumber>0423</itemNumber>
							<strength>20mg/mL</strength>
							<dosageForm>Inj Sol-5mL Pk (Preservative-Free)</dosageForm>
							<drug id="02243716" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Venofer</name>
								<manufacturerId>LUI</manufacturerId>
								<listingDate>2021-03-29</listingDate>
							</drug>
							<drug id="02502917" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>PMS-Iron Sucrose</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>27.5000</individualPrice>
								<listingDate>2021-03-29</listingDate>
								<amountMOHLTCPays>27.5000</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="201200000">
				<name>COAGULANTS AND ANTI-COAGULANTS</name>
				<genericName id="01922">
					<name>APIXABAN</name>
					<pcgGroup lccId="00239">
						<pcg9 id="201200089">
							<itemNumber>0424</itemNumber>
							<strength>2.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02377233" sec3="Y" sec12="Y">
								<name>Eliquis</name>
								<manufacturerId>BQU</manufacturerId>
								<individualPrice>1.6336</individualPrice>
								<listingDate>2013-08-29</listingDate>
								<amountMOHLTCPays>1.6336</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="433">For the prevention of venous thromboembolic events in patients who have undergone elective total knee replacement (TKR) surgery.
Note: Limited to 14 days of reimbursement in TKR. Limited to 1 claim in a 120 day period.
</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="003" reasonForUseId="434">For the prevention of venous thromboembolic events in patients who have undergone elective total hip replacement (THR).
Note: Limited to 35 days of reimbursement in THR. Limited to 1 claim in a 120 day period.
</lccNote>
						<lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
					<pcgGroup lccId="00242">
						<pcg9 id="201200094">
							<itemNumber>0425</itemNumber>
							<strength>2.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="09857463" sec3="Y" sec12="Y">
								<name>Eliquis</name>
								<manufacturerId>BQU</manufacturerId>
								<individualPrice>1.6336</individualPrice>
								<listingDate>2014-04-03</listingDate>
								<amountMOHLTCPays>1.6336</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="448">INCLUSION CRITERIA:
At risk patients with non-valvular atrial fibrillation, for the prevention of stroke and systemic embolism AND in whom:
1. Anticoagulation is inadequate following at least a 2-month trial on warfarin; OR
2. Anticoagulation using warfarin is contraindicated or not possible due to inability to regularly monitor the patient via International Normalized Ratio (INR) testing (i.e. no access to INR testing services at a laboratory, clinic, pharmacy, and at home)
EXCLUSION CRITERIA:
1. Patients with impaired renal function (creatinine clearance or estimated glomerular filtration rate less than 25mL per min); OR
2. Patients who are greater than or equal to 75 years of age and who do not have documented stable renal function; OR
3. Patients who have hemodynamically significant rheumatoid valvular heart disease (especially mitral stenosis); OR
4. Patients who have prosthetic heart valves.
NOTES:
At-risk patients with atrial fibrillation are defined as those with a CHADS2 score of greater than or equal to 1. Prescribers may consider an antiplatelet regimen or oral anticoagulation for patients with a CHADS2 score of 1.
Inadequate anticoagulation is defined as INR testing results that are outside the desired INR range for at least 35% of the tests during the monitoring period (i.e., adequate anticoagulation is defined as INR test results that are within the desired INR range for at least 65% of the tests during the monitoring period).
Documented stable renal function is defined as creatinine clearance or estimated glomerular filtration rate maintained for at least 3 months.
DOSING: the usual recommended dose is 5mg twice daily; a reduced dose of apixaban 2.5mg twice daily is recommended for patients with at least two (2) of the following: age greater than or equal to 80 years old, body weight less than or equal to 60kg, or serum creatinine greater than or equal to 133 micromole per litre.
Since renal impairment can increase bleeding risk, renal function should be regularly monitored. Other factors that increase bleeding risk should also be assessed and monitored (see apixaban product monograph).
Patients starting apixaban should have ready access to appropriate medical services to manage a major bleeding event.
There is currently no data to support that apixaban provides adequate anticoagulation in patients with rheumatic valvular disease or those with prosthetic heart valves. As a result, apixaban is not recommended for these patient populations.
</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: Indefinite.</lccNote>
						<lccNote seq="003" reasonForUseId="444">For the treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE) for up to six (6) months.</lccNote>
						<lccNote seq="004" type="R">LU Authorization Period: 6 Months.</lccNote>
						<lccNote seq="005" type="N">- The recommended dose of apixaban for patients initiating DVT or PE treatment is 10 mg twice daily for 7 days, followed by 5 mg twice daily.
- ODB Program coverage for apixaban is an alternative to heparin/warfarin for up to 6 months. When used for greater than 6 months, apixaban is more costly than heparin/warfarin. As such, patients with an intended duration of therapy greater than 6 months should be considered for initiation on heparin/warfarin.
- For clarity, coverage will not be provided for patients who have already received 6 months of treatment with rivaroxaban for the same DVT or PE.
- Since renal impairment can increase bleeding risk, it is important to monitor renal function regularly. Other factors that increase bleeding risks should also be assessed and monitored (see product monograph).</lccNote>
					</pcgGroup>
					<pcgGroup lccId="00237">
						<pcg9 id="201200090">
							<itemNumber>0426</itemNumber>
							<strength>5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02397714" sec3="Y" sec12="Y">
								<name>Eliquis</name>
								<manufacturerId>BQU</manufacturerId>
								<individualPrice>1.6336</individualPrice>
								<listingDate>2013-08-29</listingDate>
								<amountMOHLTCPays>1.6336</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="448">INCLUSION CRITERIA:
At risk patients with non-valvular atrial fibrillation, for the prevention of stroke and systemic embolism AND in whom:
1. Anticoagulation is inadequate following at least a 2-month trial on warfarin; OR
2. Anticoagulation using warfarin is contraindicated or not possible due to inability to regularly monitor the patient via International Normalized Ratio (INR) testing (i.e. no access to INR testing services at a laboratory, clinic, pharmacy, and at home)
EXCLUSION CRITERIA:
1. Patients with impaired renal function (creatinine clearance or estimated glomerular filtration rate less than 25mL per min); OR
2. Patients who are greater than or equal to 75 years of age and who do not have documented stable renal function; OR
3. Patients who have hemodynamically significant rheumatoid valvular heart disease (especially mitral stenosis); OR
4. Patients who have prosthetic heart valves.
NOTES:
At-risk patients with atrial fibrillation are defined as those with a CHADS2 score of greater than or equal to 1. Prescribers may consider an antiplatelet regimen or oral anticoagulation for patients with a CHADS2 score of 1.
Inadequate anticoagulation is defined as INR testing results that are outside the desired INR range for at least 35% of the tests during the monitoring period (i.e., adequate anticoagulation is defined as INR test results that are within the desired INR range for at least 65% of the tests during the monitoring period).
Documented stable renal function is defined as creatinine clearance or estimated glomerular filtration rate maintained for at least 3 months.
DOSING: the usual recommended dose is 5mg twice daily; a reduced dose of apixaban 2.5mg twice daily is recommended for patients with at least two (2) of the following: age greater than or equal to 80 years old, body weight less than or equal to 60kg, or serum creatinine greater than or equal to 133 micromole per litre.
Since renal impairment can increase bleeding risk, renal function should be regularly monitored. Other factors that increase bleeding risk should also be assessed and monitored (see apixaban product monograph).
Patients starting apixaban should have ready access to appropriate medical services to manage a major bleeding event.
There is currently no data to support that apixaban provides adequate anticoagulation in patients with rheumatic valvular disease or those with prosthetic heart valves. As a result, apixaban is not recommended for these patient populations.
</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: Indefinite.</lccNote>
						<lccNote seq="003" reasonForUseId="444">For the treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE) for up to six (6) months.</lccNote>
						<lccNote seq="004" type="R">LU Authorization Period: 6 Months.</lccNote>
						<lccNote seq="005" type="N">- The recommended dose of apixaban for patients initiating DVT or PE treatment is 10 mg twice daily for 7 days, followed by 5 mg twice daily.
- ODB Program coverage for apixaban is an alternative to heparin/warfarin for up to 6 months. When used for greater than 6 months, apixaban is more costly than heparin/warfarin. As such, patients with an intended duration of therapy greater than 6 months should be considered for initiation on heparin/warfarin.
- For clarity, coverage will not be provided for patients who have already received 6 months of treatment with rivaroxaban for the same DVT or PE.
- Since renal impairment can increase bleeding risk, it is important to monitor renal function regularly. Other factors that increase bleeding risks should also be assessed and monitored (see product monograph).</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="01882">
					<name>DABIGATRAN ETEXILATE</name>
					<pcgGroup>
						<pcg9 id="201200098">
							<itemNumber>0427</itemNumber>
							<strength>75mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02312433" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Pradaxa</name>
								<manufacturerId>BOE</manufacturerId>
								<listingDate>2019-10-31</listingDate>
							</drug>
							<drug id="02468891" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Dabigatran</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.4552</individualPrice>
								<listingDate>2019-10-31</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
					<pcgGroup lccId="00222">
						<pcg9 id="201200084">
							<itemNumber>0428</itemNumber>
							<strength>110mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02312441" sec3="Y" sec12="Y">
								<name>Pradaxa</name>
								<manufacturerId>BOE</manufacturerId>
								<individualPrice>1.7121</individualPrice>
								<listingDate>2012-04-24</listingDate>
								<amountMOHLTCPays>1.2540</amountMOHLTCPays>
							</drug>
							<drug id="02468905" sec3="Y" sec12="Y">
								<name>Apo-Dabigatran</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.2540</individualPrice>
								<listingDate>2019-05-31</listingDate>
								<amountMOHLTCPays>1.2540</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200085">
							<itemNumber>0429</itemNumber>
							<strength>150mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02358808" sec3="Y" sec12="Y">
								<name>Pradaxa</name>
								<manufacturerId>BOE</manufacturerId>
								<individualPrice>1.7121</individualPrice>
								<listingDate>2012-04-24</listingDate>
								<amountMOHLTCPays>1.2540</amountMOHLTCPays>
							</drug>
							<drug id="02468913" sec3="Y" sec12="Y">
								<name>Apo-Dabigatran</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.2540</individualPrice>
								<listingDate>2019-05-31</listingDate>
								<amountMOHLTCPays>1.2540</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="431">For the prevention of stroke and systemic embolism in at risk patients with non-valvular atrial fibrillation (AF), AND in whom:
1) Anticoagulation is inadequate following a reasonable trial on warfarin; OR
2) Anticoagulation with warfarin is contraindicated or not possible due to inability to regularly monitor via International Normalized Ratio (INR) testing (i.e., no access to INR testing services at a laboratory, clinic, pharmacy, and at home).
Exclusion Criteria:
Impaired renal function (creatinine clearance or estimated glomerular filtration rate less than 30mL/min); OR greater than or equal to 75 years of age without documented stable renal function; OR hemodynamically significant rheumatic valvular heart disease, especially mitral stenosis; OR prosthetic heart valves.
Note:
(a) Documented stable renal function is defined as creatinine clearance or estimated glomerular filtration rate maintained for at least 3 months (i.e., 30-49mL/min for 110mg twice daily dosing and, greater than or equal to 50mL/min for 150mg twice daily dosing for at least 3 months).
(b) At risk patients with atrial fibrillation are defined as those with a CHADS2 score of greater than or equal to 1.
(c) Inadequate anticoagulation is defined as INR testing results that are outside of the desired INR range for at least 35% of the tests during the monitoring period (i.e., adequate anticoagulation is defined as INR test results that are within the desired INR range for at least 65% of the tests during the monitoring period).
(d) A reasonable trial on warfarin is defined as at least 2 months of therapy.
(e) Since renal impairment can increase bleeding risk, renal function should be regularly monitored. Other factors that increase bleeding risk should also be assessed and monitored (see product monograph).
(f) Patients starting dabigatran should have ready access to appropriate medical services to manage a major bleeding event.
(g) There are currently no data to support that dabigatran provides adequate anticoagulation in patients with rheumatic valvular disease or those with prosthetic heart valves; dabigatran is not recommended in these populations.
</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00298">
					<name>DALTEPARIN SODIUM</name>
					<pcgGroup lccId="00045">
						<pcg9 id="201200099">
							<itemNumber>0430</itemNumber>
							<strength>3500IU/0.28mL</strength>
							<dosageForm>Inj Pref Syr</dosageForm>
							<drug id="02430789" sec3="Y" sec12="Y">
								<name>Fragmin</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>8.1000</individualPrice>
								<listingDate>2016-03-30</listingDate>
								<amountMOHLTCPays>8.1000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200083">
							<itemNumber>0431</itemNumber>
							<strength>7500IU/0.3mL</strength>
							<dosageForm>Inj Pref Syr</dosageForm>
							<drug id="02352648" sec3="Y" sec12="Y">
								<name>Fragmin</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>17.3560</individualPrice>
								<listingDate>2012-02-29</listingDate>
								<amountMOHLTCPays>17.3560</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200038">
							<itemNumber>0432</itemNumber>
							<strength>2500IU/0.2mL</strength>
							<dosageForm>Inj Pref Syr</dosageForm>
							<drug id="02132621" sec3="Y" sec12="Y">
								<name>Fragmin</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>5.7870</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>5.7870</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200040">
							<itemNumber>0433</itemNumber>
							<strength>5000IU/0.2mL</strength>
							<dosageForm>Inj Pref Syr</dosageForm>
							<drug id="02132648" sec3="Y" sec12="Y">
								<name>Fragmin</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>11.5720</individualPrice>
								<listingDate>1997-04-10</listingDate>
								<amountMOHLTCPays>11.5720</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200064">
							<itemNumber>0434</itemNumber>
							<strength>10000IU/0.4mL</strength>
							<dosageForm>Inj Pref Syr</dosageForm>
							<drug id="02352656" sec3="Y" sec12="Y">
								<name>Fragmin</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>23.1440</individualPrice>
								<listingDate>2011-03-15</listingDate>
								<amountMOHLTCPays>23.1440</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200065">
							<itemNumber>0435</itemNumber>
							<strength>12500IU/0.5mL</strength>
							<dosageForm>Inj Pref Syr</dosageForm>
							<drug id="02352664" sec3="Y" sec12="Y">
								<name>Fragmin</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>28.9280</individualPrice>
								<listingDate>2011-03-15</listingDate>
								<amountMOHLTCPays>28.9280</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200066">
							<itemNumber>0436</itemNumber>
							<strength>15000IU/0.6mL</strength>
							<dosageForm>Inj Pref Syr</dosageForm>
							<drug id="02352672" sec3="Y" sec12="Y">
								<name>Fragmin</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>34.7120</individualPrice>
								<listingDate>2011-03-15</listingDate>
								<amountMOHLTCPays>34.7120</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200067">
							<itemNumber>0437</itemNumber>
							<strength>18000IU/0.72mL</strength>
							<dosageForm>Inj Pref Syr</dosageForm>
							<drug id="02352680" sec3="Y" sec12="Y">
								<name>Fragmin</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>41.6560</individualPrice>
								<listingDate>2011-03-15</listingDate>
								<amountMOHLTCPays>41.6560</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200105">
							<itemNumber>0438</itemNumber>
							<strength>16500IU/0.66mL</strength>
							<dosageForm>Inj Pref Syr-0.66mL Pk</dosageForm>
							<drug id="02494582" sec3="Y" sec12="Y">
								<name>Fragmin</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>38.1845</individualPrice>
								<listingDate>2021-02-26</listingDate>
								<amountMOHLTCPays>38.1845</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200037">
							<itemNumber>0439</itemNumber>
							<strength>10000IU/mL</strength>
							<dosageForm>Inj Sol-1mL Pk</dosageForm>
							<drug id="02132664" sec3="Y" sec12="Y">
								<name>Fragmin</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>18.2710</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>18.2710</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200043">
							<itemNumber>0440</itemNumber>
							<strength>25000IU/mL</strength>
							<dosageForm>Multidose 3.8mL Pk</dosageForm>
							<drug id="02231171" sec3="Y" sec12="Y">
								<name>Fragmin</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>173.5600</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>173.5600</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="186">For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="003" reasonForUseId="187">For DVT in pregnant or lactating females;</lccNote>
						<lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="005" reasonForUseId="188">For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;</lccNote>
						<lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="007" reasonForUseId="189">For DVT in patients who have failed treatment with warfarin.</lccNote>
						<lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="01229">
					<name>ENOXAPARIN</name>
					<pcgGroup>
						<pcg9 id="201200121">
							<itemNumber>0441</itemNumber>
							<strength>20mg/0.2mL</strength>
							<dosageForm>Inj Sol-0.2mL Pref Syr (Preservative-Free)</dosageForm>
							<drug id="02506440" sec3="Y">
								<name>Noromby</name>
								<manufacturerId>JUN</manufacturerId>
								<individualPrice>3.5280</individualPrice>
								<listingDate>2021-06-30</listingDate>
								<amountMOHLTCPays>3.5280</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200106">
							<itemNumber>0442</itemNumber>
							<strength>30mg/0.3mL</strength>
							<dosageForm>Inj Sol-0.3mL Pref Syr (Preservative-Free)</dosageForm>
							<drug id="02509075" sec3="Y">
								<name>Redesca</name>
								<manufacturerId>SHE</manufacturerId>
								<individualPrice>4.9620</individualPrice>
								<listingDate>2021-04-30</listingDate>
								<amountMOHLTCPays>4.9620</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200114">
							<itemNumber>0443</itemNumber>
							<strength>30mg/0.3mL</strength>
							<dosageForm>Inj Sol-0.3mL Pref Syr (Preservative-Free)</dosageForm>
							<drug id="02507501" sec3="Y">
								<name>Inclunox</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>4.9620</individualPrice>
								<listingDate>2021-05-31</listingDate>
								<amountMOHLTCPays>4.9620</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200122">
							<itemNumber>0444</itemNumber>
							<strength>30mg/0.3mL</strength>
							<dosageForm>Inj Sol-0.3mL Pref Syr (Preservative-Free)</dosageForm>
							<drug id="02506459" sec3="Y">
								<name>Noromby</name>
								<manufacturerId>JUN</manufacturerId>
								<individualPrice>4.9620</individualPrice>
								<listingDate>2021-06-30</listingDate>
								<amountMOHLTCPays>4.9620</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200107">
							<itemNumber>0445</itemNumber>
							<strength>40mg/0.4mL</strength>
							<dosageForm>Inj Sol-0.4mL Pref Syr (Preservative-Free)</dosageForm>
							<drug id="02509083" sec3="Y">
								<name>Redesca</name>
								<manufacturerId>SHE</manufacturerId>
								<individualPrice>6.6160</individualPrice>
								<listingDate>2021-04-30</listingDate>
								<amountMOHLTCPays>6.6160</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200115">
							<itemNumber>0446</itemNumber>
							<strength>40mg/0.4mL</strength>
							<dosageForm>Inj Sol-0.4mL Pref Syr (Preservative-Free)</dosageForm>
							<drug id="02507528" sec3="Y">
								<name>Inclunox</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>6.6160</individualPrice>
								<listingDate>2021-05-31</listingDate>
								<amountMOHLTCPays>6.6160</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200123">
							<itemNumber>0447</itemNumber>
							<strength>40mg/0.4mL</strength>
							<dosageForm>Inj Sol-0.4mL Pref Syr (Preservative-Free)</dosageForm>
							<drug id="02506467" sec3="Y">
								<name>Noromby</name>
								<manufacturerId>JUN</manufacturerId>
								<individualPrice>6.6160</individualPrice>
								<listingDate>2021-06-30</listingDate>
								<amountMOHLTCPays>6.6160</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200108">
							<itemNumber>0448</itemNumber>
							<strength>60mg/0.6mL</strength>
							<dosageForm>Inj Sol-0.6mL Pref Syr (Preservative-Free)</dosageForm>
							<drug id="02509091" sec3="Y">
								<name>Redesca</name>
								<manufacturerId>SHE</manufacturerId>
								<individualPrice>9.9240</individualPrice>
								<listingDate>2021-04-30</listingDate>
								<amountMOHLTCPays>9.9240</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200116">
							<itemNumber>0449</itemNumber>
							<strength>60mg/0.6mL</strength>
							<dosageForm>Inj Sol-0.6mL Pref Syr (Preservative-Free)</dosageForm>
							<drug id="02507536" sec3="Y">
								<name>Inclunox</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>9.9240</individualPrice>
								<listingDate>2021-05-31</listingDate>
								<amountMOHLTCPays>9.9240</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200124">
							<itemNumber>0450</itemNumber>
							<strength>60mg/0.6mL</strength>
							<dosageForm>Inj Sol-0.6mL Pref Syr (Preservative-Free)</dosageForm>
							<drug id="02506475" sec3="Y">
								<name>Noromby</name>
								<manufacturerId>JUN</manufacturerId>
								<individualPrice>9.9240</individualPrice>
								<listingDate>2021-06-30</listingDate>
								<amountMOHLTCPays>9.9240</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200109">
							<itemNumber>0451</itemNumber>
							<strength>80mg/0.8mL</strength>
							<dosageForm>Inj Sol-0.8mL Pref Syr (Preservative-Free)</dosageForm>
							<drug id="02509105" sec3="Y">
								<name>Redesca</name>
								<manufacturerId>SHE</manufacturerId>
								<individualPrice>13.2320</individualPrice>
								<listingDate>2021-04-30</listingDate>
								<amountMOHLTCPays>13.2320</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200117">
							<itemNumber>0452</itemNumber>
							<strength>80mg/0.8mL</strength>
							<dosageForm>Inj Sol-0.8mL Pref Syr (Preservative-Free)</dosageForm>
							<drug id="02507544" sec3="Y">
								<name>Inclunox</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>13.2320</individualPrice>
								<listingDate>2021-05-31</listingDate>
								<amountMOHLTCPays>13.2320</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200125">
							<itemNumber>0453</itemNumber>
							<strength>80mg/0.8mL</strength>
							<dosageForm>Inj Sol-0.8mL Pref Syr (Preservative-Free)</dosageForm>
							<drug id="02506483" sec3="Y">
								<name>Noromby</name>
								<manufacturerId>JUN</manufacturerId>
								<individualPrice>13.2320</individualPrice>
								<listingDate>2021-06-30</listingDate>
								<amountMOHLTCPays>13.2320</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200111">
							<itemNumber>0454</itemNumber>
							<strength>120mg/0.8mL</strength>
							<dosageForm>Inj Sol-0.8mL Pref Syr (Preservative-Free)</dosageForm>
							<drug id="02509148" sec3="Y">
								<name>Redesca HP</name>
								<manufacturerId>SHE</manufacturerId>
								<individualPrice>19.8480</individualPrice>
								<listingDate>2021-04-30</listingDate>
								<amountMOHLTCPays>19.8480</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200119">
							<itemNumber>0455</itemNumber>
							<strength>120mg/0.8mL</strength>
							<dosageForm>Inj Sol-0.8mL Pref Syr (Preservative-Free)</dosageForm>
							<drug id="02507560" sec3="Y">
								<name>Inclunox HP</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>19.8480</individualPrice>
								<listingDate>2021-05-31</listingDate>
								<amountMOHLTCPays>19.8480</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200127">
							<itemNumber>0456</itemNumber>
							<strength>120mg/0.8mL</strength>
							<dosageForm>Inj Sol-0.8mL Pref Syr (Preservative-Free)</dosageForm>
							<drug id="02506505" sec3="Y">
								<name>Noromby HP</name>
								<manufacturerId>JUN</manufacturerId>
								<individualPrice>19.8480</individualPrice>
								<listingDate>2021-06-30</listingDate>
								<amountMOHLTCPays>19.8480</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200110">
							<itemNumber>0457</itemNumber>
							<strength>100mg/mL</strength>
							<dosageForm>Inj Sol-1mL Pref Syr (Preservative-Free)</dosageForm>
							<drug id="02509113" sec3="Y">
								<name>Redesca</name>
								<manufacturerId>SHE</manufacturerId>
								<individualPrice>16.5400</individualPrice>
								<listingDate>2021-04-30</listingDate>
								<amountMOHLTCPays>16.5400</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200118">
							<itemNumber>0458</itemNumber>
							<strength>100mg/mL</strength>
							<dosageForm>Inj Sol-1mL Pref Syr (Preservative-Free)</dosageForm>
							<drug id="02507552" sec3="Y">
								<name>Inclunox</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>16.5400</individualPrice>
								<listingDate>2021-05-31</listingDate>
								<amountMOHLTCPays>16.5400</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200126">
							<itemNumber>0459</itemNumber>
							<strength>100mg/mL</strength>
							<dosageForm>Inj Sol-1mL Pref Syr (Preservative-Free)</dosageForm>
							<drug id="02506491" sec3="Y">
								<name>Noromby</name>
								<manufacturerId>JUN</manufacturerId>
								<individualPrice>16.5400</individualPrice>
								<listingDate>2021-06-30</listingDate>
								<amountMOHLTCPays>16.5400</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200112">
							<itemNumber>0460</itemNumber>
							<strength>150mg/mL</strength>
							<dosageForm>Inj Sol-1mL Pref Syr (Preservative-Free)</dosageForm>
							<drug id="02509156" sec3="Y">
								<name>Redesca HP</name>
								<manufacturerId>SHE</manufacturerId>
								<individualPrice>24.8100</individualPrice>
								<listingDate>2021-04-30</listingDate>
								<amountMOHLTCPays>24.8100</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200120">
							<itemNumber>0461</itemNumber>
							<strength>150mg/mL</strength>
							<dosageForm>Inj Sol-1mL Pref Syr (Preservative-Free)</dosageForm>
							<drug id="02507579" sec3="Y">
								<name>Inclunox HP</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>24.8100</individualPrice>
								<listingDate>2021-05-31</listingDate>
								<amountMOHLTCPays>24.8100</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200128">
							<itemNumber>0462</itemNumber>
							<strength>150mg/mL</strength>
							<dosageForm>Inj Sol-1mL Pref Syr (Preservative-Free)</dosageForm>
							<drug id="02506513" sec3="Y">
								<name>Noromby HP</name>
								<manufacturerId>JUN</manufacturerId>
								<individualPrice>24.8100</individualPrice>
								<listingDate>2021-06-30</listingDate>
								<amountMOHLTCPays>24.8100</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200113">
							<itemNumber>0463</itemNumber>
							<strength>300mg/3mL</strength>
							<dosageForm>Inj Sol-3mL Vial Pk (With Preservative)</dosageForm>
							<drug id="02509121" sec3="Y">
								<name>Redesca</name>
								<manufacturerId>SHE</manufacturerId>
								<individualPrice>49.6200</individualPrice>
								<listingDate>2021-04-30</listingDate>
								<amountMOHLTCPays>49.6200</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
					<pcgGroup lccId="00046">
						<pcg9 id="201200070">
							<itemNumber>0464</itemNumber>
							<strength>100mg/mL</strength>
							<dosageForm>Inj Sol-3mLVial Pk</dosageForm>
							<drug id="02236564" sec3="Y" sec12="Y">
								<name>Lovenox</name>
								<manufacturerId>SAV</manufacturerId>
								<individualPrice>66.1700</individualPrice>
								<listingDate>2003-01-30</listingDate>
								<amountMOHLTCPays>66.1700</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200071">
							<itemNumber>0465</itemNumber>
							<strength>30mg/0.3mL</strength>
							<dosageForm>Pref Syr-0.3mL Pk</dosageForm>
							<drug id="02012472" sec3="Y" sec12="Y">
								<name>Lovenox</name>
								<manufacturerId>SAV</manufacturerId>
								<individualPrice>6.6170</individualPrice>
								<listingDate>2003-01-30</listingDate>
								<amountMOHLTCPays>6.6170</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200055">
							<itemNumber>0466</itemNumber>
							<strength>40mg/0.4mL</strength>
							<dosageForm>Pref Syr-0.4mL Pk</dosageForm>
							<drug id="02236883" sec3="Y" sec12="Y">
								<name>Lovenox</name>
								<manufacturerId>SAV</manufacturerId>
								<individualPrice>8.8220</individualPrice>
								<listingDate>2003-01-30</listingDate>
								<amountMOHLTCPays>8.8220</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200056">
							<itemNumber>0467</itemNumber>
							<strength>60mg/0.6mL</strength>
							<dosageForm>Pref Syr-0.6mL Pk</dosageForm>
							<drug id="02378426" sec3="Y" sec12="Y">
								<name>Lovenox</name>
								<manufacturerId>SAV</manufacturerId>
								<individualPrice>13.2330</individualPrice>
								<listingDate>2012-12-21</listingDate>
								<amountMOHLTCPays>13.2330</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200057">
							<itemNumber>0468</itemNumber>
							<strength>80mg/0.8mL</strength>
							<dosageForm>Pref Syr-0.8mL Pk</dosageForm>
							<drug id="02378434" sec3="Y" sec12="Y">
								<name>Lovenox</name>
								<manufacturerId>SAV</manufacturerId>
								<individualPrice>17.6450</individualPrice>
								<listingDate>2012-10-30</listingDate>
								<amountMOHLTCPays>17.6450</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200073">
							<itemNumber>0469</itemNumber>
							<strength>120mg/0.8mL</strength>
							<dosageForm>Pref Syr-0.8mL Pk</dosageForm>
							<drug id="02242692" sec3="Y" sec12="Y">
								<name>Lovenox HP</name>
								<manufacturerId>SAV</manufacturerId>
								<individualPrice>26.4670</individualPrice>
								<listingDate>2005-02-22</listingDate>
								<amountMOHLTCPays>26.4670</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200058">
							<itemNumber>0470</itemNumber>
							<strength>100mg/mL</strength>
							<dosageForm>Pref Syr-1mL Pk</dosageForm>
							<drug id="02378442" sec3="Y" sec12="Y">
								<name>Lovenox</name>
								<manufacturerId>SAV</manufacturerId>
								<individualPrice>22.0560</individualPrice>
								<listingDate>2012-10-30</listingDate>
								<amountMOHLTCPays>22.0560</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200074">
							<itemNumber>0471</itemNumber>
							<strength>150mg/mL</strength>
							<dosageForm>Pref Syr-1mL Pk</dosageForm>
							<drug id="02378469" sec3="Y" sec12="Y">
								<name>Lovenox HP</name>
								<manufacturerId>SAV</manufacturerId>
								<individualPrice>33.0850</individualPrice>
								<listingDate>2013-01-29</listingDate>
								<amountMOHLTCPays>33.0850</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="186">For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="003" reasonForUseId="187">For DVT in pregnant or lactating females;</lccNote>
						<lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="005" reasonForUseId="188">For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;</lccNote>
						<lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="007" reasonForUseId="189">For DVT in patients who have failed treatment with warfarin.</lccNote>
						<lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="009" reasonForUseId="323">For the acute treatment of pulmonary embolism, maximum of three weeks.</lccNote>
						<lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="01927">
					<name>EPTIFIBATIDE</name>
					<pcgGroup>
						<pcg9 id="201200091">
							<itemNumber>0472</itemNumber>
							<strength>0.75mg/mL</strength>
							<dosageForm>100mL Vial Pk</dosageForm>
							<drug id="02240351" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Integrilin</name>
								<manufacturerId>MEK</manufacturerId>
								<listingDate>2013-09-27</listingDate>
							</drug>
							<drug id="02405083" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Eptifibatide Injection</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>94.5600</individualPrice>
								<listingDate>2013-09-27</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="201200092">
							<itemNumber>0473</itemNumber>
							<strength>2mg/mL</strength>
							<dosageForm>10mL Vial Pk</dosageForm>
							<drug id="02240352" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Integrilin</name>
								<manufacturerId>MEK</manufacturerId>
								<listingDate>2013-09-27</listingDate>
							</drug>
							<drug id="02367858" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Eptifibatide Injection</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>32.3000</individualPrice>
								<listingDate>2013-09-27</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01576">
					<name>FONDAPARINUX SODIUM</name>
					<pcgGroup lccId="00148">
						<pcg9 id="201200072">
							<itemNumber>0474</itemNumber>
							<strength>2.5mg/0.5mL</strength>
							<dosageForm>Inj Sol-Pref Syr 0.5mL Pk (Preservative Free)</dosageForm>
							<drug id="02245531" sec3="Y" sec12="Y">
								<name>Arixtra</name>
								<manufacturerId>ASN</manufacturerId>
								<individualPrice>10.6000</individualPrice>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>10.6000</amountMOHLTCPays>
							</drug>
							<drug id="02406853" sec3="Y" sec12="Y">
								<name>Fondaparinux Sodium Injection</name>
								<manufacturerId>DRR</manufacturerId>
								<individualPrice>11.1944</individualPrice>
								<listingDate>2014-07-30</listingDate>
								<amountMOHLTCPays>10.6000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="378">For the post-operative prophylaxis of venous thromboembolic events in patients undergoing orthopedic surgery of the lower limbs such as hip fracture, hip replacement or knee surgery.</lccNote>
						<lccNote seq="002" type="N">Limited to 9 days of reimbursement.</lccNote>
						<lccNote seq="003" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
					<pcgGroup>
						<pcg9 id="201200080">
							<itemNumber>0475</itemNumber>
							<strength>7.5mg/0.6mL</strength>
							<dosageForm>Inj Sol-Pref Syr 0.6mL Pk (Preservative Free)</dosageForm>
							<drug id="02258056" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Arixtra</name>
								<manufacturerId>ASN</manufacturerId>
								<listingDate>2014-07-30</listingDate>
							</drug>
							<drug id="02406896" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Fondaparinux Sodium Injection</name>
								<manufacturerId>DRR</manufacturerId>
								<individualPrice>18.1356</individualPrice>
								<listingDate>2014-07-30</listingDate>
								<amountMOHLTCPays>18.1356</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01409">
					<name>NADROPARIN CALCIUM</name>
					<pcgGroup lccId="00047">
						<pcg9 id="201200050">
							<itemNumber>0476</itemNumber>
							<strength>9500IU/mL</strength>
							<dosageForm>Pref Syr-0.3mL Pk</dosageForm>
							<drug id="09853936" sec3="Y" sec12="Y">
								<name>Fraxiparine</name>
								<manufacturerId>ASN</manufacturerId>
								<individualPrice>5.4150</individualPrice>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>5.4150</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200051">
							<itemNumber>0477</itemNumber>
							<strength>9500IU/mL</strength>
							<dosageForm>Pref Syr-0.4mL Pk</dosageForm>
							<drug id="09853944" sec3="Y" sec12="Y">
								<name>Fraxiparine</name>
								<manufacturerId>ASN</manufacturerId>
								<individualPrice>6.8400</individualPrice>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>6.8400</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200052">
							<itemNumber>0478</itemNumber>
							<strength>9500IU/mL</strength>
							<dosageForm>Pref Syr-0.6mL Pk</dosageForm>
							<drug id="09853952" sec3="Y" sec12="Y">
								<name>Fraxiparine</name>
								<manufacturerId>ASN</manufacturerId>
								<individualPrice>9.0580</individualPrice>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>9.0580</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200059">
							<itemNumber>0479</itemNumber>
							<strength>19000IU/mL</strength>
							<dosageForm>Pref Syr-0.6mL Pk</dosageForm>
							<drug id="02240114" sec3="Y" sec12="Y">
								<name>Fraxiparine Forte</name>
								<manufacturerId>ASN</manufacturerId>
								<individualPrice>18.1170</individualPrice>
								<listingDate>2000-01-17</listingDate>
								<amountMOHLTCPays>18.1170</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200060">
							<itemNumber>0480</itemNumber>
							<strength>19000IU/mL</strength>
							<dosageForm>Pref Syr-0.8mL Pk</dosageForm>
							<drug id="09854100" sec3="Y" sec12="Y">
								<name>Fraxiparine Forte</name>
								<manufacturerId>ASN</manufacturerId>
								<individualPrice>18.1170</individualPrice>
								<listingDate>2000-01-17</listingDate>
								<amountMOHLTCPays>18.1170</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200054">
							<itemNumber>0481</itemNumber>
							<strength>9500IU/mL</strength>
							<dosageForm>Pref Syr-1.0mL Pk</dosageForm>
							<drug id="09853987" sec3="Y" sec12="Y">
								<name>Fraxiparine</name>
								<manufacturerId>ASN</manufacturerId>
								<individualPrice>9.0580</individualPrice>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>9.0580</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200061">
							<itemNumber>0482</itemNumber>
							<strength>19000IU/mL</strength>
							<dosageForm>Pref Syr-1.0mL Pk</dosageForm>
							<drug id="09854118" sec3="Y" sec12="Y">
								<name>Fraxiparine Forte</name>
								<manufacturerId>ASN</manufacturerId>
								<individualPrice>18.1170</individualPrice>
								<listingDate>2000-01-17</listingDate>
								<amountMOHLTCPays>18.1170</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="186">For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="003" reasonForUseId="187">For DVT in pregnant or lactating females;</lccNote>
						<lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="005" reasonForUseId="188">For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;</lccNote>
						<lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="007" reasonForUseId="189">For DVT in patients who have failed treatment with warfarin.</lccNote>
						<lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="01855">
					<name>PRASUGREL</name>
					<pcgGroup lccId="00238">
						<pcg9 id="201200082">
							<itemNumber>0483</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02349124" notABenefit="Y" sec3="Y">
								<name>Effient</name>
								<manufacturerId>LIL</manufacturerId>
								<listingDate>2013-09-27</listingDate>
							</drug>
							<drug id="02502429" sec3="Y" sec12="Y">
								<name>Jamp Prasugrel</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>1.6680</individualPrice>
								<listingDate>2021-06-30</listingDate>
								<amountMOHLTCPays>1.6680</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="449">In combination with ASA for patients with:
ST-elevated myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) who have not received antiplatelet therapy prior to arrival in the catheterization lab.
OR
Acute coronary syndrome who failed on optimal clopidogrel and ASA therapy as defined by definite stent thrombosis (see note 1), or recurrent STEMI, or NSTEMI or UA after prior revascularization via PCI.
Treatment must be initiated in hospital. Funding approval is for up to 1 year.
Notes:
1. Definite stent thrombosis, according to the Academic Research Consortium, is a total occlusion originating in or within 5mm of the stent OR is a visible thrombus within the stent OR is within 5mm of the stent in the presence of an acute ischemic clinical syndrome within 48 hours. Definite stent thrombosis must be confirmed by angiography or by pathologic evidence of acute thrombosis.
2. As per the product monograph, prasugrel is contraindicated in patients with a known history of transient ischemic attack or stroke; those with active pathological bleeding such as gastrointestinal bleeding or intracranial hemorrhage; and those with severe hepatic impairment (Child-Pugh Class C).
3. As per the product monograph, prasugrel is not recommended in patients greater than or equal to 75 years of age because of the increased risk of fatal and intracranial bleeding; or those with body weight less than 60kg because of increased risk of major bleeding due to an increase in exposure to the active metabolite of prasugrel.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="01756">
					<name>RIVAROXABAN</name>
					<pcgGroup lccId="00323">
						<pcg9 id="201200104">
							<itemNumber>0484</itemNumber>
							<strength>2.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02480808" sec3="Y" sec12="Y">
								<name>Xarelto</name>
								<manufacturerId>BAH</manufacturerId>
								<individualPrice>1.4200</individualPrice>
								<listingDate>2019-12-20</listingDate>
								<amountMOHLTCPays>1.4200</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="539">In combination with acetylsalicylic acid (ASA; 75mg to 100mg) for the prevention of stroke, myocardial infarction, and cardiovascular death, and for the prevention of acute limb ischemia and mortality in patients with concomitant coronary artery disease (CAD) and peripheral artery disease (PAD) if the following conditions are met:
Patients with CAD are defined as having one or more of the following:
- myocardial infarction within the last 20 years
- multi-vessel coronary disease(i.e., stenosis of greater than or equal to 50% in two or more coronary arteries, or in one coronary territory if at least one other territory has been revascularized) with symptoms or history of stable or unstable angina.
- multi-vessel precutaneous coronary intervation
- multi-vessel coronary artery bypass graft surgery
- and meet at least one of the following criteria:
- aged 65 years or older, or
- aged younger than 65 years with documented atherosclerosis or revascularization involving at least two vascular beds (coronary and other vascular) or at least two additional risk factors (current smoker, diabetes mellitus, estimated glomerular filtration rate less than 60mL/min, heart failure, non-lacunar ischemic stroke 1 month or more ago).
Patients with PAD are defined as having one or more of the following:
- previous aorto-femoral bypass surgery, limb bypass surgery, or percutaneous transluminal angioplasty revascularization of the iliac or infrainguinal arteries
- previous limb or foot amputation for arterial vascular disease
- history of intermittent claudication and one or more of the following:
- an anklebrachial index less than 0.90, or
- significant peripheral artery stenosis (greater than or equal to 50%) documented by angiography or by duplex ultrasound
- previous carotid revascularization or asymptomatic carotid artery stenosis greater than or equal to 50%, as diagnosed by duplex ultrasound or angiography.
Exclusion Criteria
The Drug Product should not be reimbursed for patients who have CAD or PAD alone or in patients with any one of the following characteristics:
- at high risk of bleeding
- a history of stroke within one month of treatment initiation or any history of hemorrhagic or lacunar stroke
- severe heart failure with a known ejection fraction less than 30% or New York Heart Association class III or IV symptoms
- an estimated glomerular filtration rate less than 15mL/min require dual antiplatelet therapy, other non-ASA antiplatelet therapy, or oral anticoagulant therapy.
</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
					<pcgGroup lccId="00225">
						<pcg9 id="201200079">
							<itemNumber>0485</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02316986" sec3="Y" sec12="Y">
								<name>Xarelto</name>
								<manufacturerId>BAH</manufacturerId>
								<individualPrice>2.8700</individualPrice>
								<listingDate>2009-06-23</listingDate>
								<amountMOHLTCPays>2.8700</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="433">For the prevention of venous thromboembolic events in patients who have undergone elective total knee replacement (TKR) surgery.
Note: Limited to 14 days of reimbursement in TKR. Limited to 1 claim in a 120 day period.
</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="003" reasonForUseId="434">For the prevention of venous thromboembolic events in patients who have undergone elective total hip replacement (THR).
Note: Limited to 35 days of reimbursement in THR. Limited to 1 claim in a 120 day period.
</lccNote>
						<lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
					<pcgGroup lccId="00224">
						<pcg9 id="201200086">
							<itemNumber>0486</itemNumber>
							<strength>15mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02378604" sec3="Y" sec12="Y">
								<name>Xarelto</name>
								<manufacturerId>BAH</manufacturerId>
								<individualPrice>2.8700</individualPrice>
								<listingDate>2012-07-27</listingDate>
								<amountMOHLTCPays>2.8700</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200087">
							<itemNumber>0487</itemNumber>
							<strength>20mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02378612" sec3="Y" sec12="Y">
								<name>Xarelto</name>
								<manufacturerId>BAH</manufacturerId>
								<individualPrice>2.8700</individualPrice>
								<listingDate>2012-07-27</listingDate>
								<amountMOHLTCPays>2.8700</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="435">For the prevention of stroke and systemic embolism in at-risk patients who have non-valvular atrial fibrillation (AF) AND in whom:
1) Anticoagulation is inadequate following a reasonable trial on warfarin; OR
2) Anticoagulation with warfarin is contraindicated or not possible due to inability to regularly monitor via International Normalized Ratio (INR) testing (i.e., no access to INR testing service at a laboratory, clinic, pharmacy, and at home).
Exclusion Criteria: Patients who:
(a) have impaired renal function (creatinine clearance or estimated glomerular filtration rate less than 30mL/min); OR
(b) are greater than or equal to 75 years in age without documented stable renal function; OR
(c) have hemodynamically significant rheumatic valvular heart disease, especially mitral stenosis; OR
(d) have prosthetic heart valves.
Definitions and Clarification:
(a) &quot;documented stable renal function&quot; is defined as creatinine clearance or estimated glomerular filtration rate that maintained for at least 3 months (i.e., 30-49mL/min for 15mg once daily dosing or greater than or equal to 50mL/min for 20mg once daily dosing
for at least 3 months).
(b) &quot;at-risk patients with atrial fibrillation&quot; are defined as those with a CHADS2 score of greater than or equal to 1. Although the ROCKET-AF trial included patients with higher CHADS2 score (greater than or equal to 2), other landmark studies with the other newer oral anticoagulants demonstrated a therapeutic benefit in patients with a CHADS2 score of 1. Prescribers may consider an antiplatelet regimen or oral anticoagulation for patients with a CHADS2 score of 1.
(c) &quot;inadequate anticoagulation&quot; is defined as INR testing results that are outside of the desired INR range for at least 35% of the tests during the monitoring period (i.e., adequate anticoagulation is defined as INR test results that are within the desired INR range for at least 65% of the tests during the monitoring period).
(d) &quot;a reasonable trial on warfarin&quot; is defined as at least 2 months of therapy.
(e) Since renal impairment can increase bleeding risk, renal function should be regularly monitored. Other factors that increase bleeding risk should also be assessed and monitored
(see Xarelto product monograph).
(f) Patients starting rivaroxaban should have ready access to appropriate medical services to manage a major bleeding event.
(g) There is currently no data to support that rivaroxaban provides adequate anticoagulation in patients with rheumatic valvular disease or those with prosthetic heart valves, so rivaroxaban is not recommended in these populations.
</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: Indefinite.</lccNote>
						<lccNote seq="003" reasonForUseId="444">For the treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE) for up to six (6) months.</lccNote>
						<lccNote seq="004" type="R">LU Authorization Period: 6 Months.</lccNote>
						<lccNote seq="005" type="N">-The recommended dose of rivaroxaban for patients initiating DVT or PE treatment is 15 mg twice daily for 3 weeks, followed by 20 mg once daily.
-ODB Program coverage for rivaroxaban is an alternative to heparin/warfarin for up to 6 months. When used for greater than 6 months, rivaroxaban is more costly than heparin/warfarin. As such, patients with an intended duration of therapy greater than 6 months should be considered for initiation on heparin/warfarin.
-For clarity, coverage will not be provided for patients who have already received 6 months of treatment with apixaban for the same DVT or PE.
-Since renal impairment can increase bleeding risk, it is important to monitor renal function regularly. Other factors that increase bleeding risks should also be assessed and monitored (see product monograph).
</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="01913">
					<name>TICAGRELOR</name>
					<pcgGroup lccId="00230">
						<pcg9 id="201200088">
							<itemNumber>0488</itemNumber>
							<strength>90mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02368544" sec3="Y" sec12="Y">
								<name>Brilinta</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>1.5840</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>1.5840</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="441">In combination with low-dose ASA for patients with:
- Non-ST elevation acute coronary syndrome (ACS)* (unstable angina or myocardial infarction [MI]); OR
- ST-segment elevation myocardial infarction (STEMI); OR
- Stent thrombosis while taking clopidogrel plus low-dose ASA.
Treatment must be initiated in hospital.
Notes:
A) *ACS without ST elevation is defined as 2 of 3 of the following criteria:
1. ST-segment changes on electrocardiogram (ECG) indicating ischemia
2. Positive biomarker indicating myocardial necrosis
3. One of the following:
- Greater than or equal to 60 years of age
- Previous MI or coronary artery bypass graft (CABG)
- Coronary artery disease (CAD) with greater than or equal to 50% stenosis in greater than or equal to 2 vessels
- Previous ischemic stroke, transient ischemic attack (TIA; hospital-based diagnosis), carotid stenosis (greater than or equal to 50%), or cerebral revascularization
- Diabetes mellitus
- Peripheral artery disease
- Chronic renal dysfunction
B) Co-administration of ticagrelor with high maintenance dose ASA (greater than 150mg daily) is not recommended.
C) Definite stent thrombosis, according to the Academic Research Consortium, is a total occlusion originating in or within 5 mm of the stent, or is a visible thrombus within the stent, or is within 5 mm of the stent in the presence of an acute ischemic clinical syndrome within 48 hours. Definite stent thrombosis must be confirmed by angiography or by pathologic confirmation of acute thrombosis.
D) Ticagrelor is contraindicated in patients with active pathological bleeding, in those with a history of intracranial hemorrhage and moderate to severe hepatic impairment.
</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00299">
					<name>TINZAPARIN SODIUM</name>
					<pcgGroup lccId="00048">
						<pcg9 id="201200081">
							<itemNumber>0489</itemNumber>
							<strength>2500IU/0.25mL</strength>
							<dosageForm>Inj Pref Syr</dosageForm>
							<drug id="09857367" sec3="Y" sec12="Y">
								<name>Innohep</name>
								<manufacturerId>LEO</manufacturerId>
								<individualPrice>6.0984</individualPrice>
								<listingDate>2010-07-20</listingDate>
								<amountMOHLTCPays>6.0984</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200095">
							<itemNumber>0490</itemNumber>
							<strength>8000IU/0.4mL</strength>
							<dosageForm>Inj Pref Syr</dosageForm>
							<drug id="02429462" sec3="Y" sec12="Y">
								<name>Innohep</name>
								<manufacturerId>LEO</manufacturerId>
								<individualPrice>18.9689</individualPrice>
								<listingDate>2015-08-26</listingDate>
								<amountMOHLTCPays>18.9689</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200096">
							<itemNumber>0491</itemNumber>
							<strength>12000IU/0.6mL</strength>
							<dosageForm>Inj Pref Syr</dosageForm>
							<drug id="02429470" sec3="Y" sec12="Y">
								<name>Innohep</name>
								<manufacturerId>LEO</manufacturerId>
								<individualPrice>29.8766</individualPrice>
								<listingDate>2015-08-26</listingDate>
								<amountMOHLTCPays>29.8766</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200097">
							<itemNumber>0492</itemNumber>
							<strength>16000IU/0.8mL</strength>
							<dosageForm>Inj Pref Syr</dosageForm>
							<drug id="02429489" sec3="Y" sec12="Y">
								<name>Innohep</name>
								<manufacturerId>LEO</manufacturerId>
								<individualPrice>39.8359</individualPrice>
								<listingDate>2015-08-26</listingDate>
								<amountMOHLTCPays>39.8359</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200044">
							<itemNumber>0493</itemNumber>
							<strength>3500IU/0.35mL</strength>
							<dosageForm>Inj Pref Syr</dosageForm>
							<drug id="02358158" sec3="Y" sec12="Y">
								<name>Innohep</name>
								<manufacturerId>LEO</manufacturerId>
								<individualPrice>8.5284</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>8.5284</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200045">
							<itemNumber>0494</itemNumber>
							<strength>4500IU/0.45mL</strength>
							<dosageForm>Inj Pref Syr</dosageForm>
							<drug id="02358166" sec3="Y" sec12="Y">
								<name>Innohep</name>
								<manufacturerId>LEO</manufacturerId>
								<individualPrice>10.9682</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>10.9682</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200046">
							<itemNumber>0495</itemNumber>
							<strength>10000IU/0.5mL</strength>
							<dosageForm>Inj Pref Syr</dosageForm>
							<drug id="02231478" sec3="Y" sec12="Y">
								<name>Innohep</name>
								<manufacturerId>LEO</manufacturerId>
								<individualPrice>24.8740</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>24.8740</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200047">
							<itemNumber>0496</itemNumber>
							<strength>14000IU/0.7mL</strength>
							<dosageForm>Inj Pref Syr</dosageForm>
							<drug id="02358174" sec3="Y" sec12="Y">
								<name>Innohep</name>
								<manufacturerId>LEO</manufacturerId>
								<individualPrice>34.8556</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>34.8556</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200048">
							<itemNumber>0497</itemNumber>
							<strength>18000IU/0.9mL</strength>
							<dosageForm>Inj Pref Syr</dosageForm>
							<drug id="02358182" sec3="Y" sec12="Y">
								<name>Innohep</name>
								<manufacturerId>LEO</manufacturerId>
								<individualPrice>44.8099</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>44.8099</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200039">
							<itemNumber>0498</itemNumber>
							<strength>10000IU/mL</strength>
							<dosageForm>Inj-2mL Pk</dosageForm>
							<drug id="02167840" sec3="Y" sec12="Y">
								<name>Innohep</name>
								<manufacturerId>LEO</manufacturerId>
								<individualPrice>46.0399</individualPrice>
								<listingDate>1997-04-10</listingDate>
								<amountMOHLTCPays>46.0399</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200042">
							<itemNumber>0499</itemNumber>
							<strength>20000IU/mL</strength>
							<dosageForm>Inj-2mL Pk</dosageForm>
							<drug id="02229515" sec3="Y" sec12="Y">
								<name>Innohep</name>
								<manufacturerId>LEO</manufacturerId>
								<individualPrice>98.2029</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>98.2029</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="186">For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="003" reasonForUseId="187">For DVT in pregnant or lactating females;</lccNote>
						<lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="005" reasonForUseId="188">For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;</lccNote>
						<lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="007" reasonForUseId="189">For DVT in patients who have failed treatment with warfarin.</lccNote>
						<lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="009" reasonForUseId="323">For the acute treatment of pulmonary embolism, maximum of three weeks.</lccNote>
						<lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00292">
					<name>WARFARIN</name>
					<note>The use of International Normalized Ratio (INR) instead of Prothrombin Time results to control warfarin dosing is strongly recommended. Prothrombin Time results can vary three-fold depending on the reagent used; INR corrects for this and substantially improves safety and efficacy of warfarin therapy.</note>
					<pcgGroup>
						<pcg9 id="201200026">
							<itemNumber>0500</itemNumber>
							<strength>1mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="01918311" notABenefit="Y" sec3="Y">
								<name>Coumadin</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02242680" sec3="Y">
								<name>Taro-Warfarin</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>.0796</individualPrice>
								<listingDate>2001-06-07</listingDate>
								<amountMOHLTCPays>.0796</amountMOHLTCPays>
							</drug>
							<drug id="02242924" sec3="Y">
								<name>Apo-Warfarin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0796</individualPrice>
								<listingDate>2001-06-07</listingDate>
								<amountMOHLTCPays>.0796</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200027">
							<itemNumber>0501</itemNumber>
							<strength>2mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="01918338" notABenefit="Y" sec3="Y">
								<name>Coumadin</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02242681" sec3="Y">
								<name>Taro-Warfarin</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>.0841</individualPrice>
								<listingDate>2001-06-07</listingDate>
								<amountMOHLTCPays>.0841</amountMOHLTCPays>
							</drug>
							<drug id="02242925" sec3="Y">
								<name>Apo-Warfarin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0841</individualPrice>
								<listingDate>2001-06-07</listingDate>
								<amountMOHLTCPays>.0841</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200010">
							<itemNumber>0502</itemNumber>
							<strength>2.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="01918346" notABenefit="Y" sec3="Y">
								<name>Coumadin</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02242682" sec3="Y">
								<name>Taro-Warfarin</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>.0674</individualPrice>
								<listingDate>2001-06-07</listingDate>
								<amountMOHLTCPays>.0674</amountMOHLTCPays>
							</drug>
							<drug id="02242926" sec3="Y">
								<name>Apo-Warfarin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0674</individualPrice>
								<listingDate>2001-06-07</listingDate>
								<amountMOHLTCPays>.0674</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200062">
							<itemNumber>0503</itemNumber>
							<strength>3mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02240205" notABenefit="Y" sec3="Y">
								<name>Coumadin</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>2001-06-07</listingDate>
							</drug>
							<drug id="02242683" sec3="Y">
								<name>Taro-Warfarin</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>.1043</individualPrice>
								<listingDate>2002-04-04</listingDate>
								<amountMOHLTCPays>.1043</amountMOHLTCPays>
							</drug>
							<drug id="02245618" sec3="Y">
								<name>Apo-Warfarin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1043</individualPrice>
								<listingDate>2003-01-30</listingDate>
								<amountMOHLTCPays>.1043</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200028">
							<itemNumber>0504</itemNumber>
							<strength>4mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02007959" notABenefit="Y" sec3="Y">
								<name>Coumadin</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02242684" sec3="Y">
								<name>Taro-Warfarin</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>.1043</individualPrice>
								<listingDate>2001-06-07</listingDate>
								<amountMOHLTCPays>.1043</amountMOHLTCPays>
							</drug>
							<drug id="02242927" sec3="Y">
								<name>Apo-Warfarin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1043</individualPrice>
								<listingDate>2001-06-07</listingDate>
								<amountMOHLTCPays>.1043</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200035">
							<itemNumber>0505</itemNumber>
							<strength>5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="01918354" notABenefit="Y" sec3="Y">
								<name>Coumadin</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02242685" sec3="Y">
								<name>Taro-Warfarin</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>.0675</individualPrice>
								<listingDate>2001-06-07</listingDate>
								<amountMOHLTCPays>.0675</amountMOHLTCPays>
							</drug>
							<drug id="02242928" sec3="Y">
								<name>Apo-Warfarin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0675</individualPrice>
								<listingDate>2001-06-07</listingDate>
								<amountMOHLTCPays>.0675</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201200077">
							<itemNumber>0506</itemNumber>
							<strength>6mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02240206" notABenefit="Y" sec3="Y">
								<name>Coumadin</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>2008-06-27</listingDate>
							</drug>
							<drug id="02242686" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Taro-Warfarin</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>.2805</individualPrice>
								<listingDate>2008-12-03</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="201200008">
							<itemNumber>0507</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="01918362" notABenefit="Y" sec3="Y">
								<name>Coumadin</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02242687" sec3="Y">
								<name>Taro-Warfarin</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>.1211</individualPrice>
								<listingDate>2001-06-07</listingDate>
								<amountMOHLTCPays>.1211</amountMOHLTCPays>
							</drug>
							<drug id="02242929" sec3="Y">
								<name>Apo-Warfarin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1211</individualPrice>
								<listingDate>2001-06-07</listingDate>
								<amountMOHLTCPays>.1211</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="201204000">
				<name>COAGULANTS AND ANTI-COAGULANTS DIRECT FACTOR XA INHIBITORS</name>
				<genericName id="02082">
					<name>EDOXABAN</name>
					<pcgGroup lccId="00317">
						<pcg9 id="201204001">
							<itemNumber>0508</itemNumber>
							<strength>15mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02458640" sec3="Y" sec12="Y">
								<name>Lixiana</name>
								<manufacturerId>SEV</manufacturerId>
								<individualPrice>2.9250</individualPrice>
								<listingDate>2019-04-30</listingDate>
								<amountMOHLTCPays>2.9250</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201204002">
							<itemNumber>0509</itemNumber>
							<strength>30mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02458659" sec3="Y" sec12="Y">
								<name>Lixiana</name>
								<manufacturerId>SEV</manufacturerId>
								<individualPrice>2.9250</individualPrice>
								<listingDate>2019-04-30</listingDate>
								<amountMOHLTCPays>2.9250</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201204003">
							<itemNumber>0510</itemNumber>
							<strength>60mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02458667" sec3="Y" sec12="Y">
								<name>Lixiana</name>
								<manufacturerId>SEV</manufacturerId>
								<individualPrice>2.9250</individualPrice>
								<listingDate>2019-04-30</listingDate>
								<amountMOHLTCPays>2.9250</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="444">For the treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE) for up to six (6) months.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 6 Months.</lccNote>
						<lccNote seq="003" type="N">The recommeded dose of edoxaban for patients initiating DVT or PE treatment is 60mg once daily following initial use of a parenteral anticoagulant for 5 to 10 days. Edoxaban 30mg once daily is recommended in patients with one or more of the following clinical factors:
a) Moderate renal impairment (creatinine clearance (CrCl) 30-50 mL/min);
b) Low body weight less than or equal to 60kg, and
c) Concomitant use of P-glycoprotein (P-gp) inhibitors except amiodarone and verapamil.
ODB Program coverage for edoxaban is an alternative to heparin/warfarin for up to 6 months. When used for greater than 6 months, edoxaban is more costly than heparin/warfarin. As such, patients with an intended duration of therapy greater than 6 months should be considered for initiation on heparin/warfarin.
For clarity, coverage will not be provided for patients who have already received 6 months of treatment with apixaban or rivaroxaban for the same DVT or PE.
Since renal impairment can increase bleeding risk, it is important to monitor renal function regularly. Other factors that increase bleeding risks should also be assessed and monitored (see product monograph).</lccNote>
						<lccNote seq="004" reasonForUseId="554">INCLUSION CRITERIA:
At risk patients with non-valvular atrial fibrillation, for the prevention of stroke and systemic embolism AND in whom:
1. Anticoagulation is inadequate following at least a 2-month trial on warfarin;
OR
2. Anticoagulation using warfarin is contraindicated or not possible due to inability to regularly monitor the patient via International Normalized Ratio (INR) testing (i.e. no access to INR testing services at a laboratory, clinic, pharmacy, and at home).
EXCLUSION CRITERIA:
1. Patients with impaired renal function (creatinine clearance or estimated glomerular filtration rate less than 30 mL per min);
OR
2. Patients who are greater than or equal to 75 years of age and who do not have documented stable renal function;
OR
3. Patients who have hemodynamically significant rheumatoid valvular heart disease (especially mitral stenosis);
OR
4. Patients who have prosthetic heart valves.
NOTES:
At-risk patients with atrial fibrillation are defined as those with a CHADS2 score of greater than or equal to 1. Prescribers may consider an antiplatelet regimen or oral anticoagulation for patients with a CHADS2 score of 1.
Inadequate anticoagulation is defined as INR testing results that are outside the desired INR range for at least 35% of the tests during the monitoring period (i.e., adequate anticoagulation is defined as INR test results that are within the desired INR range for at least 65% of the tests during the monitoring period).
Documented stable renal function is defined as creatinine clearance or estimated glomerular filtration rate maintained for at least 3 months.
DOSING:
The usual recmommended dose is 60mg once daily for the prevention of stroke and systemic embolisms in patients with nonvalvular atrial fibrillation is 60mg once daily; a reduced dose of Edoxaban 30mg once daily is recommended for patients in patients with once or more of the following clinical factors:
a) Moderate renal impairment (creatinine clearance (CrCL) 30-50 mL/min);
b) Low body weight less than or equal to 60kg, and
c) Concomitant use of P-glycoprotein (P-gp) inhibitors excepted amiodarone and verapamil.
Duration of therapy should be individualized after careful assessment of the treatment benefit against the individual risk of bleeding.
Since renal impairment can increase bleeding risk, renal function should be regularly monitored. Other factors that increase bleeding risk should also be assessed and monitored (see edoxaban product monograph).
Patients starting edoxaban should have ready access to appropriate medical services to manage a major bleeding event.
There is currently no data to support that edoxaban provides adequate anticoagulation in patients with rheumatic valvular disease or those with prosthetic heart valves. As a result, edoxaban is not recommended for these patient populations.
</lccNote>
						<lccNote seq="005" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="201216000">
				<name>COAGULANTS AND ANTI-COAGULANTS HEMOSTATICS</name>
				<genericName id="00302">
					<name>FILGRASTIM</name>
					<pcgGroup lccId="00235">
						<pcg9 id="201216005">
							<itemNumber>0511</itemNumber>
							<strength>480mcg/1.6mL</strength>
							<dosageForm>1.6mL Vial</dosageForm>
							<drug id="09853464" sec3="Y" sec12="Y">
								<name>Neupogen</name>
								<manufacturerId>AMG</manufacturerId>
								<individualPrice>281.8120</individualPrice>
								<listingDate>2013-07-30</listingDate>
								<amountMOHLTCPays>281.8120</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201216002">
							<itemNumber>0512</itemNumber>
							<strength>300mcg/mL</strength>
							<dosageForm>1mL Vial</dosageForm>
							<drug id="01968017" sec3="Y" sec12="Y">
								<name>Neupogen</name>
								<manufacturerId>AMG</manufacturerId>
								<individualPrice>176.1330</individualPrice>
								<listingDate>2013-07-30</listingDate>
								<amountMOHLTCPays>176.1330</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="447">Pre-Stem Cell Transplant Mobilization:
For Peripheral Blood Progenitor Cell (PBPC) collection for peripheral stem cell transplant as treatment for malignant disease.
Approval for Neupogen 300mcg and 480mcg vial format only.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 14 days</lccNote>
						<lccNote seq="003" type="N">Reimbursement is limited to the duration required per the treatment protocol and to prescriptions written by an oncologist or hematologist.</lccNote>
						<lccNote seq="004" reasonForUseId="500">For pediatric patients (less than 18 years age) who are unable to achieve the appropriate dose of granulocyte colony-stimulating factor with the formulary listed formats of pre-filled syringes.
Approval for Neupogen 300mcg vial format only.</lccNote>
						<lccNote seq="005" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="006" reasonForUseId="501">For patients who are unable to use available formats of Grastofil due to a documented latex allergy.
Approval for Neupogen 300mcg and 480mcg vial format only.</lccNote>
						<lccNote seq="007" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00296">
					<name>TRANEXAMIC ACID</name>
					<pcgGroup>
						<pcg9 id="201216003">
							<itemNumber>0513</itemNumber>
							<strength>500mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02064405" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Cyklokapron</name>
								<manufacturerId>PFI</manufacturerId>
								<listingDate>2013-04-30</listingDate>
							</drug>
							<drug id="02401231" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Tranexamic Acid Tablets</name>
								<manufacturerId>STE</manufacturerId>
								<individualPrice>.8071</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.8071</amountMOHLTCPays>
							</drug>
							<drug id="02409097" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Gd-Tranexamic Acid</name>
								<manufacturerId>GEM</manufacturerId>
								<individualPrice>.8071</individualPrice>
								<listingDate>2015-07-29</listingDate>
								<amountMOHLTCPays>.8071</amountMOHLTCPays>
							</drug>
							<drug id="02496232" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Mar-Tranexamic Acid</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.8071</individualPrice>
								<listingDate>2020-08-28</listingDate>
								<amountMOHLTCPays>.8071</amountMOHLTCPays>
							</drug>
							<drug id="02519194" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Tranexamic Acid</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.8071</individualPrice>
								<listingDate>2022-01-31</listingDate>
								<amountMOHLTCPays>.8071</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="201600000">
				<name>HEMATOPOIETIC AGENTS</name>
				<genericName id="01573">
					<name>DARBEPOETIN ALFA</name>
					<pcgGroup lccId="00213">
						<pcg9 id="201600013">
							<itemNumber>0514</itemNumber>
							<strength>150mcg/0.3mL</strength>
							<dosageForm>Pref Syr-0.3mL Pk</dosageForm>
							<drug id="02391791" sec3="Y" sec12="Y">
								<name>Aranesp</name>
								<manufacturerId>AMG</manufacturerId>
								<individualPrice>402.0000</individualPrice>
								<listingDate>2014-12-18</listingDate>
								<amountMOHLTCPays>402.0000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201600037">
							<itemNumber>0515</itemNumber>
							<strength>200mcg/0.4mL</strength>
							<dosageForm>Pref Syr-0.4mL Pk</dosageForm>
							<drug id="02391805" sec3="Y" sec12="Y">
								<name>Aranesp</name>
								<manufacturerId>AMG</manufacturerId>
								<individualPrice>641.3600</individualPrice>
								<listingDate>2014-08-28</listingDate>
								<amountMOHLTCPays>641.3600</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201600038">
							<itemNumber>0516</itemNumber>
							<strength>300mcg/0.6mL</strength>
							<dosageForm>Pref Syr-0.6mL Pk</dosageForm>
							<drug id="02391821" sec3="Y" sec12="Y">
								<name>Aranesp</name>
								<manufacturerId>AMG</manufacturerId>
								<individualPrice>990.7700</individualPrice>
								<listingDate>2014-01-30</listingDate>
								<amountMOHLTCPays>990.7700</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201600039">
							<itemNumber>0517</itemNumber>
							<strength>500mcg/1.0mL</strength>
							<dosageForm>Pref Syr-1.0mL Pk</dosageForm>
							<drug id="02392364" sec3="Y" sec12="Y">
								<name>Aranesp</name>
								<manufacturerId>AMG</manufacturerId>
								<individualPrice>1651.3100</individualPrice>
								<listingDate>2014-04-30</listingDate>
								<amountMOHLTCPays>1651.3100</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="420">ESAs (Eprex or Aranesp) for patients with:
-Cancer diagnosis and receiving chemotherapy; AND
-Presence of anemia caused by chemotherapy with a hemoglobin count less than 100g/L; AND
-Patient has been informed of the risks and benefits of ESA therapy
AND
Anemia cannot be managed by use of blood transfusions due to at least one of the following:
-Religious beliefs do not allow the patient to receive transfusions.
-Previous severe (potentially life-threatening) reaction to a transfusion or difficulty cross-matching.
-Myeloid cancers that cannot be managed with blood transfusions
-Patient lives far away from treatment centre and/or transfusions cannot be coordinated with chemotherapy
-Patients receiving neoadjuvant chemotherapy with anemia and at risk of high blood losses due to surgery
Please refer to the product monograph for starting dose, dose adjustment and discontinuation recommendations.
NOTE: Health Canada has issued the following statements regarding ESA therapy for the treatment of anemia due to chemotherapy in patients with non-myeloid malignancies:
In patients with a long life expectancy, the decision to administer ESAs should be based on a benefit-risk assessment with the participation of the individual patient. This should take into account the specific clinical context such as (but not limited to) the type of tumor and its stage, the degree of anemia, life expectancy, the environment in which the patient is being treated and known risks of transfusions and ESAs.
If appropriate, red blood cell transfusion should be the preferred treatment for the management of anemia in patients with a long life expectancy and who are receiving myelosuppressive chemotherapy.
ESAs are not indicated for use in patients receiving hormonal agents, therapeutic biologic products, or radiotherapy unless receiving concomitant myelosuppressive chemotherapy.
Health Canada has also issued the following Serious Warnings and Precautions for cancer patients regarding ESAs:
ESAs increased the risks for death and serious cardiovascular and thromboembolic events in some controlled clinical trials.
ESAs shortened overall survival and/or increased the risk of tumour progression or recurrence in some clinical studies in patients with breast, head and neck, lymphoid, cervical and non-small cell lung cancers when dosed to target a hemoglobin of greater than or equal to 120g/L.
To minimize the above risks, use the lowest dose needed to avoid red blood cell (RBC) transfusions.
Use ESAs only for treatment of anemia due to concomitant myelosuppressive chemotherapy.
If appropriate, red blood cell transfusion should be the preferred treatment for the management of anemia in patients with a long life expectancy and who are receiving myelosuppressive chemotherapy.
Discontinue ESAs following completion of a chemotherapy course.
</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00304">
					<name>EPOETIN ALFA</name>
					<pcgGroup lccId="00214">
						<pcg9 id="201600002">
							<itemNumber>0518</itemNumber>
							<strength>10,000IU/mL</strength>
							<dosageForm>Pref Syr - 1mL Pk</dosageForm>
							<drug id="02231587" sec3="Y" sec12="Y">
								<name>Eprex</name>
								<manufacturerId>JAN</manufacturerId>
								<individualPrice>142.5000</individualPrice>
								<listingDate>2007-01-02</listingDate>
								<amountMOHLTCPays>142.5000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201600006">
							<itemNumber>0519</itemNumber>
							<strength>40,000IU/mL</strength>
							<dosageForm>Pref Syr - 1mL Pk</dosageForm>
							<drug id="02240722" sec3="Y" sec12="Y">
								<name>Eprex</name>
								<manufacturerId>JAN</manufacturerId>
								<individualPrice>486.7900</individualPrice>
								<listingDate>2007-01-02</listingDate>
								<amountMOHLTCPays>486.7900</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201600046">
							<itemNumber>0520</itemNumber>
							<strength>20,000IU/0.5mL</strength>
							<dosageForm>Pref Syr-0.5mL Pk</dosageForm>
							<drug id="02243239" sec3="Y" sec12="Y">
								<name>Eprex</name>
								<manufacturerId>JAN</manufacturerId>
								<individualPrice>325.0900</individualPrice>
								<listingDate>2009-03-02</listingDate>
								<amountMOHLTCPays>325.0900</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="420">ESAs (Eprex or Aranesp) for patients with:
-Cancer diagnosis and receiving chemotherapy; AND
-Presence of anemia caused by chemotherapy with a hemoglobin count less than 100g/L; AND
-Patient has been informed of the risks and benefits of ESA therapy
AND
Anemia cannot be managed by use of blood transfusions due to at least one of the following:
-Religious beliefs do not allow the patient to receive transfusions.
-Previous severe (potentially life-threatening) reaction to a transfusion or difficulty cross-matching.
-Myeloid cancers that cannot be managed with blood transfusions
-Patient lives far away from treatment centre and/or transfusions cannot be coordinated with chemotherapy
-Patients receiving neoadjuvant chemotherapy with anemia and at risk of high blood losses due to surgery
Please refer to the product monograph for starting dose, dose adjustment and discontinuation recommendations.
NOTE: Health Canada has issued the following statements regarding ESA therapy for the treatment of anemia due to chemotherapy in patients with non-myeloid malignancies:
In patients with a long life expectancy, the decision to administer ESAs should be based on a benefit-risk assessment with the participation of the individual patient. This should take into account the specific clinical context such as (but not limited to) the type of tumor and its stage, the degree of anemia, life expectancy, the environment in which the patient is being treated and known risks of transfusions and ESAs.
If appropriate, red blood cell transfusion should be the preferred treatment for the management of anemia in patients with a long life expectancy and who are receiving myelosuppressive chemotherapy.
ESAs are not indicated for use in patients receiving hormonal agents, therapeutic biologic products, or radiotherapy unless receiving concomitant myelosuppressive chemotherapy.
Health Canada has also issued the following Serious Warnings and Precautions for cancer patients regarding ESAs:
ESAs increased the risks for death and serious cardiovascular and thromboembolic events in some controlled clinical trials.
ESAs shortened overall survival and/or increased the risk of tumour progression or recurrence in some clinical studies in patients with breast, head and neck, lymphoid, cervical and non-small cell lung cancers when dosed to target a hemoglobin of greater than or equal to 120g/L.
To minimize the above risks, use the lowest dose needed to avoid red blood cell (RBC) transfusions.
Use ESAs only for treatment of anemia due to concomitant myelosuppressive chemotherapy.
If appropriate, red blood cell transfusion should be the preferred treatment for the management of anemia in patients with a long life expectancy and who are receiving myelosuppressive chemotherapy.
Discontinue ESAs following completion of a chemotherapy course.
</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00302">
					<name>FILGRASTIM</name>
					<pcgGroup>
						<pcg9 id="201600056">
							<itemNumber>0521</itemNumber>
							<strength>300mcg/0.5mL</strength>
							<dosageForm>Inj Sol-0.5mL Pref Syr</dosageForm>
							<drug id="02485575" sec3="Y">
								<name>Nivestym</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>144.3100</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>144.3100</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201600058">
							<itemNumber>0522</itemNumber>
							<strength>480mcg/0.8mL</strength>
							<dosageForm>Inj Sol-0.8mL Pref Syr</dosageForm>
							<drug id="02485583" sec3="Y">
								<name>Nivestym</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>230.9000</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>230.9000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201600059">
							<itemNumber>0523</itemNumber>
							<strength>480mcg/1.6mL</strength>
							<dosageForm>Inj Sol-1.6mL Vial Pk</dosageForm>
							<drug id="02485656" sec3="Y">
								<name>Nivestym</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>230.9000</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>230.9000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201600057">
							<itemNumber>0524</itemNumber>
							<strength>300mcg/mL</strength>
							<dosageForm>Inj Sol-1mL Vial Pk</dosageForm>
							<drug id="02485591" sec3="Y">
								<name>Nivestym</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>144.3100</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>144.3100</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201600051">
							<itemNumber>0525</itemNumber>
							<strength>300mcg/0.5mL</strength>
							<dosageForm>Pref Syr-0.5mL Pk</dosageForm>
							<drug id="02441489" sec3="Y">
								<name>Grastofil</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>144.3135</individualPrice>
								<listingDate>2016-12-22</listingDate>
								<amountMOHLTCPays>144.3135</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201600052">
							<itemNumber>0526</itemNumber>
							<strength>480mcg/0.8mL</strength>
							<dosageForm>Pref Syr-0.8mL Pk</dosageForm>
							<drug id="02454548" sec3="Y">
								<name>Grastofil</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>230.9017</individualPrice>
								<listingDate>2016-12-22</listingDate>
								<amountMOHLTCPays>230.9017</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="02097">
					<name>PEGFILGRASTIM</name>
					<pcgGroup>
						<pcg9 id="201600060">
							<itemNumber>0527</itemNumber>
							<strength>6mg/0.6mL</strength>
							<dosageForm>Inj Sol-0.6mL Pref Syr (Preservative-Free)</dosageForm>
							<drug id="02497395" sec3="Y">
								<name>Ziextenzo</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>1375.0000</individualPrice>
								<listingDate>2020-08-28</listingDate>
								<amountMOHLTCPays>1375.0000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201600061">
							<itemNumber>0528</itemNumber>
							<strength>6mg/0.6mL</strength>
							<dosageForm>Inj Sol-0.6mL Pref Syr Pk (Preservative-Free)</dosageForm>
							<drug id="02506238" sec3="Y">
								<name>Nyvepria</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>1375.0000</individualPrice>
								<listingDate>2021-08-31</listingDate>
								<amountMOHLTCPays>1375.0000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201600055">
							<itemNumber>0529</itemNumber>
							<strength>10mg/mL</strength>
							<dosageForm>Inj Sol-Pref Syr</dosageForm>
							<drug id="02484153" sec3="Y">
								<name>Fulphila</name>
								<manufacturerId>BGP</manufacturerId>
								<individualPrice>1375.0000</individualPrice>
								<listingDate>2020-05-29</listingDate>
								<amountMOHLTCPays>1375.0000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="201600054">
							<itemNumber>0530</itemNumber>
							<strength>10mg/mL</strength>
							<dosageForm>Inj Sol-Pref Syr - 0.6mL Pk (Preservative Free)</dosageForm>
							<drug id="02474565" sec3="Y">
								<name>Lapelga</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1375.0000</individualPrice>
								<listingDate>2019-08-30</listingDate>
								<amountMOHLTCPays>1375.0000</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="202400000">
				<name>HEMORRHEOLOGIC AGENTS</name>
				<genericName id="00306">
					<name>PENTOXIFYLLINE</name>
					<pcgGroup lccId="00049">
						<pcg9 id="202400001">
							<itemNumber>0531</itemNumber>
							<strength>400mg</strength>
							<dosageForm>SR Tab</dosageForm>
							<drug id="02221977" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Trental</name>
								<manufacturerId>SAV</manufacturerId>
								<listingDate>1999-01-07</listingDate>
							</drug>
							<drug id="02230090" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Pentoxifylline SR</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.8042</individualPrice>
								<listingDate>1997-08-28</listingDate>
								<amountMOHLTCPays>.8042</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="76">For the treatment of patients with critical limb ischemia (with arterial ulcers, gangrene and/or rest pain) and documented arterial vascular disease.</lccNote>
						<lccNote seq="002" type="N">Limited Use form must specify if arterial ulcers, gangrene and/or rest pain are present.</lccNote>
						<lccNote seq="003" type="R">LU Authorization Period: Indefinite.</lccNote>
						<lccNote seq="004" reasonForUseId="529">For the treatment of patients with venous ulcers lasting, or expected to last, more than 8 weeks.
Treatment should be discontinued after 3 months if there is no indication of objective benefit.
The duration of therapy with pentoxifylline should not exceed 12 months.</lccNote>
						<lccNote seq="005" type="N">Pentoxifylline should be used in combination with compression therapy.</lccNote>
						<lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
				</genericName>
			</pcg6>
		</pcg2>
		<pcg2 id="240000000">
			<name>CARDIOVASCULAR DRUGS</name>
			<pcg6 id="240400000">
				<name>CARDIAC DRUGS</name>
				<genericName id="00325">
					<name>ACEBUTOLOL HCL</name>
					<pcgGroup>
						<pcg9 id="240400084">
							<itemNumber>0532</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.1574</dailyCost>
							<drug id="01910140" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Rhotral</name>
								<manufacturerId>SAV</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="01926543" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Sectral</name>
								<manufacturerId>SAV</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02036290" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Monitan</name>
								<manufacturerId>WAY</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02147602" chronicUseMed="Y" sec3="Y">
								<name>Apo-Acebutolol</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0787</individualPrice>
								<dailyCost>.1574</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0787</amountMOHLTCPays>
							</drug>
							<drug id="02204517" chronicUseMed="Y" sec3="Y">
								<name>Teva-Acebutolol</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.0787</individualPrice>
								<dailyCost>.1574</dailyCost>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.0787</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400085">
							<itemNumber>0533</itemNumber>
							<strength>200mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.2354</dailyCost>
							<drug id="01910159" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Rhotral</name>
								<manufacturerId>SAV</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="01926551" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Sectral</name>
								<manufacturerId>SAV</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02036436" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Monitan</name>
								<manufacturerId>WAY</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02147610" chronicUseMed="Y" sec3="Y">
								<name>Apo-Acebutolol</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1177</individualPrice>
								<dailyCost>.2354</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1177</amountMOHLTCPays>
							</drug>
							<drug id="02204525" chronicUseMed="Y" sec3="Y">
								<name>Teva-Acebutolol</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1177</individualPrice>
								<dailyCost>.2354</dailyCost>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.1177</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400116">
							<itemNumber>0534</itemNumber>
							<strength>400mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.4932</dailyCost>
							<drug id="01910167" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Rhotral</name>
								<manufacturerId>SAV</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="01926578" chronicUseMed="Y" sec3="Y">
								<name>Sectral</name>
								<manufacturerId>SAV</manufacturerId>
								<individualPrice>1.0695</individualPrice>
								<dailyCost>2.1390</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2466</amountMOHLTCPays>
							</drug>
							<drug id="02036444" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Monitan</name>
								<manufacturerId>WAY</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02147629" chronicUseMed="Y" sec3="Y">
								<name>Apo-Acebutolol</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2466</individualPrice>
								<dailyCost>.4932</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2466</amountMOHLTCPays>
							</drug>
							<drug id="02204533" chronicUseMed="Y" sec3="Y">
								<name>Teva-Acebutolol</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2466</individualPrice>
								<dailyCost>.4932</dailyCost>
								<listingDate>1997-08-28</listingDate>
								<amountMOHLTCPays>.2466</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00323">
					<name>AMIODARONE HCL</name>
					<pcgGroup>
						<pcg9 id="240400072">
							<itemNumber>0535</itemNumber>
							<strength>200mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02036282" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Cordarone</name>
								<manufacturerId>PFI</manufacturerId>
								<note>The manufacturer recommends that treatment with amiodarone be initiated in hospital and continued in a monitored environment under the care of a cardiologist, or internist with equivalent experience in such care.
</note>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02239835" chronicUseMed="Y" sec3="Y">
								<name>Teva-Amiodarone</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3706</individualPrice>
								<note>The manufacturer recommends that treatment with amiodarone be initiated in hospital and continued in a monitored environment under the care of a cardiologist, or internist with equivalent experience in such care.</note>
								<listingDate>1999-09-15</listingDate>
								<amountMOHLTCPays>.3706</amountMOHLTCPays>
							</drug>
							<drug id="02242472" chronicUseMed="Y" sec3="Y">
								<name>PMS-Amiodarone</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3706</individualPrice>
								<note>The manufacturer recommends that treatment with amiodarone be initiated in hospital and continued in a monitored environment under the care of a cardiologist, or internist with equivalent experience in such care.</note>
								<listingDate>2001-06-07</listingDate>
								<amountMOHLTCPays>.3706</amountMOHLTCPays>
							</drug>
							<drug id="02243836" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Amiodarone</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.3706</individualPrice>
								<note>The manufacturer recommends that treatment with amiodarone be initiated in hospital and continued in a monitored environment under the care of a cardiologist, or internist with equivalent experience in such care.</note>
								<listingDate>2002-07-29</listingDate>
								<amountMOHLTCPays>.3706</amountMOHLTCPays>
							</drug>
							<drug id="02246194" chronicUseMed="Y" sec3="Y">
								<name>Apo-Amiodarone</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3706</individualPrice>
								<note>The manufacturer recommends that treatment with amiodarone be initiated in hospital and continued in a monitored environment under the care of a cardiologist, or internist with equivalent experience in such care.</note>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.3706</amountMOHLTCPays>
							</drug>
							<drug id="02247217" chronicUseMed="Y" sec3="Y">
								<name>Riva-Amiodarone</name>
								<manufacturerId>RIA</manufacturerId>
								<individualPrice>.3706</individualPrice>
								<listingDate>2021-08-31</listingDate>
								<amountMOHLTCPays>.3706</amountMOHLTCPays>
							</drug>
							<drug id="02364336" chronicUseMed="Y" sec3="Y">
								<name>Amiodarone</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.3706</individualPrice>
								<note>The manufacturer recommends that treatment with amiodarone be initiated in hospital and continued in a monitored environment under the care of a cardiologist, or internist with equivalent experience in such care.</note>
								<listingDate>2011-10-25</listingDate>
								<amountMOHLTCPays>.3706</amountMOHLTCPays>
							</drug>
							<drug id="02385465" chronicUseMed="Y" sec3="Y">
								<name>Amiodarone</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.3706</individualPrice>
								<note>The manufacturer recommends that treatment with amiodarone be initiated in hospital and continued in a monitored environment under the care of a cardiologist, or internist with equivalent experience in such care.</note>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.3706</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00328">
					<name>AMLODIPINE</name>
					<pcgGroup>
						<pcg9 id="240400120">
							<itemNumber>0536</itemNumber>
							<strength>5mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.1343</dailyCost>
							<drug id="00878928" chronicUseMed="Y" sec3="Y">
								<name>Norvasc</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>1.5637</individualPrice>
								<dailyCost>1.5637</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1343</amountMOHLTCPays>
							</drug>
							<drug id="02250497" chronicUseMed="Y" sec3="Y">
								<name>Teva-Amlodipine</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1343</individualPrice>
								<dailyCost>.1343</dailyCost>
								<listingDate>2009-09-30</listingDate>
								<amountMOHLTCPays>.1343</amountMOHLTCPays>
							</drug>
							<drug id="02259605" chronicUseMed="Y" sec3="Y">
								<name>Ratio-Amlodipine</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>.1343</individualPrice>
								<dailyCost>.1343</dailyCost>
								<listingDate>2009-09-30</listingDate>
								<amountMOHLTCPays>.1343</amountMOHLTCPays>
							</drug>
							<drug id="02272113" chronicUseMed="Y" sec3="Y">
								<name>Mylan-Amlodipine</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.1343</individualPrice>
								<dailyCost>.1343</dailyCost>
								<listingDate>2009-09-30</listingDate>
								<amountMOHLTCPays>.1343</amountMOHLTCPays>
							</drug>
							<drug id="02273373" chronicUseMed="Y" sec3="Y">
								<name>Apo-Amlodipine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1343</individualPrice>
								<dailyCost>.1343</dailyCost>
								<listingDate>2009-09-30</listingDate>
								<amountMOHLTCPays>.1343</amountMOHLTCPays>
							</drug>
							<drug id="02280132" chronicUseMed="Y" sec3="Y">
								<name>Gd-Amlodipine</name>
								<manufacturerId>GEM</manufacturerId>
								<individualPrice>.1343</individualPrice>
								<dailyCost>.1343</dailyCost>
								<listingDate>2009-09-30</listingDate>
								<amountMOHLTCPays>.1343</amountMOHLTCPays>
							</drug>
							<drug id="02284065" chronicUseMed="Y" sec3="Y">
								<name>PMS-Amlodipine</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1343</individualPrice>
								<dailyCost>.1343</dailyCost>
								<listingDate>2009-09-30</listingDate>
								<amountMOHLTCPays>.1343</amountMOHLTCPays>
							</drug>
							<drug id="02284383" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Amlodipine</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.1343</individualPrice>
								<dailyCost>.1343</dailyCost>
								<listingDate>2009-09-30</listingDate>
								<amountMOHLTCPays>.1343</amountMOHLTCPays>
							</drug>
							<drug id="02297485" chronicUseMed="Y" sec3="Y">
								<name>Act Amlodipine</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1343</individualPrice>
								<dailyCost>.1343</dailyCost>
								<listingDate>2009-09-30</listingDate>
								<amountMOHLTCPays>.1343</amountMOHLTCPays>
							</drug>
							<drug id="02321858" chronicUseMed="Y" sec3="Y">
								<name>Ran-Amlodipine</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.1343</individualPrice>
								<dailyCost>.1343</dailyCost>
								<listingDate>2009-09-30</listingDate>
								<amountMOHLTCPays>.1343</amountMOHLTCPays>
							</drug>
							<drug id="02331284" chronicUseMed="Y" sec3="Y">
								<name>Amlodipine</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.1343</individualPrice>
								<dailyCost>.1343</dailyCost>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.1343</amountMOHLTCPays>
							</drug>
							<drug id="02357194" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Amlodipine</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1343</individualPrice>
								<dailyCost>.1343</dailyCost>
								<listingDate>2012-02-29</listingDate>
								<amountMOHLTCPays>.1343</amountMOHLTCPays>
							</drug>
							<drug id="02357712" chronicUseMed="Y" sec3="Y">
								<name>Septa-Amlodipine</name>
								<manufacturerId>SET</manufacturerId>
								<individualPrice>.1343</individualPrice>
								<dailyCost>.1343</dailyCost>
								<listingDate>2011-03-15</listingDate>
								<amountMOHLTCPays>.1343</amountMOHLTCPays>
							</drug>
							<drug id="02362651" chronicUseMed="Y" sec3="Y">
								<name>Mint-Amlodipine</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.1343</individualPrice>
								<dailyCost>.1343</dailyCost>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.1343</amountMOHLTCPays>
							</drug>
							<drug id="02371715" chronicUseMed="Y" sec3="Y">
								<name>Mar-Amlodipine Tablets</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.1343</individualPrice>
								<dailyCost>.1343</dailyCost>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.1343</amountMOHLTCPays>
							</drug>
							<drug id="02385791" chronicUseMed="Y" sec3="Y">
								<name>Amlodipine</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.1343</individualPrice>
								<dailyCost>.1343</dailyCost>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.1343</amountMOHLTCPays>
							</drug>
							<drug id="02397072" chronicUseMed="Y" sec3="Y">
								<name>Auro-Amlodipine</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.1343</individualPrice>
								<dailyCost>.1343</dailyCost>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.1343</amountMOHLTCPays>
							</drug>
							<drug id="02419564" chronicUseMed="Y" sec3="Y">
								<name>Amlodipine Besylate Tablets USP</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.1343</individualPrice>
								<dailyCost>.1343</dailyCost>
								<listingDate>2019-01-31</listingDate>
								<amountMOHLTCPays>.1343</amountMOHLTCPays>
							</drug>
							<drug id="02426986" dinStatus="E" chronicUseMed="Y" sec3="Y">
								<name>Van-Amlodipine</name>
								<manufacturerId>VAN</manufacturerId>
								<individualPrice>.1343</individualPrice>
								<dailyCost>.1343</dailyCost>
								<listingDate>2015-08-26</listingDate>
								<amountMOHLTCPays>.1343</amountMOHLTCPays>
							</drug>
							<drug id="02429217" chronicUseMed="Y" sec3="Y">
								<name>Amlodipine</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1343</individualPrice>
								<dailyCost>.1343</dailyCost>
								<listingDate>2015-01-28</listingDate>
								<amountMOHLTCPays>.1343</amountMOHLTCPays>
							</drug>
							<drug id="02468026" chronicUseMed="Y" sec3="Y">
								<name>M-Amlodipine</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.1343</individualPrice>
								<dailyCost>.1343</dailyCost>
								<listingDate>2021-09-30</listingDate>
								<amountMOHLTCPays>.1343</amountMOHLTCPays>
							</drug>
							<drug id="02469030" chronicUseMed="Y" sec3="Y">
								<name>Pharma-Amlodipine</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1343</individualPrice>
								<dailyCost>.1343</dailyCost>
								<listingDate>2018-09-27</listingDate>
								<amountMOHLTCPays>.1343</amountMOHLTCPays>
							</drug>
							<drug id="02476460" chronicUseMed="Y" sec3="Y">
								<name>NRA-Amlodipine</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.1343</individualPrice>
								<dailyCost>.1343</dailyCost>
								<listingDate>2020-08-28</listingDate>
								<amountMOHLTCPays>.1343</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400121">
							<itemNumber>0537</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.1993</dailyCost>
							<drug id="00878936" chronicUseMed="Y" sec3="Y">
								<name>Norvasc</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>2.2823</individualPrice>
								<dailyCost>2.2823</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1993</amountMOHLTCPays>
							</drug>
							<drug id="02250500" chronicUseMed="Y" sec3="Y">
								<name>Teva-Amlodipine</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1993</individualPrice>
								<dailyCost>.1993</dailyCost>
								<listingDate>2009-09-30</listingDate>
								<amountMOHLTCPays>.1993</amountMOHLTCPays>
							</drug>
							<drug id="02259613" chronicUseMed="Y" sec3="Y">
								<name>Ratio-Amlodipine</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>.1993</individualPrice>
								<dailyCost>.1993</dailyCost>
								<listingDate>2009-09-30</listingDate>
								<amountMOHLTCPays>.1993</amountMOHLTCPays>
							</drug>
							<drug id="02272121" chronicUseMed="Y" sec3="Y">
								<name>Mylan-Amlodipine</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.1993</individualPrice>
								<dailyCost>.1993</dailyCost>
								<listingDate>2009-09-30</listingDate>
								<amountMOHLTCPays>.1993</amountMOHLTCPays>
							</drug>
							<drug id="02273381" chronicUseMed="Y" sec3="Y">
								<name>Apo-Amlodipine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1993</individualPrice>
								<dailyCost>.1993</dailyCost>
								<listingDate>2009-09-30</listingDate>
								<amountMOHLTCPays>.1993</amountMOHLTCPays>
							</drug>
							<drug id="02280140" chronicUseMed="Y" sec3="Y">
								<name>Gd-Amlodipine</name>
								<manufacturerId>GEM</manufacturerId>
								<individualPrice>.1993</individualPrice>
								<dailyCost>.1993</dailyCost>
								<listingDate>2009-09-30</listingDate>
								<amountMOHLTCPays>.1993</amountMOHLTCPays>
							</drug>
							<drug id="02284073" chronicUseMed="Y" sec3="Y">
								<name>PMS-Amlodipine</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1993</individualPrice>
								<dailyCost>.1993</dailyCost>
								<listingDate>2009-09-30</listingDate>
								<amountMOHLTCPays>.1993</amountMOHLTCPays>
							</drug>
							<drug id="02284391" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Amlodipine</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.1993</individualPrice>
								<dailyCost>.1993</dailyCost>
								<listingDate>2009-09-30</listingDate>
								<amountMOHLTCPays>.1993</amountMOHLTCPays>
							</drug>
							<drug id="02297493" chronicUseMed="Y" sec3="Y">
								<name>Act Amlodipine</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1993</individualPrice>
								<dailyCost>.1993</dailyCost>
								<listingDate>2009-09-30</listingDate>
								<amountMOHLTCPays>.1993</amountMOHLTCPays>
							</drug>
							<drug id="02321866" chronicUseMed="Y" sec3="Y">
								<name>Ran-Amlodipine</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.1993</individualPrice>
								<dailyCost>.1993</dailyCost>
								<listingDate>2009-09-30</listingDate>
								<amountMOHLTCPays>.1993</amountMOHLTCPays>
							</drug>
							<drug id="02331292" chronicUseMed="Y" sec3="Y">
								<name>Amlodipine</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.1993</individualPrice>
								<dailyCost>.1993</dailyCost>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.1993</amountMOHLTCPays>
							</drug>
							<drug id="02357208" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Amlodipine</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1993</individualPrice>
								<dailyCost>.1993</dailyCost>
								<listingDate>2012-02-29</listingDate>
								<amountMOHLTCPays>.1993</amountMOHLTCPays>
							</drug>
							<drug id="02357720" chronicUseMed="Y" sec3="Y">
								<name>Septa-Amlodipine</name>
								<manufacturerId>SET</manufacturerId>
								<individualPrice>.1993</individualPrice>
								<dailyCost>.1993</dailyCost>
								<listingDate>2011-03-15</listingDate>
								<amountMOHLTCPays>.1993</amountMOHLTCPays>
							</drug>
							<drug id="02362678" chronicUseMed="Y" sec3="Y">
								<name>Mint-Amlodipine</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.1993</individualPrice>
								<dailyCost>.1993</dailyCost>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.1993</amountMOHLTCPays>
							</drug>
							<drug id="02371723" chronicUseMed="Y" sec3="Y">
								<name>Mar-Amlodipine Tablets</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.1993</individualPrice>
								<dailyCost>.1993</dailyCost>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.1993</amountMOHLTCPays>
							</drug>
							<drug id="02385805" chronicUseMed="Y" sec3="Y">
								<name>Amlodipine</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.1993</individualPrice>
								<dailyCost>.1993</dailyCost>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.1993</amountMOHLTCPays>
							</drug>
							<drug id="02397080" chronicUseMed="Y" sec3="Y">
								<name>Auro-Amlodipine</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.1993</individualPrice>
								<dailyCost>.1993</dailyCost>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.1993</amountMOHLTCPays>
							</drug>
							<drug id="02419572" chronicUseMed="Y" sec3="Y">
								<name>Amlodipine Besylate Tablets USP</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.1993</individualPrice>
								<dailyCost>.1993</dailyCost>
								<listingDate>2019-01-31</listingDate>
								<amountMOHLTCPays>.1993</amountMOHLTCPays>
							</drug>
							<drug id="02426994" dinStatus="E" chronicUseMed="Y" sec3="Y">
								<name>Van-Amlodipine</name>
								<manufacturerId>VAN</manufacturerId>
								<individualPrice>.1993</individualPrice>
								<dailyCost>.1993</dailyCost>
								<listingDate>2015-08-26</listingDate>
								<amountMOHLTCPays>.1993</amountMOHLTCPays>
							</drug>
							<drug id="02429225" chronicUseMed="Y" sec3="Y">
								<name>Amlodipine</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1993</individualPrice>
								<dailyCost>.1993</dailyCost>
								<listingDate>2015-01-28</listingDate>
								<amountMOHLTCPays>.1993</amountMOHLTCPays>
							</drug>
							<drug id="02468034" chronicUseMed="Y" sec3="Y">
								<name>M-Amlodipine</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.1993</individualPrice>
								<dailyCost>.1993</dailyCost>
								<listingDate>2021-09-30</listingDate>
								<amountMOHLTCPays>.1993</amountMOHLTCPays>
							</drug>
							<drug id="02469049" chronicUseMed="Y" sec3="Y">
								<name>Pharma-Amlodipine</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1993</individualPrice>
								<dailyCost>.1993</dailyCost>
								<listingDate>2018-09-27</listingDate>
								<amountMOHLTCPays>.1993</amountMOHLTCPays>
							</drug>
							<drug id="02476479" chronicUseMed="Y" sec3="Y">
								<name>NRA-Amlodipine</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.1993</individualPrice>
								<dailyCost>.1993</dailyCost>
								<listingDate>2020-08-28</listingDate>
								<amountMOHLTCPays>.1993</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00324">
					<name>ATENOLOL</name>
					<pcgGroup>
						<pcg9 id="240400079">
							<itemNumber>0538</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.1107</dailyCost>
							<drug id="00773689" chronicUseMed="Y" sec3="Y">
								<name>Apo-Atenol</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1107</individualPrice>
								<dailyCost>.1107</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1107</amountMOHLTCPays>
							</drug>
							<drug id="01912062" chronicUseMed="Y" sec3="Y">
								<name>Teva-Atenolol</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1107</individualPrice>
								<dailyCost>.1107</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1107</amountMOHLTCPays>
							</drug>
							<drug id="02039532" chronicUseMed="Y" sec3="Y">
								<name>Tenormin</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>.6150</individualPrice>
								<dailyCost>.6150</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1107</amountMOHLTCPays>
							</drug>
							<drug id="02171791" chronicUseMed="Y" sec3="Y">
								<name>Ratio-Atenolol</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1107</individualPrice>
								<dailyCost>.1107</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1107</amountMOHLTCPays>
							</drug>
							<drug id="02237600" chronicUseMed="Y" sec3="Y">
								<name>PMS-Atenolol</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1107</individualPrice>
								<dailyCost>.1107</dailyCost>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>.1107</amountMOHLTCPays>
							</drug>
							<drug id="02255545" chronicUseMed="Y" sec3="Y">
								<name>Co Atenolol</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.1107</individualPrice>
								<dailyCost>.1107</dailyCost>
								<listingDate>2004-10-14</listingDate>
								<amountMOHLTCPays>.1107</amountMOHLTCPays>
							</drug>
							<drug id="02267985" chronicUseMed="Y" sec3="Y">
								<name>Ran-Atenolol</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.1107</individualPrice>
								<dailyCost>.1107</dailyCost>
								<listingDate>2006-03-01</listingDate>
								<amountMOHLTCPays>.1107</amountMOHLTCPays>
							</drug>
							<drug id="02367564" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Atenolol</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1107</individualPrice>
								<dailyCost>.1107</dailyCost>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.1107</amountMOHLTCPays>
							</drug>
							<drug id="02368021" chronicUseMed="Y" sec3="Y">
								<name>Mint-Atenol</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.1107</individualPrice>
								<dailyCost>.1107</dailyCost>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.1107</amountMOHLTCPays>
							</drug>
							<drug id="02368641" chronicUseMed="Y" sec3="Y">
								<name>Septa-Atenolol</name>
								<manufacturerId>SET</manufacturerId>
								<individualPrice>.1107</individualPrice>
								<dailyCost>.1107</dailyCost>
								<listingDate>2012-03-26</listingDate>
								<amountMOHLTCPays>.1107</amountMOHLTCPays>
							</drug>
							<drug id="02369184" chronicUseMed="Y" sec3="Y">
								<name>AG-Atenolol</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.1107</individualPrice>
								<dailyCost>.1107</dailyCost>
								<listingDate>2020-12-18</listingDate>
								<amountMOHLTCPays>.1107</amountMOHLTCPays>
							</drug>
							<drug id="02371987" chronicUseMed="Y" sec3="Y">
								<name>Mar-Atenolol</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.1107</individualPrice>
								<dailyCost>.1107</dailyCost>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.1107</amountMOHLTCPays>
							</drug>
							<drug id="02466465" chronicUseMed="Y" sec3="Y">
								<name>Atenolol</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.1107</individualPrice>
								<dailyCost>.1107</dailyCost>
								<listingDate>2018-04-01</listingDate>
								<amountMOHLTCPays>.1107</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400078">
							<itemNumber>0539</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.1821</dailyCost>
							<drug id="00773697" chronicUseMed="Y" sec3="Y">
								<name>Apo-Atenol</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1821</individualPrice>
								<dailyCost>.1821</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1821</amountMOHLTCPays>
							</drug>
							<drug id="01912054" chronicUseMed="Y" sec3="Y">
								<name>Teva-Atenolol</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1821</individualPrice>
								<dailyCost>.1821</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1821</amountMOHLTCPays>
							</drug>
							<drug id="02039540" chronicUseMed="Y" sec3="Y">
								<name>Tenormin</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>1.0117</individualPrice>
								<dailyCost>1.0117</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1821</amountMOHLTCPays>
							</drug>
							<drug id="02171805" chronicUseMed="Y" sec3="Y">
								<name>Ratio-Atenolol</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1821</individualPrice>
								<dailyCost>.1821</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1821</amountMOHLTCPays>
							</drug>
							<drug id="02237601" chronicUseMed="Y" sec3="Y">
								<name>PMS-Atenolol</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1821</individualPrice>
								<dailyCost>.1821</dailyCost>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>.1821</amountMOHLTCPays>
							</drug>
							<drug id="02255553" chronicUseMed="Y" sec3="Y">
								<name>Co Atenolol</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.1821</individualPrice>
								<dailyCost>.1821</dailyCost>
								<listingDate>2004-10-14</listingDate>
								<amountMOHLTCPays>.1821</amountMOHLTCPays>
							</drug>
							<drug id="02267993" chronicUseMed="Y" sec3="Y">
								<name>Ran-Atenolol</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.1821</individualPrice>
								<dailyCost>.1821</dailyCost>
								<listingDate>2006-03-01</listingDate>
								<amountMOHLTCPays>.1821</amountMOHLTCPays>
							</drug>
							<drug id="02367572" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Atenolol</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1821</individualPrice>
								<dailyCost>.1821</dailyCost>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.1821</amountMOHLTCPays>
							</drug>
							<drug id="02368048" chronicUseMed="Y" sec3="Y">
								<name>Mint-Atenol</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.1821</individualPrice>
								<dailyCost>.1821</dailyCost>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.1821</amountMOHLTCPays>
							</drug>
							<drug id="02368668" chronicUseMed="Y" sec3="Y">
								<name>Septa-Atenolol</name>
								<manufacturerId>SET</manufacturerId>
								<individualPrice>.1821</individualPrice>
								<dailyCost>.1821</dailyCost>
								<listingDate>2012-03-26</listingDate>
								<amountMOHLTCPays>.1821</amountMOHLTCPays>
							</drug>
							<drug id="02369192" chronicUseMed="Y" sec3="Y">
								<name>AG-Atenolol</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.1821</individualPrice>
								<dailyCost>.1821</dailyCost>
								<listingDate>2020-12-18</listingDate>
								<amountMOHLTCPays>.1821</amountMOHLTCPays>
							</drug>
							<drug id="02371995" chronicUseMed="Y" sec3="Y">
								<name>Mar-Atenolol</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.1821</individualPrice>
								<dailyCost>.1821</dailyCost>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.1821</amountMOHLTCPays>
							</drug>
							<drug id="02466473" chronicUseMed="Y" sec3="Y">
								<name>Atenolol</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.1821</individualPrice>
								<dailyCost>.1821</dailyCost>
								<listingDate>2018-04-01</listingDate>
								<amountMOHLTCPays>.1821</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01508">
					<name>BISOPROLOL FUMARATE</name>
					<pcgGroup>
						<pcg9 id="240400157">
							<itemNumber>0540</itemNumber>
							<strength>5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02241148" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Monocor</name>
								<manufacturerId>BIO</manufacturerId>
								<listingDate>2001-06-07</listingDate>
							</drug>
							<drug id="02256134" chronicUseMed="Y" sec3="Y">
								<name>Apo-Bisoprolol</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0715</individualPrice>
								<listingDate>2004-11-16</listingDate>
								<amountMOHLTCPays>.0715</amountMOHLTCPays>
							</drug>
							<drug id="02267470" chronicUseMed="Y" sec3="Y">
								<name>Teva-Bisoprolol</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.0715</individualPrice>
								<listingDate>2005-08-19</listingDate>
								<amountMOHLTCPays>.0715</amountMOHLTCPays>
							</drug>
							<drug id="02391589" chronicUseMed="Y" sec3="Y">
								<name>Bisoprolol</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.0715</individualPrice>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.0715</amountMOHLTCPays>
							</drug>
							<drug id="02465612" chronicUseMed="Y" sec3="Y">
								<name>Mint-Bisoprolol</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.0715</individualPrice>
								<listingDate>2019-03-28</listingDate>
								<amountMOHLTCPays>.0715</amountMOHLTCPays>
							</drug>
							<drug id="02494035" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Bisoprolol Tablets</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.0715</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.0715</amountMOHLTCPays>
							</drug>
							<drug id="02495562" chronicUseMed="Y" sec3="Y">
								<name>Bisoprolol Tablets</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.0715</individualPrice>
								<listingDate>2020-12-18</listingDate>
								<amountMOHLTCPays>.0715</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400158">
							<itemNumber>0541</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02241149" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Monocor</name>
								<manufacturerId>CRY</manufacturerId>
								<listingDate>2001-06-07</listingDate>
							</drug>
							<drug id="02256177" chronicUseMed="Y" sec3="Y">
								<name>Apo-Bisoprolol</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1044</individualPrice>
								<listingDate>2004-11-16</listingDate>
								<amountMOHLTCPays>.1044</amountMOHLTCPays>
							</drug>
							<drug id="02267489" chronicUseMed="Y" sec3="Y">
								<name>Teva-Bisoprolol</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1044</individualPrice>
								<listingDate>2005-08-19</listingDate>
								<amountMOHLTCPays>.1044</amountMOHLTCPays>
							</drug>
							<drug id="02391597" chronicUseMed="Y" sec3="Y">
								<name>Bisoprolol</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.1044</individualPrice>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.1044</amountMOHLTCPays>
							</drug>
							<drug id="02465620" chronicUseMed="Y" sec3="Y">
								<name>Mint-Bisoprolol</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.1044</individualPrice>
								<listingDate>2019-03-28</listingDate>
								<amountMOHLTCPays>.1044</amountMOHLTCPays>
							</drug>
							<drug id="02494043" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Bisoprolol Tablets</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.1044</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.1044</amountMOHLTCPays>
							</drug>
							<drug id="02495570" chronicUseMed="Y" sec3="Y">
								<name>Bisoprolol Tablets</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.1044</individualPrice>
								<listingDate>2020-12-18</listingDate>
								<amountMOHLTCPays>.1044</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00334">
					<name>CARVEDILOL</name>
					<pcgGroup lccId="00050">
						<pcg9 id="240400140">
							<itemNumber>0542</itemNumber>
							<strength>3.125mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.4862</dailyCost>
							<drug id="02229650" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Coreg</name>
								<manufacturerId>GSK</manufacturerId>
								<listingDate>1997-04-10</listingDate>
							</drug>
							<drug id="02245914" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>PMS-Carvedilol</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2431</individualPrice>
								<dailyCost>.4862</dailyCost>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.2431</amountMOHLTCPays>
							</drug>
							<drug id="02247933" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Apo-Carvedilol</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2431</individualPrice>
								<dailyCost>.4862</dailyCost>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.2431</amountMOHLTCPays>
							</drug>
							<drug id="02248752" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Carvedilol</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2431</individualPrice>
								<dailyCost>.4862</dailyCost>
								<listingDate>2010-03-02</listingDate>
								<amountMOHLTCPays>.2431</amountMOHLTCPays>
							</drug>
							<drug id="02252309" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Ratio-Carvedilol</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>.2431</individualPrice>
								<dailyCost>.4862</dailyCost>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.2431</amountMOHLTCPays>
							</drug>
							<drug id="02268027" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Ran-Carvedilol</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.2431</individualPrice>
								<dailyCost>.4862</dailyCost>
								<listingDate>2005-12-06</listingDate>
								<amountMOHLTCPays>.2431</amountMOHLTCPays>
							</drug>
							<drug id="02364913" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Carvedilol</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2431</individualPrice>
								<dailyCost>.4862</dailyCost>
								<listingDate>2011-10-25</listingDate>
								<amountMOHLTCPays>.2431</amountMOHLTCPays>
							</drug>
							<drug id="02368897" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Jamp-Carvedilol</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2431</individualPrice>
								<dailyCost>.4862</dailyCost>
								<listingDate>2012-08-27</listingDate>
								<amountMOHLTCPays>.2431</amountMOHLTCPays>
							</drug>
							<drug id="02418495" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Auro-Carvedilol</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2431</individualPrice>
								<dailyCost>.4862</dailyCost>
								<listingDate>2014-04-30</listingDate>
								<amountMOHLTCPays>.2431</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400141">
							<itemNumber>0543</itemNumber>
							<strength>6.25mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.4862</dailyCost>
							<drug id="02229651" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Coreg</name>
								<manufacturerId>GSK</manufacturerId>
								<listingDate>1997-04-10</listingDate>
							</drug>
							<drug id="02245915" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>PMS-Carvedilol</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2431</individualPrice>
								<dailyCost>.4862</dailyCost>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.2431</amountMOHLTCPays>
							</drug>
							<drug id="02247934" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Apo-Carvedilol</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2431</individualPrice>
								<dailyCost>.4862</dailyCost>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.2431</amountMOHLTCPays>
							</drug>
							<drug id="02248753" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Carvedilol</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2431</individualPrice>
								<dailyCost>.4862</dailyCost>
								<listingDate>2010-03-02</listingDate>
								<amountMOHLTCPays>.2431</amountMOHLTCPays>
							</drug>
							<drug id="02252317" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Ratio-Carvedilol</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>.2431</individualPrice>
								<dailyCost>.4862</dailyCost>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.2431</amountMOHLTCPays>
							</drug>
							<drug id="02268035" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Ran-Carvedilol</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.2431</individualPrice>
								<dailyCost>.4862</dailyCost>
								<listingDate>2005-12-06</listingDate>
								<amountMOHLTCPays>.2431</amountMOHLTCPays>
							</drug>
							<drug id="02364921" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Carvedilol</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2431</individualPrice>
								<dailyCost>.4862</dailyCost>
								<listingDate>2011-10-25</listingDate>
								<amountMOHLTCPays>.2431</amountMOHLTCPays>
							</drug>
							<drug id="02368900" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Jamp-Carvedilol</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2431</individualPrice>
								<dailyCost>.4862</dailyCost>
								<listingDate>2012-08-27</listingDate>
								<amountMOHLTCPays>.2431</amountMOHLTCPays>
							</drug>
							<drug id="02418509" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Auro-Carvedilol</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2431</individualPrice>
								<dailyCost>.4862</dailyCost>
								<listingDate>2014-04-30</listingDate>
								<amountMOHLTCPays>.2431</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400142">
							<itemNumber>0544</itemNumber>
							<strength>12.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.4862</dailyCost>
							<drug id="02229652" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Coreg</name>
								<manufacturerId>GSK</manufacturerId>
								<listingDate>1997-04-10</listingDate>
							</drug>
							<drug id="02245916" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>PMS-Carvedilol</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2431</individualPrice>
								<dailyCost>.4862</dailyCost>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.2431</amountMOHLTCPays>
							</drug>
							<drug id="02247935" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Apo-Carvedilol</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2431</individualPrice>
								<dailyCost>.4862</dailyCost>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.2431</amountMOHLTCPays>
							</drug>
							<drug id="02248754" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Carvedilol</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2431</individualPrice>
								<dailyCost>.4862</dailyCost>
								<listingDate>2010-03-02</listingDate>
								<amountMOHLTCPays>.2431</amountMOHLTCPays>
							</drug>
							<drug id="02252325" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Ratio-Carvedilol</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>.2431</individualPrice>
								<dailyCost>.4862</dailyCost>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.2431</amountMOHLTCPays>
							</drug>
							<drug id="02268043" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Ran-Carvedilol</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.2431</individualPrice>
								<dailyCost>.4862</dailyCost>
								<listingDate>2005-12-06</listingDate>
								<amountMOHLTCPays>.2431</amountMOHLTCPays>
							</drug>
							<drug id="02364948" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Carvedilol</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2431</individualPrice>
								<dailyCost>.4862</dailyCost>
								<listingDate>2011-10-25</listingDate>
								<amountMOHLTCPays>.2431</amountMOHLTCPays>
							</drug>
							<drug id="02368919" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Jamp-Carvedilol</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2431</individualPrice>
								<dailyCost>.4862</dailyCost>
								<listingDate>2012-08-27</listingDate>
								<amountMOHLTCPays>.2431</amountMOHLTCPays>
							</drug>
							<drug id="02418517" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Auro-Carvedilol</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2431</individualPrice>
								<dailyCost>.4862</dailyCost>
								<listingDate>2014-04-30</listingDate>
								<amountMOHLTCPays>.2431</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400143">
							<itemNumber>0545</itemNumber>
							<strength>25mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.4862</dailyCost>
							<drug id="02229653" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Coreg</name>
								<manufacturerId>GSK</manufacturerId>
								<listingDate>1997-04-10</listingDate>
							</drug>
							<drug id="02245917" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>PMS-Carvedilol</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2431</individualPrice>
								<dailyCost>.4862</dailyCost>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.2431</amountMOHLTCPays>
							</drug>
							<drug id="02247936" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Apo-Carvedilol</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2431</individualPrice>
								<dailyCost>.4862</dailyCost>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.2431</amountMOHLTCPays>
							</drug>
							<drug id="02248755" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Carvedilol</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2431</individualPrice>
								<dailyCost>.4862</dailyCost>
								<listingDate>2010-03-02</listingDate>
								<amountMOHLTCPays>.2431</amountMOHLTCPays>
							</drug>
							<drug id="02252333" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Ratio-Carvedilol</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>.2431</individualPrice>
								<dailyCost>.4862</dailyCost>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.2431</amountMOHLTCPays>
							</drug>
							<drug id="02268051" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Ran-Carvedilol</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.2431</individualPrice>
								<dailyCost>.4862</dailyCost>
								<listingDate>2005-12-06</listingDate>
								<amountMOHLTCPays>.2431</amountMOHLTCPays>
							</drug>
							<drug id="02364956" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Carvedilol</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2431</individualPrice>
								<dailyCost>.4862</dailyCost>
								<listingDate>2011-10-25</listingDate>
								<amountMOHLTCPays>.2431</amountMOHLTCPays>
							</drug>
							<drug id="02368927" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Jamp-Carvedilol</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2431</individualPrice>
								<dailyCost>.4862</dailyCost>
								<listingDate>2012-08-27</listingDate>
								<amountMOHLTCPays>.2431</amountMOHLTCPays>
							</drug>
							<drug id="02418525" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Auro-Carvedilol</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2431</individualPrice>
								<dailyCost>.4862</dailyCost>
								<listingDate>2014-04-30</listingDate>
								<amountMOHLTCPays>.2431</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" type="R">For patients with:</lccNote>
						<lccNote seq="002" reasonForUseId="183">a) NYHA Class II or III Congestive Heart Failure (CHF); and
b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and
c) An ejection fraction less than or equal to 35%; and
d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management.</lccNote>
						<lccNote seq="003" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00307">
					<name>DIGOXIN</name>
					<note>Digoxin toxicity is common and serious: digoxin levels should be monitored in the elderly, after adding drugs that affect urea clearance including diuretics, particularly spironolactone; verapamil and quinidine also interact significantly with digoxin. Dose should be reduced in renal impairment and in elderly patients. Chronic therapy should be re-evaluated.</note>
					<pcgGroup>
						<pcg9 id="240400004">
							<itemNumber>0546</itemNumber>
							<strength>0.05mg/mL</strength>
							<dosageForm>O/L</dosageForm>
							<drug id="02242320" sec3="Y">
								<name>Toloxin</name>
								<manufacturerId>PEN</manufacturerId>
								<individualPrice>.3692</individualPrice>
								<listingDate>2002-04-04</listingDate>
								<amountMOHLTCPays>.3692</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400090">
							<itemNumber>0547</itemNumber>
							<strength>0.0625mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02335700" chronicUseMed="Y" sec3="Y">
								<name>Toloxin</name>
								<manufacturerId>PEN</manufacturerId>
								<individualPrice>.2177</individualPrice>
								<listingDate>2010-06-14</listingDate>
								<amountMOHLTCPays>.2177</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400003">
							<itemNumber>0548</itemNumber>
							<strength>0.125mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02281228" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Apo-Digoxin</name>
								<manufacturerId>APX</manufacturerId>
								<listingDate>2006-08-24</listingDate>
							</drug>
							<drug id="02335719" chronicUseMed="Y" sec3="Y">
								<name>Toloxin</name>
								<manufacturerId>PEN</manufacturerId>
								<individualPrice>.2060</individualPrice>
								<listingDate>2010-06-14</listingDate>
								<amountMOHLTCPays>.2060</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400002">
							<itemNumber>0549</itemNumber>
							<strength>0.25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02281201" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Apo-Digoxin</name>
								<manufacturerId>APX</manufacturerId>
								<listingDate>2006-08-24</listingDate>
							</drug>
							<drug id="02335727" chronicUseMed="Y" sec3="Y">
								<name>Toloxin</name>
								<manufacturerId>PEN</manufacturerId>
								<individualPrice>.2060</individualPrice>
								<listingDate>2010-06-14</listingDate>
								<amountMOHLTCPays>.2060</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00320">
					<name>DILTIAZEM HCL</name>
					<pcgGroup>
						<pcg9 id="240400161">
							<itemNumber>0550</itemNumber>
							<strength>120mg</strength>
							<dosageForm>ER Tab</dosageForm>
							<drug id="02256738" chronicUseMed="Y" sec3="Y">
								<name>Tiazac XC</name>
								<manufacturerId>BIO</manufacturerId>
								<individualPrice>.8956</individualPrice>
								<listingDate>2005-05-25</listingDate>
								<amountMOHLTCPays>.8956</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400162">
							<itemNumber>0551</itemNumber>
							<strength>180mg</strength>
							<dosageForm>ER Tab</dosageForm>
							<drug id="02256746" chronicUseMed="Y" sec3="Y">
								<name>Tiazac XC</name>
								<manufacturerId>BIO</manufacturerId>
								<individualPrice>1.1903</individualPrice>
								<listingDate>2005-05-25</listingDate>
								<amountMOHLTCPays>1.1903</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400163">
							<itemNumber>0552</itemNumber>
							<strength>240mg</strength>
							<dosageForm>ER Tab</dosageForm>
							<drug id="02256754" chronicUseMed="Y" sec3="Y">
								<name>Tiazac XC</name>
								<manufacturerId>BIO</manufacturerId>
								<individualPrice>1.5808</individualPrice>
								<listingDate>2005-05-25</listingDate>
								<amountMOHLTCPays>1.5808</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400164">
							<itemNumber>0553</itemNumber>
							<strength>300mg</strength>
							<dosageForm>ER Tab</dosageForm>
							<drug id="02256762" chronicUseMed="Y" sec3="Y">
								<name>Tiazac XC</name>
								<manufacturerId>BIO</manufacturerId>
								<individualPrice>1.5760</individualPrice>
								<listingDate>2005-05-25</listingDate>
								<amountMOHLTCPays>1.5760</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400165">
							<itemNumber>0554</itemNumber>
							<strength>360mg</strength>
							<dosageForm>ER Tab</dosageForm>
							<drug id="02256770" chronicUseMed="Y" sec3="Y">
								<name>Tiazac XC</name>
								<manufacturerId>BIO</manufacturerId>
								<individualPrice>1.5807</individualPrice>
								<listingDate>2005-05-25</listingDate>
								<amountMOHLTCPays>1.5807</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400133">
							<itemNumber>0555</itemNumber>
							<strength>120mg</strength>
							<dosageForm>LA Cap</dosageForm>
							<dailyCost>.3634</dailyCost>
							<drug id="02097249" chronicUseMed="Y" sec3="Y">
								<name>Cardizem CD</name>
								<manufacturerId>VAL</manufacturerId>
								<individualPrice>1.6244</individualPrice>
								<dailyCost>1.6244</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3634</amountMOHLTCPays>
							</drug>
							<drug id="02230997" chronicUseMed="Y" sec3="Y">
								<name>Apo-Diltiaz CD</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3634</individualPrice>
								<dailyCost>.3634</dailyCost>
								<listingDate>1997-08-28</listingDate>
								<amountMOHLTCPays>.3634</amountMOHLTCPays>
							</drug>
							<drug id="02242538" chronicUseMed="Y" sec3="Y">
								<name>Teva-Diltazem CD</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3634</individualPrice>
								<dailyCost>.3634</dailyCost>
								<listingDate>2001-06-07</listingDate>
								<amountMOHLTCPays>.3634</amountMOHLTCPays>
							</drug>
							<drug id="02243338" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Diltiazem CD</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.3634</individualPrice>
								<dailyCost>.3634</dailyCost>
								<listingDate>2001-10-11</listingDate>
								<amountMOHLTCPays>.3634</amountMOHLTCPays>
							</drug>
							<drug id="02355752" chronicUseMed="Y" sec3="Y">
								<name>PMS-Diltiazem CD</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3634</individualPrice>
								<dailyCost>.3634</dailyCost>
								<listingDate>2011-05-19</listingDate>
								<amountMOHLTCPays>.3634</amountMOHLTCPays>
							</drug>
							<drug id="02370611" chronicUseMed="Y" sec3="Y">
								<name>Co Diltiazem CD</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.3634</individualPrice>
								<dailyCost>.3634</dailyCost>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.3634</amountMOHLTCPays>
							</drug>
							<drug id="02445999" chronicUseMed="Y" sec3="Y">
								<name>Diltiazem CD</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.3634</individualPrice>
								<dailyCost>.3634</dailyCost>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>.3634</amountMOHLTCPays>
							</drug>
							<drug id="02484064" chronicUseMed="Y" sec3="Y">
								<name>Mar-Diltiazem CD</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.3634</individualPrice>
								<dailyCost>.3634</dailyCost>
								<listingDate>2020-05-29</listingDate>
								<amountMOHLTCPays>.3634</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400123">
							<itemNumber>0556</itemNumber>
							<strength>180mg</strength>
							<dosageForm>LA Cap</dosageForm>
							<dailyCost>.4824</dailyCost>
							<drug id="02097257" chronicUseMed="Y" sec3="Y">
								<name>Cardizem CD</name>
								<manufacturerId>VAL</manufacturerId>
								<individualPrice>2.1565</individualPrice>
								<dailyCost>2.1565</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.4824</amountMOHLTCPays>
							</drug>
							<drug id="02230998" chronicUseMed="Y" sec3="Y">
								<name>Apo-Diltiaz CD</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.4824</individualPrice>
								<dailyCost>.4824</dailyCost>
								<listingDate>1997-08-28</listingDate>
								<amountMOHLTCPays>.4824</amountMOHLTCPays>
							</drug>
							<drug id="02242539" chronicUseMed="Y" sec3="Y">
								<name>Teva-Diltazem CD</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.4824</individualPrice>
								<dailyCost>.4824</dailyCost>
								<listingDate>2001-06-07</listingDate>
								<amountMOHLTCPays>.4824</amountMOHLTCPays>
							</drug>
							<drug id="02243339" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Diltiazem CD</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.4824</individualPrice>
								<dailyCost>.4824</dailyCost>
								<listingDate>2001-10-11</listingDate>
								<amountMOHLTCPays>.4824</amountMOHLTCPays>
							</drug>
							<drug id="02355760" chronicUseMed="Y" sec3="Y">
								<name>PMS-Diltiazem CD</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.4824</individualPrice>
								<dailyCost>.4824</dailyCost>
								<listingDate>2011-05-19</listingDate>
								<amountMOHLTCPays>.4824</amountMOHLTCPays>
							</drug>
							<drug id="02370638" chronicUseMed="Y" sec3="Y">
								<name>Co Diltiazem CD</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.4824</individualPrice>
								<dailyCost>.4824</dailyCost>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.4824</amountMOHLTCPays>
							</drug>
							<drug id="02446006" chronicUseMed="Y" sec3="Y">
								<name>Diltiazem CD</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.4824</individualPrice>
								<dailyCost>.4824</dailyCost>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>.4824</amountMOHLTCPays>
							</drug>
							<drug id="02484072" chronicUseMed="Y" sec3="Y">
								<name>Mar-Diltiazem CD</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.4824</individualPrice>
								<dailyCost>.4824</dailyCost>
								<listingDate>2020-05-29</listingDate>
								<amountMOHLTCPays>.4824</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400122">
							<itemNumber>0557</itemNumber>
							<strength>240mg</strength>
							<dosageForm>LA Cap</dosageForm>
							<dailyCost>.6399</dailyCost>
							<drug id="02097265" chronicUseMed="Y" sec3="Y">
								<name>Cardizem CD</name>
								<manufacturerId>VAL</manufacturerId>
								<individualPrice>2.8604</individualPrice>
								<dailyCost>2.8604</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.6399</amountMOHLTCPays>
							</drug>
							<drug id="02230999" chronicUseMed="Y" sec3="Y">
								<name>Apo-Diltiaz CD</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.6399</individualPrice>
								<dailyCost>.6399</dailyCost>
								<listingDate>1997-08-28</listingDate>
								<amountMOHLTCPays>.6399</amountMOHLTCPays>
							</drug>
							<drug id="02242540" chronicUseMed="Y" sec3="Y">
								<name>Teva-Diltazem CD</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.6399</individualPrice>
								<dailyCost>.6399</dailyCost>
								<listingDate>2001-06-07</listingDate>
								<amountMOHLTCPays>.6399</amountMOHLTCPays>
							</drug>
							<drug id="02243340" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Diltiazem CD</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.6399</individualPrice>
								<dailyCost>.6399</dailyCost>
								<listingDate>2001-10-11</listingDate>
								<amountMOHLTCPays>.6399</amountMOHLTCPays>
							</drug>
							<drug id="02355779" chronicUseMed="Y" sec3="Y">
								<name>PMS-Diltiazem CD</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.6399</individualPrice>
								<dailyCost>.6399</dailyCost>
								<listingDate>2011-05-19</listingDate>
								<amountMOHLTCPays>.6399</amountMOHLTCPays>
							</drug>
							<drug id="02370646" chronicUseMed="Y" sec3="Y">
								<name>Co Diltiazem CD</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.6399</individualPrice>
								<dailyCost>.6399</dailyCost>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.6399</amountMOHLTCPays>
							</drug>
							<drug id="02446014" chronicUseMed="Y" sec3="Y">
								<name>Diltiazem CD</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.6399</individualPrice>
								<dailyCost>.6399</dailyCost>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>.6399</amountMOHLTCPays>
							</drug>
							<drug id="02484080" chronicUseMed="Y" sec3="Y">
								<name>Mar-Diltiazem CD</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.6399</individualPrice>
								<dailyCost>.6399</dailyCost>
								<listingDate>2020-05-29</listingDate>
								<amountMOHLTCPays>.6399</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400134">
							<itemNumber>0558</itemNumber>
							<strength>300mg</strength>
							<dosageForm>LA Cap</dosageForm>
							<dailyCost>.7999</dailyCost>
							<drug id="02097273" chronicUseMed="Y" sec3="Y">
								<name>Cardizem CD</name>
								<manufacturerId>VAL</manufacturerId>
								<individualPrice>3.5755</individualPrice>
								<dailyCost>3.5755</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.7999</amountMOHLTCPays>
							</drug>
							<drug id="02229526" chronicUseMed="Y" sec3="Y">
								<name>Apo-Diltiaz CD</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.7999</individualPrice>
								<dailyCost>.7999</dailyCost>
								<listingDate>1997-04-10</listingDate>
								<amountMOHLTCPays>.7999</amountMOHLTCPays>
							</drug>
							<drug id="02242541" chronicUseMed="Y" sec3="Y">
								<name>Teva-Diltazem CD</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.7999</individualPrice>
								<dailyCost>.7999</dailyCost>
								<listingDate>2001-06-07</listingDate>
								<amountMOHLTCPays>.7999</amountMOHLTCPays>
							</drug>
							<drug id="02243341" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Diltiazem CD</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.7999</individualPrice>
								<dailyCost>.7999</dailyCost>
								<listingDate>2001-10-11</listingDate>
								<amountMOHLTCPays>.7999</amountMOHLTCPays>
							</drug>
							<drug id="02355787" chronicUseMed="Y" sec3="Y">
								<name>PMS-Diltiazem CD</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.7999</individualPrice>
								<dailyCost>.7999</dailyCost>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.7999</amountMOHLTCPays>
							</drug>
							<drug id="02370654" chronicUseMed="Y" sec3="Y">
								<name>Co Diltiazem CD</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.7999</individualPrice>
								<dailyCost>.7999</dailyCost>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.7999</amountMOHLTCPays>
							</drug>
							<drug id="02446022" chronicUseMed="Y" sec3="Y">
								<name>Diltiazem CD</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.7999</individualPrice>
								<dailyCost>.7999</dailyCost>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>.7999</amountMOHLTCPays>
							</drug>
							<drug id="02484099" chronicUseMed="Y" sec3="Y">
								<name>Mar-Diltiazem CD</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.7999</individualPrice>
								<dailyCost>.7999</dailyCost>
								<listingDate>2020-05-29</listingDate>
								<amountMOHLTCPays>.7999</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400145">
							<itemNumber>0559</itemNumber>
							<strength>120mg</strength>
							<dosageForm>SR Cap</dosageForm>
							<dailyCost>.2133</dailyCost>
							<drug id="02231150" chronicUseMed="Y" sec3="Y">
								<name>Tiazac</name>
								<manufacturerId>VAL</manufacturerId>
								<individualPrice>1.0066</individualPrice>
								<dailyCost>1.0066</dailyCost>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.2133</amountMOHLTCPays>
							</drug>
							<drug id="02245918" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Diltiazem T</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2133</individualPrice>
								<dailyCost>.2133</dailyCost>
								<listingDate>2006-01-24</listingDate>
								<amountMOHLTCPays>.2133</amountMOHLTCPays>
							</drug>
							<drug id="02271605" chronicUseMed="Y" sec3="Y">
								<name>Teva-Diltiazem HCL ER</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2133</individualPrice>
								<dailyCost>.2133</dailyCost>
								<listingDate>2006-03-01</listingDate>
								<amountMOHLTCPays>.2133</amountMOHLTCPays>
							</drug>
							<drug id="02370441" chronicUseMed="Y" sec3="Y">
								<name>Co Diltiazem T</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.2133</individualPrice>
								<dailyCost>.2133</dailyCost>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.2133</amountMOHLTCPays>
							</drug>
							<drug id="02465353" chronicUseMed="Y" sec3="Y">
								<name>Mar-Diltiazem T</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.2133</individualPrice>
								<dailyCost>.2133</dailyCost>
								<listingDate>2018-08-30</listingDate>
								<amountMOHLTCPays>.2133</amountMOHLTCPays>
							</drug>
							<drug id="02495376" chronicUseMed="Y" sec3="Y">
								<name>Jamp Diltiazem T</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2133</individualPrice>
								<dailyCost>.2133</dailyCost>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.2133</amountMOHLTCPays>
							</drug>
							<drug id="02516101" chronicUseMed="Y" sec3="Y">
								<name>Diltiazem T</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2133</individualPrice>
								<dailyCost>.2133</dailyCost>
								<listingDate>2021-12-17</listingDate>
								<amountMOHLTCPays>.2133</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400146">
							<itemNumber>0560</itemNumber>
							<strength>180mg</strength>
							<dosageForm>SR Cap</dosageForm>
							<dailyCost>.2889</dailyCost>
							<drug id="02231151" chronicUseMed="Y" sec3="Y">
								<name>Tiazac</name>
								<manufacturerId>VAL</manufacturerId>
								<individualPrice>1.3447</individualPrice>
								<dailyCost>1.3447</dailyCost>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.2889</amountMOHLTCPays>
							</drug>
							<drug id="02245919" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Diltiazem T</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2889</individualPrice>
								<dailyCost>.2889</dailyCost>
								<listingDate>2006-01-24</listingDate>
								<amountMOHLTCPays>.2889</amountMOHLTCPays>
							</drug>
							<drug id="02271613" chronicUseMed="Y" sec3="Y">
								<name>Teva-Diltiazem HCL ER</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2889</individualPrice>
								<dailyCost>.2889</dailyCost>
								<listingDate>2006-03-01</listingDate>
								<amountMOHLTCPays>.2889</amountMOHLTCPays>
							</drug>
							<drug id="02370492" chronicUseMed="Y" sec3="Y">
								<name>Co Diltiazem T</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.2889</individualPrice>
								<dailyCost>.2889</dailyCost>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.2889</amountMOHLTCPays>
							</drug>
							<drug id="02465361" chronicUseMed="Y" sec3="Y">
								<name>Mar-Diltiazem T</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.2889</individualPrice>
								<dailyCost>.2889</dailyCost>
								<listingDate>2018-08-30</listingDate>
								<amountMOHLTCPays>.2889</amountMOHLTCPays>
							</drug>
							<drug id="02495384" chronicUseMed="Y" sec3="Y">
								<name>Jamp Diltiazem T</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2889</individualPrice>
								<dailyCost>.2889</dailyCost>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.2889</amountMOHLTCPays>
							</drug>
							<drug id="02516128" chronicUseMed="Y" sec3="Y">
								<name>Diltiazem T</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2889</individualPrice>
								<dailyCost>.2889</dailyCost>
								<listingDate>2021-12-17</listingDate>
								<amountMOHLTCPays>.2889</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400147">
							<itemNumber>0561</itemNumber>
							<strength>240mg</strength>
							<dosageForm>SR Cap</dosageForm>
							<dailyCost>.3832</dailyCost>
							<drug id="02231152" chronicUseMed="Y" sec3="Y">
								<name>Tiazac</name>
								<manufacturerId>VAL</manufacturerId>
								<individualPrice>1.7836</individualPrice>
								<dailyCost>1.7836</dailyCost>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.3832</amountMOHLTCPays>
							</drug>
							<drug id="02245920" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Diltiazem T</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.3832</individualPrice>
								<dailyCost>.3832</dailyCost>
								<listingDate>2006-01-24</listingDate>
								<amountMOHLTCPays>.3832</amountMOHLTCPays>
							</drug>
							<drug id="02271621" chronicUseMed="Y" sec3="Y">
								<name>Teva-Diltiazem HCL ER</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3832</individualPrice>
								<dailyCost>.3832</dailyCost>
								<listingDate>2006-03-01</listingDate>
								<amountMOHLTCPays>.3832</amountMOHLTCPays>
							</drug>
							<drug id="02370506" chronicUseMed="Y" sec3="Y">
								<name>Co Diltiazem T</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.3832</individualPrice>
								<dailyCost>.3832</dailyCost>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.3832</amountMOHLTCPays>
							</drug>
							<drug id="02465388" chronicUseMed="Y" sec3="Y">
								<name>Mar-Diltiazem T</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.3832</individualPrice>
								<dailyCost>.3832</dailyCost>
								<listingDate>2018-08-30</listingDate>
								<amountMOHLTCPays>.3832</amountMOHLTCPays>
							</drug>
							<drug id="02495392" chronicUseMed="Y" sec3="Y">
								<name>Jamp Diltiazem T</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.3832</individualPrice>
								<dailyCost>.3832</dailyCost>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.3832</amountMOHLTCPays>
							</drug>
							<drug id="02516136" chronicUseMed="Y" sec3="Y">
								<name>Diltiazem T</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.3832</individualPrice>
								<dailyCost>.3832</dailyCost>
								<listingDate>2021-12-17</listingDate>
								<amountMOHLTCPays>.3832</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400148">
							<itemNumber>0562</itemNumber>
							<strength>300mg</strength>
							<dosageForm>SR Cap</dosageForm>
							<dailyCost>.4720</dailyCost>
							<drug id="02231154" chronicUseMed="Y" sec3="Y">
								<name>Tiazac</name>
								<manufacturerId>VAL</manufacturerId>
								<individualPrice>2.2338</individualPrice>
								<dailyCost>2.2338</dailyCost>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.4720</amountMOHLTCPays>
							</drug>
							<drug id="02245921" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Diltiazem T</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.4720</individualPrice>
								<dailyCost>.4720</dailyCost>
								<listingDate>2006-01-24</listingDate>
								<amountMOHLTCPays>.4720</amountMOHLTCPays>
							</drug>
							<drug id="02271648" chronicUseMed="Y" sec3="Y">
								<name>Teva-Diltiazem HCL ER</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.4720</individualPrice>
								<dailyCost>.4720</dailyCost>
								<listingDate>2006-03-01</listingDate>
								<amountMOHLTCPays>.4720</amountMOHLTCPays>
							</drug>
							<drug id="02370514" chronicUseMed="Y" sec3="Y">
								<name>Co Diltiazem T</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.4720</individualPrice>
								<dailyCost>.4720</dailyCost>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.4720</amountMOHLTCPays>
							</drug>
							<drug id="02465396" chronicUseMed="Y" sec3="Y">
								<name>Mar-Diltiazem T</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.4720</individualPrice>
								<dailyCost>.4720</dailyCost>
								<listingDate>2018-08-30</listingDate>
								<amountMOHLTCPays>.4720</amountMOHLTCPays>
							</drug>
							<drug id="02495406" chronicUseMed="Y" sec3="Y">
								<name>Jamp Diltiazem T</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.4720</individualPrice>
								<dailyCost>.4720</dailyCost>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.4720</amountMOHLTCPays>
							</drug>
							<drug id="02516144" chronicUseMed="Y" sec3="Y">
								<name>Diltiazem T</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.4720</individualPrice>
								<dailyCost>.4720</dailyCost>
								<listingDate>2021-12-17</listingDate>
								<amountMOHLTCPays>.4720</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400149">
							<itemNumber>0563</itemNumber>
							<strength>360mg</strength>
							<dosageForm>SR Cap</dosageForm>
							<dailyCost>.5778</dailyCost>
							<drug id="02231155" chronicUseMed="Y" sec3="Y">
								<name>Tiazac</name>
								<manufacturerId>VAL</manufacturerId>
								<individualPrice>2.6894</individualPrice>
								<dailyCost>2.6894</dailyCost>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.5778</amountMOHLTCPays>
							</drug>
							<drug id="02245922" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Diltiazem T</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.5778</individualPrice>
								<dailyCost>.5778</dailyCost>
								<listingDate>2006-01-24</listingDate>
								<amountMOHLTCPays>.5778</amountMOHLTCPays>
							</drug>
							<drug id="02271656" chronicUseMed="Y" sec3="Y">
								<name>Teva-Diltiazem HCL ER</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.5778</individualPrice>
								<dailyCost>.5778</dailyCost>
								<listingDate>2006-03-01</listingDate>
								<amountMOHLTCPays>.5778</amountMOHLTCPays>
							</drug>
							<drug id="02370522" chronicUseMed="Y" sec3="Y">
								<name>Co Diltiazem T</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.5778</individualPrice>
								<dailyCost>.5778</dailyCost>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.5778</amountMOHLTCPays>
							</drug>
							<drug id="02465418" chronicUseMed="Y" sec3="Y">
								<name>Mar-Diltiazem T</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.5778</individualPrice>
								<dailyCost>.5778</dailyCost>
								<listingDate>2018-08-30</listingDate>
								<amountMOHLTCPays>.5778</amountMOHLTCPays>
							</drug>
							<drug id="02495414" chronicUseMed="Y" sec3="Y">
								<name>Jamp Diltiazem T</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.5778</individualPrice>
								<dailyCost>.5778</dailyCost>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.5778</amountMOHLTCPays>
							</drug>
							<drug id="02516152" chronicUseMed="Y" sec3="Y">
								<name>Diltiazem T</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.5778</individualPrice>
								<dailyCost>.5778</dailyCost>
								<listingDate>2021-12-17</listingDate>
								<amountMOHLTCPays>.5778</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400054">
							<itemNumber>0564</itemNumber>
							<strength>30mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00771376" chronicUseMed="Y" sec3="Y">
								<name>AA-Diltiaz</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.1866</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1866</amountMOHLTCPays>
							</drug>
							<drug id="00862924" chronicUseMed="Y" sec3="Y">
								<name>Teva-Diltazem</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1866</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1866</amountMOHLTCPays>
							</drug>
							<drug id="02097370" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Cardizem</name>
								<manufacturerId>BIO</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="240400053">
							<itemNumber>0565</itemNumber>
							<strength>60mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00771384" chronicUseMed="Y" sec3="Y">
								<name>AA-Diltiaz</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.3273</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3273</amountMOHLTCPays>
							</drug>
							<drug id="00862932" chronicUseMed="Y" sec3="Y">
								<name>Teva-Diltazem</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3273</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3273</amountMOHLTCPays>
							</drug>
							<drug id="02097389" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Cardizem</name>
								<manufacturerId>BIO</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00313">
					<name>DISOPYRAMIDE</name>
					<pcgGroup>
						<pcg9 id="240400019">
							<itemNumber>0566</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02030799" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Norpace</name>
								<manufacturerId>RBT</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02224801" chronicUseMed="Y" sec3="Y">
								<name>Rythmodan</name>
								<manufacturerId>CHE</manufacturerId>
								<individualPrice>.2950</individualPrice>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.2950</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00327">
					<name>FLECAINIDE ACETATE</name>
					<pcgGroup>
						<pcg9 id="240400119">
							<itemNumber>0567</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="01966197" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Tambocor</name>
								<manufacturerId>GRA</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02275538" chronicUseMed="Y" sec3="Y">
								<name>Apo-Flecainide</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1389</individualPrice>
								<listingDate>2006-07-19</listingDate>
								<amountMOHLTCPays>.1389</amountMOHLTCPays>
							</drug>
							<drug id="02459957" chronicUseMed="Y" sec3="Y">
								<name>Auro-Flecainide</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.1389</individualPrice>
								<listingDate>2017-11-30</listingDate>
								<amountMOHLTCPays>.1389</amountMOHLTCPays>
							</drug>
							<drug id="02476177" chronicUseMed="Y" sec3="Y">
								<name>Mar-Flecainide</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.1389</individualPrice>
								<listingDate>2021-03-29</listingDate>
								<amountMOHLTCPays>.1389</amountMOHLTCPays>
							</drug>
							<drug id="02493705" chronicUseMed="Y" sec3="Y">
								<name>Jamp Flecainide</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1389</individualPrice>
								<listingDate>2021-01-29</listingDate>
								<amountMOHLTCPays>.1389</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400095">
							<itemNumber>0568</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="01966200" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Tambocor</name>
								<manufacturerId>GRA</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02275546" chronicUseMed="Y" sec3="Y">
								<name>Apo-Flecainide</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2779</individualPrice>
								<listingDate>2006-07-19</listingDate>
								<amountMOHLTCPays>.2779</amountMOHLTCPays>
							</drug>
							<drug id="02459965" chronicUseMed="Y" sec3="Y">
								<name>Auro-Flecainide</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2779</individualPrice>
								<listingDate>2017-11-30</listingDate>
								<amountMOHLTCPays>.2779</amountMOHLTCPays>
							</drug>
							<drug id="02476185" chronicUseMed="Y" sec3="Y">
								<name>Mar-Flecainide</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.2779</individualPrice>
								<listingDate>2021-03-29</listingDate>
								<amountMOHLTCPays>.2779</amountMOHLTCPays>
							</drug>
							<drug id="02493713" chronicUseMed="Y" sec3="Y">
								<name>Jamp Flecainide</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2779</individualPrice>
								<listingDate>2021-01-29</listingDate>
								<amountMOHLTCPays>.2779</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="02068">
					<name>IVABRADINE HCL</name>
					<pcgGroup lccId="00311">
						<pcg9 id="240400174">
							<itemNumber>0569</itemNumber>
							<strength>5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02459973" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Lancora</name>
								<manufacturerId>SEV</manufacturerId>
								<individualPrice>.8934</individualPrice>
								<listingDate>2018-10-31</listingDate>
								<amountMOHLTCPays>.8934</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400175">
							<itemNumber>0570</itemNumber>
							<strength>7.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02459981" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Lancora</name>
								<manufacturerId>SEV</manufacturerId>
								<individualPrice>1.6339</individualPrice>
								<listingDate>2018-10-31</listingDate>
								<amountMOHLTCPays>1.6339</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="538">For the treatment of stable chronic heart failure with reduced left ventricular ejection fraction (LVEF) (less than or equal to 35%) in adult patients with New York Heart Association (NYHA) classes II or III who are in sinus rhythm with a resting heart rate greater than or equal to 77 beats per minute (bpm), to reduce the incidence of cardiovascular mortality and hospitalizations for worsening heart failure, administered in combination with standard chronic heart failure therapies if the following are met:
- Patients with NYHA class II to III symptoms despite at least four weeks of treatment with a stable dose of an angiotensin converting enzyme inhibitor (ACEI) or an angiotensin II receptor blocker (ARB) in combination with a beta blocker and, if tolerated, a mineralocorticoid receptor antagonist (MRA); AND
- Patients with at least one hospitalization due to heart failure in the last year; AND
- Resting heart rate must be documented as greater than or equal to 77 bpm on average using either an ECG on at least three separate visits or by continuous monitoring.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00315">
					<name>METOPROLOL TARTRATE</name>
					<pcgGroup>
						<pcg9 id="240400069">
							<itemNumber>0571</itemNumber>
							<strength>100mg</strength>
							<dosageForm>LA Tab</dosageForm>
							<drug id="00658855" chronicUseMed="Y" sec3="Y">
								<name>Lopresor SR</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>.4012</individualPrice>
								<listingDate>2001-10-11</listingDate>
								<amountMOHLTCPays>.1415</amountMOHLTCPays>
							</drug>
							<drug id="02285169" chronicUseMed="Y" sec3="Y">
								<name>Apo-Metoprolol SR</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1415</individualPrice>
								<listingDate>2007-11-10</listingDate>
								<amountMOHLTCPays>.1415</amountMOHLTCPays>
							</drug>
							<drug id="02303396" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Metoprolol SR</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.1415</individualPrice>
								<listingDate>2008-06-27</listingDate>
								<amountMOHLTCPays>.1415</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400044">
							<itemNumber>0572</itemNumber>
							<strength>200mg</strength>
							<dosageForm>LA Tab</dosageForm>
							<drug id="00534560" chronicUseMed="Y" sec3="Y">
								<name>Lopresor SR</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>.7282</individualPrice>
								<listingDate>2001-10-11</listingDate>
								<amountMOHLTCPays>.2568</amountMOHLTCPays>
							</drug>
							<drug id="02285177" chronicUseMed="Y" sec3="Y">
								<name>Apo-Metoprolol SR</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2568</individualPrice>
								<listingDate>2007-11-10</listingDate>
								<amountMOHLTCPays>.2568</amountMOHLTCPays>
							</drug>
							<drug id="02303418" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Metoprolol SR</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2568</individualPrice>
								<listingDate>2008-06-27</listingDate>
								<amountMOHLTCPays>.2568</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400037">
							<itemNumber>0573</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.1248</dailyCost>
							<drug id="00397423" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Lopresor</name>
								<manufacturerId>NOV</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00402605" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Betaloc</name>
								<manufacturerId>AZC</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00618632" chronicUseMed="Y" sec3="Y">
								<name>Apo-Metoprolol</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0624</individualPrice>
								<dailyCost>.1248</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0624</amountMOHLTCPays>
							</drug>
							<drug id="00648035" chronicUseMed="Y" sec3="Y">
								<name>Teva-Metoprolol</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.0624</individualPrice>
								<dailyCost>.1248</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0624</amountMOHLTCPays>
							</drug>
							<drug id="00749354" chronicUseMed="Y" sec3="Y">
								<name>Apo-Metoprolol (Type L)</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0624</individualPrice>
								<dailyCost>.1248</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0624</amountMOHLTCPays>
							</drug>
							<drug id="00842648" chronicUseMed="Y" sec3="Y">
								<name>Teva-Metoprolol (Uncoated)</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.0624</individualPrice>
								<dailyCost>.1248</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0624</amountMOHLTCPays>
							</drug>
							<drug id="02230803" chronicUseMed="Y" sec3="Y">
								<name>PMS-Metoprolol-L</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.0624</individualPrice>
								<dailyCost>.1248</dailyCost>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.0624</amountMOHLTCPays>
							</drug>
							<drug id="02350394" chronicUseMed="Y" sec3="Y">
								<name>Metoprolol</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.0624</individualPrice>
								<dailyCost>.1248</dailyCost>
								<listingDate>2016-09-29</listingDate>
								<amountMOHLTCPays>.0624</amountMOHLTCPays>
							</drug>
							<drug id="02354187" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Metoprolol (Type L)</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.0624</individualPrice>
								<dailyCost>.1248</dailyCost>
								<listingDate>2011-03-15</listingDate>
								<amountMOHLTCPays>.0624</amountMOHLTCPays>
							</drug>
							<drug id="02356821" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Metoprolol-L</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.0624</individualPrice>
								<dailyCost>.1248</dailyCost>
								<listingDate>2011-12-15</listingDate>
								<amountMOHLTCPays>.0624</amountMOHLTCPays>
							</drug>
							<drug id="02481316" chronicUseMed="Y" sec3="Y">
								<name>AG-Metoprolol-L</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.0624</individualPrice>
								<dailyCost>.1248</dailyCost>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.0624</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400036">
							<itemNumber>0574</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.2722</dailyCost>
							<drug id="00397431" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Lopresor</name>
								<manufacturerId>NOV</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00402540" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Betaloc</name>
								<manufacturerId>AZC</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00618640" chronicUseMed="Y" sec3="Y">
								<name>Apo-Metoprolol</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1361</individualPrice>
								<dailyCost>.2722</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1361</amountMOHLTCPays>
							</drug>
							<drug id="00648043" chronicUseMed="Y" sec3="Y">
								<name>Teva-Metoprolol</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1361</individualPrice>
								<dailyCost>.2722</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1361</amountMOHLTCPays>
							</drug>
							<drug id="00751170" chronicUseMed="Y" sec3="Y">
								<name>Apo-Metoprolol (Type L)</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1361</individualPrice>
								<dailyCost>.2722</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1361</amountMOHLTCPays>
							</drug>
							<drug id="00842656" chronicUseMed="Y" sec3="Y">
								<name>Teva-Metoprolol (Uncoated)</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1361</individualPrice>
								<dailyCost>.2722</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1361</amountMOHLTCPays>
							</drug>
							<drug id="02230804" chronicUseMed="Y" sec3="Y">
								<name>PMS-Metoprolol-L</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1361</individualPrice>
								<dailyCost>.2722</dailyCost>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.1361</amountMOHLTCPays>
							</drug>
							<drug id="02350408" chronicUseMed="Y" sec3="Y">
								<name>Metoprolol</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.1361</individualPrice>
								<dailyCost>.2722</dailyCost>
								<listingDate>2016-09-29</listingDate>
								<amountMOHLTCPays>.1361</amountMOHLTCPays>
							</drug>
							<drug id="02354195" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Metoprolol (Type L)</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.1361</individualPrice>
								<dailyCost>.2722</dailyCost>
								<listingDate>2011-03-15</listingDate>
								<amountMOHLTCPays>.1361</amountMOHLTCPays>
							</drug>
							<drug id="02356848" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Metoprolol-L</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1361</individualPrice>
								<dailyCost>.2722</dailyCost>
								<listingDate>2011-12-15</listingDate>
								<amountMOHLTCPays>.1361</amountMOHLTCPays>
							</drug>
							<drug id="02481324" chronicUseMed="Y" sec3="Y">
								<name>AG-Metoprolol-L</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.1361</individualPrice>
								<dailyCost>.2722</dailyCost>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.1361</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00321">
					<name>MEXILETINE HCL</name>
					<pcgGroup>
						<pcg9 id="240400064">
							<itemNumber>0575</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00599956" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Mexitil</name>
								<manufacturerId>BOE</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02230359" chronicUseMed="Y" sec3="Y">
								<name>Novo-Mexiletine</name>
								<manufacturerId>NOP</manufacturerId>
								<individualPrice>.8162</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.8162</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400063">
							<itemNumber>0576</itemNumber>
							<strength>200mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00599964" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Mexitil</name>
								<manufacturerId>BOE</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02230360" chronicUseMed="Y" sec3="Y">
								<name>Novo-Mexiletine</name>
								<manufacturerId>NOP</manufacturerId>
								<individualPrice>1.0930</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>1.0930</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00308">
					<name>NADOLOL</name>
					<pcgGroup>
						<pcg9 id="240400058">
							<itemNumber>0577</itemNumber>
							<strength>40mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.2375</dailyCost>
							<drug id="00607126" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Corgard</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00782505" chronicUseMed="Y" sec3="Y">
								<name>Apo-Nadolol</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2375</individualPrice>
								<dailyCost>.2375</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2375</amountMOHLTCPays>
							</drug>
							<drug id="02496380" chronicUseMed="Y" sec3="Y">
								<name>Mint-Nadolol</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.2375</individualPrice>
								<dailyCost>.2375</dailyCost>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.2375</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400042">
							<itemNumber>0578</itemNumber>
							<strength>80mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.6820</dailyCost>
							<drug id="00463256" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Corgard</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00782467" chronicUseMed="Y" sec3="Y">
								<name>Apo-Nadolol</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3410</individualPrice>
								<dailyCost>.6820</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3410</amountMOHLTCPays>
							</drug>
							<drug id="02496399" chronicUseMed="Y" sec3="Y">
								<name>Mint-Nadolol</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.3410</individualPrice>
								<dailyCost>.6820</dailyCost>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.3410</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400008">
							<itemNumber>0579</itemNumber>
							<strength>160mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>1.2046</dailyCost>
							<drug id="00523372" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Corgard</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00782475" chronicUseMed="Y" sec3="Y">
								<name>Apo-Nadolol</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.2046</individualPrice>
								<dailyCost>1.2046</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>1.2046</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00318">
					<name>NIFEDIPINE</name>
					<pcgGroup>
						<pcg9 id="240400081">
							<itemNumber>0580</itemNumber>
							<strength>5mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00725110" chronicUseMed="Y" sec3="Y">
								<name>Nifedipine</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.3679</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3679</amountMOHLTCPays>
							</drug>
							<drug id="02155869" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Adalat</name>
								<manufacturerId>BAH</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="240400049">
							<itemNumber>0581</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00755907" chronicUseMed="Y" sec3="Y">
								<name>Nifedipine</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.4877</individualPrice>
								<note>Rapid absorption of liquid nifedipine from pulvules can cause severe hypotension and aggravation of myocardial or cerebral ischemia.</note>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.4877</amountMOHLTCPays>
							</drug>
							<drug id="02155877" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Adalat</name>
								<manufacturerId>BAH</manufacturerId>
								<note>Rapid absorption of liquid nifedipine from pulvules can cause severe hypotension and aggravation of myocardial or cerebral ischemia.</note>
								<listingDate>1996-10-01</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00326">
					<name>PROPAFENONE HCL</name>
					<pcgGroup>
						<pcg9 id="240400091">
							<itemNumber>0582</itemNumber>
							<strength>150mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00603708" chronicUseMed="Y" sec3="Y">
								<name>Rythmol</name>
								<manufacturerId>ABB</manufacturerId>
								<individualPrice>1.3436</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2966</amountMOHLTCPays>
							</drug>
							<drug id="02243324" chronicUseMed="Y" sec3="Y">
								<name>Apo-Propafenone</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2966</individualPrice>
								<listingDate>2001-10-11</listingDate>
								<amountMOHLTCPays>.2966</amountMOHLTCPays>
							</drug>
							<drug id="02294559" chronicUseMed="Y" sec3="Y">
								<name>PMS-Propafenone</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2966</individualPrice>
								<listingDate>2008-04-09</listingDate>
								<amountMOHLTCPays>.2966</amountMOHLTCPays>
							</drug>
							<drug id="02343053" chronicUseMed="Y" sec3="Y">
								<name>Propafenone</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2966</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2966</amountMOHLTCPays>
							</drug>
							<drug id="02457172" chronicUseMed="Y" sec3="Y">
								<name>Mylan-Propafenone</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.2966</individualPrice>
								<listingDate>2018-01-31</listingDate>
								<amountMOHLTCPays>.2966</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400092">
							<itemNumber>0583</itemNumber>
							<strength>300mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00603716" chronicUseMed="Y" sec3="Y">
								<name>Rythmol</name>
								<manufacturerId>ABB</manufacturerId>
								<individualPrice>2.3684</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.5227</amountMOHLTCPays>
							</drug>
							<drug id="02243325" chronicUseMed="Y" sec3="Y">
								<name>Apo-Propafenone</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.5227</individualPrice>
								<listingDate>2001-10-11</listingDate>
								<amountMOHLTCPays>.5227</amountMOHLTCPays>
							</drug>
							<drug id="02294575" chronicUseMed="Y" sec3="Y">
								<name>PMS-Propafenone</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.5227</individualPrice>
								<listingDate>2008-04-09</listingDate>
								<amountMOHLTCPays>.5227</amountMOHLTCPays>
							</drug>
							<drug id="02343061" chronicUseMed="Y" sec3="Y">
								<name>Propafenone</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.5227</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.5227</amountMOHLTCPays>
							</drug>
							<drug id="02457164" chronicUseMed="Y" sec3="Y">
								<name>Mylan-Propafenone</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.5227</individualPrice>
								<listingDate>2018-01-31</listingDate>
								<amountMOHLTCPays>.5227</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00310">
					<name>PROPRANOLOL</name>
					<pcgGroup>
						<pcg9 id="240400013">
							<itemNumber>0584</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00496480" chronicUseMed="Y" sec3="Y">
								<name>Teva-Propranolol</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.0689</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0689</amountMOHLTCPays>
							</drug>
							<drug id="02042177" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Inderal</name>
								<manufacturerId>WAY</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="240400059">
							<itemNumber>0585</itemNumber>
							<strength>20mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00740675" chronicUseMed="Y" sec3="Y">
								<name>Teva-Propranolol</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1107</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1107</amountMOHLTCPays>
							</drug>
							<drug id="02042193" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Inderal</name>
								<manufacturerId>WAY</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="240400012">
							<itemNumber>0586</itemNumber>
							<strength>40mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.2450</dailyCost>
							<drug id="00496499" chronicUseMed="Y" sec3="Y">
								<name>Teva-Propranolol</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1225</individualPrice>
								<dailyCost>.2450</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1225</amountMOHLTCPays>
							</drug>
							<drug id="02042207" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Inderal-40</name>
								<manufacturerId>AYE</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="240400015">
							<itemNumber>0587</itemNumber>
							<strength>80mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.4068</dailyCost>
							<drug id="00496502" chronicUseMed="Y" sec3="Y">
								<name>Teva-Propranolol</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2034</individualPrice>
								<dailyCost>.4068</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2034</amountMOHLTCPays>
							</drug>
							<drug id="02042215" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Inderal</name>
								<manufacturerId>WAY</manufacturerId>
								<listingDate>1997-02-04</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00322">
					<name>SOTALOL HCL</name>
					<pcgGroup>
						<pcg9 id="240400131">
							<itemNumber>0588</itemNumber>
							<strength>80mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00897272" notABenefit="Y" sec3="Y">
								<name>Sotacor</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>2007-12-19</listingDate>
							</drug>
							<drug id="02210428" chronicUseMed="Y" sec3="Y">
								<name>Apo-Sotalol</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2966</individualPrice>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.2966</amountMOHLTCPays>
							</drug>
							<drug id="02238326" chronicUseMed="Y" sec3="Y">
								<name>PMS-Sotalol</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2966</individualPrice>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.2966</amountMOHLTCPays>
							</drug>
							<drug id="02368617" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Sotalol</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2966</individualPrice>
								<listingDate>2012-08-27</listingDate>
								<amountMOHLTCPays>.2966</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400068">
							<itemNumber>0589</itemNumber>
							<strength>160mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00483923" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Sotacor</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02084236" chronicUseMed="Y" sec3="Y">
								<name>Ratio-Sotalol</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>.1623</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1623</amountMOHLTCPays>
							</drug>
							<drug id="02167794" chronicUseMed="Y" sec3="Y">
								<name>Apo-Sotalol</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1623</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1623</amountMOHLTCPays>
							</drug>
							<drug id="02231182" chronicUseMed="Y" sec3="Y">
								<name>Novo-Sotalol</name>
								<manufacturerId>NOP</manufacturerId>
								<individualPrice>.1623</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.1623</amountMOHLTCPays>
							</drug>
							<drug id="02238327" chronicUseMed="Y" sec3="Y">
								<name>PMS-Sotalol</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1623</individualPrice>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>.1623</amountMOHLTCPays>
							</drug>
							<drug id="02270633" chronicUseMed="Y" sec3="Y">
								<name>Co Sotalol</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.1623</individualPrice>
								<listingDate>2006-10-23</listingDate>
								<amountMOHLTCPays>.1623</amountMOHLTCPays>
							</drug>
							<drug id="02368625" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Sotalol</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1623</individualPrice>
								<listingDate>2012-08-27</listingDate>
								<amountMOHLTCPays>.1623</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00314">
					<name>TIMOLOL MALEATE</name>
					<pcgGroup>
						<pcg9 id="240400023">
							<itemNumber>0590</itemNumber>
							<strength>5mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.4154</dailyCost>
							<drug id="00353914" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Blocadren</name>
								<manufacturerId>FRS</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00755842" chronicUseMed="Y" sec3="Y">
								<name>Timolol</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.2077</individualPrice>
								<dailyCost>.4154</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2077</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400022">
							<itemNumber>0591</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.6478</dailyCost>
							<drug id="00353922" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Blocadren</name>
								<manufacturerId>FRS</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00755850" chronicUseMed="Y" sec3="Y">
								<name>Timolol</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.3239</individualPrice>
								<dailyCost>.6478</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3239</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400043">
							<itemNumber>0592</itemNumber>
							<strength>20mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>1.2608</dailyCost>
							<drug id="00495611" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Blocadren</name>
								<manufacturerId>FRS</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00755869" chronicUseMed="Y" sec3="Y">
								<name>Timolol</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.6304</individualPrice>
								<dailyCost>1.2608</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.6304</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00319">
					<name>VERAPAMIL HCL</name>
					<pcgGroup>
						<pcg9 id="240400051">
							<itemNumber>0593</itemNumber>
							<strength>80mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.8205</dailyCost>
							<drug id="00554316" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Isoptin</name>
								<manufacturerId>ABB</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00782483" chronicUseMed="Y" sec3="Y">
								<name>Apo-Verap</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2735</individualPrice>
								<dailyCost>.8205</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2735</amountMOHLTCPays>
							</drug>
							<drug id="02237921" chronicUseMed="Y" sec3="Y">
								<name>Mylan-Verapamil</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.2735</individualPrice>
								<dailyCost>.8205</dailyCost>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>.2735</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240400050">
							<itemNumber>0594</itemNumber>
							<strength>120mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>1.2750</dailyCost>
							<drug id="00554324" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Isoptin</name>
								<manufacturerId>ABB</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00782491" chronicUseMed="Y" sec3="Y">
								<name>Apo-Verap</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.4250</individualPrice>
								<dailyCost>1.2750</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.4250</amountMOHLTCPays>
							</drug>
							<drug id="02237922" chronicUseMed="Y" sec3="Y">
								<name>Mylan-Verapamil</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.4250</individualPrice>
								<dailyCost>1.2750</dailyCost>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>.4250</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="240600000">
				<name>ANTILIPEMIC DRUGS</name>
				<genericName id="01685">
					<name>AMLODIPINE BESYLATE &amp; ATORVASTATIN CALCIUM</name>
					<pcgGroup>
						<pcg9 id="240600056">
							<itemNumber>0595</itemNumber>
							<strength>5mg &amp; 10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02273233" chronicUseMed="Y" sec3="Y">
								<name>Caduet</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>2.5111</individualPrice>
								<note>Note: Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note>
								<listingDate>2006-10-23</listingDate>
								<amountMOHLTCPays>1.1603</amountMOHLTCPays>
							</drug>
							<drug id="02362759" chronicUseMed="Y" sec3="Y">
								<name>Gd-Amlodipine/Atorvastatin</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>1.1603</individualPrice>
								<note>Note: Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note>
								<listingDate>2011-10-25</listingDate>
								<amountMOHLTCPays>1.1603</amountMOHLTCPays>
							</drug>
							<drug id="02411253" chronicUseMed="Y" sec3="Y">
								<name>Apo-Amlodipine-Atorvastatin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.1603</individualPrice>
								<note>Note: Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note>
								<listingDate>2013-11-28</listingDate>
								<amountMOHLTCPays>1.1603</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240600057">
							<itemNumber>0596</itemNumber>
							<strength>5mg &amp; 20mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02273241" chronicUseMed="Y" sec3="Y">
								<name>Caduet</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>2.9612</individualPrice>
								<note>Note: Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note>
								<listingDate>2006-10-23</listingDate>
								<amountMOHLTCPays>1.3683</amountMOHLTCPays>
							</drug>
							<drug id="02362767" chronicUseMed="Y" sec3="Y">
								<name>Gd-Amlodipine/Atorvastatin</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>1.3683</individualPrice>
								<note>Note: Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note>
								<listingDate>2011-10-25</listingDate>
								<amountMOHLTCPays>1.3683</amountMOHLTCPays>
							</drug>
							<drug id="02411261" chronicUseMed="Y" sec3="Y">
								<name>Apo-Amlodipine-Atorvastatin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.3683</individualPrice>
								<note>Note: Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note>
								<listingDate>2013-11-28</listingDate>
								<amountMOHLTCPays>1.3683</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240600058">
							<itemNumber>0597</itemNumber>
							<strength>5mg &amp; 40mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02273268" chronicUseMed="Y" sec3="Y">
								<name>Caduet</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>3.1301</individualPrice>
								<note>Note: Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note>
								<listingDate>2006-10-23</listingDate>
								<amountMOHLTCPays>.7232</amountMOHLTCPays>
							</drug>
							<drug id="02362775" chronicUseMed="Y" sec3="Y">
								<name>Gd-Amlodipine/Atorvastatin</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>.7232</individualPrice>
								<note>Note: Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note>
								<listingDate>2011-10-25</listingDate>
								<amountMOHLTCPays>.7232</amountMOHLTCPays>
							</drug>
							<drug id="02411288" chronicUseMed="Y" sec3="Y">
								<name>Apo-Amlodipine-Atorvastatin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.7232</individualPrice>
								<note>Note: Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note>
								<listingDate>2013-11-28</listingDate>
								<amountMOHLTCPays>.7232</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240600059">
							<itemNumber>0598</itemNumber>
							<strength>5mg &amp; 80mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02273276" chronicUseMed="Y" sec3="Y">
								<name>Caduet</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>3.1301</individualPrice>
								<note>Note: Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note>
								<listingDate>2006-10-23</listingDate>
								<amountMOHLTCPays>.7232</amountMOHLTCPays>
							</drug>
							<drug id="02362783" chronicUseMed="Y" sec3="Y">
								<name>Gd-Amlodipine/Atorvastatin</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>.7232</individualPrice>
								<note>Note: Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note>
								<listingDate>2011-10-25</listingDate>
								<amountMOHLTCPays>.7232</amountMOHLTCPays>
							</drug>
							<drug id="02411296" chronicUseMed="Y" sec3="Y">
								<name>Apo-Amlodipine-Atorvastatin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.7232</individualPrice>
								<note>Note: Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note>
								<listingDate>2013-11-28</listingDate>
								<amountMOHLTCPays>.7232</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240600060">
							<itemNumber>0599</itemNumber>
							<strength>10mg &amp; 10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02273284" chronicUseMed="Y" sec3="Y">
								<name>Caduet</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>2.6512</individualPrice>
								<note>Note: Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note>
								<listingDate>2006-10-23</listingDate>
								<amountMOHLTCPays>1.2250</amountMOHLTCPays>
							</drug>
							<drug id="02362791" chronicUseMed="Y" sec3="Y">
								<name>Gd-Amlodipine/Atorvastatin</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>1.2250</individualPrice>
								<note>Note: Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note>
								<listingDate>2011-10-25</listingDate>
								<amountMOHLTCPays>1.2250</amountMOHLTCPays>
							</drug>
							<drug id="02411318" chronicUseMed="Y" sec3="Y">
								<name>Apo-Amlodipine-Atorvastatin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.2250</individualPrice>
								<note>Note: Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note>
								<listingDate>2013-11-28</listingDate>
								<amountMOHLTCPays>1.2250</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240600061">
							<itemNumber>0600</itemNumber>
							<strength>10mg &amp; 20mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02273292" chronicUseMed="Y" sec3="Y">
								<name>Caduet</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>3.3052</individualPrice>
								<note>Note: Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note>
								<listingDate>2006-10-23</listingDate>
								<amountMOHLTCPays>1.5272</amountMOHLTCPays>
							</drug>
							<drug id="02362805" chronicUseMed="Y" sec3="Y">
								<name>Gd-Amlodipine/Atorvastatin</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>1.5272</individualPrice>
								<note>Note: Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note>
								<listingDate>2011-10-25</listingDate>
								<amountMOHLTCPays>1.5272</amountMOHLTCPays>
							</drug>
							<drug id="02411326" chronicUseMed="Y" sec3="Y">
								<name>Apo-Amlodipine-Atorvastatin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.5272</individualPrice>
								<note>Note: Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note>
								<listingDate>2013-11-28</listingDate>
								<amountMOHLTCPays>1.5272</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240600062">
							<itemNumber>0601</itemNumber>
							<strength>10mg &amp; 40mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02273306" chronicUseMed="Y" sec3="Y">
								<name>Caduet</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>3.4628</individualPrice>
								<note>Note: Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note>
								<listingDate>2006-10-23</listingDate>
								<amountMOHLTCPays>.8000</amountMOHLTCPays>
							</drug>
							<drug id="02362813" chronicUseMed="Y" sec3="Y">
								<name>Gd-Amlodipine/Atorvastatin</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>.8000</individualPrice>
								<note>Note: Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note>
								<listingDate>2011-10-25</listingDate>
								<amountMOHLTCPays>.8000</amountMOHLTCPays>
							</drug>
							<drug id="02411334" chronicUseMed="Y" sec3="Y">
								<name>Apo-Amlodipine-Atorvastatin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.8000</individualPrice>
								<note>Note: Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note>
								<listingDate>2013-11-28</listingDate>
								<amountMOHLTCPays>.8000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240600063">
							<itemNumber>0602</itemNumber>
							<strength>10mg &amp; 80mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02273314" chronicUseMed="Y" sec3="Y">
								<name>Caduet</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>3.4628</individualPrice>
								<note>Note: Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note>
								<listingDate>2006-10-23</listingDate>
								<amountMOHLTCPays>.8000</amountMOHLTCPays>
							</drug>
							<drug id="02362821" chronicUseMed="Y" sec3="Y">
								<name>Gd-Amlodipine/Atorvastatin</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>.8000</individualPrice>
								<note>Note: Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note>
								<listingDate>2011-10-25</listingDate>
								<amountMOHLTCPays>.8000</amountMOHLTCPays>
							</drug>
							<drug id="02411342" chronicUseMed="Y" sec3="Y">
								<name>Apo-Amlodipine-Atorvastatin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.8000</individualPrice>
								<note>Note: Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note>
								<listingDate>2013-11-28</listingDate>
								<amountMOHLTCPays>.8000</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00347">
					<name>ATORVASTATIN CALCIUM</name>
					<pcgGroup>
						<pcg9 id="240600036">
							<itemNumber>0603</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02230711" chronicUseMed="Y" sec3="Y">
								<name>Lipitor</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>1.9240</individualPrice>
								<listingDate>1997-08-28</listingDate>
								<amountMOHLTCPays>.1743</amountMOHLTCPays>
							</drug>
							<drug id="02295261" chronicUseMed="Y" sec3="Y">
								<name>Apo-Atorvastatin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1743</individualPrice>
								<listingDate>2010-06-18</listingDate>
								<amountMOHLTCPays>.1743</amountMOHLTCPays>
							</drug>
							<drug id="02310899" chronicUseMed="Y" sec3="Y">
								<name>Teva-Atorvastatin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1743</individualPrice>
								<listingDate>2010-06-18</listingDate>
								<amountMOHLTCPays>.1743</amountMOHLTCPays>
							</drug>
							<drug id="02313707" chronicUseMed="Y" sec3="Y">
								<name>Taro-Atorvastatin</name>
								<manufacturerId>SPC</manufacturerId>
								<individualPrice>.1743</individualPrice>
								<listingDate>2010-06-18</listingDate>
								<amountMOHLTCPays>.1743</amountMOHLTCPays>
							</drug>
							<drug id="02324946" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Atorvastatin</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.1743</individualPrice>
								<listingDate>2010-07-20</listingDate>
								<amountMOHLTCPays>.1743</amountMOHLTCPays>
							</drug>
							<drug id="02348705" chronicUseMed="Y" sec3="Y">
								<name>Atorvastatin</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.1743</individualPrice>
								<listingDate>2011-12-15</listingDate>
								<amountMOHLTCPays>.1743</amountMOHLTCPays>
							</drug>
							<drug id="02350297" chronicUseMed="Y" sec3="Y">
								<name>Ratio-Atorvastatin</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>.1743</individualPrice>
								<listingDate>2010-06-18</listingDate>
								<amountMOHLTCPays>.1743</amountMOHLTCPays>
							</drug>
							<drug id="02391058" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Atorvastatin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1743</individualPrice>
								<listingDate>2012-12-21</listingDate>
								<amountMOHLTCPays>.1743</amountMOHLTCPays>
							</drug>
							<drug id="02392933" chronicUseMed="Y" sec3="Y">
								<name>Mylan-Atorvastatin</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.1743</individualPrice>
								<listingDate>2014-07-30</listingDate>
								<amountMOHLTCPays>.1743</amountMOHLTCPays>
							</drug>
							<drug id="02399377" chronicUseMed="Y" sec3="Y">
								<name>PMS-Atorvastatin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1743</individualPrice>
								<listingDate>2013-06-27</listingDate>
								<amountMOHLTCPays>.1743</amountMOHLTCPays>
							</drug>
							<drug id="02407256" chronicUseMed="Y" sec3="Y">
								<name>Auro-Atorvastatin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.1743</individualPrice>
								<listingDate>2013-09-27</listingDate>
								<amountMOHLTCPays>.1743</amountMOHLTCPays>
							</drug>
							<drug id="02411350" chronicUseMed="Y" sec3="Y">
								<name>Atorvastatin-10</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.1743</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.1743</amountMOHLTCPays>
							</drug>
							<drug id="02417936" chronicUseMed="Y" sec3="Y">
								<name>Reddy-Atorvastatin</name>
								<manufacturerId>DRR</manufacturerId>
								<individualPrice>.1743</individualPrice>
								<listingDate>2015-10-29</listingDate>
								<amountMOHLTCPays>.1743</amountMOHLTCPays>
							</drug>
							<drug id="02454017" chronicUseMed="Y" sec3="Y">
								<name>Mar-Atorvastatin</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.1743</individualPrice>
								<listingDate>2016-10-27</listingDate>
								<amountMOHLTCPays>.1743</amountMOHLTCPays>
							</drug>
							<drug id="02457741" chronicUseMed="Y" sec3="Y">
								<name>Ach-Atorvastatin Calcium</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.1743</individualPrice>
								<listingDate>2019-12-20</listingDate>
								<amountMOHLTCPays>.1743</amountMOHLTCPays>
							</drug>
							<drug id="02471167" chronicUseMed="Y" sec3="Y">
								<name>M-Atorvastatin</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.1743</individualPrice>
								<listingDate>2021-09-30</listingDate>
								<amountMOHLTCPays>.1743</amountMOHLTCPays>
							</drug>
							<drug id="02475022" chronicUseMed="Y" sec3="Y">
								<name>Atorvastatin</name>
								<manufacturerId>RIA</manufacturerId>
								<individualPrice>.1743</individualPrice>
								<listingDate>2021-08-31</listingDate>
								<amountMOHLTCPays>.1743</amountMOHLTCPays>
							</drug>
							<drug id="02476517" chronicUseMed="Y" sec3="Y">
								<name>NRA-Atorvastatin</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.1743</individualPrice>
								<listingDate>2020-09-30</listingDate>
								<amountMOHLTCPays>.1743</amountMOHLTCPays>
							</drug>
							<drug id="02477149" chronicUseMed="Y" sec3="Y">
								<name>PMS-Atorvastatin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1743</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.1743</amountMOHLTCPays>
							</drug>
							<drug id="02478145" chronicUseMed="Y" sec3="Y">
								<name>AG-Atorvastatin</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.1743</individualPrice>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.1743</amountMOHLTCPays>
							</drug>
							<drug id="02479508" chronicUseMed="Y" sec3="Y">
								<name>Mint-Atorvastatin</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.1743</individualPrice>
								<listingDate>2020-04-30</listingDate>
								<amountMOHLTCPays>.1743</amountMOHLTCPays>
							</drug>
							<drug id="02504197" chronicUseMed="Y" sec3="Y">
								<name>Jamp Atorvastatin Calcium</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1743</individualPrice>
								<listingDate>2022-02-28</listingDate>
								<amountMOHLTCPays>.1743</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240600034">
							<itemNumber>0604</itemNumber>
							<strength>20mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02230713" chronicUseMed="Y" sec3="Y">
								<name>Lipitor</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>2.4049</individualPrice>
								<listingDate>1997-08-28</listingDate>
								<amountMOHLTCPays>.2179</amountMOHLTCPays>
							</drug>
							<drug id="02295288" chronicUseMed="Y" sec3="Y">
								<name>Apo-Atorvastatin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2179</individualPrice>
								<listingDate>2010-06-18</listingDate>
								<amountMOHLTCPays>.2179</amountMOHLTCPays>
							</drug>
							<drug id="02310902" chronicUseMed="Y" sec3="Y">
								<name>Teva-Atorvastatin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2179</individualPrice>
								<listingDate>2010-06-18</listingDate>
								<amountMOHLTCPays>.2179</amountMOHLTCPays>
							</drug>
							<drug id="02313715" chronicUseMed="Y" sec3="Y">
								<name>Taro-Atorvastatin</name>
								<manufacturerId>SPC</manufacturerId>
								<individualPrice>.2179</individualPrice>
								<listingDate>2010-06-18</listingDate>
								<amountMOHLTCPays>.2179</amountMOHLTCPays>
							</drug>
							<drug id="02324954" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Atorvastatin</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2179</individualPrice>
								<listingDate>2010-07-20</listingDate>
								<amountMOHLTCPays>.2179</amountMOHLTCPays>
							</drug>
							<drug id="02348713" chronicUseMed="Y" sec3="Y">
								<name>Atorvastatin</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2179</individualPrice>
								<listingDate>2011-12-15</listingDate>
								<amountMOHLTCPays>.2179</amountMOHLTCPays>
							</drug>
							<drug id="02350319" chronicUseMed="Y" sec3="Y">
								<name>Ratio-Atorvastatin</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>.2179</individualPrice>
								<listingDate>2010-06-18</listingDate>
								<amountMOHLTCPays>.2179</amountMOHLTCPays>
							</drug>
							<drug id="02391066" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Atorvastatin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2179</individualPrice>
								<listingDate>2012-12-21</listingDate>
								<amountMOHLTCPays>.2179</amountMOHLTCPays>
							</drug>
							<drug id="02392941" chronicUseMed="Y" sec3="Y">
								<name>Mylan-Atorvastatin</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.2179</individualPrice>
								<listingDate>2014-07-30</listingDate>
								<amountMOHLTCPays>.2179</amountMOHLTCPays>
							</drug>
							<drug id="02399385" chronicUseMed="Y" sec3="Y">
								<name>PMS-Atorvastatin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2179</individualPrice>
								<listingDate>2013-06-27</listingDate>
								<amountMOHLTCPays>.2179</amountMOHLTCPays>
							</drug>
							<drug id="02407264" chronicUseMed="Y" sec3="Y">
								<name>Auro-Atorvastatin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2179</individualPrice>
								<listingDate>2013-09-27</listingDate>
								<amountMOHLTCPays>.2179</amountMOHLTCPays>
							</drug>
							<drug id="02411369" chronicUseMed="Y" sec3="Y">
								<name>Atorvastatin-20</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2179</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.2179</amountMOHLTCPays>
							</drug>
							<drug id="02417944" chronicUseMed="Y" sec3="Y">
								<name>Reddy-Atorvastatin</name>
								<manufacturerId>DRR</manufacturerId>
								<individualPrice>.2179</individualPrice>
								<listingDate>2015-10-29</listingDate>
								<amountMOHLTCPays>.2179</amountMOHLTCPays>
							</drug>
							<drug id="02454025" chronicUseMed="Y" sec3="Y">
								<name>Mar-Atorvastatin</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.2179</individualPrice>
								<listingDate>2016-10-27</listingDate>
								<amountMOHLTCPays>.2179</amountMOHLTCPays>
							</drug>
							<drug id="02457768" chronicUseMed="Y" sec3="Y">
								<name>Ach-Atorvastatin Calcium</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.2179</individualPrice>
								<listingDate>2019-12-20</listingDate>
								<amountMOHLTCPays>.2179</amountMOHLTCPays>
							</drug>
							<drug id="02471175" chronicUseMed="Y" sec3="Y">
								<name>M-Atorvastatin</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.2179</individualPrice>
								<listingDate>2021-09-30</listingDate>
								<amountMOHLTCPays>.2179</amountMOHLTCPays>
							</drug>
							<drug id="02475030" chronicUseMed="Y" sec3="Y">
								<name>Atorvastatin</name>
								<manufacturerId>RIA</manufacturerId>
								<individualPrice>.2179</individualPrice>
								<listingDate>2021-08-31</listingDate>
								<amountMOHLTCPays>.2179</amountMOHLTCPays>
							</drug>
							<drug id="02476525" chronicUseMed="Y" sec3="Y">
								<name>NRA-Atorvastatin</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.2179</individualPrice>
								<listingDate>2020-09-30</listingDate>
								<amountMOHLTCPays>.2179</amountMOHLTCPays>
							</drug>
							<drug id="02477157" chronicUseMed="Y" sec3="Y">
								<name>PMS-Atorvastatin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2179</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.2179</amountMOHLTCPays>
							</drug>
							<drug id="02478153" chronicUseMed="Y" sec3="Y">
								<name>AG-Atorvastatin</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.2179</individualPrice>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.2179</amountMOHLTCPays>
							</drug>
							<drug id="02479516" chronicUseMed="Y" sec3="Y">
								<name>Mint-Atorvastatin</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.2179</individualPrice>
								<listingDate>2020-04-30</listingDate>
								<amountMOHLTCPays>.2179</amountMOHLTCPays>
							</drug>
							<drug id="02504200" chronicUseMed="Y" sec3="Y">
								<name>Jamp Atorvastatin Calcium</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2179</individualPrice>
								<listingDate>2022-02-28</listingDate>
								<amountMOHLTCPays>.2179</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240600037">
							<itemNumber>0605</itemNumber>
							<strength>40mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02230714" chronicUseMed="Y" sec3="Y">
								<name>Lipitor</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>2.5853</individualPrice>
								<listingDate>1997-08-28</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02295296" chronicUseMed="Y" sec3="Y">
								<name>Apo-Atorvastatin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2010-06-18</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02310910" chronicUseMed="Y" sec3="Y">
								<name>Teva-Atorvastatin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2010-06-18</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02313723" chronicUseMed="Y" sec3="Y">
								<name>Taro-Atorvastatin</name>
								<manufacturerId>SPC</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2010-06-18</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02324962" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Atorvastatin</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2010-07-20</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02348721" chronicUseMed="Y" sec3="Y">
								<name>Atorvastatin</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2011-12-15</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02350327" chronicUseMed="Y" sec3="Y">
								<name>Ratio-Atorvastatin</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2010-06-18</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02391074" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Atorvastatin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2012-12-21</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02392968" chronicUseMed="Y" sec3="Y">
								<name>Mylan-Atorvastatin</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2014-07-30</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02399393" chronicUseMed="Y" sec3="Y">
								<name>PMS-Atorvastatin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2013-06-27</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02407272" chronicUseMed="Y" sec3="Y">
								<name>Auro-Atorvastatin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2013-09-27</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02411377" chronicUseMed="Y" sec3="Y">
								<name>Atorvastatin-40</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02417952" chronicUseMed="Y" sec3="Y">
								<name>Reddy-Atorvastatin</name>
								<manufacturerId>DRR</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2015-10-29</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02454033" chronicUseMed="Y" sec3="Y">
								<name>Mar-Atorvastatin</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2016-10-27</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02457776" chronicUseMed="Y" sec3="Y">
								<name>Ach-Atorvastatin Calcium</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2019-12-20</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02471183" chronicUseMed="Y" sec3="Y">
								<name>M-Atorvastatin</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2021-09-30</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02475049" chronicUseMed="Y" sec3="Y">
								<name>Atorvastatin</name>
								<manufacturerId>RIA</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2021-08-31</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02476533" chronicUseMed="Y" sec3="Y">
								<name>NRA-Atorvastatin</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2020-09-30</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02477165" chronicUseMed="Y" sec3="Y">
								<name>PMS-Atorvastatin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02478161" chronicUseMed="Y" sec3="Y">
								<name>AG-Atorvastatin</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02479524" chronicUseMed="Y" sec3="Y">
								<name>Mint-Atorvastatin</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2020-04-30</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02504219" chronicUseMed="Y" sec3="Y">
								<name>Jamp Atorvastatin Calcium</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2022-02-28</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240600045">
							<itemNumber>0606</itemNumber>
							<strength>80mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02243097" chronicUseMed="Y" sec3="Y">
								<name>Lipitor</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>2.5853</individualPrice>
								<listingDate>2002-04-04</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02295318" chronicUseMed="Y" sec3="Y">
								<name>Apo-Atorvastatin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2010-06-18</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02310929" chronicUseMed="Y" sec3="Y">
								<name>Teva-Atorvastatin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2010-06-18</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02313758" chronicUseMed="Y" sec3="Y">
								<name>Taro-Atorvastatin</name>
								<manufacturerId>SPC</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2010-06-18</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02324970" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Atorvastatin</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2010-07-20</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02348748" chronicUseMed="Y" sec3="Y">
								<name>Atorvastatin</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2011-12-15</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02350335" chronicUseMed="Y" sec3="Y">
								<name>Ratio-Atorvastatin</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2010-06-18</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02391082" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Atorvastatin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2012-12-21</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02392976" chronicUseMed="Y" sec3="Y">
								<name>Mylan-Atorvastatin</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2014-07-30</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02399407" chronicUseMed="Y" sec3="Y">
								<name>PMS-Atorvastatin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2013-06-27</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02407280" chronicUseMed="Y" sec3="Y">
								<name>Auro-Atorvastatin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2013-09-27</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02411385" chronicUseMed="Y" sec3="Y">
								<name>Atorvastatin-80</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02417960" chronicUseMed="Y" sec3="Y">
								<name>Reddy-Atorvastatin</name>
								<manufacturerId>DRR</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2015-10-29</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02454041" chronicUseMed="Y" sec3="Y">
								<name>Mar-Atorvastatin</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2016-10-27</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02457784" chronicUseMed="Y" sec3="Y">
								<name>Ach-Atorvastatin Calcium</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2019-12-20</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02471191" chronicUseMed="Y" sec3="Y">
								<name>M-Atorvastatin</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2021-09-30</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02475057" chronicUseMed="Y" sec3="Y">
								<name>Atorvastatin</name>
								<manufacturerId>RIA</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2021-08-31</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02476541" chronicUseMed="Y" sec3="Y">
								<name>NRA-Atorvastatin</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2020-09-30</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02477173" chronicUseMed="Y" sec3="Y">
								<name>PMS-Atorvastatin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02478188" chronicUseMed="Y" sec3="Y">
								<name>AG-Atorvastatin</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02504235" chronicUseMed="Y" sec3="Y">
								<name>Jamp Atorvastatin Calcium</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2022-02-28</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
							<drug id="02507269" chronicUseMed="Y" sec3="Y">
								<name>PMSC-Atorvastatin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2342</individualPrice>
								<listingDate>2021-12-17</listingDate>
								<amountMOHLTCPays>.2342</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00346">
					<name>BEZAFIBRATE</name>
					<pcgGroup>
						<pcg9 id="240600027">
							<itemNumber>0607</itemNumber>
							<strength>400mg</strength>
							<dosageForm>SR Tab</dosageForm>
							<drug id="02083523" chronicUseMed="Y" sec3="Y">
								<name>Bezalip</name>
								<manufacturerId>ALL</manufacturerId>
								<individualPrice>2.4654</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>1.7460</amountMOHLTCPays>
							</drug>
							<drug id="02453312" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Bezafibrate SR</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>1.7460</individualPrice>
								<listingDate>2016-08-30</listingDate>
								<amountMOHLTCPays>1.7460</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00336">
					<name>CHOLESTYRAMINE RESIN</name>
					<pcgGroup>
						<pcg9 id="240600003">
							<itemNumber>0608</itemNumber>
							<dosageForm>Oral Pd-Pouch Pk</dosageForm>
							<drug id="00464880" notABenefit="Y" sec3="Y">
								<name>Questran 9g Pk</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00890960" sec3="Y">
								<name>Olestyr 4g/5g Pk</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3693</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3693</amountMOHLTCPays>
							</drug>
							<drug id="01918486" notABenefit="Y" sec3="Y">
								<name>Questran Light 4g Pk</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>2004-07-20</listingDate>
							</drug>
							<drug id="02210320" sec3="Y">
								<name>Olestyr 4g/9g Pk</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3693</individualPrice>
								<listingDate>1997-04-10</listingDate>
								<amountMOHLTCPays>.3693</amountMOHLTCPays>
							</drug>
							<drug id="02455609" sec3="Y">
								<name>Cholestyramine-Odan 4g/sachet</name>
								<manufacturerId>ODN</manufacturerId>
								<individualPrice>.3693</individualPrice>
								<listingDate>2017-03-28</listingDate>
								<amountMOHLTCPays>.3693</amountMOHLTCPays>
							</drug>
							<drug id="02478595" sec3="Y">
								<name>Jamp-Cholestyramine 4g/Sachet</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.3693</individualPrice>
								<listingDate>2019-09-30</listingDate>
								<amountMOHLTCPays>.3693</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00335">
					<name>CLOFIBRATE</name>
					<pcgGroup>
						<pcg9 id="240600001">
							<itemNumber>0609</itemNumber>
							<strength>500mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00002038" notABenefit="Y" sec3="Y">
								<name>Atromid-S</name>
								<manufacturerId>AYE</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00337382" notABenefit="Y" sec3="Y">
								<name>Novo-Fibrate</name>
								<manufacturerId>NOP</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01946">
					<name>COLESEVELAM HYDROCHLORIDE</name>
					<pcgGroup>
						<pcg9 id="240600074">
							<itemNumber>0610</itemNumber>
							<strength>3.75g/Pk</strength>
							<dosageForm>Pd for Oral Susp</dosageForm>
							<note>Lodalis is indicated for the reduction of cholesterol blood level in patients with hypercholesterolemia (Frederickson Type IIa) as an adjunct to diet and lifestyle changes, when the response to these measures has been inadequate, in patients:
. who are not adequately controlled with an HMG-CoA reductase inhibitor (statin) alone,
or
. who are unable to tolerate a statin.</note>
							<drug id="02432463" chronicUseMed="Y" sec3="Y">
								<name>Lodalis</name>
								<manufacturerId>VAL</manufacturerId>
								<individualPrice>7.1167</individualPrice>
								<listingDate>2015-12-22</listingDate>
								<amountMOHLTCPays>7.1167</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240600072">
							<itemNumber>0611</itemNumber>
							<strength>625mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>Colesevelam Hydrochloride is indicated for the reduction of cholesterol blood level in patients with hypercholesterolemia (Frederickson Type IIa) as an adjunct to diet and lifestyle changes, when the response to these measures has been inadequate, in patients:
. who are not adequately controlled with an HMG-CoA reductase inhibitor (statin) alone,
or
. who are unable to tolerate a statin.</note>
							<drug id="02373955" chronicUseMed="Y" sec3="Y">
								<name>Lodalis</name>
								<manufacturerId>VAL</manufacturerId>
								<individualPrice>1.1861</individualPrice>
								<listingDate>2014-05-29</listingDate>
								<amountMOHLTCPays>.8896</amountMOHLTCPays>
							</drug>
							<drug id="02494051" chronicUseMed="Y" sec3="Y">
								<name>Apo-Colesevelam</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.8896</individualPrice>
								<listingDate>2022-01-31</listingDate>
								<amountMOHLTCPays>.8896</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00338">
					<name>COLESTIPOL HCL</name>
					<note>Combining psyllium with Colestid therapy improves the efficacy, and decreases costs, of antilipemic treatment.</note>
					<pcgGroup>
						<pcg9 id="240600009">
							<itemNumber>0612</itemNumber>
							<dosageForm>Gran-5g Pk</dosageForm>
							<drug id="00642975" chronicUseMed="Y" sec3="Y">
								<name>Colestid Regular</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>1.4595</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>1.4595</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="02052">
					<name>EVOLOCUMAB</name>
					<pcgGroup lccId="00302">
						<pcg9 id="240600076">
							<itemNumber>0613</itemNumber>
							<strength>120mg/mL</strength>
							<dosageForm>Inj Sol-Pref Cart of 3.5mL Pk</dosageForm>
							<drug id="02459779" sec3="Y" sec12="Y">
								<name>Repatha</name>
								<manufacturerId>AMG</manufacturerId>
								<individualPrice>564.5500</individualPrice>
								<listingDate>2018-04-30</listingDate>
								<amountMOHLTCPays>564.5500</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240600075">
							<itemNumber>0614</itemNumber>
							<strength>140mg/mL</strength>
							<dosageForm>Inj Sol-Pref Syr Autoinj</dosageForm>
							<drug id="02446057" sec3="Y" sec12="Y">
								<name>Repatha</name>
								<manufacturerId>AMG</manufacturerId>
								<individualPrice>260.5650</individualPrice>
								<listingDate>2018-04-30</listingDate>
								<amountMOHLTCPays>260.5650</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="527">For the treatment of Heterozygous Familial Hypercholesterolemia (HeFH) in patients 18 years of age or older who meet the following criteria:
- Definite or probable diagnosis of HeFH using the Simon Broome or Dutch Lipid Network criteria or genetic testing;
AND
- Unable to reach Low Density Lipoprotein Cholesterol (LDL-C) target (i.e., LDL-C less than 2.0 mmol/L for secondary prevention) or at least a 50% reduction in LDL-C from untreated baseline despite:
A. Confirmed adherence to high dose statin (e.g., atorvastatin 80mg or rosuvastatin 40mg) in combination with ezetimibe for at least a total of 3 months;
OR
B. Confirmed adherence to ezetimibe for at least a total of 3 months and inability to tolerate high dose statin defined as:
(i). Inability to tolerate at least 2 statins with at least one started at the lowest starting dose; AND
(ii). For each statin (two statins in total), dose reduction is attempted for intolerable symptom (myopathy) or biomarker abnormality (creatine kinase (CK) greater than 5 times the upper limit of normal) resolution rather than discontinuation of statin altogether; AND
(iii). For each statin (two statins in total), intolerable symptoms (myopathy) or abnormal biomarker (creatine kinase (CK) greater than 5 times the upper limit of normal) changes are reversible upon statin discontinuation but reproducible by re-challenge of statins where clinically appropriate; AND
(iv). One of the following:
I) Other known determinants of intolerable symptoms or abnormal biomarkers have been ruled out; OR
II) Patient developed confirmed and documented rhabdomyolysis; OR
III) Patient is statin contraindicated i.e. active liver disease, unexplained persistent elevations of serum transaminases exceeding 3 times the upper limit of normal
Treatment with Repatha should be discontinued if the patient does not meet all of the following:
1. Patient is adherent to therapy.
2. Patient has achieved a reduction in LDL-C of at least 40% from baseline (4-8 weeks after initiation of Repatha).
3. Patient continues to have a significant reduction in LDL-C (with continuation of Repatha) of at least 40% from baseline since initiation of PCSK9 inhibitor. LDL-C should be checked periodically with continued treatment with PCSK9 inhibitors (e.g., every 6 months).
Patients prescribed Repatha 140mg every two weeks are limited to 26 prefilled syringes (PFS) per year. Patients prescribed Repatha 420mg every month must use the automated mini doser (AMD) and are limited to 12 AMD per year.
</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="01607">
					<name>EZETIMIBE</name>
					<pcgGroup lccId="00150">
						<pcg9 id="240600049">
							<itemNumber>0615</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02247521" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Ezetrol</name>
								<manufacturerId>OCI</manufacturerId>
								<individualPrice>1.9443</individualPrice>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.1811</amountMOHLTCPays>
							</drug>
							<drug id="02354101" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Teva-Ezetimibe</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1811</individualPrice>
								<listingDate>2014-11-27</listingDate>
								<amountMOHLTCPays>.1811</amountMOHLTCPays>
							</drug>
							<drug id="02414716" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Act Ezetimibe</name>
								<manufacturerId>ACV</manufacturerId>
								<individualPrice>.1811</individualPrice>
								<listingDate>2014-11-27</listingDate>
								<amountMOHLTCPays>.1811</amountMOHLTCPays>
							</drug>
							<drug id="02416409" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>PMS-Ezetimibe</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1811</individualPrice>
								<listingDate>2014-11-27</listingDate>
								<amountMOHLTCPays>.1811</amountMOHLTCPays>
							</drug>
							<drug id="02416778" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Sandoz Ezetimibe</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.1811</individualPrice>
								<listingDate>2014-11-27</listingDate>
								<amountMOHLTCPays>.1811</amountMOHLTCPays>
							</drug>
							<drug id="02419548" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Ran-Ezetimibe</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.1811</individualPrice>
								<listingDate>2014-11-27</listingDate>
								<amountMOHLTCPays>.1811</amountMOHLTCPays>
							</drug>
							<drug id="02422662" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Mar-Ezetimibe</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.1811</individualPrice>
								<listingDate>2014-11-27</listingDate>
								<amountMOHLTCPays>.1811</amountMOHLTCPays>
							</drug>
							<drug id="02423235" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Jamp-Ezetimibe</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1811</individualPrice>
								<listingDate>2014-11-27</listingDate>
								<amountMOHLTCPays>.1811</amountMOHLTCPays>
							</drug>
							<drug id="02423243" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Mint-Ezetimibe</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.1811</individualPrice>
								<listingDate>2014-11-27</listingDate>
								<amountMOHLTCPays>.1811</amountMOHLTCPays>
							</drug>
							<drug id="02425610" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Ach-Ezetimibe</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.1811</individualPrice>
								<listingDate>2014-11-27</listingDate>
								<amountMOHLTCPays>.1811</amountMOHLTCPays>
							</drug>
							<drug id="02427826" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Apo-Ezetimibe</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1811</individualPrice>
								<listingDate>2014-11-27</listingDate>
								<amountMOHLTCPays>.1811</amountMOHLTCPays>
							</drug>
							<drug id="02429659" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Ezetimibe</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.1811</individualPrice>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.1811</amountMOHLTCPays>
							</drug>
							<drug id="02431300" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Ezetimibe</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.1811</individualPrice>
								<listingDate>2020-05-29</listingDate>
								<amountMOHLTCPays>.1811</amountMOHLTCPays>
							</drug>
							<drug id="02460750" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>GLN-Ezetimibe</name>
								<manufacturerId>GLP</manufacturerId>
								<individualPrice>.1811</individualPrice>
								<listingDate>2020-12-18</listingDate>
								<amountMOHLTCPays>.1811</amountMOHLTCPays>
							</drug>
							<drug id="02467437" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>M-Ezetimibe</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.1811</individualPrice>
								<listingDate>2021-10-29</listingDate>
								<amountMOHLTCPays>.1811</amountMOHLTCPays>
							</drug>
							<drug id="02469286" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Auro-Ezetimibe</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.1811</individualPrice>
								<listingDate>2018-07-31</listingDate>
								<amountMOHLTCPays>.1811</amountMOHLTCPays>
							</drug>
							<drug id="02475898" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>AG-Ezetimibe</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.1811</individualPrice>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>.1811</amountMOHLTCPays>
							</drug>
							<drug id="02481669" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>NRA-Ezetimibe</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.1811</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.1811</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="380">For use in combination with a HMG-CoA reductase inhibitor (&apos;statin&apos;) in patients with hypercholesterolemia who have not reached target LDL levels despite the use of maximally tolerated doses.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: Indefinite.</lccNote>
						<lccNote seq="003" reasonForUseId="381">For use as monotherapy in the management of hypercholesterolemia in patients who are intolerant to HMG-CoA reductase inhibitors or where HMG-CoA reductase inhibitors are contraindicated.</lccNote>
						<lccNote seq="004" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00342">
					<name>FENOFIBRATE</name>
					<pcgGroup>
						<pcg9 id="240600018">
							<itemNumber>0616</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00885827" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Lipidil</name>
								<manufacturerId>JOU</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02225980" chronicUseMed="Y" sec3="Y">
								<name>Apo-Fenofibrate</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.6105</individualPrice>
								<listingDate>1996-12-19</listingDate>
								<amountMOHLTCPays>.6105</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240600067">
							<itemNumber>0617</itemNumber>
							<strength>67mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02230283" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Lipidil Micro</name>
								<manufacturerId>FOU</manufacturerId>
								<listingDate>2008-01-15</listingDate>
							</drug>
							<drug id="02243180" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>AA-Feno-Micro</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.5479</individualPrice>
								<listingDate>2008-01-15</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="240600030">
							<itemNumber>0618</itemNumber>
							<strength>200mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02146959" chronicUseMed="Y" sec3="Y">
								<name>Lipidil Micro</name>
								<manufacturerId>SPH</manufacturerId>
								<individualPrice>1.0890</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2723</amountMOHLTCPays>
							</drug>
							<drug id="02239864" chronicUseMed="Y" sec3="Y">
								<name>AA-Feno-Micro</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.2723</individualPrice>
								<listingDate>2000-01-17</listingDate>
								<amountMOHLTCPays>.2723</amountMOHLTCPays>
							</drug>
							<drug id="02250039" chronicUseMed="Y" sec3="Y">
								<name>Ratio-Fenofibrate MC</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>.2723</individualPrice>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.2723</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240600046">
							<itemNumber>0619</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02241601" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Lipidil Supra</name>
								<manufacturerId>LAF</manufacturerId>
								<listingDate>2008-11-04</listingDate>
							</drug>
							<drug id="02246859" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Feno-Super</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.7875</individualPrice>
								<listingDate>2008-12-03</listingDate>
							</drug>
							<drug id="02288044" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Sandoz Fenofibrate S</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.7874</individualPrice>
								<listingDate>2009-08-18</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="240600043">
							<itemNumber>0620</itemNumber>
							<strength>160mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02241602" chronicUseMed="Y" sec3="Y">
								<name>Lipidil Supra</name>
								<manufacturerId>BGP</manufacturerId>
								<individualPrice>1.3509</individualPrice>
								<listingDate>2001-06-07</listingDate>
								<amountMOHLTCPays>1.0022</amountMOHLTCPays>
							</drug>
							<drug id="02246860" chronicUseMed="Y" sec3="Y">
								<name>Apo-Feno-Super</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.0022</individualPrice>
								<listingDate>2006-06-14</listingDate>
								<amountMOHLTCPays>1.0022</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240600054">
							<itemNumber>0621</itemNumber>
							<strength>48mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02269074" chronicUseMed="Y" sec3="Y">
								<name>Lipidil EZ</name>
								<manufacturerId>FOU</manufacturerId>
								<individualPrice>.4659</individualPrice>
								<listingDate>2006-10-23</listingDate>
								<amountMOHLTCPays>.3560</amountMOHLTCPays>
							</drug>
							<drug id="02390698" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Fenofibrate E</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.3560</individualPrice>
								<listingDate>2013-03-20</listingDate>
								<amountMOHLTCPays>.3560</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240600055">
							<itemNumber>0622</itemNumber>
							<strength>145mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02269082" chronicUseMed="Y" sec3="Y">
								<name>Lipidil EZ</name>
								<manufacturerId>FOU</manufacturerId>
								<individualPrice>1.1931</individualPrice>
								<listingDate>2006-10-23</listingDate>
								<amountMOHLTCPays>.5489</amountMOHLTCPays>
							</drug>
							<drug id="02390701" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Fenofibrate E</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.5489</individualPrice>
								<listingDate>2012-10-30</listingDate>
								<amountMOHLTCPays>.5489</amountMOHLTCPays>
							</drug>
							<drug id="02454696" chronicUseMed="Y" sec3="Y">
								<name>Taro-Fenofibrate E</name>
								<manufacturerId>SPC</manufacturerId>
								<individualPrice>.5489</individualPrice>
								<listingDate>2021-01-29</listingDate>
								<amountMOHLTCPays>.5489</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00345">
					<name>FLUVASTATIN SODIUM</name>
					<pcgGroup>
						<pcg9 id="240600024">
							<itemNumber>0623</itemNumber>
							<strength>20mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02061562" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Lescol</name>
								<manufacturerId>NOV</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02299224" chronicUseMed="Y" sec3="Y">
								<name>Teva-Fluvastatin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.6882</individualPrice>
								<listingDate>2013-02-28</listingDate>
								<amountMOHLTCPays>.6882</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240600025">
							<itemNumber>0624</itemNumber>
							<strength>40mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02061570" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Lescol</name>
								<manufacturerId>NOV</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02299232" chronicUseMed="Y" sec3="Y">
								<name>Teva-Fluvastatin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.9671</individualPrice>
								<listingDate>2013-02-28</listingDate>
								<amountMOHLTCPays>.9671</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240600050">
							<itemNumber>0625</itemNumber>
							<strength>80mg</strength>
							<dosageForm>ER Tab</dosageForm>
							<drug id="02250527" chronicUseMed="Y" sec3="Y">
								<name>Lescol XL</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>1.6225</individualPrice>
								<listingDate>2005-02-22</listingDate>
								<amountMOHLTCPays>1.6225</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00337">
					<name>GEMFIBROZIL</name>
					<pcgGroup>
						<pcg9 id="240600007">
							<itemNumber>0626</itemNumber>
							<strength>300mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00599026" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Lopid</name>
								<manufacturerId>PFI</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="01979574" chronicUseMed="Y" sec3="Y">
								<name>Apo-Gemfibrozil</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1340</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1340</amountMOHLTCPays>
							</drug>
							<drug id="02241704" chronicUseMed="Y" sec3="Y">
								<name>Teva-Gemfibrozil</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1340</individualPrice>
								<listingDate>2001-06-07</listingDate>
								<amountMOHLTCPays>.1340</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240600068">
							<itemNumber>0627</itemNumber>
							<strength>600mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00659606" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Lopid</name>
								<manufacturerId>PFI</manufacturerId>
								<listingDate>2008-02-12</listingDate>
							</drug>
							<drug id="01979582" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Gemfibrozil</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.7520</individualPrice>
								<listingDate>2008-02-12</listingDate>
							</drug>
							<drug id="02142074" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Teva-Gemfibrozil</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.7520</individualPrice>
								<listingDate>2008-02-12</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00339">
					<name>LOVASTATIN</name>
					<pcgGroup>
						<pcg9 id="240600011">
							<itemNumber>0628</itemNumber>
							<strength>20mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00795860" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Mevacor</name>
								<manufacturerId>MFC</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02220172" chronicUseMed="Y" sec3="Y">
								<name>Lovastatin</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>1.0846</individualPrice>
								<listingDate>1997-08-28</listingDate>
								<amountMOHLTCPays>1.0846</amountMOHLTCPays>
							</drug>
							<drug id="02248572" chronicUseMed="Y" sec3="Y">
								<name>Co Lovastatin</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>1.0846</individualPrice>
								<listingDate>2004-09-14</listingDate>
								<amountMOHLTCPays>1.0846</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240600015">
							<itemNumber>0629</itemNumber>
							<strength>40mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00795852" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Mevacor</name>
								<manufacturerId>MFC</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02220180" chronicUseMed="Y" sec3="Y">
								<name>Lovastatin</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>1.9812</individualPrice>
								<listingDate>1997-08-28</listingDate>
								<amountMOHLTCPays>1.9812</amountMOHLTCPays>
							</drug>
							<drug id="02248573" chronicUseMed="Y" sec3="Y">
								<name>Co Lovastatin</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>1.9812</individualPrice>
								<listingDate>2004-09-14</listingDate>
								<amountMOHLTCPays>1.9812</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00340">
					<name>PRAVASTATIN SODIUM</name>
					<pcgGroup>
						<pcg9 id="240600013">
							<itemNumber>0630</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00893749" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Pravachol</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02243506" chronicUseMed="Y" sec3="Y">
								<name>Apo-Pravastatin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2916</individualPrice>
								<listingDate>2001-06-07</listingDate>
								<amountMOHLTCPays>.2916</amountMOHLTCPays>
							</drug>
							<drug id="02246930" chronicUseMed="Y" sec3="Y">
								<name>Ratio-Pravastatin</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>.2916</individualPrice>
								<listingDate>2003-09-04</listingDate>
								<amountMOHLTCPays>.2916</amountMOHLTCPays>
							</drug>
							<drug id="02247008" chronicUseMed="Y" sec3="Y">
								<name>Teva-Pravastatin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2916</individualPrice>
								<listingDate>2003-09-04</listingDate>
								<amountMOHLTCPays>.2916</amountMOHLTCPays>
							</drug>
							<drug id="02247655" chronicUseMed="Y" sec3="Y">
								<name>PMS-Pravastatin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2916</individualPrice>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.2916</amountMOHLTCPays>
							</drug>
							<drug id="02248182" chronicUseMed="Y" sec3="Y">
								<name>Co Pravastatin</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.2916</individualPrice>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.2916</amountMOHLTCPays>
							</drug>
							<drug id="02284421" chronicUseMed="Y" sec3="Y">
								<name>Ran-Pravastatin</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.2916</individualPrice>
								<listingDate>2007-09-04</listingDate>
								<amountMOHLTCPays>.2916</amountMOHLTCPays>
							</drug>
							<drug id="02317451" chronicUseMed="Y" sec3="Y">
								<name>Mint-Pravastatin</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.2916</individualPrice>
								<listingDate>2010-04-23</listingDate>
								<amountMOHLTCPays>.2916</amountMOHLTCPays>
							</drug>
							<drug id="02330954" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Pravastatin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2916</individualPrice>
								<listingDate>2010-04-23</listingDate>
								<amountMOHLTCPays>.2916</amountMOHLTCPays>
							</drug>
							<drug id="02356546" chronicUseMed="Y" sec3="Y">
								<name>Pravastatin</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2916</individualPrice>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>.2916</amountMOHLTCPays>
							</drug>
							<drug id="02389703" chronicUseMed="Y" sec3="Y">
								<name>Pravastatin</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2916</individualPrice>
								<listingDate>2020-12-18</listingDate>
								<amountMOHLTCPays>.2916</amountMOHLTCPays>
							</drug>
							<drug id="02432048" chronicUseMed="Y" sec3="Y">
								<name>Mar-Pravastatin</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.2916</individualPrice>
								<listingDate>2018-08-30</listingDate>
								<amountMOHLTCPays>.2916</amountMOHLTCPays>
							</drug>
							<drug id="02440644" chronicUseMed="Y" sec3="Y">
								<name>Ach-Pravastatin</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.2916</individualPrice>
								<listingDate>2020-04-30</listingDate>
								<amountMOHLTCPays>.2916</amountMOHLTCPays>
							</drug>
							<drug id="02458977" chronicUseMed="Y" sec3="Y">
								<name>Auro-Pravastatin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2916</individualPrice>
								<listingDate>2018-07-31</listingDate>
								<amountMOHLTCPays>.2916</amountMOHLTCPays>
							</drug>
							<drug id="02468700" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Pravastatin Tablets</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2916</individualPrice>
								<listingDate>2018-08-30</listingDate>
								<amountMOHLTCPays>.2916</amountMOHLTCPays>
							</drug>
							<drug id="02476142" chronicUseMed="Y" sec3="Y">
								<name>AG-Pravastatin</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.2916</individualPrice>
								<listingDate>2020-12-18</listingDate>
								<amountMOHLTCPays>.2916</amountMOHLTCPays>
							</drug>
							<drug id="02476274" chronicUseMed="Y" sec3="Y">
								<name>M-Pravastatin</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.2916</individualPrice>
								<listingDate>2021-10-29</listingDate>
								<amountMOHLTCPays>.2916</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240600014">
							<itemNumber>0631</itemNumber>
							<strength>20mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00893757" chronicUseMed="Y" sec3="Y">
								<name>Pravachol</name>
								<manufacturerId>BQU</manufacturerId>
								<individualPrice>.8926</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3440</amountMOHLTCPays>
							</drug>
							<drug id="02243507" chronicUseMed="Y" sec3="Y">
								<name>Apo-Pravastatin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3440</individualPrice>
								<listingDate>2001-06-07</listingDate>
								<amountMOHLTCPays>.3440</amountMOHLTCPays>
							</drug>
							<drug id="02246931" chronicUseMed="Y" sec3="Y">
								<name>Ratio-Pravastatin</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>.3440</individualPrice>
								<listingDate>2003-09-04</listingDate>
								<amountMOHLTCPays>.3440</amountMOHLTCPays>
							</drug>
							<drug id="02247009" chronicUseMed="Y" sec3="Y">
								<name>Teva-Pravastatin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3440</individualPrice>
								<listingDate>2003-09-04</listingDate>
								<amountMOHLTCPays>.3440</amountMOHLTCPays>
							</drug>
							<drug id="02247656" chronicUseMed="Y" sec3="Y">
								<name>PMS-Pravastatin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3440</individualPrice>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.3440</amountMOHLTCPays>
							</drug>
							<drug id="02248183" chronicUseMed="Y" sec3="Y">
								<name>Co Pravastatin</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.3440</individualPrice>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.3440</amountMOHLTCPays>
							</drug>
							<drug id="02284448" chronicUseMed="Y" sec3="Y">
								<name>Ran-Pravastatin</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.3440</individualPrice>
								<listingDate>2007-09-04</listingDate>
								<amountMOHLTCPays>.3440</amountMOHLTCPays>
							</drug>
							<drug id="02317478" chronicUseMed="Y" sec3="Y">
								<name>Mint-Pravastatin</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.3440</individualPrice>
								<listingDate>2010-04-23</listingDate>
								<amountMOHLTCPays>.3440</amountMOHLTCPays>
							</drug>
							<drug id="02330962" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Pravastatin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.3440</individualPrice>
								<listingDate>2010-04-23</listingDate>
								<amountMOHLTCPays>.3440</amountMOHLTCPays>
							</drug>
							<drug id="02356554" chronicUseMed="Y" sec3="Y">
								<name>Pravastatin</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.3440</individualPrice>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>.3440</amountMOHLTCPays>
							</drug>
							<drug id="02389738" chronicUseMed="Y" sec3="Y">
								<name>Pravastatin</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.3440</individualPrice>
								<listingDate>2020-12-18</listingDate>
								<amountMOHLTCPays>.3440</amountMOHLTCPays>
							</drug>
							<drug id="02432056" chronicUseMed="Y" sec3="Y">
								<name>Mar-Pravastatin</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.3440</individualPrice>
								<listingDate>2018-08-30</listingDate>
								<amountMOHLTCPays>.3440</amountMOHLTCPays>
							</drug>
							<drug id="02440652" chronicUseMed="Y" sec3="Y">
								<name>Ach-Pravastatin</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.3440</individualPrice>
								<listingDate>2020-04-30</listingDate>
								<amountMOHLTCPays>.3440</amountMOHLTCPays>
							</drug>
							<drug id="02458985" chronicUseMed="Y" sec3="Y">
								<name>Auro-Pravastatin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.3440</individualPrice>
								<listingDate>2018-07-31</listingDate>
								<amountMOHLTCPays>.3440</amountMOHLTCPays>
							</drug>
							<drug id="02468719" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Pravastatin Tablets</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.3440</individualPrice>
								<listingDate>2018-08-30</listingDate>
								<amountMOHLTCPays>.3440</amountMOHLTCPays>
							</drug>
							<drug id="02476150" chronicUseMed="Y" sec3="Y">
								<name>AG-Pravastatin</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.3440</individualPrice>
								<listingDate>2020-12-18</listingDate>
								<amountMOHLTCPays>.3440</amountMOHLTCPays>
							</drug>
							<drug id="02476282" chronicUseMed="Y" sec3="Y">
								<name>M-Pravastatin</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.3440</individualPrice>
								<listingDate>2021-10-29</listingDate>
								<amountMOHLTCPays>.3440</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240600035">
							<itemNumber>0632</itemNumber>
							<strength>40mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02222051" chronicUseMed="Y" sec3="Y">
								<name>Pravachol</name>
								<manufacturerId>BQU</manufacturerId>
								<individualPrice>1.0750</individualPrice>
								<listingDate>1997-08-28</listingDate>
								<amountMOHLTCPays>.4143</amountMOHLTCPays>
							</drug>
							<drug id="02243508" chronicUseMed="Y" sec3="Y">
								<name>Apo-Pravastatin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.4143</individualPrice>
								<listingDate>2001-06-07</listingDate>
								<amountMOHLTCPays>.4143</amountMOHLTCPays>
							</drug>
							<drug id="02246932" chronicUseMed="Y" sec3="Y">
								<name>Ratio-Pravastatin</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>.4143</individualPrice>
								<listingDate>2003-09-04</listingDate>
								<amountMOHLTCPays>.4143</amountMOHLTCPays>
							</drug>
							<drug id="02247010" chronicUseMed="Y" sec3="Y">
								<name>Teva-Pravastatin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.4143</individualPrice>
								<listingDate>2003-09-04</listingDate>
								<amountMOHLTCPays>.4143</amountMOHLTCPays>
							</drug>
							<drug id="02247657" chronicUseMed="Y" sec3="Y">
								<name>PMS-Pravastatin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.4143</individualPrice>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.4143</amountMOHLTCPays>
							</drug>
							<drug id="02248184" chronicUseMed="Y" sec3="Y">
								<name>Co Pravastatin</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.4143</individualPrice>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.4143</amountMOHLTCPays>
							</drug>
							<drug id="02284456" chronicUseMed="Y" sec3="Y">
								<name>Ran-Pravastatin</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.4143</individualPrice>
								<listingDate>2007-09-04</listingDate>
								<amountMOHLTCPays>.4143</amountMOHLTCPays>
							</drug>
							<drug id="02317486" chronicUseMed="Y" sec3="Y">
								<name>Mint-Pravastatin</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.4143</individualPrice>
								<listingDate>2010-04-23</listingDate>
								<amountMOHLTCPays>.4143</amountMOHLTCPays>
							</drug>
							<drug id="02330970" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Pravastatin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.4143</individualPrice>
								<listingDate>2010-04-23</listingDate>
								<amountMOHLTCPays>.4143</amountMOHLTCPays>
							</drug>
							<drug id="02356562" chronicUseMed="Y" sec3="Y">
								<name>Pravastatin</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.4143</individualPrice>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>.4143</amountMOHLTCPays>
							</drug>
							<drug id="02389746" chronicUseMed="Y" sec3="Y">
								<name>Pravastatin</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.4143</individualPrice>
								<listingDate>2020-12-18</listingDate>
								<amountMOHLTCPays>.4143</amountMOHLTCPays>
							</drug>
							<drug id="02432064" chronicUseMed="Y" sec3="Y">
								<name>Mar-Pravastatin</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.4143</individualPrice>
								<listingDate>2018-08-30</listingDate>
								<amountMOHLTCPays>.4143</amountMOHLTCPays>
							</drug>
							<drug id="02440660" chronicUseMed="Y" sec3="Y">
								<name>Ach-Pravastatin</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.4143</individualPrice>
								<listingDate>2020-04-30</listingDate>
								<amountMOHLTCPays>.4143</amountMOHLTCPays>
							</drug>
							<drug id="02458993" chronicUseMed="Y" sec3="Y">
								<name>Auro-Pravastatin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.4143</individualPrice>
								<listingDate>2018-07-31</listingDate>
								<amountMOHLTCPays>.4143</amountMOHLTCPays>
							</drug>
							<drug id="02468727" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Pravastatin Tablets</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.4143</individualPrice>
								<listingDate>2018-08-30</listingDate>
								<amountMOHLTCPays>.4143</amountMOHLTCPays>
							</drug>
							<drug id="02476169" chronicUseMed="Y" sec3="Y">
								<name>AG-Pravastatin</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.4143</individualPrice>
								<listingDate>2020-12-18</listingDate>
								<amountMOHLTCPays>.4143</amountMOHLTCPays>
							</drug>
							<drug id="02476290" chronicUseMed="Y" sec3="Y">
								<name>M-Pravastatin</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.4143</individualPrice>
								<listingDate>2021-10-29</listingDate>
								<amountMOHLTCPays>.4143</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01590">
					<name>ROSUVASTATIN CALCIUM</name>
					<pcgGroup>
						<pcg9 id="240600066">
							<itemNumber>0633</itemNumber>
							<strength>5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02265540" chronicUseMed="Y" sec3="Y">
								<name>Crestor</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>1.3217</individualPrice>
								<listingDate>2007-01-02</listingDate>
								<amountMOHLTCPays>.1284</amountMOHLTCPays>
							</drug>
							<drug id="02337975" chronicUseMed="Y" sec3="Y">
								<name>Apo-Rosuvastatin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1284</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.1284</amountMOHLTCPays>
							</drug>
							<drug id="02338726" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Rosuvastatin</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.1284</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.1284</amountMOHLTCPays>
							</drug>
							<drug id="02339765" chronicUseMed="Y" sec3="Y">
								<name>Co Rosuvastatin</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.1284</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.1284</amountMOHLTCPays>
							</drug>
							<drug id="02354608" chronicUseMed="Y" sec3="Y">
								<name>Teva-Rosuvastatin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1284</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.1284</amountMOHLTCPays>
							</drug>
							<drug id="02378523" chronicUseMed="Y" sec3="Y">
								<name>PMS-Rosuvastatin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1284</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.1284</amountMOHLTCPays>
							</drug>
							<drug id="02382644" chronicUseMed="Y" sec3="Y">
								<name>Taro-Rosuvastatin</name>
								<manufacturerId>SPC</manufacturerId>
								<individualPrice>.1284</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.1284</amountMOHLTCPays>
							</drug>
							<drug id="02391252" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Rosuvastatin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1284</individualPrice>
								<listingDate>2012-12-21</listingDate>
								<amountMOHLTCPays>.1284</amountMOHLTCPays>
							</drug>
							<drug id="02397781" chronicUseMed="Y" sec3="Y">
								<name>Mint-Rosuvastatin</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.1284</individualPrice>
								<listingDate>2013-08-29</listingDate>
								<amountMOHLTCPays>.1284</amountMOHLTCPays>
							</drug>
							<drug id="02399164" chronicUseMed="Y" sec3="Y">
								<name>Med-Rosuvastatin</name>
								<manufacturerId>GMP</manufacturerId>
								<individualPrice>.1284</individualPrice>
								<listingDate>2014-01-30</listingDate>
								<amountMOHLTCPays>.1284</amountMOHLTCPays>
							</drug>
							<drug id="02405628" chronicUseMed="Y" sec3="Y">
								<name>Rosuvastatin</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.1284</individualPrice>
								<listingDate>2016-05-31</listingDate>
								<amountMOHLTCPays>.1284</amountMOHLTCPays>
							</drug>
							<drug id="02411628" chronicUseMed="Y" sec3="Y">
								<name>Rosuvastatin</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.1284</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.1284</amountMOHLTCPays>
							</drug>
							<drug id="02413051" chronicUseMed="Y" sec3="Y">
								<name>Mar-Rosuvastatin</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.1284</individualPrice>
								<listingDate>2014-04-01</listingDate>
								<amountMOHLTCPays>.1284</amountMOHLTCPays>
							</drug>
							<drug id="02438917" chronicUseMed="Y" sec3="Y">
								<name>Ach-Rosuvastatin</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.1284</individualPrice>
								<listingDate>2019-07-31</listingDate>
								<amountMOHLTCPays>.1284</amountMOHLTCPays>
							</drug>
							<drug id="02442574" chronicUseMed="Y" sec3="Y">
								<name>Auro-Rosuvastatin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.1284</individualPrice>
								<listingDate>2016-04-01</listingDate>
								<amountMOHLTCPays>.1284</amountMOHLTCPays>
							</drug>
							<drug id="02477483" chronicUseMed="Y" sec3="Y">
								<name>NRA-Rosuvastatin</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.1284</individualPrice>
								<listingDate>2020-09-30</listingDate>
								<amountMOHLTCPays>.1284</amountMOHLTCPays>
							</drug>
							<drug id="02496534" chronicUseMed="Y" sec3="Y">
								<name>M-Rosuvastatin</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.1284</individualPrice>
								<listingDate>2021-10-29</listingDate>
								<amountMOHLTCPays>.1284</amountMOHLTCPays>
							</drug>
							<drug id="02498332" chronicUseMed="Y" sec3="Y">
								<name>Jamp Rosuvastatin Calcium</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1284</individualPrice>
								<listingDate>2021-04-30</listingDate>
								<amountMOHLTCPays>.1284</amountMOHLTCPays>
							</drug>
							<drug id="02505576" chronicUseMed="Y" sec3="Y">
								<name>PRZ-Rosuvastatin</name>
								<manufacturerId>PRZ</manufacturerId>
								<individualPrice>.1284</individualPrice>
								<listingDate>2022-01-31</listingDate>
								<amountMOHLTCPays>.1284</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240600044">
							<itemNumber>0634</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02247162" chronicUseMed="Y" sec3="Y">
								<name>Crestor</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>1.4033</individualPrice>
								<listingDate>2003-09-04</listingDate>
								<amountMOHLTCPays>.1354</amountMOHLTCPays>
							</drug>
							<drug id="02337983" chronicUseMed="Y" sec3="Y">
								<name>Apo-Rosuvastatin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1354</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.1354</amountMOHLTCPays>
							</drug>
							<drug id="02338734" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Rosuvastatin</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.1354</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.1354</amountMOHLTCPays>
							</drug>
							<drug id="02339773" chronicUseMed="Y" sec3="Y">
								<name>Co Rosuvastatin</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.1354</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.1354</amountMOHLTCPays>
							</drug>
							<drug id="02354616" chronicUseMed="Y" sec3="Y">
								<name>Teva-Rosuvastatin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1354</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.1354</amountMOHLTCPays>
							</drug>
							<drug id="02378531" chronicUseMed="Y" sec3="Y">
								<name>PMS-Rosuvastatin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1354</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.1354</amountMOHLTCPays>
							</drug>
							<drug id="02382652" chronicUseMed="Y" sec3="Y">
								<name>Taro-Rosuvastatin</name>
								<manufacturerId>SPC</manufacturerId>
								<individualPrice>.1354</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.1354</amountMOHLTCPays>
							</drug>
							<drug id="02391260" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Rosuvastatin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1354</individualPrice>
								<listingDate>2012-12-21</listingDate>
								<amountMOHLTCPays>.1354</amountMOHLTCPays>
							</drug>
							<drug id="02397803" chronicUseMed="Y" sec3="Y">
								<name>Mint-Rosuvastatin</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.1354</individualPrice>
								<listingDate>2013-08-29</listingDate>
								<amountMOHLTCPays>.1354</amountMOHLTCPays>
							</drug>
							<drug id="02399172" chronicUseMed="Y" sec3="Y">
								<name>Med-Rosuvastatin</name>
								<manufacturerId>GMP</manufacturerId>
								<individualPrice>.1354</individualPrice>
								<listingDate>2014-01-30</listingDate>
								<amountMOHLTCPays>.1354</amountMOHLTCPays>
							</drug>
							<drug id="02405636" chronicUseMed="Y" sec3="Y">
								<name>Rosuvastatin</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.1354</individualPrice>
								<listingDate>2016-05-31</listingDate>
								<amountMOHLTCPays>.1354</amountMOHLTCPays>
							</drug>
							<drug id="02411636" chronicUseMed="Y" sec3="Y">
								<name>Rosuvastatin</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.1354</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.1354</amountMOHLTCPays>
							</drug>
							<drug id="02413078" chronicUseMed="Y" sec3="Y">
								<name>Mar-Rosuvastatin</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.1354</individualPrice>
								<listingDate>2014-04-01</listingDate>
								<amountMOHLTCPays>.1354</amountMOHLTCPays>
							</drug>
							<drug id="02438925" chronicUseMed="Y" sec3="Y">
								<name>Ach-Rosuvastatin</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.1354</individualPrice>
								<listingDate>2019-07-31</listingDate>
								<amountMOHLTCPays>.1354</amountMOHLTCPays>
							</drug>
							<drug id="02442582" chronicUseMed="Y" sec3="Y">
								<name>Auro-Rosuvastatin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.1354</individualPrice>
								<listingDate>2016-04-01</listingDate>
								<amountMOHLTCPays>.1354</amountMOHLTCPays>
							</drug>
							<drug id="02477491" chronicUseMed="Y" sec3="Y">
								<name>NRA-Rosuvastatin</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.1354</individualPrice>
								<listingDate>2020-09-30</listingDate>
								<amountMOHLTCPays>.1354</amountMOHLTCPays>
							</drug>
							<drug id="02496542" chronicUseMed="Y" sec3="Y">
								<name>M-Rosuvastatin</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.1354</individualPrice>
								<listingDate>2021-10-29</listingDate>
								<amountMOHLTCPays>.1354</amountMOHLTCPays>
							</drug>
							<drug id="02498340" chronicUseMed="Y" sec3="Y">
								<name>Jamp Rosuvastatin Calcium</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1354</individualPrice>
								<listingDate>2021-04-30</listingDate>
								<amountMOHLTCPays>.1354</amountMOHLTCPays>
							</drug>
							<drug id="02505584" chronicUseMed="Y" sec3="Y">
								<name>PRZ-Rosuvastatin</name>
								<manufacturerId>PRZ</manufacturerId>
								<individualPrice>.1354</individualPrice>
								<listingDate>2022-01-31</listingDate>
								<amountMOHLTCPays>.1354</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240600047">
							<itemNumber>0635</itemNumber>
							<strength>20mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02247163" chronicUseMed="Y" sec3="Y">
								<name>Crestor</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>1.7467</individualPrice>
								<listingDate>2003-09-04</listingDate>
								<amountMOHLTCPays>.1692</amountMOHLTCPays>
							</drug>
							<drug id="02337991" chronicUseMed="Y" sec3="Y">
								<name>Apo-Rosuvastatin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1692</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.1692</amountMOHLTCPays>
							</drug>
							<drug id="02338742" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Rosuvastatin</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.1692</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.1692</amountMOHLTCPays>
							</drug>
							<drug id="02339781" chronicUseMed="Y" sec3="Y">
								<name>Co Rosuvastatin</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.1692</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.1692</amountMOHLTCPays>
							</drug>
							<drug id="02354624" chronicUseMed="Y" sec3="Y">
								<name>Teva-Rosuvastatin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1692</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.1692</amountMOHLTCPays>
							</drug>
							<drug id="02378558" chronicUseMed="Y" sec3="Y">
								<name>PMS-Rosuvastatin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1692</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.1692</amountMOHLTCPays>
							</drug>
							<drug id="02382660" chronicUseMed="Y" sec3="Y">
								<name>Taro-Rosuvastatin</name>
								<manufacturerId>SPC</manufacturerId>
								<individualPrice>.1692</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.1692</amountMOHLTCPays>
							</drug>
							<drug id="02391279" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Rosuvastatin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1692</individualPrice>
								<listingDate>2012-12-21</listingDate>
								<amountMOHLTCPays>.1692</amountMOHLTCPays>
							</drug>
							<drug id="02397811" chronicUseMed="Y" sec3="Y">
								<name>Mint-Rosuvastatin</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.1692</individualPrice>
								<listingDate>2013-08-29</listingDate>
								<amountMOHLTCPays>.1692</amountMOHLTCPays>
							</drug>
							<drug id="02399180" chronicUseMed="Y" sec3="Y">
								<name>Med-Rosuvastatin</name>
								<manufacturerId>GMP</manufacturerId>
								<individualPrice>.1692</individualPrice>
								<listingDate>2014-01-30</listingDate>
								<amountMOHLTCPays>.1692</amountMOHLTCPays>
							</drug>
							<drug id="02405644" chronicUseMed="Y" sec3="Y">
								<name>Rosuvastatin</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.1692</individualPrice>
								<listingDate>2016-05-31</listingDate>
								<amountMOHLTCPays>.1692</amountMOHLTCPays>
							</drug>
							<drug id="02411644" chronicUseMed="Y" sec3="Y">
								<name>Rosuvastatin</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.1692</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.1692</amountMOHLTCPays>
							</drug>
							<drug id="02413086" chronicUseMed="Y" sec3="Y">
								<name>Mar-Rosuvastatin</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.1692</individualPrice>
								<listingDate>2014-04-01</listingDate>
								<amountMOHLTCPays>.1692</amountMOHLTCPays>
							</drug>
							<drug id="02438933" chronicUseMed="Y" sec3="Y">
								<name>Ach-Rosuvastatin</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.1692</individualPrice>
								<listingDate>2019-07-31</listingDate>
								<amountMOHLTCPays>.1692</amountMOHLTCPays>
							</drug>
							<drug id="02442590" chronicUseMed="Y" sec3="Y">
								<name>Auro-Rosuvastatin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.1692</individualPrice>
								<listingDate>2016-04-01</listingDate>
								<amountMOHLTCPays>.1692</amountMOHLTCPays>
							</drug>
							<drug id="02477505" chronicUseMed="Y" sec3="Y">
								<name>NRA-Rosuvastatin</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.1692</individualPrice>
								<listingDate>2020-09-30</listingDate>
								<amountMOHLTCPays>.1692</amountMOHLTCPays>
							</drug>
							<drug id="02496550" chronicUseMed="Y" sec3="Y">
								<name>M-Rosuvastatin</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.1692</individualPrice>
								<listingDate>2021-10-29</listingDate>
								<amountMOHLTCPays>.1692</amountMOHLTCPays>
							</drug>
							<drug id="02498359" chronicUseMed="Y" sec3="Y">
								<name>Jamp Rosuvastatin Calcium</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1692</individualPrice>
								<listingDate>2021-04-30</listingDate>
								<amountMOHLTCPays>.1692</amountMOHLTCPays>
							</drug>
							<drug id="02505592" chronicUseMed="Y" sec3="Y">
								<name>PRZ-Rosuvastatin</name>
								<manufacturerId>PRZ</manufacturerId>
								<individualPrice>.1692</individualPrice>
								<listingDate>2022-01-31</listingDate>
								<amountMOHLTCPays>.1692</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240600048">
							<itemNumber>0636</itemNumber>
							<strength>40mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02247164" chronicUseMed="Y" sec3="Y">
								<name>Crestor</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>2.0500</individualPrice>
								<listingDate>2003-09-04</listingDate>
								<amountMOHLTCPays>.1990</amountMOHLTCPays>
							</drug>
							<drug id="02338009" chronicUseMed="Y" sec3="Y">
								<name>Apo-Rosuvastatin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1990</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.1990</amountMOHLTCPays>
							</drug>
							<drug id="02338750" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Rosuvastatin</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.1990</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.1990</amountMOHLTCPays>
							</drug>
							<drug id="02339803" chronicUseMed="Y" sec3="Y">
								<name>Co Rosuvastatin</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.1990</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.1990</amountMOHLTCPays>
							</drug>
							<drug id="02354632" chronicUseMed="Y" sec3="Y">
								<name>Teva-Rosuvastatin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1990</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.1990</amountMOHLTCPays>
							</drug>
							<drug id="02378566" chronicUseMed="Y" sec3="Y">
								<name>PMS-Rosuvastatin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1990</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.1990</amountMOHLTCPays>
							</drug>
							<drug id="02382679" chronicUseMed="Y" sec3="Y">
								<name>Taro-Rosuvastatin</name>
								<manufacturerId>SPC</manufacturerId>
								<individualPrice>.1990</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.1990</amountMOHLTCPays>
							</drug>
							<drug id="02391287" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Rosuvastatin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1990</individualPrice>
								<listingDate>2012-12-21</listingDate>
								<amountMOHLTCPays>.1990</amountMOHLTCPays>
							</drug>
							<drug id="02397838" chronicUseMed="Y" sec3="Y">
								<name>Mint-Rosuvastatin</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.1990</individualPrice>
								<listingDate>2013-08-29</listingDate>
								<amountMOHLTCPays>.1990</amountMOHLTCPays>
							</drug>
							<drug id="02399199" chronicUseMed="Y" sec3="Y">
								<name>Med-Rosuvastatin</name>
								<manufacturerId>GMP</manufacturerId>
								<individualPrice>.1990</individualPrice>
								<listingDate>2014-01-30</listingDate>
								<amountMOHLTCPays>.1990</amountMOHLTCPays>
							</drug>
							<drug id="02405652" chronicUseMed="Y" sec3="Y">
								<name>Rosuvastatin</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.1990</individualPrice>
								<listingDate>2016-05-31</listingDate>
								<amountMOHLTCPays>.1990</amountMOHLTCPays>
							</drug>
							<drug id="02411652" chronicUseMed="Y" sec3="Y">
								<name>Rosuvastatin</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.1990</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.1990</amountMOHLTCPays>
							</drug>
							<drug id="02413108" chronicUseMed="Y" sec3="Y">
								<name>Mar-Rosuvastatin</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.1990</individualPrice>
								<listingDate>2014-04-01</listingDate>
								<amountMOHLTCPays>.1990</amountMOHLTCPays>
							</drug>
							<drug id="02438941" chronicUseMed="Y" sec3="Y">
								<name>Ach-Rosuvastatin</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.1990</individualPrice>
								<listingDate>2019-07-31</listingDate>
								<amountMOHLTCPays>.1990</amountMOHLTCPays>
							</drug>
							<drug id="02442604" chronicUseMed="Y" sec3="Y">
								<name>Auro-Rosuvastatin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.1990</individualPrice>
								<listingDate>2016-04-01</listingDate>
								<amountMOHLTCPays>.1990</amountMOHLTCPays>
							</drug>
							<drug id="02477513" chronicUseMed="Y" sec3="Y">
								<name>NRA-Rosuvastatin</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.1990</individualPrice>
								<listingDate>2021-04-30</listingDate>
								<amountMOHLTCPays>.1990</amountMOHLTCPays>
							</drug>
							<drug id="02496569" chronicUseMed="Y" sec3="Y">
								<name>M-Rosuvastatin</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.1990</individualPrice>
								<listingDate>2021-10-29</listingDate>
								<amountMOHLTCPays>.1990</amountMOHLTCPays>
							</drug>
							<drug id="02498367" chronicUseMed="Y" sec3="Y">
								<name>Jamp Rosuvastatin Calcium</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1990</individualPrice>
								<listingDate>2021-04-30</listingDate>
								<amountMOHLTCPays>.1990</amountMOHLTCPays>
							</drug>
							<drug id="02505606" chronicUseMed="Y" sec3="Y">
								<name>PRZ-Rosuvastatin</name>
								<manufacturerId>PRZ</manufacturerId>
								<individualPrice>.1990</individualPrice>
								<listingDate>2022-01-31</listingDate>
								<amountMOHLTCPays>.1990</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00341">
					<name>SIMVASTATIN</name>
					<pcgGroup>
						<pcg9 id="240600017">
							<itemNumber>0637</itemNumber>
							<strength>5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00884324" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Zocor</name>
								<manufacturerId>MFC</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02247011" chronicUseMed="Y" sec3="Y">
								<name>Apo-Simvastatin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1023</individualPrice>
								<listingDate>2003-04-16</listingDate>
								<amountMOHLTCPays>.1023</amountMOHLTCPays>
							</drug>
							<drug id="02248103" chronicUseMed="Y" sec3="Y">
								<name>Co Simvastatin</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.1023</individualPrice>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.1023</amountMOHLTCPays>
							</drug>
							<drug id="02250144" chronicUseMed="Y" sec3="Y">
								<name>Teva-Simvastatin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1023</individualPrice>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.1023</amountMOHLTCPays>
							</drug>
							<drug id="02269252" chronicUseMed="Y" sec3="Y">
								<name>PMS-Simvastatin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1023</individualPrice>
								<listingDate>2006-04-04</listingDate>
								<amountMOHLTCPays>.1023</amountMOHLTCPays>
							</drug>
							<drug id="02284723" chronicUseMed="Y" sec3="Y">
								<name>Simvastatin</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.1023</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.1023</amountMOHLTCPays>
							</drug>
							<drug id="02329131" chronicUseMed="Y" sec3="Y">
								<name>Ran-Simvastatin</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.1023</individualPrice>
								<listingDate>2009-11-13</listingDate>
								<amountMOHLTCPays>.1023</amountMOHLTCPays>
							</drug>
							<drug id="02372932" chronicUseMed="Y" sec3="Y">
								<name>Mint-Simvastatin</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.1023</individualPrice>
								<listingDate>2011-12-15</listingDate>
								<amountMOHLTCPays>.1023</amountMOHLTCPays>
							</drug>
							<drug id="02375036" chronicUseMed="Y" sec3="Y">
								<name>Mar-Simvastatin</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.1023</individualPrice>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.1023</amountMOHLTCPays>
							</drug>
							<drug id="02375591" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Simvastatin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1023</individualPrice>
								<listingDate>2012-08-27</listingDate>
								<amountMOHLTCPays>.1023</amountMOHLTCPays>
							</drug>
							<drug id="02405148" chronicUseMed="Y" sec3="Y">
								<name>Auro-Simvastatin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.1023</individualPrice>
								<listingDate>2013-09-27</listingDate>
								<amountMOHLTCPays>.1023</amountMOHLTCPays>
							</drug>
							<drug id="02469979" chronicUseMed="Y" sec3="Y">
								<name>Pharma-Simvastatin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1023</individualPrice>
								<listingDate>2018-07-31</listingDate>
								<amountMOHLTCPays>.1023</amountMOHLTCPays>
							</drug>
							<drug id="02480050" chronicUseMed="Y" sec3="Y">
								<name>AG-Simvastatin</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.1023</individualPrice>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.1023</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240600016">
							<itemNumber>0638</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00884332" chronicUseMed="Y" sec3="Y">
								<name>Zocor</name>
								<manufacturerId>OCI</manufacturerId>
								<individualPrice>2.6848</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2023</amountMOHLTCPays>
							</drug>
							<drug id="02247012" chronicUseMed="Y" sec3="Y">
								<name>Apo-Simvastatin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2023</individualPrice>
								<listingDate>2003-04-16</listingDate>
								<amountMOHLTCPays>.2023</amountMOHLTCPays>
							</drug>
							<drug id="02248104" chronicUseMed="Y" sec3="Y">
								<name>Co Simvastatin</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.2023</individualPrice>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.2023</amountMOHLTCPays>
							</drug>
							<drug id="02250152" chronicUseMed="Y" sec3="Y">
								<name>Teva-Simvastatin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2023</individualPrice>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.2023</amountMOHLTCPays>
							</drug>
							<drug id="02265885" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Taro-Simvastatin</name>
								<manufacturerId>TAR</manufacturerId>
								<listingDate>2005-10-06</listingDate>
							</drug>
							<drug id="02269260" chronicUseMed="Y" sec3="Y">
								<name>PMS-Simvastatin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2023</individualPrice>
								<listingDate>2006-04-04</listingDate>
								<amountMOHLTCPays>.2023</amountMOHLTCPays>
							</drug>
							<drug id="02284731" chronicUseMed="Y" sec3="Y">
								<name>Simvastatin</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2023</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2023</amountMOHLTCPays>
							</drug>
							<drug id="02329158" chronicUseMed="Y" sec3="Y">
								<name>Ran-Simvastatin</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.2023</individualPrice>
								<listingDate>2009-11-13</listingDate>
								<amountMOHLTCPays>.2023</amountMOHLTCPays>
							</drug>
							<drug id="02372940" chronicUseMed="Y" sec3="Y">
								<name>Mint-Simvastatin</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.2023</individualPrice>
								<listingDate>2011-12-15</listingDate>
								<amountMOHLTCPays>.2023</amountMOHLTCPays>
							</drug>
							<drug id="02375044" chronicUseMed="Y" sec3="Y">
								<name>Mar-Simvastatin</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.2023</individualPrice>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.2023</amountMOHLTCPays>
							</drug>
							<drug id="02375605" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Simvastatin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2023</individualPrice>
								<listingDate>2012-08-27</listingDate>
								<amountMOHLTCPays>.2023</amountMOHLTCPays>
							</drug>
							<drug id="02405156" chronicUseMed="Y" sec3="Y">
								<name>Auro-Simvastatin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2023</individualPrice>
								<listingDate>2013-09-27</listingDate>
								<amountMOHLTCPays>.2023</amountMOHLTCPays>
							</drug>
							<drug id="02469987" chronicUseMed="Y" sec3="Y">
								<name>Pharma-Simvastatin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2023</individualPrice>
								<listingDate>2018-04-30</listingDate>
								<amountMOHLTCPays>.2023</amountMOHLTCPays>
							</drug>
							<drug id="02480069" chronicUseMed="Y" sec3="Y">
								<name>AG-Simvastatin</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.2023</individualPrice>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.2023</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240600028">
							<itemNumber>0639</itemNumber>
							<strength>20mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00884340" chronicUseMed="Y" sec3="Y">
								<name>Zocor</name>
								<manufacturerId>OCI</manufacturerId>
								<individualPrice>3.3182</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
							<drug id="02247013" chronicUseMed="Y" sec3="Y">
								<name>Apo-Simvastatin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2003-04-16</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
							<drug id="02248105" chronicUseMed="Y" sec3="Y">
								<name>Co Simvastatin</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
							<drug id="02250160" chronicUseMed="Y" sec3="Y">
								<name>Teva-Simvastatin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
							<drug id="02265893" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Taro-Simvastatin</name>
								<manufacturerId>TAR</manufacturerId>
								<listingDate>2005-10-06</listingDate>
							</drug>
							<drug id="02269279" chronicUseMed="Y" sec3="Y">
								<name>PMS-Simvastatin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2006-04-04</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
							<drug id="02284758" chronicUseMed="Y" sec3="Y">
								<name>Simvastatin</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
							<drug id="02329166" chronicUseMed="Y" sec3="Y">
								<name>Ran-Simvastatin</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2009-11-13</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
							<drug id="02372959" chronicUseMed="Y" sec3="Y">
								<name>Mint-Simvastatin</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2011-12-15</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
							<drug id="02375052" chronicUseMed="Y" sec3="Y">
								<name>Mar-Simvastatin</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
							<drug id="02375613" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Simvastatin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2012-08-27</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
							<drug id="02405164" chronicUseMed="Y" sec3="Y">
								<name>Auro-Simvastatin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2013-09-27</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
							<drug id="02469995" chronicUseMed="Y" sec3="Y">
								<name>Pharma-Simvastatin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2018-05-31</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
							<drug id="02480077" chronicUseMed="Y" sec3="Y">
								<name>AG-Simvastatin</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240600032">
							<itemNumber>0640</itemNumber>
							<strength>40mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00884359" chronicUseMed="Y" sec3="Y">
								<name>Zocor</name>
								<manufacturerId>OCI</manufacturerId>
								<individualPrice>3.3182</individualPrice>
								<listingDate>1996-12-19</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
							<drug id="02247014" chronicUseMed="Y" sec3="Y">
								<name>Apo-Simvastatin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2003-04-16</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
							<drug id="02248106" chronicUseMed="Y" sec3="Y">
								<name>Co Simvastatin</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
							<drug id="02250179" chronicUseMed="Y" sec3="Y">
								<name>Teva-Simvastatin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
							<drug id="02265907" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Taro-Simvastatin</name>
								<manufacturerId>TAR</manufacturerId>
								<listingDate>2005-10-06</listingDate>
							</drug>
							<drug id="02269287" chronicUseMed="Y" sec3="Y">
								<name>PMS-Simvastatin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2006-04-04</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
							<drug id="02284766" chronicUseMed="Y" sec3="Y">
								<name>Simvastatin</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
							<drug id="02329174" chronicUseMed="Y" sec3="Y">
								<name>Ran-Simvastatin</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2009-11-13</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
							<drug id="02372967" chronicUseMed="Y" sec3="Y">
								<name>Mint-Simvastatin</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2011-12-15</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
							<drug id="02375060" chronicUseMed="Y" sec3="Y">
								<name>Mar-Simvastatin</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
							<drug id="02375621" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Simvastatin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2012-08-27</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
							<drug id="02405172" chronicUseMed="Y" sec3="Y">
								<name>Auro-Simvastatin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2013-09-27</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
							<drug id="02470004" chronicUseMed="Y" sec3="Y">
								<name>Pharma-Simvastatin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2018-05-31</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
							<drug id="02480085" chronicUseMed="Y" sec3="Y">
								<name>AG-Simvastatin</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240600040">
							<itemNumber>0641</itemNumber>
							<strength>80mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02240332" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Zocor</name>
								<manufacturerId>MFC</manufacturerId>
								<listingDate>2000-04-17</listingDate>
							</drug>
							<drug id="02247015" chronicUseMed="Y" sec3="Y">
								<name>Apo-Simvastatin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2003-04-16</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
							<drug id="02248107" chronicUseMed="Y" sec3="Y">
								<name>Co Simvastatin</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
							<drug id="02250187" chronicUseMed="Y" sec3="Y">
								<name>Teva-Simvastatin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
							<drug id="02269295" chronicUseMed="Y" sec3="Y">
								<name>PMS-Simvastatin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2006-04-04</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
							<drug id="02284774" chronicUseMed="Y" sec3="Y">
								<name>Simvastatin</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
							<drug id="02329182" chronicUseMed="Y" sec3="Y">
								<name>Ran-Simvastatin</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2009-11-13</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
							<drug id="02372975" chronicUseMed="Y" sec3="Y">
								<name>Mint-Simvastatin</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2011-12-15</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
							<drug id="02375079" chronicUseMed="Y" sec3="Y">
								<name>Mar-Simvastatin</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
							<drug id="02375648" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Simvastatin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2012-08-27</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
							<drug id="02405180" chronicUseMed="Y" sec3="Y">
								<name>Auro-Simvastatin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2013-09-27</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
							<drug id="02470012" chronicUseMed="Y" sec3="Y">
								<name>Pharma-Simvastatin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2018-07-31</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
							<drug id="02480093" chronicUseMed="Y" sec3="Y">
								<name>AG-Simvastatin</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.2501</individualPrice>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.2501</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="240624000">
				<name>ANTILIPEMIC DRUGS PCSK9 INHIBITORS</name>
				<genericName id="02078">
					<name>ALIROCUMAB</name>
					<pcgGroup lccId="00315">
						<pcg9 id="240624002">
							<itemNumber>0642</itemNumber>
							<strength>75mg/mL</strength>
							<dosageForm>Inj Sol-Pref Pen</dosageForm>
							<drug id="02453819" sec3="Y" sec12="Y">
								<name>Praluent</name>
								<manufacturerId>SAC</manufacturerId>
								<individualPrice>256.2100</individualPrice>
								<listingDate>2019-03-28</listingDate>
								<amountMOHLTCPays>256.2100</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240624004">
							<itemNumber>0643</itemNumber>
							<strength>150mg/mL</strength>
							<dosageForm>Inj Sol-Pref Pen</dosageForm>
							<drug id="02453835" sec3="Y" sec12="Y">
								<name>Praluent</name>
								<manufacturerId>SAC</manufacturerId>
								<individualPrice>256.2100</individualPrice>
								<listingDate>2019-03-28</listingDate>
								<amountMOHLTCPays>256.2100</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="555">For the treatment of Heterozygous Familial Hypercholesterolemia (HeFH) in patients 18 years of age or older who meet the following criteria:
- Definite or probable diagnosis of HeFH using the Simon Broome or Dutch Lipid Network criteria or genetic testing;
AND
- Unable to reach Low Density Lipoprotein Cholesterol (LDL-C) target (i.e., LDL-C less than 2.0 mmol/L for secondary prevention) or at least 50% reduction in LDL-C from untreated baseline for primary prevention despite:
A) Confirmed adherence to ezetimibe for at least a total of 3 months in combination with high dose statin (e.g., atorvastatin 80mg or rosuvastatin 40mg);
OR
B) Confirmed adherence to ezetimibe for at least a total of 3 months and inability to tolerate high dose statin defined as:
(i) Inability to tolerate at least 2 statins with a least one started at the lowest starting dose;
(ii) For each statin (two statins in total), dose reduction is attempted for intolerable symptom (myopathy) or biomarker abnormality (creatine kinase (CK) greater than 5 times the upper limit of normal) resolution rather than discontinuation of statin altogether;
(iii) For each statin (two statins in total), intolerable symptoms (myopathy) or abnormal biomarker (creatine kinase (CK) greater than 5 times the upper limit of normal) changes are reversible upon statin discontinuation but reproducible by re-challenge of statins where clinically appropriate; and
(iv) One of the following:
(I.) Other known determinants of intolerable symptoms or abnormal biomarkers have been ruled out;
(II.) Patient developed confirmed and documented rhabdomyolysis;
(III.) Patient is statin contraindicated i.e. active liver disease, unexplained persistent elevations of serum transaminases exceeding 3 times the upper limit of normal.
Treatment with Praluent should be discontinued if the patient does not meet all of the following:
1. Patient is adherent to therapy.
2. Patient has achieved a reduction in LDL-C of at least 40% from baseline (4-8 weeks after initiation of Praluent).
3. Patient continues to have a significant reduction in LDL-C (with continuation of Praluent) of at least 40% from baseline since initiation of PCSK9 inhibitor. LDL-C should be checked periodically with continued treatment with PCSK9 inhibitors (e.g., every 6 months).
Patients prescribed Praluent 75mg every two weeks are limited to 26 prefilled syringes (PFS) or pre-filled pens (PFP) per year. Patients prescribed Praluent 150mg every two weeks or 300mg every four weeks must use the 150mg/mL dosage strength and are limited to 26 PFS or PFP per year.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="240800000">
				<name>HYPOTENSIVE DRUGS (FOR DIURETICS SEE 40:28)</name>
				<genericName id="00369">
					<name>ATENOLOL &amp; CHLORTHALIDONE</name>
					<pcgGroup>
						<pcg9 id="240800107">
							<itemNumber>0644</itemNumber>
							<strength>50 &amp; 25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02049961" dinStatus="E" chronicUseMed="Y" sec3="Y">
								<name>Tenoretic 50/25</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>.7122</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.5342</amountMOHLTCPays>
							</drug>
							<drug id="02248763" chronicUseMed="Y" sec3="Y">
								<name>AA-Atenidone</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.5342</individualPrice>
								<listingDate>2004-09-14</listingDate>
								<amountMOHLTCPays>.5342</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800108">
							<itemNumber>0645</itemNumber>
							<strength>100 &amp; 25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02049988" dinStatus="E" chronicUseMed="Y" sec3="Y">
								<name>Tenoretic 100/25</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>1.1673</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.8755</amountMOHLTCPays>
							</drug>
							<drug id="02248764" chronicUseMed="Y" sec3="Y">
								<name>AA-Atenidone</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.8755</individualPrice>
								<listingDate>2004-09-14</listingDate>
								<amountMOHLTCPays>.8755</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00381">
					<name>BENAZEPRIL</name>
					<pcgGroup>
						<pcg9 id="240800186">
							<itemNumber>0646</itemNumber>
							<strength>5mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.8333</dailyCost>
							<drug id="00885835" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Lotensin</name>
								<manufacturerId>NOV</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02290332" chronicUseMed="Y" sec3="Y">
								<name>Benazepril</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.8333</individualPrice>
								<dailyCost>.8333</dailyCost>
								<listingDate>2007-10-03</listingDate>
								<amountMOHLTCPays>.8333</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800187">
							<itemNumber>0647</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.9870</dailyCost>
							<drug id="00885843" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Lotensin</name>
								<manufacturerId>NOV</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02290340" chronicUseMed="Y" sec3="Y">
								<name>Benazepril</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.9870</individualPrice>
								<dailyCost>.9870</dailyCost>
								<listingDate>2007-10-03</listingDate>
								<amountMOHLTCPays>.9870</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800188">
							<itemNumber>0648</itemNumber>
							<strength>20mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>1.1311</dailyCost>
							<drug id="00885851" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Lotensin</name>
								<manufacturerId>NOV</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02273918" chronicUseMed="Y" sec3="Y">
								<name>Benazepril</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>1.1311</individualPrice>
								<dailyCost>1.1311</dailyCost>
								<listingDate>2006-06-14</listingDate>
								<amountMOHLTCPays>1.1311</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01422">
					<name>CANDESARTAN CILEXETIL</name>
					<pcgGroup>
						<pcg9 id="240800260">
							<itemNumber>0649</itemNumber>
							<strength>4mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02239090" chronicUseMed="Y" sec3="Y">
								<name>Atacand</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>.8443</individualPrice>
								<listingDate>2006-04-19</listingDate>
								<amountMOHLTCPays>.1700</amountMOHLTCPays>
							</drug>
							<drug id="02326957" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Candesartan</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.1700</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.1700</amountMOHLTCPays>
							</drug>
							<drug id="02365340" chronicUseMed="Y" sec3="Y">
								<name>Apo-Candesartan</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1700</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.1700</amountMOHLTCPays>
							</drug>
							<drug id="02376520" chronicUseMed="Y" sec3="Y">
								<name>Co Candesartan</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.1700</individualPrice>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.1700</amountMOHLTCPays>
							</drug>
							<drug id="02379260" chronicUseMed="Y" sec3="Y">
								<name>Candesartan Cilexetil Tablets</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.1700</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.1700</amountMOHLTCPays>
							</drug>
							<drug id="02380684" chronicUseMed="Y" sec3="Y">
								<name>Ran-Candesartan</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.1700</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.1700</amountMOHLTCPays>
							</drug>
							<drug id="02386496" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Candesartan</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1700</individualPrice>
								<listingDate>2012-09-28</listingDate>
								<amountMOHLTCPays>.1700</amountMOHLTCPays>
							</drug>
							<drug id="02388901" chronicUseMed="Y" sec3="Y">
								<name>Candesartan</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.1700</individualPrice>
								<listingDate>2020-08-28</listingDate>
								<amountMOHLTCPays>.1700</amountMOHLTCPays>
							</drug>
							<drug id="02391171" chronicUseMed="Y" sec3="Y">
								<name>PMS-Candesartan</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1700</individualPrice>
								<listingDate>2012-10-30</listingDate>
								<amountMOHLTCPays>.1700</amountMOHLTCPays>
							</drug>
							<drug id="02445786" chronicUseMed="Y" sec3="Y">
								<name>Auro-Candesartan</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.1700</individualPrice>
								<listingDate>2018-08-30</listingDate>
								<amountMOHLTCPays>.1700</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800235">
							<itemNumber>0650</itemNumber>
							<strength>8mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02239091" chronicUseMed="Y" sec3="Y">
								<name>Atacand</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>1.4043</individualPrice>
								<listingDate>1999-09-15</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02326965" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Candesartan</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02365359" chronicUseMed="Y" sec3="Y">
								<name>Apo-Candesartan</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02366312" chronicUseMed="Y" sec3="Y">
								<name>Teva-Candesartan</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02376539" chronicUseMed="Y" sec3="Y">
								<name>Co Candesartan</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02379279" chronicUseMed="Y" sec3="Y">
								<name>Candesartan Cilexetil Tablets</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02380692" chronicUseMed="Y" sec3="Y">
								<name>Ran-Candesartan</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02386518" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Candesartan</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2012-09-28</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02388707" chronicUseMed="Y" sec3="Y">
								<name>Candesartan</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02388928" chronicUseMed="Y" sec3="Y">
								<name>Candesartan</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2020-08-28</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02391198" chronicUseMed="Y" sec3="Y">
								<name>PMS-Candesartan</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2012-10-30</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02445794" chronicUseMed="Y" sec3="Y">
								<name>Auro-Candesartan</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2018-08-30</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02476916" chronicUseMed="Y" sec3="Y">
								<name>Mint-Candesartan</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2019-01-31</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800234">
							<itemNumber>0651</itemNumber>
							<strength>16mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02239092" chronicUseMed="Y" sec3="Y">
								<name>Atacand</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>1.4043</individualPrice>
								<listingDate>1999-09-15</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02326973" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Candesartan</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02365367" chronicUseMed="Y" sec3="Y">
								<name>Apo-Candesartan</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02366320" chronicUseMed="Y" sec3="Y">
								<name>Teva-Candesartan</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02376547" chronicUseMed="Y" sec3="Y">
								<name>Co Candesartan</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02379287" chronicUseMed="Y" sec3="Y">
								<name>Candesartan Cilexetil Tablets</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02380706" chronicUseMed="Y" sec3="Y">
								<name>Ran-Candesartan</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02386526" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Candesartan</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2012-09-28</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02388715" chronicUseMed="Y" sec3="Y">
								<name>Candesartan</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02388936" chronicUseMed="Y" sec3="Y">
								<name>Candesartan</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2020-08-28</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02391201" chronicUseMed="Y" sec3="Y">
								<name>PMS-Candesartan</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2012-10-30</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02445808" chronicUseMed="Y" sec3="Y">
								<name>Auro-Candesartan</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2019-04-30</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02476924" chronicUseMed="Y" sec3="Y">
								<name>Mint-Candesartan</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2019-01-31</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800279">
							<itemNumber>0652</itemNumber>
							<strength>32mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02311658" chronicUseMed="Y" sec3="Y">
								<name>Atacand</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>1.4043</individualPrice>
								<listingDate>2009-05-20</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02366339" chronicUseMed="Y" sec3="Y">
								<name>Teva-Candesartan</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02376555" chronicUseMed="Y" sec3="Y">
								<name>Co Candesartan</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02379295" chronicUseMed="Y" sec3="Y">
								<name>Candesartan Cilexetil Tablets</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02380714" chronicUseMed="Y" sec3="Y">
								<name>Ran-Candesartan</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02386534" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Candesartan</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2012-09-28</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02391228" chronicUseMed="Y" sec3="Y">
								<name>PMS-Candesartan</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2012-10-30</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02399105" chronicUseMed="Y" sec3="Y">
								<name>Apo-Candesartan</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2013-02-28</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02417340" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Candesartan</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2014-07-30</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02435845" chronicUseMed="Y" sec3="Y">
								<name>Candesartan</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2020-08-28</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02445816" chronicUseMed="Y" sec3="Y">
								<name>Auro-Candesartan</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2019-04-30</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01558">
					<name>CANDESARTAN CILEXETIL &amp; HYDROCHLOROTHIAZIDE</name>
					<pcgGroup>
						<pcg9 id="240800248">
							<itemNumber>0653</itemNumber>
							<strength>16mg &amp; 12.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02244021" chronicUseMed="Y" sec3="Y">
								<name>Atacand Plus</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>1.4043</individualPrice>
								<listingDate>2002-07-29</listingDate>
								<amountMOHLTCPays>.2156</amountMOHLTCPays>
							</drug>
							<drug id="02327902" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Candesartan Plus</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2156</individualPrice>
								<listingDate>2012-11-27</listingDate>
								<amountMOHLTCPays>.2156</amountMOHLTCPays>
							</drug>
							<drug id="02391295" chronicUseMed="Y" sec3="Y">
								<name>PMS-Candesartan-HCTZ</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2156</individualPrice>
								<listingDate>2012-11-27</listingDate>
								<amountMOHLTCPays>.2156</amountMOHLTCPays>
							</drug>
							<drug id="02394804" chronicUseMed="Y" sec3="Y">
								<name>Candesartan/HCTZ</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2156</individualPrice>
								<listingDate>2020-08-28</listingDate>
								<amountMOHLTCPays>.2156</amountMOHLTCPays>
							</drug>
							<drug id="02394812" chronicUseMed="Y" sec3="Y">
								<name>Candesartan HCT</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2156</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.2156</amountMOHLTCPays>
							</drug>
							<drug id="02395541" chronicUseMed="Y" sec3="Y">
								<name>Teva-Candesartan/HCTZ</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2156</individualPrice>
								<listingDate>2012-12-21</listingDate>
								<amountMOHLTCPays>.2156</amountMOHLTCPays>
							</drug>
							<drug id="02421038" chronicUseMed="Y" sec3="Y">
								<name>Auro-Candesartan HCT</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2156</individualPrice>
								<listingDate>2015-05-28</listingDate>
								<amountMOHLTCPays>.2156</amountMOHLTCPays>
							</drug>
							<drug id="02473240" chronicUseMed="Y" sec3="Y">
								<name>Jamp Candesartan-HCT</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2156</individualPrice>
								<listingDate>2019-07-31</listingDate>
								<amountMOHLTCPays>.2156</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800291">
							<itemNumber>0654</itemNumber>
							<strength>32mg &amp; 12.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02332922" chronicUseMed="Y" sec3="Y">
								<name>Atacand Plus</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>1.4043</individualPrice>
								<listingDate>2010-07-20</listingDate>
								<amountMOHLTCPays>.2156</amountMOHLTCPays>
							</drug>
							<drug id="02395568" chronicUseMed="Y" sec3="Y">
								<name>Teva-Candesartan/HCTZ</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2156</individualPrice>
								<listingDate>2013-06-27</listingDate>
								<amountMOHLTCPays>.2156</amountMOHLTCPays>
							</drug>
							<drug id="02420732" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Candesartan Plus</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2156</individualPrice>
								<listingDate>2014-07-30</listingDate>
								<amountMOHLTCPays>.2156</amountMOHLTCPays>
							</drug>
							<drug id="02421046" chronicUseMed="Y" sec3="Y">
								<name>Auro-Candesartan HCT</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2156</individualPrice>
								<listingDate>2015-05-28</listingDate>
								<amountMOHLTCPays>.2156</amountMOHLTCPays>
							</drug>
							<drug id="02473259" chronicUseMed="Y" sec3="Y">
								<name>Jamp Candesartan-HCT</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2156</individualPrice>
								<listingDate>2019-07-31</listingDate>
								<amountMOHLTCPays>.2156</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800292">
							<itemNumber>0655</itemNumber>
							<strength>32mg &amp; 25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02332957" chronicUseMed="Y" sec3="Y">
								<name>Atacand Plus</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>1.4043</individualPrice>
								<listingDate>2010-07-20</listingDate>
								<amountMOHLTCPays>.3008</amountMOHLTCPays>
							</drug>
							<drug id="02420740" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Candesartan Plus</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.3008</individualPrice>
								<listingDate>2014-07-30</listingDate>
								<amountMOHLTCPays>.3008</amountMOHLTCPays>
							</drug>
							<drug id="02421054" chronicUseMed="Y" sec3="Y">
								<name>Auro-Candesartan HCT</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.3008</individualPrice>
								<listingDate>2015-05-28</listingDate>
								<amountMOHLTCPays>.3008</amountMOHLTCPays>
							</drug>
							<drug id="02473267" chronicUseMed="Y" sec3="Y">
								<name>Jamp Candesartan-HCT</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.3008</individualPrice>
								<listingDate>2019-07-31</listingDate>
								<amountMOHLTCPays>.3008</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00363">
					<name>CAPTOPRIL</name>
					<pcgGroup>
						<pcg9 id="240800130">
							<itemNumber>0656</itemNumber>
							<strength>12.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.6360</dailyCost>
							<drug id="00695661" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Capoten</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00893595" chronicUseMed="Y" sec3="Y">
								<name>Apo-Capto</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2120</individualPrice>
								<dailyCost>.6360</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2120</amountMOHLTCPays>
							</drug>
							<drug id="01942964" chronicUseMed="Y" sec3="Y">
								<name>Teva-Captopril</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2120</individualPrice>
								<dailyCost>.6360</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2120</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800078">
							<itemNumber>0657</itemNumber>
							<strength>25mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.9000</dailyCost>
							<drug id="00546283" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Capoten</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00893609" chronicUseMed="Y" sec3="Y">
								<name>Apo-Capto</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3000</individualPrice>
								<dailyCost>.9000</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3000</amountMOHLTCPays>
							</drug>
							<drug id="01942972" chronicUseMed="Y" sec3="Y">
								<name>Teva-Captopril</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3000</individualPrice>
								<dailyCost>.9000</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800077">
							<itemNumber>0658</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>1.6770</dailyCost>
							<drug id="00546291" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Capoten</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00893617" chronicUseMed="Y" sec3="Y">
								<name>Apo-Capto</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.5590</individualPrice>
								<dailyCost>1.6770</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.5590</amountMOHLTCPays>
							</drug>
							<drug id="01942980" chronicUseMed="Y" sec3="Y">
								<name>Teva-Captopril</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.5590</individualPrice>
								<dailyCost>1.6770</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.5590</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800076">
							<itemNumber>0659</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00546305" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Capoten</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00893625" chronicUseMed="Y" sec3="Y">
								<name>Apo-Capto</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.0395</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>1.0395</amountMOHLTCPays>
							</drug>
							<drug id="01942999" chronicUseMed="Y" sec3="Y">
								<name>Teva-Captopril</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>1.0395</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>1.0395</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00382">
					<name>CILAZAPRIL</name>
					<pcgGroup>
						<pcg9 id="240800189">
							<itemNumber>0660</itemNumber>
							<strength>1mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="01911465" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Inhibace</name>
								<manufacturerId>HLR</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02283778" chronicUseMed="Y" sec3="Y">
								<name>Mylan-Cilazapril</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.3115</individualPrice>
								<listingDate>2006-09-06</listingDate>
								<amountMOHLTCPays>.3115</amountMOHLTCPays>
							</drug>
							<drug id="02291134" chronicUseMed="Y" sec3="Y">
								<name>Apo-Cilazapril</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3115</individualPrice>
								<listingDate>2007-03-09</listingDate>
								<amountMOHLTCPays>.3115</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800190">
							<itemNumber>0661</itemNumber>
							<strength>2.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.4295</dailyCost>
							<drug id="01911473" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Inhibace</name>
								<manufacturerId>HLR</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02283786" chronicUseMed="Y" sec3="Y">
								<name>Mylan-Cilazapril</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.4295</individualPrice>
								<dailyCost>.4295</dailyCost>
								<listingDate>2006-09-06</listingDate>
								<amountMOHLTCPays>.4295</amountMOHLTCPays>
							</drug>
							<drug id="02291142" chronicUseMed="Y" sec3="Y">
								<name>Apo-Cilazapril</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.4295</individualPrice>
								<dailyCost>.4295</dailyCost>
								<listingDate>2007-03-09</listingDate>
								<amountMOHLTCPays>.4295</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800191">
							<itemNumber>0662</itemNumber>
							<strength>5mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.4989</dailyCost>
							<drug id="01911481" chronicUseMed="Y" sec3="Y">
								<name>Inhibace</name>
								<manufacturerId>CHE</manufacturerId>
								<individualPrice>.9978</individualPrice>
								<dailyCost>.9978</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.4989</amountMOHLTCPays>
							</drug>
							<drug id="02283794" chronicUseMed="Y" sec3="Y">
								<name>Mylan-Cilazapril</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.4989</individualPrice>
								<dailyCost>.4989</dailyCost>
								<listingDate>2006-09-06</listingDate>
								<amountMOHLTCPays>.4989</amountMOHLTCPays>
							</drug>
							<drug id="02291150" chronicUseMed="Y" sec3="Y">
								<name>Apo-Cilazapril</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.4989</individualPrice>
								<dailyCost>.4989</dailyCost>
								<listingDate>2007-03-09</listingDate>
								<amountMOHLTCPays>.4989</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01436">
					<name>CILAZAPRIL &amp; HYDROCHLOROTHIAZIDE</name>
					<pcgGroup>
						<pcg9 id="240800236">
							<itemNumber>0663</itemNumber>
							<strength>5mg/12.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02181479" chronicUseMed="Y" sec3="Y">
								<name>Inhibace Plus</name>
								<manufacturerId>CHE</manufacturerId>
								<individualPrice>.9975</individualPrice>
								<listingDate>2000-01-17</listingDate>
								<amountMOHLTCPays>.4170</amountMOHLTCPays>
							</drug>
							<drug id="02284987" chronicUseMed="Y" sec3="Y">
								<name>Apo-Cilazapril/HCTZ</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.4170</individualPrice>
								<listingDate>2007-01-02</listingDate>
								<amountMOHLTCPays>.4170</amountMOHLTCPays>
							</drug>
							<drug id="02313731" chronicUseMed="Y" sec3="Y">
								<name>Teva-Cilazapril/HCTZ</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.4170</individualPrice>
								<listingDate>2009-05-20</listingDate>
								<amountMOHLTCPays>.4170</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00355">
					<name>CLONIDINE HCL</name>
					<note>Significant rebound hypertension can occur after missing even one or two doses; this drug should be avoided in patients with cardiovascular fragility or suspected problems with compliance.</note>
					<pcgGroup>
						<pcg9 id="240800171">
							<itemNumber>0664</itemNumber>
							<strength>0.025mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00519251" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Dixarit</name>
								<manufacturerId>BOE</manufacturerId>
								<listingDate>2007-06-06</listingDate>
							</drug>
							<drug id="02304163" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Teva-Clonidine</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2713</individualPrice>
								<listingDate>2008-05-16</listingDate>
							</drug>
							<drug id="02516217" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Sandoz Clonidine</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2713</individualPrice>
								<listingDate>2022-02-28</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="240800022">
							<itemNumber>0665</itemNumber>
							<strength>0.1mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.2716</dailyCost>
							<drug id="00259527" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Catapres</name>
								<manufacturerId>BOE</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02046121" chronicUseMed="Y" sec3="Y">
								<name>Teva-Clonidine</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.0679</individualPrice>
								<dailyCost>.2716</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0679</amountMOHLTCPays>
							</drug>
							<drug id="02462192" chronicUseMed="Y" sec3="Y">
								<name>Mint-Clonidine</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.0679</individualPrice>
								<dailyCost>.2716</dailyCost>
								<listingDate>2017-10-30</listingDate>
								<amountMOHLTCPays>.0679</amountMOHLTCPays>
							</drug>
							<drug id="02515784" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Clonidine</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.0679</individualPrice>
								<dailyCost>.2716</dailyCost>
								<listingDate>2022-03-31</listingDate>
								<amountMOHLTCPays>.0679</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800021">
							<itemNumber>0666</itemNumber>
							<strength>0.2mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.4848</dailyCost>
							<drug id="00291889" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Catapres</name>
								<manufacturerId>BOE</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02046148" chronicUseMed="Y" sec3="Y">
								<name>Teva-Clonidine</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1212</individualPrice>
								<dailyCost>.4848</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1212</amountMOHLTCPays>
							</drug>
							<drug id="02462206" chronicUseMed="Y" sec3="Y">
								<name>Mint-Clonidine</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.1212</individualPrice>
								<dailyCost>.4848</dailyCost>
								<listingDate>2017-10-30</listingDate>
								<amountMOHLTCPays>.1212</amountMOHLTCPays>
							</drug>
							<drug id="02515792" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Clonidine</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.1212</individualPrice>
								<dailyCost>.4848</dailyCost>
								<listingDate>2022-03-31</listingDate>
								<amountMOHLTCPays>.1212</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00375">
					<name>DOXAZOSIN MESYLATE</name>
					<pcgGroup>
						<pcg9 id="240800168">
							<itemNumber>0667</itemNumber>
							<strength>1mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.1719</dailyCost>
							<drug id="01958100" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Cardura-1</name>
								<manufacturerId>AZC</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02240588" chronicUseMed="Y" sec3="Y">
								<name>Apo-Doxazosin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1719</individualPrice>
								<dailyCost>.1719</dailyCost>
								<listingDate>2000-01-17</listingDate>
								<amountMOHLTCPays>.1719</amountMOHLTCPays>
							</drug>
							<drug id="02242728" chronicUseMed="Y" sec3="Y">
								<name>Teva-Doxazosin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1719</individualPrice>
								<dailyCost>.1719</dailyCost>
								<listingDate>2001-03-07</listingDate>
								<amountMOHLTCPays>.1719</amountMOHLTCPays>
							</drug>
							<drug id="02489937" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Doxazosin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1719</individualPrice>
								<dailyCost>.1719</dailyCost>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.1719</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800169">
							<itemNumber>0668</itemNumber>
							<strength>2mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.2062</dailyCost>
							<drug id="01958097" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Cardura-2</name>
								<manufacturerId>AZC</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02240589" chronicUseMed="Y" sec3="Y">
								<name>Apo-Doxazosin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2062</individualPrice>
								<dailyCost>.2062</dailyCost>
								<listingDate>2000-01-17</listingDate>
								<amountMOHLTCPays>.2062</amountMOHLTCPays>
							</drug>
							<drug id="02242729" chronicUseMed="Y" sec3="Y">
								<name>Teva-Doxazosin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2062</individualPrice>
								<dailyCost>.2062</dailyCost>
								<listingDate>2001-03-07</listingDate>
								<amountMOHLTCPays>.2062</amountMOHLTCPays>
							</drug>
							<drug id="02489945" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Doxazosin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2062</individualPrice>
								<dailyCost>.2062</dailyCost>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.2062</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800170">
							<itemNumber>0669</itemNumber>
							<strength>4mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.2681</dailyCost>
							<drug id="01958119" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Cardura-4</name>
								<manufacturerId>AZC</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02240590" chronicUseMed="Y" sec3="Y">
								<name>Apo-Doxazosin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2681</individualPrice>
								<dailyCost>.2681</dailyCost>
								<listingDate>2000-01-17</listingDate>
								<amountMOHLTCPays>.2681</amountMOHLTCPays>
							</drug>
							<drug id="02242730" chronicUseMed="Y" sec3="Y">
								<name>Teva-Doxazosin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2681</individualPrice>
								<dailyCost>.2681</dailyCost>
								<listingDate>2001-03-07</listingDate>
								<amountMOHLTCPays>.2681</amountMOHLTCPays>
							</drug>
							<drug id="02489953" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Doxazosin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2681</individualPrice>
								<dailyCost>.2681</dailyCost>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.2681</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00368">
					<name>ENALAPRIL MALEATE</name>
					<pcgGroup>
						<pcg9 id="240800149">
							<itemNumber>0670</itemNumber>
							<strength>2.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.1863</dailyCost>
							<drug id="00851795" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Vasotec</name>
								<manufacturerId>MFC</manufacturerId>
								<note>** Each tablet is made with 2.5mg of enalapril maleate that is equivalent to 2mg of enalapril sodium, in the finished tablets.
Discontinuation Letter from MFR.</note>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02020025" chronicUseMed="Y" sec3="Y">
								<name>Apo-Enalapril</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1863</individualPrice>
								<dailyCost>.1863</dailyCost>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.1863</amountMOHLTCPays>
							</drug>
							<drug id="02291878" chronicUseMed="Y" sec3="Y">
								<name>Co Enalapril</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.1863</individualPrice>
								<dailyCost>.1863</dailyCost>
								<note>** Each tablet is made with 2.5mg of enalapril maleate that is equivalent to 2mg of enalapril sodium, in the finished tablets.</note>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.1863</amountMOHLTCPays>
							</drug>
							<drug id="02299933" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Enalapril</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.1863</individualPrice>
								<dailyCost>.1863</dailyCost>
								<note>** Each tablet is made with 2.5mg of enalapril maleate that is equivalent to 2mg of enalapril sodium, in the finished tablets.</note>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.1863</amountMOHLTCPays>
							</drug>
							<drug id="02299984" chronicUseMed="Y" sec3="Y">
								<name>Ratio-Enalapril</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>.1863</individualPrice>
								<dailyCost>.1863</dailyCost>
								<note>** Each tablet is made with 2.5mg of enalapril maleate that is equivalent to 2mg of enalapril sodium, in the finished tablets.</note>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.1863</amountMOHLTCPays>
							</drug>
							<drug id="02300036" chronicUseMed="Y" sec3="Y">
								<name>Mylan-Enalapril</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.1863</individualPrice>
								<dailyCost>.1863</dailyCost>
								<note>** Each tablet is made with 2.5mg of enalapril maleate that is equivalent to 2mg of enalapril sodium, in the finished tablets.</note>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.1863</amountMOHLTCPays>
							</drug>
							<drug id="02300117" chronicUseMed="Y" sec3="Y">
								<name>Taro-Enalapril</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>.1863</individualPrice>
								<dailyCost>.1863</dailyCost>
								<note>** Each tablet is made with 2.5mg of enalapril maleate that is equivalent to 2mg of enalapril sodium, in the finished tablets.</note>
								<listingDate>2008-01-15</listingDate>
								<amountMOHLTCPays>.1863</amountMOHLTCPays>
							</drug>
							<drug id="02300680" chronicUseMed="Y" sec3="Y">
								<name>Novo-Enalapril</name>
								<manufacturerId>NOP</manufacturerId>
								<individualPrice>.1863</individualPrice>
								<dailyCost>.1863</dailyCost>
								<note>** Each tablet is made with 2.5mg of enalapril maleate that is equivalent to 2mg of enalapril sodium, in the finished tablets.</note>
								<listingDate>2008-05-16</listingDate>
								<amountMOHLTCPays>.1863</amountMOHLTCPays>
							</drug>
							<drug id="02352230" chronicUseMed="Y" sec3="Y">
								<name>Ran-Enalapril</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.1863</individualPrice>
								<dailyCost>.1863</dailyCost>
								<listingDate>2011-01-07</listingDate>
								<amountMOHLTCPays>.1863</amountMOHLTCPays>
							</drug>
							<drug id="02400650" chronicUseMed="Y" sec3="Y">
								<name>Enalapril</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.1863</individualPrice>
								<dailyCost>.1863</dailyCost>
								<listingDate>2022-02-28</listingDate>
								<amountMOHLTCPays>.1863</amountMOHLTCPays>
							</drug>
							<drug id="02442957" chronicUseMed="Y" sec3="Y">
								<name>Enalapril</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.1863</individualPrice>
								<dailyCost>.1863</dailyCost>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.1863</amountMOHLTCPays>
							</drug>
							<drug id="02459450" chronicUseMed="Y" sec3="Y">
								<name>Mar-Enalapril</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.1863</individualPrice>
								<dailyCost>.1863</dailyCost>
								<listingDate>2019-06-28</listingDate>
								<amountMOHLTCPays>.1863</amountMOHLTCPays>
							</drug>
							<drug id="02474786" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Enalapril</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1863</individualPrice>
								<dailyCost>.1863</dailyCost>
								<listingDate>2019-04-30</listingDate>
								<amountMOHLTCPays>.1863</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800105">
							<itemNumber>0671</itemNumber>
							<strength>5mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.2203</dailyCost>
							<drug id="00708879" chronicUseMed="Y" sec3="Y">
								<name>Vasotec</name>
								<manufacturerId>OCI</manufacturerId>
								<individualPrice>1.2182</individualPrice>
								<dailyCost>1.2182</dailyCost>
								<note>** Each tablet is made with 5mg of enalapril maleate that is equivalent to 4mg of enalapril sodium, in the finished tablets.</note>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2203</amountMOHLTCPays>
							</drug>
							<drug id="02019884" chronicUseMed="Y" sec3="Y">
								<name>Apo-Enalapril</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2203</individualPrice>
								<dailyCost>.2203</dailyCost>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.2203</amountMOHLTCPays>
							</drug>
							<drug id="02233005" chronicUseMed="Y" sec3="Y">
								<name>Teva-Enalapril</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2203</individualPrice>
								<dailyCost>.2203</dailyCost>
								<note>** Each tablet is made with 5mg of enalapril maleate that is equivalent to 4mg of enalapril sodium, in the finished tablets.</note>
								<listingDate>2008-05-16</listingDate>
								<amountMOHLTCPays>.2203</amountMOHLTCPays>
							</drug>
							<drug id="02291886" chronicUseMed="Y" sec3="Y">
								<name>Co Enalapril</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.2203</individualPrice>
								<dailyCost>.2203</dailyCost>
								<note>** Each tablet is made with 5mg of enalapril maleate that is equivalent to 4mg of enalapril sodium, in the finished tablets.</note>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.2203</amountMOHLTCPays>
							</drug>
							<drug id="02299941" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Enalapril</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2203</individualPrice>
								<dailyCost>.2203</dailyCost>
								<note>** Each tablet is made with 5mg of enalapril maleate that is equivalent to 4mg of enalapril sodium, in the finished tablets.</note>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.2203</amountMOHLTCPays>
							</drug>
							<drug id="02299992" chronicUseMed="Y" sec3="Y">
								<name>Ratio-Enalapril</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>.2203</individualPrice>
								<dailyCost>.2203</dailyCost>
								<note>** Each tablet is made with 5mg of enalapril maleate that is equivalent to 4mg of enalapril sodium, in the finished tablets.</note>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.2203</amountMOHLTCPays>
							</drug>
							<drug id="02300044" chronicUseMed="Y" sec3="Y">
								<name>Mylan-Enalapril</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.2203</individualPrice>
								<dailyCost>.2203</dailyCost>
								<note>** Each tablet is made with 5mg of enalapril maleate that is equivalent to 4mg of enalapril sodium, in the finished tablets.</note>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.2203</amountMOHLTCPays>
							</drug>
							<drug id="02300125" chronicUseMed="Y" sec3="Y">
								<name>Taro-Enalapril</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>.2203</individualPrice>
								<dailyCost>.2203</dailyCost>
								<note>** Each tablet is made with 5mg of enalapril maleate that is equivalent to 4mg of enalapril sodium, in the finished tablets.</note>
								<listingDate>2008-01-15</listingDate>
								<amountMOHLTCPays>.2203</amountMOHLTCPays>
							</drug>
							<drug id="02352249" chronicUseMed="Y" sec3="Y">
								<name>Ran-Enalapril</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.2203</individualPrice>
								<dailyCost>.2203</dailyCost>
								<listingDate>2011-01-07</listingDate>
								<amountMOHLTCPays>.2203</amountMOHLTCPays>
							</drug>
							<drug id="02400669" chronicUseMed="Y" sec3="Y">
								<name>Enalapril</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2203</individualPrice>
								<dailyCost>.2203</dailyCost>
								<listingDate>2022-02-28</listingDate>
								<amountMOHLTCPays>.2203</amountMOHLTCPays>
							</drug>
							<drug id="02442965" chronicUseMed="Y" sec3="Y">
								<name>Enalapril</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2203</individualPrice>
								<dailyCost>.2203</dailyCost>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.2203</amountMOHLTCPays>
							</drug>
							<drug id="02459469" chronicUseMed="Y" sec3="Y">
								<name>Mar-Enalapril</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.2203</individualPrice>
								<dailyCost>.2203</dailyCost>
								<listingDate>2019-06-28</listingDate>
								<amountMOHLTCPays>.2203</amountMOHLTCPays>
							</drug>
							<drug id="02474794" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Enalapril</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2203</individualPrice>
								<dailyCost>.2203</dailyCost>
								<listingDate>2019-04-30</listingDate>
								<amountMOHLTCPays>.2203</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800104">
							<itemNumber>0672</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.2647</dailyCost>
							<drug id="00670901" chronicUseMed="Y" sec3="Y">
								<name>Vasotec</name>
								<manufacturerId>OCI</manufacturerId>
								<individualPrice>1.4638</individualPrice>
								<dailyCost>1.4638</dailyCost>
								<note>** Each tablet is made with 10mg of enalapril maleate that is equivalent to 8mg of enalapril sodium, in the finished tablets.</note>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2647</amountMOHLTCPays>
							</drug>
							<drug id="02019892" chronicUseMed="Y" sec3="Y">
								<name>Apo-Enalapril</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2647</individualPrice>
								<dailyCost>.2647</dailyCost>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.2647</amountMOHLTCPays>
							</drug>
							<drug id="02233006" chronicUseMed="Y" sec3="Y">
								<name>Teva-Enalapril</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2647</individualPrice>
								<dailyCost>.2647</dailyCost>
								<note>** Each tablet is made with 10mg of enalapril maleate that is equivalent to 8mg of enalapril sodium, in the finished tablets.</note>
								<listingDate>2008-05-16</listingDate>
								<amountMOHLTCPays>.2647</amountMOHLTCPays>
							</drug>
							<drug id="02291894" chronicUseMed="Y" sec3="Y">
								<name>Co Enalapril</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.2647</individualPrice>
								<dailyCost>.2647</dailyCost>
								<note>** Each tablet is made with 10mg of enalapril maleate that is equivalent to 8mg of enalapril sodium, in the finished tablets.</note>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.2647</amountMOHLTCPays>
							</drug>
							<drug id="02299968" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Enalapril</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2647</individualPrice>
								<dailyCost>.2647</dailyCost>
								<note>** Each tablet is made with 10mg of enalapril maleate that is equivalent to 8mg of enalapril sodium, in the finished tablets.</note>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.2647</amountMOHLTCPays>
							</drug>
							<drug id="02300001" chronicUseMed="Y" sec3="Y">
								<name>Ratio-Enalapril</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>.2647</individualPrice>
								<dailyCost>.2647</dailyCost>
								<note>** Each tablet is made with 10mg of enalapril maleate that is equivalent to 8mg of enalapril sodium, in the finished tablets.</note>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.2647</amountMOHLTCPays>
							</drug>
							<drug id="02300052" chronicUseMed="Y" sec3="Y">
								<name>Mylan-Enalapril</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.2647</individualPrice>
								<dailyCost>.2647</dailyCost>
								<note>** Each tablet is made with 10mg of enalapril maleate that is equivalent to 8mg of enalapril sodium, in the finished tablets.</note>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.2647</amountMOHLTCPays>
							</drug>
							<drug id="02300133" chronicUseMed="Y" sec3="Y">
								<name>Taro-Enalapril</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>.2647</individualPrice>
								<dailyCost>.2647</dailyCost>
								<note>** Each tablet is made with 10mg of enalapril maleate that is equivalent to 8mg of enalapril sodium, in the finished tablets.</note>
								<listingDate>2008-01-15</listingDate>
								<amountMOHLTCPays>.2647</amountMOHLTCPays>
							</drug>
							<drug id="02352257" chronicUseMed="Y" sec3="Y">
								<name>Ran-Enalapril</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.2647</individualPrice>
								<dailyCost>.2647</dailyCost>
								<listingDate>2011-01-07</listingDate>
								<amountMOHLTCPays>.2647</amountMOHLTCPays>
							</drug>
							<drug id="02400677" chronicUseMed="Y" sec3="Y">
								<name>Enalapril</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2647</individualPrice>
								<dailyCost>.2647</dailyCost>
								<listingDate>2022-02-28</listingDate>
								<amountMOHLTCPays>.2647</amountMOHLTCPays>
							</drug>
							<drug id="02442973" chronicUseMed="Y" sec3="Y">
								<name>Enalapril</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2647</individualPrice>
								<dailyCost>.2647</dailyCost>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.2647</amountMOHLTCPays>
							</drug>
							<drug id="02444771" chronicUseMed="Y" sec3="Y">
								<name>Mar-Enalapril</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.2647</individualPrice>
								<dailyCost>.2647</dailyCost>
								<listingDate>2019-06-28</listingDate>
								<amountMOHLTCPays>.2647</amountMOHLTCPays>
							</drug>
							<drug id="02474808" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Enalapril</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2647</individualPrice>
								<dailyCost>.2647</dailyCost>
								<listingDate>2019-04-30</listingDate>
								<amountMOHLTCPays>.2647</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800103">
							<itemNumber>0673</itemNumber>
							<strength>20mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.3195</dailyCost>
							<drug id="00670928" chronicUseMed="Y" sec3="Y">
								<name>Vasotec</name>
								<manufacturerId>OCI</manufacturerId>
								<individualPrice>1.7665</individualPrice>
								<dailyCost>1.7665</dailyCost>
								<note>** Each tablet is made with 20mg of enalapril maleate that is equivalent to 16mg of enalapril sodium, in the finished tablets.</note>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3195</amountMOHLTCPays>
							</drug>
							<drug id="02019906" chronicUseMed="Y" sec3="Y">
								<name>Apo-Enalapril</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3195</individualPrice>
								<dailyCost>.3195</dailyCost>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.3195</amountMOHLTCPays>
							</drug>
							<drug id="02233007" chronicUseMed="Y" sec3="Y">
								<name>Teva-Enalapril</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3195</individualPrice>
								<dailyCost>.3195</dailyCost>
								<note>** Each tablet is made with 20mg of enalapril maleate that is equivalent to 16mg of enalapril sodium, in the finished tablets.</note>
								<listingDate>2008-05-16</listingDate>
								<amountMOHLTCPays>.3195</amountMOHLTCPays>
							</drug>
							<drug id="02291908" chronicUseMed="Y" sec3="Y">
								<name>Co Enalapril</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.3195</individualPrice>
								<dailyCost>.3195</dailyCost>
								<note>** Each tablet is made with 20mg of enalapril maleate that is equivalent to 16mg of enalapril sodium, in the finished tablets.</note>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.3195</amountMOHLTCPays>
							</drug>
							<drug id="02299976" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Enalapril</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.3195</individualPrice>
								<dailyCost>.3195</dailyCost>
								<note>** Each tablet is made with 20mg of enalapril maleate that is equivalent to 16mg of enalapril sodium, in the finished tablets.</note>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.3195</amountMOHLTCPays>
							</drug>
							<drug id="02300028" chronicUseMed="Y" sec3="Y">
								<name>Ratio-Enalapril</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>.3195</individualPrice>
								<dailyCost>.3195</dailyCost>
								<note>** Each tablet is made with 20mg of enalapril maleate that is equivalent to 16mg of enalapril sodium, in the finished tablets.</note>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.3195</amountMOHLTCPays>
							</drug>
							<drug id="02300060" chronicUseMed="Y" sec3="Y">
								<name>Mylan-Enalapril</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.3195</individualPrice>
								<dailyCost>.3195</dailyCost>
								<note>** Each tablet is made with 20mg of enalapril maleate that is equivalent to 16mg of enalapril sodium, in the finished tablets.</note>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.3195</amountMOHLTCPays>
							</drug>
							<drug id="02300141" chronicUseMed="Y" sec3="Y">
								<name>Taro-Enalapril</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>.3195</individualPrice>
								<dailyCost>.3195</dailyCost>
								<note>** Each tablet is made with 20mg of enalapril maleate that is equivalent to 16mg of enalapril sodium, in the finished tablets.</note>
								<listingDate>2008-01-15</listingDate>
								<amountMOHLTCPays>.3195</amountMOHLTCPays>
							</drug>
							<drug id="02352265" chronicUseMed="Y" sec3="Y">
								<name>Ran-Enalapril</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.3195</individualPrice>
								<dailyCost>.3195</dailyCost>
								<listingDate>2011-01-07</listingDate>
								<amountMOHLTCPays>.3195</amountMOHLTCPays>
							</drug>
							<drug id="02400685" chronicUseMed="Y" sec3="Y">
								<name>Enalapril</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.3195</individualPrice>
								<dailyCost>.3195</dailyCost>
								<listingDate>2022-02-28</listingDate>
								<amountMOHLTCPays>.3195</amountMOHLTCPays>
							</drug>
							<drug id="02442981" chronicUseMed="Y" sec3="Y">
								<name>Enalapril</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.3195</individualPrice>
								<dailyCost>.3195</dailyCost>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.3195</amountMOHLTCPays>
							</drug>
							<drug id="02444798" chronicUseMed="Y" sec3="Y">
								<name>Mar-Enalapril</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.3195</individualPrice>
								<dailyCost>.3195</dailyCost>
								<listingDate>2019-06-28</listingDate>
								<amountMOHLTCPays>.3195</amountMOHLTCPays>
							</drug>
							<drug id="02474816" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Enalapril</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.3195</individualPrice>
								<dailyCost>.3195</dailyCost>
								<listingDate>2019-04-30</listingDate>
								<amountMOHLTCPays>.3195</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01838">
					<name>ENALAPRIL MALEATE &amp; HYDROCHLOROTHIAZIDE</name>
					<pcgGroup>
						<pcg9 id="240800293">
							<itemNumber>0674</itemNumber>
							<strength>5mg &amp; 12.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02242826" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Vaseretic</name>
								<manufacturerId>MFC</manufacturerId>
								<listingDate>2011-05-19</listingDate>
							</drug>
							<drug id="02352923" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Enalapril Maleate/HCTZ</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.7493</individualPrice>
								<listingDate>2011-05-19</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="240800294">
							<itemNumber>0675</itemNumber>
							<strength>10mg &amp; 25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00657298" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Vaseretic</name>
								<manufacturerId>OCI</manufacturerId>
								<listingDate>2011-05-19</listingDate>
							</drug>
							<drug id="02352931" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Enalapril Maleate/HCTZ</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>1.0741</individualPrice>
								<listingDate>2011-05-19</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01777">
					<name>EPLERENONE</name>
					<pcgGroup lccId="00251">
						<pcg9 id="240800289">
							<itemNumber>0676</itemNumber>
							<strength>25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02323052" sec3="Y" sec12="Y">
								<name>Inspra</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>2.9543</individualPrice>
								<listingDate>2015-05-28</listingDate>
								<amountMOHLTCPays>2.0595</amountMOHLTCPays>
							</drug>
							<drug id="02471442" sec3="Y" sec12="Y">
								<name>Mint-Eplerenone</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>2.0595</individualPrice>
								<listingDate>2018-06-29</listingDate>
								<amountMOHLTCPays>2.0595</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800290">
							<itemNumber>0677</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02323060" sec3="Y" sec12="Y">
								<name>Inspra</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>2.9543</individualPrice>
								<listingDate>2015-05-28</listingDate>
								<amountMOHLTCPays>2.0595</amountMOHLTCPays>
							</drug>
							<drug id="02471450" sec3="Y" sec12="Y">
								<name>Mint-Eplerenone</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>2.0595</individualPrice>
								<listingDate>2018-06-29</listingDate>
								<amountMOHLTCPays>2.0595</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="458">For persons suffering from New York Heart Association (NYHA) class II chronic heart failure with left ventricular systolic dysfunction (with ejection fraction less than or equal to 35 percent), as a complement to standard therapy.
Note: Patients must be on optimal therapy with an angiotensin-converting-enzyme (ACE) inhibitor, an angiotensin-receptor blocker (ARB), or both and a beta-blocker (unless contraindicated) at the recommended dose or maximal tolerated dose.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="01561">
					<name>EPROSARTAN MESYLATE</name>
					<pcgGroup>
						<pcg9 id="240800247">
							<itemNumber>0678</itemNumber>
							<strength>400mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02240432" chronicUseMed="Y" sec3="Y">
								<name>Teveten</name>
								<manufacturerId>SPH</manufacturerId>
								<individualPrice>.7790</individualPrice>
								<listingDate>2002-07-29</listingDate>
								<amountMOHLTCPays>.7790</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800252">
							<itemNumber>0679</itemNumber>
							<strength>600mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02243942" chronicUseMed="Y" sec3="Y">
								<name>Teveten</name>
								<manufacturerId>SPH</manufacturerId>
								<individualPrice>1.1910</individualPrice>
								<listingDate>2002-07-29</listingDate>
								<amountMOHLTCPays>1.1910</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01632">
					<name>EPROSARTAN MESYLATE &amp; HYDROCHLOROTHIAZIDE</name>
					<pcgGroup>
						<pcg9 id="240800259">
							<itemNumber>0680</itemNumber>
							<strength>600mg &amp; 12.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02253631" chronicUseMed="Y" sec3="Y">
								<name>Teveten Plus</name>
								<manufacturerId>SPH</manufacturerId>
								<individualPrice>1.1910</individualPrice>
								<listingDate>2005-05-25</listingDate>
								<amountMOHLTCPays>1.1910</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00372">
					<name>FELODIPINE</name>
					<note>Grapefruit juice or erythromycin triple the blood levels of felodipine and markedly increase both efficacy and adverse effects. Other dihydropyridines are affected to differing degrees by grapefruit juice.</note>
					<pcgGroup>
						<pcg9 id="240800202">
							<itemNumber>0681</itemNumber>
							<strength>2.5mg</strength>
							<dosageForm>ER Tab</dosageForm>
							<drug id="02057778" chronicUseMed="Y" sec3="Y">
								<name>Plendil</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>.5710</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.4050</amountMOHLTCPays>
							</drug>
							<drug id="02452367" chronicUseMed="Y" sec3="Y">
								<name>Apo-Felodipine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.4050</individualPrice>
								<listingDate>2016-05-31</listingDate>
								<amountMOHLTCPays>.4050</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800164">
							<itemNumber>0682</itemNumber>
							<strength>5mg</strength>
							<dosageForm>ER Tab</dosageForm>
							<dailyCost>.3565</dailyCost>
							<drug id="00851779" chronicUseMed="Y" sec3="Y">
								<name>Plendil</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>.7553</individualPrice>
								<dailyCost>.7553</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3565</amountMOHLTCPays>
							</drug>
							<drug id="02280264" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Felodipine</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.3565</individualPrice>
								<dailyCost>.3565</dailyCost>
								<listingDate>2007-01-02</listingDate>
								<amountMOHLTCPays>.3565</amountMOHLTCPays>
							</drug>
							<drug id="02452375" chronicUseMed="Y" sec3="Y">
								<name>Apo-Felodipine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3565</individualPrice>
								<dailyCost>.3565</dailyCost>
								<listingDate>2016-05-31</listingDate>
								<amountMOHLTCPays>.3565</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800165">
							<itemNumber>0683</itemNumber>
							<strength>10mg</strength>
							<dosageForm>ER Tab</dosageForm>
							<dailyCost>.5350</dailyCost>
							<drug id="00851787" chronicUseMed="Y" sec3="Y">
								<name>Plendil</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>1.1330</individualPrice>
								<dailyCost>1.1330</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.5350</amountMOHLTCPays>
							</drug>
							<drug id="02280272" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Felodipine</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.5350</individualPrice>
								<dailyCost>.5350</dailyCost>
								<listingDate>2007-01-02</listingDate>
								<amountMOHLTCPays>.5350</amountMOHLTCPays>
							</drug>
							<drug id="02452383" chronicUseMed="Y" sec3="Y">
								<name>Apo-Felodipine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.5350</individualPrice>
								<dailyCost>.5350</dailyCost>
								<listingDate>2016-05-31</listingDate>
								<amountMOHLTCPays>.5350</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800154">
							<itemNumber>0684</itemNumber>
							<strength>5mg</strength>
							<dosageForm>SR Tab</dosageForm>
							<dailyCost>.5592</dailyCost>
							<drug id="02221993" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Renedil</name>
								<manufacturerId>SAV</manufacturerId>
								<listingDate>1999-01-07</listingDate>
							</drug>
							<drug id="09857203" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Felodipine</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.5592</individualPrice>
								<dailyCost>.5592</dailyCost>
								<listingDate>2007-01-02</listingDate>
								<amountMOHLTCPays>.5592</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800155">
							<itemNumber>0685</itemNumber>
							<strength>10mg</strength>
							<dosageForm>SR Tab</dosageForm>
							<dailyCost>.8390</dailyCost>
							<drug id="02222000" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Renedil</name>
								<manufacturerId>SAV</manufacturerId>
								<listingDate>1999-01-07</listingDate>
							</drug>
							<drug id="09857204" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Felodipine</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.8390</individualPrice>
								<dailyCost>.8390</dailyCost>
								<listingDate>2007-01-02</listingDate>
								<amountMOHLTCPays>.8390</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00373">
					<name>FOSINOPRIL SODIUM</name>
					<pcgGroup>
						<pcg9 id="240800156">
							<itemNumber>0686</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.2178</dailyCost>
							<drug id="01907107" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Monopril</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02247802" chronicUseMed="Y" sec3="Y">
								<name>Teva-Fosinopril</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2178</individualPrice>
								<dailyCost>.2178</dailyCost>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.2178</amountMOHLTCPays>
							</drug>
							<drug id="02266008" chronicUseMed="Y" sec3="Y">
								<name>Apo-Fosinopril</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2178</individualPrice>
								<dailyCost>.2178</dailyCost>
								<listingDate>2005-07-14</listingDate>
								<amountMOHLTCPays>.2178</amountMOHLTCPays>
							</drug>
							<drug id="02294524" chronicUseMed="Y" sec3="Y">
								<name>Ran-Fosinopril</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.2178</individualPrice>
								<dailyCost>.2178</dailyCost>
								<listingDate>2010-03-02</listingDate>
								<amountMOHLTCPays>.2178</amountMOHLTCPays>
							</drug>
							<drug id="02331004" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Fosinopril</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2178</individualPrice>
								<dailyCost>.2178</dailyCost>
								<listingDate>2010-04-23</listingDate>
								<amountMOHLTCPays>.2178</amountMOHLTCPays>
							</drug>
							<drug id="02459388" chronicUseMed="Y" sec3="Y">
								<name>Fosinopril</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2178</individualPrice>
								<dailyCost>.2178</dailyCost>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.2178</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800157">
							<itemNumber>0687</itemNumber>
							<strength>20mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.2619</dailyCost>
							<drug id="01907115" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Monopril</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02247803" chronicUseMed="Y" sec3="Y">
								<name>Teva-Fosinopril</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2619</individualPrice>
								<dailyCost>.2619</dailyCost>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.2619</amountMOHLTCPays>
							</drug>
							<drug id="02266016" chronicUseMed="Y" sec3="Y">
								<name>Apo-Fosinopril</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2619</individualPrice>
								<dailyCost>.2619</dailyCost>
								<listingDate>2005-07-14</listingDate>
								<amountMOHLTCPays>.2619</amountMOHLTCPays>
							</drug>
							<drug id="02294532" chronicUseMed="Y" sec3="Y">
								<name>Ran-Fosinopril</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.2619</individualPrice>
								<dailyCost>.2619</dailyCost>
								<listingDate>2010-03-02</listingDate>
								<amountMOHLTCPays>.2619</amountMOHLTCPays>
							</drug>
							<drug id="02331012" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Fosinopril</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2619</individualPrice>
								<dailyCost>.2619</dailyCost>
								<listingDate>2010-04-23</listingDate>
								<amountMOHLTCPays>.2619</amountMOHLTCPays>
							</drug>
							<drug id="02459396" chronicUseMed="Y" sec3="Y">
								<name>Fosinopril</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2619</individualPrice>
								<dailyCost>.2619</dailyCost>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.2619</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00350">
					<name>HYDRALAZINE HCL</name>
					<pcgGroup>
						<pcg9 id="240800044">
							<itemNumber>0688</itemNumber>
							<strength>20mg/mL</strength>
							<dosageForm>Inj Sol-1mL Pk</dosageForm>
							<drug id="00723754" sec3="Y">
								<name>Apresoline</name>
								<manufacturerId>STE</manufacturerId>
								<individualPrice>11.6500</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>11.6500</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800010">
							<itemNumber>0689</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.1420</dailyCost>
							<drug id="00005525" notABenefit="Y" sec3="Y">
								<name>Apresoline</name>
								<manufacturerId>NOV</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00441619" sec3="Y">
								<name>Apo-Hydralazine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0355</individualPrice>
								<dailyCost>.1420</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0355</amountMOHLTCPays>
							</drug>
							<drug id="02457865" sec3="Y">
								<name>Jamp-Hydralazine</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.0355</individualPrice>
								<dailyCost>.1420</dailyCost>
								<listingDate>2017-11-30</listingDate>
								<amountMOHLTCPays>.0355</amountMOHLTCPays>
							</drug>
							<drug id="02468778" sec3="Y">
								<name>Mint-Hydralazine</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.0355</individualPrice>
								<dailyCost>.1420</dailyCost>
								<listingDate>2018-05-31</listingDate>
								<amountMOHLTCPays>.0355</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800041">
							<itemNumber>0690</itemNumber>
							<strength>25mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.2436</dailyCost>
							<drug id="00005533" notABenefit="Y" sec3="Y">
								<name>Apresoline</name>
								<manufacturerId>STE</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00441627" sec3="Y">
								<name>Apo-Hydralazine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0609</individualPrice>
								<dailyCost>.2436</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0609</amountMOHLTCPays>
							</drug>
							<drug id="02457873" sec3="Y">
								<name>Jamp-Hydralazine</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.0609</individualPrice>
								<dailyCost>.2436</dailyCost>
								<listingDate>2017-11-30</listingDate>
								<amountMOHLTCPays>.0609</amountMOHLTCPays>
							</drug>
							<drug id="02468786" sec3="Y">
								<name>Mint-Hydralazine</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.0609</individualPrice>
								<dailyCost>.2436</dailyCost>
								<listingDate>2018-05-31</listingDate>
								<amountMOHLTCPays>.0609</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800008">
							<itemNumber>0691</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.3824</dailyCost>
							<drug id="00005541" notABenefit="Y" sec3="Y">
								<name>Apresoline</name>
								<manufacturerId>NOV</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00441635" sec3="Y">
								<name>Apo-Hydralazine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0956</individualPrice>
								<dailyCost>.3824</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0956</amountMOHLTCPays>
							</drug>
							<drug id="02457881" sec3="Y">
								<name>Jamp-Hydralazine</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.0956</individualPrice>
								<dailyCost>.3824</dailyCost>
								<listingDate>2017-11-30</listingDate>
								<amountMOHLTCPays>.0956</amountMOHLTCPays>
							</drug>
							<drug id="02468794" sec3="Y">
								<name>Mint-Hydralazine</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.0956</individualPrice>
								<dailyCost>.3824</dailyCost>
								<listingDate>2018-05-31</listingDate>
								<amountMOHLTCPays>.0956</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01402">
					<name>IRBESARTAN</name>
					<pcgGroup>
						<pcg9 id="240800231">
							<itemNumber>0692</itemNumber>
							<strength>75mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02237923" chronicUseMed="Y" sec3="Y">
								<name>Avapro</name>
								<manufacturerId>SAV</manufacturerId>
								<individualPrice>1.2671</individualPrice>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02316390" chronicUseMed="Y" sec3="Y">
								<name>Teva-Irbesartan</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02317060" chronicUseMed="Y" sec3="Y">
								<name>PMS-Irbesartan</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02328461" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Irbesartan</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02372347" chronicUseMed="Y" sec3="Y">
								<name>Irbesartan</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02385287" chronicUseMed="Y" sec3="Y">
								<name>Irbesartan</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02386968" chronicUseMed="Y" sec3="Y">
								<name>Apo-Irbesartan</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2012-08-27</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02406098" chronicUseMed="Y" sec3="Y">
								<name>Auro-Irbesartan</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2013-09-27</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02406810" chronicUseMed="Y" sec3="Y">
								<name>Ran-Irbesartan</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2013-11-28</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02418193" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Irbesartan</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2014-03-27</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02422980" chronicUseMed="Y" sec3="Y">
								<name>Mint-Irbesartan</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2015-05-28</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02427087" dinStatus="E" chronicUseMed="Y" sec3="Y">
								<name>Van-Irbesartan</name>
								<manufacturerId>VAN</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2015-08-26</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800232">
							<itemNumber>0693</itemNumber>
							<strength>150mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02237924" chronicUseMed="Y" sec3="Y">
								<name>Avapro</name>
								<manufacturerId>SAV</manufacturerId>
								<individualPrice>1.2671</individualPrice>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02316404" chronicUseMed="Y" sec3="Y">
								<name>Teva-Irbesartan</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02317079" chronicUseMed="Y" sec3="Y">
								<name>PMS-Irbesartan</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02328089" chronicUseMed="Y" sec3="Y">
								<name>Co Irbesartan</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02328488" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Irbesartan</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02372371" chronicUseMed="Y" sec3="Y">
								<name>Irbesartan</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02385295" chronicUseMed="Y" sec3="Y">
								<name>Irbesartan</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02386976" chronicUseMed="Y" sec3="Y">
								<name>Apo-Irbesartan</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2012-08-27</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02406101" chronicUseMed="Y" sec3="Y">
								<name>Auro-Irbesartan</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2013-09-27</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02406829" chronicUseMed="Y" sec3="Y">
								<name>Ran-Irbesartan</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2013-11-28</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02418207" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Irbesartan</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2014-03-27</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02422999" chronicUseMed="Y" sec3="Y">
								<name>Mint-Irbesartan</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2015-05-28</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02427095" dinStatus="E" chronicUseMed="Y" sec3="Y">
								<name>Van-Irbesartan</name>
								<manufacturerId>VAN</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2015-08-26</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800233">
							<itemNumber>0694</itemNumber>
							<strength>300mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02237925" chronicUseMed="Y" sec3="Y">
								<name>Avapro</name>
								<manufacturerId>SAV</manufacturerId>
								<individualPrice>1.2671</individualPrice>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02316412" chronicUseMed="Y" sec3="Y">
								<name>Teva-Irbesartan</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02317087" chronicUseMed="Y" sec3="Y">
								<name>PMS-Irbesartan</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02328100" chronicUseMed="Y" sec3="Y">
								<name>Co Irbesartan</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02328496" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Irbesartan</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02372398" chronicUseMed="Y" sec3="Y">
								<name>Irbesartan</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02385309" chronicUseMed="Y" sec3="Y">
								<name>Irbesartan</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02386984" chronicUseMed="Y" sec3="Y">
								<name>Apo-Irbesartan</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2012-08-27</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02406128" chronicUseMed="Y" sec3="Y">
								<name>Auro-Irbesartan</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2013-09-27</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02406837" chronicUseMed="Y" sec3="Y">
								<name>Ran-Irbesartan</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2013-11-28</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02418215" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Irbesartan</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2014-03-27</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02423006" chronicUseMed="Y" sec3="Y">
								<name>Mint-Irbesartan</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2015-05-28</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02427109" dinStatus="E" chronicUseMed="Y" sec3="Y">
								<name>Van-Irbesartan</name>
								<manufacturerId>VAN</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2015-08-26</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01500">
					<name>IRBESARTAN &amp; HYDROCHLOROTHIAZIDE</name>
					<pcgGroup>
						<pcg9 id="240800242">
							<itemNumber>0695</itemNumber>
							<strength>150mg &amp; 12.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02241818" chronicUseMed="Y" sec3="Y">
								<name>Avalide</name>
								<manufacturerId>SAV</manufacturerId>
								<individualPrice>1.2671</individualPrice>
								<listingDate>2001-03-07</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02328518" chronicUseMed="Y" sec3="Y">
								<name>PMS-Irbesartan-HCTZ</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02330512" chronicUseMed="Y" sec3="Y">
								<name>Teva-Irbesartan HCTZ</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02337428" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Irbesartan HCT</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02357399" chronicUseMed="Y" sec3="Y">
								<name>Co Irbesartan/HCT</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02363208" chronicUseMed="Y" sec3="Y">
								<name>Ran-Irbesartan HCTZ</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02372886" chronicUseMed="Y" sec3="Y">
								<name>Irbesartan/HCTZ</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02385317" chronicUseMed="Y" sec3="Y">
								<name>Irbesartan HCT</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02387646" chronicUseMed="Y" sec3="Y">
								<name>Apo-Irbesartan/HCTZ</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2013-03-20</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02392992" chronicUseMed="Y" sec3="Y">
								<name>Mint Irbesartan/HCTZ</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2012-11-27</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02418223" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Irbesartan and Hydrochlorothiazide</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2014-03-27</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02447878" chronicUseMed="Y" sec3="Y">
								<name>Auro-Irbesartan HCT</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2017-07-31</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800243">
							<itemNumber>0696</itemNumber>
							<strength>300mg &amp; 12.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02241819" chronicUseMed="Y" sec3="Y">
								<name>Avalide</name>
								<manufacturerId>SAV</manufacturerId>
								<individualPrice>1.2671</individualPrice>
								<listingDate>2001-03-07</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02328526" chronicUseMed="Y" sec3="Y">
								<name>PMS-Irbesartan-HCTZ</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02330520" chronicUseMed="Y" sec3="Y">
								<name>Teva-Irbesartan HCTZ</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02337436" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Irbesartan HCT</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02357402" chronicUseMed="Y" sec3="Y">
								<name>Co Irbesartan/HCT</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02363216" chronicUseMed="Y" sec3="Y">
								<name>Ran-Irbesartan HCTZ</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02372894" chronicUseMed="Y" sec3="Y">
								<name>Irbesartan/HCTZ</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2021-10-29</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02385325" chronicUseMed="Y" sec3="Y">
								<name>Irbesartan HCT</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02387654" chronicUseMed="Y" sec3="Y">
								<name>Apo-Irbesartan/HCTZ</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2013-03-20</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02393018" chronicUseMed="Y" sec3="Y">
								<name>Mint Irbesartan/HCTZ</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2012-11-27</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02418231" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Irbesartan and Hydrochlorothiazide</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2014-03-27</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
							<drug id="02447886" chronicUseMed="Y" sec3="Y">
								<name>Auro-Irbesartan HCT</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2281</individualPrice>
								<listingDate>2017-07-31</listingDate>
								<amountMOHLTCPays>.2281</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800263">
							<itemNumber>0697</itemNumber>
							<strength>300mg &amp; 25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02280213" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Avalide</name>
								<manufacturerId>SAV</manufacturerId>
								<listingDate>2007-03-09</listingDate>
							</drug>
							<drug id="02328534" chronicUseMed="Y" sec3="Y">
								<name>PMS-Irbesartan-HCTZ</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2184</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2184</amountMOHLTCPays>
							</drug>
							<drug id="02330539" chronicUseMed="Y" sec3="Y">
								<name>Teva-Irbesartan HCTZ</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2184</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2184</amountMOHLTCPays>
							</drug>
							<drug id="02337444" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Irbesartan HCT</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2184</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2184</amountMOHLTCPays>
							</drug>
							<drug id="02357410" chronicUseMed="Y" sec3="Y">
								<name>Co Irbesartan/HCT</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.2184</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2184</amountMOHLTCPays>
							</drug>
							<drug id="02363224" chronicUseMed="Y" sec3="Y">
								<name>Ran-Irbesartan HCTZ</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.2184</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2184</amountMOHLTCPays>
							</drug>
							<drug id="02372908" chronicUseMed="Y" sec3="Y">
								<name>Irbesartan/HCTZ</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2184</individualPrice>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>.2184</amountMOHLTCPays>
							</drug>
							<drug id="02385333" chronicUseMed="Y" sec3="Y">
								<name>Irbesartan HCT</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2184</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.2184</amountMOHLTCPays>
							</drug>
							<drug id="02387662" chronicUseMed="Y" sec3="Y">
								<name>Apo-Irbesartan/HCTZ</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2184</individualPrice>
								<listingDate>2013-03-20</listingDate>
								<amountMOHLTCPays>.2184</amountMOHLTCPays>
							</drug>
							<drug id="02393026" chronicUseMed="Y" sec3="Y">
								<name>Mint Irbesartan/HCTZ</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.2184</individualPrice>
								<listingDate>2012-11-27</listingDate>
								<amountMOHLTCPays>.2184</amountMOHLTCPays>
							</drug>
							<drug id="02418258" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Irbesartan and Hydrochlorothiazide</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2184</individualPrice>
								<listingDate>2014-03-27</listingDate>
								<amountMOHLTCPays>.2184</amountMOHLTCPays>
							</drug>
							<drug id="02447894" chronicUseMed="Y" sec3="Y">
								<name>Auro-Irbesartan HCT</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2184</individualPrice>
								<listingDate>2017-07-31</listingDate>
								<amountMOHLTCPays>.2184</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00367">
					<name>LABETALOL HCL</name>
					<pcgGroup>
						<pcg9 id="240800093">
							<itemNumber>0698</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02106272" chronicUseMed="Y" sec3="Y">
								<name>Trandate</name>
								<manufacturerId>PAL</manufacturerId>
								<individualPrice>.4044</individualPrice>
								<listingDate>1998-03-17</listingDate>
								<amountMOHLTCPays>.1983</amountMOHLTCPays>
							</drug>
							<drug id="02243538" chronicUseMed="Y" sec3="Y">
								<name>Apo-Labetalol</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1983</individualPrice>
								<listingDate>2001-10-11</listingDate>
								<amountMOHLTCPays>.1983</amountMOHLTCPays>
							</drug>
							<drug id="02489406" chronicUseMed="Y" sec3="Y">
								<name>Riva-Labetalol</name>
								<manufacturerId>RIA</manufacturerId>
								<individualPrice>.1983</individualPrice>
								<listingDate>2019-10-31</listingDate>
								<amountMOHLTCPays>.1983</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800094">
							<itemNumber>0699</itemNumber>
							<strength>200mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02106280" chronicUseMed="Y" sec3="Y">
								<name>Trandate</name>
								<manufacturerId>PAL</manufacturerId>
								<individualPrice>.7148</individualPrice>
								<listingDate>1998-03-17</listingDate>
								<amountMOHLTCPays>.3504</amountMOHLTCPays>
							</drug>
							<drug id="02243539" chronicUseMed="Y" sec3="Y">
								<name>Apo-Labetalol</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3504</individualPrice>
								<listingDate>2001-10-11</listingDate>
								<amountMOHLTCPays>.3504</amountMOHLTCPays>
							</drug>
							<drug id="02489414" chronicUseMed="Y" sec3="Y">
								<name>Riva-Labetalol</name>
								<manufacturerId>RIA</manufacturerId>
								<individualPrice>.3504</individualPrice>
								<listingDate>2019-10-31</listingDate>
								<amountMOHLTCPays>.3504</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00371">
					<name>LISINOPRIL</name>
					<pcgGroup>
						<pcg9 id="240800146">
							<itemNumber>0700</itemNumber>
							<strength>5mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.1428</dailyCost>
							<drug id="00839388" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Prinivil</name>
								<manufacturerId>MFC</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02285061" chronicUseMed="Y" sec3="Y">
								<name>Teva-Lisinopril (Type P)</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1428</individualPrice>
								<dailyCost>.1428</dailyCost>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.1428</amountMOHLTCPays>
							</drug>
							<drug id="09853685" chronicUseMed="Y" sec3="Y">
								<name>Apo-Lisinopril</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1428</individualPrice>
								<dailyCost>.1428</dailyCost>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>.1428</amountMOHLTCPays>
							</drug>
							<drug id="09857272" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Lisinopril</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.1428</individualPrice>
								<dailyCost>.1428</dailyCost>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.1428</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800147">
							<itemNumber>0701</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.1716</dailyCost>
							<drug id="00839396" chronicUseMed="Y" sec3="Y">
								<name>Prinivil</name>
								<manufacturerId>MFC</manufacturerId>
								<individualPrice>.9489</individualPrice>
								<dailyCost>.9489</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1716</amountMOHLTCPays>
							</drug>
							<drug id="02285088" chronicUseMed="Y" sec3="Y">
								<name>Teva-Lisinopril (Type P)</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1716</individualPrice>
								<dailyCost>.1716</dailyCost>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.1716</amountMOHLTCPays>
							</drug>
							<drug id="09853960" chronicUseMed="Y" sec3="Y">
								<name>Apo-Lisinopril</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1716</individualPrice>
								<dailyCost>.1716</dailyCost>
								<listingDate>2001-06-07</listingDate>
								<amountMOHLTCPays>.1716</amountMOHLTCPays>
							</drug>
							<drug id="09857286" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Lisinopril</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.1716</individualPrice>
								<dailyCost>.1716</dailyCost>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.1716</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800148">
							<itemNumber>0702</itemNumber>
							<strength>20mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.2063</dailyCost>
							<drug id="00839418" chronicUseMed="Y" sec3="Y">
								<name>Prinivil</name>
								<manufacturerId>MFC</manufacturerId>
								<individualPrice>1.1408</individualPrice>
								<dailyCost>1.1408</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2063</amountMOHLTCPays>
							</drug>
							<drug id="02285096" chronicUseMed="Y" sec3="Y">
								<name>Teva-Lisinopril (Type P)</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2063</individualPrice>
								<dailyCost>.2063</dailyCost>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.2063</amountMOHLTCPays>
							</drug>
							<drug id="09854010" chronicUseMed="Y" sec3="Y">
								<name>Apo-Lisinopril</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2063</individualPrice>
								<dailyCost>.2063</dailyCost>
								<listingDate>2001-06-07</listingDate>
								<amountMOHLTCPays>.2063</amountMOHLTCPays>
							</drug>
							<drug id="09857287" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Lisinopril</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2063</individualPrice>
								<dailyCost>.2063</dailyCost>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.2063</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800150">
							<itemNumber>0703</itemNumber>
							<strength>5mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.1347</dailyCost>
							<drug id="02049333" chronicUseMed="Y" sec3="Y">
								<name>Zestril</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>.5770</individualPrice>
								<dailyCost>.5770</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1347</amountMOHLTCPays>
							</drug>
							<drug id="02217481" chronicUseMed="Y" sec3="Y">
								<name>Apo-Lisinopril</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1347</individualPrice>
								<dailyCost>.1347</dailyCost>
								<listingDate>1997-08-28</listingDate>
								<amountMOHLTCPays>.1347</amountMOHLTCPays>
							</drug>
							<drug id="02271443" chronicUseMed="Y" sec3="Y">
								<name>Co Lisinopril</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.1347</individualPrice>
								<dailyCost>.1347</dailyCost>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.1347</amountMOHLTCPays>
							</drug>
							<drug id="02285118" chronicUseMed="Y" sec3="Y">
								<name>Teva-Lisinopril (Type Z)</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1347</individualPrice>
								<dailyCost>.1347</dailyCost>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.1347</amountMOHLTCPays>
							</drug>
							<drug id="02289199" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Lisinopril</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.1347</individualPrice>
								<dailyCost>.1347</dailyCost>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.1347</amountMOHLTCPays>
							</drug>
							<drug id="02294230" chronicUseMed="Y" sec3="Y">
								<name>Ran-Lisinopril</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.1347</individualPrice>
								<dailyCost>.1347</dailyCost>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.1347</amountMOHLTCPays>
							</drug>
							<drug id="02361531" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Lisinopril</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1347</individualPrice>
								<dailyCost>.1347</dailyCost>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.1347</amountMOHLTCPays>
							</drug>
							<drug id="02386232" chronicUseMed="Y" sec3="Y">
								<name>Lisinopril</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.1347</individualPrice>
								<dailyCost>.1347</dailyCost>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>.1347</amountMOHLTCPays>
							</drug>
							<drug id="02394472" chronicUseMed="Y" sec3="Y">
								<name>Auro-Lisinopril</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.1347</individualPrice>
								<dailyCost>.1347</dailyCost>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.1347</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800151">
							<itemNumber>0704</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.1619</dailyCost>
							<drug id="02049376" chronicUseMed="Y" sec3="Y">
								<name>Zestril</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>.6935</individualPrice>
								<dailyCost>.6935</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1619</amountMOHLTCPays>
							</drug>
							<drug id="02217503" chronicUseMed="Y" sec3="Y">
								<name>Apo-Lisinopril</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1619</individualPrice>
								<dailyCost>.1619</dailyCost>
								<listingDate>2001-06-07</listingDate>
								<amountMOHLTCPays>.1619</amountMOHLTCPays>
							</drug>
							<drug id="02271451" chronicUseMed="Y" sec3="Y">
								<name>Co Lisinopril</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.1619</individualPrice>
								<dailyCost>.1619</dailyCost>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.1619</amountMOHLTCPays>
							</drug>
							<drug id="02285126" chronicUseMed="Y" sec3="Y">
								<name>Teva-Lisinopril (Type Z)</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1619</individualPrice>
								<dailyCost>.1619</dailyCost>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.1619</amountMOHLTCPays>
							</drug>
							<drug id="02289202" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Lisinopril</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.1619</individualPrice>
								<dailyCost>.1619</dailyCost>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.1619</amountMOHLTCPays>
							</drug>
							<drug id="02294249" chronicUseMed="Y" sec3="Y">
								<name>Ran-Lisinopril</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.1619</individualPrice>
								<dailyCost>.1619</dailyCost>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.1619</amountMOHLTCPays>
							</drug>
							<drug id="02361558" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Lisinopril</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1619</individualPrice>
								<dailyCost>.1619</dailyCost>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.1619</amountMOHLTCPays>
							</drug>
							<drug id="02386240" chronicUseMed="Y" sec3="Y">
								<name>Lisinopril</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.1619</individualPrice>
								<dailyCost>.1619</dailyCost>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>.1619</amountMOHLTCPays>
							</drug>
							<drug id="02394480" chronicUseMed="Y" sec3="Y">
								<name>Auro-Lisinopril</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.1619</individualPrice>
								<dailyCost>.1619</dailyCost>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.1619</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800152">
							<itemNumber>0705</itemNumber>
							<strength>20mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.1945</dailyCost>
							<drug id="02049384" chronicUseMed="Y" sec3="Y">
								<name>Zestril</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>.8330</individualPrice>
								<dailyCost>.8330</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1945</amountMOHLTCPays>
							</drug>
							<drug id="02217511" chronicUseMed="Y" sec3="Y">
								<name>Apo-Lisinopril</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1945</individualPrice>
								<dailyCost>.1945</dailyCost>
								<listingDate>2001-06-07</listingDate>
								<amountMOHLTCPays>.1945</amountMOHLTCPays>
							</drug>
							<drug id="02271478" chronicUseMed="Y" sec3="Y">
								<name>Co Lisinopril</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.1945</individualPrice>
								<dailyCost>.1945</dailyCost>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.1945</amountMOHLTCPays>
							</drug>
							<drug id="02285134" chronicUseMed="Y" sec3="Y">
								<name>Teva-Lisinopril (Type Z)</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1945</individualPrice>
								<dailyCost>.1945</dailyCost>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.1945</amountMOHLTCPays>
							</drug>
							<drug id="02289229" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Lisinopril</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.1945</individualPrice>
								<dailyCost>.1945</dailyCost>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.1945</amountMOHLTCPays>
							</drug>
							<drug id="02294257" chronicUseMed="Y" sec3="Y">
								<name>Ran-Lisinopril</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.1945</individualPrice>
								<dailyCost>.1945</dailyCost>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.1945</amountMOHLTCPays>
							</drug>
							<drug id="02361566" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Lisinopril</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1945</individualPrice>
								<dailyCost>.1945</dailyCost>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.1945</amountMOHLTCPays>
							</drug>
							<drug id="02386259" chronicUseMed="Y" sec3="Y">
								<name>Lisinopril</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.1945</individualPrice>
								<dailyCost>.1945</dailyCost>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>.1945</amountMOHLTCPays>
							</drug>
							<drug id="02394499" chronicUseMed="Y" sec3="Y">
								<name>Auro-Lisinopril</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.1945</individualPrice>
								<dailyCost>.1945</dailyCost>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.1945</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00383">
					<name>LISINOPRIL &amp; HYDROCHLOROTHIAZIDE</name>
					<pcgGroup>
						<pcg9 id="240800207">
							<itemNumber>0706</itemNumber>
							<strength>10mg &amp; 12.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02103729" chronicUseMed="Y" sec3="Y">
								<name>Zestoretic</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>.9286</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2084</amountMOHLTCPays>
							</drug>
							<drug id="02301768" chronicUseMed="Y" sec3="Y">
								<name>Teva-Lisinopril/HCTZ (Type Z)</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2084</individualPrice>
								<listingDate>2008-01-15</listingDate>
								<amountMOHLTCPays>.2084</amountMOHLTCPays>
							</drug>
							<drug id="02302365" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Lisinopril HCT</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2084</individualPrice>
								<listingDate>2008-01-15</listingDate>
								<amountMOHLTCPays>.2084</amountMOHLTCPays>
							</drug>
							<drug id="02362945" chronicUseMed="Y" sec3="Y">
								<name>Lisinopril/HCTZ (Type Z)</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2084</individualPrice>
								<listingDate>2011-10-25</listingDate>
								<amountMOHLTCPays>.2084</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800214">
							<itemNumber>0707</itemNumber>
							<strength>10mg &amp; 12.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02108194" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Prinzide</name>
								<manufacturerId>MFC</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02302136" chronicUseMed="Y" sec3="Y">
								<name>Teva-Lisinopril/HCTZ (Type P)</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3334</individualPrice>
								<listingDate>2008-01-15</listingDate>
								<amountMOHLTCPays>.3334</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800196">
							<itemNumber>0708</itemNumber>
							<strength>20mg &amp; 12.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00884413" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Prinzide</name>
								<manufacturerId>MFC</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02302144" chronicUseMed="Y" sec3="Y">
								<name>Teva-Lisinopril/HCTZ (Type P)</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.4006</individualPrice>
								<listingDate>2008-01-15</listingDate>
								<amountMOHLTCPays>.4006</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800215">
							<itemNumber>0709</itemNumber>
							<strength>20mg &amp; 12.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02045737" chronicUseMed="Y" sec3="Y">
								<name>Zestoretic</name>
								<manufacturerId>AZC</manufacturerId>
								<individualPrice>1.1159</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2504</amountMOHLTCPays>
							</drug>
							<drug id="02301776" chronicUseMed="Y" sec3="Y">
								<name>Teva-Lisinopril/HCTZ (Type Z)</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2504</individualPrice>
								<listingDate>2008-01-15</listingDate>
								<amountMOHLTCPays>.2504</amountMOHLTCPays>
							</drug>
							<drug id="02302373" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Lisinopril HCT</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2504</individualPrice>
								<listingDate>2008-01-15</listingDate>
								<amountMOHLTCPays>.2504</amountMOHLTCPays>
							</drug>
							<drug id="02362953" chronicUseMed="Y" sec3="Y">
								<name>Lisinopril/HCTZ (Type Z)</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2504</individualPrice>
								<listingDate>2011-10-25</listingDate>
								<amountMOHLTCPays>.2504</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800274">
							<itemNumber>0710</itemNumber>
							<strength>20mg &amp; 25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02045729" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Zestoretic</name>
								<manufacturerId>AZC</manufacturerId>
								<listingDate>2008-08-28</listingDate>
							</drug>
							<drug id="02301784" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Teva-Lisinopril/HCTZ (Type Z)</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.7011</individualPrice>
								<listingDate>2008-08-28</listingDate>
							</drug>
							<drug id="02302381" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Sandoz Lisinopril HCT</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.7011</individualPrice>
								<listingDate>2008-12-23</listingDate>
							</drug>
							<drug id="02362961" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Lisinopril/HCTZ (Type Z)</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.7011</individualPrice>
								<listingDate>2011-12-15</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="240800273">
							<itemNumber>0711</itemNumber>
							<strength>20mg/25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00884421" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Prinzide</name>
								<manufacturerId>MFC</manufacturerId>
								<listingDate>2008-08-28</listingDate>
							</drug>
							<drug id="02302152" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Teva-Lisinopril/HCTZ (Type P)</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.7011</individualPrice>
								<listingDate>2008-08-28</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00387">
					<name>LOSARTAN POTASSIUM</name>
					<pcgGroup>
						<pcg9 id="240800212">
							<itemNumber>0712</itemNumber>
							<strength>25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02182815" chronicUseMed="Y" sec3="Y">
								<name>Cozaar</name>
								<manufacturerId>OCI</manufacturerId>
								<individualPrice>1.9344</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02309750" chronicUseMed="Y" sec3="Y">
								<name>PMS-Losartan</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2012-03-26</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02313332" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Losartan</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2012-03-26</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02354829" chronicUseMed="Y" sec3="Y">
								<name>Co Losartan</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.3148</individualPrice>
								<listingDate>2012-03-26</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02379058" chronicUseMed="Y" sec3="Y">
								<name>Apo-Losartan</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3148</individualPrice>
								<listingDate>2012-03-26</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02380838" chronicUseMed="Y" sec3="Y">
								<name>Teva-Losartan</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3148</individualPrice>
								<listingDate>2012-04-24</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02388790" chronicUseMed="Y" sec3="Y">
								<name>Losartan</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02388863" chronicUseMed="Y" sec3="Y">
								<name>Losartan</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2021-01-29</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02398834" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Losartan</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2013-05-31</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02403323" chronicUseMed="Y" sec3="Y">
								<name>Auro-Losartan</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2013-05-31</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02404451" chronicUseMed="Y" sec3="Y">
								<name>Ran-Losartan</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2013-09-27</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02405733" chronicUseMed="Y" sec3="Y">
								<name>Mint-Losartan</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2014-05-29</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02424967" chronicUseMed="Y" sec3="Y">
								<name>Septa-Losartan</name>
								<manufacturerId>SET</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2014-09-25</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02426595" dinStatus="E" chronicUseMed="Y" sec3="Y">
								<name>Van-Losartan</name>
								<manufacturerId>VAN</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2015-08-26</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02445964" chronicUseMed="Y" sec3="Y">
								<name>Bio-Losartan</name>
								<manufacturerId>BMP</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2016-02-25</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800216">
							<itemNumber>0713</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02182874" chronicUseMed="Y" sec3="Y">
								<name>Cozaar</name>
								<manufacturerId>OCI</manufacturerId>
								<individualPrice>1.9343</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02309769" chronicUseMed="Y" sec3="Y">
								<name>PMS-Losartan</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2012-03-26</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02313340" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Losartan</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2012-03-26</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02353504" chronicUseMed="Y" sec3="Y">
								<name>Apo-Losartan</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3148</individualPrice>
								<listingDate>2012-03-26</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02354837" chronicUseMed="Y" sec3="Y">
								<name>Co Losartan</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.3148</individualPrice>
								<listingDate>2012-03-26</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02357968" chronicUseMed="Y" sec3="Y">
								<name>Teva-Losartan</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3148</individualPrice>
								<listingDate>2012-03-26</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02388804" chronicUseMed="Y" sec3="Y">
								<name>Losartan</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02388871" chronicUseMed="Y" sec3="Y">
								<name>Losartan</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2021-01-29</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02398842" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Losartan</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2013-05-31</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02403331" chronicUseMed="Y" sec3="Y">
								<name>Auro-Losartan</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2013-05-31</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02404478" chronicUseMed="Y" sec3="Y">
								<name>Ran-Losartan</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2013-09-27</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02405741" chronicUseMed="Y" sec3="Y">
								<name>Mint-Losartan</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2014-05-29</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02424975" chronicUseMed="Y" sec3="Y">
								<name>Septa-Losartan</name>
								<manufacturerId>SET</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2014-09-25</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02426609" dinStatus="E" chronicUseMed="Y" sec3="Y">
								<name>Van-Losartan</name>
								<manufacturerId>VAN</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2015-08-26</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02445972" chronicUseMed="Y" sec3="Y">
								<name>Bio-Losartan</name>
								<manufacturerId>BMP</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2016-02-25</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800230">
							<itemNumber>0714</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02182882" chronicUseMed="Y" sec3="Y">
								<name>Cozaar</name>
								<manufacturerId>OCI</manufacturerId>
								<individualPrice>1.9343</individualPrice>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02309777" chronicUseMed="Y" sec3="Y">
								<name>PMS-Losartan</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2012-03-26</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02313359" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Losartan</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2012-03-26</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02353512" chronicUseMed="Y" sec3="Y">
								<name>Apo-Losartan</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3148</individualPrice>
								<listingDate>2012-03-26</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02354845" chronicUseMed="Y" sec3="Y">
								<name>Co Losartan</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.3148</individualPrice>
								<listingDate>2012-03-26</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02357976" chronicUseMed="Y" sec3="Y">
								<name>Teva-Losartan</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3148</individualPrice>
								<listingDate>2012-03-26</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02388812" chronicUseMed="Y" sec3="Y">
								<name>Losartan</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02388898" chronicUseMed="Y" sec3="Y">
								<name>Losartan</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2021-01-29</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02398850" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Losartan</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2013-05-31</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02403358" chronicUseMed="Y" sec3="Y">
								<name>Auro-Losartan</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2013-05-31</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02404486" chronicUseMed="Y" sec3="Y">
								<name>Ran-Losartan</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2013-09-27</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02405768" chronicUseMed="Y" sec3="Y">
								<name>Mint-Losartan</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2014-05-29</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02424983" chronicUseMed="Y" sec3="Y">
								<name>Septa-Losartan</name>
								<manufacturerId>SET</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2014-09-25</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02426617" dinStatus="E" chronicUseMed="Y" sec3="Y">
								<name>Van-Losartan</name>
								<manufacturerId>VAN</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2015-08-26</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02445980" chronicUseMed="Y" sec3="Y">
								<name>Bio-Losartan</name>
								<manufacturerId>BMP</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2016-02-25</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01378">
					<name>LOSARTAN POTASSIUM &amp; HYDROCHLOROTHIAZIDE</name>
					<pcgGroup>
						<pcg9 id="240800282">
							<itemNumber>0715</itemNumber>
							<strength>100mg &amp; 12.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02297841" chronicUseMed="Y" sec3="Y">
								<name>Hyzaar</name>
								<manufacturerId>OCI</manufacturerId>
								<individualPrice>1.8939</individualPrice>
								<listingDate>2008-11-04</listingDate>
								<amountMOHLTCPays>.3082</amountMOHLTCPays>
							</drug>
							<drug id="02362449" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Losartan HCT</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.3082</individualPrice>
								<listingDate>2012-03-26</listingDate>
								<amountMOHLTCPays>.3082</amountMOHLTCPays>
							</drug>
							<drug id="02371243" chronicUseMed="Y" sec3="Y">
								<name>Apo-Losartan/HCTZ</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3082</individualPrice>
								<listingDate>2012-03-26</listingDate>
								<amountMOHLTCPays>.3082</amountMOHLTCPays>
							</drug>
							<drug id="02377144" chronicUseMed="Y" sec3="Y">
								<name>Teva-Losartan/HCTZ</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3082</individualPrice>
								<listingDate>2012-03-26</listingDate>
								<amountMOHLTCPays>.3082</amountMOHLTCPays>
							</drug>
							<drug id="02388278" chronicUseMed="Y" sec3="Y">
								<name>Co Losartan/HCT</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.3082</individualPrice>
								<listingDate>2012-08-27</listingDate>
								<amountMOHLTCPays>.3082</amountMOHLTCPays>
							</drug>
							<drug id="02388979" chronicUseMed="Y" sec3="Y">
								<name>Losartan HCT</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.3082</individualPrice>
								<listingDate>2020-09-30</listingDate>
								<amountMOHLTCPays>.3082</amountMOHLTCPays>
							</drug>
							<drug id="02389665" chronicUseMed="Y" sec3="Y">
								<name>Mint-Losartan/HCTZ</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.3082</individualPrice>
								<listingDate>2012-09-28</listingDate>
								<amountMOHLTCPays>.3082</amountMOHLTCPays>
							</drug>
							<drug id="02392232" chronicUseMed="Y" sec3="Y">
								<name>PMS-Losartan-HCTZ</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3082</individualPrice>
								<listingDate>2012-10-30</listingDate>
								<amountMOHLTCPays>.3082</amountMOHLTCPays>
							</drug>
							<drug id="02423650" chronicUseMed="Y" sec3="Y">
								<name>Auro-Losartan HCT</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.3082</individualPrice>
								<listingDate>2014-06-26</listingDate>
								<amountMOHLTCPays>.3082</amountMOHLTCPays>
							</drug>
							<drug id="02427656" chronicUseMed="Y" sec3="Y">
								<name>Losartan/HCTZ</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.3082</individualPrice>
								<listingDate>2021-01-29</listingDate>
								<amountMOHLTCPays>.3082</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800226">
							<itemNumber>0716</itemNumber>
							<strength>50mg &amp; 12.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02230047" chronicUseMed="Y" sec3="Y">
								<name>Hyzaar</name>
								<manufacturerId>OCI</manufacturerId>
								<individualPrice>1.9345</individualPrice>
								<listingDate>2000-11-30</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02313375" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Losartan HCT</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2012-03-26</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02358263" chronicUseMed="Y" sec3="Y">
								<name>Teva-Losartan/HCTZ</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3148</individualPrice>
								<listingDate>2012-03-26</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02371235" chronicUseMed="Y" sec3="Y">
								<name>Apo-Losartan/HCTZ</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3148</individualPrice>
								<listingDate>2012-03-26</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02388251" chronicUseMed="Y" sec3="Y">
								<name>Co Losartan/HCT</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2012-08-27</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02388960" chronicUseMed="Y" sec3="Y">
								<name>Losartan HCT</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2020-09-30</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02389657" chronicUseMed="Y" sec3="Y">
								<name>Mint-Losartan/HCTZ</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2012-09-28</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02392224" chronicUseMed="Y" sec3="Y">
								<name>PMS-Losartan-HCTZ</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2012-10-30</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02408244" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Losartan HCTZ</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2013-10-31</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02423642" chronicUseMed="Y" sec3="Y">
								<name>Auro-Losartan HCT</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2014-07-30</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02427648" chronicUseMed="Y" sec3="Y">
								<name>Losartan/HCTZ</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2021-01-29</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02428539" chronicUseMed="Y" sec3="Y">
								<name>Septa-Losartan HCTZ</name>
								<manufacturerId>SET</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2014-12-18</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800241">
							<itemNumber>0717</itemNumber>
							<strength>100mg &amp; 25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02241007" chronicUseMed="Y" sec3="Y">
								<name>Hyzaar DS</name>
								<manufacturerId>OCI</manufacturerId>
								<individualPrice>1.9345</individualPrice>
								<listingDate>2000-11-30</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02313383" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Losartan HCT DS</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2012-03-26</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02371251" chronicUseMed="Y" sec3="Y">
								<name>Apo-Losartan/HCTZ</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3148</individualPrice>
								<listingDate>2012-03-26</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02377152" chronicUseMed="Y" sec3="Y">
								<name>Teva-Losartan/HCTZ</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3148</individualPrice>
								<listingDate>2012-03-26</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02388286" chronicUseMed="Y" sec3="Y">
								<name>Co Losartan/HCT</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2012-08-27</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02388987" chronicUseMed="Y" sec3="Y">
								<name>Losartan HCT</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2020-09-30</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02389673" chronicUseMed="Y" sec3="Y">
								<name>Mint-Losartan/HCTZ DS</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2012-09-28</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02392240" chronicUseMed="Y" sec3="Y">
								<name>PMS-Losartan-HCTZ</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2012-10-30</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02408252" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Losartan HCTZ</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2013-10-31</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02423669" chronicUseMed="Y" sec3="Y">
								<name>Auro-Losartan HCT</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2014-06-26</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02427664" chronicUseMed="Y" sec3="Y">
								<name>Losartan/HCTZ</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2021-01-29</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
							<drug id="02428547" chronicUseMed="Y" sec3="Y">
								<name>Septa-Losartan HCTZ</name>
								<manufacturerId>SET</manufacturerId>
								<individualPrice>.3147</individualPrice>
								<listingDate>2014-12-18</listingDate>
								<amountMOHLTCPays>.3147</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00353">
					<name>METHYLDOPA</name>
					<pcgGroup>
						<pcg9 id="240800023">
							<itemNumber>0718</itemNumber>
							<strength>125mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.4036</dailyCost>
							<drug id="00016551" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Aldomet</name>
								<manufacturerId>MSD</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00360252" chronicUseMed="Y" sec3="Y">
								<name>Methyldopa</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.1009</individualPrice>
								<dailyCost>.4036</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1009</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800013">
							<itemNumber>0719</itemNumber>
							<strength>250mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.6316</dailyCost>
							<drug id="00016578" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Aldomet</name>
								<manufacturerId>MSD</manufacturerId>
								<listingDate>2002-11-22</listingDate>
							</drug>
							<drug id="00360260" chronicUseMed="Y" sec3="Y">
								<name>Methyldopa</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.1579</individualPrice>
								<dailyCost>.6316</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1579</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800045">
							<itemNumber>0720</itemNumber>
							<strength>500mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.5176</dailyCost>
							<drug id="00016586" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Aldomet</name>
								<manufacturerId>MSD</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00426830" chronicUseMed="Y" sec3="Y">
								<name>Methyldopa</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.2588</individualPrice>
								<dailyCost>.5176</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2588</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00362">
					<name>MINOXIDIL</name>
					<pcgGroup>
						<pcg9 id="240800072">
							<itemNumber>0721</itemNumber>
							<strength>2.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00514497" chronicUseMed="Y" sec3="Y">
								<name>Loniten</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>.4886</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.4886</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800071">
							<itemNumber>0722</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00514500" chronicUseMed="Y" sec3="Y">
								<name>Loniten</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>1.0772</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>1.0772</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00318">
					<name>NIFEDIPINE</name>
					<pcgGroup>
						<pcg9 id="240800227">
							<itemNumber>0723</itemNumber>
							<strength>20mg</strength>
							<dosageForm>ER Tab</dosageForm>
							<dailyCost>1.2864</dailyCost>
							<drug id="02237618" chronicUseMed="Y" sec3="Y">
								<name>Adalat XL</name>
								<manufacturerId>BAY</manufacturerId>
								<individualPrice>1.2864</individualPrice>
								<dailyCost>1.2864</dailyCost>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>1.2864</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800158">
							<itemNumber>0724</itemNumber>
							<strength>30mg</strength>
							<dosageForm>ER Tab</dosageForm>
							<dailyCost>.6171</dailyCost>
							<drug id="02155907" chronicUseMed="Y" sec3="Y">
								<name>Adalat XL</name>
								<manufacturerId>BAY</manufacturerId>
								<individualPrice>.6171</individualPrice>
								<dailyCost>.6171</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.6171</amountMOHLTCPays>
							</drug>
							<drug id="02349167" chronicUseMed="Y" sec3="Y">
								<name>Mylan-Nifedipine Extended Release</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.6171</individualPrice>
								<dailyCost>.6171</dailyCost>
								<listingDate>2010-07-20</listingDate>
								<amountMOHLTCPays>.6171</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800159">
							<itemNumber>0725</itemNumber>
							<strength>60mg</strength>
							<dosageForm>ER Tab</dosageForm>
							<dailyCost>.9374</dailyCost>
							<drug id="02155990" chronicUseMed="Y" sec3="Y">
								<name>Adalat XL</name>
								<manufacturerId>BAY</manufacturerId>
								<individualPrice>.9374</individualPrice>
								<dailyCost>.9374</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.9374</amountMOHLTCPays>
							</drug>
							<drug id="02321149" chronicUseMed="Y" sec3="Y">
								<name>Mylan-Nifedipine Extended Release</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.9374</individualPrice>
								<dailyCost>.9374</dailyCost>
								<listingDate>2009-03-02</listingDate>
								<amountMOHLTCPays>.9374</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01768">
					<name>OLMESARTAN MEDOXOMIL</name>
					<pcgGroup>
						<pcg9 id="240800284">
							<itemNumber>0726</itemNumber>
							<strength>20mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02318660" chronicUseMed="Y" sec3="Y">
								<name>Olmetec</name>
								<manufacturerId>OCI</manufacturerId>
								<individualPrice>1.3327</individualPrice>
								<listingDate>2010-04-23</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02442191" chronicUseMed="Y" sec3="Y">
								<name>Act Olmesartan</name>
								<manufacturerId>ACV</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2017-06-29</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02443414" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Olmesartan</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2017-06-29</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02443864" chronicUseMed="Y" sec3="Y">
								<name>Auro-Olmesartan</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2017-06-29</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02453452" chronicUseMed="Y" sec3="Y">
								<name>Apo-Olmesartan</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2017-06-29</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02456311" chronicUseMed="Y" sec3="Y">
								<name>Ach-Olmesartan</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2020-08-28</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02461307" chronicUseMed="Y" sec3="Y">
								<name>PMS-Olmesartan</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2017-07-31</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02461641" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Olmesartan</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2017-06-29</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02469812" chronicUseMed="Y" sec3="Y">
								<name>GLN-Olmesartan</name>
								<manufacturerId>GLP</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2020-12-18</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02481057" chronicUseMed="Y" sec3="Y">
								<name>Olmesartan</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02499258" chronicUseMed="Y" sec3="Y">
								<name>NRA-Olmesartan</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2020-12-18</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800285">
							<itemNumber>0727</itemNumber>
							<strength>40mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02318679" chronicUseMed="Y" sec3="Y">
								<name>Olmetec</name>
								<manufacturerId>OCI</manufacturerId>
								<individualPrice>1.3327</individualPrice>
								<listingDate>2010-04-23</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02442205" chronicUseMed="Y" sec3="Y">
								<name>Act Olmesartan</name>
								<manufacturerId>ACV</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2017-06-29</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02443422" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Olmesartan</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2017-06-29</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02443872" chronicUseMed="Y" sec3="Y">
								<name>Auro-Olmesartan</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2017-06-29</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02453460" chronicUseMed="Y" sec3="Y">
								<name>Apo-Olmesartan</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2017-06-29</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02456338" chronicUseMed="Y" sec3="Y">
								<name>Ach-Olmesartan</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2020-08-28</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02461315" chronicUseMed="Y" sec3="Y">
								<name>PMS-Olmesartan</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2017-07-31</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02461668" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Olmesartan</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2017-06-29</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02469820" chronicUseMed="Y" sec3="Y">
								<name>GLN-Olmesartan</name>
								<manufacturerId>GLP</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2020-12-18</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02481065" chronicUseMed="Y" sec3="Y">
								<name>Olmesartan</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02499266" chronicUseMed="Y" sec3="Y">
								<name>NRA-Olmesartan</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2020-12-18</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01769">
					<name>OLMESARTAN MEDOXOMIL &amp; HYDROCHLOROTHIAZIDE</name>
					<pcgGroup>
						<pcg9 id="240800286">
							<itemNumber>0728</itemNumber>
							<strength>20mg &amp; 12.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02319616" chronicUseMed="Y" sec3="Y">
								<name>Olmetec Plus</name>
								<manufacturerId>OCI</manufacturerId>
								<individualPrice>1.3327</individualPrice>
								<listingDate>2010-04-23</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02443112" chronicUseMed="Y" sec3="Y">
								<name>Act Olmesartan HCT</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2017-06-29</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02453606" chronicUseMed="Y" sec3="Y">
								<name>Apo-Olmesartan/HCTZ</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2017-06-29</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02468948" chronicUseMed="Y" sec3="Y">
								<name>Ach-Olmesartan HCTZ</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2019-08-30</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02475707" chronicUseMed="Y" sec3="Y">
								<name>GLN-Olmesartan HCTZ</name>
								<manufacturerId>GLP</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2021-04-30</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02476487" chronicUseMed="Y" sec3="Y">
								<name>Auro-Olmesartan HCTZ</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2019-11-29</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02508273" chronicUseMed="Y" sec3="Y">
								<name>NRA-Olmesartan HCTZ</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2021-10-29</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02509601" chronicUseMed="Y" sec3="Y">
								<name>Olmesartan/HCTZ</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2021-08-31</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800287">
							<itemNumber>0729</itemNumber>
							<strength>40mg &amp; 12.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02319624" chronicUseMed="Y" sec3="Y">
								<name>Olmetec Plus</name>
								<manufacturerId>OCI</manufacturerId>
								<individualPrice>1.3327</individualPrice>
								<listingDate>2010-04-23</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02443120" chronicUseMed="Y" sec3="Y">
								<name>Act Olmesartan HCT</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2017-06-29</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02453614" chronicUseMed="Y" sec3="Y">
								<name>Apo-Olmesartan/HCTZ</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2017-06-29</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02468956" chronicUseMed="Y" sec3="Y">
								<name>Ach-Olmesartan HCTZ</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2019-08-30</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02475715" chronicUseMed="Y" sec3="Y">
								<name>GLN-Olmesartan HCTZ</name>
								<manufacturerId>GLP</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2021-04-30</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02476495" chronicUseMed="Y" sec3="Y">
								<name>Auro-Olmesartan HCTZ</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2019-11-29</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02508281" chronicUseMed="Y" sec3="Y">
								<name>NRA-Olmesartan HCTZ</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2021-10-29</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02509636" chronicUseMed="Y" sec3="Y">
								<name>Olmesartan/HCTZ</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2021-08-31</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800288">
							<itemNumber>0730</itemNumber>
							<strength>40mg &amp; 25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02319632" chronicUseMed="Y" sec3="Y">
								<name>Olmetec Plus</name>
								<manufacturerId>OCI</manufacturerId>
								<individualPrice>1.3327</individualPrice>
								<listingDate>2010-04-23</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02443139" chronicUseMed="Y" sec3="Y">
								<name>Act Olmesartan HCT</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2017-06-29</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02453622" chronicUseMed="Y" sec3="Y">
								<name>Apo-Olmesartan/HCTZ</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2017-06-29</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02468964" chronicUseMed="Y" sec3="Y">
								<name>Ach-Olmesartan HCTZ</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2019-08-30</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02475723" chronicUseMed="Y" sec3="Y">
								<name>GLN-Olmesartan HCTZ</name>
								<manufacturerId>GLP</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2021-04-30</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02476509" chronicUseMed="Y" sec3="Y">
								<name>Auro-Olmesartan HCTZ</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2019-11-29</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02508303" chronicUseMed="Y" sec3="Y">
								<name>NRA-Olmesartan HCTZ</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2021-10-29</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
							<drug id="02509628" chronicUseMed="Y" sec3="Y">
								<name>Olmesartan/HCTZ</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.3019</individualPrice>
								<listingDate>2021-08-31</listingDate>
								<amountMOHLTCPays>.3019</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="02096">
					<name>PERINDOPRIL ARGININE &amp; AMLODIPINE BESYLATE</name>
					<pcgGroup>
						<pcg9 id="240800304">
							<itemNumber>0731</itemNumber>
							<strength>3.5mg &amp; 2.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02451530" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Viacoram</name>
								<manufacturerId>SEV</manufacturerId>
								<listingDate>2019-07-31</listingDate>
							</drug>
							<drug id="02468565" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Perindopril/Amlodipine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.8075</individualPrice>
								<listingDate>2019-07-31</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="240800305">
							<itemNumber>0732</itemNumber>
							<strength>7mg &amp; 5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02451549" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Viacoram</name>
								<manufacturerId>SEV</manufacturerId>
								<listingDate>2019-07-31</listingDate>
							</drug>
							<drug id="02468573" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Perindopril/Amlodipine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.8925</individualPrice>
								<listingDate>2019-07-31</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="240800306">
							<itemNumber>0733</itemNumber>
							<strength>14mg &amp; 10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02451557" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Viacoram</name>
								<manufacturerId>SEV</manufacturerId>
								<listingDate>2019-07-31</listingDate>
							</drug>
							<drug id="02468581" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Perindopril/Amlodipine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.9775</individualPrice>
								<listingDate>2019-07-31</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00386">
					<name>PERINDOPRIL ERBUMINE</name>
					<pcgGroup>
						<pcg9 id="240800208">
							<itemNumber>0734</itemNumber>
							<strength>2mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02123274" chronicUseMed="Y" sec3="Y">
								<name>Coversyl</name>
								<manufacturerId>SEV</manufacturerId>
								<individualPrice>.7057</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1632</amountMOHLTCPays>
							</drug>
							<drug id="02289261" chronicUseMed="Y" sec3="Y">
								<name>Apo-Perindopril</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1632</individualPrice>
								<listingDate>2018-04-30</listingDate>
								<amountMOHLTCPays>.1632</amountMOHLTCPays>
							</drug>
							<drug id="02459817" chronicUseMed="Y" sec3="Y">
								<name>Auro-Perindopril</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.1632</individualPrice>
								<listingDate>2018-04-30</listingDate>
								<amountMOHLTCPays>.1632</amountMOHLTCPays>
							</drug>
							<drug id="02464985" chronicUseMed="Y" sec3="Y">
								<name>Teva-Perindopril</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1632</individualPrice>
								<listingDate>2018-04-30</listingDate>
								<amountMOHLTCPays>.1632</amountMOHLTCPays>
							</drug>
							<drug id="02470225" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Perindopril Erbumine</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.1632</individualPrice>
								<listingDate>2018-04-30</listingDate>
								<amountMOHLTCPays>.1632</amountMOHLTCPays>
							</drug>
							<drug id="02470675" chronicUseMed="Y" sec3="Y">
								<name>PMS-Perindopril</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1632</individualPrice>
								<listingDate>2018-04-30</listingDate>
								<amountMOHLTCPays>.1632</amountMOHLTCPays>
							</drug>
							<drug id="02474824" chronicUseMed="Y" sec3="Y">
								<name>Mar-Perindopril</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.1632</individualPrice>
								<listingDate>2019-06-28</listingDate>
								<amountMOHLTCPays>.1632</amountMOHLTCPays>
							</drug>
							<drug id="02476762" chronicUseMed="Y" sec3="Y">
								<name>Mint-Perindopril</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.1632</individualPrice>
								<listingDate>2019-06-28</listingDate>
								<amountMOHLTCPays>.1632</amountMOHLTCPays>
							</drug>
							<drug id="02477009" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Perindopril</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1632</individualPrice>
								<listingDate>2019-09-30</listingDate>
								<amountMOHLTCPays>.1632</amountMOHLTCPays>
							</drug>
							<drug id="02479877" chronicUseMed="Y" sec3="Y">
								<name>Perindopril Erbumine</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.1632</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>.1632</amountMOHLTCPays>
							</drug>
							<drug id="02481634" chronicUseMed="Y" sec3="Y">
								<name>Perindopril Erbumine</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.1632</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>.1632</amountMOHLTCPays>
							</drug>
							<drug id="02481677" chronicUseMed="Y" sec3="Y">
								<name>AG-Perindopril</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.1632</individualPrice>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>.1632</amountMOHLTCPays>
							</drug>
							<drug id="02482924" chronicUseMed="Y" sec3="Y">
								<name>M-Perindopril Erbumine</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.1632</individualPrice>
								<listingDate>2021-09-30</listingDate>
								<amountMOHLTCPays>.1632</amountMOHLTCPays>
							</drug>
							<drug id="02489015" chronicUseMed="Y" sec3="Y">
								<name>NRA-Perindopril</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.1632</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>.1632</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800209">
							<itemNumber>0735</itemNumber>
							<strength>4mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02123282" chronicUseMed="Y" sec3="Y">
								<name>Coversyl</name>
								<manufacturerId>SEV</manufacturerId>
								<individualPrice>.8832</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2042</amountMOHLTCPays>
							</drug>
							<drug id="02289288" chronicUseMed="Y" sec3="Y">
								<name>Apo-Perindopril</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2042</individualPrice>
								<listingDate>2018-04-30</listingDate>
								<amountMOHLTCPays>.2042</amountMOHLTCPays>
							</drug>
							<drug id="02459825" chronicUseMed="Y" sec3="Y">
								<name>Auro-Perindopril</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2042</individualPrice>
								<listingDate>2018-04-30</listingDate>
								<amountMOHLTCPays>.2042</amountMOHLTCPays>
							</drug>
							<drug id="02464993" chronicUseMed="Y" sec3="Y">
								<name>Teva-Perindopril</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2042</individualPrice>
								<listingDate>2018-04-30</listingDate>
								<amountMOHLTCPays>.2042</amountMOHLTCPays>
							</drug>
							<drug id="02470233" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Perindopril Erbumine</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2042</individualPrice>
								<listingDate>2018-04-30</listingDate>
								<amountMOHLTCPays>.2042</amountMOHLTCPays>
							</drug>
							<drug id="02470683" chronicUseMed="Y" sec3="Y">
								<name>PMS-Perindopril</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2042</individualPrice>
								<listingDate>2018-04-30</listingDate>
								<amountMOHLTCPays>.2042</amountMOHLTCPays>
							</drug>
							<drug id="02474832" chronicUseMed="Y" sec3="Y">
								<name>Mar-Perindopril</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.2042</individualPrice>
								<listingDate>2019-06-28</listingDate>
								<amountMOHLTCPays>.2042</amountMOHLTCPays>
							</drug>
							<drug id="02476770" chronicUseMed="Y" sec3="Y">
								<name>Mint-Perindopril</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.2042</individualPrice>
								<listingDate>2019-04-30</listingDate>
								<amountMOHLTCPays>.2042</amountMOHLTCPays>
							</drug>
							<drug id="02477017" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Perindopril</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2042</individualPrice>
								<listingDate>2019-04-30</listingDate>
								<amountMOHLTCPays>.2042</amountMOHLTCPays>
							</drug>
							<drug id="02479885" chronicUseMed="Y" sec3="Y">
								<name>Perindopril Erbumine</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2042</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>.2042</amountMOHLTCPays>
							</drug>
							<drug id="02481642" chronicUseMed="Y" sec3="Y">
								<name>Perindopril Erbumine</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2042</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>.2042</amountMOHLTCPays>
							</drug>
							<drug id="02481685" chronicUseMed="Y" sec3="Y">
								<name>AG-Perindopril</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.2042</individualPrice>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>.2042</amountMOHLTCPays>
							</drug>
							<drug id="02482932" chronicUseMed="Y" sec3="Y">
								<name>M-Perindopril Erbumine</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.2042</individualPrice>
								<listingDate>2021-09-30</listingDate>
								<amountMOHLTCPays>.2042</amountMOHLTCPays>
							</drug>
							<drug id="02489023" chronicUseMed="Y" sec3="Y">
								<name>NRA-Perindopril</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.2042</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>.2042</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800257">
							<itemNumber>0736</itemNumber>
							<strength>8mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02246624" chronicUseMed="Y" sec3="Y">
								<name>Coversyl</name>
								<manufacturerId>SEV</manufacturerId>
								<individualPrice>1.2245</individualPrice>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.2831</amountMOHLTCPays>
							</drug>
							<drug id="02289296" chronicUseMed="Y" sec3="Y">
								<name>Apo-Perindopril</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2831</individualPrice>
								<listingDate>2008-03-25</listingDate>
								<amountMOHLTCPays>.2831</amountMOHLTCPays>
							</drug>
							<drug id="02459833" chronicUseMed="Y" sec3="Y">
								<name>Auro-Perindopril</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2831</individualPrice>
								<listingDate>2018-04-30</listingDate>
								<amountMOHLTCPays>.2831</amountMOHLTCPays>
							</drug>
							<drug id="02465000" chronicUseMed="Y" sec3="Y">
								<name>Teva-Perindopril</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2831</individualPrice>
								<listingDate>2018-04-30</listingDate>
								<amountMOHLTCPays>.2831</amountMOHLTCPays>
							</drug>
							<drug id="02470241" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Perindopril Erbumine</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2831</individualPrice>
								<listingDate>2018-04-30</listingDate>
								<amountMOHLTCPays>.2831</amountMOHLTCPays>
							</drug>
							<drug id="02470691" chronicUseMed="Y" sec3="Y">
								<name>PMS-Perindopril</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2831</individualPrice>
								<listingDate>2018-04-30</listingDate>
								<amountMOHLTCPays>.2831</amountMOHLTCPays>
							</drug>
							<drug id="02474840" chronicUseMed="Y" sec3="Y">
								<name>Mar-Perindopril</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.2831</individualPrice>
								<listingDate>2019-06-28</listingDate>
								<amountMOHLTCPays>.2831</amountMOHLTCPays>
							</drug>
							<drug id="02476789" chronicUseMed="Y" sec3="Y">
								<name>Mint-Perindopril</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.2831</individualPrice>
								<listingDate>2019-04-30</listingDate>
								<amountMOHLTCPays>.2831</amountMOHLTCPays>
							</drug>
							<drug id="02477025" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Perindopril</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2831</individualPrice>
								<listingDate>2019-04-30</listingDate>
								<amountMOHLTCPays>.2831</amountMOHLTCPays>
							</drug>
							<drug id="02479893" chronicUseMed="Y" sec3="Y">
								<name>Perindopril Erbumine</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2831</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>.2831</amountMOHLTCPays>
							</drug>
							<drug id="02481650" chronicUseMed="Y" sec3="Y">
								<name>Perindopril Erbumine</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2831</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>.2831</amountMOHLTCPays>
							</drug>
							<drug id="02481693" chronicUseMed="Y" sec3="Y">
								<name>AG-Perindopril</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.2831</individualPrice>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>.2831</amountMOHLTCPays>
							</drug>
							<drug id="02482940" chronicUseMed="Y" sec3="Y">
								<name>M-Perindopril Erbumine</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.2831</individualPrice>
								<listingDate>2021-09-30</listingDate>
								<amountMOHLTCPays>.2831</amountMOHLTCPays>
							</drug>
							<drug id="02489031" chronicUseMed="Y" sec3="Y">
								<name>NRA-Perindopril</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.2831</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>.2831</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01699">
					<name>PERINDOPRIL ERBUMINE &amp; INDAPAMIDE</name>
					<pcgGroup>
						<pcg9 id="240800265">
							<itemNumber>0737</itemNumber>
							<strength>2mg &amp; 0.625mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02246568" chronicUseMed="Y" sec3="Y">
								<name>Coversyl Plus LD</name>
								<manufacturerId>SEV</manufacturerId>
								<individualPrice>.9140</individualPrice>
								<listingDate>2007-04-02</listingDate>
								<amountMOHLTCPays>.6338</amountMOHLTCPays>
							</drug>
							<drug id="02470411" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Perindopril Erbumine/IndapamideLD</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.6338</individualPrice>
								<listingDate>2018-04-30</listingDate>
								<amountMOHLTCPays>.6338</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800264">
							<itemNumber>0738</itemNumber>
							<strength>4mg &amp; 1.25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02246569" chronicUseMed="Y" sec3="Y">
								<name>Coversyl Plus</name>
								<manufacturerId>SEV</manufacturerId>
								<individualPrice>1.1056</individualPrice>
								<listingDate>2007-04-02</listingDate>
								<amountMOHLTCPays>.2556</amountMOHLTCPays>
							</drug>
							<drug id="02297574" chronicUseMed="Y" sec3="Y">
								<name>Apo-Perindopril-Indapamide</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2556</individualPrice>
								<listingDate>2021-03-29</listingDate>
								<amountMOHLTCPays>.2556</amountMOHLTCPays>
							</drug>
							<drug id="02464020" chronicUseMed="Y" sec3="Y">
								<name>Teva-Perindopril/Indapamide</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2556</individualPrice>
								<listingDate>2018-04-30</listingDate>
								<amountMOHLTCPays>.2556</amountMOHLTCPays>
							</drug>
							<drug id="02470438" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Perindopril Erbumine/Indapamide</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2556</individualPrice>
								<listingDate>2018-04-30</listingDate>
								<amountMOHLTCPays>.2556</amountMOHLTCPays>
							</drug>
							<drug id="02479834" chronicUseMed="Y" sec3="Y">
								<name>Perindopril Erbumine/Indapamide</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2556</individualPrice>
								<listingDate>2022-03-31</listingDate>
								<amountMOHLTCPays>.2556</amountMOHLTCPays>
							</drug>
							<drug id="02519720" chronicUseMed="Y" sec3="Y">
								<name>Perindopril/Indapamide</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2556</individualPrice>
								<listingDate>2022-02-28</listingDate>
								<amountMOHLTCPays>.2556</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800283">
							<itemNumber>0739</itemNumber>
							<strength>8mg &amp; 2.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02321653" chronicUseMed="Y" sec3="Y">
								<name>Coversyl Plus HD</name>
								<manufacturerId>SEV</manufacturerId>
								<individualPrice>1.2365</individualPrice>
								<listingDate>2010-04-23</listingDate>
								<amountMOHLTCPays>.2859</amountMOHLTCPays>
							</drug>
							<drug id="02453061" chronicUseMed="Y" sec3="Y">
								<name>Apo-Perindopril-Indapamide</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2859</individualPrice>
								<listingDate>2021-03-29</listingDate>
								<amountMOHLTCPays>.2859</amountMOHLTCPays>
							</drug>
							<drug id="02464039" chronicUseMed="Y" sec3="Y">
								<name>Teva-Perindopril/Indapamide</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2859</individualPrice>
								<listingDate>2018-04-30</listingDate>
								<amountMOHLTCPays>.2859</amountMOHLTCPays>
							</drug>
							<drug id="02470446" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Perindopril Erbumine/IndapamideHD</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2859</individualPrice>
								<listingDate>2018-04-30</listingDate>
								<amountMOHLTCPays>.2859</amountMOHLTCPays>
							</drug>
							<drug id="02479842" chronicUseMed="Y" sec3="Y">
								<name>Perindopril Erbumine/Indapamide HD</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2859</individualPrice>
								<listingDate>2022-03-31</listingDate>
								<amountMOHLTCPays>.2859</amountMOHLTCPays>
							</drug>
							<drug id="02519739" chronicUseMed="Y" sec3="Y">
								<name>Perindopril/Indapamide</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2859</individualPrice>
								<listingDate>2022-02-28</listingDate>
								<amountMOHLTCPays>.2859</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00359">
					<name>PINDOLOL</name>
					<pcgGroup>
						<pcg9 id="240800058">
							<itemNumber>0740</itemNumber>
							<strength>5mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.7398</dailyCost>
							<drug id="00417270" chronicUseMed="Y" sec3="Y">
								<name>Visken</name>
								<manufacturerId>ARZ</manufacturerId>
								<individualPrice>.7397</individualPrice>
								<dailyCost>1.4794</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3699</amountMOHLTCPays>
							</drug>
							<drug id="00755877" chronicUseMed="Y" sec3="Y">
								<name>Apo-Pindol</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3699</individualPrice>
								<dailyCost>.7398</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3699</amountMOHLTCPays>
							</drug>
							<drug id="00869007" chronicUseMed="Y" sec3="Y">
								<name>Teva-Pindolol</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3699</individualPrice>
								<dailyCost>.7398</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3699</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800057">
							<itemNumber>0741</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>1.2630</dailyCost>
							<drug id="00443174" chronicUseMed="Y" sec3="Y">
								<name>Visken</name>
								<manufacturerId>ARZ</manufacturerId>
								<individualPrice>1.2630</individualPrice>
								<dailyCost>2.5260</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.6315</amountMOHLTCPays>
							</drug>
							<drug id="00755885" chronicUseMed="Y" sec3="Y">
								<name>Apo-Pindol</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.6315</individualPrice>
								<dailyCost>1.2630</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.6315</amountMOHLTCPays>
							</drug>
							<drug id="00869015" chronicUseMed="Y" sec3="Y">
								<name>Teva-Pindolol</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.6315</individualPrice>
								<dailyCost>1.2630</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.6315</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800056">
							<itemNumber>0742</itemNumber>
							<strength>15mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>1.7788</dailyCost>
							<drug id="00417289" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Visken</name>
								<manufacturerId>NOV</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00755893" chronicUseMed="Y" sec3="Y">
								<name>Apo-Pindol</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.8894</individualPrice>
								<dailyCost>1.7788</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.8894</amountMOHLTCPays>
							</drug>
							<drug id="00869023" chronicUseMed="Y" sec3="Y">
								<name>Teva-Pindolol</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.8894</individualPrice>
								<dailyCost>1.7788</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.8894</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00365">
					<name>PINDOLOL &amp; HYDROCHLOROTHIAZIDE</name>
					<pcgGroup>
						<pcg9 id="240800086">
							<itemNumber>0743</itemNumber>
							<strength>10mg &amp; 25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00568627" chronicUseMed="Y" sec3="Y">
								<name>Viskazide</name>
								<manufacturerId>ARZ</manufacturerId>
								<individualPrice>1.1656</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>1.1656</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800085">
							<itemNumber>0744</itemNumber>
							<strength>10mg &amp; 50mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00568635" chronicUseMed="Y" sec3="Y">
								<name>Viskazide</name>
								<manufacturerId>ARZ</manufacturerId>
								<individualPrice>1.1656</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>1.1656</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00366">
					<name>PRAZOSIN HCL</name>
					<pcgGroup>
						<pcg9 id="240800089">
							<itemNumber>0745</itemNumber>
							<strength>1mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.5486</dailyCost>
							<drug id="00560952" chronicUseMed="Y" sec3="Y">
								<name>Minipress</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>.2743</individualPrice>
								<dailyCost>.5486</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2743</amountMOHLTCPays>
							</drug>
							<drug id="00882801" chronicUseMed="Y" sec3="Y">
								<name>Apo-Prazo</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2743</individualPrice>
								<dailyCost>.5486</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2743</amountMOHLTCPays>
							</drug>
							<drug id="01934198" chronicUseMed="Y" sec3="Y">
								<name>Teva-Prazosin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2743</individualPrice>
								<dailyCost>.5486</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2743</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800088">
							<itemNumber>0746</itemNumber>
							<strength>2mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.7450</dailyCost>
							<drug id="00560960" chronicUseMed="Y" sec3="Y">
								<name>Minipress</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>.3725</individualPrice>
								<dailyCost>.7450</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3725</amountMOHLTCPays>
							</drug>
							<drug id="00882828" chronicUseMed="Y" sec3="Y">
								<name>Apo-Prazo</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3725</individualPrice>
								<dailyCost>.7450</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3725</amountMOHLTCPays>
							</drug>
							<drug id="01934201" chronicUseMed="Y" sec3="Y">
								<name>Teva-Prazosin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3725</individualPrice>
								<dailyCost>.7450</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3725</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800087">
							<itemNumber>0747</itemNumber>
							<strength>5mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>1.0242</dailyCost>
							<drug id="00560979" chronicUseMed="Y" sec3="Y">
								<name>Minipress</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>.5121</individualPrice>
								<dailyCost>1.0242</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.5121</amountMOHLTCPays>
							</drug>
							<drug id="00882836" chronicUseMed="Y" sec3="Y">
								<name>Apo-Prazo</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.5121</individualPrice>
								<dailyCost>1.0242</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.5121</amountMOHLTCPays>
							</drug>
							<drug id="01934228" chronicUseMed="Y" sec3="Y">
								<name>Teva-Prazosin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.5121</individualPrice>
								<dailyCost>1.0242</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.5121</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01930">
					<name>QUINAPRIL</name>
					<pcgGroup>
						<pcg9 id="240800160">
							<itemNumber>0748</itemNumber>
							<strength>5mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.4642</dailyCost>
							<drug id="01947664" chronicUseMed="Y" sec3="Y">
								<name>Accupril</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>1.0131</individualPrice>
								<dailyCost>1.0131</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.4642</amountMOHLTCPays>
							</drug>
							<drug id="02248499" chronicUseMed="Y" sec3="Y">
								<name>Apo-Quinapril</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.4642</individualPrice>
								<dailyCost>.4642</dailyCost>
								<listingDate>2013-10-31</listingDate>
								<amountMOHLTCPays>.4642</amountMOHLTCPays>
							</drug>
							<drug id="02340550" chronicUseMed="Y" sec3="Y">
								<name>PMS-Quinapril</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.4642</individualPrice>
								<dailyCost>.4642</dailyCost>
								<listingDate>2019-11-29</listingDate>
								<amountMOHLTCPays>.4642</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800161">
							<itemNumber>0749</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.4642</dailyCost>
							<drug id="01947672" chronicUseMed="Y" sec3="Y">
								<name>Accupril</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>1.0131</individualPrice>
								<dailyCost>1.0131</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.4642</amountMOHLTCPays>
							</drug>
							<drug id="02248500" chronicUseMed="Y" sec3="Y">
								<name>Apo-Quinapril</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.4642</individualPrice>
								<dailyCost>.4642</dailyCost>
								<listingDate>2013-10-31</listingDate>
								<amountMOHLTCPays>.4642</amountMOHLTCPays>
							</drug>
							<drug id="02340569" chronicUseMed="Y" sec3="Y">
								<name>PMS-Quinapril</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.4642</individualPrice>
								<dailyCost>.4642</dailyCost>
								<listingDate>2019-11-29</listingDate>
								<amountMOHLTCPays>.4642</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800162">
							<itemNumber>0750</itemNumber>
							<strength>20mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.4642</dailyCost>
							<drug id="01947680" chronicUseMed="Y" sec3="Y">
								<name>Accupril</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>1.0131</individualPrice>
								<dailyCost>1.0131</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.4642</amountMOHLTCPays>
							</drug>
							<drug id="02248501" chronicUseMed="Y" sec3="Y">
								<name>Apo-Quinapril</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.4642</individualPrice>
								<dailyCost>.4642</dailyCost>
								<listingDate>2013-10-31</listingDate>
								<amountMOHLTCPays>.4642</amountMOHLTCPays>
							</drug>
							<drug id="02340577" chronicUseMed="Y" sec3="Y">
								<name>PMS-Quinapril</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.4642</individualPrice>
								<dailyCost>.4642</dailyCost>
								<listingDate>2019-11-29</listingDate>
								<amountMOHLTCPays>.4642</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800163">
							<itemNumber>0751</itemNumber>
							<strength>40mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.4642</dailyCost>
							<drug id="01947699" chronicUseMed="Y" sec3="Y">
								<name>Accupril</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>1.0131</individualPrice>
								<dailyCost>1.0131</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.4642</amountMOHLTCPays>
							</drug>
							<drug id="02248502" chronicUseMed="Y" sec3="Y">
								<name>Apo-Quinapril</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.4642</individualPrice>
								<dailyCost>.4642</dailyCost>
								<listingDate>2013-10-31</listingDate>
								<amountMOHLTCPays>.4642</amountMOHLTCPays>
							</drug>
							<drug id="02340585" chronicUseMed="Y" sec3="Y">
								<name>PMS-Quinapril</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.4642</individualPrice>
								<dailyCost>.4642</dailyCost>
								<listingDate>2019-11-29</listingDate>
								<amountMOHLTCPays>.4642</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01931">
					<name>QUINAPRIL &amp; HYDROCHLOROTHIAZIDE</name>
					<pcgGroup>
						<pcg9 id="240800239">
							<itemNumber>0752</itemNumber>
							<strength>10mg &amp; 12.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02237367" chronicUseMed="Y" sec3="Y">
								<name>Accuretic</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>1.0189</individualPrice>
								<listingDate>2000-07-17</listingDate>
								<amountMOHLTCPays>.4786</amountMOHLTCPays>
							</drug>
							<drug id="02408767" chronicUseMed="Y" sec3="Y">
								<name>Apo-Quinapril/HCTZ</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.4786</individualPrice>
								<listingDate>2013-10-31</listingDate>
								<amountMOHLTCPays>.4786</amountMOHLTCPays>
							</drug>
							<drug id="02473291" chronicUseMed="Y" sec3="Y">
								<name>Auro-Quinapril HCTZ</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.4786</individualPrice>
								<listingDate>2019-03-28</listingDate>
								<amountMOHLTCPays>.4786</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800240">
							<itemNumber>0753</itemNumber>
							<strength>20mg &amp; 12.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02237368" chronicUseMed="Y" sec3="Y">
								<name>Accuretic</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>1.0189</individualPrice>
								<listingDate>2000-07-17</listingDate>
								<amountMOHLTCPays>.4786</amountMOHLTCPays>
							</drug>
							<drug id="02408775" chronicUseMed="Y" sec3="Y">
								<name>Apo-Quinapril/HCTZ</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.4786</individualPrice>
								<listingDate>2013-10-31</listingDate>
								<amountMOHLTCPays>.4786</amountMOHLTCPays>
							</drug>
							<drug id="02473305" chronicUseMed="Y" sec3="Y">
								<name>Auro-Quinapril HCTZ</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.4786</individualPrice>
								<listingDate>2019-03-28</listingDate>
								<amountMOHLTCPays>.4786</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800256">
							<itemNumber>0754</itemNumber>
							<strength>20mg &amp; 25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02237369" chronicUseMed="Y" sec3="Y">
								<name>Accuretic</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>.9797</individualPrice>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.4602</amountMOHLTCPays>
							</drug>
							<drug id="02408783" chronicUseMed="Y" sec3="Y">
								<name>Apo-Quinapril/HCTZ</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.4602</individualPrice>
								<listingDate>2013-10-31</listingDate>
								<amountMOHLTCPays>.4602</amountMOHLTCPays>
							</drug>
							<drug id="02473321" chronicUseMed="Y" sec3="Y">
								<name>Auro-Quinapril HCTZ</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.4602</individualPrice>
								<listingDate>2019-03-28</listingDate>
								<amountMOHLTCPays>.4602</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00385">
					<name>RAMIPRIL</name>
					<pcgGroup>
						<pcg9 id="240800203">
							<itemNumber>0755</itemNumber>
							<strength>1.25mg</strength>
							<drug id="02221829" chronicUseMed="Y" sec3="Y">
								<name>Altace Cap</name>
								<manufacturerId>SAV</manufacturerId>
								<individualPrice>.8230</individualPrice>
								<listingDate>1999-01-06</listingDate>
								<amountMOHLTCPays>.0708</amountMOHLTCPays>
							</drug>
							<drug id="02251515" chronicUseMed="Y" sec3="Y">
								<name>Apo-Ramipril Cap</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0708</individualPrice>
								<listingDate>2007-03-09</listingDate>
								<amountMOHLTCPays>.0708</amountMOHLTCPays>
							</drug>
							<drug id="02295369" chronicUseMed="Y" sec3="Y">
								<name>PMS-Ramipril Cap</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.0708</individualPrice>
								<listingDate>2010-04-23</listingDate>
								<amountMOHLTCPays>.0708</amountMOHLTCPays>
							</drug>
							<drug id="02295482" chronicUseMed="Y" sec3="Y">
								<name>Co Ramipril Cap</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.0708</individualPrice>
								<listingDate>2007-11-10</listingDate>
								<amountMOHLTCPays>.0708</amountMOHLTCPays>
							</drug>
							<drug id="02299372" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Ramipril Cap</name>
								<manufacturerId>RIA</manufacturerId>
								<listingDate>2008-08-28</listingDate>
							</drug>
							<drug id="02308363" chronicUseMed="Y" sec3="Y">
								<name>Ramipril Cap</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.0708</individualPrice>
								<listingDate>2010-06-14</listingDate>
								<amountMOHLTCPays>.0708</amountMOHLTCPays>
							</drug>
							<drug id="02310503" chronicUseMed="Y" sec3="Y">
								<name>Ran-Ramipril Cap</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.0708</individualPrice>
								<listingDate>2008-11-04</listingDate>
								<amountMOHLTCPays>.0708</amountMOHLTCPays>
							</drug>
							<drug id="02331101" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Ramipril Cap</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.0708</individualPrice>
								<listingDate>2010-04-23</listingDate>
								<amountMOHLTCPays>.0708</amountMOHLTCPays>
							</drug>
							<drug id="02387387" chronicUseMed="Y" sec3="Y">
								<name>Auro-Ramipril Cap</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.0708</individualPrice>
								<listingDate>2013-02-28</listingDate>
								<amountMOHLTCPays>.0708</amountMOHLTCPays>
							</drug>
							<drug id="02420457" chronicUseMed="Y" sec3="Y">
								<name>Mar-Ramipril Cap</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.0708</individualPrice>
								<listingDate>2014-05-29</listingDate>
								<amountMOHLTCPays>.0708</amountMOHLTCPays>
							</drug>
							<drug id="02438860" dinStatus="E" chronicUseMed="Y" sec3="Y">
								<name>Van-Ramipril Cap</name>
								<manufacturerId>VAN</manufacturerId>
								<individualPrice>.0708</individualPrice>
								<listingDate>2016-04-29</listingDate>
								<amountMOHLTCPays>.0708</amountMOHLTCPays>
							</drug>
							<drug id="02469057" chronicUseMed="Y" sec3="Y">
								<name>Pharma-Ramipril</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.0708</individualPrice>
								<listingDate>2018-09-27</listingDate>
								<amountMOHLTCPays>.0708</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800204">
							<itemNumber>0756</itemNumber>
							<strength>2.5mg</strength>
							<drug id="02221837" chronicUseMed="Y" sec3="Y">
								<name>Altace Cap</name>
								<manufacturerId>SAV</manufacturerId>
								<individualPrice>.9257</individualPrice>
								<listingDate>1999-01-06</listingDate>
								<amountMOHLTCPays>.0817</amountMOHLTCPays>
							</drug>
							<drug id="02247917" chronicUseMed="Y" sec3="Y">
								<name>PMS-Ramipril Cap</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.0817</individualPrice>
								<listingDate>2010-04-23</listingDate>
								<amountMOHLTCPays>.0817</amountMOHLTCPays>
							</drug>
							<drug id="02247945" chronicUseMed="Y" sec3="Y">
								<name>Teva-Ramipril Cap</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.0817</individualPrice>
								<listingDate>2007-06-06</listingDate>
								<amountMOHLTCPays>.0817</amountMOHLTCPays>
							</drug>
							<drug id="02251531" chronicUseMed="Y" sec3="Y">
								<name>Apo-Ramipril Cap</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0817</individualPrice>
								<listingDate>2007-03-09</listingDate>
								<amountMOHLTCPays>.0817</amountMOHLTCPays>
							</drug>
							<drug id="02255316" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Ramipril Cap</name>
								<manufacturerId>RIA</manufacturerId>
								<listingDate>2008-08-28</listingDate>
							</drug>
							<drug id="02287706" chronicUseMed="Y" sec3="Y">
								<name>Ratio-Ramipril Cap</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>.0817</individualPrice>
								<listingDate>2007-03-09</listingDate>
								<amountMOHLTCPays>.0817</amountMOHLTCPays>
							</drug>
							<drug id="02287927" chronicUseMed="Y" sec3="Y">
								<name>Ramipril Cap</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.0817</individualPrice>
								<listingDate>2010-06-14</listingDate>
								<amountMOHLTCPays>.0817</amountMOHLTCPays>
							</drug>
							<drug id="02295490" chronicUseMed="Y" sec3="Y">
								<name>Co Ramipril Cap</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.0817</individualPrice>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.0817</amountMOHLTCPays>
							</drug>
							<drug id="02310511" chronicUseMed="Y" sec3="Y">
								<name>Ran-Ramipril Cap</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.0817</individualPrice>
								<listingDate>2008-11-04</listingDate>
								<amountMOHLTCPays>.0817</amountMOHLTCPays>
							</drug>
							<drug id="02331128" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Ramipril Cap</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.0817</individualPrice>
								<listingDate>2010-04-23</listingDate>
								<amountMOHLTCPays>.0817</amountMOHLTCPays>
							</drug>
							<drug id="02374846" chronicUseMed="Y" sec3="Y">
								<name>Ramipril Cap</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.0817</individualPrice>
								<listingDate>2016-04-01</listingDate>
								<amountMOHLTCPays>.0817</amountMOHLTCPays>
							</drug>
							<drug id="02387395" chronicUseMed="Y" sec3="Y">
								<name>Auro-Ramipril Cap</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.0817</individualPrice>
								<listingDate>2013-02-28</listingDate>
								<amountMOHLTCPays>.0817</amountMOHLTCPays>
							</drug>
							<drug id="02420465" chronicUseMed="Y" sec3="Y">
								<name>Mar-Ramipril Cap</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.0817</individualPrice>
								<listingDate>2014-05-29</listingDate>
								<amountMOHLTCPays>.0817</amountMOHLTCPays>
							</drug>
							<drug id="02421305" chronicUseMed="Y" sec3="Y">
								<name>Mint-Ramipril Cap</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.0817</individualPrice>
								<listingDate>2014-06-26</listingDate>
								<amountMOHLTCPays>.0817</amountMOHLTCPays>
							</drug>
							<drug id="02438879" dinStatus="E" chronicUseMed="Y" sec3="Y">
								<name>Van-Ramipril Cap</name>
								<manufacturerId>VAN</manufacturerId>
								<individualPrice>.0817</individualPrice>
								<listingDate>2016-04-29</listingDate>
								<amountMOHLTCPays>.0817</amountMOHLTCPays>
							</drug>
							<drug id="02469065" chronicUseMed="Y" sec3="Y">
								<name>Pharma-Ramipril</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.0817</individualPrice>
								<listingDate>2018-09-27</listingDate>
								<amountMOHLTCPays>.0817</amountMOHLTCPays>
							</drug>
							<drug id="02477572" chronicUseMed="Y" sec3="Y">
								<name>AG-Ramipril Cap</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.0817</individualPrice>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.0817</amountMOHLTCPays>
							</drug>
							<drug id="02486172" chronicUseMed="Y" sec3="Y">
								<name>NRA-Ramipril Cap</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.0817</individualPrice>
								<listingDate>2020-09-30</listingDate>
								<amountMOHLTCPays>.0817</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800205">
							<itemNumber>0757</itemNumber>
							<strength>5mg</strength>
							<drug id="02221845" chronicUseMed="Y" sec3="Y">
								<name>Altace Cap</name>
								<manufacturerId>SAV</manufacturerId>
								<individualPrice>.9500</individualPrice>
								<listingDate>1999-01-06</listingDate>
								<amountMOHLTCPays>.0817</amountMOHLTCPays>
							</drug>
							<drug id="02247918" chronicUseMed="Y" sec3="Y">
								<name>PMS-Ramipril Cap</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.0817</individualPrice>
								<listingDate>2010-04-23</listingDate>
								<amountMOHLTCPays>.0817</amountMOHLTCPays>
							</drug>
							<drug id="02247946" chronicUseMed="Y" sec3="Y">
								<name>Teva-Ramipril Cap</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.0817</individualPrice>
								<listingDate>2007-06-06</listingDate>
								<amountMOHLTCPays>.0817</amountMOHLTCPays>
							</drug>
							<drug id="02251574" chronicUseMed="Y" sec3="Y">
								<name>Apo-Ramipril Cap</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0817</individualPrice>
								<listingDate>2007-03-09</listingDate>
								<amountMOHLTCPays>.0817</amountMOHLTCPays>
							</drug>
							<drug id="02255324" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Ramipril Cap</name>
								<manufacturerId>RIA</manufacturerId>
								<listingDate>2008-08-28</listingDate>
							</drug>
							<drug id="02287935" chronicUseMed="Y" sec3="Y">
								<name>Ramipril Cap</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.0817</individualPrice>
								<listingDate>2010-06-14</listingDate>
								<amountMOHLTCPays>.0817</amountMOHLTCPays>
							</drug>
							<drug id="02295504" chronicUseMed="Y" sec3="Y">
								<name>Co Ramipril Cap</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.0817</individualPrice>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.0817</amountMOHLTCPays>
							</drug>
							<drug id="02310538" chronicUseMed="Y" sec3="Y">
								<name>Ran-Ramipril Cap</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.0817</individualPrice>
								<listingDate>2008-11-04</listingDate>
								<amountMOHLTCPays>.0817</amountMOHLTCPays>
							</drug>
							<drug id="02331136" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Ramipril Cap</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.0817</individualPrice>
								<listingDate>2010-04-23</listingDate>
								<amountMOHLTCPays>.0817</amountMOHLTCPays>
							</drug>
							<drug id="02374854" chronicUseMed="Y" sec3="Y">
								<name>Ramipril Cap</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.0817</individualPrice>
								<listingDate>2016-04-01</listingDate>
								<amountMOHLTCPays>.0817</amountMOHLTCPays>
							</drug>
							<drug id="02387409" chronicUseMed="Y" sec3="Y">
								<name>Auro-Ramipril Cap</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.0817</individualPrice>
								<listingDate>2013-02-28</listingDate>
								<amountMOHLTCPays>.0817</amountMOHLTCPays>
							</drug>
							<drug id="02420473" chronicUseMed="Y" sec3="Y">
								<name>Mar-Ramipril Cap</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.0817</individualPrice>
								<listingDate>2014-05-29</listingDate>
								<amountMOHLTCPays>.0817</amountMOHLTCPays>
							</drug>
							<drug id="02421313" chronicUseMed="Y" sec3="Y">
								<name>Mint-Ramipril Cap</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.0817</individualPrice>
								<listingDate>2014-06-26</listingDate>
								<amountMOHLTCPays>.0817</amountMOHLTCPays>
							</drug>
							<drug id="02438887" dinStatus="E" chronicUseMed="Y" sec3="Y">
								<name>Van-Ramipril Cap</name>
								<manufacturerId>VAN</manufacturerId>
								<individualPrice>.0817</individualPrice>
								<listingDate>2016-04-29</listingDate>
								<amountMOHLTCPays>.0817</amountMOHLTCPays>
							</drug>
							<drug id="02469073" chronicUseMed="Y" sec3="Y">
								<name>Pharma-Ramipril</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.0817</individualPrice>
								<listingDate>2018-09-27</listingDate>
								<amountMOHLTCPays>.0817</amountMOHLTCPays>
							</drug>
							<drug id="02477580" chronicUseMed="Y" sec3="Y">
								<name>AG-Ramipril Cap</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.0817</individualPrice>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.0817</amountMOHLTCPays>
							</drug>
							<drug id="02486180" chronicUseMed="Y" sec3="Y">
								<name>NRA-Ramipril Cap</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.0817</individualPrice>
								<listingDate>2020-09-30</listingDate>
								<amountMOHLTCPays>.0817</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800206">
							<itemNumber>0758</itemNumber>
							<strength>10mg</strength>
							<drug id="02221853" chronicUseMed="Y" sec3="Y">
								<name>Altace Cap</name>
								<manufacturerId>SAV</manufacturerId>
								<individualPrice>1.2203</individualPrice>
								<listingDate>1999-01-06</listingDate>
								<amountMOHLTCPays>.1034</amountMOHLTCPays>
							</drug>
							<drug id="02247919" chronicUseMed="Y" sec3="Y">
								<name>PMS-Ramipril Cap</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1034</individualPrice>
								<listingDate>2010-04-23</listingDate>
								<amountMOHLTCPays>.1034</amountMOHLTCPays>
							</drug>
							<drug id="02247947" chronicUseMed="Y" sec3="Y">
								<name>Teva-Ramipril Cap</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1034</individualPrice>
								<listingDate>2007-06-06</listingDate>
								<amountMOHLTCPays>.1034</amountMOHLTCPays>
							</drug>
							<drug id="02251582" chronicUseMed="Y" sec3="Y">
								<name>Apo-Ramipril Cap</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1034</individualPrice>
								<listingDate>2007-03-09</listingDate>
								<amountMOHLTCPays>.1034</amountMOHLTCPays>
							</drug>
							<drug id="02255332" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Ramipril Cap</name>
								<manufacturerId>RIA</manufacturerId>
								<listingDate>2008-08-28</listingDate>
							</drug>
							<drug id="02287943" chronicUseMed="Y" sec3="Y">
								<name>Ramipril Cap</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.1034</individualPrice>
								<listingDate>2010-06-14</listingDate>
								<amountMOHLTCPays>.1034</amountMOHLTCPays>
							</drug>
							<drug id="02295512" chronicUseMed="Y" sec3="Y">
								<name>Co Ramipril Cap</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.1034</individualPrice>
								<listingDate>2007-11-10</listingDate>
								<amountMOHLTCPays>.1034</amountMOHLTCPays>
							</drug>
							<drug id="02310546" chronicUseMed="Y" sec3="Y">
								<name>Ran-Ramipril Cap</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.1034</individualPrice>
								<listingDate>2008-11-04</listingDate>
								<amountMOHLTCPays>.1034</amountMOHLTCPays>
							</drug>
							<drug id="02331144" chronicUseMed="Y" sec3="Y">
								<name>Jamp-Ramipril Cap</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1034</individualPrice>
								<listingDate>2010-04-23</listingDate>
								<amountMOHLTCPays>.1034</amountMOHLTCPays>
							</drug>
							<drug id="02374862" chronicUseMed="Y" sec3="Y">
								<name>Ramipril Cap</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.1034</individualPrice>
								<listingDate>2016-04-01</listingDate>
								<amountMOHLTCPays>.1034</amountMOHLTCPays>
							</drug>
							<drug id="02387417" chronicUseMed="Y" sec3="Y">
								<name>Auro-Ramipril Cap</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.1034</individualPrice>
								<listingDate>2013-02-28</listingDate>
								<amountMOHLTCPays>.1034</amountMOHLTCPays>
							</drug>
							<drug id="02420481" chronicUseMed="Y" sec3="Y">
								<name>Mar-Ramipril Cap</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.1034</individualPrice>
								<listingDate>2014-05-29</listingDate>
								<amountMOHLTCPays>.1034</amountMOHLTCPays>
							</drug>
							<drug id="02421321" chronicUseMed="Y" sec3="Y">
								<name>Mint-Ramipril Cap</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.1034</individualPrice>
								<listingDate>2014-06-26</listingDate>
								<amountMOHLTCPays>.1034</amountMOHLTCPays>
							</drug>
							<drug id="02438895" dinStatus="E" chronicUseMed="Y" sec3="Y">
								<name>Van-Ramipril Cap</name>
								<manufacturerId>VAN</manufacturerId>
								<individualPrice>.1034</individualPrice>
								<listingDate>2016-04-29</listingDate>
								<amountMOHLTCPays>.1034</amountMOHLTCPays>
							</drug>
							<drug id="02469081" chronicUseMed="Y" sec3="Y">
								<name>Pharma-Ramipril</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1034</individualPrice>
								<listingDate>2018-09-27</listingDate>
								<amountMOHLTCPays>.1034</amountMOHLTCPays>
							</drug>
							<drug id="02477599" chronicUseMed="Y" sec3="Y">
								<name>AG-Ramipril Cap</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.1034</individualPrice>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.1034</amountMOHLTCPays>
							</drug>
							<drug id="02486199" chronicUseMed="Y" sec3="Y">
								<name>NRA-Ramipril Cap</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.1034</individualPrice>
								<listingDate>2020-09-30</listingDate>
								<amountMOHLTCPays>.1034</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800280">
							<itemNumber>0759</itemNumber>
							<strength>15mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02281112" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Altace</name>
								<manufacturerId>SAV</manufacturerId>
								<listingDate>2009-06-23</listingDate>
							</drug>
							<drug id="02325381" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Ramipril</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.8550</individualPrice>
								<listingDate>2009-06-23</listingDate>
							</drug>
							<drug id="02420503" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mar-Ramipril</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.8550</individualPrice>
								<listingDate>2014-05-29</listingDate>
							</drug>
							<drug id="02421348" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mint-Ramipril</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.8132</individualPrice>
								<listingDate>2014-06-26</listingDate>
							</drug>
							<drug id="02425548" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Ran-Ramipril</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.8550</individualPrice>
								<listingDate>2015-02-26</listingDate>
							</drug>
							<drug id="02440334" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Jamp-Ramipril</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.8550</individualPrice>
								<listingDate>2016-09-29</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01705">
					<name>RAMIPRIL &amp; HYDROCHLOROTHIAZIDE</name>
					<pcgGroup>
						<pcg9 id="240800266">
							<itemNumber>0760</itemNumber>
							<strength>2.5mg &amp; 12.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02283131" chronicUseMed="Y" sec3="Y">
								<name>Altace HCT</name>
								<manufacturerId>SAV</manufacturerId>
								<individualPrice>.3332</individualPrice>
								<listingDate>2007-06-06</listingDate>
								<amountMOHLTCPays>.2242</amountMOHLTCPays>
							</drug>
							<drug id="02449439" chronicUseMed="Y" sec3="Y">
								<name>Ran-Ramipril HCTZ</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.2242</individualPrice>
								<listingDate>2018-05-31</listingDate>
								<amountMOHLTCPays>.2242</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800267">
							<itemNumber>0761</itemNumber>
							<strength>5mg &amp; 12.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02283158" chronicUseMed="Y" sec3="Y">
								<name>Altace HCT</name>
								<manufacturerId>SAV</manufacturerId>
								<individualPrice>.4268</individualPrice>
								<listingDate>2007-06-06</listingDate>
								<amountMOHLTCPays>.3016</amountMOHLTCPays>
							</drug>
							<drug id="02449447" chronicUseMed="Y" sec3="Y">
								<name>Ran-Ramipril HCTZ</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.3016</individualPrice>
								<listingDate>2018-12-21</listingDate>
								<amountMOHLTCPays>.3016</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800269">
							<itemNumber>0762</itemNumber>
							<strength>5mg &amp; 25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02283174" chronicUseMed="Y" sec3="Y">
								<name>Altace HCT</name>
								<manufacturerId>SAV</manufacturerId>
								<individualPrice>.4268</individualPrice>
								<listingDate>2007-06-06</listingDate>
								<amountMOHLTCPays>.2872</amountMOHLTCPays>
							</drug>
							<drug id="02449463" chronicUseMed="Y" sec3="Y">
								<name>Ran-Ramipril HCTZ</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.2872</individualPrice>
								<listingDate>2018-05-31</listingDate>
								<amountMOHLTCPays>.2872</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800268">
							<itemNumber>0763</itemNumber>
							<strength>10mg &amp; 12.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02283166" chronicUseMed="Y" sec3="Y">
								<name>Altace HCT</name>
								<manufacturerId>SAV</manufacturerId>
								<individualPrice>.5589</individualPrice>
								<listingDate>2007-06-06</listingDate>
								<amountMOHLTCPays>.2634</amountMOHLTCPays>
							</drug>
							<drug id="02342154" chronicUseMed="Y" sec3="Y">
								<name>PMS-Ramipril-HCTZ</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2634</individualPrice>
								<listingDate>2011-03-15</listingDate>
								<amountMOHLTCPays>.2634</amountMOHLTCPays>
							</drug>
							<drug id="02449455" chronicUseMed="Y" sec3="Y">
								<name>Ran-Ramipril HCTZ</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.2634</individualPrice>
								<listingDate>2018-12-21</listingDate>
								<amountMOHLTCPays>.2634</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800270">
							<itemNumber>0764</itemNumber>
							<strength>10mg &amp; 25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02283182" chronicUseMed="Y" sec3="Y">
								<name>Altace HCT</name>
								<manufacturerId>SAV</manufacturerId>
								<individualPrice>.5589</individualPrice>
								<listingDate>2007-06-06</listingDate>
								<amountMOHLTCPays>.2634</amountMOHLTCPays>
							</drug>
							<drug id="02342170" chronicUseMed="Y" sec3="Y">
								<name>PMS-Ramipril-HCTZ</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2634</individualPrice>
								<listingDate>2011-03-15</listingDate>
								<amountMOHLTCPays>.2634</amountMOHLTCPays>
							</drug>
							<drug id="02449471" chronicUseMed="Y" sec3="Y">
								<name>Ran-Ramipril HCTZ</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.2634</individualPrice>
								<listingDate>2018-12-21</listingDate>
								<amountMOHLTCPays>.2634</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01435">
					<name>TELMISARTAN</name>
					<pcgGroup>
						<pcg9 id="240800237">
							<itemNumber>0765</itemNumber>
							<strength>40mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02240769" chronicUseMed="Y" sec3="Y">
								<name>Micardis</name>
								<manufacturerId>BOE</manufacturerId>
								<individualPrice>1.2474</individualPrice>
								<listingDate>2000-04-17</listingDate>
								<amountMOHLTCPays>.2161</amountMOHLTCPays>
							</drug>
							<drug id="02320177" chronicUseMed="Y" sec3="Y">
								<name>Teva-Telmisartan</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2161</individualPrice>
								<listingDate>2012-03-26</listingDate>
								<amountMOHLTCPays>.2161</amountMOHLTCPays>
							</drug>
							<drug id="02375958" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Telmisartan</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2161</individualPrice>
								<listingDate>2012-02-29</listingDate>
								<amountMOHLTCPays>.2161</amountMOHLTCPays>
							</drug>
							<drug id="02386755" chronicUseMed="Y" sec3="Y">
								<name>Jamp Telmisartan</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2161</individualPrice>
								<listingDate>2021-02-26</listingDate>
								<amountMOHLTCPays>.2161</amountMOHLTCPays>
							</drug>
							<drug id="02388944" chronicUseMed="Y" sec3="Y">
								<name>Telmisartan</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2161</individualPrice>
								<listingDate>2020-09-30</listingDate>
								<amountMOHLTCPays>.2161</amountMOHLTCPays>
							</drug>
							<drug id="02390345" chronicUseMed="Y" sec3="Y">
								<name>Telmisartan</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2161</individualPrice>
								<listingDate>2021-05-31</listingDate>
								<amountMOHLTCPays>.2161</amountMOHLTCPays>
							</drug>
							<drug id="02407485" chronicUseMed="Y" sec3="Y">
								<name>Telmisartan Tablets</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.2161</individualPrice>
								<listingDate>2014-09-25</listingDate>
								<amountMOHLTCPays>.2161</amountMOHLTCPays>
							</drug>
							<drug id="02420082" chronicUseMed="Y" sec3="Y">
								<name>Apo-Telmisartan</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2161</individualPrice>
								<listingDate>2014-03-27</listingDate>
								<amountMOHLTCPays>.2161</amountMOHLTCPays>
							</drug>
							<drug id="02432897" chronicUseMed="Y" sec3="Y">
								<name>Telmisartan</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2161</individualPrice>
								<listingDate>2015-04-30</listingDate>
								<amountMOHLTCPays>.2161</amountMOHLTCPays>
							</drug>
							<drug id="02434164" dinStatus="E" chronicUseMed="Y" sec3="Y">
								<name>Van-Telmisartan</name>
								<manufacturerId>VAN</manufacturerId>
								<individualPrice>.2161</individualPrice>
								<listingDate>2015-11-26</listingDate>
								<amountMOHLTCPays>.2161</amountMOHLTCPays>
							</drug>
							<drug id="02453568" chronicUseMed="Y" sec3="Y">
								<name>Auro-Telmisartan</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2161</individualPrice>
								<listingDate>2016-12-22</listingDate>
								<amountMOHLTCPays>.2161</amountMOHLTCPays>
							</drug>
							<drug id="02486369" chronicUseMed="Y" sec3="Y">
								<name>Mint-Telmisartan</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.2161</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>.2161</amountMOHLTCPays>
							</drug>
							<drug id="02499622" chronicUseMed="Y" sec3="Y">
								<name>PMS-Telmisartan</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2161</individualPrice>
								<listingDate>2021-05-31</listingDate>
								<amountMOHLTCPays>.2161</amountMOHLTCPays>
							</drug>
							<drug id="02503794" chronicUseMed="Y" sec3="Y">
								<name>NRA-Telmisartan</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.2161</individualPrice>
								<listingDate>2022-02-28</listingDate>
								<amountMOHLTCPays>.2161</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800238">
							<itemNumber>0766</itemNumber>
							<strength>80mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02240770" chronicUseMed="Y" sec3="Y">
								<name>Micardis</name>
								<manufacturerId>BOE</manufacturerId>
								<individualPrice>1.2474</individualPrice>
								<listingDate>2000-04-17</listingDate>
								<amountMOHLTCPays>.2161</amountMOHLTCPays>
							</drug>
							<drug id="02320185" chronicUseMed="Y" sec3="Y">
								<name>Teva-Telmisartan</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2161</individualPrice>
								<listingDate>2012-03-26</listingDate>
								<amountMOHLTCPays>.2161</amountMOHLTCPays>
							</drug>
							<drug id="02375966" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Telmisartan</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2161</individualPrice>
								<listingDate>2012-02-29</listingDate>
								<amountMOHLTCPays>.2161</amountMOHLTCPays>
							</drug>
							<drug id="02386763" chronicUseMed="Y" sec3="Y">
								<name>Jamp Telmisartan</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2161</individualPrice>
								<listingDate>2021-02-26</listingDate>
								<amountMOHLTCPays>.2161</amountMOHLTCPays>
							</drug>
							<drug id="02388952" chronicUseMed="Y" sec3="Y">
								<name>Telmisartan</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2161</individualPrice>
								<listingDate>2020-09-30</listingDate>
								<amountMOHLTCPays>.2161</amountMOHLTCPays>
							</drug>
							<drug id="02390353" chronicUseMed="Y" sec3="Y">
								<name>Telmisartan</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2161</individualPrice>
								<listingDate>2021-05-31</listingDate>
								<amountMOHLTCPays>.2161</amountMOHLTCPays>
							</drug>
							<drug id="02393255" chronicUseMed="Y" sec3="Y">
								<name>Co Telmisartan</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.2161</individualPrice>
								<listingDate>2012-12-21</listingDate>
								<amountMOHLTCPays>.2161</amountMOHLTCPays>
							</drug>
							<drug id="02407493" chronicUseMed="Y" sec3="Y">
								<name>Telmisartan Tablets</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.2161</individualPrice>
								<listingDate>2014-09-25</listingDate>
								<amountMOHLTCPays>.2161</amountMOHLTCPays>
							</drug>
							<drug id="02420090" chronicUseMed="Y" sec3="Y">
								<name>Apo-Telmisartan</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2161</individualPrice>
								<listingDate>2014-03-27</listingDate>
								<amountMOHLTCPays>.2161</amountMOHLTCPays>
							</drug>
							<drug id="02432900" chronicUseMed="Y" sec3="Y">
								<name>Telmisartan</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2161</individualPrice>
								<listingDate>2015-04-30</listingDate>
								<amountMOHLTCPays>.2161</amountMOHLTCPays>
							</drug>
							<drug id="02434172" dinStatus="E" chronicUseMed="Y" sec3="Y">
								<name>Van-Telmisartan</name>
								<manufacturerId>VAN</manufacturerId>
								<individualPrice>.2161</individualPrice>
								<listingDate>2015-11-26</listingDate>
								<amountMOHLTCPays>.2161</amountMOHLTCPays>
							</drug>
							<drug id="02453576" chronicUseMed="Y" sec3="Y">
								<name>Auro-Telmisartan</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2161</individualPrice>
								<listingDate>2016-12-22</listingDate>
								<amountMOHLTCPays>.2161</amountMOHLTCPays>
							</drug>
							<drug id="02486377" chronicUseMed="Y" sec3="Y">
								<name>Mint-Telmisartan</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.2161</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>.2161</amountMOHLTCPays>
							</drug>
							<drug id="02499630" chronicUseMed="Y" sec3="Y">
								<name>PMS-Telmisartan</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2161</individualPrice>
								<listingDate>2021-05-31</listingDate>
								<amountMOHLTCPays>.2161</amountMOHLTCPays>
							</drug>
							<drug id="02503808" chronicUseMed="Y" sec3="Y">
								<name>NRA-Telmisartan</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.2161</individualPrice>
								<listingDate>2022-02-28</listingDate>
								<amountMOHLTCPays>.2161</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01875">
					<name>TELMISARTAN &amp; AMLODIPINE BESYLATE</name>
					<pcgGroup>
						<pcg9 id="240800298">
							<itemNumber>0767</itemNumber>
							<strength>40mg &amp; 10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02371030" chronicUseMed="Y" sec3="Y">
								<name>Twynsta</name>
								<manufacturerId>BOE</manufacturerId>
								<individualPrice>.7296</individualPrice>
								<listingDate>2012-02-29</listingDate>
								<amountMOHLTCPays>.7296</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800296">
							<itemNumber>0768</itemNumber>
							<strength>40mg &amp; 5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02371022" chronicUseMed="Y" sec3="Y">
								<name>Twynsta</name>
								<manufacturerId>BOE</manufacturerId>
								<individualPrice>.7296</individualPrice>
								<listingDate>2012-02-29</listingDate>
								<amountMOHLTCPays>.7296</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800299">
							<itemNumber>0769</itemNumber>
							<strength>80mg &amp; 10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02371057" chronicUseMed="Y" sec3="Y">
								<name>Twynsta</name>
								<manufacturerId>BOE</manufacturerId>
								<individualPrice>.7296</individualPrice>
								<listingDate>2012-02-29</listingDate>
								<amountMOHLTCPays>.5472</amountMOHLTCPays>
							</drug>
							<drug id="02473496" chronicUseMed="Y" sec3="Y">
								<name>AA-Telmisartan-Amlodipine</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.5472</individualPrice>
								<listingDate>2022-01-31</listingDate>
								<amountMOHLTCPays>.5472</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800297">
							<itemNumber>0770</itemNumber>
							<strength>80mg &amp; 5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02371049" chronicUseMed="Y" sec3="Y">
								<name>Twynsta</name>
								<manufacturerId>BOE</manufacturerId>
								<individualPrice>.7296</individualPrice>
								<listingDate>2012-02-29</listingDate>
								<amountMOHLTCPays>.5472</amountMOHLTCPays>
							</drug>
							<drug id="02473488" chronicUseMed="Y" sec3="Y">
								<name>AA-Telmisartan-Amlodipine</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.5472</individualPrice>
								<listingDate>2022-01-31</listingDate>
								<amountMOHLTCPays>.5472</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01559">
					<name>TELMISARTAN &amp; HYDROCHLOROTHIAZIDE</name>
					<pcgGroup>
						<pcg9 id="240800249">
							<itemNumber>0771</itemNumber>
							<strength>80mg &amp; 12.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02244344" chronicUseMed="Y" sec3="Y">
								<name>Micardis Plus</name>
								<manufacturerId>BOE</manufacturerId>
								<individualPrice>1.2474</individualPrice>
								<listingDate>2002-07-29</listingDate>
								<amountMOHLTCPays>.2098</amountMOHLTCPays>
							</drug>
							<drug id="02330288" chronicUseMed="Y" sec3="Y">
								<name>Teva-Telmisartan HCTZ</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2098</individualPrice>
								<listingDate>2012-04-24</listingDate>
								<amountMOHLTCPays>.2098</amountMOHLTCPays>
							</drug>
							<drug id="02389940" chronicUseMed="Y" sec3="Y">
								<name>Jamp Telmisartan-HCT</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2098</individualPrice>
								<listingDate>2021-03-29</listingDate>
								<amountMOHLTCPays>.2098</amountMOHLTCPays>
							</drug>
							<drug id="02390302" chronicUseMed="Y" sec3="Y">
								<name>Telmisartan HCTZ</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2098</individualPrice>
								<listingDate>2020-12-18</listingDate>
								<amountMOHLTCPays>.2098</amountMOHLTCPays>
							</drug>
							<drug id="02393263" chronicUseMed="Y" sec3="Y">
								<name>Co Telmisartan/HCT</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.2098</individualPrice>
								<listingDate>2012-11-27</listingDate>
								<amountMOHLTCPays>.2098</amountMOHLTCPays>
							</drug>
							<drug id="02393557" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Telmisartan HCT</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2098</individualPrice>
								<listingDate>2012-11-27</listingDate>
								<amountMOHLTCPays>.2098</amountMOHLTCPays>
							</drug>
							<drug id="02395355" chronicUseMed="Y" sec3="Y">
								<name>Telmisartan/HCTZ</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2098</individualPrice>
								<listingDate>2020-09-30</listingDate>
								<amountMOHLTCPays>.2098</amountMOHLTCPays>
							</drug>
							<drug id="02419114" chronicUseMed="Y" sec3="Y">
								<name>Telmisartan and Hydrochlorothiazide Tab</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.2098</individualPrice>
								<listingDate>2014-09-25</listingDate>
								<amountMOHLTCPays>.2098</amountMOHLTCPays>
							</drug>
							<drug id="02420023" chronicUseMed="Y" sec3="Y">
								<name>Apo-Telmisartan/HCTZ</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2098</individualPrice>
								<listingDate>2014-03-27</listingDate>
								<amountMOHLTCPays>.2098</amountMOHLTCPays>
							</drug>
							<drug id="02456389" chronicUseMed="Y" sec3="Y">
								<name>Auro-Telmisartan HCTZ</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2098</individualPrice>
								<listingDate>2016-12-22</listingDate>
								<amountMOHLTCPays>.2098</amountMOHLTCPays>
							</drug>
							<drug id="02504146" chronicUseMed="Y" sec3="Y">
								<name>NRA-Telmisartan HCTZ</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.2098</individualPrice>
								<listingDate>2021-05-31</listingDate>
								<amountMOHLTCPays>.2098</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800281">
							<itemNumber>0772</itemNumber>
							<strength>80mg &amp; 25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02318709" chronicUseMed="Y" sec3="Y">
								<name>Micardis Plus</name>
								<manufacturerId>BOE</manufacturerId>
								<individualPrice>1.2474</individualPrice>
								<listingDate>2009-11-13</listingDate>
								<amountMOHLTCPays>.2098</amountMOHLTCPays>
							</drug>
							<drug id="02379252" chronicUseMed="Y" sec3="Y">
								<name>Teva-Telmisartan HCTZ</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2098</individualPrice>
								<listingDate>2012-04-24</listingDate>
								<amountMOHLTCPays>.2098</amountMOHLTCPays>
							</drug>
							<drug id="02389959" chronicUseMed="Y" sec3="Y">
								<name>Jamp Telmisartan-HCT</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2098</individualPrice>
								<listingDate>2021-03-29</listingDate>
								<amountMOHLTCPays>.2098</amountMOHLTCPays>
							</drug>
							<drug id="02390310" chronicUseMed="Y" sec3="Y">
								<name>Telmisartan HCTZ</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2098</individualPrice>
								<listingDate>2020-12-18</listingDate>
								<amountMOHLTCPays>.2098</amountMOHLTCPays>
							</drug>
							<drug id="02393271" chronicUseMed="Y" sec3="Y">
								<name>Co Telmisartan/HCT</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.2098</individualPrice>
								<listingDate>2012-11-27</listingDate>
								<amountMOHLTCPays>.2098</amountMOHLTCPays>
							</drug>
							<drug id="02393565" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Telmisartan HCT</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2098</individualPrice>
								<listingDate>2012-11-27</listingDate>
								<amountMOHLTCPays>.2098</amountMOHLTCPays>
							</drug>
							<drug id="02395363" chronicUseMed="Y" sec3="Y">
								<name>Telmisartan/HCTZ</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2098</individualPrice>
								<listingDate>2020-09-30</listingDate>
								<amountMOHLTCPays>.2098</amountMOHLTCPays>
							</drug>
							<drug id="02419122" chronicUseMed="Y" sec3="Y">
								<name>Telmisartan and Hydrochlorothiazide Tab</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.2098</individualPrice>
								<listingDate>2014-09-25</listingDate>
								<amountMOHLTCPays>.2098</amountMOHLTCPays>
							</drug>
							<drug id="02420031" chronicUseMed="Y" sec3="Y">
								<name>Apo-Telmisartan/HCTZ</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2098</individualPrice>
								<listingDate>2014-03-27</listingDate>
								<amountMOHLTCPays>.2098</amountMOHLTCPays>
							</drug>
							<drug id="02456397" chronicUseMed="Y" sec3="Y">
								<name>Auro-Telmisartan HCTZ</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2098</individualPrice>
								<listingDate>2016-12-22</listingDate>
								<amountMOHLTCPays>.2098</amountMOHLTCPays>
							</drug>
							<drug id="02504138" chronicUseMed="Y" sec3="Y">
								<name>NRA-Telmisartan HCTZ</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.2098</individualPrice>
								<listingDate>2021-05-31</listingDate>
								<amountMOHLTCPays>.2098</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00370">
					<name>TERAZOSIN HCL</name>
					<pcgGroup>
						<pcg9 id="240800131">
							<itemNumber>0773</itemNumber>
							<strength>1mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.1835</dailyCost>
							<drug id="00818658" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Hytrin</name>
								<manufacturerId>ABB</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02230805" chronicUseMed="Y" sec3="Y">
								<name>Teva-Terazosin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1835</individualPrice>
								<dailyCost>.1835</dailyCost>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>.1835</amountMOHLTCPays>
							</drug>
							<drug id="02234502" chronicUseMed="Y" sec3="Y">
								<name>Apo-Terazosin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1835</individualPrice>
								<dailyCost>.1835</dailyCost>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.1835</amountMOHLTCPays>
							</drug>
							<drug id="02243518" chronicUseMed="Y" sec3="Y">
								<name>PMS-Terazosin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1835</individualPrice>
								<dailyCost>.1835</dailyCost>
								<listingDate>2001-10-11</listingDate>
								<amountMOHLTCPays>.1835</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800132">
							<itemNumber>0774</itemNumber>
							<strength>2mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.2333</dailyCost>
							<drug id="00818682" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Hytrin</name>
								<manufacturerId>ABB</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02230806" chronicUseMed="Y" sec3="Y">
								<name>Teva-Terazosin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2333</individualPrice>
								<dailyCost>.2333</dailyCost>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>.2333</amountMOHLTCPays>
							</drug>
							<drug id="02234503" chronicUseMed="Y" sec3="Y">
								<name>Apo-Terazosin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2333</individualPrice>
								<dailyCost>.2333</dailyCost>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.2333</amountMOHLTCPays>
							</drug>
							<drug id="02243519" chronicUseMed="Y" sec3="Y">
								<name>PMS-Terazosin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2333</individualPrice>
								<dailyCost>.2333</dailyCost>
								<listingDate>2001-10-11</listingDate>
								<amountMOHLTCPays>.2333</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800133">
							<itemNumber>0775</itemNumber>
							<strength>5mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.3168</dailyCost>
							<drug id="00818666" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Hytrin</name>
								<manufacturerId>ABB</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02230807" chronicUseMed="Y" sec3="Y">
								<name>Teva-Terazosin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3168</individualPrice>
								<dailyCost>.3168</dailyCost>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>.3168</amountMOHLTCPays>
							</drug>
							<drug id="02234504" chronicUseMed="Y" sec3="Y">
								<name>Apo-Terazosin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3168</individualPrice>
								<dailyCost>.3168</dailyCost>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.3168</amountMOHLTCPays>
							</drug>
							<drug id="02243520" chronicUseMed="Y" sec3="Y">
								<name>PMS-Terazosin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3168</individualPrice>
								<dailyCost>.3168</dailyCost>
								<listingDate>2001-10-11</listingDate>
								<amountMOHLTCPays>.3168</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800213">
							<itemNumber>0776</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<dailyCost>.4637</dailyCost>
							<drug id="00818674" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Hytrin</name>
								<manufacturerId>ABB</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02230808" chronicUseMed="Y" sec3="Y">
								<name>Teva-Terazosin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.4637</individualPrice>
								<dailyCost>.4637</dailyCost>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>.4637</amountMOHLTCPays>
							</drug>
							<drug id="02234505" chronicUseMed="Y" sec3="Y">
								<name>Apo-Terazosin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.4637</individualPrice>
								<dailyCost>.4637</dailyCost>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.4637</amountMOHLTCPays>
							</drug>
							<drug id="02243521" chronicUseMed="Y" sec3="Y">
								<name>PMS-Terazosin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.4637</individualPrice>
								<dailyCost>.4637</dailyCost>
								<listingDate>2001-10-11</listingDate>
								<amountMOHLTCPays>.4637</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01398">
					<name>TRANDOLAPRIL</name>
					<pcgGroup>
						<pcg9 id="240800303">
							<itemNumber>0777</itemNumber>
							<strength>0.5mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02231457" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mavik</name>
								<manufacturerId>BGP</manufacturerId>
								<listingDate>2018-07-31</listingDate>
							</drug>
							<drug id="02325721" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Sandoz Trandolapril</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2372</individualPrice>
								<listingDate>2018-09-27</listingDate>
							</drug>
							<drug id="02357755" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>PMS-Trandolapril</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2372</individualPrice>
								<listingDate>2018-07-31</listingDate>
							</drug>
							<drug id="02415429" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Teva-Trandolapril</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2372</individualPrice>
								<listingDate>2018-11-29</listingDate>
							</drug>
							<drug id="02471868" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Auro-Trandolapril</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2372</individualPrice>
								<listingDate>2018-11-29</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="240800228">
							<itemNumber>0778</itemNumber>
							<strength>1mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02231459" chronicUseMed="Y" sec3="Y">
								<name>Mavik</name>
								<manufacturerId>BGP</manufacturerId>
								<individualPrice>.7191</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.1762</amountMOHLTCPays>
							</drug>
							<drug id="02325748" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Trandolapril</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.1762</individualPrice>
								<listingDate>2018-09-27</listingDate>
								<amountMOHLTCPays>.1762</amountMOHLTCPays>
							</drug>
							<drug id="02357763" chronicUseMed="Y" sec3="Y">
								<name>PMS-Trandolapril</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1762</individualPrice>
								<listingDate>2018-07-31</listingDate>
								<amountMOHLTCPays>.1762</amountMOHLTCPays>
							</drug>
							<drug id="02415437" chronicUseMed="Y" sec3="Y">
								<name>Teva-Trandolapril</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1762</individualPrice>
								<listingDate>2018-11-29</listingDate>
								<amountMOHLTCPays>.1762</amountMOHLTCPays>
							</drug>
							<drug id="02471876" chronicUseMed="Y" sec3="Y">
								<name>Auro-Trandolapril</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.1762</individualPrice>
								<listingDate>2018-11-29</listingDate>
								<amountMOHLTCPays>.1762</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800229">
							<itemNumber>0779</itemNumber>
							<strength>2mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02231460" chronicUseMed="Y" sec3="Y">
								<name>Mavik</name>
								<manufacturerId>BGP</manufacturerId>
								<individualPrice>.8264</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.2025</amountMOHLTCPays>
							</drug>
							<drug id="02325756" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Trandolapril</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2025</individualPrice>
								<listingDate>2018-09-27</listingDate>
								<amountMOHLTCPays>.2025</amountMOHLTCPays>
							</drug>
							<drug id="02357771" chronicUseMed="Y" sec3="Y">
								<name>PMS-Trandolapril</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2025</individualPrice>
								<listingDate>2018-07-31</listingDate>
								<amountMOHLTCPays>.2025</amountMOHLTCPays>
							</drug>
							<drug id="02415445" chronicUseMed="Y" sec3="Y">
								<name>Teva-Trandolapril</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2025</individualPrice>
								<listingDate>2018-11-29</listingDate>
								<amountMOHLTCPays>.2025</amountMOHLTCPays>
							</drug>
							<drug id="02471884" chronicUseMed="Y" sec3="Y">
								<name>Auro-Trandolapril</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2025</individualPrice>
								<listingDate>2018-11-29</listingDate>
								<amountMOHLTCPays>.2025</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800258">
							<itemNumber>0780</itemNumber>
							<strength>4mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02239267" chronicUseMed="Y" sec3="Y">
								<name>Mavik</name>
								<manufacturerId>BGP</manufacturerId>
								<individualPrice>1.0196</individualPrice>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.2498</amountMOHLTCPays>
							</drug>
							<drug id="02325764" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Trandolapril</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2498</individualPrice>
								<listingDate>2018-09-27</listingDate>
								<amountMOHLTCPays>.2498</amountMOHLTCPays>
							</drug>
							<drug id="02357798" chronicUseMed="Y" sec3="Y">
								<name>PMS-Trandolapril</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2498</individualPrice>
								<listingDate>2018-07-31</listingDate>
								<amountMOHLTCPays>.2498</amountMOHLTCPays>
							</drug>
							<drug id="02415453" chronicUseMed="Y" sec3="Y">
								<name>Teva-Trandolapril</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2498</individualPrice>
								<listingDate>2018-11-29</listingDate>
								<amountMOHLTCPays>.2498</amountMOHLTCPays>
							</drug>
							<drug id="02471892" chronicUseMed="Y" sec3="Y">
								<name>Auro-Trandolapril</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2498</individualPrice>
								<listingDate>2018-11-29</listingDate>
								<amountMOHLTCPays>.2498</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01362">
					<name>VALSARTAN</name>
					<pcgGroup>
						<pcg9 id="240800295">
							<itemNumber>0781</itemNumber>
							<strength>40mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02270528" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Diovan</name>
								<manufacturerId>NOV</manufacturerId>
								<listingDate>2011-06-08</listingDate>
							</drug>
							<drug id="02337487" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Co Valsartan</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.5823</individualPrice>
								<listingDate>2011-08-04</listingDate>
							</drug>
							<drug id="02356643" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Teva-Valsartan</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.5823</individualPrice>
								<listingDate>2011-06-08</listingDate>
							</drug>
							<drug id="02356740" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Sandoz Valsartan</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.5823</individualPrice>
								<listingDate>2011-08-04</listingDate>
							</drug>
							<drug id="02363062" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Taro-Valsartan</name>
								<manufacturerId>SPC</manufacturerId>
								<individualPrice>.5823</individualPrice>
								<listingDate>2011-06-08</listingDate>
							</drug>
							<drug id="02366940" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Valsartan</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.5823</individualPrice>
								<listingDate>2020-10-30</listingDate>
							</drug>
							<drug id="02371510" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Valsartan</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.5823</individualPrice>
								<listingDate>2011-12-15</listingDate>
							</drug>
							<drug id="02384523" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Valsartan</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.5823</individualPrice>
								<listingDate>2021-09-30</listingDate>
							</drug>
							<drug id="02414201" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Auro-Valsartan</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.5823</individualPrice>
								<listingDate>2014-08-28</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="240800254">
							<itemNumber>0782</itemNumber>
							<strength>80mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02244781" chronicUseMed="Y" sec3="Y">
								<name>Diovan</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>1.3325</individualPrice>
								<listingDate>2003-09-04</listingDate>
								<amountMOHLTCPays>.2159</amountMOHLTCPays>
							</drug>
							<drug id="02337495" chronicUseMed="Y" sec3="Y">
								<name>Co Valsartan</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.2159</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2159</amountMOHLTCPays>
							</drug>
							<drug id="02356651" chronicUseMed="Y" sec3="Y">
								<name>Teva-Valsartan</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2159</individualPrice>
								<listingDate>2011-06-08</listingDate>
								<amountMOHLTCPays>.2159</amountMOHLTCPays>
							</drug>
							<drug id="02356759" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Valsartan</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2159</individualPrice>
								<listingDate>2011-06-08</listingDate>
								<amountMOHLTCPays>.2159</amountMOHLTCPays>
							</drug>
							<drug id="02363100" chronicUseMed="Y" sec3="Y">
								<name>Taro-Valsartan</name>
								<manufacturerId>SPC</manufacturerId>
								<individualPrice>.2159</individualPrice>
								<listingDate>2011-06-08</listingDate>
								<amountMOHLTCPays>.2159</amountMOHLTCPays>
							</drug>
							<drug id="02366959" chronicUseMed="Y" sec3="Y">
								<name>Valsartan</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2159</individualPrice>
								<listingDate>2020-09-30</listingDate>
								<amountMOHLTCPays>.2159</amountMOHLTCPays>
							</drug>
							<drug id="02371529" chronicUseMed="Y" sec3="Y">
								<name>Apo-Valsartan</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2159</individualPrice>
								<listingDate>2011-12-15</listingDate>
								<amountMOHLTCPays>.2159</amountMOHLTCPays>
							</drug>
							<drug id="02384531" chronicUseMed="Y" sec3="Y">
								<name>Valsartan</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2159</individualPrice>
								<listingDate>2021-09-30</listingDate>
								<amountMOHLTCPays>.2159</amountMOHLTCPays>
							</drug>
							<drug id="02414228" chronicUseMed="Y" sec3="Y">
								<name>Auro-Valsartan</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2159</individualPrice>
								<listingDate>2014-05-29</listingDate>
								<amountMOHLTCPays>.2159</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800255">
							<itemNumber>0783</itemNumber>
							<strength>160mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02244782" chronicUseMed="Y" sec3="Y">
								<name>Diovan</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>1.3275</individualPrice>
								<listingDate>2003-09-04</listingDate>
								<amountMOHLTCPays>.2159</amountMOHLTCPays>
							</drug>
							<drug id="02337509" chronicUseMed="Y" sec3="Y">
								<name>Co Valsartan</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.2159</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2159</amountMOHLTCPays>
							</drug>
							<drug id="02356678" chronicUseMed="Y" sec3="Y">
								<name>Teva-Valsartan</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2159</individualPrice>
								<listingDate>2011-06-08</listingDate>
								<amountMOHLTCPays>.2159</amountMOHLTCPays>
							</drug>
							<drug id="02356767" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Valsartan</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2159</individualPrice>
								<listingDate>2011-06-08</listingDate>
								<amountMOHLTCPays>.2159</amountMOHLTCPays>
							</drug>
							<drug id="02363119" chronicUseMed="Y" sec3="Y">
								<name>Taro-Valsartan</name>
								<manufacturerId>SPC</manufacturerId>
								<individualPrice>.2159</individualPrice>
								<listingDate>2011-06-08</listingDate>
								<amountMOHLTCPays>.2159</amountMOHLTCPays>
							</drug>
							<drug id="02366967" chronicUseMed="Y" sec3="Y">
								<name>Valsartan</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2159</individualPrice>
								<listingDate>2020-09-30</listingDate>
								<amountMOHLTCPays>.2159</amountMOHLTCPays>
							</drug>
							<drug id="02371537" chronicUseMed="Y" sec3="Y">
								<name>Apo-Valsartan</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2159</individualPrice>
								<listingDate>2011-12-15</listingDate>
								<amountMOHLTCPays>.2159</amountMOHLTCPays>
							</drug>
							<drug id="02384558" chronicUseMed="Y" sec3="Y">
								<name>Valsartan</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2159</individualPrice>
								<listingDate>2021-09-30</listingDate>
								<amountMOHLTCPays>.2159</amountMOHLTCPays>
							</drug>
							<drug id="02414236" chronicUseMed="Y" sec3="Y">
								<name>Auro-Valsartan</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2159</individualPrice>
								<listingDate>2014-05-29</listingDate>
								<amountMOHLTCPays>.2159</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800272">
							<itemNumber>0784</itemNumber>
							<strength>320mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02289504" chronicUseMed="Y" sec3="Y">
								<name>Diovan</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>1.2925</individualPrice>
								<listingDate>2008-02-12</listingDate>
								<amountMOHLTCPays>.2098</amountMOHLTCPays>
							</drug>
							<drug id="02337517" chronicUseMed="Y" sec3="Y">
								<name>Co Valsartan</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.2098</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2098</amountMOHLTCPays>
							</drug>
							<drug id="02356686" chronicUseMed="Y" sec3="Y">
								<name>Teva-Valsartan</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2098</individualPrice>
								<listingDate>2011-06-08</listingDate>
								<amountMOHLTCPays>.2098</amountMOHLTCPays>
							</drug>
							<drug id="02356775" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Valsartan</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2098</individualPrice>
								<listingDate>2011-06-08</listingDate>
								<amountMOHLTCPays>.2098</amountMOHLTCPays>
							</drug>
							<drug id="02366975" chronicUseMed="Y" sec3="Y">
								<name>Valsartan</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2098</individualPrice>
								<listingDate>2020-09-30</listingDate>
								<amountMOHLTCPays>.2098</amountMOHLTCPays>
							</drug>
							<drug id="02371545" chronicUseMed="Y" sec3="Y">
								<name>Apo-Valsartan</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2098</individualPrice>
								<listingDate>2011-12-15</listingDate>
								<amountMOHLTCPays>.2098</amountMOHLTCPays>
							</drug>
							<drug id="02384566" chronicUseMed="Y" sec3="Y">
								<name>Valsartan</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2098</individualPrice>
								<listingDate>2021-09-30</listingDate>
								<amountMOHLTCPays>.2098</amountMOHLTCPays>
							</drug>
							<drug id="02414244" chronicUseMed="Y" sec3="Y">
								<name>Auro-Valsartan</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2098</individualPrice>
								<listingDate>2014-05-29</listingDate>
								<amountMOHLTCPays>.2098</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01490">
					<name>VALSARTAN &amp; HYDROCHLOROTHIAZIDE</name>
					<pcgGroup>
						<pcg9 id="240800244">
							<itemNumber>0785</itemNumber>
							<strength>80mg &amp; 12.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02241900" chronicUseMed="Y" sec3="Y">
								<name>Diovan-HCT</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>1.3200</individualPrice>
								<listingDate>2001-03-07</listingDate>
								<amountMOHLTCPays>.2213</amountMOHLTCPays>
							</drug>
							<drug id="02356694" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Valsartan HCT</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2213</individualPrice>
								<listingDate>2011-06-08</listingDate>
								<amountMOHLTCPays>.2213</amountMOHLTCPays>
							</drug>
							<drug id="02356996" chronicUseMed="Y" sec3="Y">
								<name>Teva-Valsartan/HCTZ</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2213</individualPrice>
								<listingDate>2011-06-08</listingDate>
								<amountMOHLTCPays>.2213</amountMOHLTCPays>
							</drug>
							<drug id="02367009" chronicUseMed="Y" sec3="Y">
								<name>Valsartan HCT</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2213</individualPrice>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>.2213</amountMOHLTCPays>
							</drug>
							<drug id="02382547" chronicUseMed="Y" sec3="Y">
								<name>Apo-Valsartan/HCTZ</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2213</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.2213</amountMOHLTCPays>
							</drug>
							<drug id="02384736" chronicUseMed="Y" sec3="Y">
								<name>Valsartan HCT</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2213</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>.2213</amountMOHLTCPays>
							</drug>
							<drug id="02408112" chronicUseMed="Y" sec3="Y">
								<name>Auro-Valsartan HCT</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2213</individualPrice>
								<listingDate>2013-08-29</listingDate>
								<amountMOHLTCPays>.2213</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800245">
							<itemNumber>0786</itemNumber>
							<strength>160mg &amp; 12.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02241901" chronicUseMed="Y" sec3="Y">
								<name>Diovan-HCT</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>1.3350</individualPrice>
								<listingDate>2001-03-07</listingDate>
								<amountMOHLTCPays>.2240</amountMOHLTCPays>
							</drug>
							<drug id="02356708" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Valsartan HCT</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2240</individualPrice>
								<listingDate>2011-06-08</listingDate>
								<amountMOHLTCPays>.2240</amountMOHLTCPays>
							</drug>
							<drug id="02357003" chronicUseMed="Y" sec3="Y">
								<name>Teva-Valsartan/HCTZ</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2240</individualPrice>
								<listingDate>2011-06-08</listingDate>
								<amountMOHLTCPays>.2240</amountMOHLTCPays>
							</drug>
							<drug id="02367017" chronicUseMed="Y" sec3="Y">
								<name>Valsartan HCT</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2240</individualPrice>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>.2240</amountMOHLTCPays>
							</drug>
							<drug id="02382555" chronicUseMed="Y" sec3="Y">
								<name>Apo-Valsartan/HCTZ</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2240</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.2240</amountMOHLTCPays>
							</drug>
							<drug id="02384744" chronicUseMed="Y" sec3="Y">
								<name>Valsartan HCT</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2240</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>.2240</amountMOHLTCPays>
							</drug>
							<drug id="02408120" chronicUseMed="Y" sec3="Y">
								<name>Auro-Valsartan HCT</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2240</individualPrice>
								<listingDate>2013-08-29</listingDate>
								<amountMOHLTCPays>.2240</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800253">
							<itemNumber>0787</itemNumber>
							<strength>160mg &amp; 25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02246955" chronicUseMed="Y" sec3="Y">
								<name>Diovan-HCT</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>1.3350</individualPrice>
								<listingDate>2003-09-04</listingDate>
								<amountMOHLTCPays>.2238</amountMOHLTCPays>
							</drug>
							<drug id="02356716" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Valsartan HCT</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2238</individualPrice>
								<listingDate>2011-06-08</listingDate>
								<amountMOHLTCPays>.2238</amountMOHLTCPays>
							</drug>
							<drug id="02357011" chronicUseMed="Y" sec3="Y">
								<name>Teva-Valsartan/HCTZ</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2238</individualPrice>
								<listingDate>2011-06-08</listingDate>
								<amountMOHLTCPays>.2238</amountMOHLTCPays>
							</drug>
							<drug id="02367025" chronicUseMed="Y" sec3="Y">
								<name>Valsartan HCT</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2238</individualPrice>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>.2238</amountMOHLTCPays>
							</drug>
							<drug id="02382563" chronicUseMed="Y" sec3="Y">
								<name>Apo-Valsartan/HCTZ</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2238</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.2238</amountMOHLTCPays>
							</drug>
							<drug id="02384752" chronicUseMed="Y" sec3="Y">
								<name>Valsartan HCT</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2238</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>.2238</amountMOHLTCPays>
							</drug>
							<drug id="02408139" chronicUseMed="Y" sec3="Y">
								<name>Auro-Valsartan HCT</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2238</individualPrice>
								<listingDate>2013-08-29</listingDate>
								<amountMOHLTCPays>.2238</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800277">
							<itemNumber>0788</itemNumber>
							<strength>320mg &amp; 12.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02308908" chronicUseMed="Y" sec3="Y">
								<name>Diovan-HCT</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>1.3325</individualPrice>
								<listingDate>2009-03-02</listingDate>
								<amountMOHLTCPays>.2235</amountMOHLTCPays>
							</drug>
							<drug id="02356724" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Valsartan HCT</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2235</individualPrice>
								<listingDate>2011-06-08</listingDate>
								<amountMOHLTCPays>.2235</amountMOHLTCPays>
							</drug>
							<drug id="02357038" chronicUseMed="Y" sec3="Y">
								<name>Teva-Valsartan/HCTZ</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2235</individualPrice>
								<listingDate>2011-06-08</listingDate>
								<amountMOHLTCPays>.2235</amountMOHLTCPays>
							</drug>
							<drug id="02367033" chronicUseMed="Y" sec3="Y">
								<name>Valsartan HCT</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2235</individualPrice>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>.2235</amountMOHLTCPays>
							</drug>
							<drug id="02382571" chronicUseMed="Y" sec3="Y">
								<name>Apo-Valsartan/HCTZ</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2235</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.2235</amountMOHLTCPays>
							</drug>
							<drug id="02384760" chronicUseMed="Y" sec3="Y">
								<name>Valsartan HCT</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2235</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>.2235</amountMOHLTCPays>
							</drug>
							<drug id="02408147" chronicUseMed="Y" sec3="Y">
								<name>Auro-Valsartan HCT</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2235</individualPrice>
								<listingDate>2013-08-29</listingDate>
								<amountMOHLTCPays>.2235</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800278">
							<itemNumber>0789</itemNumber>
							<strength>320mg &amp; 25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02308916" chronicUseMed="Y" sec3="Y">
								<name>Diovan-HCT</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>1.3300</individualPrice>
								<listingDate>2009-03-02</listingDate>
								<amountMOHLTCPays>.2231</amountMOHLTCPays>
							</drug>
							<drug id="02356732" chronicUseMed="Y" sec3="Y">
								<name>Sandoz Valsartan HCT</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2231</individualPrice>
								<listingDate>2011-06-08</listingDate>
								<amountMOHLTCPays>.2231</amountMOHLTCPays>
							</drug>
							<drug id="02357046" chronicUseMed="Y" sec3="Y">
								<name>Teva-Valsartan/HCTZ</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2231</individualPrice>
								<listingDate>2011-06-08</listingDate>
								<amountMOHLTCPays>.2231</amountMOHLTCPays>
							</drug>
							<drug id="02367041" chronicUseMed="Y" sec3="Y">
								<name>Valsartan HCT</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2231</individualPrice>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>.2231</amountMOHLTCPays>
							</drug>
							<drug id="02382598" chronicUseMed="Y" sec3="Y">
								<name>Apo-Valsartan/HCTZ</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2231</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.2231</amountMOHLTCPays>
							</drug>
							<drug id="02408155" chronicUseMed="Y" sec3="Y">
								<name>Auro-Valsartan HCT</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2231</individualPrice>
								<listingDate>2013-08-29</listingDate>
								<amountMOHLTCPays>.2231</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00319">
					<name>VERAPAMIL HCL</name>
					<pcgGroup>
						<pcg9 id="240800271">
							<itemNumber>0790</itemNumber>
							<strength>120mg</strength>
							<dosageForm>LA Tab</dosageForm>
							<drug id="01907123" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Isoptin SR</name>
								<manufacturerId>BGP</manufacturerId>
								<listingDate>2007-09-04</listingDate>
							</drug>
							<drug id="02210347" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mylan-Verapamil SR</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.6900</individualPrice>
								<listingDate>2007-10-03</listingDate>
							</drug>
							<drug id="02246893" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Verap SR</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.6900</individualPrice>
								<listingDate>2007-09-04</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="240800197">
							<itemNumber>0791</itemNumber>
							<strength>180mg</strength>
							<dosageForm>LA Tab</dosageForm>
							<dailyCost>.5204</dailyCost>
							<drug id="01934317" chronicUseMed="Y" sec3="Y">
								<name>Isoptin SR</name>
								<manufacturerId>BGP</manufacturerId>
								<individualPrice>1.8426</individualPrice>
								<dailyCost>1.8426</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.5204</amountMOHLTCPays>
							</drug>
							<drug id="02246894" chronicUseMed="Y" sec3="Y">
								<name>Apo-Verap SR</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.5204</individualPrice>
								<dailyCost>.5204</dailyCost>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.5204</amountMOHLTCPays>
							</drug>
							<drug id="02450488" chronicUseMed="Y" sec3="Y">
								<name>Mylan-Verapamil SR</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.5204</individualPrice>
								<dailyCost>.5204</dailyCost>
								<listingDate>2016-11-30</listingDate>
								<amountMOHLTCPays>.5204</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240800128">
							<itemNumber>0792</itemNumber>
							<strength>240mg</strength>
							<dosageForm>LA Tab</dosageForm>
							<dailyCost>1.7143</dailyCost>
							<drug id="00742554" chronicUseMed="Y" sec3="Y">
								<name>Isoptin SR</name>
								<manufacturerId>BGP</manufacturerId>
								<individualPrice>2.4572</individualPrice>
								<dailyCost>2.4572</dailyCost>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>1.7143</amountMOHLTCPays>
							</drug>
							<drug id="02450496" chronicUseMed="Y" sec3="Y">
								<name>Mylan-Verapamil SR</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>1.7143</individualPrice>
								<dailyCost>1.7143</dailyCost>
								<listingDate>2016-10-27</listingDate>
								<amountMOHLTCPays>1.7143</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="240816000">
				<name>HYPOTENSIVE DRUGS (FOR DIURETICS SEE 40:28) CENTRAL ALPHA-AGONISTS</name>
				<genericName id="02117">
					<name>GUANFACINE</name>
					<pcgGroup lccId="00326">
						<pcg9 id="240816001">
							<itemNumber>0793</itemNumber>
							<strength>1mg</strength>
							<dosageForm>ER Tab</dosageForm>
							<drug id="02409100" sec3="Y" sec12="Y">
								<name>Intuniv XR</name>
								<manufacturerId>TAK</manufacturerId>
								<individualPrice>3.0750</individualPrice>
								<listingDate>2020-01-31</listingDate>
								<amountMOHLTCPays>1.5375</amountMOHLTCPays>
							</drug>
							<drug id="02523558" sec3="Y" sec12="Y">
								<name>Jamp Guanfacine XR</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>1.5375</individualPrice>
								<listingDate>2022-03-31</listingDate>
								<amountMOHLTCPays>1.5375</amountMOHLTCPays>
							</drug>
							<drug id="02523728" sec3="Y" sec12="Y">
								<name>Apo-Guanfacine XR</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.5375</individualPrice>
								<listingDate>2022-03-31</listingDate>
								<amountMOHLTCPays>1.5375</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240816002">
							<itemNumber>0794</itemNumber>
							<strength>2mg</strength>
							<dosageForm>ER Tab</dosageForm>
							<drug id="02409119" sec3="Y" sec12="Y">
								<name>Intuniv XR</name>
								<manufacturerId>TAK</manufacturerId>
								<individualPrice>3.7413</individualPrice>
								<listingDate>2020-01-31</listingDate>
								<amountMOHLTCPays>1.8707</amountMOHLTCPays>
							</drug>
							<drug id="02523566" sec3="Y" sec12="Y">
								<name>Jamp Guanfacine XR</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>1.8707</individualPrice>
								<listingDate>2022-03-31</listingDate>
								<amountMOHLTCPays>1.8707</amountMOHLTCPays>
							</drug>
							<drug id="02523736" sec3="Y" sec12="Y">
								<name>Apo-Guanfacine XR</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.8707</individualPrice>
								<listingDate>2022-03-31</listingDate>
								<amountMOHLTCPays>1.8707</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240816003">
							<itemNumber>0795</itemNumber>
							<strength>3mg</strength>
							<dosageForm>ER Tab</dosageForm>
							<drug id="02409127" sec3="Y" sec12="Y">
								<name>Intuniv XR</name>
								<manufacturerId>TAK</manufacturerId>
								<individualPrice>4.4075</individualPrice>
								<listingDate>2020-01-31</listingDate>
								<amountMOHLTCPays>2.2038</amountMOHLTCPays>
							</drug>
							<drug id="02523574" sec3="Y" sec12="Y">
								<name>Jamp Guanfacine XR</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>2.2038</individualPrice>
								<listingDate>2022-03-31</listingDate>
								<amountMOHLTCPays>2.2038</amountMOHLTCPays>
							</drug>
							<drug id="02523744" sec3="Y" sec12="Y">
								<name>Apo-Guanfacine XR</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>2.2038</individualPrice>
								<listingDate>2022-03-31</listingDate>
								<amountMOHLTCPays>2.2038</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="240816004">
							<itemNumber>0796</itemNumber>
							<strength>4mg</strength>
							<dosageForm>ER Tab</dosageForm>
							<drug id="02409135" sec3="Y" sec12="Y">
								<name>Intuniv XR</name>
								<manufacturerId>TAK</manufacturerId>
								<individualPrice>5.0738</individualPrice>
								<listingDate>2020-01-31</listingDate>
								<amountMOHLTCPays>2.5369</amountMOHLTCPays>
							</drug>
							<drug id="02523582" sec3="Y" sec12="Y">
								<name>Jamp Guanfacine XR</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>2.5369</individualPrice>
								<listingDate>2022-03-31</listingDate>
								<amountMOHLTCPays>2.5369</amountMOHLTCPays>
							</drug>
							<drug id="02523752" sec3="Y" sec12="Y">
								<name>Apo-Guanfacine XR</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>2.5369</individualPrice>
								<listingDate>2022-03-31</listingDate>
								<amountMOHLTCPays>2.5369</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="540">For the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 to 17 years who meet the following criteria:
(i) As adjunctive therapy to psychostimulants; OR
(ii) As monotherapy in patients who have significant intolerance to psychostimulants AND who have had an inadequate response to either atomoxetine or other non-stimulant alternative(s).</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="241200000">
				<name>VASODILATING DRUGS</name>
				<genericName id="01753">
					<name>AMBRISENTAN</name>
					<pcgGroup>
						<pcg9 id="241200092">
							<itemNumber>0797</itemNumber>
							<strength>5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02307065" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Volibris</name>
								<manufacturerId>GSK</manufacturerId>
								<listingDate>2019-01-31</listingDate>
							</drug>
							<drug id="02475375" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Apo-Ambrisentan</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>106.3288</individualPrice>
								<listingDate>2019-01-31</listingDate>
								<amountMOHLTCPays>106.3288</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="241200093">
							<itemNumber>0798</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02307073" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Volibris</name>
								<manufacturerId>GSK</manufacturerId>
								<listingDate>2019-01-31</listingDate>
							</drug>
							<drug id="02475383" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Apo-Ambrisentan</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>106.3288</individualPrice>
								<listingDate>2019-01-31</listingDate>
								<amountMOHLTCPays>106.3288</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00393">
					<name>BETAHISTINE DIHYDROCHLORIDE</name>
					<pcgGroup>
						<pcg9 id="241200077">
							<itemNumber>0799</itemNumber>
							<strength>8mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02240601" sec3b="Y" sec3="Y">
								<name>Serc</name>
								<manufacturerId>SPH</manufacturerId>
								<listingDate>2011-05-19</listingDate>
							</drug>
							<drug id="02280183" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Teva-Betahistine</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2259</individualPrice>
								<listingDate>2011-05-19</listingDate>
								<amountMOHLTCPays>.2259</amountMOHLTCPays>
							</drug>
							<drug id="02449145" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Auro-Betahistine</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2070</individualPrice>
								<listingDate>2016-02-25</listingDate>
								<amountMOHLTCPays>.2070</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="241200080">
							<itemNumber>0800</itemNumber>
							<strength>16mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02243878" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Serc</name>
								<manufacturerId>BGP</manufacturerId>
								<listingDate>2007-09-04</listingDate>
							</drug>
							<drug id="02280191" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Teva-Betahistine</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3557</individualPrice>
								<listingDate>2007-09-04</listingDate>
								<amountMOHLTCPays>.3557</amountMOHLTCPays>
							</drug>
							<drug id="02330210" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>PMS-Betahistine</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3557</individualPrice>
								<listingDate>2014-04-30</listingDate>
								<amountMOHLTCPays>.3557</amountMOHLTCPays>
							</drug>
							<drug id="02374757" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Co Betahistine</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.3557</individualPrice>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.3557</amountMOHLTCPays>
							</drug>
							<drug id="02449153" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Auro-Betahistine</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.3557</individualPrice>
								<listingDate>2016-02-25</listingDate>
								<amountMOHLTCPays>.3557</amountMOHLTCPays>
							</drug>
							<drug id="02466449" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Betahistine</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.3557</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.3557</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="241200087">
							<itemNumber>0801</itemNumber>
							<strength>24mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02247998" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Serc</name>
								<manufacturerId>BGP</manufacturerId>
								<listingDate>2007-09-04</listingDate>
							</drug>
							<drug id="02280205" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Teva-Betahistine</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.4983</individualPrice>
								<listingDate>2007-09-04</listingDate>
							</drug>
							<drug id="02330237" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>PMS-Betahistine</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.4983</individualPrice>
								<listingDate>2014-04-30</listingDate>
							</drug>
							<drug id="02374765" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Co Betahistine</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.4983</individualPrice>
								<listingDate>2012-01-19</listingDate>
							</drug>
							<drug id="02449161" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Auro-Betahistine</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.4983</individualPrice>
								<listingDate>2016-02-25</listingDate>
							</drug>
							<drug id="02466457" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Betahistine</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.4983</individualPrice>
								<listingDate>2020-06-30</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01549">
					<name>BOSENTAN MONOHYDRATE</name>
					<pcgGroup>
						<pcg9 id="241200096">
							<itemNumber>0802</itemNumber>
							<strength>62.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02244981" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Tracleer</name>
								<manufacturerId>JAN</manufacturerId>
								<individualPrice>71.9800</individualPrice>
								<listingDate>2012-07-27</listingDate>
								<amountMOHLTCPays>32.0893</amountMOHLTCPays>
							</drug>
							<drug id="02383012" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>PMS-Bosentan</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>32.0893</individualPrice>
								<listingDate>2012-07-27</listingDate>
								<amountMOHLTCPays>32.0893</amountMOHLTCPays>
							</drug>
							<drug id="02386194" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Co Bosentan</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>32.0893</individualPrice>
								<listingDate>2012-07-27</listingDate>
								<amountMOHLTCPays>32.0893</amountMOHLTCPays>
							</drug>
							<drug id="02386275" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Sandoz Bosentan</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>32.0893</individualPrice>
								<listingDate>2012-07-27</listingDate>
								<amountMOHLTCPays>32.0893</amountMOHLTCPays>
							</drug>
							<drug id="02399202" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Apo-Bosentan</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>32.0893</individualPrice>
								<listingDate>2014-10-29</listingDate>
								<amountMOHLTCPays>32.0893</amountMOHLTCPays>
							</drug>
							<drug id="02467984" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Nat-Bosentan</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>32.0893</individualPrice>
								<listingDate>2019-01-31</listingDate>
								<amountMOHLTCPays>32.0893</amountMOHLTCPays>
							</drug>
							<drug id="02483130" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Taro-Bosentan</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>32.0893</individualPrice>
								<listingDate>2020-05-29</listingDate>
								<amountMOHLTCPays>32.0893</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="241200097">
							<itemNumber>0803</itemNumber>
							<strength>125mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02244982" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Tracleer</name>
								<manufacturerId>JAN</manufacturerId>
								<individualPrice>71.9800</individualPrice>
								<listingDate>2012-07-27</listingDate>
								<amountMOHLTCPays>32.0893</amountMOHLTCPays>
							</drug>
							<drug id="02383020" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>PMS-Bosentan</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>32.0893</individualPrice>
								<listingDate>2012-07-27</listingDate>
								<amountMOHLTCPays>32.0893</amountMOHLTCPays>
							</drug>
							<drug id="02386208" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Co Bosentan</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>32.0893</individualPrice>
								<listingDate>2012-07-27</listingDate>
								<amountMOHLTCPays>32.0893</amountMOHLTCPays>
							</drug>
							<drug id="02386283" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Sandoz Bosentan</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>32.0893</individualPrice>
								<listingDate>2012-07-27</listingDate>
								<amountMOHLTCPays>32.0893</amountMOHLTCPays>
							</drug>
							<drug id="02399210" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Apo-Bosentan</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>32.0893</individualPrice>
								<listingDate>2014-10-29</listingDate>
								<amountMOHLTCPays>32.0893</amountMOHLTCPays>
							</drug>
							<drug id="02467992" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Nat-Bosentan</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>32.0893</individualPrice>
								<listingDate>2019-01-31</listingDate>
								<amountMOHLTCPays>32.0893</amountMOHLTCPays>
							</drug>
							<drug id="02483149" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Taro-Bosentan</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>32.0893</individualPrice>
								<listingDate>2020-05-29</listingDate>
								<amountMOHLTCPays>32.0893</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00394">
					<name>DIPYRIDAMOLE</name>
					<pcgGroup>
						<pcg9 id="241200081">
							<itemNumber>0804</itemNumber>
							<strength>25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00067385" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Persantine</name>
								<manufacturerId>BOE</manufacturerId>
								<listingDate>2009-03-02</listingDate>
							</drug>
							<drug id="00895644" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Dipyridamole</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2633</individualPrice>
								<listingDate>2009-03-02</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="241200090">
							<itemNumber>0805</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00067393" sec3b="Y" sec3="Y">
								<name>Persantine</name>
								<manufacturerId>BOE</manufacturerId>
								<listingDate>2009-03-02</listingDate>
							</drug>
							<drug id="00895652" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Apo-Dipyridamole</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3685</individualPrice>
								<listingDate>2009-03-02</listingDate>
								<amountMOHLTCPays>.3685</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="241200091">
							<itemNumber>0806</itemNumber>
							<strength>75mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00452092" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Persantine</name>
								<manufacturerId>BOE</manufacturerId>
								<listingDate>2009-03-02</listingDate>
							</drug>
							<drug id="00895660" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Dipyridamole</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.4963</individualPrice>
								<listingDate>2009-03-02</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00400">
					<name>DIPYRIDAMOLE &amp; ACETYLSALICYLIC ACID</name>
					<pcgGroup lccId="00062">
						<pcg9 id="241200078">
							<itemNumber>0807</itemNumber>
							<strength>200mg/25mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02242119" notABenefit="Y" sec3="Y">
								<name>Aggrenox</name>
								<manufacturerId>BOE</manufacturerId>
								<listingDate>2001-10-11</listingDate>
							</drug>
							<drug id="02471051" sec3="Y" sec12="Y">
								<name>Taro-Dipyridamole/ASA</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>.6656</individualPrice>
								<listingDate>2019-01-31</listingDate>
								<amountMOHLTCPays>.6656</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="349">For the secondary prevention of stroke.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00389">
					<name>ISOSORBIDE DINITRATE</name>
					<pcgGroup>
						<pcg9 id="241200002">
							<itemNumber>0808</itemNumber>
							<strength>5mg</strength>
							<dosageForm>SL Tab</dosageForm>
							<drug id="00670944" sec3="Y">
								<name>ISDN</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.0633</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0633</amountMOHLTCPays>
							</drug>
							<drug id="02042606" notABenefit="Y" sec3="Y">
								<name>Isordil</name>
								<manufacturerId>WAY</manufacturerId>
								<listingDate>1997-02-04</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="241200006">
							<itemNumber>0809</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00441686" chronicUseMed="Y" sec3="Y">
								<name>ISDN</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.0372</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0372</amountMOHLTCPays>
							</drug>
							<drug id="02042622" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Isordil</name>
								<manufacturerId>WAY</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="241200005">
							<itemNumber>0810</itemNumber>
							<strength>30mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00441694" chronicUseMed="Y" sec3="Y">
								<name>ISDN</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.0874</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0874</amountMOHLTCPays>
							</drug>
							<drug id="02042614" notABenefit="Y" chronicUseMed="Y" sec3="Y">
								<name>Isordil</name>
								<manufacturerId>WAY</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00401">
					<name>ISOSORBIDE-5-MONONITRATE</name>
					<pcgGroup>
						<pcg9 id="241200088">
							<itemNumber>0811</itemNumber>
							<strength>60mg</strength>
							<dosageForm>ER Tab</dosageForm>
							<drug id="02126559" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Imdur</name>
								<manufacturerId>AZC</manufacturerId>
								<listingDate>2008-06-27</listingDate>
							</drug>
							<drug id="02272830" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Apo-ISMN</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.4950</individualPrice>
								<listingDate>2008-06-27</listingDate>
								<amountMOHLTCPays>.4950</amountMOHLTCPays>
							</drug>
							<drug id="02301288" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>PMS-ISMN</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.4950</individualPrice>
								<listingDate>2008-08-28</listingDate>
								<amountMOHLTCPays>.4950</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00402">
					<name>NIMODIPINE</name>
					<pcgGroup lccId="00215">
						<pcg9 id="241200095">
							<itemNumber>0812</itemNumber>
							<strength>30mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02325926" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Nimotop</name>
								<manufacturerId>BAH</manufacturerId>
								<individualPrice>10.3006</individualPrice>
								<listingDate>2011-10-25</listingDate>
								<amountMOHLTCPays>10.3006</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="42">As adjunctive therapy to improve the neurologic outcome following subarachnoid haemorrhage during the acute management period (within 4 days of haemorrhage).</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="003" reasonForUseId="43">As prophylaxis of ischemia if surgery is delayed.</lccNote>
						<lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00390">
					<name>NITROGLYCERIN</name>
					<pcgGroup>
						<pcg9 id="241200034">
							<itemNumber>0813</itemNumber>
							<strength>0.4mg/Hr/20 Sq Cm</strength>
							<dosageForm>Patch</dosageForm>
							<drug id="00852384" sec3="Y">
								<name>Transderm-Nitro</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>1.0010</individualPrice>
								<listingDate>1996-12-19</listingDate>
								<amountMOHLTCPays>1.0010</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="241200059">
							<itemNumber>0814</itemNumber>
							<strength>0.6mg/Hr/30 Sq Cm</strength>
							<dosageForm>Patch</dosageForm>
							<drug id="02046156" sec3="Y">
								<name>Transderm-Nitro</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>1.0290</individualPrice>
								<listingDate>1997-04-10</listingDate>
								<amountMOHLTCPays>1.0290</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="241200063">
							<itemNumber>0815</itemNumber>
							<strength>0.4mg/Hr/13.3 Sq Cm</strength>
							<dosageForm>Patch</dosageForm>
							<drug id="02163527" sec3="Y">
								<name>Minitran</name>
								<manufacturerId>GRA</manufacturerId>
								<individualPrice>.7813</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.7813</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="241200067">
							<itemNumber>0816</itemNumber>
							<strength>0.4mg/Hr/14 Sq Cm</strength>
							<dosageForm>Patch</dosageForm>
							<drug id="02230733" sec3="Y">
								<name>Trinipatch</name>
								<manufacturerId>PAL</manufacturerId>
								<individualPrice>.7717</individualPrice>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>.7717</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="241200064">
							<itemNumber>0817</itemNumber>
							<strength>0.6mg/Hr/20 Sq Cm</strength>
							<dosageForm>Patch</dosageForm>
							<drug id="02163535" sec3="Y">
								<name>Minitran</name>
								<manufacturerId>GRA</manufacturerId>
								<individualPrice>.7817</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.7817</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="241200068">
							<itemNumber>0818</itemNumber>
							<strength>0.6mg/Hr/21 Sq Cm</strength>
							<dosageForm>Patch</dosageForm>
							<drug id="02230734" sec3="Y">
								<name>Trinipatch</name>
								<manufacturerId>PAL</manufacturerId>
								<individualPrice>.7717</individualPrice>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>.7717</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="241200004">
							<itemNumber>0819</itemNumber>
							<strength>0.3mg</strength>
							<dosageForm>SL Tab</dosageForm>
							<drug id="00037613" sec3="Y">
								<name>Nitrostat</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>.1661</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1661</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="241200003" suppliedBy="L">
							<itemNumber>0820</itemNumber>
							<strength>0.6mg</strength>
							<dosageForm>SL Tab</dosageForm>
							<drug id="00037621" selfMed="Y" sec3="Y">
								<name>Nitrostat</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>.1661</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1661</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="241200017">
							<itemNumber>0821</itemNumber>
							<strength>0.4mg/Metered Dose</strength>
							<dosageForm>Spray-200 Dose Pk</dosageForm>
							<drug id="01926721" notABenefit="Y" sec3="Y">
								<name>Nitrolingual</name>
								<manufacturerId>AVE</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02243588" sec3="Y">
								<name>Mylan-Nitro Sublingual Spray</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>8.4600</individualPrice>
								<listingDate>2003-01-30</listingDate>
								<amountMOHLTCPays>8.4600</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="241200069">
							<itemNumber>0822</itemNumber>
							<strength>0.4mg/Metered Dose</strength>
							<dosageForm>Spray-200 Dose Pk</dosageForm>
							<drug id="02231441" sec3="Y">
								<name>Nitrolingual Pump Spray</name>
								<manufacturerId>SAV</manufacturerId>
								<individualPrice>15.2400</individualPrice>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>8.4200</amountMOHLTCPays>
							</drug>
							<drug id="02238998" sec3="Y">
								<name>Rho-Nitro Pumpspray</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>8.4200</individualPrice>
								<listingDate>2014-06-26</listingDate>
								<amountMOHLTCPays>8.4200</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="241200033">
							<itemNumber>0823</itemNumber>
							<strength>0.2mg/Hr</strength>
							<dosageForm>Transdermal Patch</dosageForm>
							<drug id="01911910" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Nitro-Dur 0.2</name>
								<manufacturerId>DRR</manufacturerId>
								<listingDate>2013-11-28</listingDate>
							</drug>
							<drug id="02407442" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mylan-Nitro 0.2</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.4463</individualPrice>
								<listingDate>2013-11-28</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="241200071">
							<itemNumber>0824</itemNumber>
							<strength>0.4mg/Hr</strength>
							<dosageForm>Transdermal Patch</dosageForm>
							<drug id="01911902" sec3="Y">
								<name>Nitro-Dur</name>
								<manufacturerId>DRR</manufacturerId>
								<individualPrice>.5040</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.5040</amountMOHLTCPays>
							</drug>
							<drug id="02407450" sec3="Y">
								<name>Mylan-Nitro 0.4</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.5040</individualPrice>
								<listingDate>2013-11-28</listingDate>
								<amountMOHLTCPays>.5040</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="241200072">
							<itemNumber>0825</itemNumber>
							<strength>0.6mg/Hr</strength>
							<dosageForm>Transdermal Patch</dosageForm>
							<drug id="01911929" sec3="Y">
								<name>Nitro-Dur</name>
								<manufacturerId>DRR</manufacturerId>
								<individualPrice>.5040</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.5040</amountMOHLTCPays>
							</drug>
							<drug id="02407469" sec3="Y">
								<name>Mylan-Nitro 0.6</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.5040</individualPrice>
								<listingDate>2013-11-28</listingDate>
								<amountMOHLTCPays>.5040</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="241200058">
							<itemNumber>0826</itemNumber>
							<strength>0.8mg/Hr</strength>
							<dosageForm>Transdermal Patch</dosageForm>
							<drug id="02011271" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Nitro-Dur 0.8</name>
								<manufacturerId>DRR</manufacturerId>
								<listingDate>2013-11-28</listingDate>
							</drug>
							<drug id="02407477" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mylan-Nitro 0.8</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.8743</individualPrice>
								<listingDate>2013-11-28</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01792">
					<name>TADALAFIL</name>
					<pcgGroup>
						<pcg9 id="241200103">
							<itemNumber>0827</itemNumber>
							<strength>2.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02296888" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Cialis</name>
								<manufacturerId>LIL</manufacturerId>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02409410" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>PMS-Tadalafil</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>3.6471</individualPrice>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02410621" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mylan-Tadalafil</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>3.6471</individualPrice>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02422085" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Tadalafil</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>3.6470</individualPrice>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02428628" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Act Tadalafil</name>
								<manufacturerId>ACV</manufacturerId>
								<individualPrice>3.6471</individualPrice>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02435896" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Auro-Tadalafil</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>3.6470</individualPrice>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02440148" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Teva-Tadalafil</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>3.8616</individualPrice>
								<listingDate>2016-10-27</listingDate>
							</drug>
							<drug id="02451824" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Jamp-Tadalafil</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>3.6471</individualPrice>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02452081" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Ran-Tadalafil</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>3.6471</individualPrice>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02452286" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mar-Tadalafil</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>3.6471</individualPrice>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02512262" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>PRZ-Tadalafil</name>
								<manufacturerId>PRZ</manufacturerId>
								<individualPrice>3.6470</individualPrice>
								<listingDate>2022-02-28</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="241200104">
							<itemNumber>0828</itemNumber>
							<strength>5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02296896" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Cialis</name>
								<manufacturerId>LIL</manufacturerId>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02409429" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>PMS-Tadalafil</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>3.6471</individualPrice>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02410648" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mylan-Tadalafil</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>3.6471</individualPrice>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02422093" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Tadalafil</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>3.6470</individualPrice>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02428636" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Act Tadalafil</name>
								<manufacturerId>ACV</manufacturerId>
								<individualPrice>3.6471</individualPrice>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02435926" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Auro-Tadalafil</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>3.6471</individualPrice>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02440156" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Teva-Tadalafil</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>3.8616</individualPrice>
								<listingDate>2016-10-27</listingDate>
							</drug>
							<drug id="02451670" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mint-Tadalafil</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>3.6472</individualPrice>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02451832" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Jamp-Tadalafil</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>3.6471</individualPrice>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02452073" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Ran-Tadalafil</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>3.6471</individualPrice>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02452278" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mar-Tadalafil</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>3.6471</individualPrice>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02454726" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Riva-Tadalafil</name>
								<manufacturerId>RIA</manufacturerId>
								<individualPrice>3.6471</individualPrice>
								<listingDate>2021-08-31</listingDate>
							</drug>
							<drug id="02457016" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Tadalafil</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>3.6471</individualPrice>
								<listingDate>2021-02-26</listingDate>
							</drug>
							<drug id="02512114" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>M-Tadalafil</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>3.6470</individualPrice>
								<listingDate>2021-11-30</listingDate>
							</drug>
							<drug id="02512270" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>PRZ-Tadalafil</name>
								<manufacturerId>PRZ</manufacturerId>
								<individualPrice>3.6471</individualPrice>
								<listingDate>2022-02-28</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="241200105">
							<itemNumber>0829</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02248088" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Cialis</name>
								<manufacturerId>LIL</manufacturerId>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02409437" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>PMS-Tadalafil</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>11.9255</individualPrice>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02410656" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mylan-Tadalafil</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>11.9255</individualPrice>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02422107" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Tadalafil</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>11.9250</individualPrice>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02428644" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Act Tadalafil</name>
								<manufacturerId>ACV</manufacturerId>
								<individualPrice>11.9255</individualPrice>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02435934" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Auro-Tadalafil</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>11.9250</individualPrice>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02440164" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Teva-Tadalafil</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>12.6270</individualPrice>
								<listingDate>2016-10-27</listingDate>
							</drug>
							<drug id="02451840" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Jamp-Tadalafil</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>11.9255</individualPrice>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02452103" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Ran-Tadalafil</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>11.9255</individualPrice>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02452251" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mar-Tadalafil</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>11.9250</individualPrice>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02457024" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Tadalafil</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>11.9250</individualPrice>
								<listingDate>2021-02-26</listingDate>
							</drug>
							<drug id="02512122" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>M-Tadalafil</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>11.9250</individualPrice>
								<listingDate>2021-11-30</listingDate>
							</drug>
							<drug id="02512289" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>PRZ-Tadalafil</name>
								<manufacturerId>PRZ</manufacturerId>
								<individualPrice>11.9250</individualPrice>
								<listingDate>2022-02-28</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="241200094">
							<itemNumber>0830</itemNumber>
							<strength>20mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02338327" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Adcirca</name>
								<manufacturerId>LIL</manufacturerId>
								<individualPrice>12.5220</individualPrice>
								<listingDate>2015-12-22</listingDate>
								<amountMOHLTCPays>11.4725</amountMOHLTCPays>
							</drug>
							<drug id="02421933" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Apo-Tadalafil PAH</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>11.4725</individualPrice>
								<listingDate>2015-12-22</listingDate>
								<amountMOHLTCPays>11.4725</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="241200106">
							<itemNumber>0831</itemNumber>
							<strength>20mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02248089" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Cialis</name>
								<manufacturerId>LIL</manufacturerId>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02409445" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>PMS-Tadalafil</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>12.3569</individualPrice>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02410664" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mylan-Tadalafil</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>12.3569</individualPrice>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02422115" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Tadalafil</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>12.3575</individualPrice>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02428652" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Act Tadalafil</name>
								<manufacturerId>ACV</manufacturerId>
								<individualPrice>12.3569</individualPrice>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02435942" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Auro-Tadalafil</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>12.3575</individualPrice>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02440172" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Teva-Tadalafil</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>13.0838</individualPrice>
								<listingDate>2016-10-27</listingDate>
							</drug>
							<drug id="02451697" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mint-Tadalafil</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>12.3576</individualPrice>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02451859" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Jamp-Tadalafil</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>12.3569</individualPrice>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02452111" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Ran-Tadalafil</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>12.3569</individualPrice>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02452243" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mar-Tadalafil</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>12.3575</individualPrice>
								<listingDate>2016-09-29</listingDate>
							</drug>
							<drug id="02454742" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Riva-Tadalafil</name>
								<manufacturerId>RIA</manufacturerId>
								<individualPrice>12.3569</individualPrice>
								<listingDate>2021-08-31</listingDate>
							</drug>
							<drug id="02457032" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Tadalafil</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>12.3569</individualPrice>
								<listingDate>2021-02-26</listingDate>
							</drug>
							<drug id="02481421" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>AG-Tadalafil</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>12.3569</individualPrice>
								<listingDate>2021-09-30</listingDate>
							</drug>
							<drug id="02512130" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>M-Tadalafil</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>12.3575</individualPrice>
								<listingDate>2021-11-30</listingDate>
							</drug>
							<drug id="02512297" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>PRZ-Tadalafil</name>
								<manufacturerId>PRZ</manufacturerId>
								<individualPrice>12.3575</individualPrice>
								<listingDate>2022-02-28</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="02071">
					<name>VARDENAFIL HCL</name>
					<pcgGroup>
						<pcg9 id="241200110">
							<itemNumber>0832</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Orally Disintergrating Tab</dosageForm>
							<drug id="02372436" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Staxyn</name>
								<manufacturerId>BAH</manufacturerId>
								<listingDate>2019-09-30</listingDate>
							</drug>
							<drug id="02476088" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Jamp-Vardenafil ODT</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>5.8778</individualPrice>
								<listingDate>2019-09-30</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="241200107">
							<itemNumber>0833</itemNumber>
							<strength>5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02250462" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Levitra</name>
								<manufacturerId>BAY</manufacturerId>
								<listingDate>2018-12-21</listingDate>
							</drug>
							<drug id="02464209" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mylan-Vardenafil</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>9.3203</individualPrice>
								<listingDate>2018-12-21</listingDate>
							</drug>
							<drug id="02471647" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Vardenafil</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>9.3203</individualPrice>
								<listingDate>2019-01-31</listingDate>
							</drug>
							<drug id="02475677" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Jamp-Vardenafil IR</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>9.3203</individualPrice>
								<listingDate>2018-12-21</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="241200108">
							<itemNumber>0834</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02250470" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Levitra</name>
								<manufacturerId>BAY</manufacturerId>
								<listingDate>2018-12-21</listingDate>
							</drug>
							<drug id="02464225" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mylan-Vardenafil</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>10.3976</individualPrice>
								<listingDate>2018-12-21</listingDate>
							</drug>
							<drug id="02471655" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Vardenafil</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>10.3976</individualPrice>
								<listingDate>2019-01-31</listingDate>
							</drug>
							<drug id="02475685" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Jamp-Vardenafil IR</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>10.4019</individualPrice>
								<listingDate>2018-12-21</listingDate>
							</drug>
							<drug id="02520397" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Vardenafil</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>10.3976</individualPrice>
								<listingDate>2021-12-17</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="241200109">
							<itemNumber>0835</itemNumber>
							<strength>20mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02250489" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Levitra</name>
								<manufacturerId>BAY</manufacturerId>
								<listingDate>2018-12-21</listingDate>
							</drug>
							<drug id="02464233" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mylan-Vardenafil</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>11.6811</individualPrice>
								<listingDate>2018-12-21</listingDate>
							</drug>
							<drug id="02471663" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Vardenafil</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>11.6811</individualPrice>
								<listingDate>2019-01-31</listingDate>
							</drug>
							<drug id="02475693" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Jamp-Vardenafil IR</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>11.6811</individualPrice>
								<listingDate>2018-12-21</listingDate>
							</drug>
							<drug id="02520400" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Vardenafil</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>11.6811</individualPrice>
								<listingDate>2021-12-17</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="243208000">
				<name>RENIN-ANGIOTENSIN ALDOSTERONE INHIBITORS ANGIOTENSIN II RECEPTOR ANTAGONISTS</name>
				<genericName id="02033">
					<name>SACUBITRIL &amp; VALSARTAN</name>
					<pcgGroup lccId="00283">
						<pcg9 id="243208002">
							<itemNumber>0836</itemNumber>
							<strength>24.3mg &amp; 25.7mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02446928" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Entresto</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>3.7060</individualPrice>
								<listingDate>2017-04-27</listingDate>
								<amountMOHLTCPays>3.7060</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="243208003">
							<itemNumber>0837</itemNumber>
							<strength>48.6mg &amp; 51.4mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02446936" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Entresto</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>3.7060</individualPrice>
								<listingDate>2017-04-27</listingDate>
								<amountMOHLTCPays>3.7060</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="243208004">
							<itemNumber>0838</itemNumber>
							<strength>97.2mg &amp; 102.8mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02446944" chronicUseMed="Y" sec3="Y" sec12="Y">
								<name>Entresto</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>3.7060</individualPrice>
								<listingDate>2017-04-27</listingDate>
								<amountMOHLTCPays>3.7060</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="497">For the treatment of heart failure (HF) with reduced ejection fraction in patients with New York Heart Association (NYHA) class II or III HF to reduce the incidence of cardiovascular (CV) death and HF hospitalization, if all of the following clinical criteria are met:
- Reduced left ventricular ejection fraction (LVEF) (Less than 40%);
- Patient has NYHA class II to III symptoms despite at least four weeks of treatment with a stable dose of an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin II receptor antagonist (ARB); and
- In combination with a beta blocker and other recommended therapies, including an aldosterone antagonist (if tolerable).</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
				</genericName>
			</pcg6>
		</pcg2>
		<pcg2 id="280000000">
			<name>CENTRAL NERVOUS SYSTEM DRUGS</name>
			<pcg6 id="280804000">
				<name>ANALGESICS NONSTEROIDAL ANTI-INFLAMMATORY AGENTS</name>
				<genericName id="01430">
					<name>CELECOXIB</name>
					<pcgGroup lccId="00064">
						<pcg9 id="280804075">
							<itemNumber>0839</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Cap</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="02239941" sec3="Y" sec12="Y">
								<name>Celebrex</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>.7464</individualPrice>
								<listingDate>2000-04-17</listingDate>
								<amountMOHLTCPays>.1279</amountMOHLTCPays>
							</drug>
							<drug id="02288915" sec3="Y" sec12="Y">
								<name>Teva-Celecoxib</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1279</individualPrice>
								<listingDate>2015-01-28</listingDate>
								<amountMOHLTCPays>.1279</amountMOHLTCPays>
							</drug>
							<drug id="02355442" sec3="Y" sec12="Y">
								<name>PMS-Celecoxib</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1279</individualPrice>
								<listingDate>2015-01-28</listingDate>
								<amountMOHLTCPays>.1279</amountMOHLTCPays>
							</drug>
							<drug id="02412373" sec3="Y" sec12="Y">
								<name>Ran-Celecoxib</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.1279</individualPrice>
								<listingDate>2015-01-28</listingDate>
								<amountMOHLTCPays>.1279</amountMOHLTCPays>
							</drug>
							<drug id="02412497" sec3="Y" sec12="Y">
								<name>Mint-Celecoxib</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.1279</individualPrice>
								<listingDate>2015-01-28</listingDate>
								<amountMOHLTCPays>.1279</amountMOHLTCPays>
							</drug>
							<drug id="02418932" sec3="Y" sec12="Y">
								<name>Apo-Celecoxib</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1279</individualPrice>
								<listingDate>2015-01-28</listingDate>
								<amountMOHLTCPays>.1279</amountMOHLTCPays>
							</drug>
							<drug id="02420058" sec3="Y" sec12="Y">
								<name>Mar-Celecoxib</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.1279</individualPrice>
								<listingDate>2015-01-28</listingDate>
								<amountMOHLTCPays>.1279</amountMOHLTCPays>
							</drug>
							<drug id="02420155" sec3="Y" sec12="Y">
								<name>Act Celecoxib</name>
								<manufacturerId>ACV</manufacturerId>
								<individualPrice>.1279</individualPrice>
								<listingDate>2015-01-28</listingDate>
								<amountMOHLTCPays>.1279</amountMOHLTCPays>
							</drug>
							<drug id="02424533" sec3="Y" sec12="Y">
								<name>Jamp-Celecoxib</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1279</individualPrice>
								<listingDate>2015-01-28</listingDate>
								<amountMOHLTCPays>.1279</amountMOHLTCPays>
							</drug>
							<drug id="02426382" sec3="Y" sec12="Y">
								<name>Bio-Celecoxib</name>
								<manufacturerId>BMP</manufacturerId>
								<individualPrice>.1279</individualPrice>
								<listingDate>2016-02-25</listingDate>
								<amountMOHLTCPays>.1279</amountMOHLTCPays>
							</drug>
							<drug id="02429675" sec3="Y" sec12="Y">
								<name>Celecoxib</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.1279</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.1279</amountMOHLTCPays>
							</drug>
							<drug id="02435632" sec3="Y" sec12="Y">
								<name>Accel-Celecoxib</name>
								<manufacturerId>ACC</manufacturerId>
								<individualPrice>.1279</individualPrice>
								<listingDate>2016-01-28</listingDate>
								<amountMOHLTCPays>.1279</amountMOHLTCPays>
							</drug>
							<drug id="02436299" sec3="Y" sec12="Y">
								<name>Celecoxib</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.1279</individualPrice>
								<listingDate>2021-03-29</listingDate>
								<amountMOHLTCPays>.1279</amountMOHLTCPays>
							</drug>
							<drug id="02437570" sec3="Y" sec12="Y">
								<name>AG-Celecoxib</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.1279</individualPrice>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.1279</amountMOHLTCPays>
							</drug>
							<drug id="02442639" sec3="Y" sec12="Y">
								<name>Sdz Celecoxib</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.1279</individualPrice>
								<listingDate>2015-09-30</listingDate>
								<amountMOHLTCPays>.1279</amountMOHLTCPays>
							</drug>
							<drug id="02445670" sec3="Y" sec12="Y">
								<name>Auro-Celecoxib</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.1279</individualPrice>
								<listingDate>2016-07-28</listingDate>
								<amountMOHLTCPays>.1279</amountMOHLTCPays>
							</drug>
							<drug id="02479737" sec3="Y" sec12="Y">
								<name>NRA-Celecoxib</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.1279</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.1279</amountMOHLTCPays>
							</drug>
							<drug id="02495465" sec3="Y" sec12="Y">
								<name>M-Celecoxib</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.1279</individualPrice>
								<listingDate>2021-10-29</listingDate>
								<amountMOHLTCPays>.1279</amountMOHLTCPays>
							</drug>
							<drug id="02517116" sec3="Y" sec12="Y">
								<name>PMSC-Celecoxib</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1279</individualPrice>
								<listingDate>2022-01-31</listingDate>
								<amountMOHLTCPays>.1279</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280804076">
							<itemNumber>0840</itemNumber>
							<strength>200mg</strength>
							<dosageForm>Cap</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="02239942" sec3="Y" sec12="Y">
								<name>Celebrex</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>1.4930</individualPrice>
								<listingDate>2000-04-17</listingDate>
								<amountMOHLTCPays>.2558</amountMOHLTCPays>
							</drug>
							<drug id="02288923" sec3="Y" sec12="Y">
								<name>Teva-Celecoxib</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2558</individualPrice>
								<listingDate>2015-01-28</listingDate>
								<amountMOHLTCPays>.2558</amountMOHLTCPays>
							</drug>
							<drug id="02355450" sec3="Y" sec12="Y">
								<name>PMS-Celecoxib</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2558</individualPrice>
								<listingDate>2015-01-28</listingDate>
								<amountMOHLTCPays>.2558</amountMOHLTCPays>
							</drug>
							<drug id="02412381" sec3="Y" sec12="Y">
								<name>Ran-Celecoxib</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.2558</individualPrice>
								<listingDate>2015-01-28</listingDate>
								<amountMOHLTCPays>.2558</amountMOHLTCPays>
							</drug>
							<drug id="02412500" sec3="Y" sec12="Y">
								<name>Mint-Celecoxib</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.2558</individualPrice>
								<listingDate>2015-01-28</listingDate>
								<amountMOHLTCPays>.2558</amountMOHLTCPays>
							</drug>
							<drug id="02418940" sec3="Y" sec12="Y">
								<name>Apo-Celecoxib</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2558</individualPrice>
								<listingDate>2015-01-28</listingDate>
								<amountMOHLTCPays>.2558</amountMOHLTCPays>
							</drug>
							<drug id="02420066" sec3="Y" sec12="Y">
								<name>Mar-Celecoxib</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.2558</individualPrice>
								<listingDate>2015-01-28</listingDate>
								<amountMOHLTCPays>.2558</amountMOHLTCPays>
							</drug>
							<drug id="02420163" sec3="Y" sec12="Y">
								<name>Act Celecoxib</name>
								<manufacturerId>ACV</manufacturerId>
								<individualPrice>.2558</individualPrice>
								<listingDate>2015-01-28</listingDate>
								<amountMOHLTCPays>.2558</amountMOHLTCPays>
							</drug>
							<drug id="02424541" sec3="Y" sec12="Y">
								<name>Jamp-Celecoxib</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2558</individualPrice>
								<listingDate>2015-01-28</listingDate>
								<amountMOHLTCPays>.2558</amountMOHLTCPays>
							</drug>
							<drug id="02426390" sec3="Y" sec12="Y">
								<name>Bio-Celecoxib</name>
								<manufacturerId>BMP</manufacturerId>
								<individualPrice>.2558</individualPrice>
								<listingDate>2016-02-25</listingDate>
								<amountMOHLTCPays>.2558</amountMOHLTCPays>
							</drug>
							<drug id="02429683" sec3="Y" sec12="Y">
								<name>Celecoxib</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2558</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.2558</amountMOHLTCPays>
							</drug>
							<drug id="02435640" sec3="Y" sec12="Y">
								<name>Accel-Celecoxib</name>
								<manufacturerId>ACC</manufacturerId>
								<individualPrice>.2558</individualPrice>
								<listingDate>2016-01-28</listingDate>
								<amountMOHLTCPays>.2558</amountMOHLTCPays>
							</drug>
							<drug id="02436302" sec3="Y" sec12="Y">
								<name>Celecoxib</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2558</individualPrice>
								<listingDate>2021-03-29</listingDate>
								<amountMOHLTCPays>.2558</amountMOHLTCPays>
							</drug>
							<drug id="02437589" sec3="Y" sec12="Y">
								<name>AG-Celecoxib</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.2558</individualPrice>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.2558</amountMOHLTCPays>
							</drug>
							<drug id="02442647" sec3="Y" sec12="Y">
								<name>Sdz Celecoxib</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2558</individualPrice>
								<listingDate>2015-09-30</listingDate>
								<amountMOHLTCPays>.2558</amountMOHLTCPays>
							</drug>
							<drug id="02445689" sec3="Y" sec12="Y">
								<name>Auro-Celecoxib</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2558</individualPrice>
								<listingDate>2016-07-28</listingDate>
								<amountMOHLTCPays>.2558</amountMOHLTCPays>
							</drug>
							<drug id="02479745" sec3="Y" sec12="Y">
								<name>NRA-Celecoxib</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.2558</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.2558</amountMOHLTCPays>
							</drug>
							<drug id="02495473" sec3="Y" sec12="Y">
								<name>M-Celecoxib</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.2558</individualPrice>
								<listingDate>2021-10-29</listingDate>
								<amountMOHLTCPays>.2558</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" type="T">Osteoarthritis</lccNote>
						<lccNote seq="002" reasonForUseId="316">For patients who have failed an adequate trial of acetaminophen (e.g. acetaminophen 1g QID for several weeks) and have had:</lccNote>
						<lccNote seq="003" type="R">History of a documented, clinically significant ulcer or GI bleed; or
Failure or intolerance to at least three listed NSAIDS.</lccNote>
						<lccNote seq="004" type="N">The maximum daily dose of celecoxib which will be reimbursed for the treatment of osteoarthritis is 200mg.</lccNote>
						<lccNote seq="005" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="006" type="T">Rheumatoid arthritis</lccNote>
						<lccNote seq="007" reasonForUseId="317">For patients who have had:</lccNote>
						<lccNote seq="008" type="R">History of a documented, clinically significant ulcer or GI bleed; or
Failure or intolerance to at least three listed NSAIDS.</lccNote>
						<lccNote seq="009" type="N">The maximum daily dose of celecoxib which will be reimbursed for the treatment of rheumatoid arthritis is 400mg.</lccNote>
						<lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="01721">
					<name>DICLOFENAC POTASSIUM</name>
					<pcgGroup>
						<pcg9 id="280804099">
							<itemNumber>0841</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="00881635" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Voltaren Rapide</name>
								<manufacturerId>NOV</manufacturerId>
								<listingDate>2008-01-15</listingDate>
							</drug>
							<drug id="02239355" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Teva-Diclofenac-K</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3937</individualPrice>
								<listingDate>2008-01-15</listingDate>
							</drug>
							<drug id="02239753" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>PMS-Diclofenac K</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3937</individualPrice>
								<listingDate>2008-02-12</listingDate>
							</drug>
							<drug id="02243433" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Diclo Rapide</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3937</individualPrice>
								<listingDate>2008-01-15</listingDate>
							</drug>
							<drug id="02261774" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Sandoz Diclofenac Rapide</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.3937</individualPrice>
								<listingDate>2008-01-15</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00425">
					<name>DICLOFENAC SODIUM</name>
					<pcgGroup>
						<pcg9 id="280804005">
							<itemNumber>0842</itemNumber>
							<strength>25mg</strength>
							<dosageForm>Ent Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="00514004" notABenefit="Y" sec3="Y">
								<name>Voltaren</name>
								<manufacturerId>GEI</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00808539" sec3="Y">
								<name>Teva-Diclofenac</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.0781</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0781</amountMOHLTCPays>
							</drug>
							<drug id="00839175" sec3="Y">
								<name>Apo-Diclo</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0781</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0781</amountMOHLTCPays>
							</drug>
							<drug id="02302616" sec3="Y">
								<name>PMS-Diclofenac</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.0781</individualPrice>
								<listingDate>2008-10-01</listingDate>
								<amountMOHLTCPays>.0781</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280804006">
							<itemNumber>0843</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Ent Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="00514012" sec3="Y">
								<name>Voltaren</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>1.1384</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2064</amountMOHLTCPays>
							</drug>
							<drug id="00808547" sec3="Y">
								<name>Teva-Diclofenac</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2064</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2064</amountMOHLTCPays>
							</drug>
							<drug id="00839183" sec3="Y">
								<name>Apo-Diclo</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2064</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2064</amountMOHLTCPays>
							</drug>
							<drug id="02261960" sec3="Y">
								<name>Sandoz Diclofenac</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2064</individualPrice>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.2064</amountMOHLTCPays>
							</drug>
							<drug id="02302624" sec3="Y">
								<name>PMS-Diclofenac</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2064</individualPrice>
								<listingDate>2008-10-01</listingDate>
								<amountMOHLTCPays>.2064</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280804058">
							<itemNumber>0844</itemNumber>
							<strength>75mg</strength>
							<dosageForm>LA Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="00782459" notABenefit="Y" sec3="Y">
								<name>Voltaren SR</name>
								<manufacturerId>NOV</manufacturerId>
								<listingDate>1998-08-26</listingDate>
							</drug>
							<drug id="02158582" sec3="Y">
								<name>Teva-Diclofenac SR</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2433</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.2433</amountMOHLTCPays>
							</drug>
							<drug id="02162814" sec3="Y">
								<name>Apo-Diclo SR</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2433</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.2433</amountMOHLTCPays>
							</drug>
							<drug id="02231504" sec3="Y">
								<name>PMS-Diclofenac-SR</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2433</individualPrice>
								<listingDate>1999-09-15</listingDate>
								<amountMOHLTCPays>.2433</amountMOHLTCPays>
							</drug>
							<drug id="02261901" sec3="Y">
								<name>Sandoz Diclofenac SR</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2433</individualPrice>
								<listingDate>2008-03-25</listingDate>
								<amountMOHLTCPays>.2433</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280804059">
							<itemNumber>0845</itemNumber>
							<strength>100mg</strength>
							<dosageForm>LA Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="00590827" notABenefit="Y" sec3="Y">
								<name>Voltaren SR</name>
								<manufacturerId>NOV</manufacturerId>
								<listingDate>1998-08-26</listingDate>
							</drug>
							<drug id="02048698" sec3="Y">
								<name>Teva-Diclofenac SR</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.4048</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.4048</amountMOHLTCPays>
							</drug>
							<drug id="02091194" sec3="Y">
								<name>Apo-Diclo SR</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.4048</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.4048</amountMOHLTCPays>
							</drug>
							<drug id="02231505" sec3="Y">
								<name>PMS-Diclofenac-SR</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.4048</individualPrice>
								<listingDate>1999-09-15</listingDate>
								<amountMOHLTCPays>.4048</amountMOHLTCPays>
							</drug>
							<drug id="02261944" sec3="Y">
								<name>Sandoz Diclofenac SR</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.4048</individualPrice>
								<listingDate>2008-03-25</listingDate>
								<amountMOHLTCPays>.4048</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280804007">
							<itemNumber>0846</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Sup</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="00632724" sec3="Y">
								<name>Voltaren</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>1.7560</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.8545</amountMOHLTCPays>
							</drug>
							<drug id="02231506" sec3="Y">
								<name>PMS-Diclofenac</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.8545</individualPrice>
								<listingDate>2000-01-17</listingDate>
								<amountMOHLTCPays>.8545</amountMOHLTCPays>
							</drug>
							<drug id="02261928" sec3="Y">
								<name>Sandoz Diclofenac</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.8545</individualPrice>
								<listingDate>2009-03-02</listingDate>
								<amountMOHLTCPays>.8545</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280804008">
							<itemNumber>0847</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Sup</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="00632732" notABenefit="Y" sec3="Y">
								<name>Voltaren</name>
								<manufacturerId>NOV</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02231508" sec3="Y">
								<name>PMS-Diclofenac</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.5840</individualPrice>
								<listingDate>2000-01-17</listingDate>
								<amountMOHLTCPays>.5840</amountMOHLTCPays>
							</drug>
							<drug id="02261936" sec3="Y">
								<name>Sandoz Diclofenac</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.5840</individualPrice>
								<listingDate>2009-03-02</listingDate>
								<amountMOHLTCPays>.5840</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280804098">
							<itemNumber>0848</itemNumber>
							<strength>1.5% W/W</strength>
							<dosageForm>Top Sol</dosageForm>
							<drug id="02247265" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Pennsaid</name>
								<manufacturerId>PAL</manufacturerId>
								<listingDate>2014-10-29</listingDate>
							</drug>
							<drug id="02356783" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>PMS-Diclofenac</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.6227</individualPrice>
								<listingDate>2015-01-28</listingDate>
							</drug>
							<drug id="02420988" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Taro-Diclofenac</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>.6226</individualPrice>
								<listingDate>2014-10-29</listingDate>
							</drug>
							<drug id="02434571" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Diclofenac Topical Solution</name>
								<manufacturerId>STE</manufacturerId>
								<individualPrice>.6226</individualPrice>
								<listingDate>2018-06-29</listingDate>
							</drug>
							<drug id="02472309" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Jamp-Diclofenac</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.6226</individualPrice>
								<listingDate>2018-06-29</listingDate>
							</drug>
							<drug id="02476134" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Diclofenac Sodium Solution</name>
								<manufacturerId>TEL</manufacturerId>
								<individualPrice>.6226</individualPrice>
								<listingDate>2018-11-29</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00460">
					<name>DICLOFENAC SODIUM &amp; MISOPROSTOL</name>
					<pcgGroup>
						<pcg9 id="280804049">
							<itemNumber>0849</itemNumber>
							<strength>50mg &amp; 200mcg</strength>
							<dosageForm>Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="01917056" sec3="Y">
								<name>Arthrotec 50</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>.7094</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3149</amountMOHLTCPays>
							</drug>
							<drug id="02341689" sec3="Y">
								<name>Gd-Diclofenac/Misoprostol 50</name>
								<manufacturerId>GEM</manufacturerId>
								<individualPrice>.3149</individualPrice>
								<listingDate>2015-03-31</listingDate>
								<amountMOHLTCPays>.3149</amountMOHLTCPays>
							</drug>
							<drug id="02413469" sec3="Y">
								<name>PMS-Diclofenac-Misoprostol</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3149</individualPrice>
								<listingDate>2021-01-29</listingDate>
								<amountMOHLTCPays>.3149</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280804056">
							<itemNumber>0850</itemNumber>
							<strength>75mg &amp; 200mcg</strength>
							<dosageForm>Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="02229837" sec3="Y">
								<name>Arthrotec 75</name>
								<manufacturerId>PFI</manufacturerId>
								<individualPrice>.9655</individualPrice>
								<listingDate>1997-08-28</listingDate>
								<amountMOHLTCPays>.4286</amountMOHLTCPays>
							</drug>
							<drug id="02341697" sec3="Y">
								<name>Gd-Diclofenac/Misoprostol 75</name>
								<manufacturerId>GEM</manufacturerId>
								<individualPrice>.4286</individualPrice>
								<listingDate>2015-03-31</listingDate>
								<amountMOHLTCPays>.4286</amountMOHLTCPays>
							</drug>
							<drug id="02413477" sec3="Y">
								<name>PMS-Diclofenac-Misoprostol</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.4286</individualPrice>
								<listingDate>2021-01-29</listingDate>
								<amountMOHLTCPays>.4286</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00433">
					<name>FLURBIPROFEN</name>
					<pcgGroup>
						<pcg9 id="280804017">
							<itemNumber>0851</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="00647942" notABenefit="Y" sec3="Y">
								<name>Ansaid</name>
								<manufacturerId>PFI</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="01912046" sec3="Y">
								<name>Flurbiprofen</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.4530</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.4530</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280804018">
							<itemNumber>0852</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="00600792" notABenefit="Y" sec3="Y">
								<name>Ansaid</name>
								<manufacturerId>PFI</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="01912038" sec3="Y">
								<name>Flurbiprofen</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.3039</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3039</amountMOHLTCPays>
							</drug>
							<drug id="02100517" sec3="Y">
								<name>Teva-Flurbiprofen</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3039</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3039</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00407">
					<name>IBUPROFEN</name>
					<pcgGroup>
						<pcg9 id="280804019">
							<itemNumber>0853</itemNumber>
							<strength>200mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="00252409" notABenefit="Y" sec3="Y">
								<name>Motrin</name>
								<manufacturerId>UPJ</manufacturerId>
								<listingDate>2006-06-15</listingDate>
							</drug>
							<drug id="00441643" sec3="Y">
								<name>Apo-Ibuprofen</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0510</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0510</amountMOHLTCPays>
							</drug>
							<drug id="00629324" sec3="Y">
								<name>Novo-Profen</name>
								<manufacturerId>NOP</manufacturerId>
								<individualPrice>.0510</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0510</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280804020">
							<itemNumber>0854</itemNumber>
							<strength>300mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="00327794" notABenefit="Y" sec3="Y">
								<name>Motrin</name>
								<manufacturerId>UPJ</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00441651" sec3="Y">
								<name>Apo-Ibuprofen</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1377</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1377</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280804021">
							<itemNumber>0855</itemNumber>
							<strength>400mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="00364142" sec3="Y">
								<name>Motrin</name>
								<manufacturerId>UPJ</manufacturerId>
								<individualPrice>.1871</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0936</amountMOHLTCPays>
							</drug>
							<drug id="00506052" sec3="Y">
								<name>Apo-Ibuprofen</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0936</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0936</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280804022">
							<itemNumber>0856</itemNumber>
							<strength>600mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="00484911" notABenefit="Y" sec3="Y">
								<name>Motrin</name>
								<manufacturerId>UPJ</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00585114" sec3="Y">
								<name>Apo-Ibuprofen</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1313</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1313</amountMOHLTCPays>
							</drug>
							<drug id="00629359" sec3="Y">
								<name>Novo-Profen</name>
								<manufacturerId>NOP</manufacturerId>
								<individualPrice>.1313</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1313</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00408">
					<name>INDOMETHACIN</name>
					<pcgGroup>
						<pcg9 id="280804023">
							<itemNumber>0857</itemNumber>
							<strength>25mg</strength>
							<dosageForm>Cap</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="00016039" notABenefit="Y" sec3="Y">
								<name>Indocid</name>
								<manufacturerId>MSD</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00337420" sec3="Y">
								<name>Teva-Indomethacin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1519</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1519</amountMOHLTCPays>
							</drug>
							<drug id="02461811" sec3="Y">
								<name>Mint-Indomethacin</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.1519</individualPrice>
								<listingDate>2017-06-29</listingDate>
								<amountMOHLTCPays>.1519</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280804024">
							<itemNumber>0858</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Cap</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="00016047" notABenefit="Y" sec3="Y">
								<name>Indocid</name>
								<manufacturerId>MSD</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00337439" sec3="Y">
								<name>Teva-Indomethacin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1234</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1234</amountMOHLTCPays>
							</drug>
							<drug id="02461536" sec3="Y">
								<name>Mint-Indomethacin</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.1234</individualPrice>
								<listingDate>2017-06-29</listingDate>
								<amountMOHLTCPays>.1234</amountMOHLTCPays>
							</drug>
							<drug id="02499223" sec3="Y">
								<name>Auro-Indomethacin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.1234</individualPrice>
								<listingDate>2021-08-31</listingDate>
								<amountMOHLTCPays>.1234</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280804025">
							<itemNumber>0859</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Sup</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="00594466" notABenefit="Y" sec3="Y">
								<name>Indocid</name>
								<manufacturerId>MSD</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02231799" sec3="Y">
								<name>Sab-Indomethacin</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.8840</individualPrice>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>.8840</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280804026">
							<itemNumber>0860</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Sup</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="00016233" notABenefit="Y" sec3="Y">
								<name>Indocid</name>
								<manufacturerId>MSD</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02231800" sec3="Y">
								<name>Sab-Indomethacin</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>1.2033</individualPrice>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>1.2033</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00420">
					<name>KETOPROFEN</name>
					<pcgGroup>
						<pcg9 id="280804027">
							<itemNumber>0861</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Cap</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="00790427" sec3="Y">
								<name>Ketoprofen</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.3440</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3440</amountMOHLTCPays>
							</drug>
							<drug id="01926403" notABenefit="Y" sec3="Y">
								<name>Orudis</name>
								<manufacturerId>RPP</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="280804028">
							<itemNumber>0862</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Ent Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="00790435" sec3="Y">
								<name>Ketoprofen-E</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.3379</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3379</amountMOHLTCPays>
							</drug>
							<drug id="01926381" notABenefit="Y" sec3="Y">
								<name>Orudis E-50</name>
								<manufacturerId>RPP</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="280804029">
							<itemNumber>0863</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Ent Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="00761680" notABenefit="Y" sec3="Y">
								<name>Rhodis-EC</name>
								<manufacturerId>SAV</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00842664" sec3="Y">
								<name>Ketoprofen-E</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.6959</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.6959</amountMOHLTCPays>
							</drug>
							<drug id="01926365" notABenefit="Y" sec3="Y">
								<name>Orudis E-100</name>
								<manufacturerId>RPP</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="280804060">
							<itemNumber>0864</itemNumber>
							<strength>200mg</strength>
							<dosageForm>LA Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="01926373" notABenefit="Y" sec3="Y">
								<name>Orudis SR-200</name>
								<manufacturerId>RPP</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02172577" sec3="Y">
								<name>Ketoprofen SR</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>1.3925</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>1.3925</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00442">
					<name>KETOROLAC TROMETHAMINE</name>
					<pcgGroup>
						<pcg9 id="280804105">
							<itemNumber>0865</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="02162660" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Toradol</name>
								<manufacturerId>AAP</manufacturerId>
								<listingDate>2008-10-01</listingDate>
							</drug>
							<drug id="02229080" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Ketorolac</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.6028</individualPrice>
								<listingDate>2008-10-01</listingDate>
							</drug>
							<drug id="02461455" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mint-Ketorolac</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.6028</individualPrice>
								<listingDate>2019-11-29</listingDate>
							</drug>
							<drug id="02465124" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mar-Ketorolac</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.6028</individualPrice>
								<listingDate>2017-08-30</listingDate>
							</drug>
							<drug id="02510855" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Jamp Ketorolac</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.6028</individualPrice>
								<listingDate>2021-04-30</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00427">
					<name>MEFENAMIC ACID</name>
					<pcgGroup>
						<pcg9 id="280804031">
							<itemNumber>0866</itemNumber>
							<strength>250mg</strength>
							<dosageForm>Cap</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="00155225" notABenefit="Y" sec3="Y">
								<name>Ponstan</name>
								<manufacturerId>AAP</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02229452" sec3="Y">
								<name>Mefenamic</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.4988</individualPrice>
								<listingDate>1997-04-10</listingDate>
								<amountMOHLTCPays>.4988</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01501">
					<name>MELOXICAM</name>
					<pcgGroup>
						<pcg9 id="280804083">
							<itemNumber>0867</itemNumber>
							<strength>7.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="02242785" sec3="Y">
								<name>Mobicox</name>
								<manufacturerId>BOE</manufacturerId>
								<individualPrice>.8572</individualPrice>
								<listingDate>2001-03-07</listingDate>
								<amountMOHLTCPays>.2003</amountMOHLTCPays>
							</drug>
							<drug id="02248267" sec3="Y">
								<name>PMS-Meloxicam</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2003</individualPrice>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.2003</amountMOHLTCPays>
							</drug>
							<drug id="02248973" sec3="Y">
								<name>Apo-Meloxicam</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2003</individualPrice>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.2003</amountMOHLTCPays>
							</drug>
							<drug id="02250012" sec3="Y">
								<name>Co Meloxicam</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.2003</individualPrice>
								<listingDate>2004-09-14</listingDate>
								<amountMOHLTCPays>.2003</amountMOHLTCPays>
							</drug>
							<drug id="02258315" sec3="Y">
								<name>Teva-Meloxicam</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2003</individualPrice>
								<listingDate>2004-11-16</listingDate>
								<amountMOHLTCPays>.2003</amountMOHLTCPays>
							</drug>
							<drug id="02353148" sec3="Y">
								<name>Meloxicam</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2003</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2003</amountMOHLTCPays>
							</drug>
							<drug id="02390884" sec3="Y">
								<name>Auro-Meloxicam</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2003</individualPrice>
								<listingDate>2012-12-21</listingDate>
								<amountMOHLTCPays>.2003</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280804084">
							<itemNumber>0868</itemNumber>
							<strength>15mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="02242786" sec3="Y">
								<name>Mobicox</name>
								<manufacturerId>BOE</manufacturerId>
								<individualPrice>.9891</individualPrice>
								<listingDate>2001-03-07</listingDate>
								<amountMOHLTCPays>.2311</amountMOHLTCPays>
							</drug>
							<drug id="02248268" sec3="Y">
								<name>PMS-Meloxicam</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2311</individualPrice>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.2311</amountMOHLTCPays>
							</drug>
							<drug id="02248974" sec3="Y">
								<name>Apo-Meloxicam</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2311</individualPrice>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.2311</amountMOHLTCPays>
							</drug>
							<drug id="02250020" sec3="Y">
								<name>Co Meloxicam</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.2311</individualPrice>
								<listingDate>2004-09-14</listingDate>
								<amountMOHLTCPays>.2311</amountMOHLTCPays>
							</drug>
							<drug id="02258323" sec3="Y">
								<name>Teva-Meloxicam</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2311</individualPrice>
								<listingDate>2004-11-16</listingDate>
								<amountMOHLTCPays>.2311</amountMOHLTCPays>
							</drug>
							<drug id="02353156" sec3="Y">
								<name>Meloxicam</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2311</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2311</amountMOHLTCPays>
							</drug>
							<drug id="02390892" sec3="Y">
								<name>Auro-Meloxicam</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2311</individualPrice>
								<listingDate>2012-12-21</listingDate>
								<amountMOHLTCPays>.2311</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00456">
					<name>NABUMETONE</name>
					<pcgGroup>
						<pcg9 id="280804072">
							<itemNumber>0869</itemNumber>
							<strength>500mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="02083531" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Relafen</name>
								<manufacturerId>GSK</manufacturerId>
								<listingDate>2007-07-12</listingDate>
							</drug>
							<drug id="02238639" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Nabumetone</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.5025</individualPrice>
								<listingDate>2007-09-04</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00416">
					<name>NAPROXEN</name>
					<pcgGroup>
						<pcg9 id="280804100">
							<itemNumber>0870</itemNumber>
							<strength>250mg</strength>
							<dosageForm>Ent Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="02162792" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Naprosyn E</name>
								<manufacturerId>HLR</manufacturerId>
								<listingDate>2008-01-15</listingDate>
							</drug>
							<drug id="02243312" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Teva-Naproxen EC</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2835</individualPrice>
								<listingDate>2008-11-04</listingDate>
							</drug>
							<drug id="02246699" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Naproxen EC</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2835</individualPrice>
								<listingDate>2008-01-15</listingDate>
							</drug>
							<drug id="02350785" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Naproxen EC</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2835</individualPrice>
								<listingDate>2011-10-25</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="280804101">
							<itemNumber>0871</itemNumber>
							<strength>375mg</strength>
							<dosageForm>Ent Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="02162415" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Naprosyn E</name>
								<manufacturerId>HLR</manufacturerId>
								<listingDate>2008-01-15</listingDate>
							</drug>
							<drug id="02243313" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Teva-Naproxen EC</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3675</individualPrice>
								<listingDate>2008-11-04</listingDate>
							</drug>
							<drug id="02246700" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Naproxen EC</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3675</individualPrice>
								<listingDate>2008-01-15</listingDate>
							</drug>
							<drug id="02294702" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>PMS-Naproxen EC</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3675</individualPrice>
								<listingDate>2008-01-15</listingDate>
							</drug>
							<drug id="02350793" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Naproxen EC</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.3675</individualPrice>
								<listingDate>2011-10-25</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="280804102">
							<itemNumber>0872</itemNumber>
							<strength>500mg</strength>
							<dosageForm>Ent Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="02162423" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Naprosyn E</name>
								<manufacturerId>HLR</manufacturerId>
								<listingDate>2008-01-15</listingDate>
							</drug>
							<drug id="02243314" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Teva-Naproxen EC</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.6894</individualPrice>
								<listingDate>2008-11-04</listingDate>
							</drug>
							<drug id="02246701" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Naproxen EC</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.6894</individualPrice>
								<listingDate>2008-01-15</listingDate>
							</drug>
							<drug id="02294710" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>PMS-Naproxen EC</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.6894</individualPrice>
								<listingDate>2008-01-15</listingDate>
							</drug>
							<drug id="02350807" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Naproxen EC</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.6894</individualPrice>
								<listingDate>2011-10-25</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="280804054">
							<itemNumber>0873</itemNumber>
							<strength>25mg/mL</strength>
							<dosageForm>O/L</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="02162431" sec3="Y">
								<name>Pediapharm Naproxen Suspension</name>
								<manufacturerId>PED</manufacturerId>
								<individualPrice>.0949</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0949</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280804037">
							<itemNumber>0874</itemNumber>
							<strength>500mg</strength>
							<dosageForm>Sup</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="02017237" sec3="Y">
								<name>PMS-Naproxen</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.9567</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.9567</amountMOHLTCPays>
							</drug>
							<drug id="02162458" notABenefit="Y" sec3="Y">
								<name>Naprosyn</name>
								<manufacturerId>HLR</manufacturerId>
								<listingDate>2000-04-17</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="280804033">
							<itemNumber>0875</itemNumber>
							<strength>125mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="00299413" notABenefit="Y" sec3="Y">
								<name>Naprosyn</name>
								<manufacturerId>SYN</manufacturerId>
								<listingDate>2001-02-28</listingDate>
							</drug>
							<drug id="00522678" sec3="Y">
								<name>Apo-Naproxen</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0781</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0781</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280804034">
							<itemNumber>0876</itemNumber>
							<strength>250mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="00522651" sec3="Y">
								<name>Apo-Naproxen</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1068</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1068</amountMOHLTCPays>
							</drug>
							<drug id="00565350" sec3="Y">
								<name>Teva-Naproxen</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1068</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1068</amountMOHLTCPays>
							</drug>
							<drug id="02162474" notABenefit="Y" sec3="Y">
								<name>Naprosyn</name>
								<manufacturerId>HLR</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02350750" sec3="Y">
								<name>Naproxen</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.1068</individualPrice>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>.1068</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280804035">
							<itemNumber>0877</itemNumber>
							<strength>375mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="00600806" sec3="Y">
								<name>Apo-Naproxen</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1458</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1458</amountMOHLTCPays>
							</drug>
							<drug id="00627097" sec3="Y">
								<name>Teva-Naproxen</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1458</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1458</amountMOHLTCPays>
							</drug>
							<drug id="02162482" notABenefit="Y" sec3="Y">
								<name>Naprosyn</name>
								<manufacturerId>HLR</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02350769" sec3="Y">
								<name>Naproxen</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.1458</individualPrice>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>.1458</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280804036">
							<itemNumber>0878</itemNumber>
							<strength>500mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="00589861" sec3="Y">
								<name>Teva-Naproxen</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2244</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2244</amountMOHLTCPays>
							</drug>
							<drug id="00592277" sec3="Y">
								<name>Apo-Naproxen</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2244</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2244</amountMOHLTCPays>
							</drug>
							<drug id="02162490" notABenefit="Y" sec3="Y">
								<name>Naprosyn</name>
								<manufacturerId>HLR</manufacturerId>
								<listingDate>2000-04-17</listingDate>
							</drug>
							<drug id="02350777" sec3="Y">
								<name>Naproxen</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2244</individualPrice>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>.2244</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="02034">
					<name>NAPROXEN &amp; ESOMEPRAZOLE MAGNESIUM</name>
					<pcgGroup>
						<pcg9 id="280804106">
							<itemNumber>0879</itemNumber>
							<strength>375mg &amp; 20mg</strength>
							<dosageForm>MR Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="02361701" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Vimovo</name>
								<manufacturerId>AZC</manufacturerId>
								<listingDate>2017-04-27</listingDate>
							</drug>
							<drug id="02458608" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mylan-Naproxen &amp; Esomeprazole MR</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.9308</individualPrice>
								<listingDate>2017-04-27</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="280804107">
							<itemNumber>0880</itemNumber>
							<strength>500mg &amp; 20mg</strength>
							<dosageForm>MR Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="02361728" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Vimovo</name>
								<manufacturerId>AZC</manufacturerId>
								<listingDate>2017-04-27</listingDate>
							</drug>
							<drug id="02443449" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mylan-Naproxen &amp; Esomeprazole MR</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.9274</individualPrice>
								<listingDate>2017-04-27</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00446">
					<name>NAPROXEN SODIUM</name>
					<pcgGroup>
						<pcg9 id="280804103">
							<itemNumber>0881</itemNumber>
							<strength>275mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="00784354" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Napro-Na</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3422</individualPrice>
								<listingDate>2007-12-19</listingDate>
							</drug>
							<drug id="02162725" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Anaprox</name>
								<manufacturerId>HLR</manufacturerId>
								<listingDate>2007-12-19</listingDate>
							</drug>
							<drug id="02351013" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Naproxen Sodium</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.3422</individualPrice>
								<listingDate>2020-10-30</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="280804104">
							<itemNumber>0882</itemNumber>
							<strength>550mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="01940309" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Napro-Na DS</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.6667</individualPrice>
								<listingDate>2007-12-19</listingDate>
							</drug>
							<drug id="02162717" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Anaprox DS</name>
								<manufacturerId>HLR</manufacturerId>
								<listingDate>2007-12-19</listingDate>
							</drug>
							<drug id="02351021" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Naproxen Sodium DS</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.6667</individualPrice>
								<listingDate>2020-10-30</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01317">
					<name>OXAPROZIN.</name>
					<pcgGroup>
						<pcg9 id="280804055">
							<itemNumber>0883</itemNumber>
							<strength>600mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="02027860" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Daypro</name>
								<manufacturerId>HLR</manufacturerId>
								<listingDate>2007-07-12</listingDate>
							</drug>
							<drug id="02243661" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Oxaprozin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.6892</individualPrice>
								<listingDate>2007-07-12</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00429">
					<name>PIROXICAM</name>
					<pcgGroup>
						<pcg9 id="280804038">
							<itemNumber>0884</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Cap</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="00525596" notABenefit="Y" sec3="Y">
								<name>Feldene</name>
								<manufacturerId>PFI</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00642886" sec3="Y">
								<name>Apo-Piroxicam</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.4426</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.4426</amountMOHLTCPays>
							</drug>
							<drug id="00695718" sec3="Y">
								<name>Teva-Piroxicam</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.4426</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.4426</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280804039">
							<itemNumber>0885</itemNumber>
							<strength>20mg</strength>
							<dosageForm>Cap</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="00525618" notABenefit="Y" sec3="Y">
								<name>Feldene</name>
								<manufacturerId>PFI</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00642894" sec3="Y">
								<name>Apo-Piroxicam</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.7422</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.7422</amountMOHLTCPays>
							</drug>
							<drug id="00695696" sec3="Y">
								<name>Teva-Piroxicam</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.7422</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.7422</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00422">
					<name>SULINDAC</name>
					<pcgGroup>
						<pcg9 id="280804042">
							<itemNumber>0886</itemNumber>
							<strength>150mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="00456888" notABenefit="Y" sec3="Y">
								<name>Clinoril</name>
								<manufacturerId>FRS</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00745588" sec3="Y">
								<name>Teva-Sulindac</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.4216</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.4216</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280804043">
							<itemNumber>0887</itemNumber>
							<strength>200mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="00432369" notABenefit="Y" sec3="Y">
								<name>Clinoril</name>
								<manufacturerId>FRS</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00745596" sec3="Y">
								<name>Teva-Sulindac</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.4840</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.4840</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00434">
					<name>TIAPROFENIC ACID</name>
					<pcgGroup>
						<pcg9 id="280804044">
							<itemNumber>0888</itemNumber>
							<strength>200mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="01989782" notABenefit="Y" sec3="Y">
								<name>Surgam</name>
								<manufacturerId>HRU</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02179679" sec3="Y">
								<name>Teva-Tiaprofenic</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.5455</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.5455</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280804045">
							<itemNumber>0889</itemNumber>
							<strength>300mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note>
							<drug id="02179687" sec3="Y">
								<name>Teva-Tiaprofenic</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.8070</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.8070</amountMOHLTCPays>
							</drug>
							<drug id="02221950" notABenefit="Y" sec3="Y">
								<name>Surgam</name>
								<manufacturerId>SAV</manufacturerId>
								<listingDate>1999-01-07</listingDate>
							</drug>
							<drug id="02230828" notABenefit="Y" sec3="Y">
								<name>PMS-Tiaprofenic</name>
								<manufacturerId>PMS</manufacturerId>
								<listingDate>1998-12-31</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="280808000">
				<name>ANALGESICS OPIATE AGONISTS</name>
				<note>Narcotic analgesics can produce dependence and may be abused. Physical dependence, psychological dependence and tolerance may develop. Prescribers are cautioned about ordering these drugs for patients with a history of either emotional disturbances or drug abuse, including alcohol.</note>
				<genericName id="01867">
					<name>ACETAMINOPHEN &amp; CAFFEINE &amp; CODEINE PHOSPHATE</name>
					<pcgGroup>
						<pcg9 id="280808004">
							<itemNumber>0890</itemNumber>
							<strength>300mg &amp; 15mg &amp; 15mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00653241" sec3="Y">
								<name>Teva-Lenoltec No.2</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.0889</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0889</amountMOHLTCPays>
							</drug>
							<drug id="02163934" notABenefit="Y" sec3="Y">
								<name>Tylenol with Codeine No. 2</name>
								<manufacturerId>JAN</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="280808005">
							<itemNumber>0891</itemNumber>
							<strength>300mg &amp; 15mg &amp; 30mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00653276" sec3="Y">
								<name>Teva-Lenoltec No.3</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.0933</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0933</amountMOHLTCPays>
							</drug>
							<drug id="02163926" notABenefit="Y" sec3="Y">
								<name>Tylenol with Codeine No. 3</name>
								<manufacturerId>JAN</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00421">
					<name>ACETAMINOPHEN &amp; CODEINE PHOSPHATE</name>
					<pcgGroup>
						<pcg9 id="280808001">
							<itemNumber>0892</itemNumber>
							<strength>160mg &amp; 8mg/5mL</strength>
							<dosageForm>O/L</dosageForm>
							<drug id="00816027" sec3="Y">
								<name>PMS-Acetaminophen With Codeine</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.0769</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.0769</amountMOHLTCPays>
							</drug>
							<drug id="02163942" notABenefit="Y" sec3="Y">
								<name>Tylenol With Codeine Elixir</name>
								<manufacturerId>JAN</manufacturerId>
								<listingDate>2007-01-02</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="280808002">
							<itemNumber>0893</itemNumber>
							<strength>300mg &amp; 30mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00608882" sec3="Y">
								<name>Teva-Emtec-30</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1300</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1300</amountMOHLTCPays>
							</drug>
							<drug id="00666130" notABenefit="Y" sec3="Y">
								<name>Empracet-30</name>
								<manufacturerId>BWE</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="280808003">
							<itemNumber>0894</itemNumber>
							<strength>300mg &amp; 60mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00621463" sec3="Y">
								<name>Teva-Lenoltec No.4</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1685</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1685</amountMOHLTCPays>
							</drug>
							<drug id="02163918" notABenefit="Y" sec3="Y">
								<name>Tylenol with Codeine No. 4</name>
								<manufacturerId>JAN</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01743">
					<name>ACETYLSALICYLIC ACID &amp; BUTALBITAL &amp; CAFFEINE</name>
					<pcgGroup>
						<pcg9 id="280808136">
							<itemNumber>0895</itemNumber>
							<strength>330mg &amp; 50mg &amp; 40mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00226327" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Fiorinal</name>
								<manufacturerId>NOV</manufacturerId>
								<listingDate>2008-12-23</listingDate>
							</drug>
							<drug id="00608238" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Ratio-Tecnal</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>1.4687</individualPrice>
								<listingDate>2008-12-23</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01744">
					<name>ACETYLSALICYLIC ACID &amp; BUTALBITAL &amp; CAFFEINE &amp; CODEINE PHOSPHATE</name>
					<pcgGroup>
						<pcg9 id="280808168">
							<itemNumber>0896</itemNumber>
							<strength>330mg &amp; 50mg &amp; 40mg &amp; 15mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00176192" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Fiorinal C1/4</name>
								<manufacturerId>NOV</manufacturerId>
								<listingDate>2008-12-23</listingDate>
							</drug>
							<drug id="00608203" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Ratio-Tecnal C1/4</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>1.5749</individualPrice>
								<listingDate>2008-12-23</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="280808138">
							<itemNumber>0897</itemNumber>
							<strength>330mg &amp; 50mg &amp; 40mg &amp; 30mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00176206" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Fiorinal C1/2</name>
								<manufacturerId>NOV</manufacturerId>
								<listingDate>2008-12-23</listingDate>
							</drug>
							<drug id="00608181" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Ratio-Tecnal C1/2</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>1.9285</individualPrice>
								<listingDate>2008-12-23</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00405">
					<name>ACETYLSALICYLIC ACID COMPOUND WITH CODEINE</name>
					<pcgGroup>
						<pcg9 id="280808007">
							<itemNumber>0898</itemNumber>
							<strength>30mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02238645" sec3="Y">
								<name>292</name>
								<manufacturerId>PEN</manufacturerId>
								<individualPrice>.1730</individualPrice>
								<listingDate>2006-10-23</listingDate>
								<amountMOHLTCPays>.1730</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00406">
					<name>CODEINE PHOSPHATE</name>
					<pcgGroup>
						<pcg9 id="280808010">
							<itemNumber>0899</itemNumber>
							<strength>15mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00593435" sec3="Y">
								<name>Teva-Codeine</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.0542</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0542</amountMOHLTCPays>
							</drug>
							<drug id="00779458" notABenefit="Y" sec3="Y">
								<name>Codeine</name>
								<manufacturerId>ROG</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="280808011">
							<itemNumber>0900</itemNumber>
							<strength>30mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00593451" sec3="Y">
								<name>Teva-Codeine</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.0966</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0966</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00462">
					<name>CODEINE SULFATE TRIHYDRATE &amp; MONOHYDRATE</name>
					<pcgGroup lccId="00066">
						<pcg9 id="280808101">
							<itemNumber>0901</itemNumber>
							<strength>50mg</strength>
							<dosageForm>CR Tab</dosageForm>
							<drug id="02230302" sec3="Y" sec12="Y">
								<name>Codeine Contin</name>
								<manufacturerId>PFP</manufacturerId>
								<individualPrice>.4230</individualPrice>
								<listingDate>2002-04-04</listingDate>
								<amountMOHLTCPays>.4230</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808107">
							<itemNumber>0902</itemNumber>
							<strength>100mg</strength>
							<dosageForm>CR Tab</dosageForm>
							<drug id="02163748" sec3="Y" sec12="Y">
								<name>Codeine Contin</name>
								<manufacturerId>PFP</manufacturerId>
								<individualPrice>.8460</individualPrice>
								<listingDate>2002-04-04</listingDate>
								<amountMOHLTCPays>.8460</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808108">
							<itemNumber>0903</itemNumber>
							<strength>150mg</strength>
							<dosageForm>CR Tab</dosageForm>
							<drug id="02163780" sec3="Y" sec12="Y">
								<name>Codeine Contin</name>
								<manufacturerId>PFP</manufacturerId>
								<individualPrice>1.2690</individualPrice>
								<listingDate>2002-04-04</listingDate>
								<amountMOHLTCPays>1.2690</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808109">
							<itemNumber>0904</itemNumber>
							<strength>200mg</strength>
							<dosageForm>CR Tab</dosageForm>
							<drug id="02163799" sec3="Y" sec12="Y">
								<name>Codeine Contin</name>
								<manufacturerId>PFP</manufacturerId>
								<individualPrice>1.6920</individualPrice>
								<listingDate>2002-04-04</listingDate>
								<amountMOHLTCPays>1.6920</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="201">For the treatment of chronic pain in patients who cannot tolerate, or have failed treatment with a listed long-acting opioid.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00466">
					<name>FENTANYL TRANSDERMAL SYSTEM</name>
					<pcgGroup>
						<pcg9 id="280808169">
							<itemNumber>0905</itemNumber>
							<strength>12mcg/hr</strength>
							<dosageForm>Trans Patch</dosageForm>
							<drug id="02280345" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Duragesic 12</name>
								<manufacturerId>JNO</manufacturerId>
								<listingDate>2008-12-23</listingDate>
							</drug>
							<drug id="02311925" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Teva-Fentanyl</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>3.1980</individualPrice>
								<listingDate>2008-12-23</listingDate>
							</drug>
							<drug id="02327112" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Sandoz Fentanyl Patch</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>3.1980</individualPrice>
								<listingDate>2010-03-02</listingDate>
							</drug>
							<drug id="02330105" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Ran-Fentanyl Matrix Patch</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>3.1980</individualPrice>
								<listingDate>2010-03-02</listingDate>
							</drug>
							<drug id="02341379" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>PMS-Fentanyl MTX</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>3.1980</individualPrice>
								<listingDate>2010-07-20</listingDate>
							</drug>
							<drug id="02386844" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Co Fentanyl Matrix Patch</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>3.1980</individualPrice>
								<listingDate>2013-03-20</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
					<pcgGroup lccId="00067">
						<pcg9 id="280808079">
							<itemNumber>0906</itemNumber>
							<strength>25mcg/hr</strength>
							<dosageForm>Trans Patch</dosageForm>
							<drug id="01937383" notABenefit="Y" sec3="Y">
								<name>Duragesic 25</name>
								<manufacturerId>JNO</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02275813" notABenefit="Y" sec3="Y">
								<name>Duragesic</name>
								<manufacturerId>JAN</manufacturerId>
								<listingDate>2010-04-23</listingDate>
							</drug>
							<drug id="02282941" sec3="Y" sec12="Y">
								<name>Teva-Fentanyl</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>3.6582</individualPrice>
								<listingDate>2007-01-02</listingDate>
								<amountMOHLTCPays>3.6582</amountMOHLTCPays>
							</drug>
							<drug id="02314630" sec3="Y" sec12="Y">
								<name>Apo-Fentanyl Matrix</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>3.6582</individualPrice>
								<listingDate>2009-09-30</listingDate>
								<amountMOHLTCPays>3.6582</amountMOHLTCPays>
							</drug>
							<drug id="02327120" sec3="Y" sec12="Y">
								<name>Sandoz Fentanyl Patch</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>3.6582</individualPrice>
								<listingDate>2010-03-02</listingDate>
								<amountMOHLTCPays>3.6582</amountMOHLTCPays>
							</drug>
							<drug id="02330113" sec3="Y" sec12="Y">
								<name>Ran-Fentanyl Matrix Patch</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>3.6582</individualPrice>
								<listingDate>2010-03-02</listingDate>
								<amountMOHLTCPays>3.6582</amountMOHLTCPays>
							</drug>
							<drug id="02341387" sec3="Y" sec12="Y">
								<name>PMS-Fentanyl MTX</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>3.6582</individualPrice>
								<listingDate>2010-07-20</listingDate>
								<amountMOHLTCPays>3.6582</amountMOHLTCPays>
							</drug>
							<drug id="02386852" sec3="Y" sec12="Y">
								<name>Co Fentanyl Matrix Patch</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>3.6582</individualPrice>
								<listingDate>2013-03-20</listingDate>
								<amountMOHLTCPays>3.6582</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808080">
							<itemNumber>0907</itemNumber>
							<strength>50mcg/hr</strength>
							<dosageForm>Trans Patch</dosageForm>
							<drug id="01937391" notABenefit="Y" sec3="Y">
								<name>Duragesic 50</name>
								<manufacturerId>JNO</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02275821" notABenefit="Y" sec3="Y">
								<name>Duragesic</name>
								<manufacturerId>JAN</manufacturerId>
								<listingDate>2010-04-23</listingDate>
							</drug>
							<drug id="02282968" sec3="Y" sec12="Y">
								<name>Teva-Fentanyl</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>6.8838</individualPrice>
								<listingDate>2007-01-02</listingDate>
								<amountMOHLTCPays>6.8838</amountMOHLTCPays>
							</drug>
							<drug id="02327147" sec3="Y" sec12="Y">
								<name>Sandoz Fentanyl Patch</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>6.8838</individualPrice>
								<listingDate>2010-03-02</listingDate>
								<amountMOHLTCPays>6.8838</amountMOHLTCPays>
							</drug>
							<drug id="02330121" sec3="Y" sec12="Y">
								<name>Ran-Fentanyl Matrix Patch</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>6.8838</individualPrice>
								<listingDate>2010-03-02</listingDate>
								<amountMOHLTCPays>6.8838</amountMOHLTCPays>
							</drug>
							<drug id="02341395" sec3="Y" sec12="Y">
								<name>PMS-Fentanyl MTX</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>6.8838</individualPrice>
								<listingDate>2010-07-20</listingDate>
								<amountMOHLTCPays>6.8838</amountMOHLTCPays>
							</drug>
							<drug id="02386879" sec3="Y" sec12="Y">
								<name>Co Fentanyl Matrix Patch</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>6.8838</individualPrice>
								<listingDate>2013-03-20</listingDate>
								<amountMOHLTCPays>6.8838</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="511">For the treatment of chronic pain in patients who cannot tolerate, or have failed treatment with a long-acting opioid. Intolerance or failed treatment with a long-acting opioid will be subject to verification at the time of dispensing.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
					<pcgGroup>
						<pcg9 id="280808081">
							<itemNumber>0908</itemNumber>
							<strength>75mcg/hr</strength>
							<dosageForm>Trans Patch</dosageForm>
							<drug id="01937405" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Duragesic 75</name>
								<manufacturerId>JNO</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02275848" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Duragesic</name>
								<manufacturerId>JAN</manufacturerId>
								<listingDate>2010-04-23</listingDate>
							</drug>
							<drug id="02282976" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Teva-Fentanyl</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>9.6817</individualPrice>
								<listingDate>2007-01-02</listingDate>
							</drug>
							<drug id="02314657" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Fentanyl Matrix</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>9.6817</individualPrice>
								<listingDate>2009-09-30</listingDate>
							</drug>
							<drug id="02327155" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Sandoz Fentanyl Patch</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>9.6817</individualPrice>
								<listingDate>2010-03-02</listingDate>
							</drug>
							<drug id="02330148" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Ran-Fentanyl Matrix Patch</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>9.6817</individualPrice>
								<listingDate>2010-03-02</listingDate>
							</drug>
							<drug id="02341409" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>PMS-Fentanyl MTX</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>9.6817</individualPrice>
								<listingDate>2010-07-20</listingDate>
							</drug>
							<drug id="02386887" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Co Fentanyl Matrix Patch</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>9.6817</individualPrice>
								<listingDate>2013-03-20</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="280808082">
							<itemNumber>0909</itemNumber>
							<strength>100mcg/hr</strength>
							<dosageForm>Trans Patch</dosageForm>
							<drug id="01937413" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Duragesic 100</name>
								<manufacturerId>JNO</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02275856" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Duragesic</name>
								<manufacturerId>JAN</manufacturerId>
								<listingDate>2010-04-23</listingDate>
							</drug>
							<drug id="02282984" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Teva-Fentanyl</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>12.0512</individualPrice>
								<listingDate>2007-01-02</listingDate>
							</drug>
							<drug id="02314665" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Fentanyl Matrix</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>12.0512</individualPrice>
								<listingDate>2009-09-30</listingDate>
							</drug>
							<drug id="02327163" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Sandoz Fentanyl Patch</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>12.0512</individualPrice>
								<listingDate>2010-03-02</listingDate>
							</drug>
							<drug id="02330156" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Ran-Fentanyl Matrix Patch</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>12.0512</individualPrice>
								<listingDate>2010-03-02</listingDate>
							</drug>
							<drug id="02341417" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>PMS-Fentanyl MTX</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>12.0512</individualPrice>
								<listingDate>2010-07-20</listingDate>
							</drug>
							<drug id="02386895" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Co Fentanyl Matrix Patch</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>12.0512</individualPrice>
								<listingDate>2013-03-20</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00432">
					<name>HYDROMORPHONE HCL</name>
					<pcgGroup>
						<pcg9 id="280808306">
							<itemNumber>0910</itemNumber>
							<strength>4.5mg</strength>
							<dosageForm>CR Cap</dosageForm>
							<drug id="02359502" sec3="Y">
								<name>Hydromorph Contin</name>
								<manufacturerId>PFP</manufacturerId>
								<individualPrice>.8020</individualPrice>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.8020</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808307">
							<itemNumber>0911</itemNumber>
							<strength>9mg</strength>
							<dosageForm>CR Cap</dosageForm>
							<drug id="02359510" sec3="Y">
								<name>Hydromorph Contin</name>
								<manufacturerId>PFP</manufacturerId>
								<individualPrice>1.3140</individualPrice>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>1.3140</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808097">
							<itemNumber>0912</itemNumber>
							<strength>3mg</strength>
							<dosageForm>CR Cap</dosageForm>
							<drug id="02125323" sec3="Y">
								<name>Hydromorph Contin</name>
								<manufacturerId>PFP</manufacturerId>
								<individualPrice>.6645</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.6645</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808098">
							<itemNumber>0913</itemNumber>
							<strength>6mg</strength>
							<dosageForm>CR Cap</dosageForm>
							<drug id="02125331" sec3="Y">
								<name>Hydromorph Contin</name>
								<manufacturerId>PFP</manufacturerId>
								<individualPrice>.9950</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.9950</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808099">
							<itemNumber>0914</itemNumber>
							<strength>12mg</strength>
							<dosageForm>CR Cap</dosageForm>
							<drug id="02125366" sec3="Y">
								<name>Hydromorph Contin</name>
								<manufacturerId>PFP</manufacturerId>
								<individualPrice>1.7260</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>1.7260</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808123">
							<itemNumber>0915</itemNumber>
							<strength>18mg</strength>
							<dosageForm>CR Cap</dosageForm>
							<drug id="02243562" sec3="Y">
								<name>Hydromorph Contin</name>
								<manufacturerId>PFP</manufacturerId>
								<individualPrice>2.4900</individualPrice>
								<listingDate>2002-04-04</listingDate>
								<amountMOHLTCPays>2.4900</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808100">
							<itemNumber>0916</itemNumber>
							<strength>24mg</strength>
							<dosageForm>CR Cap</dosageForm>
							<drug id="02125382" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Hydromorph Contin</name>
								<manufacturerId>PFP</manufacturerId>
								<individualPrice>3.6120</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>3.6120</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808102">
							<itemNumber>0917</itemNumber>
							<strength>30mg</strength>
							<dosageForm>CR Cap</dosageForm>
							<drug id="02125390" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Hydromorph Contin</name>
								<manufacturerId>PFP</manufacturerId>
								<individualPrice>4.3260</individualPrice>
								<listingDate>1999-09-15</listingDate>
								<amountMOHLTCPays>4.3260</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808014">
							<itemNumber>0918</itemNumber>
							<strength>2mg/mL</strength>
							<dosageForm>Inj Sol-1mL Pk</dosageForm>
							<drug id="00627100" notABenefit="Y" sec3="Y">
								<name>Dilaudid</name>
								<manufacturerId>PFP</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02145901" sec3="Y">
								<name>Hydromorphone</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>1.7830</individualPrice>
								<listingDate>1996-12-19</listingDate>
								<amountMOHLTCPays>1.7830</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808015">
							<itemNumber>0919</itemNumber>
							<strength>10mg/mL</strength>
							<dosageForm>Inj Sol-1mL Pk</dosageForm>
							<drug id="00622133" notABenefit="Y" sec3="Y">
								<name>Dilaudid-HP</name>
								<manufacturerId>PFP</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02145928" sec3="Y">
								<name>Hydromorphone HP-10</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>4.3460</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>4.3460</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808013">
							<itemNumber>0920</itemNumber>
							<strength>1mg/mL</strength>
							<dosageForm>Oral Sol</dosageForm>
							<drug id="00786535" dinStatus="E" sec3="Y">
								<name>Dilaudid</name>
								<manufacturerId>PFP</manufacturerId>
								<individualPrice>.0931</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0698</amountMOHLTCPays>
							</drug>
							<drug id="01916386" sec3="Y">
								<name>PMS-HYDROmorphone</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.0698</individualPrice>
								<listingDate>2006-01-24</listingDate>
								<amountMOHLTCPays>.0698</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808017">
							<itemNumber>0921</itemNumber>
							<strength>1mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00705438" sec3="Y">
								<name>Dilaudid</name>
								<manufacturerId>PFP</manufacturerId>
								<individualPrice>.0959</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0959</amountMOHLTCPays>
							</drug>
							<drug id="00885444" sec3="Y">
								<name>PMS-HYDROmorphone</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.0959</individualPrice>
								<listingDate>2001-10-11</listingDate>
								<amountMOHLTCPays>.0959</amountMOHLTCPays>
							</drug>
							<drug id="02319403" sec3="Y">
								<name>Teva-Hydromorphone</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.0959</individualPrice>
								<listingDate>2012-06-26</listingDate>
								<amountMOHLTCPays>.0959</amountMOHLTCPays>
							</drug>
							<drug id="02364115" sec3="Y">
								<name>Apo-Hydromorphone</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0959</individualPrice>
								<listingDate>2012-06-26</listingDate>
								<amountMOHLTCPays>.0959</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808018">
							<itemNumber>0922</itemNumber>
							<strength>2mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00125083" sec3="Y">
								<name>Dilaudid</name>
								<manufacturerId>PFP</manufacturerId>
								<individualPrice>.1417</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1417</amountMOHLTCPays>
							</drug>
							<drug id="00885436" sec3="Y">
								<name>PMS-HYDROmorphone</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1417</individualPrice>
								<listingDate>1997-04-10</listingDate>
								<amountMOHLTCPays>.1417</amountMOHLTCPays>
							</drug>
							<drug id="02319411" sec3="Y">
								<name>Teva-Hydromorphone</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1417</individualPrice>
								<listingDate>2012-06-26</listingDate>
								<amountMOHLTCPays>.1417</amountMOHLTCPays>
							</drug>
							<drug id="02364123" sec3="Y">
								<name>Apo-Hydromorphone</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1417</individualPrice>
								<listingDate>2012-06-26</listingDate>
								<amountMOHLTCPays>.1417</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808019">
							<itemNumber>0923</itemNumber>
							<strength>4mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00125121" sec3="Y">
								<name>Dilaudid</name>
								<manufacturerId>PFP</manufacturerId>
								<individualPrice>.2240</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2240</amountMOHLTCPays>
							</drug>
							<drug id="00885401" sec3="Y">
								<name>PMS-HYDROmorphone</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2240</individualPrice>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>.2240</amountMOHLTCPays>
							</drug>
							<drug id="02319438" sec3="Y">
								<name>Teva-Hydromorphone</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2240</individualPrice>
								<listingDate>2012-06-26</listingDate>
								<amountMOHLTCPays>.2240</amountMOHLTCPays>
							</drug>
							<drug id="02364131" sec3="Y">
								<name>Apo-Hydromorphone</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2240</individualPrice>
								<listingDate>2012-06-26</listingDate>
								<amountMOHLTCPays>.2240</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808020">
							<itemNumber>0924</itemNumber>
							<strength>8mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00786543" sec3="Y">
								<name>Dilaudid</name>
								<manufacturerId>PFP</manufacturerId>
								<individualPrice>.3528</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3528</amountMOHLTCPays>
							</drug>
							<drug id="00885428" sec3="Y">
								<name>PMS-HYDROmorphone</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3528</individualPrice>
								<listingDate>2001-10-11</listingDate>
								<amountMOHLTCPays>.3528</amountMOHLTCPays>
							</drug>
							<drug id="02319446" sec3="Y">
								<name>Teva-Hydromorphone</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3528</individualPrice>
								<listingDate>2012-06-26</listingDate>
								<amountMOHLTCPays>.3528</amountMOHLTCPays>
							</drug>
							<drug id="02364158" sec3="Y">
								<name>Apo-Hydromorphone</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3528</individualPrice>
								<listingDate>2012-06-26</listingDate>
								<amountMOHLTCPays>.3528</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01643">
					<name>METHADONE HCL</name>
					<pcgGroup>
						<pcg9 id="280808450">
							<itemNumber>0925</itemNumber>
							<strength>10mg/mL</strength>
							<dosageForm>Oral Concentrate</dosageForm>
							<note>For methadone maintenance treatment for addiction.</note>
							<drug id="02244290" sec3="Y">
								<name>Metadol-D</name>
								<manufacturerId>PAL</manufacturerId>
								<individualPrice>.1500</individualPrice>
								<listingDate>2017-01-31</listingDate>
								<amountMOHLTCPays>.1500</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808421">
							<itemNumber>0926</itemNumber>
							<strength>10mg/mL</strength>
							<dosageForm>Oral Concentrate (Cherry Flavour)</dosageForm>
							<note>For methadone maintenance treatment for addiction.</note>
							<drug id="02394596" sec3="Y">
								<name>Methadose</name>
								<manufacturerId>MAL</manufacturerId>
								<individualPrice>.1500</individualPrice>
								<listingDate>2014-06-26</listingDate>
								<amountMOHLTCPays>.1500</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808422">
							<itemNumber>0927</itemNumber>
							<strength>10mg/mL</strength>
							<dosageForm>Oral Concentrate (Unflavoured)</dosageForm>
							<note>For methadone maintenance treatment for addiction.</note>
							<drug id="02394618" sec3="Y">
								<name>Methadose</name>
								<manufacturerId>MAL</manufacturerId>
								<individualPrice>.1500</individualPrice>
								<listingDate>2014-06-26</listingDate>
								<amountMOHLTCPays>.1500</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00411">
					<name>MORPHINE SULFATE</name>
					<pcgGroup>
						<pcg9 id="280808068">
							<itemNumber>0928</itemNumber>
							<strength>10mg</strength>
							<dosageForm>ER Cap</dosageForm>
							<drug id="02019930" sec3="Y">
								<name>M-Eslon</name>
								<manufacturerId>ETH</manufacturerId>
								<individualPrice>.3250</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3250</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808086">
							<itemNumber>0929</itemNumber>
							<strength>15mg</strength>
							<dosageForm>ER Cap</dosageForm>
							<drug id="02177749" sec3="Y">
								<name>M-Eslon</name>
								<manufacturerId>ETH</manufacturerId>
								<individualPrice>.3750</individualPrice>
								<listingDate>1996-12-19</listingDate>
								<amountMOHLTCPays>.3750</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808069">
							<itemNumber>0930</itemNumber>
							<strength>30mg</strength>
							<dosageForm>ER Cap</dosageForm>
							<drug id="02019949" sec3="Y">
								<name>M-Eslon</name>
								<manufacturerId>ETH</manufacturerId>
								<individualPrice>.5590</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.5590</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808070">
							<itemNumber>0931</itemNumber>
							<strength>60mg</strength>
							<dosageForm>ER Cap</dosageForm>
							<drug id="02019957" sec3="Y">
								<name>M-Eslon</name>
								<manufacturerId>ETH</manufacturerId>
								<individualPrice>.9900</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.9900</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808071">
							<itemNumber>0932</itemNumber>
							<strength>100mg</strength>
							<dosageForm>ER Cap</dosageForm>
							<drug id="02019965" sec3="Y">
								<name>M-Eslon</name>
								<manufacturerId>ETH</manufacturerId>
								<individualPrice>2.1460</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>2.1460</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
					<pcgGroup lccId="00292">
						<pcg9 id="280808150">
							<itemNumber>0933</itemNumber>
							<strength>2mg/mL</strength>
							<dosageForm>Inj Sol Amp</dosageForm>
							<drug id="02242484" sec3="Y" sec12="Y">
								<name>Morphine Sulfate Injection USP</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>2.2510</individualPrice>
								<listingDate>2018-01-31</listingDate>
								<amountMOHLTCPays>2.2510</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="481">For the management of patients receiving palliative care*.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="003" type="N">*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.</lccNote>
					</pcgGroup>
					<pcgGroup lccId="00293">
						<pcg9 id="280808151">
							<itemNumber>0934</itemNumber>
							<strength>10mg/mL</strength>
							<dosageForm>Inj Sol Amp</dosageForm>
							<drug id="00392588" sec3="Y" sec12="Y">
								<name>Morphine Sulfate</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>2.3860</individualPrice>
								<listingDate>2018-01-31</listingDate>
								<amountMOHLTCPays>2.3860</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="481">For the management of patients receiving palliative care*.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="003" type="N">*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.</lccNote>
					</pcgGroup>
					<pcgGroup>
						<pcg9 id="280808040">
							<itemNumber>0935</itemNumber>
							<strength>15mg/mL</strength>
							<dosageForm>Inj Sol Amp</dosageForm>
							<drug id="00392561" sec3="Y">
								<name>Morphine Sulfate</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>2.0940</individualPrice>
								<listingDate>1996-12-19</listingDate>
								<amountMOHLTCPays>2.0940</amountMOHLTCPays>
							</drug>
							<drug id="00850330" notABenefit="Y" sec3="Y">
								<name>Morphine Sulfate Injection USP</name>
								<manufacturerId>HOS</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="280808041">
							<itemNumber>0936</itemNumber>
							<strength>50mg/mL</strength>
							<dosageForm>Inj Sol-1mL Pk</dosageForm>
							<drug id="00617288" sec3="Y">
								<name>Morphine HP-50</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>6.8195</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>6.8195</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808042">
							<itemNumber>0937</itemNumber>
							<strength>1mg/mL</strength>
							<dosageForm>O/L</dosageForm>
							<drug id="00591467" sec3="Y">
								<name>Statex</name>
								<manufacturerId>PAL</manufacturerId>
								<individualPrice>.0200</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0200</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808043">
							<itemNumber>0938</itemNumber>
							<strength>5mg/mL</strength>
							<dosageForm>O/L</dosageForm>
							<drug id="00591475" sec3="Y">
								<name>Statex</name>
								<manufacturerId>PAL</manufacturerId>
								<individualPrice>.0803</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0803</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808125">
							<itemNumber>0939</itemNumber>
							<strength>10mg</strength>
							<dosageForm>SR Cap</dosageForm>
							<drug id="02242163" sec3="Y">
								<name>Kadian</name>
								<manufacturerId>BGP</manufacturerId>
								<individualPrice>.4110</individualPrice>
								<listingDate>2003-01-30</listingDate>
								<amountMOHLTCPays>.4110</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808093">
							<itemNumber>0940</itemNumber>
							<strength>20mg</strength>
							<dosageForm>SR Cap</dosageForm>
							<drug id="02184435" sec3="Y">
								<name>Kadian</name>
								<manufacturerId>BGP</manufacturerId>
								<individualPrice>.7985</individualPrice>
								<listingDate>1997-08-28</listingDate>
								<amountMOHLTCPays>.7985</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808094">
							<itemNumber>0941</itemNumber>
							<strength>50mg</strength>
							<dosageForm>SR Cap</dosageForm>
							<drug id="02184443" sec3="Y">
								<name>Kadian</name>
								<manufacturerId>BGP</manufacturerId>
								<individualPrice>1.5105</individualPrice>
								<listingDate>1997-08-28</listingDate>
								<amountMOHLTCPays>1.5105</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808095">
							<itemNumber>0942</itemNumber>
							<strength>100mg</strength>
							<dosageForm>SR Cap</dosageForm>
							<drug id="02184451" sec3="Y">
								<name>Kadian</name>
								<manufacturerId>BGP</manufacturerId>
								<individualPrice>2.6348</individualPrice>
								<listingDate>1997-08-28</listingDate>
								<amountMOHLTCPays>2.6348</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808053">
							<itemNumber>0943</itemNumber>
							<strength>15mg</strength>
							<dosageForm>SR Tab</dosageForm>
							<drug id="02015439" sec3="Y">
								<name>MS Contin</name>
								<manufacturerId>PFP</manufacturerId>
								<individualPrice>.8290</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.4145</amountMOHLTCPays>
							</drug>
							<drug id="02244790" sec3="Y">
								<name>Sandoz Morphine SR</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.4145</individualPrice>
								<listingDate>2002-07-29</listingDate>
								<amountMOHLTCPays>.4145</amountMOHLTCPays>
							</drug>
							<drug id="02302764" sec3="Y">
								<name>Teva-Morphine SR</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.4145</individualPrice>
								<listingDate>2009-04-01</listingDate>
								<amountMOHLTCPays>.4145</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808054">
							<itemNumber>0944</itemNumber>
							<strength>30mg</strength>
							<dosageForm>SR Tab</dosageForm>
							<drug id="02014297" sec3="Y">
								<name>MS Contin</name>
								<manufacturerId>PFP</manufacturerId>
								<individualPrice>1.2535</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3500</amountMOHLTCPays>
							</drug>
							<drug id="02244791" sec3="Y">
								<name>Sandoz Morphine SR</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.3500</individualPrice>
								<listingDate>2002-07-29</listingDate>
								<amountMOHLTCPays>.3500</amountMOHLTCPays>
							</drug>
							<drug id="02302772" sec3="Y">
								<name>Teva-Morphine SR</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3500</individualPrice>
								<listingDate>2009-06-23</listingDate>
								<amountMOHLTCPays>.3500</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808055">
							<itemNumber>0945</itemNumber>
							<strength>60mg</strength>
							<dosageForm>SR Tab</dosageForm>
							<drug id="02014300" sec3="Y">
								<name>MS Contin</name>
								<manufacturerId>PFP</manufacturerId>
								<individualPrice>2.2100</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.6167</amountMOHLTCPays>
							</drug>
							<drug id="02244792" sec3="Y">
								<name>Sandoz Morphine SR</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.6167</individualPrice>
								<listingDate>2002-07-29</listingDate>
								<amountMOHLTCPays>.6167</amountMOHLTCPays>
							</drug>
							<drug id="02302780" sec3="Y">
								<name>Teva-Morphine SR</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.6167</individualPrice>
								<listingDate>2008-04-09</listingDate>
								<amountMOHLTCPays>.6167</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808056">
							<itemNumber>0946</itemNumber>
							<strength>100mg</strength>
							<dosageForm>SR Tab</dosageForm>
							<drug id="02014319" sec3="Y">
								<name>MS Contin</name>
								<manufacturerId>PFP</manufacturerId>
								<individualPrice>3.3640</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>1.5395</amountMOHLTCPays>
							</drug>
							<drug id="02302799" sec3="Y">
								<name>Teva-Morphine SR</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>1.5395</individualPrice>
								<listingDate>2008-04-09</listingDate>
								<amountMOHLTCPays>1.5395</amountMOHLTCPays>
							</drug>
							<drug id="02478889" sec3="Y">
								<name>Sandoz Morphine SR</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>1.5395</individualPrice>
								<listingDate>2019-02-28</listingDate>
								<amountMOHLTCPays>1.5395</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808057">
							<itemNumber>0947</itemNumber>
							<strength>200mg</strength>
							<dosageForm>SR Tab</dosageForm>
							<drug id="02014327" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>MS Contin</name>
								<manufacturerId>PFP</manufacturerId>
								<individualPrice>6.2720</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>4.5738</amountMOHLTCPays>
							</drug>
							<drug id="02302802" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Teva-Morphine SR</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>4.5737</individualPrice>
								<listingDate>2008-04-09</listingDate>
								<amountMOHLTCPays>4.5737</amountMOHLTCPays>
							</drug>
							<drug id="02478897" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Sandoz Morphine SR</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>4.5738</individualPrice>
								<listingDate>2019-02-28</listingDate>
								<amountMOHLTCPays>4.5738</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808051">
							<itemNumber>0948</itemNumber>
							<strength>20mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02014238" sec3="Y">
								<name>MS-IR</name>
								<manufacturerId>PFP</manufacturerId>
								<individualPrice>.3870</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3870</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808052">
							<itemNumber>0949</itemNumber>
							<strength>30mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02014254" sec3="Y">
								<name>MS-IR</name>
								<manufacturerId>PFP</manufacturerId>
								<individualPrice>.4965</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.4965</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808047">
							<itemNumber>0950</itemNumber>
							<strength>5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00594652" sec3="Y">
								<name>Statex</name>
								<manufacturerId>PAL</manufacturerId>
								<individualPrice>.1190</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1190</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808048">
							<itemNumber>0951</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00594644" sec3="Y">
								<name>Statex</name>
								<manufacturerId>PAL</manufacturerId>
								<individualPrice>.1840</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1840</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808049">
							<itemNumber>0952</itemNumber>
							<strength>25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00594636" sec3="Y">
								<name>Statex</name>
								<manufacturerId>PAL</manufacturerId>
								<individualPrice>.2388</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2388</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808050">
							<itemNumber>0953</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00675962" sec3="Y">
								<name>Statex</name>
								<manufacturerId>PAL</manufacturerId>
								<individualPrice>.3661</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3661</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00448">
					<name>OXYCODONE HCL</name>
					<pcgGroup>
						<pcg9 id="280808119">
							<itemNumber>0954</itemNumber>
							<strength>5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00789739" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Supeudol</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2333</individualPrice>
								<listingDate>2010-04-23</listingDate>
								<amountMOHLTCPays>.2333</amountMOHLTCPays>
							</drug>
							<drug id="02231934" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Oxy.IR</name>
								<manufacturerId>PFP</manufacturerId>
								<listingDate>2009-01-30</listingDate>
							</drug>
							<drug id="02319977" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>PMS-Oxycodone</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2333</individualPrice>
								<listingDate>2009-01-30</listingDate>
								<amountMOHLTCPays>.2333</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808120">
							<itemNumber>0955</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00443948" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Supeudol</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.3451</individualPrice>
								<listingDate>2010-04-23</listingDate>
								<amountMOHLTCPays>.3451</amountMOHLTCPays>
							</drug>
							<drug id="02240131" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Oxy.IR</name>
								<manufacturerId>PFP</manufacturerId>
								<listingDate>2009-01-30</listingDate>
							</drug>
							<drug id="02319985" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>PMS-Oxycodone</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3451</individualPrice>
								<listingDate>2009-01-30</listingDate>
								<amountMOHLTCPays>.3451</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280808121">
							<itemNumber>0956</itemNumber>
							<strength>20mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02240132" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Oxy.IR</name>
								<manufacturerId>PFP</manufacturerId>
								<listingDate>2008-10-01</listingDate>
							</drug>
							<drug id="02262983" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Supeudol</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.6001</individualPrice>
								<listingDate>2008-10-01</listingDate>
								<amountMOHLTCPays>.6001</amountMOHLTCPays>
							</drug>
							<drug id="02319993" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>PMS-Oxycodone</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.6001</individualPrice>
								<listingDate>2009-01-30</listingDate>
								<amountMOHLTCPays>.6001</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00424">
					<name>OXYCODONE HCL &amp; ACETAMINOPHEN</name>
					<pcgGroup>
						<pcg9 id="280808064">
							<itemNumber>0957</itemNumber>
							<strength>5mg &amp; 325mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00608165" sec3="Y">
								<name>Teva-Oxycocet</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1285</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1285</amountMOHLTCPays>
							</drug>
							<drug id="01916475" notABenefit="Y" sec3="Y">
								<name>Percocet</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>2008-12-23</listingDate>
							</drug>
							<drug id="01916548" sec3="Y">
								<name>Endocet</name>
								<manufacturerId>BQU</manufacturerId>
								<individualPrice>.1285</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1285</amountMOHLTCPays>
							</drug>
							<drug id="02307898" sec3="Y">
								<name>Sandoz Oxycodone/Acetaminophen</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.1285</individualPrice>
								<listingDate>2008-10-01</listingDate>
								<amountMOHLTCPays>.1285</amountMOHLTCPays>
							</drug>
							<drug id="02324628" sec3="Y">
								<name>Apo-Oxycodone/Acet</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1285</individualPrice>
								<listingDate>2009-09-30</listingDate>
								<amountMOHLTCPays>.1285</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00418">
					<name>OXYCODONE HCL &amp; ACETYLSALICYLIC ACID</name>
					<pcgGroup>
						<pcg9 id="280808065">
							<itemNumber>0958</itemNumber>
							<strength>5mg &amp; 325mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00608157" sec3="Y">
								<name>Ratio-Oxycodan</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>.4380</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.4380</amountMOHLTCPays>
							</drug>
							<drug id="01916572" notABenefit="Y" sec3="Y">
								<name>Percodan</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>2008-12-23</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01840">
					<name>TRAMADOL HCL</name>
					<pcgGroup>
						<pcg9 id="280808298">
							<itemNumber>0959</itemNumber>
							<strength>100mg</strength>
							<dosageForm>ER Tab</dosageForm>
							<drug id="02296381" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Tridural</name>
								<manufacturerId>PAL</manufacturerId>
								<listingDate>2016-04-29</listingDate>
							</drug>
							<drug id="02450429" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Taro-Tramadol ER</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>.7853</individualPrice>
								<listingDate>2016-04-29</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="280808288">
							<itemNumber>0960</itemNumber>
							<strength>200mg</strength>
							<dosageForm>ER Tab</dosageForm>
							<drug id="02296403" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Tridural</name>
								<manufacturerId>PAL</manufacturerId>
								<listingDate>2016-06-29</listingDate>
							</drug>
							<drug id="02450437" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Taro-Tramadol ER</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>.9244</individualPrice>
								<listingDate>2016-06-29</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="280808281">
							<itemNumber>0961</itemNumber>
							<strength>300mg</strength>
							<dosageForm>ER Tab</dosageForm>
							<drug id="02296411" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Tridural</name>
								<manufacturerId>PAL</manufacturerId>
								<listingDate>2016-06-29</listingDate>
							</drug>
							<drug id="02450445" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Taro-Tramadol ER</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>1.2854</individualPrice>
								<listingDate>2016-06-29</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="280808287">
							<itemNumber>0962</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02349469" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Ultram</name>
								<manufacturerId>JAN</manufacturerId>
								<listingDate>2014-08-28</listingDate>
							</drug>
							<drug id="02426153" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Tramadol</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.6386</individualPrice>
								<listingDate>2014-08-28</listingDate>
							</drug>
							<drug id="02479672" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Auro-Tramadol</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.6386</individualPrice>
								<listingDate>2019-06-28</listingDate>
							</drug>
							<drug id="02480859" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mar-Tramadol</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.6386</individualPrice>
								<listingDate>2019-09-30</listingDate>
							</drug>
							<drug id="02493764" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Sandoz Tramadol</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.6386</individualPrice>
								<listingDate>2021-02-26</listingDate>
							</drug>
							<drug id="02507005" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Jamp Tramadol</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.6386</individualPrice>
								<listingDate>2021-05-31</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01766">
					<name>TRAMADOL HCL &amp; ACETAMINOPHEN</name>
					<pcgGroup>
						<pcg9 id="280808299">
							<itemNumber>0963</itemNumber>
							<strength>37.5mg &amp; 325mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02264846" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Tramacet</name>
								<manufacturerId>JAN</manufacturerId>
								<listingDate>2010-03-02</listingDate>
							</drug>
							<drug id="02336790" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Tramadol/Acet</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.6264</individualPrice>
								<listingDate>2010-03-02</listingDate>
							</drug>
							<drug id="02347180" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Teva-Tramadol/Acetaminophen</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.6264</individualPrice>
								<listingDate>2012-10-30</listingDate>
							</drug>
							<drug id="02383209" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Co Tramadol/Acet</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.6264</individualPrice>
								<listingDate>2012-06-26</listingDate>
							</drug>
							<drug id="02388197" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Taro-Tramadol/Acet</name>
								<manufacturerId>SPC</manufacturerId>
								<individualPrice>.6264</individualPrice>
								<listingDate>2012-11-27</listingDate>
							</drug>
							<drug id="02388308" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Jamp-Acet-Tramadol</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.6264</individualPrice>
								<listingDate>2012-12-21</listingDate>
							</drug>
							<drug id="02388324" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mar-Tramadol/Acet</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.6264</individualPrice>
								<listingDate>2012-10-30</listingDate>
							</drug>
							<drug id="02389800" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mint-Tramadol/Acet</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.6264</individualPrice>
								<listingDate>2012-12-21</listingDate>
							</drug>
							<drug id="02401657" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>PMS-Tramadol-Acet</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.6264</individualPrice>
								<listingDate>2013-06-27</listingDate>
							</drug>
							<drug id="02439050" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Auro-Tramadol/Acetaminophen</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.6264</individualPrice>
								<listingDate>2016-02-25</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="280812000">
				<name>ANALGESICS OPIATE PARTIAL AGONISTS</name>
				<genericName id="01803">
					<name>BUPRENORPHINE</name>
					<pcgGroup lccId="00331">
						<pcg9 id="280812024">
							<itemNumber>0964</itemNumber>
							<strength>100mg/0.5mL</strength>
							<dosageForm>Inj Sol- 0.5mL Pref Syr</dosageForm>
							<drug id="02483084" sec3="Y" sec12="Y">
								<name>Sublocade</name>
								<manufacturerId>IND</manufacturerId>
								<individualPrice>550.0000</individualPrice>
								<listingDate>2020-04-30</listingDate>
								<amountMOHLTCPays>550.0000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280812025">
							<itemNumber>0965</itemNumber>
							<strength>300mg/1.5mL</strength>
							<dosageForm>Inj Sol- 1.5mL Pref Syr</dosageForm>
							<drug id="02483092" sec3="Y" sec12="Y">
								<name>Sublocade</name>
								<manufacturerId>IND</manufacturerId>
								<individualPrice>550.0000</individualPrice>
								<listingDate>2020-04-30</listingDate>
								<amountMOHLTCPays>550.0000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="577">For the management of moderate to severe opioid use disorder as a part of a complete treatment plan that includes counselling and psychosocial support in adult patients who meet the following criteria:
- The patient has been induced and is stabilized on an equivalent of 8mg to 24mg per day of transmucosal buprenorphine for a minimum of seven days; AND
- The patient is under the care of a health care provider with experience in the diagnosis and management of opioid use disorder; AND
- Each dose is administered subcutaneously in the abdominal region by a certified healthcare provider who has received instruction and training.
Recommended dose: 300mg/month for two months, followed by a maintenance dose of 100mg/month. Maintenance dose may be increased to 300mg/month only if patient does not demonstrate satisfactory clinical response.
NOTE: In clinical trials, the 300mg/month maintenance dose did not provide additional efficacy as compared to the 100mg/month dose and was associated with a higher incidence of adverse events and study discontinuations. A minimum of 26 days is required between consecutive doses.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="01790">
					<name>BUPRENORPHINE &amp; NALOXONE</name>
					<pcgGroup>
						<pcg9 id="280812006">
							<itemNumber>0966</itemNumber>
							<strength>2mg &amp; 0.5mg</strength>
							<dosageForm>SL Tab</dosageForm>
							<drug id="02295695" sec3="Y">
								<name>Suboxone</name>
								<manufacturerId>IND</manufacturerId>
								<individualPrice>2.7261</individualPrice>
								<listingDate>2012-10-30</listingDate>
								<amountMOHLTCPays>1.3350</amountMOHLTCPays>
							</drug>
							<drug id="02424851" sec3="Y">
								<name>PMS-Buprenorphine-Naloxone</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>1.3350</individualPrice>
								<listingDate>2015-02-26</listingDate>
								<amountMOHLTCPays>1.3350</amountMOHLTCPays>
							</drug>
							<drug id="02453908" sec3="Y">
								<name>Act Buprenorphine/Naloxone</name>
								<manufacturerId>ACV</manufacturerId>
								<individualPrice>1.3350</individualPrice>
								<listingDate>2018-01-31</listingDate>
								<amountMOHLTCPays>1.3350</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280812010">
							<itemNumber>0967</itemNumber>
							<strength>8mg &amp; 2mg</strength>
							<dosageForm>SL Tab</dosageForm>
							<drug id="02295709" sec3="Y">
								<name>Suboxone</name>
								<manufacturerId>IND</manufacturerId>
								<individualPrice>4.8293</individualPrice>
								<listingDate>2012-10-30</listingDate>
								<amountMOHLTCPays>2.3650</amountMOHLTCPays>
							</drug>
							<drug id="02424878" sec3="Y">
								<name>PMS-Buprenorphine-Naloxone</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>2.3650</individualPrice>
								<listingDate>2015-02-26</listingDate>
								<amountMOHLTCPays>2.3650</amountMOHLTCPays>
							</drug>
							<drug id="02453916" sec3="Y">
								<name>Act Buprenorphine/Naloxone</name>
								<manufacturerId>ACV</manufacturerId>
								<individualPrice>2.3650</individualPrice>
								<listingDate>2018-01-31</listingDate>
								<amountMOHLTCPays>2.3650</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="02085">
					<name>BUPRENORPHINE HYDROCHLORIDE</name>
					<pcgGroup lccId="00333">
						<pcg9 id="280812023">
							<itemNumber>0968</itemNumber>
							<strength>80mg</strength>
							<dosageForm>Subdermal Implant-Kit Pk</dosageForm>
							<drug id="02474921" sec3="Y" sec12="Y">
								<name>Probuphine</name>
								<manufacturerId>KNT</manufacturerId>
								<individualPrice>1495.0000</individualPrice>
								<listingDate>2020-04-30</listingDate>
								<amountMOHLTCPays>1495.0000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="578">For the management of opioid use disorder in combination with counseling and psychosocial support in adult patients who meet the following criteria:
- The patient is stabilized on a dose of no more than 8mg per day of sublingual buprenorphine for the preceding 90 days; AND
- The patient is under the care of a health care provider with experience in the diagnosis and management of opioid use disorder and has been trained to implant and remove the buprenorphine subdermal implant.
Recommended dose: Four 80mg implants inserted subdermally in the inner side of the upper arm for up to six months.
The maximum quantity that can be claimed per patient is four (4) implant cycles (i.e. two (2) years of therapy).
NOTE: The product monograph indicates that dosing beyond two (2) years cannot be recommended at this time. Probuphine subdermal implants are intended to be in place for six months of treatment. Probuphine implants are removed at the end of the six-month period. If continued treatment is desired, the implants should be replaced by new implants (implanted in the opposite arm) at the time of removal.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 2 years</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00461">
					<name>BUTORPHANOL TARTRATE</name>
					<pcgGroup>
						<pcg9 id="280812003">
							<itemNumber>0969</itemNumber>
							<strength>10mg/mL</strength>
							<dosageForm>Nas Sp-2.5mL Pk</dosageForm>
							<drug id="02113031" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Stadol NS</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>2020-11-30</listingDate>
							</drug>
							<drug id="02242504" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Butorphanol Nasal Spray</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>61.1800</individualPrice>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>61.1800</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="280892000">
				<name>ANALGESICS MISCELLANEOUS ANALGESICS AND ANTIPYRETICS</name>
				<genericName id="00403">
					<name>ACETAMINOPHEN</name>
					<pcgGroup>
						<pcg9 id="280892006" suppliedBy="L">
							<itemNumber>0970</itemNumber>
							<strength>325mg</strength>
							<drug id="00293482" notABenefit="Y" sec3="Y">
								<name>Atasol Tab</name>
								<manufacturerId>HOR</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00389218" selfMed="Y" sec3="Y">
								<name>Novo-Gesic Tab</name>
								<manufacturerId>NOP</manufacturerId>
								<individualPrice>.0245</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0245</amountMOHLTCPays>
							</drug>
							<drug id="00544981" selfMed="Y" sec3="Y">
								<name>Apo-Acetaminophen Tab</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0245</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0245</amountMOHLTCPays>
							</drug>
							<drug id="02229873" selfMed="Y" sec3="Y">
								<name>Apo-Acetaminophen Caplets</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0245</individualPrice>
								<listingDate>2012-02-29</listingDate>
								<amountMOHLTCPays>.0245</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280892007" suppliedBy="L">
							<itemNumber>0971</itemNumber>
							<strength>500mg</strength>
							<drug id="00013668" notABenefit="Y" sec3="Y">
								<name>Atasol Forte Tab</name>
								<manufacturerId>HOR</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00482323" selfMed="Y" sec3="Y">
								<name>Novo-Gesic Forte Tab</name>
								<manufacturerId>NOP</manufacturerId>
								<individualPrice>.0285</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0285</amountMOHLTCPays>
							</drug>
							<drug id="00545007" selfMed="Y" sec3="Y">
								<name>Apo-Acetaminophen Tab</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0285</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0285</amountMOHLTCPays>
							</drug>
							<drug id="02229977" selfMed="Y" sec3="Y">
								<name>Apo-Acetaminophen Caplets</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0285</individualPrice>
								<listingDate>2012-02-29</listingDate>
								<amountMOHLTCPays>.0285</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280892002">
							<itemNumber>0972</itemNumber>
							<strength>80mg/mL</strength>
							<dosageForm>O/L</dosageForm>
							<drug id="00631353" notABenefit="Y" sec3="Y">
								<name>Atasol</name>
								<manufacturerId>HOR</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00642401" notABenefit="Y" sec3="Y">
								<name>Tempra</name>
								<manufacturerId>MJS</manufacturerId>
								<listingDate>1999-01-01</listingDate>
							</drug>
							<drug id="02027801" sec3="Y">
								<name>Pediatrix</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>.1436</individualPrice>
								<listingDate>2001-10-11</listingDate>
								<amountMOHLTCPays>.1436</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280892003">
							<itemNumber>0973</itemNumber>
							<strength>120mg</strength>
							<dosageForm>Sup</dosageForm>
							<drug id="01919385" notABenefit="Y" sec3="Y">
								<name>Abenol</name>
								<manufacturerId>PEN</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02230434" sec3="Y">
								<name>ACET 120</name>
								<manufacturerId>PEN</manufacturerId>
								<individualPrice>.5367</individualPrice>
								<listingDate>1998-03-17</listingDate>
								<amountMOHLTCPays>.5367</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280892004">
							<itemNumber>0974</itemNumber>
							<strength>325mg</strength>
							<dosageForm>Sup</dosageForm>
							<drug id="01919393" notABenefit="Y" sec3="Y">
								<name>Abenol</name>
								<manufacturerId>PEN</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02230436" sec3="Y">
								<name>ACET 325</name>
								<manufacturerId>PEN</manufacturerId>
								<individualPrice>.6625</individualPrice>
								<listingDate>1998-03-17</listingDate>
								<amountMOHLTCPays>.6625</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="280892005">
							<itemNumber>0975</itemNumber>
							<strength>650mg</strength>
							<dosageForm>Sup</dosageForm>
							<drug id="01919407" notABenefit="Y" sec3="Y">
								<name>Abenol</name>
								<manufacturerId>PEN</manufacturerId>
								<listingDate>2007-01-02</listingDate>
							</drug>
							<drug id="02230437" sec3="Y">
								<name>ACET 650</name>
								<manufacturerId>PEN</manufacturerId>
								<individualPrice>.7608</individualPrice>
								<listingDate>1998-03-17</listingDate>
								<amountMOHLTCPays>.7608</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="281000000">
				<name>OPIATE ANTAGONISTS</name>
				<genericName id="00470">
					<name>NALTREXONE HCL</name>
					<pcgGroup lccId="00304">
						<pcg9 id="281000003">
							<itemNumber>0976</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02213826" sec3="Y" sec12="Y">
								<name>Revia</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>2.8075</individualPrice>
								<listingDate>2015-11-26</listingDate>
								<amountMOHLTCPays>2.8075</amountMOHLTCPays>
							</drug>
							<drug id="02444275" sec3="Y" sec12="Y">
								<name>Apo-Naltrexone</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>2.8075</individualPrice>
								<listingDate>2015-11-26</listingDate>
								<amountMOHLTCPays>2.8075</amountMOHLTCPays>
							</drug>
							<drug id="02451883" sec3="Y" sec12="Y">
								<name>Naltrexone Hydrochloride Tablets USP</name>
								<manufacturerId>STN</manufacturerId>
								<individualPrice>2.8075</individualPrice>
								<listingDate>2017-08-30</listingDate>
								<amountMOHLTCPays>2.8075</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="532">For the treatment of alcohol use disorder in patients who:
- Meet clinical criteria for alcohol use disorder; and
- Express a commitment to reduce or abstain from alcohol; and
- Have confirmed participation in counselling and treatment for alcohol use disorder*
* An individualized treatment plan will have one or more of the following components: Counselling and follow-up with the patient&apos;s family physician, addiction physician, or psychiatrist; self-help groups such as Alcoholics Anonymous; and outpatient, day, or inpatient psychosocial rehabilitation programs.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="281200000">
				<name>ANTICONVULSANTS</name>
				<genericName id="02070">
					<name>BRIVARACETAM</name>
					<pcgGroup lccId="00312">
						<pcg9 id="281200177">
							<itemNumber>0977</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02452936" sec3="Y" sec12="Y">
								<name>Brivlera</name>
								<manufacturerId>UCB</manufacturerId>
								<individualPrice>4.3200</individualPrice>
								<listingDate>2018-12-21</listingDate>
								<amountMOHLTCPays>4.3200</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200178">
							<itemNumber>0978</itemNumber>
							<strength>25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02452944" sec3="Y" sec12="Y">
								<name>Brivlera</name>
								<manufacturerId>UCB</manufacturerId>
								<individualPrice>4.3200</individualPrice>
								<listingDate>2018-12-21</listingDate>
								<amountMOHLTCPays>4.3200</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200179">
							<itemNumber>0979</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02452952" sec3="Y" sec12="Y">
								<name>Brivlera</name>
								<manufacturerId>UCB</manufacturerId>
								<individualPrice>4.3200</individualPrice>
								<listingDate>2018-12-21</listingDate>
								<amountMOHLTCPays>4.3200</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200180">
							<itemNumber>0980</itemNumber>
							<strength>75mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02452960" sec3="Y" sec12="Y">
								<name>Brivlera</name>
								<manufacturerId>UCB</manufacturerId>
								<individualPrice>4.3200</individualPrice>
								<listingDate>2018-12-21</listingDate>
								<amountMOHLTCPays>4.3200</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200181">
							<itemNumber>0981</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02452979" sec3="Y" sec12="Y">
								<name>Brivlera</name>
								<manufacturerId>UCB</manufacturerId>
								<individualPrice>4.3200</individualPrice>
								<listingDate>2018-12-21</listingDate>
								<amountMOHLTCPays>4.3200</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="548">- As adjunctive therapy in the treatment of patients with partial-onset seizures (POS) who have had an inadequate response or have significant intolerance to at least 2 other less costly anticonvulsant therapies (prior or current use); AND
- Patients are not receiving concurrent therapy with levetiracetam; AND
- Patients are under the care of a physician experienced in the treatment of epilepsy.
Note: Less costly anticonvulsant therapies may include the following:
Phenytoin, carbamazepine, gabapentin, lamotrigine, vigabatrin, topiramate, etc.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00476">
					<name>CARBAMAZEPINE</name>
					<pcgGroup>
						<pcg9 id="281200049">
							<itemNumber>0982</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Chew Tab</dosageForm>
							<drug id="00369810" notABenefit="Y" sec3="Y">
								<name>Tegretol</name>
								<manufacturerId>NOV</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02244403" sec3="Y">
								<name>Taro-Carbamazepine</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>.1702</individualPrice>
								<listingDate>2003-04-16</listingDate>
								<amountMOHLTCPays>.1702</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200050">
							<itemNumber>0983</itemNumber>
							<strength>200mg</strength>
							<dosageForm>Chew Tab</dosageForm>
							<drug id="00665088" notABenefit="Y" sec3="Y">
								<name>Tegretol</name>
								<manufacturerId>NOV</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02244404" sec3="Y">
								<name>Taro-Carbamazepine</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>.3302</individualPrice>
								<listingDate>2003-04-16</listingDate>
								<amountMOHLTCPays>.3302</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
					<pcgGroup lccId="00070">
						<pcg9 id="281200065">
							<itemNumber>0984</itemNumber>
							<strength>200mg</strength>
							<dosageForm>LA Tab</dosageForm>
							<drug id="00773611" sec3="Y" sec12="Y">
								<name>Tegretol CR</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>.5269</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2563</amountMOHLTCPays>
							</drug>
							<drug id="02231543" sec3="Y" sec12="Y">
								<name>PMS-Carbamazepine CR</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2563</individualPrice>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>.2563</amountMOHLTCPays>
							</drug>
							<drug id="02261839" sec3="Y" sec12="Y">
								<name>Sandoz Carbamazepine CR</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2563</individualPrice>
								<listingDate>2006-07-19</listingDate>
								<amountMOHLTCPays>.2563</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200066">
							<itemNumber>0985</itemNumber>
							<strength>400mg</strength>
							<dosageForm>LA Tab</dosageForm>
							<drug id="00755583" sec3="Y" sec12="Y">
								<name>Tegretol CR</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>1.0539</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.5126</amountMOHLTCPays>
							</drug>
							<drug id="02231544" sec3="Y" sec12="Y">
								<name>PMS-Carbamazepine CR</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.5126</individualPrice>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>.5126</amountMOHLTCPays>
							</drug>
							<drug id="02261847" sec3="Y" sec12="Y">
								<name>Sandoz Carbamazepine CR</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.5126</individualPrice>
								<listingDate>2006-07-19</listingDate>
								<amountMOHLTCPays>.5126</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="67">For patients who have been tried on conventional carbamazepine with unsatisfactory results due to adverse effects or poor control of symptoms.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
					<pcgGroup>
						<pcg9 id="281200067">
							<itemNumber>0986</itemNumber>
							<strength>100mg/5mL</strength>
							<dosageForm>Oral Susp</dosageForm>
							<drug id="02194333" sec3="Y">
								<name>Tegretol</name>
								<manufacturerId>NOV</manufacturerId>
								<individualPrice>.1012</individualPrice>
								<listingDate>1996-12-19</listingDate>
								<amountMOHLTCPays>.0578</amountMOHLTCPays>
							</drug>
							<drug id="02367394" sec3="Y">
								<name>Taro-Carbamazepine</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>.0578</individualPrice>
								<listingDate>2012-03-26</listingDate>
								<amountMOHLTCPays>.0578</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200015">
							<itemNumber>0987</itemNumber>
							<strength>200mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00010405" notABenefit="Y" sec3="Y">
								<name>Tegretol</name>
								<manufacturerId>NOV</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00782718" sec3="Y">
								<name>Teva-Carbamazepine</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1540</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1540</amountMOHLTCPays>
							</drug>
							<drug id="02407515" sec3="Y">
								<name>Taro-Carbamazepine</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>.1540</individualPrice>
								<listingDate>2014-07-30</listingDate>
								<amountMOHLTCPays>.1540</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00488">
					<name>CLOBAZAM</name>
					<pcgGroup lccId="00071">
						<pcg9 id="281200061">
							<itemNumber>0988</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02221799" notABenefit="Y" sec3="Y">
								<name>Frisium</name>
								<manufacturerId>OVA</manufacturerId>
								<listingDate>1999-01-06</listingDate>
							</drug>
							<drug id="02238334" sec3="Y" sec12="Y">
								<name>Teva-Clobazam</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2197</individualPrice>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>.2197</amountMOHLTCPays>
							</drug>
							<drug id="02244638" sec3="Y" sec12="Y">
								<name>Apo-Clobazam</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2197</individualPrice>
								<listingDate>2003-01-30</listingDate>
								<amountMOHLTCPays>.2197</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="23">As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.</lccNote>
						<lccNote seq="002" type="N">Because a large number of patients will become refractory to the anticonvulsant effects of the drug over a period of time, the effectiveness of this drug must be re-evaluated after a period of six months.</lccNote>
						<lccNote seq="003" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00479">
					<name>CLONAZEPAM</name>
					<pcgGroup>
						<pcg9 id="281200032">
							<itemNumber>0989</itemNumber>
							<strength>0.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00382825" sec3="Y">
								<name>Rivotril</name>
								<manufacturerId>HLR</manufacturerId>
								<individualPrice>.2479</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0418</amountMOHLTCPays>
							</drug>
							<drug id="02048701" sec3="Y">
								<name>PMS-Clonazepam</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.0418</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0418</amountMOHLTCPays>
							</drug>
							<drug id="02177889" sec3="Y">
								<name>Apo-Clonazepam</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0418</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0418</amountMOHLTCPays>
							</drug>
							<drug id="02207818" sec3="Y">
								<name>PMS-Clonazepam-R</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.0418</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0418</amountMOHLTCPays>
							</drug>
							<drug id="02239024" sec3="Y">
								<name>Teva-Clonazepam</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.0418</individualPrice>
								<listingDate>2000-04-17</listingDate>
								<amountMOHLTCPays>.0418</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200031">
							<itemNumber>0990</itemNumber>
							<strength>2mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00382841" sec3="Y">
								<name>Rivotril</name>
								<manufacturerId>HLR</manufacturerId>
								<individualPrice>.4274</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0721</amountMOHLTCPays>
							</drug>
							<drug id="02048736" sec3="Y">
								<name>PMS-Clonazepam</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.0721</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0721</amountMOHLTCPays>
							</drug>
							<drug id="02177897" sec3="Y">
								<name>Apo-Clonazepam</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0721</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0721</amountMOHLTCPays>
							</drug>
							<drug id="02239025" sec3="Y">
								<name>Teva-Clonazepam</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.0721</individualPrice>
								<listingDate>2000-04-17</listingDate>
								<amountMOHLTCPays>.0721</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00483">
					<name>DIVALPROEX SODIUM</name>
					<pcgGroup>
						<pcg9 id="281200047">
							<itemNumber>0991</itemNumber>
							<strength>125mg</strength>
							<dosageForm>Ent Tab</dosageForm>
							<drug id="00596418" sec3="Y">
								<name>Epival</name>
								<manufacturerId>BGP</manufacturerId>
								<individualPrice>.3369</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1539</amountMOHLTCPays>
							</drug>
							<drug id="02239698" sec3="Y">
								<name>Apo-Divalproex</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1539</individualPrice>
								<listingDate>1999-09-15</listingDate>
								<amountMOHLTCPays>.1539</amountMOHLTCPays>
							</drug>
							<drug id="02458926" sec3="Y">
								<name>Mylan-Divalproex</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.1539</individualPrice>
								<listingDate>2017-06-29</listingDate>
								<amountMOHLTCPays>.1539</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200046">
							<itemNumber>0992</itemNumber>
							<strength>250mg</strength>
							<dosageForm>Ent Tab</dosageForm>
							<drug id="00596426" sec3="Y">
								<name>Epival</name>
								<manufacturerId>BGP</manufacturerId>
								<individualPrice>.6057</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2767</amountMOHLTCPays>
							</drug>
							<drug id="02239699" sec3="Y">
								<name>Apo-Divalproex</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2767</individualPrice>
								<listingDate>1999-09-15</listingDate>
								<amountMOHLTCPays>.2767</amountMOHLTCPays>
							</drug>
							<drug id="02458934" sec3="Y">
								<name>Mylan-Divalproex</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.2767</individualPrice>
								<listingDate>2017-06-29</listingDate>
								<amountMOHLTCPays>.2767</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200045">
							<itemNumber>0993</itemNumber>
							<strength>500mg</strength>
							<dosageForm>Ent Tab</dosageForm>
							<drug id="00596434" sec3="Y">
								<name>Epival</name>
								<manufacturerId>BGP</manufacturerId>
								<individualPrice>1.2120</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.5537</amountMOHLTCPays>
							</drug>
							<drug id="02239700" sec3="Y">
								<name>Apo-Divalproex</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.5537</individualPrice>
								<listingDate>1999-09-15</listingDate>
								<amountMOHLTCPays>.5537</amountMOHLTCPays>
							</drug>
							<drug id="02459019" sec3="Y">
								<name>Mylan-Divalproex</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.5537</individualPrice>
								<listingDate>2017-06-29</listingDate>
								<amountMOHLTCPays>.5537</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01990">
					<name>ESLICARBAZEPINE ACETATE</name>
					<pcgGroup lccId="00259">
						<pcg9 id="281200169">
							<itemNumber>0994</itemNumber>
							<strength>200mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02426862" sec3="Y" sec12="Y">
								<name>Aptiom</name>
								<manufacturerId>SUO</manufacturerId>
								<individualPrice>9.8700</individualPrice>
								<listingDate>2015-11-26</listingDate>
								<amountMOHLTCPays>9.8700</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200170">
							<itemNumber>0995</itemNumber>
							<strength>400mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02426870" sec3="Y" sec12="Y">
								<name>Aptiom</name>
								<manufacturerId>SUO</manufacturerId>
								<individualPrice>9.8700</individualPrice>
								<listingDate>2015-11-26</listingDate>
								<amountMOHLTCPays>9.8700</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200171">
							<itemNumber>0996</itemNumber>
							<strength>600mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02426889" sec3="Y" sec12="Y">
								<name>Aptiom</name>
								<manufacturerId>SUO</manufacturerId>
								<individualPrice>9.8700</individualPrice>
								<listingDate>2015-11-26</listingDate>
								<amountMOHLTCPays>9.8700</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200172">
							<itemNumber>0997</itemNumber>
							<strength>800mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02426897" sec3="Y" sec12="Y">
								<name>Aptiom</name>
								<manufacturerId>SUO</manufacturerId>
								<individualPrice>9.8700</individualPrice>
								<listingDate>2015-11-26</listingDate>
								<amountMOHLTCPays>9.8700</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="430">As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND
Patients are under the care of a physician experienced in the treatment of epilepsy.
Note: Less costly anticonvulsant therapies may include the following:
Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00473">
					<name>ETHOSUXIMIDE</name>
					<pcgGroup>
						<pcg9 id="281200008">
							<itemNumber>0998</itemNumber>
							<strength>250mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00022799" sec3="Y">
								<name>Zarontin</name>
								<manufacturerId>ERF</manufacturerId>
								<individualPrice>.5000</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.5000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200009">
							<itemNumber>0999</itemNumber>
							<strength>50mg/mL</strength>
							<dosageForm>O/L</dosageForm>
							<drug id="00023485" sec3="Y">
								<name>Zarontin</name>
								<manufacturerId>ERF</manufacturerId>
								<individualPrice>.0704</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0704</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00487">
					<name>GABAPENTIN</name>
					<pcgGroup>
						<pcg9 id="281200062">
							<itemNumber>1000</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02084260" sec3="Y">
								<name>Neurontin</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>.4941</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0416</amountMOHLTCPays>
							</drug>
							<drug id="02243446" sec3="Y">
								<name>PMS-Gabapentin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.0416</individualPrice>
								<listingDate>2001-10-11</listingDate>
								<amountMOHLTCPays>.0416</amountMOHLTCPays>
							</drug>
							<drug id="02244304" sec3="Y">
								<name>Apo-Gabapentin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0416</individualPrice>
								<listingDate>2002-07-29</listingDate>
								<amountMOHLTCPays>.0416</amountMOHLTCPays>
							</drug>
							<drug id="02244513" sec3="Y">
								<name>Teva-Gabapentin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.0416</individualPrice>
								<listingDate>2002-07-29</listingDate>
								<amountMOHLTCPays>.0416</amountMOHLTCPays>
							</drug>
							<drug id="02246314" sec3="Y">
								<name>Gabapentin</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.0416</individualPrice>
								<listingDate>2009-11-19</listingDate>
								<amountMOHLTCPays>.0416</amountMOHLTCPays>
							</drug>
							<drug id="02256142" sec3="Y">
								<name>Co Gabapentin</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.0416</individualPrice>
								<listingDate>2005-03-31</listingDate>
								<amountMOHLTCPays>.0416</amountMOHLTCPays>
							</drug>
							<drug id="02319055" sec3="Y">
								<name>Ran-Gabapentin</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.0416</individualPrice>
								<listingDate>2010-03-02</listingDate>
								<amountMOHLTCPays>.0416</amountMOHLTCPays>
							</drug>
							<drug id="02321203" sec3="Y">
								<name>Auro-Gabapentin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.0416</individualPrice>
								<listingDate>2011-12-15</listingDate>
								<amountMOHLTCPays>.0416</amountMOHLTCPays>
							</drug>
							<drug id="02353245" sec3="Y">
								<name>Gabapentin</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.0416</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.0416</amountMOHLTCPays>
							</drug>
							<drug id="02361469" sec3="Y">
								<name>Jamp-Gabapentin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.0416</individualPrice>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.0416</amountMOHLTCPays>
							</drug>
							<drug id="02391473" sec3="Y">
								<name>Mar-Gabapentin</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.0416</individualPrice>
								<listingDate>2013-06-27</listingDate>
								<amountMOHLTCPays>.0416</amountMOHLTCPays>
							</drug>
							<drug id="02416840" sec3="Y">
								<name>Gabapentin Capsules USP</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.0416</individualPrice>
								<listingDate>2015-05-28</listingDate>
								<amountMOHLTCPays>.0416</amountMOHLTCPays>
							</drug>
							<drug id="02431408" dinStatus="E" sec3="Y">
								<name>Van-Gabapentin</name>
								<manufacturerId>VAN</manufacturerId>
								<individualPrice>.0416</individualPrice>
								<listingDate>2015-08-26</listingDate>
								<amountMOHLTCPays>.0416</amountMOHLTCPays>
							</drug>
							<drug id="02477912" sec3="Y">
								<name>AG-Gabapentin</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.0416</individualPrice>
								<listingDate>2021-01-29</listingDate>
								<amountMOHLTCPays>.0416</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200063">
							<itemNumber>1001</itemNumber>
							<strength>300mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02084279" sec3="Y">
								<name>Neurontin</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>1.1818</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1012</amountMOHLTCPays>
							</drug>
							<drug id="02243447" sec3="Y">
								<name>PMS-Gabapentin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1012</individualPrice>
								<listingDate>2001-10-11</listingDate>
								<amountMOHLTCPays>.1012</amountMOHLTCPays>
							</drug>
							<drug id="02244305" sec3="Y">
								<name>Apo-Gabapentin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1012</individualPrice>
								<listingDate>2002-07-29</listingDate>
								<amountMOHLTCPays>.1012</amountMOHLTCPays>
							</drug>
							<drug id="02244514" sec3="Y">
								<name>Teva-Gabapentin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1012</individualPrice>
								<listingDate>2002-07-29</listingDate>
								<amountMOHLTCPays>.1012</amountMOHLTCPays>
							</drug>
							<drug id="02246315" sec3="Y">
								<name>Gabapentin</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.1012</individualPrice>
								<listingDate>2009-11-19</listingDate>
								<amountMOHLTCPays>.1012</amountMOHLTCPays>
							</drug>
							<drug id="02256150" sec3="Y">
								<name>Co Gabapentin</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.1012</individualPrice>
								<listingDate>2005-03-31</listingDate>
								<amountMOHLTCPays>.1012</amountMOHLTCPays>
							</drug>
							<drug id="02319063" sec3="Y">
								<name>Ran-Gabapentin</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.1012</individualPrice>
								<listingDate>2010-03-02</listingDate>
								<amountMOHLTCPays>.1012</amountMOHLTCPays>
							</drug>
							<drug id="02321211" sec3="Y">
								<name>Auro-Gabapentin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.1012</individualPrice>
								<listingDate>2011-12-15</listingDate>
								<amountMOHLTCPays>.1012</amountMOHLTCPays>
							</drug>
							<drug id="02353253" sec3="Y">
								<name>Gabapentin</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.1012</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.1012</amountMOHLTCPays>
							</drug>
							<drug id="02361485" sec3="Y">
								<name>Jamp-Gabapentin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1012</individualPrice>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.1012</amountMOHLTCPays>
							</drug>
							<drug id="02391481" sec3="Y">
								<name>Mar-Gabapentin</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.1012</individualPrice>
								<listingDate>2013-06-27</listingDate>
								<amountMOHLTCPays>.1012</amountMOHLTCPays>
							</drug>
							<drug id="02416859" sec3="Y">
								<name>Gabapentin Capsules USP</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.1012</individualPrice>
								<listingDate>2015-05-28</listingDate>
								<amountMOHLTCPays>.1012</amountMOHLTCPays>
							</drug>
							<drug id="02431416" dinStatus="E" sec3="Y">
								<name>Van-Gabapentin</name>
								<manufacturerId>VAN</manufacturerId>
								<individualPrice>.1012</individualPrice>
								<listingDate>2015-08-26</listingDate>
								<amountMOHLTCPays>.1012</amountMOHLTCPays>
							</drug>
							<drug id="02477920" sec3="Y">
								<name>AG-Gabapentin</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.1012</individualPrice>
								<listingDate>2021-01-29</listingDate>
								<amountMOHLTCPays>.1012</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200064">
							<itemNumber>1002</itemNumber>
							<strength>400mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02084287" sec3="Y">
								<name>Neurontin</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>1.4084</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1206</amountMOHLTCPays>
							</drug>
							<drug id="02243448" sec3="Y">
								<name>PMS-Gabapentin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1206</individualPrice>
								<listingDate>2001-10-11</listingDate>
								<amountMOHLTCPays>.1206</amountMOHLTCPays>
							</drug>
							<drug id="02244306" sec3="Y">
								<name>Apo-Gabapentin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1206</individualPrice>
								<listingDate>2002-07-29</listingDate>
								<amountMOHLTCPays>.1206</amountMOHLTCPays>
							</drug>
							<drug id="02244515" sec3="Y">
								<name>Teva-Gabapentin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1206</individualPrice>
								<listingDate>2002-07-29</listingDate>
								<amountMOHLTCPays>.1206</amountMOHLTCPays>
							</drug>
							<drug id="02246316" sec3="Y">
								<name>Gabapentin</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.1206</individualPrice>
								<listingDate>2009-11-19</listingDate>
								<amountMOHLTCPays>.1206</amountMOHLTCPays>
							</drug>
							<drug id="02256169" sec3="Y">
								<name>Co Gabapentin</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.1206</individualPrice>
								<listingDate>2005-03-31</listingDate>
								<amountMOHLTCPays>.1206</amountMOHLTCPays>
							</drug>
							<drug id="02260905" sec3="Y">
								<name>Ratio-Gabapentin</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>.1206</individualPrice>
								<listingDate>2005-07-14</listingDate>
								<amountMOHLTCPays>.1206</amountMOHLTCPays>
							</drug>
							<drug id="02319071" sec3="Y">
								<name>Ran-Gabapentin</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.1206</individualPrice>
								<listingDate>2010-03-02</listingDate>
								<amountMOHLTCPays>.1206</amountMOHLTCPays>
							</drug>
							<drug id="02321238" sec3="Y">
								<name>Auro-Gabapentin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.1206</individualPrice>
								<listingDate>2011-12-15</listingDate>
								<amountMOHLTCPays>.1206</amountMOHLTCPays>
							</drug>
							<drug id="02353261" sec3="Y">
								<name>Gabapentin</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.1206</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.1206</amountMOHLTCPays>
							</drug>
							<drug id="02361493" sec3="Y">
								<name>Jamp-Gabapentin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1206</individualPrice>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.1206</amountMOHLTCPays>
							</drug>
							<drug id="02391503" sec3="Y">
								<name>Mar-Gabapentin</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.1206</individualPrice>
								<listingDate>2013-06-27</listingDate>
								<amountMOHLTCPays>.1206</amountMOHLTCPays>
							</drug>
							<drug id="02416867" sec3="Y">
								<name>Gabapentin Capsules USP</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.1206</individualPrice>
								<listingDate>2015-05-28</listingDate>
								<amountMOHLTCPays>.1206</amountMOHLTCPays>
							</drug>
							<drug id="02431424" dinStatus="E" sec3="Y">
								<name>Van-Gabapentin</name>
								<manufacturerId>VAN</manufacturerId>
								<individualPrice>.1206</individualPrice>
								<listingDate>2015-08-26</listingDate>
								<amountMOHLTCPays>.1206</amountMOHLTCPays>
							</drug>
							<drug id="02477939" sec3="Y">
								<name>AG-Gabapentin</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.1206</individualPrice>
								<listingDate>2021-01-29</listingDate>
								<amountMOHLTCPays>.1206</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200122">
							<itemNumber>1003</itemNumber>
							<strength>600mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02239717" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Neurontin</name>
								<manufacturerId>UJC</manufacturerId>
								<listingDate>2007-06-06</listingDate>
							</drug>
							<drug id="02248457" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Teva-Gabapentin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>1.3045</individualPrice>
								<listingDate>2007-06-06</listingDate>
							</drug>
							<drug id="02255898" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>PMS-Gabapentin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>1.3045</individualPrice>
								<listingDate>2007-06-06</listingDate>
							</drug>
							<drug id="02293358" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Gabapentin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.3045</individualPrice>
								<listingDate>2008-08-28</listingDate>
							</drug>
							<drug id="02388200" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Gabapentin</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>1.3045</individualPrice>
								<listingDate>2020-08-28</listingDate>
							</drug>
							<drug id="02392526" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Gabapentin Tablets USP</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>1.3045</individualPrice>
								<listingDate>2012-12-21</listingDate>
							</drug>
							<drug id="02402289" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Jamp-Gabapentin Tablets</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>1.3045</individualPrice>
								<listingDate>2013-06-27</listingDate>
							</drug>
							<drug id="02410990" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>GLN-Gabapentin</name>
								<manufacturerId>GLP</manufacturerId>
								<individualPrice>1.3045</individualPrice>
								<listingDate>2016-05-31</listingDate>
							</drug>
							<drug id="02428334" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Auro-Gabapentin Tablets</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>1.3045</individualPrice>
								<listingDate>2019-04-30</listingDate>
							</drug>
							<drug id="02431289" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Gabapentin</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>1.3045</individualPrice>
								<listingDate>2020-07-31</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="281200123">
							<itemNumber>1004</itemNumber>
							<strength>800mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02239718" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Neurontin</name>
								<manufacturerId>UJC</manufacturerId>
								<listingDate>2007-06-06</listingDate>
							</drug>
							<drug id="02247346" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Teva-Gabapentin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>1.7393</individualPrice>
								<listingDate>2007-06-06</listingDate>
							</drug>
							<drug id="02255901" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>PMS-Gabapentin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>1.7393</individualPrice>
								<listingDate>2007-06-06</listingDate>
							</drug>
							<drug id="02293366" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Gabapentin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.7393</individualPrice>
								<listingDate>2008-08-28</listingDate>
							</drug>
							<drug id="02388219" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Gabapentin</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>1.7393</individualPrice>
								<listingDate>2020-08-28</listingDate>
							</drug>
							<drug id="02392534" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Gabapentin Tablets USP</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>1.7393</individualPrice>
								<listingDate>2012-12-21</listingDate>
							</drug>
							<drug id="02402297" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Jamp-Gabapentin Tablets</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>1.7393</individualPrice>
								<listingDate>2013-06-27</listingDate>
							</drug>
							<drug id="02411008" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>GLN-Gabapentin</name>
								<manufacturerId>GLP</manufacturerId>
								<individualPrice>1.7393</individualPrice>
								<listingDate>2016-05-31</listingDate>
							</drug>
							<drug id="02428342" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Auro-Gabapentin Tablets</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>1.7393</individualPrice>
								<listingDate>2019-04-30</listingDate>
							</drug>
							<drug id="02431297" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Gabapentin</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>1.7393</individualPrice>
								<listingDate>2020-07-31</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01851">
					<name>LACOSAMIDE</name>
					<pcgGroup lccId="00221">
						<pcg9 id="281200148">
							<itemNumber>1005</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02357615" sec3="Y" sec12="Y">
								<name>Vimpat</name>
								<manufacturerId>UCB</manufacturerId>
								<individualPrice>2.5250</individualPrice>
								<listingDate>2012-04-24</listingDate>
								<amountMOHLTCPays>.6313</amountMOHLTCPays>
							</drug>
							<drug id="02472902" sec3="Y" sec12="Y">
								<name>Teva-Lacosamide</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.6313</individualPrice>
								<listingDate>2018-11-29</listingDate>
								<amountMOHLTCPays>.6313</amountMOHLTCPays>
							</drug>
							<drug id="02474670" sec3="Y" sec12="Y">
								<name>Sandoz Lacosamide</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.6313</individualPrice>
								<listingDate>2018-11-29</listingDate>
								<amountMOHLTCPays>.6313</amountMOHLTCPays>
							</drug>
							<drug id="02475332" sec3="Y" sec12="Y">
								<name>Auro-Lacosamide</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.6313</individualPrice>
								<listingDate>2018-11-29</listingDate>
								<amountMOHLTCPays>.6313</amountMOHLTCPays>
							</drug>
							<drug id="02478196" sec3="Y" sec12="Y">
								<name>Pharma-Lacosamide</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.6313</individualPrice>
								<listingDate>2018-11-29</listingDate>
								<amountMOHLTCPays>.6313</amountMOHLTCPays>
							</drug>
							<drug id="02487802" sec3="Y" sec12="Y">
								<name>Mar-Lacosamide</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.6313</individualPrice>
								<listingDate>2019-12-20</listingDate>
								<amountMOHLTCPays>.6313</amountMOHLTCPays>
							</drug>
							<drug id="02488388" sec3="Y" sec12="Y">
								<name>Jamp-Lacosamide</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.6313</individualPrice>
								<listingDate>2020-05-29</listingDate>
								<amountMOHLTCPays>.6313</amountMOHLTCPays>
							</drug>
							<drug id="02489287" sec3="Y" sec12="Y">
								<name>Ach-Lacosamide</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.6313</individualPrice>
								<listingDate>2021-07-30</listingDate>
								<amountMOHLTCPays>.6313</amountMOHLTCPays>
							</drug>
							<drug id="02490544" sec3="Y" sec12="Y">
								<name>Mint-Lacosamide</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.6313</individualPrice>
								<listingDate>2020-01-31</listingDate>
								<amountMOHLTCPays>.6313</amountMOHLTCPays>
							</drug>
							<drug id="02499568" sec3="Y" sec12="Y">
								<name>NRA-Lacosamide</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.6313</individualPrice>
								<listingDate>2021-04-30</listingDate>
								<amountMOHLTCPays>.6313</amountMOHLTCPays>
							</drug>
							<drug id="02512874" sec3="Y" sec12="Y">
								<name>Lacosamide</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.6313</individualPrice>
								<listingDate>2021-11-30</listingDate>
								<amountMOHLTCPays>.6313</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200149">
							<itemNumber>1006</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02357623" sec3="Y" sec12="Y">
								<name>Vimpat</name>
								<manufacturerId>UCB</manufacturerId>
								<individualPrice>3.5000</individualPrice>
								<listingDate>2012-04-24</listingDate>
								<amountMOHLTCPays>.8750</amountMOHLTCPays>
							</drug>
							<drug id="02472910" sec3="Y" sec12="Y">
								<name>Teva-Lacosamide</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.8750</individualPrice>
								<listingDate>2018-11-29</listingDate>
								<amountMOHLTCPays>.8750</amountMOHLTCPays>
							</drug>
							<drug id="02474689" sec3="Y" sec12="Y">
								<name>Sandoz Lacosamide</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.8750</individualPrice>
								<listingDate>2018-11-29</listingDate>
								<amountMOHLTCPays>.8750</amountMOHLTCPays>
							</drug>
							<drug id="02475340" sec3="Y" sec12="Y">
								<name>Auro-Lacosamide</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.8750</individualPrice>
								<listingDate>2018-11-29</listingDate>
								<amountMOHLTCPays>.8750</amountMOHLTCPays>
							</drug>
							<drug id="02478218" sec3="Y" sec12="Y">
								<name>Pharma-Lacosamide</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.8750</individualPrice>
								<listingDate>2018-11-29</listingDate>
								<amountMOHLTCPays>.8750</amountMOHLTCPays>
							</drug>
							<drug id="02487810" sec3="Y" sec12="Y">
								<name>Mar-Lacosamide</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.8750</individualPrice>
								<listingDate>2019-12-20</listingDate>
								<amountMOHLTCPays>.8750</amountMOHLTCPays>
							</drug>
							<drug id="02488396" sec3="Y" sec12="Y">
								<name>Jamp-Lacosamide</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.8750</individualPrice>
								<listingDate>2020-05-29</listingDate>
								<amountMOHLTCPays>.8750</amountMOHLTCPays>
							</drug>
							<drug id="02489295" sec3="Y" sec12="Y">
								<name>Ach-Lacosamide</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.8750</individualPrice>
								<listingDate>2021-07-30</listingDate>
								<amountMOHLTCPays>.8750</amountMOHLTCPays>
							</drug>
							<drug id="02490552" sec3="Y" sec12="Y">
								<name>Mint-Lacosamide</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.8750</individualPrice>
								<listingDate>2020-01-31</listingDate>
								<amountMOHLTCPays>.8750</amountMOHLTCPays>
							</drug>
							<drug id="02499576" sec3="Y" sec12="Y">
								<name>NRA-Lacosamide</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.8750</individualPrice>
								<listingDate>2021-04-30</listingDate>
								<amountMOHLTCPays>.8750</amountMOHLTCPays>
							</drug>
							<drug id="02512882" sec3="Y" sec12="Y">
								<name>Lacosamide</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.8750</individualPrice>
								<listingDate>2021-11-30</listingDate>
								<amountMOHLTCPays>.8750</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200150">
							<itemNumber>1007</itemNumber>
							<strength>150mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02357631" sec3="Y" sec12="Y">
								<name>Vimpat</name>
								<manufacturerId>UCB</manufacturerId>
								<individualPrice>4.7050</individualPrice>
								<listingDate>2012-04-24</listingDate>
								<amountMOHLTCPays>1.1763</amountMOHLTCPays>
							</drug>
							<drug id="02472929" sec3="Y" sec12="Y">
								<name>Teva-Lacosamide</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>1.1763</individualPrice>
								<listingDate>2018-11-29</listingDate>
								<amountMOHLTCPays>1.1763</amountMOHLTCPays>
							</drug>
							<drug id="02474697" sec3="Y" sec12="Y">
								<name>Sandoz Lacosamide</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>1.1763</individualPrice>
								<listingDate>2018-11-29</listingDate>
								<amountMOHLTCPays>1.1763</amountMOHLTCPays>
							</drug>
							<drug id="02475359" sec3="Y" sec12="Y">
								<name>Auro-Lacosamide</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>1.1763</individualPrice>
								<listingDate>2018-11-29</listingDate>
								<amountMOHLTCPays>1.1763</amountMOHLTCPays>
							</drug>
							<drug id="02478226" sec3="Y" sec12="Y">
								<name>Pharma-Lacosamide</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>1.1763</individualPrice>
								<listingDate>2018-11-29</listingDate>
								<amountMOHLTCPays>1.1763</amountMOHLTCPays>
							</drug>
							<drug id="02487829" sec3="Y" sec12="Y">
								<name>Mar-Lacosamide</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>1.1763</individualPrice>
								<listingDate>2019-12-20</listingDate>
								<amountMOHLTCPays>1.1763</amountMOHLTCPays>
							</drug>
							<drug id="02488418" sec3="Y" sec12="Y">
								<name>Jamp-Lacosamide</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>1.1763</individualPrice>
								<listingDate>2020-05-29</listingDate>
								<amountMOHLTCPays>1.1763</amountMOHLTCPays>
							</drug>
							<drug id="02489309" sec3="Y" sec12="Y">
								<name>Ach-Lacosamide</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>1.1763</individualPrice>
								<listingDate>2021-07-30</listingDate>
								<amountMOHLTCPays>1.1763</amountMOHLTCPays>
							</drug>
							<drug id="02490560" sec3="Y" sec12="Y">
								<name>Mint-Lacosamide</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>1.1763</individualPrice>
								<listingDate>2020-01-31</listingDate>
								<amountMOHLTCPays>1.1763</amountMOHLTCPays>
							</drug>
							<drug id="02499584" sec3="Y" sec12="Y">
								<name>NRA-Lacosamide</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>1.1763</individualPrice>
								<listingDate>2021-04-30</listingDate>
								<amountMOHLTCPays>1.1763</amountMOHLTCPays>
							</drug>
							<drug id="02512890" sec3="Y" sec12="Y">
								<name>Lacosamide</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>1.1763</individualPrice>
								<listingDate>2021-11-30</listingDate>
								<amountMOHLTCPays>1.1763</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200151">
							<itemNumber>1008</itemNumber>
							<strength>200mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02357658" sec3="Y" sec12="Y">
								<name>Vimpat</name>
								<manufacturerId>UCB</manufacturerId>
								<individualPrice>5.8000</individualPrice>
								<listingDate>2012-04-24</listingDate>
								<amountMOHLTCPays>1.4500</amountMOHLTCPays>
							</drug>
							<drug id="02472937" sec3="Y" sec12="Y">
								<name>Teva-Lacosamide</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>1.4500</individualPrice>
								<listingDate>2018-11-29</listingDate>
								<amountMOHLTCPays>1.4500</amountMOHLTCPays>
							</drug>
							<drug id="02474700" sec3="Y" sec12="Y">
								<name>Sandoz Lacosamide</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>1.4500</individualPrice>
								<listingDate>2018-11-29</listingDate>
								<amountMOHLTCPays>1.4500</amountMOHLTCPays>
							</drug>
							<drug id="02475367" sec3="Y" sec12="Y">
								<name>Auro-Lacosamide</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>1.4500</individualPrice>
								<listingDate>2018-11-29</listingDate>
								<amountMOHLTCPays>1.4500</amountMOHLTCPays>
							</drug>
							<drug id="02478234" sec3="Y" sec12="Y">
								<name>Pharma-Lacosamide</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>1.4500</individualPrice>
								<listingDate>2018-11-29</listingDate>
								<amountMOHLTCPays>1.4500</amountMOHLTCPays>
							</drug>
							<drug id="02487837" sec3="Y" sec12="Y">
								<name>Mar-Lacosamide</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>1.4500</individualPrice>
								<listingDate>2019-12-20</listingDate>
								<amountMOHLTCPays>1.4500</amountMOHLTCPays>
							</drug>
							<drug id="02488426" sec3="Y" sec12="Y">
								<name>Jamp-Lacosamide</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>1.4500</individualPrice>
								<listingDate>2020-05-29</listingDate>
								<amountMOHLTCPays>1.4500</amountMOHLTCPays>
							</drug>
							<drug id="02489317" sec3="Y" sec12="Y">
								<name>Ach-Lacosamide</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>1.4500</individualPrice>
								<listingDate>2021-07-30</listingDate>
								<amountMOHLTCPays>1.4500</amountMOHLTCPays>
							</drug>
							<drug id="02490579" sec3="Y" sec12="Y">
								<name>Mint-Lacosamide</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>1.4500</individualPrice>
								<listingDate>2020-01-31</listingDate>
								<amountMOHLTCPays>1.4500</amountMOHLTCPays>
							</drug>
							<drug id="02499592" sec3="Y" sec12="Y">
								<name>NRA-Lacosamide</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>1.4500</individualPrice>
								<listingDate>2021-04-30</listingDate>
								<amountMOHLTCPays>1.4500</amountMOHLTCPays>
							</drug>
							<drug id="02512904" sec3="Y" sec12="Y">
								<name>Lacosamide</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>1.4500</individualPrice>
								<listingDate>2021-11-30</listingDate>
								<amountMOHLTCPays>1.4500</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="430">As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND
Patients are under the care of a physician experienced in the treatment of epilepsy.
Note: Less costly anticonvulsant therapies may include the following:
Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc.</lccNote>
						<lccNote seq="003" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00486">
					<name>LAMOTRIGINE</name>
					<pcgGroup>
						<pcg9 id="281200055">
							<itemNumber>1009</itemNumber>
							<strength>25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02142082" sec3="Y">
								<name>Lamictal</name>
								<manufacturerId>GSK</manufacturerId>
								<individualPrice>.4345</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0698</amountMOHLTCPays>
							</drug>
							<drug id="02243352" sec3="Y">
								<name>Ratio-Lamotrigine</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>.0698</individualPrice>
								<listingDate>2003-04-16</listingDate>
								<amountMOHLTCPays>.0698</amountMOHLTCPays>
							</drug>
							<drug id="02245208" sec3="Y">
								<name>Apo-Lamotrigine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0698</individualPrice>
								<listingDate>2003-01-30</listingDate>
								<amountMOHLTCPays>.0698</amountMOHLTCPays>
							</drug>
							<drug id="02246897" sec3="Y">
								<name>PMS-Lamotrigine</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.0698</individualPrice>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.0698</amountMOHLTCPays>
							</drug>
							<drug id="02248232" sec3="Y">
								<name>Teva-Lamotrigine</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.0698</individualPrice>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.0698</amountMOHLTCPays>
							</drug>
							<drug id="02265494" sec3="Y">
								<name>Mylan-Lamotrigine</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.0698</individualPrice>
								<listingDate>2005-07-14</listingDate>
								<amountMOHLTCPays>.0698</amountMOHLTCPays>
							</drug>
							<drug id="02343010" sec3="Y">
								<name>Lamotrigine</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.0698</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.0698</amountMOHLTCPays>
							</drug>
							<drug id="02381354" sec3="Y">
								<name>Auro-Lamotrigine</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.0698</individualPrice>
								<listingDate>2012-08-27</listingDate>
								<amountMOHLTCPays>.0698</amountMOHLTCPays>
							</drug>
							<drug id="02428202" sec3="Y">
								<name>Lamotrigine</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.0698</individualPrice>
								<listingDate>2020-08-28</listingDate>
								<amountMOHLTCPays>.0698</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200059">
							<itemNumber>1010</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02142104" sec3="Y">
								<name>Lamictal</name>
								<manufacturerId>GSK</manufacturerId>
								<individualPrice>1.7356</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2787</amountMOHLTCPays>
							</drug>
							<drug id="02245209" sec3="Y">
								<name>Apo-Lamotrigine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2787</individualPrice>
								<listingDate>2003-01-30</listingDate>
								<amountMOHLTCPays>.2787</amountMOHLTCPays>
							</drug>
							<drug id="02246898" sec3="Y">
								<name>PMS-Lamotrigine</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2787</individualPrice>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.2787</amountMOHLTCPays>
							</drug>
							<drug id="02248233" sec3="Y">
								<name>Teva-Lamotrigine</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2787</individualPrice>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.2787</amountMOHLTCPays>
							</drug>
							<drug id="02265508" sec3="Y">
								<name>Mylan-Lamotrigine</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.2787</individualPrice>
								<listingDate>2005-07-14</listingDate>
								<amountMOHLTCPays>.2787</amountMOHLTCPays>
							</drug>
							<drug id="02343029" sec3="Y">
								<name>Lamotrigine</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2787</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2787</amountMOHLTCPays>
							</drug>
							<drug id="02381362" sec3="Y">
								<name>Auro-Lamotrigine</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2787</individualPrice>
								<listingDate>2012-08-27</listingDate>
								<amountMOHLTCPays>.2787</amountMOHLTCPays>
							</drug>
							<drug id="02428210" sec3="Y">
								<name>Lamotrigine</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2787</individualPrice>
								<listingDate>2020-08-28</listingDate>
								<amountMOHLTCPays>.2787</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200060">
							<itemNumber>1011</itemNumber>
							<strength>150mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02142112" sec3="Y">
								<name>Lamictal</name>
								<manufacturerId>GSK</manufacturerId>
								<individualPrice>2.5578</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.4107</amountMOHLTCPays>
							</drug>
							<drug id="02245210" sec3="Y">
								<name>Apo-Lamotrigine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.4107</individualPrice>
								<listingDate>2003-01-30</listingDate>
								<amountMOHLTCPays>.4107</amountMOHLTCPays>
							</drug>
							<drug id="02246899" sec3="Y">
								<name>PMS-Lamotrigine</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.4107</individualPrice>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.4107</amountMOHLTCPays>
							</drug>
							<drug id="02248234" sec3="Y">
								<name>Teva-Lamotrigine</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.4107</individualPrice>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.4107</amountMOHLTCPays>
							</drug>
							<drug id="02265516" sec3="Y">
								<name>Mylan-Lamotrigine</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.4107</individualPrice>
								<listingDate>2005-07-14</listingDate>
								<amountMOHLTCPays>.4107</amountMOHLTCPays>
							</drug>
							<drug id="02343037" sec3="Y">
								<name>Lamotrigine</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.4107</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.4107</amountMOHLTCPays>
							</drug>
							<drug id="02381370" sec3="Y">
								<name>Auro-Lamotrigine</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.4107</individualPrice>
								<listingDate>2012-08-27</listingDate>
								<amountMOHLTCPays>.4107</amountMOHLTCPays>
							</drug>
							<drug id="02428229" sec3="Y">
								<name>Lamotrigine</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.4107</individualPrice>
								<listingDate>2020-08-28</listingDate>
								<amountMOHLTCPays>.4107</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01603">
					<name>LEVETIRACETAM</name>
					<pcgGroup lccId="00266">
						<pcg9 id="281200091">
							<itemNumber>1012</itemNumber>
							<strength>250mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02247027" sec3="Y" sec12="Y">
								<name>Keppra</name>
								<manufacturerId>UCB</manufacturerId>
								<individualPrice>1.7836</individualPrice>
								<listingDate>2007-11-10</listingDate>
								<amountMOHLTCPays>.3210</amountMOHLTCPays>
							</drug>
							<drug id="02274183" sec3="Y" sec12="Y">
								<name>Act Levetiracetam</name>
								<manufacturerId>ACV</manufacturerId>
								<individualPrice>.3210</individualPrice>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.3210</amountMOHLTCPays>
							</drug>
							<drug id="02285924" sec3="Y" sec12="Y">
								<name>Apo-Levetiracetam</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3210</individualPrice>
								<listingDate>2007-11-10</listingDate>
								<amountMOHLTCPays>.3210</amountMOHLTCPays>
							</drug>
							<drug id="02296101" sec3="Y" sec12="Y">
								<name>PMS-Levetiracetam</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3210</individualPrice>
								<listingDate>2007-11-10</listingDate>
								<amountMOHLTCPays>.3210</amountMOHLTCPays>
							</drug>
							<drug id="02353342" sec3="Y" sec12="Y">
								<name>Levetiracetam</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.3210</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.3210</amountMOHLTCPays>
							</drug>
							<drug id="02375249" sec3="Y" sec12="Y">
								<name>Auro-Levetiracetam</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.3210</individualPrice>
								<listingDate>2012-04-24</listingDate>
								<amountMOHLTCPays>.3210</amountMOHLTCPays>
							</drug>
							<drug id="02399776" sec3="Y" sec12="Y">
								<name>Levetiracetam Tablets</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.3210</individualPrice>
								<listingDate>2013-06-27</listingDate>
								<amountMOHLTCPays>.3210</amountMOHLTCPays>
							</drug>
							<drug id="02403005" sec3="Y" sec12="Y">
								<name>Jamp-Levetiracetam</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.3210</individualPrice>
								<listingDate>2013-06-27</listingDate>
								<amountMOHLTCPays>.3210</amountMOHLTCPays>
							</drug>
							<drug id="02440202" sec3="Y" sec12="Y">
								<name>Nat-Levetiracetam</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>.3210</individualPrice>
								<listingDate>2015-10-29</listingDate>
								<amountMOHLTCPays>.3210</amountMOHLTCPays>
							</drug>
							<drug id="02442388" sec3="Y" sec12="Y">
								<name>Mint-Levetiracetam</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.3210</individualPrice>
								<listingDate>2021-11-30</listingDate>
								<amountMOHLTCPays>.3210</amountMOHLTCPays>
							</drug>
							<drug id="02442531" sec3="Y" sec12="Y">
								<name>Levetiracetam</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.3210</individualPrice>
								<listingDate>2020-08-28</listingDate>
								<amountMOHLTCPays>.3210</amountMOHLTCPays>
							</drug>
							<drug id="02454653" sec3="Y" sec12="Y">
								<name>Levetiracetam</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3210</individualPrice>
								<listingDate>2017-03-28</listingDate>
								<amountMOHLTCPays>.3210</amountMOHLTCPays>
							</drug>
							<drug id="02461986" sec3="Y" sec12="Y">
								<name>Sandoz Levetiracetam</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.3210</individualPrice>
								<listingDate>2017-09-28</listingDate>
								<amountMOHLTCPays>.3210</amountMOHLTCPays>
							</drug>
							<drug id="02482274" sec3="Y" sec12="Y">
								<name>Riva-Levetiracetam</name>
								<manufacturerId>RIA</manufacturerId>
								<individualPrice>.3210</individualPrice>
								<listingDate>2019-12-20</listingDate>
								<amountMOHLTCPays>.3210</amountMOHLTCPays>
							</drug>
							<drug id="02499193" sec3="Y" sec12="Y">
								<name>NRA-Levetiracetam</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.3210</individualPrice>
								<listingDate>2021-05-31</listingDate>
								<amountMOHLTCPays>.3210</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200092">
							<itemNumber>1013</itemNumber>
							<strength>500mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02247028" sec3="Y" sec12="Y">
								<name>Keppra</name>
								<manufacturerId>UCB</manufacturerId>
								<individualPrice>2.1725</individualPrice>
								<listingDate>2007-11-10</listingDate>
								<amountMOHLTCPays>.3911</amountMOHLTCPays>
							</drug>
							<drug id="02274191" sec3="Y" sec12="Y">
								<name>Act Levetiracetam</name>
								<manufacturerId>ACV</manufacturerId>
								<individualPrice>.3911</individualPrice>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.3911</amountMOHLTCPays>
							</drug>
							<drug id="02285932" sec3="Y" sec12="Y">
								<name>Apo-Levetiracetam</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3911</individualPrice>
								<listingDate>2007-11-10</listingDate>
								<amountMOHLTCPays>.3911</amountMOHLTCPays>
							</drug>
							<drug id="02296128" sec3="Y" sec12="Y">
								<name>PMS-Levetiracetam</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3911</individualPrice>
								<listingDate>2007-11-10</listingDate>
								<amountMOHLTCPays>.3911</amountMOHLTCPays>
							</drug>
							<drug id="02353350" sec3="Y" sec12="Y">
								<name>Levetiracetam</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.3911</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.3911</amountMOHLTCPays>
							</drug>
							<drug id="02375257" sec3="Y" sec12="Y">
								<name>Auro-Levetiracetam</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.3911</individualPrice>
								<listingDate>2012-04-24</listingDate>
								<amountMOHLTCPays>.3911</amountMOHLTCPays>
							</drug>
							<drug id="02399784" sec3="Y" sec12="Y">
								<name>Levetiracetam Tablets</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.3911</individualPrice>
								<listingDate>2013-06-27</listingDate>
								<amountMOHLTCPays>.3911</amountMOHLTCPays>
							</drug>
							<drug id="02403021" sec3="Y" sec12="Y">
								<name>Jamp-Levetiracetam</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.3911</individualPrice>
								<listingDate>2013-06-27</listingDate>
								<amountMOHLTCPays>.3911</amountMOHLTCPays>
							</drug>
							<drug id="02440210" sec3="Y" sec12="Y">
								<name>Nat-Levetiracetam</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>.3911</individualPrice>
								<listingDate>2015-10-29</listingDate>
								<amountMOHLTCPays>.3911</amountMOHLTCPays>
							</drug>
							<drug id="02442396" sec3="Y" sec12="Y">
								<name>Mint-Levetiracetam</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.3911</individualPrice>
								<listingDate>2021-11-30</listingDate>
								<amountMOHLTCPays>.3911</amountMOHLTCPays>
							</drug>
							<drug id="02442558" sec3="Y" sec12="Y">
								<name>Levetiracetam</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.3911</individualPrice>
								<listingDate>2020-08-28</listingDate>
								<amountMOHLTCPays>.3911</amountMOHLTCPays>
							</drug>
							<drug id="02454661" sec3="Y" sec12="Y">
								<name>Levetiracetam</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3911</individualPrice>
								<listingDate>2017-03-28</listingDate>
								<amountMOHLTCPays>.3911</amountMOHLTCPays>
							</drug>
							<drug id="02461994" sec3="Y" sec12="Y">
								<name>Sandoz Levetiracetam</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.3911</individualPrice>
								<listingDate>2017-09-28</listingDate>
								<amountMOHLTCPays>.3911</amountMOHLTCPays>
							</drug>
							<drug id="02482282" sec3="Y" sec12="Y">
								<name>Riva-Levetiracetam</name>
								<manufacturerId>RIA</manufacturerId>
								<individualPrice>.3911</individualPrice>
								<listingDate>2019-12-20</listingDate>
								<amountMOHLTCPays>.3911</amountMOHLTCPays>
							</drug>
							<drug id="02499207" sec3="Y" sec12="Y">
								<name>NRA-Levetiracetam</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.3911</individualPrice>
								<listingDate>2021-05-31</listingDate>
								<amountMOHLTCPays>.3911</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200093">
							<itemNumber>1014</itemNumber>
							<strength>750mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02247029" sec3="Y" sec12="Y">
								<name>Keppra</name>
								<manufacturerId>UCB</manufacturerId>
								<individualPrice>3.0089</individualPrice>
								<listingDate>2007-11-10</listingDate>
								<amountMOHLTCPays>.5416</amountMOHLTCPays>
							</drug>
							<drug id="02274205" sec3="Y" sec12="Y">
								<name>Act Levetiracetam</name>
								<manufacturerId>ACV</manufacturerId>
								<individualPrice>.5416</individualPrice>
								<listingDate>2007-12-19</listingDate>
								<amountMOHLTCPays>.5416</amountMOHLTCPays>
							</drug>
							<drug id="02285940" sec3="Y" sec12="Y">
								<name>Apo-Levetiracetam</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.5416</individualPrice>
								<listingDate>2007-11-10</listingDate>
								<amountMOHLTCPays>.5416</amountMOHLTCPays>
							</drug>
							<drug id="02296136" sec3="Y" sec12="Y">
								<name>PMS-Levetiracetam</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.5416</individualPrice>
								<listingDate>2007-11-10</listingDate>
								<amountMOHLTCPays>.5416</amountMOHLTCPays>
							</drug>
							<drug id="02353369" sec3="Y" sec12="Y">
								<name>Levetiracetam</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.5416</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.5416</amountMOHLTCPays>
							</drug>
							<drug id="02375265" sec3="Y" sec12="Y">
								<name>Auro-Levetiracetam</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.5416</individualPrice>
								<listingDate>2012-04-24</listingDate>
								<amountMOHLTCPays>.5416</amountMOHLTCPays>
							</drug>
							<drug id="02399792" sec3="Y" sec12="Y">
								<name>Levetiracetam Tablets</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.5416</individualPrice>
								<listingDate>2013-06-27</listingDate>
								<amountMOHLTCPays>.5416</amountMOHLTCPays>
							</drug>
							<drug id="02403048" sec3="Y" sec12="Y">
								<name>Jamp-Levetiracetam</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.5416</individualPrice>
								<listingDate>2013-06-27</listingDate>
								<amountMOHLTCPays>.5416</amountMOHLTCPays>
							</drug>
							<drug id="02440229" sec3="Y" sec12="Y">
								<name>Nat-Levetiracetam</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>.5416</individualPrice>
								<listingDate>2015-10-29</listingDate>
								<amountMOHLTCPays>.5416</amountMOHLTCPays>
							</drug>
							<drug id="02442418" sec3="Y" sec12="Y">
								<name>Mint-Levetiracetam</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.5416</individualPrice>
								<listingDate>2021-11-30</listingDate>
								<amountMOHLTCPays>.5416</amountMOHLTCPays>
							</drug>
							<drug id="02442566" sec3="Y" sec12="Y">
								<name>Levetiracetam</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.5416</individualPrice>
								<listingDate>2020-08-28</listingDate>
								<amountMOHLTCPays>.5416</amountMOHLTCPays>
							</drug>
							<drug id="02454688" sec3="Y" sec12="Y">
								<name>Levetiracetam</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.5416</individualPrice>
								<listingDate>2017-03-28</listingDate>
								<amountMOHLTCPays>.5416</amountMOHLTCPays>
							</drug>
							<drug id="02462001" sec3="Y" sec12="Y">
								<name>Sandoz Levetiracetam</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.5416</individualPrice>
								<listingDate>2017-09-28</listingDate>
								<amountMOHLTCPays>.5416</amountMOHLTCPays>
							</drug>
							<drug id="02482290" sec3="Y" sec12="Y">
								<name>Riva-Levetiracetam</name>
								<manufacturerId>RIA</manufacturerId>
								<individualPrice>.5416</individualPrice>
								<listingDate>2019-12-20</listingDate>
								<amountMOHLTCPays>.5416</amountMOHLTCPays>
							</drug>
							<drug id="02499215" sec3="Y" sec12="Y">
								<name>NRA-Levetiracetam</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.5416</individualPrice>
								<listingDate>2021-05-31</listingDate>
								<amountMOHLTCPays>.5416</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="473">As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
					<pcgGroup lccId="00339">
						<pcg9 id="281200182">
							<itemNumber>1015</itemNumber>
							<strength>1000mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02462028" sec3="Y" sec12="Y">
								<name>Sandoz Levetiracetam</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.7221</individualPrice>
								<listingDate>2020-08-28</listingDate>
								<amountMOHLTCPays>.7221</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="473">As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="01593">
					<name>OXCARBAZEPINE</name>
					<pcgGroup>
						<pcg9 id="281200087">
							<itemNumber>1016</itemNumber>
							<strength>150mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02242067" notABenefit="Y" sec3="Y">
								<name>Trileptal</name>
								<manufacturerId>NOV</manufacturerId>
								<listingDate>2008-06-27</listingDate>
							</drug>
							<drug id="02284294" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Apo-Oxcarbazepine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.6209</individualPrice>
								<listingDate>2008-06-27</listingDate>
								<amountMOHLTCPays>.6209</amountMOHLTCPays>
							</drug>
							<drug id="02440717" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Jamp-Oxcarbazepine</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.6210</individualPrice>
								<listingDate>2015-10-29</listingDate>
								<amountMOHLTCPays>.6210</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200088">
							<itemNumber>1017</itemNumber>
							<strength>300mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02242068" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Trileptal</name>
								<manufacturerId>NOV</manufacturerId>
								<listingDate>2008-06-27</listingDate>
							</drug>
							<drug id="02284308" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Apo-Oxcarbazepine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.9102</individualPrice>
								<listingDate>2008-06-27</listingDate>
								<amountMOHLTCPays>.9102</amountMOHLTCPays>
							</drug>
							<drug id="02440725" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Jamp-Oxcarbazepine</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.9102</individualPrice>
								<listingDate>2015-10-29</listingDate>
								<amountMOHLTCPays>.9102</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200089">
							<itemNumber>1018</itemNumber>
							<strength>600mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02242069" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Trileptal</name>
								<manufacturerId>NOV</manufacturerId>
								<listingDate>2008-06-27</listingDate>
							</drug>
							<drug id="02284316" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Apo-Oxcarbazepine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.8204</individualPrice>
								<listingDate>2008-06-27</listingDate>
								<amountMOHLTCPays>1.8204</amountMOHLTCPays>
							</drug>
							<drug id="02440733" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Jamp-Oxcarbazepine</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>1.8204</individualPrice>
								<listingDate>2015-10-29</listingDate>
								<amountMOHLTCPays>1.8204</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01936">
					<name>PERAMPANEL</name>
					<pcgGroup lccId="00240">
						<pcg9 id="281200161">
							<itemNumber>1019</itemNumber>
							<strength>2mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02404516" sec3="Y" sec12="Y">
								<name>Fycompa</name>
								<manufacturerId>EIS</manufacturerId>
								<individualPrice>10.0075</individualPrice>
								<listingDate>2014-02-27</listingDate>
								<amountMOHLTCPays>10.0075</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200162">
							<itemNumber>1020</itemNumber>
							<strength>4mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02404524" sec3="Y" sec12="Y">
								<name>Fycompa</name>
								<manufacturerId>EIS</manufacturerId>
								<individualPrice>10.0075</individualPrice>
								<listingDate>2014-02-27</listingDate>
								<amountMOHLTCPays>10.0075</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200163">
							<itemNumber>1021</itemNumber>
							<strength>6mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02404532" sec3="Y" sec12="Y">
								<name>Fycompa</name>
								<manufacturerId>EIS</manufacturerId>
								<individualPrice>10.0075</individualPrice>
								<listingDate>2014-02-27</listingDate>
								<amountMOHLTCPays>10.0075</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200164">
							<itemNumber>1022</itemNumber>
							<strength>8mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02404540" sec3="Y" sec12="Y">
								<name>Fycompa</name>
								<manufacturerId>EIS</manufacturerId>
								<individualPrice>10.0075</individualPrice>
								<listingDate>2014-02-27</listingDate>
								<amountMOHLTCPays>10.0075</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200165">
							<itemNumber>1023</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02404559" sec3="Y" sec12="Y">
								<name>Fycompa</name>
								<manufacturerId>EIS</manufacturerId>
								<individualPrice>10.0075</individualPrice>
								<listingDate>2014-02-27</listingDate>
								<amountMOHLTCPays>10.0075</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200166">
							<itemNumber>1024</itemNumber>
							<strength>12mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02404567" sec3="Y" sec12="Y">
								<name>Fycompa</name>
								<manufacturerId>EIS</manufacturerId>
								<individualPrice>10.0075</individualPrice>
								<listingDate>2014-02-27</listingDate>
								<amountMOHLTCPays>10.0075</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="430">As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND
Patients are under the care of a physician experienced in the treatment of epilepsy.
Note: Less costly anticonvulsant therapies may include the following:
Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: Indefinite.</lccNote>
						<lccNote seq="003" reasonForUseId="564">For adjunctive therapy in the management of primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies;
AND
Patients are under the care of a physician experienced in the treatment of epilepsy.
Note: Less costly anticonvulsant therapies may include the following:
Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc.</lccNote>
						<lccNote seq="004" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00480">
					<name>PHENOBARBITAL</name>
					<pcgGroup lccId="00294">
						<pcg9 id="281200073">
							<itemNumber>1025</itemNumber>
							<strength>120mg/mL</strength>
							<dosageForm>Inj Sol-1mL Pk</dosageForm>
							<drug id="02304090" sec3="Y" sec12="Y">
								<name>Phenobarbital Injection</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>15.7000</individualPrice>
								<listingDate>2018-01-31</listingDate>
								<amountMOHLTCPays>15.7000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="481">For the management of patients receiving palliative care*.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="003" type="N">*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="00471">
					<name>PHENYTOIN (DIPHENYLHYDANTOIN)</name>
					<pcgGroup>
						<pcg9 id="281200003">
							<itemNumber>1026</itemNumber>
							<strength>6mg/mL</strength>
							<dosageForm>O/L</dosageForm>
							<drug id="00023442" sec3="Y">
								<name>Dilantin-30 Suspension</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>.0529</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0529</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200002">
							<itemNumber>1027</itemNumber>
							<strength>25mg/mL</strength>
							<dosageForm>O/L</dosageForm>
							<drug id="00023450" sec3="Y">
								<name>Dilantin-125 Suspension</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>.0627</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0428</amountMOHLTCPays>
							</drug>
							<drug id="02250896" sec3="Y">
								<name>Taro-Phenytoin</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>.0428</individualPrice>
								<listingDate>2005-11-08</listingDate>
								<amountMOHLTCPays>.0428</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200001">
							<itemNumber>1028</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00023698" sec3="Y">
								<name>Dilantin Infatabs</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>.0961</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0961</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00472">
					<name>PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM</name>
					<pcgGroup>
						<pcg9 id="281200005">
							<itemNumber>1029</itemNumber>
							<strength>30mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00022772" sec3="Y">
								<name>Dilantin</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>.1514</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1514</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200004">
							<itemNumber>1030</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00022780" sec3="Y">
								<name>Dilantin</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>.0974</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0665</amountMOHLTCPays>
							</drug>
							<drug id="02460912" sec3="Y">
								<name>Phenytoin Sodium</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.0665</individualPrice>
								<listingDate>2017-09-28</listingDate>
								<amountMOHLTCPays>.0665</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
					<pcgGroup lccId="00270">
						<pcg9 id="281200081">
							<itemNumber>1031</itemNumber>
							<strength>50mg/mL</strength>
							<dosageForm>Inj Sol (Preservative Free)</dosageForm>
							<drug id="00780626" sec3="Y" sec12="Y">
								<name>Phenytoin Sodium Injection USP</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>6.0785</individualPrice>
								<listingDate>2017-02-28</listingDate>
								<amountMOHLTCPays>6.0785</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="481">For the management of patients receiving palliative care*.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote>
						<lccNote seq="003" type="N">*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="01676">
					<name>PREGABALIN</name>
					<pcgGroup>
						<pcg9 id="281200094">
							<itemNumber>1032</itemNumber>
							<strength>25mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02268418" sec3="Y">
								<name>Lyrica</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>.8995</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.1481</amountMOHLTCPays>
							</drug>
							<drug id="02359596" sec3="Y">
								<name>PMS-Pregabalin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1481</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.1481</amountMOHLTCPays>
							</drug>
							<drug id="02361159" sec3="Y">
								<name>Teva-Pregabalin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1481</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.1481</amountMOHLTCPays>
							</drug>
							<drug id="02390817" sec3="Y">
								<name>Sandoz Pregabalin</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.1481</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.1481</amountMOHLTCPays>
							</drug>
							<drug id="02392801" sec3="Y">
								<name>Ran-Pregabalin</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.1481</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.1481</amountMOHLTCPays>
							</drug>
							<drug id="02394235" sec3="Y">
								<name>Apo-Pregabalin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1481</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.1481</amountMOHLTCPays>
							</drug>
							<drug id="02402912" sec3="Y">
								<name>Co Pregabalin</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.1481</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.1481</amountMOHLTCPays>
							</drug>
							<drug id="02403692" sec3="Y">
								<name>Pregabalin</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.1481</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>.1481</amountMOHLTCPays>
							</drug>
							<drug id="02405539" sec3="Y">
								<name>Pregabalin</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.1481</individualPrice>
								<listingDate>2016-05-31</listingDate>
								<amountMOHLTCPays>.1481</amountMOHLTCPays>
							</drug>
							<drug id="02417529" sec3="Y">
								<name>Mar-Pregabalin</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.1481</individualPrice>
								<listingDate>2014-05-29</listingDate>
								<amountMOHLTCPays>.1481</amountMOHLTCPays>
							</drug>
							<drug id="02423804" sec3="Y">
								<name>Mint-Pregabalin</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.1481</individualPrice>
								<listingDate>2014-08-28</listingDate>
								<amountMOHLTCPays>.1481</amountMOHLTCPays>
							</drug>
							<drug id="02433869" sec3="Y">
								<name>Auro-Pregabalin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.1481</individualPrice>
								<listingDate>2015-05-28</listingDate>
								<amountMOHLTCPays>.1481</amountMOHLTCPays>
							</drug>
							<drug id="02435977" sec3="Y">
								<name>Jamp-Pregabalin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1481</individualPrice>
								<listingDate>2016-01-28</listingDate>
								<amountMOHLTCPays>.1481</amountMOHLTCPays>
							</drug>
							<drug id="02449838" sec3="Y">
								<name>Ach-Pregabalin</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.1481</individualPrice>
								<listingDate>2021-08-31</listingDate>
								<amountMOHLTCPays>.1481</amountMOHLTCPays>
							</drug>
							<drug id="02467291" sec3="Y">
								<name>M-Pregabalin</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.1481</individualPrice>
								<listingDate>2021-09-30</listingDate>
								<amountMOHLTCPays>.1481</amountMOHLTCPays>
							</drug>
							<drug id="02479117" sec3="Y">
								<name>NRA-Pregabalin</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.1481</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>.1481</amountMOHLTCPays>
							</drug>
							<drug id="02480727" sec3="Y">
								<name>AG-Pregabalin</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.1481</individualPrice>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.1481</amountMOHLTCPays>
							</drug>
							<drug id="02494841" sec3="Y">
								<name>Nat-Pregabalin</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>.1481</individualPrice>
								<listingDate>2020-02-28</listingDate>
								<amountMOHLTCPays>.1481</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200095">
							<itemNumber>1033</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02268426" sec3="Y">
								<name>Lyrica</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>1.4110</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.2324</amountMOHLTCPays>
							</drug>
							<drug id="02359618" sec3="Y">
								<name>PMS-Pregabalin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2324</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.2324</amountMOHLTCPays>
							</drug>
							<drug id="02361175" sec3="Y">
								<name>Teva-Pregabalin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2324</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.2324</amountMOHLTCPays>
							</drug>
							<drug id="02390825" sec3="Y">
								<name>Sandoz Pregabalin</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2324</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.2324</amountMOHLTCPays>
							</drug>
							<drug id="02392828" sec3="Y">
								<name>Ran-Pregabalin</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.2324</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.2324</amountMOHLTCPays>
							</drug>
							<drug id="02394243" sec3="Y">
								<name>Apo-Pregabalin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2324</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.2324</amountMOHLTCPays>
							</drug>
							<drug id="02402920" sec3="Y">
								<name>Co Pregabalin</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.2324</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.2324</amountMOHLTCPays>
							</drug>
							<drug id="02403706" sec3="Y">
								<name>Pregabalin</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2324</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>.2324</amountMOHLTCPays>
							</drug>
							<drug id="02405547" sec3="Y">
								<name>Pregabalin</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2324</individualPrice>
								<listingDate>2016-05-31</listingDate>
								<amountMOHLTCPays>.2324</amountMOHLTCPays>
							</drug>
							<drug id="02417537" sec3="Y">
								<name>Mar-Pregabalin</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.2324</individualPrice>
								<listingDate>2014-05-29</listingDate>
								<amountMOHLTCPays>.2324</amountMOHLTCPays>
							</drug>
							<drug id="02423812" sec3="Y">
								<name>Mint-Pregabalin</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.2324</individualPrice>
								<listingDate>2014-08-28</listingDate>
								<amountMOHLTCPays>.2324</amountMOHLTCPays>
							</drug>
							<drug id="02433877" sec3="Y">
								<name>Auro-Pregabalin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2324</individualPrice>
								<listingDate>2015-05-28</listingDate>
								<amountMOHLTCPays>.2324</amountMOHLTCPays>
							</drug>
							<drug id="02435985" sec3="Y">
								<name>Jamp-Pregabalin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2324</individualPrice>
								<listingDate>2016-01-28</listingDate>
								<amountMOHLTCPays>.2324</amountMOHLTCPays>
							</drug>
							<drug id="02449846" sec3="Y">
								<name>Ach-Pregabalin</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.2324</individualPrice>
								<listingDate>2021-08-31</listingDate>
								<amountMOHLTCPays>.2324</amountMOHLTCPays>
							</drug>
							<drug id="02467305" sec3="Y">
								<name>M-Pregabalin</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.2324</individualPrice>
								<listingDate>2021-09-30</listingDate>
								<amountMOHLTCPays>.2324</amountMOHLTCPays>
							</drug>
							<drug id="02479125" sec3="Y">
								<name>NRA-Pregabalin</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.2324</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>.2324</amountMOHLTCPays>
							</drug>
							<drug id="02480735" sec3="Y">
								<name>AG-Pregabalin</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.2324</individualPrice>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.2324</amountMOHLTCPays>
							</drug>
							<drug id="02494868" sec3="Y">
								<name>Nat-Pregabalin</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>.2324</individualPrice>
								<listingDate>2020-02-28</listingDate>
								<amountMOHLTCPays>.2324</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200096">
							<itemNumber>1034</itemNumber>
							<strength>75mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02268434" sec3="Y">
								<name>Lyrica</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>1.8257</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.3007</amountMOHLTCPays>
							</drug>
							<drug id="02359626" sec3="Y">
								<name>PMS-Pregabalin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3007</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.3007</amountMOHLTCPays>
							</drug>
							<drug id="02361183" sec3="Y">
								<name>Teva-Pregabalin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3007</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.3007</amountMOHLTCPays>
							</drug>
							<drug id="02390833" sec3="Y">
								<name>Sandoz Pregabalin</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.3007</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.3007</amountMOHLTCPays>
							</drug>
							<drug id="02392836" sec3="Y">
								<name>Ran-Pregabalin</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.3007</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.3007</amountMOHLTCPays>
							</drug>
							<drug id="02394251" sec3="Y">
								<name>Apo-Pregabalin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3007</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.3007</amountMOHLTCPays>
							</drug>
							<drug id="02402939" sec3="Y">
								<name>Co Pregabalin</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.3007</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.3007</amountMOHLTCPays>
							</drug>
							<drug id="02403714" sec3="Y">
								<name>Pregabalin</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.3007</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>.3007</amountMOHLTCPays>
							</drug>
							<drug id="02405555" sec3="Y">
								<name>Pregabalin</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.3007</individualPrice>
								<listingDate>2016-05-31</listingDate>
								<amountMOHLTCPays>.3007</amountMOHLTCPays>
							</drug>
							<drug id="02417545" sec3="Y">
								<name>Mar-Pregabalin</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.3007</individualPrice>
								<listingDate>2014-05-29</listingDate>
								<amountMOHLTCPays>.3007</amountMOHLTCPays>
							</drug>
							<drug id="02424185" sec3="Y">
								<name>Mint-Pregabalin</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.3007</individualPrice>
								<listingDate>2014-08-28</listingDate>
								<amountMOHLTCPays>.3007</amountMOHLTCPays>
							</drug>
							<drug id="02433885" sec3="Y">
								<name>Auro-Pregabalin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.3007</individualPrice>
								<listingDate>2015-05-28</listingDate>
								<amountMOHLTCPays>.3007</amountMOHLTCPays>
							</drug>
							<drug id="02435993" sec3="Y">
								<name>Jamp-Pregabalin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.3007</individualPrice>
								<listingDate>2016-01-28</listingDate>
								<amountMOHLTCPays>.3007</amountMOHLTCPays>
							</drug>
							<drug id="02449854" sec3="Y">
								<name>Ach-Pregabalin</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.3007</individualPrice>
								<listingDate>2021-08-31</listingDate>
								<amountMOHLTCPays>.3007</amountMOHLTCPays>
							</drug>
							<drug id="02467313" sec3="Y">
								<name>M-Pregabalin</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.3007</individualPrice>
								<listingDate>2021-09-30</listingDate>
								<amountMOHLTCPays>.3007</amountMOHLTCPays>
							</drug>
							<drug id="02479133" sec3="Y">
								<name>NRA-Pregabalin</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.3007</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>.3007</amountMOHLTCPays>
							</drug>
							<drug id="02480743" sec3="Y">
								<name>AG-Pregabalin</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.3007</individualPrice>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.3007</amountMOHLTCPays>
							</drug>
							<drug id="02494876" sec3="Y">
								<name>Nat-Pregabalin</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>.3007</individualPrice>
								<listingDate>2020-02-28</listingDate>
								<amountMOHLTCPays>.3007</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200097">
							<itemNumber>1035</itemNumber>
							<strength>150mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02268450" sec3="Y">
								<name>Lyrica</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>2.5165</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.4145</amountMOHLTCPays>
							</drug>
							<drug id="02359634" sec3="Y">
								<name>PMS-Pregabalin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.4145</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.4145</amountMOHLTCPays>
							</drug>
							<drug id="02361205" sec3="Y">
								<name>Teva-Pregabalin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.4145</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.4145</amountMOHLTCPays>
							</drug>
							<drug id="02390841" sec3="Y">
								<name>Sandoz Pregabalin</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.4145</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.4145</amountMOHLTCPays>
							</drug>
							<drug id="02392844" sec3="Y">
								<name>Ran-Pregabalin</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.4145</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.4145</amountMOHLTCPays>
							</drug>
							<drug id="02394278" sec3="Y">
								<name>Apo-Pregabalin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.4145</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.4145</amountMOHLTCPays>
							</drug>
							<drug id="02402955" sec3="Y">
								<name>Co Pregabalin</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.4145</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.4145</amountMOHLTCPays>
							</drug>
							<drug id="02403722" sec3="Y">
								<name>Pregabalin</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.4145</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>.4145</amountMOHLTCPays>
							</drug>
							<drug id="02405563" sec3="Y">
								<name>Pregabalin</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.4145</individualPrice>
								<listingDate>2016-05-31</listingDate>
								<amountMOHLTCPays>.4145</amountMOHLTCPays>
							</drug>
							<drug id="02417561" sec3="Y">
								<name>Mar-Pregabalin</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.4145</individualPrice>
								<listingDate>2014-05-29</listingDate>
								<amountMOHLTCPays>.4145</amountMOHLTCPays>
							</drug>
							<drug id="02424207" sec3="Y">
								<name>Mint-Pregabalin</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.4145</individualPrice>
								<listingDate>2014-08-28</listingDate>
								<amountMOHLTCPays>.4145</amountMOHLTCPays>
							</drug>
							<drug id="02433907" sec3="Y">
								<name>Auro-Pregabalin</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.4145</individualPrice>
								<listingDate>2015-05-28</listingDate>
								<amountMOHLTCPays>.4145</amountMOHLTCPays>
							</drug>
							<drug id="02436000" sec3="Y">
								<name>Jamp-Pregabalin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.4145</individualPrice>
								<listingDate>2016-01-28</listingDate>
								<amountMOHLTCPays>.4145</amountMOHLTCPays>
							</drug>
							<drug id="02449870" sec3="Y">
								<name>Ach-Pregabalin</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.4145</individualPrice>
								<listingDate>2021-08-31</listingDate>
								<amountMOHLTCPays>.4145</amountMOHLTCPays>
							</drug>
							<drug id="02467321" sec3="Y">
								<name>M-Pregabalin</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.4145</individualPrice>
								<listingDate>2021-09-30</listingDate>
								<amountMOHLTCPays>.4145</amountMOHLTCPays>
							</drug>
							<drug id="02479168" sec3="Y">
								<name>NRA-Pregabalin</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.4145</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>.4145</amountMOHLTCPays>
							</drug>
							<drug id="02480751" sec3="Y">
								<name>AG-Pregabalin</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.4145</individualPrice>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.4145</amountMOHLTCPays>
							</drug>
							<drug id="02494884" sec3="Y">
								<name>Nat-Pregabalin</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>.4145</individualPrice>
								<listingDate>2020-02-28</listingDate>
								<amountMOHLTCPays>.4145</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200158">
							<itemNumber>1036</itemNumber>
							<strength>225mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02268477" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Lyrica</name>
								<manufacturerId>UJC</manufacturerId>
								<listingDate>2013-04-30</listingDate>
							</drug>
							<drug id="02361221" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Teva-Pregabalin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>1.7270</individualPrice>
								<listingDate>2013-04-30</listingDate>
							</drug>
							<drug id="02392852" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Ran-Pregabalin</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>1.7270</individualPrice>
								<listingDate>2013-04-30</listingDate>
							</drug>
							<drug id="02394286" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Pregabalin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.7270</individualPrice>
								<listingDate>2013-04-30</listingDate>
							</drug>
							<drug id="02398079" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>PMS-Pregabalin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>1.7270</individualPrice>
								<listingDate>2013-04-30</listingDate>
							</drug>
							<drug id="02402971" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Co Pregabalin</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>1.7270</individualPrice>
								<listingDate>2013-04-30</listingDate>
							</drug>
							<drug id="02417596" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mar-Pregabalin</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>1.7270</individualPrice>
								<listingDate>2014-05-29</listingDate>
							</drug>
							<drug id="02449897" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Ach-Pregabalin</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>1.7270</individualPrice>
								<listingDate>2021-08-31</listingDate>
							</drug>
							<drug id="02494892" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Nat-Pregabalin</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>1.7270</individualPrice>
								<listingDate>2020-02-28</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="281200098">
							<itemNumber>1037</itemNumber>
							<strength>300mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02268485" sec3="Y">
								<name>Lyrica</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>2.5165</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.4145</amountMOHLTCPays>
							</drug>
							<drug id="02359642" sec3="Y">
								<name>PMS-Pregabalin</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.4145</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.4145</amountMOHLTCPays>
							</drug>
							<drug id="02361248" sec3="Y">
								<name>Teva-Pregabalin</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.4145</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.4145</amountMOHLTCPays>
							</drug>
							<drug id="02390868" sec3="Y">
								<name>Sandoz Pregabalin</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.4145</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.4145</amountMOHLTCPays>
							</drug>
							<drug id="02392860" sec3="Y">
								<name>Ran-Pregabalin</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.4145</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.4145</amountMOHLTCPays>
							</drug>
							<drug id="02394294" sec3="Y">
								<name>Apo-Pregabalin</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.4145</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.4145</amountMOHLTCPays>
							</drug>
							<drug id="02402998" sec3="Y">
								<name>Co Pregabalin</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.4145</individualPrice>
								<listingDate>2013-04-30</listingDate>
								<amountMOHLTCPays>.4145</amountMOHLTCPays>
							</drug>
							<drug id="02403730" sec3="Y">
								<name>Pregabalin</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.4145</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>.4145</amountMOHLTCPays>
							</drug>
							<drug id="02405598" sec3="Y">
								<name>Pregabalin</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.4145</individualPrice>
								<listingDate>2016-05-31</listingDate>
								<amountMOHLTCPays>.4145</amountMOHLTCPays>
							</drug>
							<drug id="02417618" sec3="Y">
								<name>Mar-Pregabalin</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.4145</individualPrice>
								<listingDate>2014-05-29</listingDate>
								<amountMOHLTCPays>.4145</amountMOHLTCPays>
							</drug>
							<drug id="02436019" sec3="Y">
								<name>Jamp-Pregabalin</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.4145</individualPrice>
								<listingDate>2016-01-28</listingDate>
								<amountMOHLTCPays>.4145</amountMOHLTCPays>
							</drug>
							<drug id="02449900" sec3="Y">
								<name>Ach-Pregabalin</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.4145</individualPrice>
								<listingDate>2021-08-31</listingDate>
								<amountMOHLTCPays>.4145</amountMOHLTCPays>
							</drug>
							<drug id="02480778" sec3="Y">
								<name>AG-Pregabalin</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.4145</individualPrice>
								<listingDate>2021-05-31</listingDate>
								<amountMOHLTCPays>.4145</amountMOHLTCPays>
							</drug>
							<drug id="02494906" sec3="Y">
								<name>Nat-Pregabalin</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>.4145</individualPrice>
								<listingDate>2020-02-28</listingDate>
								<amountMOHLTCPays>.4145</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00477">
					<name>PRIMIDONE</name>
					<pcgGroup>
						<pcg9 id="281200025">
							<itemNumber>1038</itemNumber>
							<strength>125mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00399310" sec3="Y">
								<name>Primidone</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.0564</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0564</amountMOHLTCPays>
							</drug>
							<drug id="02042363" notABenefit="Y" sec3="Y">
								<name>Mysoline</name>
								<manufacturerId>WAY</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="281200024">
							<itemNumber>1039</itemNumber>
							<strength>250mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00396761" sec3="Y">
								<name>Primidone</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.0887</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0887</amountMOHLTCPays>
							</drug>
							<drug id="02042355" notABenefit="Y" sec3="Y">
								<name>Mysoline</name>
								<manufacturerId>WAY</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00490">
					<name>TOPIRAMATE</name>
					<pcgGroup lccId="00074">
						<pcg9 id="281200079">
							<itemNumber>1040</itemNumber>
							<strength>15mg</strength>
							<dosageForm>Sprinkle Cap</dosageForm>
							<drug id="02239907" sec3="Y" sec12="Y">
								<name>Topamax Sprinkle</name>
								<manufacturerId>JNO</manufacturerId>
								<individualPrice>1.8180</individualPrice>
								<listingDate>2000-11-30</listingDate>
								<amountMOHLTCPays>1.8180</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200080">
							<itemNumber>1041</itemNumber>
							<strength>25mg</strength>
							<dosageForm>Sprinkle Cap</dosageForm>
							<drug id="02239908" sec3="Y" sec12="Y">
								<name>Topamax Sprinkle</name>
								<manufacturerId>JNO</manufacturerId>
								<individualPrice>1.9030</individualPrice>
								<listingDate>2000-11-30</listingDate>
								<amountMOHLTCPays>1.9030</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="321">In children age 16 and under, as adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
					<pcgGroup>
						<pcg9 id="281200069">
							<itemNumber>1042</itemNumber>
							<strength>25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02230893" sec3="Y">
								<name>Topamax</name>
								<manufacturerId>JNO</manufacturerId>
								<individualPrice>1.9080</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.2433</amountMOHLTCPays>
							</drug>
							<drug id="02248860" sec3="Y">
								<name>Teva-Topiramate</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2433</individualPrice>
								<listingDate>2005-11-08</listingDate>
								<amountMOHLTCPays>.2433</amountMOHLTCPays>
							</drug>
							<drug id="02262991" sec3="Y">
								<name>PMS-Topiramate</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2433</individualPrice>
								<listingDate>2005-11-08</listingDate>
								<amountMOHLTCPays>.2433</amountMOHLTCPays>
							</drug>
							<drug id="02263351" sec3="Y">
								<name>Mylan-Topiramate</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.2433</individualPrice>
								<listingDate>2005-11-08</listingDate>
								<amountMOHLTCPays>.2433</amountMOHLTCPays>
							</drug>
							<drug id="02279614" sec3="Y">
								<name>Apo-Topiramate</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2433</individualPrice>
								<listingDate>2006-06-14</listingDate>
								<amountMOHLTCPays>.2433</amountMOHLTCPays>
							</drug>
							<drug id="02315645" sec3="Y">
								<name>Mint-Topiramate</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.2433</individualPrice>
								<listingDate>2009-03-02</listingDate>
								<amountMOHLTCPays>.2433</amountMOHLTCPays>
							</drug>
							<drug id="02345803" sec3="Y">
								<name>Auro-Topiramate</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.2433</individualPrice>
								<listingDate>2011-09-15</listingDate>
								<amountMOHLTCPays>.2433</amountMOHLTCPays>
							</drug>
							<drug id="02356856" sec3="Y">
								<name>Topiramate</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.2433</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.2433</amountMOHLTCPays>
							</drug>
							<drug id="02389460" sec3="Y">
								<name>Topiramate</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.2433</individualPrice>
								<listingDate>2020-08-28</listingDate>
								<amountMOHLTCPays>.2433</amountMOHLTCPays>
							</drug>
							<drug id="02395738" sec3="Y">
								<name>Topiramate Tablets</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.2433</individualPrice>
								<listingDate>2013-03-20</listingDate>
								<amountMOHLTCPays>.2433</amountMOHLTCPays>
							</drug>
							<drug id="02431807" sec3="Y">
								<name>Sandoz Topiramate Tablets</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.2433</individualPrice>
								<listingDate>2015-01-28</listingDate>
								<amountMOHLTCPays>.2433</amountMOHLTCPays>
							</drug>
							<drug id="02432099" sec3="Y">
								<name>Mar-Topiramate</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.2433</individualPrice>
								<listingDate>2015-02-26</listingDate>
								<amountMOHLTCPays>.2433</amountMOHLTCPays>
							</drug>
							<drug id="02435608" sec3="Y">
								<name>Jamp-Topiramate</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.2433</individualPrice>
								<listingDate>2015-05-28</listingDate>
								<amountMOHLTCPays>.2433</amountMOHLTCPays>
							</drug>
							<drug id="02475936" sec3="Y">
								<name>AG-Topiramate</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.2433</individualPrice>
								<listingDate>2020-12-18</listingDate>
								<amountMOHLTCPays>.2433</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200070">
							<itemNumber>1043</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02230894" sec3="Y">
								<name>Topamax</name>
								<manufacturerId>JNO</manufacturerId>
								<individualPrice>3.5860</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.4583</amountMOHLTCPays>
							</drug>
							<drug id="02248861" sec3="Y">
								<name>Teva-Topiramate</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.4583</individualPrice>
								<listingDate>2005-11-08</listingDate>
								<amountMOHLTCPays>.4583</amountMOHLTCPays>
							</drug>
							<drug id="02263009" sec3="Y">
								<name>PMS-Topiramate</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.4583</individualPrice>
								<listingDate>2005-11-08</listingDate>
								<amountMOHLTCPays>.4583</amountMOHLTCPays>
							</drug>
							<drug id="02263378" sec3="Y">
								<name>Mylan-Topiramate</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.4583</individualPrice>
								<listingDate>2005-11-08</listingDate>
								<amountMOHLTCPays>.4583</amountMOHLTCPays>
							</drug>
							<drug id="02279630" sec3="Y">
								<name>Apo-Topiramate</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.4583</individualPrice>
								<listingDate>2006-06-14</listingDate>
								<amountMOHLTCPays>.4583</amountMOHLTCPays>
							</drug>
							<drug id="02315653" sec3="Y">
								<name>Mint-Topiramate</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.4583</individualPrice>
								<listingDate>2009-03-02</listingDate>
								<amountMOHLTCPays>.4583</amountMOHLTCPays>
							</drug>
							<drug id="02345838" sec3="Y">
								<name>Auro-Topiramate</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.4583</individualPrice>
								<listingDate>2011-09-15</listingDate>
								<amountMOHLTCPays>.4583</amountMOHLTCPays>
							</drug>
							<drug id="02356864" sec3="Y">
								<name>Topiramate</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.4583</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.4583</amountMOHLTCPays>
							</drug>
							<drug id="02389487" sec3="Y">
								<name>Topiramate</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.4583</individualPrice>
								<listingDate>2020-08-28</listingDate>
								<amountMOHLTCPays>.4583</amountMOHLTCPays>
							</drug>
							<drug id="02395746" sec3="Y">
								<name>Topiramate Tablets</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.4583</individualPrice>
								<listingDate>2013-03-20</listingDate>
								<amountMOHLTCPays>.4583</amountMOHLTCPays>
							</drug>
							<drug id="02396084" sec3="Y">
								<name>Ran-Topiramate</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.4583</individualPrice>
								<listingDate>2013-06-27</listingDate>
								<amountMOHLTCPays>.4583</amountMOHLTCPays>
							</drug>
							<drug id="02431815" sec3="Y">
								<name>Sandoz Topiramate Tablets</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.4583</individualPrice>
								<listingDate>2015-01-28</listingDate>
								<amountMOHLTCPays>.4583</amountMOHLTCPays>
							</drug>
							<drug id="02432102" sec3="Y">
								<name>Mar-Topiramate</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.4583</individualPrice>
								<listingDate>2015-02-26</listingDate>
								<amountMOHLTCPays>.4583</amountMOHLTCPays>
							</drug>
							<drug id="02435616" sec3="Y">
								<name>Jamp-Topiramate</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.4583</individualPrice>
								<listingDate>2015-05-28</listingDate>
								<amountMOHLTCPays>.4583</amountMOHLTCPays>
							</drug>
							<drug id="02475944" sec3="Y">
								<name>AG-Topiramate</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.4583</individualPrice>
								<listingDate>2020-12-18</listingDate>
								<amountMOHLTCPays>.4583</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200071">
							<itemNumber>1044</itemNumber>
							<strength>200mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02230896" sec3="Y">
								<name>Topamax</name>
								<manufacturerId>JNO</manufacturerId>
								<individualPrice>5.2830</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.6748</amountMOHLTCPays>
							</drug>
							<drug id="02248862" sec3="Y">
								<name>Teva-Topiramate</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.6748</individualPrice>
								<listingDate>2005-11-08</listingDate>
								<amountMOHLTCPays>.6748</amountMOHLTCPays>
							</drug>
							<drug id="02263017" sec3="Y">
								<name>PMS-Topiramate</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.6748</individualPrice>
								<listingDate>2005-11-08</listingDate>
								<amountMOHLTCPays>.6748</amountMOHLTCPays>
							</drug>
							<drug id="02263386" sec3="Y">
								<name>Mylan-Topiramate</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.6748</individualPrice>
								<listingDate>2005-11-08</listingDate>
								<amountMOHLTCPays>.6748</amountMOHLTCPays>
							</drug>
							<drug id="02279649" sec3="Y">
								<name>Apo-Topiramate</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.6748</individualPrice>
								<listingDate>2006-06-14</listingDate>
								<amountMOHLTCPays>.6748</amountMOHLTCPays>
							</drug>
							<drug id="02315661" sec3="Y">
								<name>Mint-Topiramate</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.6748</individualPrice>
								<listingDate>2009-03-02</listingDate>
								<amountMOHLTCPays>.6748</amountMOHLTCPays>
							</drug>
							<drug id="02345846" sec3="Y">
								<name>Auro-Topiramate</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.6748</individualPrice>
								<listingDate>2011-09-15</listingDate>
								<amountMOHLTCPays>.6748</amountMOHLTCPays>
							</drug>
							<drug id="02356872" sec3="Y">
								<name>Topiramate</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.6748</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.6748</amountMOHLTCPays>
							</drug>
							<drug id="02395754" sec3="Y">
								<name>Topiramate Tablets</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.6748</individualPrice>
								<listingDate>2013-03-20</listingDate>
								<amountMOHLTCPays>.6748</amountMOHLTCPays>
							</drug>
							<drug id="02396092" sec3="Y">
								<name>Ran-Topiramate</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.6748</individualPrice>
								<listingDate>2013-06-27</listingDate>
								<amountMOHLTCPays>.6748</amountMOHLTCPays>
							</drug>
							<drug id="02431823" sec3="Y">
								<name>Sandoz Topiramate Tablets</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.6748</individualPrice>
								<listingDate>2015-01-28</listingDate>
								<amountMOHLTCPays>.6748</amountMOHLTCPays>
							</drug>
							<drug id="02432110" sec3="Y">
								<name>Mar-Topiramate</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.6748</individualPrice>
								<listingDate>2015-02-26</listingDate>
								<amountMOHLTCPays>.6748</amountMOHLTCPays>
							</drug>
							<drug id="02435624" sec3="Y">
								<name>Jamp-Topiramate</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.6748</individualPrice>
								<listingDate>2015-05-28</listingDate>
								<amountMOHLTCPays>.6748</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00481">
					<name>VALPROATE SODIUM</name>
					<pcgGroup>
						<pcg9 id="281200040">
							<itemNumber>1045</itemNumber>
							<strength>50mg/mL</strength>
							<dosageForm>O/L</dosageForm>
							<drug id="00443832" sec3="Y">
								<name>Depakene</name>
								<manufacturerId>BGP</manufacturerId>
								<individualPrice>.1325</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0398</amountMOHLTCPays>
							</drug>
							<drug id="02236807" sec3="Y">
								<name>PMS-Valproic Acid</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.0398</individualPrice>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>.0398</amountMOHLTCPays>
							</drug>
							<drug id="02238370" sec3="Y">
								<name>Apo-Valproic</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0605</individualPrice>
								<listingDate>1999-09-15</listingDate>
								<amountMOHLTCPays>.0398</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00482">
					<name>VALPROIC ACID</name>
					<pcgGroup>
						<pcg9 id="281200041">
							<itemNumber>1046</itemNumber>
							<strength>250mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00443840" notABenefit="Y" sec3="Y">
								<name>Depakene</name>
								<manufacturerId>ABB</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02230768" sec3="Y">
								<name>PMS-Valproic Acid</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2905</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.2905</amountMOHLTCPays>
							</drug>
							<drug id="02238048" sec3="Y">
								<name>Apo-Valproic</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2905</individualPrice>
								<listingDate>1999-04-15</listingDate>
								<amountMOHLTCPays>.2905</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281200042">
							<itemNumber>1047</itemNumber>
							<strength>500mg</strength>
							<dosageForm>Ent Cap</dosageForm>
							<drug id="00507989" notABenefit="Y" sec3="Y">
								<name>Depakene</name>
								<manufacturerId>ABB</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02229628" sec3="Y">
								<name>PMS-Valproic Acid</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.8102</individualPrice>
								<listingDate>1997-08-28</listingDate>
								<amountMOHLTCPays>.8102</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00485">
					<name>VIGABATRIN</name>
					<pcgGroup lccId="00076">
						<pcg9 id="281200054">
							<itemNumber>1048</itemNumber>
							<strength>500mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02065819" sec3="Y" sec12="Y">
								<name>Sabril</name>
								<manufacturerId>OVA</manufacturerId>
								<individualPrice>.9566</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.9566</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="136">As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.</lccNote>
						<lccNote seq="002" type="N">Because a large number of patients may become refractory to the anticonvulsant effects of the drug over a period of time, the effectiveness of this drug must be re-evaluated after a period of six months.</lccNote>
						<lccNote seq="003" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="281604000">
				<name>PSYCHOTHERAPEUTIC AGENTS ANTIDEPRESSANTS</name>
				<genericName id="00491">
					<name>AMITRIPTYLINE</name>
					<pcgGroup>
						<pcg9 id="281604003">
							<itemNumber>1049</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00335053" sec3="Y">
								<name>Elavil</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.0664</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0435</amountMOHLTCPays>
							</drug>
							<drug id="02326043" dinStatus="E" sec3="Y">
								<name>Teva-Amitriptyline</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.0435</individualPrice>
								<listingDate>2015-04-30</listingDate>
								<amountMOHLTCPays>.0435</amountMOHLTCPays>
							</drug>
							<drug id="02429861" sec3="Y">
								<name>Mar-Amitriptyline</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.0435</individualPrice>
								<listingDate>2015-04-30</listingDate>
								<amountMOHLTCPays>.0435</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604002">
							<itemNumber>1050</itemNumber>
							<strength>25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00335061" sec3="Y">
								<name>Elavil</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.1211</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0829</amountMOHLTCPays>
							</drug>
							<drug id="00654515" sec3="Y">
								<name>PMS-Amitriptyline</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.0829</individualPrice>
								<listingDate>2015-04-30</listingDate>
								<amountMOHLTCPays>.0829</amountMOHLTCPays>
							</drug>
							<drug id="02326051" sec3="Y">
								<name>Teva-Amitriptyline</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.0829</individualPrice>
								<listingDate>2015-04-30</listingDate>
								<amountMOHLTCPays>.0829</amountMOHLTCPays>
							</drug>
							<drug id="02429888" sec3="Y">
								<name>Mar-Amitriptyline</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.0829</individualPrice>
								<listingDate>2015-04-30</listingDate>
								<amountMOHLTCPays>.0829</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604001">
							<itemNumber>1051</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00335088" sec3="Y">
								<name>Elavil</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.2347</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1540</amountMOHLTCPays>
							</drug>
							<drug id="00654507" sec3="Y">
								<name>PMS-Amitriptyline</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1540</individualPrice>
								<listingDate>2015-04-30</listingDate>
								<amountMOHLTCPays>.1540</amountMOHLTCPays>
							</drug>
							<drug id="02326078" sec3="Y">
								<name>Teva-Amitriptyline</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1540</individualPrice>
								<listingDate>2015-04-30</listingDate>
								<amountMOHLTCPays>.1540</amountMOHLTCPays>
							</drug>
							<drug id="02429896" sec3="Y">
								<name>Mar-Amitriptyline</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.1540</individualPrice>
								<listingDate>2015-04-30</listingDate>
								<amountMOHLTCPays>.1540</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01383">
					<name>BUPROPION HCL</name>
					<pcgGroup lccId="00077">
						<pcg9 id="281604120">
							<itemNumber>1052</itemNumber>
							<strength>150mg</strength>
							<dosageForm>ER Tab</dosageForm>
							<drug id="02275090" sec3="Y" sec12="Y">
								<name>Wellbutrin XL</name>
								<manufacturerId>VAL</manufacturerId>
								<individualPrice>.5916</individualPrice>
								<listingDate>2007-11-10</listingDate>
								<amountMOHLTCPays>.1463</amountMOHLTCPays>
							</drug>
							<drug id="02382075" sec3="Y" sec12="Y">
								<name>Mylan-Bupropion XL</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.1463</individualPrice>
								<listingDate>2013-11-28</listingDate>
								<amountMOHLTCPays>.1463</amountMOHLTCPays>
							</drug>
							<drug id="02439654" sec3="Y" sec12="Y">
								<name>Act Bupropion XL</name>
								<manufacturerId>ACV</manufacturerId>
								<individualPrice>.1463</individualPrice>
								<listingDate>2016-07-28</listingDate>
								<amountMOHLTCPays>.1463</amountMOHLTCPays>
							</drug>
							<drug id="02475804" sec3="Y" sec12="Y">
								<name>Taro-Bupropion XL</name>
								<manufacturerId>SPC</manufacturerId>
								<individualPrice>.1463</individualPrice>
								<listingDate>2019-07-31</listingDate>
								<amountMOHLTCPays>.1463</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604121">
							<itemNumber>1053</itemNumber>
							<strength>300mg</strength>
							<dosageForm>ER Tab</dosageForm>
							<drug id="02275104" sec3="Y" sec12="Y">
								<name>Wellbutrin XL</name>
								<manufacturerId>VAL</manufacturerId>
								<individualPrice>1.1833</individualPrice>
								<listingDate>2007-11-10</listingDate>
								<amountMOHLTCPays>.2927</amountMOHLTCPays>
							</drug>
							<drug id="02382083" sec3="Y" sec12="Y">
								<name>Mylan-Bupropion XL</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.2927</individualPrice>
								<listingDate>2013-11-28</listingDate>
								<amountMOHLTCPays>.2927</amountMOHLTCPays>
							</drug>
							<drug id="02439662" sec3="Y" sec12="Y">
								<name>Act Bupropion XL</name>
								<manufacturerId>ACV</manufacturerId>
								<individualPrice>.2927</individualPrice>
								<listingDate>2016-07-28</listingDate>
								<amountMOHLTCPays>.2927</amountMOHLTCPays>
							</drug>
							<drug id="02475812" sec3="Y" sec12="Y">
								<name>Taro-Bupropion XL</name>
								<manufacturerId>SPC</manufacturerId>
								<individualPrice>.2927</individualPrice>
								<listingDate>2019-07-31</listingDate>
								<amountMOHLTCPays>.2927</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604102">
							<itemNumber>1054</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02237824" notABenefit="Y" sec3="Y">
								<name>Wellbutrin SR</name>
								<manufacturerId>BIO</manufacturerId>
								<listingDate>2000-04-17</listingDate>
							</drug>
							<drug id="02275074" sec3="Y" sec12="Y">
								<name>Odan Bupropion SR</name>
								<manufacturerId>ODN</manufacturerId>
								<individualPrice>.1547</individualPrice>
								<listingDate>2006-08-24</listingDate>
								<amountMOHLTCPays>.1547</amountMOHLTCPays>
							</drug>
							<drug id="02285657" sec3="Y" sec12="Y">
								<name>Ratio-Bupropion SR</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>.1547</individualPrice>
								<listingDate>2007-03-09</listingDate>
								<amountMOHLTCPays>.1547</amountMOHLTCPays>
							</drug>
							<drug id="02325373" sec3="Y" sec12="Y">
								<name>PMS-Bupropion SR</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1547</individualPrice>
								<listingDate>2011-05-19</listingDate>
								<amountMOHLTCPays>.1547</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604103">
							<itemNumber>1055</itemNumber>
							<strength>150mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02237825" notABenefit="Y" sec3="Y">
								<name>Wellbutrin SR</name>
								<manufacturerId>VAL</manufacturerId>
								<listingDate>2000-04-17</listingDate>
							</drug>
							<drug id="02275082" sec3="Y" sec12="Y">
								<name>Odan Bupropion SR</name>
								<manufacturerId>ODN</manufacturerId>
								<individualPrice>.2298</individualPrice>
								<listingDate>2006-08-24</listingDate>
								<amountMOHLTCPays>.2298</amountMOHLTCPays>
							</drug>
							<drug id="02285665" sec3="Y" sec12="Y">
								<name>Ratio-Bupropion SR</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>.2298</individualPrice>
								<listingDate>2007-03-09</listingDate>
								<amountMOHLTCPays>.2298</amountMOHLTCPays>
							</drug>
							<drug id="02313421" sec3="Y" sec12="Y">
								<name>PMS-Bupropion SR</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.2298</individualPrice>
								<listingDate>2008-12-23</listingDate>
								<amountMOHLTCPays>.2298</amountMOHLTCPays>
							</drug>
						</pcg9>
						<lccNote seq="001" reasonForUseId="315">For the treatment of depression.</lccNote>
						<lccNote seq="002" type="R">LU Authorization Period: Indefinite.</lccNote>
					</pcgGroup>
				</genericName>
				<genericName id="01421">
					<name>CITALOPRAM HYDROBROMIDE</name>
					<pcgGroup>
						<pcg9 id="281604096">
							<itemNumber>1056</itemNumber>
							<strength>20mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02239607" sec3="Y">
								<name>Celexa</name>
								<manufacturerId>VLH</manufacturerId>
								<individualPrice>1.5784</individualPrice>
								<listingDate>2000-01-17</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02246056" sec3="Y">
								<name>Apo-Citalopram</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02248010" sec3="Y">
								<name>PMS-Citalopram</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02248050" sec3="Y">
								<name>Co Citalopram</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02248170" sec3="Y">
								<name>Sandoz Citalopram</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02275562" sec3="Y">
								<name>Auro-Citalopram</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2012-03-26</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02285622" sec3="Y">
								<name>Ran-Citalo</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2007-05-04</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02293218" sec3="Y">
								<name>Teva-Citalopram</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2007-11-10</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02303264" sec3="Y">
								<name>Riva-Citalopram</name>
								<manufacturerId>RIA</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2021-08-31</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02353660" sec3="Y">
								<name>Citalopram</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02355256" sec3="Y">
								<name>Accel Citalopram Tablets</name>
								<manufacturerId>ACC</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2013-01-29</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02355272" sec3="Y">
								<name>Septa-Citalopram</name>
								<manufacturerId>SET</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2011-03-15</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02371898" sec3="Y">
								<name>Mar-Citalopram</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02387956" sec3="Y">
								<name>Citalopram</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02409011" sec3="Y">
								<name>Nat-Citalopram</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2014-06-26</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02429705" sec3="Y">
								<name>Mint-Citalopram</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2015-12-22</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02430541" sec3="Y">
								<name>Citalopram</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2015-01-28</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02438747" dinStatus="E" sec3="Y">
								<name>Van-Citalopram</name>
								<manufacturerId>VAN</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2016-06-29</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02459914" sec3="Y">
								<name>CCP-Citalopram</name>
								<manufacturerId>CCP</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2017-11-30</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604097">
							<itemNumber>1057</itemNumber>
							<strength>40mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02239608" sec3="Y">
								<name>Celexa</name>
								<manufacturerId>VLH</manufacturerId>
								<individualPrice>1.5784</individualPrice>
								<listingDate>2000-01-17</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02246057" sec3="Y">
								<name>Apo-Citalopram</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02248011" sec3="Y">
								<name>PMS-Citalopram</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02248051" sec3="Y">
								<name>Co Citalopram</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02248171" sec3="Y">
								<name>Sandoz Citalopram</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02275570" sec3="Y">
								<name>Auro-Citalopram</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2012-03-26</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02285630" sec3="Y">
								<name>Ran-Citalo</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2007-05-04</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02293226" sec3="Y">
								<name>Teva-Citalopram</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2008-01-15</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02303272" sec3="Y">
								<name>Riva-Citalopram</name>
								<manufacturerId>RIA</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2021-08-31</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02353679" sec3="Y">
								<name>Citalopram</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02355264" sec3="Y">
								<name>Accel Citalopram Tablets</name>
								<manufacturerId>ACC</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2013-01-29</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02355280" sec3="Y">
								<name>Septa-Citalopram</name>
								<manufacturerId>SET</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2011-03-15</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02371901" sec3="Y">
								<name>Mar-Citalopram</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02387964" sec3="Y">
								<name>Citalopram</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02409038" sec3="Y">
								<name>Nat-Citalopram</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2014-06-26</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02429713" sec3="Y">
								<name>Mint-Citalopram</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2015-12-22</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02430568" sec3="Y">
								<name>Citalopram</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2015-01-28</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02438755" dinStatus="E" sec3="Y">
								<name>Van-Citalopram</name>
								<manufacturerId>VAN</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2016-06-29</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
							<drug id="02459922" sec3="Y">
								<name>CCP-Citalopram</name>
								<manufacturerId>CCP</manufacturerId>
								<individualPrice>.1332</individualPrice>
								<listingDate>2017-11-30</listingDate>
								<amountMOHLTCPays>.1332</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00492">
					<name>CLOMIPRAMINE HCL</name>
					<pcgGroup>
						<pcg9 id="281604005">
							<itemNumber>1058</itemNumber>
							<strength>25mg</strength>
							<drug id="00324019" sec3="Y">
								<name>Anafranil Tab</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.4020</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3417</amountMOHLTCPays>
							</drug>
							<drug id="02497506" sec3="Y">
								<name>Taro-Clomipramine Cap</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>.3417</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.3417</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604035">
							<itemNumber>1059</itemNumber>
							<strength>50mg</strength>
							<drug id="00402591" sec3="Y">
								<name>Anafranil Tab</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.7401</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.6291</amountMOHLTCPays>
							</drug>
							<drug id="02497514" sec3="Y">
								<name>Taro-Clomipramine Cap</name>
								<manufacturerId>TAR</manufacturerId>
								<individualPrice>.6291</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.6291</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604026">
							<itemNumber>1060</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00330566" sec3="Y">
								<name>Anafranil</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2949</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2949</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00493">
					<name>DESIPRAMINE</name>
					<pcgGroup>
						<pcg9 id="281604007">
							<itemNumber>1061</itemNumber>
							<strength>25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00010448" notABenefit="Y" sec3="Y">
								<name>Pertofrane</name>
								<manufacturerId>GEI</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02099128" notABenefit="Y" sec3="Y">
								<name>Norpramin</name>
								<manufacturerId>SAV</manufacturerId>
								<listingDate>1999-01-07</listingDate>
							</drug>
							<drug id="02216256" sec3="Y">
								<name>Desipramine</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.4345</individualPrice>
								<listingDate>1996-12-19</listingDate>
								<amountMOHLTCPays>.4345</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604006">
							<itemNumber>1062</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02099136" notABenefit="Y" sec3="Y">
								<name>Norpramin</name>
								<manufacturerId>SAV</manufacturerId>
								<listingDate>1999-01-07</listingDate>
							</drug>
							<drug id="02216264" sec3="Y">
								<name>Desipramine</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.7659</individualPrice>
								<listingDate>1996-12-19</listingDate>
								<amountMOHLTCPays>.7659</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604034">
							<itemNumber>1063</itemNumber>
							<strength>75mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02099144" notABenefit="Y" sec3="Y">
								<name>Norpramin</name>
								<manufacturerId>HMR</manufacturerId>
								<listingDate>1999-01-07</listingDate>
							</drug>
							<drug id="02216272" sec3="Y">
								<name>Desipramine</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>1.0184</individualPrice>
								<listingDate>1996-12-19</listingDate>
								<amountMOHLTCPays>1.0184</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="02038">
					<name>DESVENLAFAXINE</name>
					<pcgGroup>
						<pcg9 id="281604130">
							<itemNumber>1064</itemNumber>
							<strength>50mg</strength>
							<dosageForm>ER Tab</dosageForm>
							<drug id="02321092" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Pristiq</name>
								<manufacturerId>PFI</manufacturerId>
								<listingDate>2017-12-21</listingDate>
							</drug>
							<drug id="02466988" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Desvenlafaxine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>2.3409</individualPrice>
								<listingDate>2017-12-21</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="281604131">
							<itemNumber>1065</itemNumber>
							<strength>100mg</strength>
							<dosageForm>ER Tab</dosageForm>
							<drug id="02321106" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Pristiq</name>
								<manufacturerId>PFI</manufacturerId>
								<listingDate>2017-12-21</listingDate>
							</drug>
							<drug id="02466996" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Desvenlafaxine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>2.3409</individualPrice>
								<listingDate>2017-12-21</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00494">
					<name>DOXEPIN HCL</name>
					<pcgGroup>
						<pcg9 id="281604010">
							<itemNumber>1066</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00024325" sec3="Y">
								<name>Sinequan</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.3835</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3835</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604009">
							<itemNumber>1067</itemNumber>
							<strength>25mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00024333" sec3="Y">
								<name>Sinequan</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.4705</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.4705</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604008">
							<itemNumber>1068</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00024341" sec3="Y">
								<name>Sinequan</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.8728</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.8728</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01745">
					<name>DULOXETINE</name>
					<pcgGroup>
						<pcg9 id="281604123">
							<itemNumber>1069</itemNumber>
							<strength>30mg</strength>
							<dosageForm>DR Cap</dosageForm>
							<drug id="02301482" sec3="Y">
								<name>Cymbalta</name>
								<manufacturerId>LIL</manufacturerId>
								<individualPrice>2.1596</individualPrice>
								<listingDate>2009-08-18</listingDate>
								<amountMOHLTCPays>.4814</amountMOHLTCPays>
							</drug>
							<drug id="02429446" sec3="Y">
								<name>PMS-Duloxetine</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.4814</individualPrice>
								<listingDate>2016-06-29</listingDate>
								<amountMOHLTCPays>.4814</amountMOHLTCPays>
							</drug>
							<drug id="02436647" sec3="Y">
								<name>Auro-Duloxetine</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.4814</individualPrice>
								<listingDate>2016-06-29</listingDate>
								<amountMOHLTCPays>.4814</amountMOHLTCPays>
							</drug>
							<drug id="02437082" sec3="Y">
								<name>Duloxetine DR</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.4814</individualPrice>
								<listingDate>2016-06-29</listingDate>
								<amountMOHLTCPays>.4814</amountMOHLTCPays>
							</drug>
							<drug id="02438259" sec3="Y">
								<name>Ran-Duloxetine</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.4814</individualPrice>
								<listingDate>2016-06-29</listingDate>
								<amountMOHLTCPays>.4814</amountMOHLTCPays>
							</drug>
							<drug id="02438984" sec3="Y">
								<name>Mint-Duloxetine</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.4814</individualPrice>
								<listingDate>2016-06-29</listingDate>
								<amountMOHLTCPays>.4814</amountMOHLTCPays>
							</drug>
							<drug id="02439948" sec3="Y">
								<name>Sandoz Duloxetine</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.4814</individualPrice>
								<listingDate>2016-06-29</listingDate>
								<amountMOHLTCPays>.4814</amountMOHLTCPays>
							</drug>
							<drug id="02440423" sec3="Y">
								<name>Apo-Duloxetine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.4814</individualPrice>
								<listingDate>2016-06-29</listingDate>
								<amountMOHLTCPays>.4814</amountMOHLTCPays>
							</drug>
							<drug id="02446081" sec3="Y">
								<name>Mar-Duloxetine</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.4814</individualPrice>
								<listingDate>2016-08-30</listingDate>
								<amountMOHLTCPays>.4814</amountMOHLTCPays>
							</drug>
							<drug id="02451913" sec3="Y">
								<name>Jamp-Duloxetine</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.4814</individualPrice>
								<listingDate>2016-07-28</listingDate>
								<amountMOHLTCPays>.4814</amountMOHLTCPays>
							</drug>
							<drug id="02453630" sec3="Y">
								<name>Duloxetine</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.4814</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.4814</amountMOHLTCPays>
							</drug>
							<drug id="02456753" sec3="Y">
								<name>Teva-Duloxetine</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.4814</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.4814</amountMOHLTCPays>
							</drug>
							<drug id="02473208" sec3="Y">
								<name>M-Duloxetine</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.4814</individualPrice>
								<listingDate>2021-11-30</listingDate>
								<amountMOHLTCPays>.4814</amountMOHLTCPays>
							</drug>
							<drug id="02475308" sec3="Y">
								<name>AG-Duloxetine</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.4814</individualPrice>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.4814</amountMOHLTCPays>
							</drug>
							<drug id="02482126" sec3="Y">
								<name>NRA-Duloxetine</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.4814</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>.4814</amountMOHLTCPays>
							</drug>
							<drug id="02490889" sec3="Y">
								<name>Duloxetine</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.4814</individualPrice>
								<listingDate>2019-11-29</listingDate>
								<amountMOHLTCPays>.4814</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604124">
							<itemNumber>1070</itemNumber>
							<strength>60mg</strength>
							<dosageForm>DR Cap</dosageForm>
							<drug id="02301490" sec3="Y">
								<name>Cymbalta</name>
								<manufacturerId>LIL</manufacturerId>
								<individualPrice>4.3832</individualPrice>
								<listingDate>2009-08-18</listingDate>
								<amountMOHLTCPays>.9769</amountMOHLTCPays>
							</drug>
							<drug id="02429454" sec3="Y">
								<name>PMS-Duloxetine</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.9769</individualPrice>
								<listingDate>2016-06-29</listingDate>
								<amountMOHLTCPays>.9769</amountMOHLTCPays>
							</drug>
							<drug id="02436655" sec3="Y">
								<name>Auro-Duloxetine</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.9769</individualPrice>
								<listingDate>2016-06-29</listingDate>
								<amountMOHLTCPays>.9769</amountMOHLTCPays>
							</drug>
							<drug id="02437090" sec3="Y">
								<name>Duloxetine DR</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.9769</individualPrice>
								<listingDate>2016-06-29</listingDate>
								<amountMOHLTCPays>.9769</amountMOHLTCPays>
							</drug>
							<drug id="02438267" sec3="Y">
								<name>Ran-Duloxetine</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.9769</individualPrice>
								<listingDate>2016-06-29</listingDate>
								<amountMOHLTCPays>.9769</amountMOHLTCPays>
							</drug>
							<drug id="02438992" sec3="Y">
								<name>Mint-Duloxetine</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.9769</individualPrice>
								<listingDate>2016-06-29</listingDate>
								<amountMOHLTCPays>.9769</amountMOHLTCPays>
							</drug>
							<drug id="02439956" sec3="Y">
								<name>Sandoz Duloxetine</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.9769</individualPrice>
								<listingDate>2016-06-29</listingDate>
								<amountMOHLTCPays>.9769</amountMOHLTCPays>
							</drug>
							<drug id="02440431" sec3="Y">
								<name>Apo-Duloxetine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.9769</individualPrice>
								<listingDate>2016-06-29</listingDate>
								<amountMOHLTCPays>.9769</amountMOHLTCPays>
							</drug>
							<drug id="02446103" sec3="Y">
								<name>Mar-Duloxetine</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.9769</individualPrice>
								<listingDate>2016-08-30</listingDate>
								<amountMOHLTCPays>.9769</amountMOHLTCPays>
							</drug>
							<drug id="02451921" sec3="Y">
								<name>Jamp-Duloxetine</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.9769</individualPrice>
								<listingDate>2016-07-28</listingDate>
								<amountMOHLTCPays>.9769</amountMOHLTCPays>
							</drug>
							<drug id="02453649" sec3="Y">
								<name>Duloxetine</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.9769</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.9769</amountMOHLTCPays>
							</drug>
							<drug id="02456761" sec3="Y">
								<name>Teva-Duloxetine</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.9769</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.9769</amountMOHLTCPays>
							</drug>
							<drug id="02473216" sec3="Y">
								<name>M-Duloxetine</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.9769</individualPrice>
								<listingDate>2021-11-30</listingDate>
								<amountMOHLTCPays>.9769</amountMOHLTCPays>
							</drug>
							<drug id="02475316" sec3="Y">
								<name>AG-Duloxetine</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.9769</individualPrice>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.9769</amountMOHLTCPays>
							</drug>
							<drug id="02482134" sec3="Y">
								<name>NRA-Duloxetine</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.9769</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>.9769</amountMOHLTCPays>
							</drug>
							<drug id="02490897" sec3="Y">
								<name>Duloxetine</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.9769</individualPrice>
								<listingDate>2019-11-29</listingDate>
								<amountMOHLTCPays>.9769</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01714">
					<name>ESCITALOPRAM</name>
					<pcgGroup>
						<pcg9 id="281604127">
							<itemNumber>1071</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Orally Disintegrating Tab</dosageForm>
							<drug id="02391449" notABenefit="Y" sec3="Y">
								<name>Cipralex MELTZ</name>
								<manufacturerId>VLH</manufacturerId>
								<listingDate>2014-01-03</listingDate>
							</drug>
							<drug id="02454297" sec3="Y">
								<name>Act Escitalopram ODT</name>
								<manufacturerId>ACV</manufacturerId>
								<individualPrice>1.3199</individualPrice>
								<listingDate>2016-11-30</listingDate>
								<amountMOHLTCPays>1.3199</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604128">
							<itemNumber>1072</itemNumber>
							<strength>20mg</strength>
							<dosageForm>Orally Disintegrating Tablet</dosageForm>
							<drug id="02391457" notABenefit="Y" sec3="Y">
								<name>Cipralex MELTZ</name>
								<manufacturerId>VLH</manufacturerId>
								<listingDate>2014-01-03</listingDate>
							</drug>
							<drug id="02454300" sec3="Y">
								<name>Act Escitalopram ODT</name>
								<manufacturerId>ACV</manufacturerId>
								<individualPrice>1.4052</individualPrice>
								<listingDate>2016-11-30</listingDate>
								<amountMOHLTCPays>1.4052</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604118">
							<itemNumber>1073</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02263238" sec3="Y">
								<name>Cipralex</name>
								<manufacturerId>VLH</manufacturerId>
								<individualPrice>2.0028</individualPrice>
								<listingDate>2008-11-04</listingDate>
								<amountMOHLTCPays>.3109</amountMOHLTCPays>
							</drug>
							<drug id="02295016" sec3="Y">
								<name>Apo-Escitalopram</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3109</individualPrice>
								<listingDate>2014-11-27</listingDate>
								<amountMOHLTCPays>.3109</amountMOHLTCPays>
							</drug>
							<drug id="02309467" sec3="Y">
								<name>Mylan-Escitalopram</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.3109</individualPrice>
								<listingDate>2014-11-27</listingDate>
								<amountMOHLTCPays>.3109</amountMOHLTCPays>
							</drug>
							<drug id="02318180" sec3="Y">
								<name>Teva-Escitalopram</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3109</individualPrice>
								<listingDate>2014-11-27</listingDate>
								<amountMOHLTCPays>.3109</amountMOHLTCPays>
							</drug>
							<drug id="02364077" sec3="Y">
								<name>Sandoz Escitalopram</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.3109</individualPrice>
								<listingDate>2014-11-27</listingDate>
								<amountMOHLTCPays>.3109</amountMOHLTCPays>
							</drug>
							<drug id="02385481" sec3="Y">
								<name>Ran-Escitalopram</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.3109</individualPrice>
								<listingDate>2014-11-27</listingDate>
								<amountMOHLTCPays>.3109</amountMOHLTCPays>
							</drug>
							<drug id="02397358" sec3="Y">
								<name>Auro-Escitalopram</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.3109</individualPrice>
								<listingDate>2014-12-18</listingDate>
								<amountMOHLTCPays>.3109</amountMOHLTCPays>
							</drug>
							<drug id="02407418" sec3="Y">
								<name>Mint-Escitalopram</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.3109</individualPrice>
								<listingDate>2016-02-25</listingDate>
								<amountMOHLTCPays>.3109</amountMOHLTCPays>
							</drug>
							<drug id="02423480" sec3="Y">
								<name>Mar-Escitalopram</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.3109</individualPrice>
								<listingDate>2014-11-27</listingDate>
								<amountMOHLTCPays>.3109</amountMOHLTCPays>
							</drug>
							<drug id="02429039" sec3="Y">
								<name>Escitalopram</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.3109</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.3109</amountMOHLTCPays>
							</drug>
							<drug id="02429780" sec3="Y">
								<name>Jamp-Escitalopram</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.3109</individualPrice>
								<listingDate>2014-11-27</listingDate>
								<amountMOHLTCPays>.3109</amountMOHLTCPays>
							</drug>
							<drug id="02430118" sec3="Y">
								<name>Escitalopram</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.3109</individualPrice>
								<listingDate>2016-09-29</listingDate>
								<amountMOHLTCPays>.3109</amountMOHLTCPays>
							</drug>
							<drug id="02434652" sec3="Y">
								<name>Ach-Escitalopram</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.3109</individualPrice>
								<listingDate>2017-12-21</listingDate>
								<amountMOHLTCPays>.3109</amountMOHLTCPays>
							</drug>
							<drug id="02440296" sec3="Y">
								<name>Nat-Escitalopram</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>.3109</individualPrice>
								<listingDate>2015-10-29</listingDate>
								<amountMOHLTCPays>.3109</amountMOHLTCPays>
							</drug>
							<drug id="02469243" sec3="Y">
								<name>PMS-Escitalopram</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3109</individualPrice>
								<listingDate>2018-09-27</listingDate>
								<amountMOHLTCPays>.3109</amountMOHLTCPays>
							</drug>
							<drug id="02471418" sec3="Y">
								<name>M-Escitalopram</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.3109</individualPrice>
								<listingDate>2021-09-30</listingDate>
								<amountMOHLTCPays>.3109</amountMOHLTCPays>
							</drug>
							<drug id="02476851" sec3="Y">
								<name>NRA-Escitalopram</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.3109</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.3109</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604119">
							<itemNumber>1074</itemNumber>
							<strength>20mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02263254" sec3="Y">
								<name>Cipralex</name>
								<manufacturerId>VLH</manufacturerId>
								<individualPrice>2.1384</individualPrice>
								<listingDate>2008-11-04</listingDate>
								<amountMOHLTCPays>.3310</amountMOHLTCPays>
							</drug>
							<drug id="02295024" sec3="Y">
								<name>Apo-Escitalopram</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3310</individualPrice>
								<listingDate>2014-11-27</listingDate>
								<amountMOHLTCPays>.3310</amountMOHLTCPays>
							</drug>
							<drug id="02309475" sec3="Y">
								<name>Mylan-Escitalopram</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.3310</individualPrice>
								<listingDate>2014-11-27</listingDate>
								<amountMOHLTCPays>.3310</amountMOHLTCPays>
							</drug>
							<drug id="02318202" sec3="Y">
								<name>Teva-Escitalopram</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3310</individualPrice>
								<listingDate>2014-11-27</listingDate>
								<amountMOHLTCPays>.3310</amountMOHLTCPays>
							</drug>
							<drug id="02364085" sec3="Y">
								<name>Sandoz Escitalopram</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.3310</individualPrice>
								<listingDate>2014-11-27</listingDate>
								<amountMOHLTCPays>.3310</amountMOHLTCPays>
							</drug>
							<drug id="02385503" sec3="Y">
								<name>Ran-Escitalopram</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.3310</individualPrice>
								<listingDate>2014-11-27</listingDate>
								<amountMOHLTCPays>.3310</amountMOHLTCPays>
							</drug>
							<drug id="02397374" sec3="Y">
								<name>Auro-Escitalopram</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.3310</individualPrice>
								<listingDate>2014-12-18</listingDate>
								<amountMOHLTCPays>.3310</amountMOHLTCPays>
							</drug>
							<drug id="02407434" sec3="Y">
								<name>Mint-Escitalopram</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.3310</individualPrice>
								<listingDate>2016-02-25</listingDate>
								<amountMOHLTCPays>.3310</amountMOHLTCPays>
							</drug>
							<drug id="02423502" sec3="Y">
								<name>Mar-Escitalopram</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.3310</individualPrice>
								<listingDate>2014-11-27</listingDate>
								<amountMOHLTCPays>.3310</amountMOHLTCPays>
							</drug>
							<drug id="02429047" sec3="Y">
								<name>Escitalopram</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.3310</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.3310</amountMOHLTCPays>
							</drug>
							<drug id="02429799" sec3="Y">
								<name>Jamp-Escitalopram</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.3310</individualPrice>
								<listingDate>2014-11-27</listingDate>
								<amountMOHLTCPays>.3310</amountMOHLTCPays>
							</drug>
							<drug id="02430126" sec3="Y">
								<name>Escitalopram</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.3310</individualPrice>
								<listingDate>2016-09-29</listingDate>
								<amountMOHLTCPays>.3310</amountMOHLTCPays>
							</drug>
							<drug id="02434660" sec3="Y">
								<name>Ach-Escitalopram</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.3310</individualPrice>
								<listingDate>2017-12-21</listingDate>
								<amountMOHLTCPays>.3310</amountMOHLTCPays>
							</drug>
							<drug id="02440318" sec3="Y">
								<name>Nat-Escitalopram</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>.3310</individualPrice>
								<listingDate>2015-10-29</listingDate>
								<amountMOHLTCPays>.3310</amountMOHLTCPays>
							</drug>
							<drug id="02469251" sec3="Y">
								<name>PMS-Escitalopram</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3310</individualPrice>
								<listingDate>2018-09-27</listingDate>
								<amountMOHLTCPays>.3310</amountMOHLTCPays>
							</drug>
							<drug id="02471426" sec3="Y">
								<name>M-Escitalopram</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.3310</individualPrice>
								<listingDate>2021-09-30</listingDate>
								<amountMOHLTCPays>.3310</amountMOHLTCPays>
							</drug>
							<drug id="02476878" sec3="Y">
								<name>NRA-Escitalopram</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.3310</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.3310</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00505">
					<name>FLUOXETINE HCL</name>
					<note>Because of the long half-life of the fluoxetine metabolite, steady-state concentrations occur only after 4-6 weeks. Use with caution in anorexic patients. Fluoxetine therapy should be discontinued for 5 weeks before starting irreversible monoamine oxidase inhibitors (MAOI). Similarly irreversible MAOI should be discontinued for 2 weeks before starting fluoxetine.</note>
					<pcgGroup>
						<pcg9 id="281604122">
							<itemNumber>1075</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02018985" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Prozac</name>
								<manufacturerId>LIL</manufacturerId>
								<listingDate>2008-02-12</listingDate>
							</drug>
							<drug id="02177579" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>PMS-Fluoxetine</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>1.1773</individualPrice>
								<listingDate>2008-02-12</listingDate>
							</drug>
							<drug id="02216353" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Fluoxetine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.1773</individualPrice>
								<listingDate>2008-02-12</listingDate>
							</drug>
							<drug id="02216582" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Teva-Fluoxetine</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>1.1773</individualPrice>
								<listingDate>2008-02-12</listingDate>
							</drug>
							<drug id="02242177" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Co Fluoxetine</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>1.1773</individualPrice>
								<listingDate>2013-06-27</listingDate>
							</drug>
							<drug id="02286068" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Fluoxetine</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>1.1773</individualPrice>
								<listingDate>2017-06-29</listingDate>
							</drug>
							<drug id="02374447" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Fluoxetine</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>1.1773</individualPrice>
								<listingDate>2021-02-26</listingDate>
							</drug>
							<drug id="02380560" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mint-Fluoxetine</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>1.1773</individualPrice>
								<listingDate>2012-05-29</listingDate>
							</drug>
							<drug id="02385627" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Auro-Fluoxetine</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>1.1773</individualPrice>
								<listingDate>2012-12-21</listingDate>
							</drug>
							<drug id="02393441" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Ach-Fluoxetine</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>1.1773</individualPrice>
								<listingDate>2012-12-21</listingDate>
							</drug>
							<drug id="02401894" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Jamp-Fluoxetine</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>1.1773</individualPrice>
								<listingDate>2013-06-27</listingDate>
							</drug>
							<drug id="02448424" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Bio-Fluoxetine</name>
								<manufacturerId>BMP</manufacturerId>
								<individualPrice>1.1773</individualPrice>
								<listingDate>2016-03-30</listingDate>
							</drug>
							<drug id="02479486" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Sandoz Fluoxetine</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>1.1773</individualPrice>
								<listingDate>2019-06-28</listingDate>
							</drug>
							<drug id="02485052" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>AG-Fluoxetine</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>1.1773</individualPrice>
								<listingDate>2020-10-30</listingDate>
							</drug>
							<drug id="02503875" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>NRA-Fluoxetine</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>1.1773</individualPrice>
								<listingDate>2021-01-29</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="281604051">
							<itemNumber>1076</itemNumber>
							<strength>20mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00636622" sec3="Y">
								<name>Prozac</name>
								<manufacturerId>LIL</manufacturerId>
								<individualPrice>2.0649</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3311</amountMOHLTCPays>
							</drug>
							<drug id="02177587" sec3="Y">
								<name>PMS-Fluoxetine</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3311</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3311</amountMOHLTCPays>
							</drug>
							<drug id="02216361" sec3="Y">
								<name>Apo-Fluoxetine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3311</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3311</amountMOHLTCPays>
							</drug>
							<drug id="02216590" sec3="Y">
								<name>Teva-Fluoxetine</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3311</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3311</amountMOHLTCPays>
							</drug>
							<drug id="02242178" sec3="Y">
								<name>Co Fluoxetine</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.3311</individualPrice>
								<listingDate>2001-03-07</listingDate>
								<amountMOHLTCPays>.3311</amountMOHLTCPays>
							</drug>
							<drug id="02286076" sec3="Y">
								<name>Fluoxetine</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.3311</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.3311</amountMOHLTCPays>
							</drug>
							<drug id="02374455" sec3="Y">
								<name>Fluoxetine</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.3311</individualPrice>
								<listingDate>2021-02-26</listingDate>
								<amountMOHLTCPays>.3311</amountMOHLTCPays>
							</drug>
							<drug id="02380579" sec3="Y">
								<name>Mint-Fluoxetine</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.3311</individualPrice>
								<listingDate>2012-05-29</listingDate>
								<amountMOHLTCPays>.3311</amountMOHLTCPays>
							</drug>
							<drug id="02383241" sec3="Y">
								<name>Ach-Fluoxetine</name>
								<manufacturerId>ACH</manufacturerId>
								<individualPrice>.3311</individualPrice>
								<listingDate>2012-07-27</listingDate>
								<amountMOHLTCPays>.3311</amountMOHLTCPays>
							</drug>
							<drug id="02385635" sec3="Y">
								<name>Auro-Fluoxetine</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.3311</individualPrice>
								<listingDate>2012-09-28</listingDate>
								<amountMOHLTCPays>.3311</amountMOHLTCPays>
							</drug>
							<drug id="02386402" sec3="Y">
								<name>Jamp-Fluoxetine</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.3311</individualPrice>
								<listingDate>2012-08-27</listingDate>
								<amountMOHLTCPays>.3311</amountMOHLTCPays>
							</drug>
							<drug id="02405709" sec3="Y">
								<name>Ran-Fluoxetine</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.3311</individualPrice>
								<listingDate>2013-09-27</listingDate>
								<amountMOHLTCPays>.3311</amountMOHLTCPays>
							</drug>
							<drug id="02432420" dinStatus="E" sec3="Y">
								<name>Van-Fluoxetine</name>
								<manufacturerId>VAN</manufacturerId>
								<individualPrice>.3311</individualPrice>
								<listingDate>2016-05-31</listingDate>
								<amountMOHLTCPays>.3311</amountMOHLTCPays>
							</drug>
							<drug id="02448432" sec3="Y">
								<name>Bio-Fluoxetine</name>
								<manufacturerId>BMP</manufacturerId>
								<individualPrice>.3311</individualPrice>
								<listingDate>2016-02-25</listingDate>
								<amountMOHLTCPays>.3311</amountMOHLTCPays>
							</drug>
							<drug id="02479494" sec3="Y">
								<name>Sandoz Fluoxetine</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.3311</individualPrice>
								<listingDate>2019-06-28</listingDate>
								<amountMOHLTCPays>.3311</amountMOHLTCPays>
							</drug>
							<drug id="02485060" sec3="Y">
								<name>AG-Fluoxetine</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.3311</individualPrice>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>.3311</amountMOHLTCPays>
							</drug>
							<drug id="02503883" sec3="Y">
								<name>NRA-Fluoxetine</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.3311</individualPrice>
								<listingDate>2021-01-29</listingDate>
								<amountMOHLTCPays>.3311</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604136">
							<itemNumber>1077</itemNumber>
							<strength>40mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02464640" sec3="Y">
								<name>PMS-Fluoxetine</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.6622</individualPrice>
								<listingDate>2021-02-26</listingDate>
								<amountMOHLTCPays>.6622</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604137">
							<itemNumber>1078</itemNumber>
							<strength>60mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02464659" sec3="Y">
								<name>PMS-Fluoxetine</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.9933</individualPrice>
								<listingDate>2021-02-26</listingDate>
								<amountMOHLTCPays>.9933</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604064">
							<itemNumber>1079</itemNumber>
							<strength>20mg/5mL</strength>
							<dosageForm>Oral Sol</dosageForm>
							<drug id="01917021" notABenefit="Y" sec3="Y">
								<name>Prozac</name>
								<manufacturerId>LIL</manufacturerId>
								<listingDate>2017-04-27</listingDate>
							</drug>
							<drug id="02231328" sec3="Y">
								<name>Apo-Fluoxetine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3084</individualPrice>
								<listingDate>2018-04-30</listingDate>
								<amountMOHLTCPays>.3084</amountMOHLTCPays>
							</drug>
							<drug id="02459361" sec3="Y">
								<name>Odan-Fluoxetine</name>
								<manufacturerId>ODN</manufacturerId>
								<individualPrice>.3084</individualPrice>
								<listingDate>2017-04-27</listingDate>
								<amountMOHLTCPays>.3084</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00506">
					<name>FLUVOXAMINE MALEATE</name>
					<note>Fluvoxamine therapy should be discontinued for 2 weeks before starting irreversible monoamine oxidase inhibitors (MAOI). Similarly irreversible MAOI should be discontinued for 2 weeks before starting fluvoxamine.</note>
					<pcgGroup>
						<pcg9 id="281604058">
							<itemNumber>1080</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="01919342" sec3="Y">
								<name>Luvox</name>
								<manufacturerId>BGP</manufacturerId>
								<individualPrice>1.0110</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2105</amountMOHLTCPays>
							</drug>
							<drug id="02218453" dinStatus="E" sec3="Y">
								<name>Ratio-Fluvoxamine</name>
								<manufacturerId>RPH</manufacturerId>
								<individualPrice>.2105</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.2105</amountMOHLTCPays>
							</drug>
							<drug id="02231329" sec3="Y">
								<name>Apo-Fluvoxamine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.2105</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.2105</amountMOHLTCPays>
							</drug>
							<drug id="02255529" sec3="Y">
								<name>Co Fluvoxamine</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.2105</individualPrice>
								<listingDate>2004-10-14</listingDate>
								<amountMOHLTCPays>.2105</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604059">
							<itemNumber>1081</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="01919369" sec3="Y">
								<name>Luvox</name>
								<manufacturerId>BGP</manufacturerId>
								<individualPrice>1.8180</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3783</amountMOHLTCPays>
							</drug>
							<drug id="02231330" sec3="Y">
								<name>Apo-Fluvoxamine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3783</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.3783</amountMOHLTCPays>
							</drug>
							<drug id="02255537" sec3="Y">
								<name>Co Fluvoxamine</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.3783</individualPrice>
								<listingDate>2004-10-14</listingDate>
								<amountMOHLTCPays>.3783</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00495">
					<name>IMIPRAMINE</name>
					<pcgGroup>
						<pcg9 id="281604013">
							<itemNumber>1082</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00010464" notABenefit="Y" sec3="Y">
								<name>Tofranil</name>
								<manufacturerId>NOV</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00360201" sec3="Y">
								<name>Imipramine</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.1397</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1397</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604012">
							<itemNumber>1083</itemNumber>
							<strength>25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00010472" notABenefit="Y" sec3="Y">
								<name>Tofranil</name>
								<manufacturerId>NOV</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00312797" sec3="Y">
								<name>Imipramine</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.2573</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2573</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604011">
							<itemNumber>1084</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00010480" notABenefit="Y" sec3="Y">
								<name>Tofranil</name>
								<manufacturerId>NOV</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00326852" sec3="Y">
								<name>Imipramine</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.5021</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.5021</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01529">
					<name>MIRTAZAPINE</name>
					<pcgGroup>
						<pcg9 id="281604112">
							<itemNumber>1085</itemNumber>
							<strength>15mg</strength>
							<dosageForm>Orally Disintegrating Tab</dosageForm>
							<drug id="02248542" sec3="Y">
								<name>Remeron RD</name>
								<manufacturerId>OCI</manufacturerId>
								<individualPrice>.5529</individualPrice>
								<listingDate>2005-02-22</listingDate>
								<amountMOHLTCPays>.4046</amountMOHLTCPays>
							</drug>
							<drug id="02299801" sec3="Y">
								<name>Auro-Mirtazapine OD</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.4046</individualPrice>
								<listingDate>2011-06-08</listingDate>
								<amountMOHLTCPays>.4046</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604113">
							<itemNumber>1086</itemNumber>
							<strength>30mg</strength>
							<dosageForm>Orally Disintegrating Tab</dosageForm>
							<drug id="02248543" sec3="Y">
								<name>Remeron RD</name>
								<manufacturerId>OCI</manufacturerId>
								<individualPrice>1.1052</individualPrice>
								<listingDate>2005-02-22</listingDate>
								<amountMOHLTCPays>.8087</amountMOHLTCPays>
							</drug>
							<drug id="02299828" sec3="Y">
								<name>Auro-Mirtazapine OD</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.8087</individualPrice>
								<listingDate>2011-06-08</listingDate>
								<amountMOHLTCPays>.8087</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604114">
							<itemNumber>1087</itemNumber>
							<strength>45mg</strength>
							<dosageForm>Orally Disintegrating Tab</dosageForm>
							<drug id="02248544" sec3="Y">
								<name>Remeron RD</name>
								<manufacturerId>OCI</manufacturerId>
								<individualPrice>1.6580</individualPrice>
								<listingDate>2005-02-22</listingDate>
								<amountMOHLTCPays>1.2132</amountMOHLTCPays>
							</drug>
							<drug id="02299836" sec3="Y">
								<name>Auro-Mirtazapine OD</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>1.2132</individualPrice>
								<listingDate>2011-06-08</listingDate>
								<amountMOHLTCPays>1.2132</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604107">
							<itemNumber>1088</itemNumber>
							<strength>30mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02243910" sec3="Y">
								<name>Remeron</name>
								<manufacturerId>OCI</manufacturerId>
								<individualPrice>1.8987</individualPrice>
								<listingDate>2002-07-29</listingDate>
								<amountMOHLTCPays>.3100</amountMOHLTCPays>
							</drug>
							<drug id="02248762" sec3="Y">
								<name>PMS-Mirtazapine</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3100</individualPrice>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.3100</amountMOHLTCPays>
							</drug>
							<drug id="02250608" sec3="Y">
								<name>Sandoz Mirtazapine</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.3100</individualPrice>
								<listingDate>2004-07-20</listingDate>
								<amountMOHLTCPays>.3100</amountMOHLTCPays>
							</drug>
							<drug id="02256118" sec3="Y">
								<name>Mylan-Mirtazapine</name>
								<manufacturerId>MYL</manufacturerId>
								<individualPrice>.3100</individualPrice>
								<listingDate>2004-09-14</listingDate>
								<amountMOHLTCPays>.3100</amountMOHLTCPays>
							</drug>
							<drug id="02259354" sec3="Y">
								<name>Teva-Mirtazapine</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3100</individualPrice>
								<listingDate>2004-12-21</listingDate>
								<amountMOHLTCPays>.3100</amountMOHLTCPays>
							</drug>
							<drug id="02286629" sec3="Y">
								<name>Apo-Mirtazapine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3100</individualPrice>
								<listingDate>2007-01-02</listingDate>
								<amountMOHLTCPays>.3100</amountMOHLTCPays>
							</drug>
							<drug id="02370689" sec3="Y">
								<name>Mirtazapine</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.3100</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.3100</amountMOHLTCPays>
							</drug>
							<drug id="02411709" sec3="Y">
								<name>Auro-Mirtazapine</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.3100</individualPrice>
								<listingDate>2014-01-03</listingDate>
								<amountMOHLTCPays>.3100</amountMOHLTCPays>
							</drug>
							<drug id="02496674" sec3="Y">
								<name>Mirtazapine</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.3100</individualPrice>
								<listingDate>2020-12-18</listingDate>
								<amountMOHLTCPays>.3100</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00509">
					<name>MOCLOBEMIDE</name>
					<pcgGroup>
						<pcg9 id="281604066">
							<itemNumber>1089</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00899348" notABenefit="Y" sec3="Y">
								<name>Manerix</name>
								<manufacturerId>HLR</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02232148" sec3="Y">
								<name>Moclobemide</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.3400</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.3400</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604067">
							<itemNumber>1090</itemNumber>
							<strength>150mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00899356" sec3="Y">
								<name>Manerix</name>
								<manufacturerId>MAB</manufacturerId>
								<individualPrice>.7490</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.5295</amountMOHLTCPays>
							</drug>
							<drug id="02232150" sec3="Y">
								<name>Moclobemide</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.5295</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.5295</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604084">
							<itemNumber>1091</itemNumber>
							<strength>300mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02166747" sec3="Y">
								<name>Manerix</name>
								<manufacturerId>MAB</manufacturerId>
								<individualPrice>1.4710</individualPrice>
								<listingDate>1997-04-10</listingDate>
								<amountMOHLTCPays>1.0399</amountMOHLTCPays>
							</drug>
							<drug id="02240456" sec3="Y">
								<name>Moclobemide</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>1.0399</individualPrice>
								<listingDate>2000-01-17</listingDate>
								<amountMOHLTCPays>1.0399</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00497">
					<name>NORTRIPTYLINE</name>
					<pcgGroup>
						<pcg9 id="281604016">
							<itemNumber>1092</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00015229" sec3="Y">
								<name>Aventyl</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.2819</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2819</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604015">
							<itemNumber>1093</itemNumber>
							<strength>25mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00015237" sec3="Y">
								<name>Aventyl</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.5697</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.5697</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00511">
					<name>PAROXETINE HCL</name>
					<pcgGroup>
						<pcg9 id="281604094">
							<itemNumber>1094</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02027887" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Paxil</name>
								<manufacturerId>SMJ</manufacturerId>
								<listingDate>2007-06-06</listingDate>
							</drug>
							<drug id="02240907" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Paroxetine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.0430</individualPrice>
								<listingDate>2007-06-06</listingDate>
							</drug>
							<drug id="02247750" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>PMS-Paroxetine</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>1.0430</individualPrice>
								<listingDate>2007-06-06</listingDate>
							</drug>
							<drug id="02248556" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Teva-Paroxetine</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>1.0430</individualPrice>
								<listingDate>2007-06-06</listingDate>
							</drug>
							<drug id="02262746" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Co Paroxetine</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>1.0430</individualPrice>
								<listingDate>2007-06-06</listingDate>
							</drug>
							<drug id="02282844" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Paroxetine</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>1.0430</individualPrice>
								<listingDate>2011-08-04</listingDate>
							</drug>
							<drug id="02368862" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Jamp-Paroxetine</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>1.0430</individualPrice>
								<listingDate>2012-08-27</listingDate>
							</drug>
							<drug id="02383276" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Auro-Paroxetine</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>1.0430</individualPrice>
								<listingDate>2012-12-21</listingDate>
							</drug>
							<drug id="02388227" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Paroxetine</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>1.0430</individualPrice>
								<listingDate>2020-12-18</listingDate>
							</drug>
							<drug id="02411946" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mar-Paroxetine</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>1.0430</individualPrice>
								<listingDate>2014-01-03</listingDate>
							</drug>
							<drug id="02421372" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Mint-Paroxetine</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>1.0430</individualPrice>
								<listingDate>2014-05-29</listingDate>
							</drug>
							<drug id="02431777" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Sandoz Paroxetine Tablets</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>1.0430</individualPrice>
								<listingDate>2015-01-28</listingDate>
							</drug>
							<drug id="02467402" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>M-Paroxetine</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>1.0430</individualPrice>
								<listingDate>2021-11-30</listingDate>
							</drug>
							<drug id="02475537" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>AG-Paroxetine</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>1.0430</individualPrice>
								<listingDate>2020-11-30</listingDate>
							</drug>
							<drug id="02479753" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>NRA-Paroxetine</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>1.0430</individualPrice>
								<listingDate>2020-07-31</listingDate>
							</drug>
							<drug id="02507773" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Jamp Paroxetine Tablets</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>1.0430</individualPrice>
								<listingDate>2021-07-30</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="281604078">
							<itemNumber>1095</itemNumber>
							<strength>20mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="01940481" sec3="Y">
								<name>Paxil</name>
								<manufacturerId>GSK</manufacturerId>
								<individualPrice>2.0123</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3250</amountMOHLTCPays>
							</drug>
							<drug id="02240908" sec3="Y">
								<name>Apo-Paroxetine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3250</individualPrice>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.3250</amountMOHLTCPays>
							</drug>
							<drug id="02247751" sec3="Y">
								<name>PMS-Paroxetine</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3250</individualPrice>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.3250</amountMOHLTCPays>
							</drug>
							<drug id="02248557" sec3="Y">
								<name>Teva-Paroxetine</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3250</individualPrice>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.3250</amountMOHLTCPays>
							</drug>
							<drug id="02262754" sec3="Y">
								<name>Co Paroxetine</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.3250</individualPrice>
								<listingDate>2005-04-28</listingDate>
								<amountMOHLTCPays>.3250</amountMOHLTCPays>
							</drug>
							<drug id="02282852" sec3="Y">
								<name>Paroxetine</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.3250</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.3250</amountMOHLTCPays>
							</drug>
							<drug id="02368870" sec3="Y">
								<name>Jamp-Paroxetine</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.3250</individualPrice>
								<listingDate>2012-08-27</listingDate>
								<amountMOHLTCPays>.3250</amountMOHLTCPays>
							</drug>
							<drug id="02383284" sec3="Y">
								<name>Auro-Paroxetine</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.3250</individualPrice>
								<listingDate>2012-09-28</listingDate>
								<amountMOHLTCPays>.3250</amountMOHLTCPays>
							</drug>
							<drug id="02388235" sec3="Y">
								<name>Paroxetine</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.3250</individualPrice>
								<listingDate>2020-12-18</listingDate>
								<amountMOHLTCPays>.3250</amountMOHLTCPays>
							</drug>
							<drug id="02411954" sec3="Y">
								<name>Mar-Paroxetine</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.3250</individualPrice>
								<listingDate>2014-01-03</listingDate>
								<amountMOHLTCPays>.3250</amountMOHLTCPays>
							</drug>
							<drug id="02421380" sec3="Y">
								<name>Mint-Paroxetine</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.3250</individualPrice>
								<listingDate>2014-05-29</listingDate>
								<amountMOHLTCPays>.3250</amountMOHLTCPays>
							</drug>
							<drug id="02431785" sec3="Y">
								<name>Sandoz Paroxetine Tablets</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.3250</individualPrice>
								<listingDate>2015-01-28</listingDate>
								<amountMOHLTCPays>.3250</amountMOHLTCPays>
							</drug>
							<drug id="02467410" sec3="Y">
								<name>M-Paroxetine</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.3250</individualPrice>
								<listingDate>2021-10-29</listingDate>
								<amountMOHLTCPays>.3250</amountMOHLTCPays>
							</drug>
							<drug id="02475545" sec3="Y">
								<name>AG-Paroxetine</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.3250</individualPrice>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.3250</amountMOHLTCPays>
							</drug>
							<drug id="02479761" sec3="Y">
								<name>NRA-Paroxetine</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.3250</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>.3250</amountMOHLTCPays>
							</drug>
							<drug id="02507781" sec3="Y">
								<name>Jamp Paroxetine Tablets</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.3250</individualPrice>
								<listingDate>2022-02-28</listingDate>
								<amountMOHLTCPays>.3250</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604079">
							<itemNumber>1096</itemNumber>
							<strength>30mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="01940473" sec3="Y">
								<name>Paxil</name>
								<manufacturerId>GSK</manufacturerId>
								<individualPrice>2.1377</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3453</amountMOHLTCPays>
							</drug>
							<drug id="02240909" sec3="Y">
								<name>Apo-Paroxetine</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3453</individualPrice>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.3453</amountMOHLTCPays>
							</drug>
							<drug id="02247752" sec3="Y">
								<name>PMS-Paroxetine</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3453</individualPrice>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.3453</amountMOHLTCPays>
							</drug>
							<drug id="02248558" sec3="Y">
								<name>Teva-Paroxetine</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3453</individualPrice>
								<listingDate>2004-04-06</listingDate>
								<amountMOHLTCPays>.3453</amountMOHLTCPays>
							</drug>
							<drug id="02282860" sec3="Y">
								<name>Paroxetine</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.3453</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.3453</amountMOHLTCPays>
							</drug>
							<drug id="02368889" sec3="Y">
								<name>Jamp-Paroxetine</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.3453</individualPrice>
								<listingDate>2012-08-27</listingDate>
								<amountMOHLTCPays>.3453</amountMOHLTCPays>
							</drug>
							<drug id="02383292" sec3="Y">
								<name>Auro-Paroxetine</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.3453</individualPrice>
								<listingDate>2012-09-28</listingDate>
								<amountMOHLTCPays>.3453</amountMOHLTCPays>
							</drug>
							<drug id="02388243" sec3="Y">
								<name>Paroxetine</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.3453</individualPrice>
								<listingDate>2020-12-18</listingDate>
								<amountMOHLTCPays>.3453</amountMOHLTCPays>
							</drug>
							<drug id="02411962" sec3="Y">
								<name>Mar-Paroxetine</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.3453</individualPrice>
								<listingDate>2014-01-03</listingDate>
								<amountMOHLTCPays>.3453</amountMOHLTCPays>
							</drug>
							<drug id="02421399" sec3="Y">
								<name>Mint-Paroxetine</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.3453</individualPrice>
								<listingDate>2014-05-29</listingDate>
								<amountMOHLTCPays>.3453</amountMOHLTCPays>
							</drug>
							<drug id="02431793" sec3="Y">
								<name>Sandoz Paroxetine Tablets</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.3453</individualPrice>
								<listingDate>2015-01-28</listingDate>
								<amountMOHLTCPays>.3453</amountMOHLTCPays>
							</drug>
							<drug id="02467429" sec3="Y">
								<name>M-Paroxetine</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.3453</individualPrice>
								<listingDate>2021-10-29</listingDate>
								<amountMOHLTCPays>.3453</amountMOHLTCPays>
							</drug>
							<drug id="02475553" sec3="Y">
								<name>AG-Paroxetine</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.3453</individualPrice>
								<listingDate>2020-11-30</listingDate>
								<amountMOHLTCPays>.3453</amountMOHLTCPays>
							</drug>
							<drug id="02479788" sec3="Y">
								<name>NRA-Paroxetine</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.3453</individualPrice>
								<listingDate>2020-07-31</listingDate>
								<amountMOHLTCPays>.3453</amountMOHLTCPays>
							</drug>
							<drug id="02507803" sec3="Y">
								<name>Jamp Paroxetine Tablets</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.3453</individualPrice>
								<listingDate>2022-02-28</listingDate>
								<amountMOHLTCPays>.3453</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00498">
					<name>PHENELZINE SULFATE</name>
					<pcgGroup>
						<pcg9 id="281604017">
							<itemNumber>1097</itemNumber>
							<strength>15mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00476552" maO="Y" sec3="Y">
								<name>Nardil</name>
								<manufacturerId>ERF</manufacturerId>
								<individualPrice>.4667</individualPrice>
								<note>Consult the scientific literature regarding cautions and contraindications prior to prescribing and/or dispensing irreversible monoamine oxidase inhibitors.
</note>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.4667</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01762">
					<name>RASAGILINE MESYLATE</name>
					<pcgGroup>
						<pcg9 id="281604125">
							<itemNumber>1098</itemNumber>
							<strength>0.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02284642" maO="Y" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Azilect</name>
								<manufacturerId>TEI</manufacturerId>
								<individualPrice>7.8013</individualPrice>
								<listingDate>2016-03-30</listingDate>
								<amountMOHLTCPays>6.1285</amountMOHLTCPays>
							</drug>
							<drug id="02404680" maO="Y" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Apo-Rasagiline</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>6.1285</individualPrice>
								<listingDate>2016-03-30</listingDate>
								<amountMOHLTCPays>6.1285</amountMOHLTCPays>
							</drug>
							<drug id="02418436" maO="Y" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Teva-Rasagiline</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>6.1285</individualPrice>
								<listingDate>2016-07-28</listingDate>
								<amountMOHLTCPays>6.1285</amountMOHLTCPays>
							</drug>
							<drug id="02491974" maO="Y" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Jamp Rasagiline</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>6.1285</individualPrice>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>6.1285</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604126">
							<itemNumber>1099</itemNumber>
							<strength>1mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02284650" maO="Y" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Azilect</name>
								<manufacturerId>TEI</manufacturerId>
								<individualPrice>7.8013</individualPrice>
								<listingDate>2016-03-30</listingDate>
								<amountMOHLTCPays>6.1285</amountMOHLTCPays>
							</drug>
							<drug id="02404699" maO="Y" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Apo-Rasagiline</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>6.1285</individualPrice>
								<listingDate>2016-03-30</listingDate>
								<amountMOHLTCPays>6.1285</amountMOHLTCPays>
							</drug>
							<drug id="02418444" maO="Y" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Teva-Rasagiline</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>6.1285</individualPrice>
								<listingDate>2016-07-28</listingDate>
								<amountMOHLTCPays>6.1285</amountMOHLTCPays>
							</drug>
							<drug id="02491982" maO="Y" sec3b="Y" sec3bEAP="Y" sec3="Y">
								<name>Jamp Rasagiline</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>6.1285</individualPrice>
								<listingDate>2020-10-30</listingDate>
								<amountMOHLTCPays>6.1285</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00507">
					<name>SERTRALINE HCL</name>
					<note>Sertraline therapy should be discontinued for 2 weeks before starting irreversible monoamine oxidase inhibitors (MAOI). Similarly irreversible MAOI should be discontinued for 2 weeks before starting sertraline.</note>
					<pcgGroup>
						<pcg9 id="281604093">
							<itemNumber>1100</itemNumber>
							<strength>25mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="02132702" sec3="Y">
								<name>Zoloft</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>.9205</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1516</amountMOHLTCPays>
							</drug>
							<drug id="02238280" sec3="Y">
								<name>Apo-Sertraline</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1516</individualPrice>
								<listingDate>2000-01-17</listingDate>
								<amountMOHLTCPays>.1516</amountMOHLTCPays>
							</drug>
							<drug id="02240485" sec3="Y">
								<name>Teva-Sertraline</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1516</individualPrice>
								<listingDate>2000-01-17</listingDate>
								<amountMOHLTCPays>.1516</amountMOHLTCPays>
							</drug>
							<drug id="02244838" sec3="Y">
								<name>PMS-Sertraline</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1516</individualPrice>
								<listingDate>2003-01-30</listingDate>
								<amountMOHLTCPays>.1516</amountMOHLTCPays>
							</drug>
							<drug id="02245159" sec3="Y">
								<name>Sandoz Sertraline</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.1516</individualPrice>
								<listingDate>2003-01-30</listingDate>
								<amountMOHLTCPays>.1516</amountMOHLTCPays>
							</drug>
							<drug id="02287390" sec3="Y">
								<name>Co Sertraline</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.1516</individualPrice>
								<listingDate>2007-04-02</listingDate>
								<amountMOHLTCPays>.1516</amountMOHLTCPays>
							</drug>
							<drug id="02353520" sec3="Y">
								<name>Sertraline</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.1516</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.1516</amountMOHLTCPays>
							</drug>
							<drug id="02357143" sec3="Y">
								<name>Jamp-Sertraline</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1516</individualPrice>
								<listingDate>2012-09-28</listingDate>
								<amountMOHLTCPays>.1516</amountMOHLTCPays>
							</drug>
							<drug id="02386070" sec3="Y">
								<name>Sertraline</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.1516</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.1516</amountMOHLTCPays>
							</drug>
							<drug id="02390906" sec3="Y">
								<name>Auro-Sertraline</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.1516</individualPrice>
								<listingDate>2012-12-21</listingDate>
								<amountMOHLTCPays>.1516</amountMOHLTCPays>
							</drug>
							<drug id="02399415" sec3="Y">
								<name>Mar-Sertraline</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.1516</individualPrice>
								<listingDate>2013-03-20</listingDate>
								<amountMOHLTCPays>.1516</amountMOHLTCPays>
							</drug>
							<drug id="02402378" sec3="Y">
								<name>Mint-Sertraline</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.1516</individualPrice>
								<listingDate>2013-06-27</listingDate>
								<amountMOHLTCPays>.1516</amountMOHLTCPays>
							</drug>
							<drug id="02427761" dinStatus="E" sec3="Y">
								<name>Van-Sertraline</name>
								<manufacturerId>VAN</manufacturerId>
								<individualPrice>.1516</individualPrice>
								<listingDate>2015-08-26</listingDate>
								<amountMOHLTCPays>.1516</amountMOHLTCPays>
							</drug>
							<drug id="02469626" sec3="Y">
								<name>Sertraline</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1516</individualPrice>
								<listingDate>2018-02-28</listingDate>
								<amountMOHLTCPays>.1516</amountMOHLTCPays>
							</drug>
							<drug id="02477882" sec3="Y">
								<name>AG-Sertraline</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.1516</individualPrice>
								<listingDate>2020-12-18</listingDate>
								<amountMOHLTCPays>.1516</amountMOHLTCPays>
							</drug>
							<drug id="02488434" sec3="Y">
								<name>NRA-Sertraline</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.1516</individualPrice>
								<listingDate>2021-03-29</listingDate>
								<amountMOHLTCPays>.1516</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604060">
							<itemNumber>1101</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="01962817" sec3="Y">
								<name>Zoloft</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>1.8408</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3032</amountMOHLTCPays>
							</drug>
							<drug id="02238281" sec3="Y">
								<name>Apo-Sertraline</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3032</individualPrice>
								<listingDate>2000-01-17</listingDate>
								<amountMOHLTCPays>.3032</amountMOHLTCPays>
							</drug>
							<drug id="02240484" sec3="Y">
								<name>Teva-Sertraline</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3032</individualPrice>
								<listingDate>2000-01-17</listingDate>
								<amountMOHLTCPays>.3032</amountMOHLTCPays>
							</drug>
							<drug id="02244839" sec3="Y">
								<name>PMS-Sertraline</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3032</individualPrice>
								<listingDate>2003-01-30</listingDate>
								<amountMOHLTCPays>.3032</amountMOHLTCPays>
							</drug>
							<drug id="02245160" sec3="Y">
								<name>Sandoz Sertraline</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.3032</individualPrice>
								<listingDate>2003-01-30</listingDate>
								<amountMOHLTCPays>.3032</amountMOHLTCPays>
							</drug>
							<drug id="02287404" sec3="Y">
								<name>Co Sertraline</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.3032</individualPrice>
								<listingDate>2007-04-02</listingDate>
								<amountMOHLTCPays>.3032</amountMOHLTCPays>
							</drug>
							<drug id="02353539" sec3="Y">
								<name>Sertraline</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.3032</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.3032</amountMOHLTCPays>
							</drug>
							<drug id="02357151" sec3="Y">
								<name>Jamp-Sertraline</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.3032</individualPrice>
								<listingDate>2012-09-28</listingDate>
								<amountMOHLTCPays>.3032</amountMOHLTCPays>
							</drug>
							<drug id="02386089" sec3="Y">
								<name>Sertraline</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.3032</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.3032</amountMOHLTCPays>
							</drug>
							<drug id="02390914" sec3="Y">
								<name>Auro-Sertraline</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.3032</individualPrice>
								<listingDate>2012-12-21</listingDate>
								<amountMOHLTCPays>.3032</amountMOHLTCPays>
							</drug>
							<drug id="02399423" sec3="Y">
								<name>Mar-Sertraline</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.3032</individualPrice>
								<listingDate>2013-03-20</listingDate>
								<amountMOHLTCPays>.3032</amountMOHLTCPays>
							</drug>
							<drug id="02402394" sec3="Y">
								<name>Mint-Sertraline</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.3032</individualPrice>
								<listingDate>2013-06-27</listingDate>
								<amountMOHLTCPays>.3032</amountMOHLTCPays>
							</drug>
							<drug id="02427788" dinStatus="E" sec3="Y">
								<name>Van-Sertraline</name>
								<manufacturerId>VAN</manufacturerId>
								<individualPrice>.3032</individualPrice>
								<listingDate>2015-08-26</listingDate>
								<amountMOHLTCPays>.3032</amountMOHLTCPays>
							</drug>
							<drug id="02469634" sec3="Y">
								<name>Sertraline</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.3032</individualPrice>
								<listingDate>2018-02-28</listingDate>
								<amountMOHLTCPays>.3032</amountMOHLTCPays>
							</drug>
							<drug id="02477890" sec3="Y">
								<name>AG-Sertraline</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.3032</individualPrice>
								<listingDate>2020-12-18</listingDate>
								<amountMOHLTCPays>.3032</amountMOHLTCPays>
							</drug>
							<drug id="02488442" sec3="Y">
								<name>NRA-Sertraline</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.3032</individualPrice>
								<listingDate>2021-03-29</listingDate>
								<amountMOHLTCPays>.3032</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604061">
							<itemNumber>1102</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="01962779" sec3="Y">
								<name>Zoloft</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>2.0056</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.3303</amountMOHLTCPays>
							</drug>
							<drug id="02238282" sec3="Y">
								<name>Apo-Sertraline</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3303</individualPrice>
								<listingDate>2000-01-17</listingDate>
								<amountMOHLTCPays>.3303</amountMOHLTCPays>
							</drug>
							<drug id="02240481" sec3="Y">
								<name>Teva-Sertraline</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.3303</individualPrice>
								<listingDate>2000-01-17</listingDate>
								<amountMOHLTCPays>.3303</amountMOHLTCPays>
							</drug>
							<drug id="02244840" sec3="Y">
								<name>PMS-Sertraline</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.3303</individualPrice>
								<listingDate>2003-01-30</listingDate>
								<amountMOHLTCPays>.3303</amountMOHLTCPays>
							</drug>
							<drug id="02245161" sec3="Y">
								<name>Sandoz Sertraline</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.3303</individualPrice>
								<listingDate>2003-01-30</listingDate>
								<amountMOHLTCPays>.3303</amountMOHLTCPays>
							</drug>
							<drug id="02287412" sec3="Y">
								<name>Co Sertraline</name>
								<manufacturerId>COB</manufacturerId>
								<individualPrice>.3303</individualPrice>
								<listingDate>2007-04-02</listingDate>
								<amountMOHLTCPays>.3303</amountMOHLTCPays>
							</drug>
							<drug id="02353547" sec3="Y">
								<name>Sertraline</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.3303</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.3303</amountMOHLTCPays>
							</drug>
							<drug id="02357178" sec3="Y">
								<name>Jamp-Sertraline</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.3303</individualPrice>
								<listingDate>2012-09-28</listingDate>
								<amountMOHLTCPays>.3303</amountMOHLTCPays>
							</drug>
							<drug id="02374579" sec3="Y">
								<name>Ran-Sertraline</name>
								<manufacturerId>RAN</manufacturerId>
								<individualPrice>.3303</individualPrice>
								<listingDate>2012-01-19</listingDate>
								<amountMOHLTCPays>.3303</amountMOHLTCPays>
							</drug>
							<drug id="02386097" sec3="Y">
								<name>Sertraline</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.3303</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.3303</amountMOHLTCPays>
							</drug>
							<drug id="02390922" sec3="Y">
								<name>Auro-Sertraline</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.3303</individualPrice>
								<listingDate>2012-12-21</listingDate>
								<amountMOHLTCPays>.3303</amountMOHLTCPays>
							</drug>
							<drug id="02399431" sec3="Y">
								<name>Mar-Sertraline</name>
								<manufacturerId>MAR</manufacturerId>
								<individualPrice>.3303</individualPrice>
								<listingDate>2013-03-20</listingDate>
								<amountMOHLTCPays>.3303</amountMOHLTCPays>
							</drug>
							<drug id="02402408" sec3="Y">
								<name>Mint-Sertraline</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.3303</individualPrice>
								<listingDate>2013-06-27</listingDate>
								<amountMOHLTCPays>.3303</amountMOHLTCPays>
							</drug>
							<drug id="02427796" dinStatus="E" sec3="Y">
								<name>Van-Sertraline</name>
								<manufacturerId>VAN</manufacturerId>
								<individualPrice>.3303</individualPrice>
								<listingDate>2015-08-26</listingDate>
								<amountMOHLTCPays>.3303</amountMOHLTCPays>
							</drug>
							<drug id="02469642" sec3="Y">
								<name>Sertraline</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.3303</individualPrice>
								<listingDate>2018-02-28</listingDate>
								<amountMOHLTCPays>.3303</amountMOHLTCPays>
							</drug>
							<drug id="02477904" sec3="Y">
								<name>AG-Sertraline</name>
								<manufacturerId>ANG</manufacturerId>
								<individualPrice>.3303</individualPrice>
								<listingDate>2020-12-18</listingDate>
								<amountMOHLTCPays>.3303</amountMOHLTCPays>
							</drug>
							<drug id="02488450" sec3="Y">
								<name>NRA-Sertraline</name>
								<manufacturerId>NRA</manufacturerId>
								<individualPrice>.3303</individualPrice>
								<listingDate>2021-03-29</listingDate>
								<amountMOHLTCPays>.3303</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00500">
					<name>TRANYLCYPROMINE SULFATE</name>
					<pcgGroup>
						<pcg9 id="281604020">
							<itemNumber>1103</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="01919598" maO="Y" sec3="Y">
								<name>Parnate</name>
								<manufacturerId>GSK</manufacturerId>
								<individualPrice>.4322</individualPrice>
								<note>Consult the scientific literature regarding cautions and contraindications prior to prescribing and/or dispensing irreversible monoamine oxidase inhibitors.
</note>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.4322</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00504">
					<name>TRAZODONE HYDROCHLORIDE</name>
					<pcgGroup>
						<pcg9 id="281604040">
							<itemNumber>1104</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00579351" notABenefit="Y" sec3="Y">
								<name>Desyrel</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="01937227" sec3="Y">
								<name>PMS-Trazodone</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.0554</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0554</amountMOHLTCPays>
							</drug>
							<drug id="02144263" sec3="Y">
								<name>Teva-Trazodone</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.0554</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0554</amountMOHLTCPays>
							</drug>
							<drug id="02147637" sec3="Y">
								<name>Apo-Trazodone</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0554</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0554</amountMOHLTCPays>
							</drug>
							<drug id="02348772" sec3="Y">
								<name>Trazodone</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.0554</individualPrice>
								<listingDate>2011-10-25</listingDate>
								<amountMOHLTCPays>.0554</amountMOHLTCPays>
							</drug>
							<drug id="02442809" sec3="Y">
								<name>Jamp Trazodone</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.0554</individualPrice>
								<listingDate>2022-01-31</listingDate>
								<amountMOHLTCPays>.0554</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604041">
							<itemNumber>1105</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00579378" notABenefit="Y" sec3="Y">
								<name>Desyrel</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="01937235" sec3="Y">
								<name>PMS-Trazodone</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.0989</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0989</amountMOHLTCPays>
							</drug>
							<drug id="02144271" sec3="Y">
								<name>Teva-Trazodone</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.0989</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0989</amountMOHLTCPays>
							</drug>
							<drug id="02147645" sec3="Y">
								<name>Apo-Trazodone</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0989</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0989</amountMOHLTCPays>
							</drug>
							<drug id="02348780" sec3="Y">
								<name>Trazodone</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.0989</individualPrice>
								<listingDate>2011-10-25</listingDate>
								<amountMOHLTCPays>.0989</amountMOHLTCPays>
							</drug>
							<drug id="02442817" sec3="Y">
								<name>Jamp Trazodone</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.0989</individualPrice>
								<listingDate>2022-01-31</listingDate>
								<amountMOHLTCPays>.0989</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604050">
							<itemNumber>1106</itemNumber>
							<strength>150mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00702277" notABenefit="Y" sec3="Y">
								<name>Desyrel Dividose</name>
								<manufacturerId>BQU</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02144298" sec3="Y">
								<name>Teva-Trazodone</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1453</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1453</amountMOHLTCPays>
							</drug>
							<drug id="02147653" sec3="Y">
								<name>Apo-Trazodone D</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1453</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1453</amountMOHLTCPays>
							</drug>
							<drug id="02348799" sec3="Y">
								<name>Trazodone</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.1453</individualPrice>
								<listingDate>2011-10-25</listingDate>
								<amountMOHLTCPays>.1453</amountMOHLTCPays>
							</drug>
							<drug id="02442825" sec3="Y">
								<name>Jamp Trazodone</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1453</individualPrice>
								<listingDate>2022-01-31</listingDate>
								<amountMOHLTCPays>.1453</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00501">
					<name>TRIMIPRAMINE</name>
					<pcgGroup>
						<pcg9 id="281604033">
							<itemNumber>1107</itemNumber>
							<strength>75mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="01926349" notABenefit="Y" sec3="Y">
								<name>Surmontil</name>
								<manufacturerId>RPP</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02070987" sec3="Y">
								<name>Trimipramine</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.7800</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.7800</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604024">
							<itemNumber>1108</itemNumber>
							<strength>12.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00740799" sec3="Y">
								<name>Trimipramine</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.2156</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2156</amountMOHLTCPays>
							</drug>
							<drug id="01926357" notABenefit="Y" sec3="Y">
								<name>Surmontil</name>
								<manufacturerId>RPP</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="281604023">
							<itemNumber>1109</itemNumber>
							<strength>25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00740802" sec3="Y">
								<name>Trimipramine</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.2960</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2960</amountMOHLTCPays>
							</drug>
							<drug id="01926322" notABenefit="Y" sec3="Y">
								<name>Surmontil</name>
								<manufacturerId>RPP</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="281604022">
							<itemNumber>1110</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00740810" sec3="Y">
								<name>Trimipramine</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.5795</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.5795</amountMOHLTCPays>
							</drug>
							<drug id="01926330" notABenefit="Y" sec3="Y">
								<name>Surmontil</name>
								<manufacturerId>RPP</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="281604021">
							<itemNumber>1111</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00740829" sec3="Y">
								<name>Trimipramine</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.9889</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.9889</amountMOHLTCPays>
							</drug>
							<drug id="01926284" notABenefit="Y" sec3="Y">
								<name>Surmontil</name>
								<manufacturerId>RPP</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00513">
					<name>VENLAFAXINE HCL</name>
					<pcgGroup>
						<pcg9 id="281604087">
							<itemNumber>1112</itemNumber>
							<strength>37.5mg</strength>
							<dosageForm>ER Cap</dosageForm>
							<drug id="02237279" sec3="Y">
								<name>Effexor XR</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>1.0224</individualPrice>
								<listingDate>2000-01-17</listingDate>
								<amountMOHLTCPays>.0913</amountMOHLTCPays>
							</drug>
							<drug id="02275023" sec3="Y">
								<name>Teva-Venlafaxine XR</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.0913</individualPrice>
								<listingDate>2007-01-02</listingDate>
								<amountMOHLTCPays>.0913</amountMOHLTCPays>
							</drug>
							<drug id="02278545" sec3="Y">
								<name>PMS-Venlafaxine XR</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.0913</individualPrice>
								<listingDate>2007-11-10</listingDate>
								<amountMOHLTCPays>.0913</amountMOHLTCPays>
							</drug>
							<drug id="02304317" sec3="Y">
								<name>ACT Venlafaxine XR</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.0913</individualPrice>
								<listingDate>2008-04-09</listingDate>
								<amountMOHLTCPays>.0913</amountMOHLTCPays>
							</drug>
							<drug id="02310317" sec3="Y">
								<name>Sandoz Venlafaxine XR</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.0913</individualPrice>
								<listingDate>2008-08-28</listingDate>
								<amountMOHLTCPays>.0913</amountMOHLTCPays>
							</drug>
							<drug id="02331683" sec3="Y">
								<name>Apo-Venlafaxine XR</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0913</individualPrice>
								<listingDate>2010-04-23</listingDate>
								<amountMOHLTCPays>.0913</amountMOHLTCPays>
							</drug>
							<drug id="02354713" sec3="Y">
								<name>Venlafaxine XR</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.0913</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.0913</amountMOHLTCPays>
							</drug>
							<drug id="02380072" sec3="Y">
								<name>Taro-Venlafaxine XR</name>
								<manufacturerId>SPC</manufacturerId>
								<individualPrice>.0913</individualPrice>
								<listingDate>2012-04-24</listingDate>
								<amountMOHLTCPays>.0913</amountMOHLTCPays>
							</drug>
							<drug id="02385929" sec3="Y">
								<name>Venlafaxine XR</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.0913</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.0913</amountMOHLTCPays>
							</drug>
							<drug id="02452839" sec3="Y">
								<name>Auro-Venlafaxine XR</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.0913</individualPrice>
								<listingDate>2016-05-31</listingDate>
								<amountMOHLTCPays>.0913</amountMOHLTCPays>
							</drug>
							<drug id="02471280" sec3="Y">
								<name>M-Venlafaxine XR</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.0913</individualPrice>
								<listingDate>2021-11-30</listingDate>
								<amountMOHLTCPays>.0913</amountMOHLTCPays>
							</drug>
							<drug id="02516535" sec3="Y">
								<name>Venlafaxine XR</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.0913</individualPrice>
								<listingDate>2022-02-28</listingDate>
								<amountMOHLTCPays>.0913</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604088">
							<itemNumber>1113</itemNumber>
							<strength>75mg</strength>
							<dosageForm>ER Cap</dosageForm>
							<drug id="02237280" sec3="Y">
								<name>Effexor XR</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>2.0442</individualPrice>
								<listingDate>2000-01-17</listingDate>
								<amountMOHLTCPays>.1825</amountMOHLTCPays>
							</drug>
							<drug id="02275031" sec3="Y">
								<name>Teva-Venlafaxine XR</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1825</individualPrice>
								<listingDate>2007-01-02</listingDate>
								<amountMOHLTCPays>.1825</amountMOHLTCPays>
							</drug>
							<drug id="02278553" sec3="Y">
								<name>PMS-Venlafaxine XR</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1825</individualPrice>
								<listingDate>2007-11-10</listingDate>
								<amountMOHLTCPays>.1825</amountMOHLTCPays>
							</drug>
							<drug id="02304325" sec3="Y">
								<name>ACT Venlafaxine XR</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1825</individualPrice>
								<listingDate>2008-04-09</listingDate>
								<amountMOHLTCPays>.1825</amountMOHLTCPays>
							</drug>
							<drug id="02310325" sec3="Y">
								<name>Sandoz Venlafaxine XR</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.1825</individualPrice>
								<listingDate>2008-08-28</listingDate>
								<amountMOHLTCPays>.1825</amountMOHLTCPays>
							</drug>
							<drug id="02331691" sec3="Y">
								<name>Apo-Venlafaxine XR</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1825</individualPrice>
								<listingDate>2010-04-23</listingDate>
								<amountMOHLTCPays>.1825</amountMOHLTCPays>
							</drug>
							<drug id="02354721" sec3="Y">
								<name>Venlafaxine XR</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.1825</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.1825</amountMOHLTCPays>
							</drug>
							<drug id="02380080" sec3="Y">
								<name>Taro-Venlafaxine XR</name>
								<manufacturerId>SPC</manufacturerId>
								<individualPrice>.1825</individualPrice>
								<listingDate>2012-04-24</listingDate>
								<amountMOHLTCPays>.1825</amountMOHLTCPays>
							</drug>
							<drug id="02385937" sec3="Y">
								<name>Venlafaxine XR</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.1825</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.1825</amountMOHLTCPays>
							</drug>
							<drug id="02452847" sec3="Y">
								<name>Auro-Venlafaxine XR</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.1825</individualPrice>
								<listingDate>2016-05-31</listingDate>
								<amountMOHLTCPays>.1825</amountMOHLTCPays>
							</drug>
							<drug id="02471299" sec3="Y">
								<name>M-Venlafaxine XR</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.1825</individualPrice>
								<listingDate>2021-11-30</listingDate>
								<amountMOHLTCPays>.1825</amountMOHLTCPays>
							</drug>
							<drug id="02516543" sec3="Y">
								<name>Venlafaxine XR</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1825</individualPrice>
								<listingDate>2022-02-28</listingDate>
								<amountMOHLTCPays>.1825</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604089">
							<itemNumber>1114</itemNumber>
							<strength>150mg</strength>
							<dosageForm>ER Cap</dosageForm>
							<drug id="02237282" sec3="Y">
								<name>Effexor XR</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>2.1590</individualPrice>
								<listingDate>2000-01-17</listingDate>
								<amountMOHLTCPays>.1927</amountMOHLTCPays>
							</drug>
							<drug id="02275058" sec3="Y">
								<name>Teva-Venlafaxine XR</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1927</individualPrice>
								<listingDate>2007-01-02</listingDate>
								<amountMOHLTCPays>.1927</amountMOHLTCPays>
							</drug>
							<drug id="02278561" sec3="Y">
								<name>PMS-Venlafaxine XR</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.1927</individualPrice>
								<listingDate>2007-11-10</listingDate>
								<amountMOHLTCPays>.1927</amountMOHLTCPays>
							</drug>
							<drug id="02304333" sec3="Y">
								<name>ACT Venlafaxine XR</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1927</individualPrice>
								<listingDate>2008-04-09</listingDate>
								<amountMOHLTCPays>.1927</amountMOHLTCPays>
							</drug>
							<drug id="02310333" sec3="Y">
								<name>Sandoz Venlafaxine XR</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.1927</individualPrice>
								<listingDate>2008-08-28</listingDate>
								<amountMOHLTCPays>.1927</amountMOHLTCPays>
							</drug>
							<drug id="02331705" sec3="Y">
								<name>Apo-Venlafaxine XR</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1927</individualPrice>
								<listingDate>2010-04-23</listingDate>
								<amountMOHLTCPays>.1927</amountMOHLTCPays>
							</drug>
							<drug id="02354748" sec3="Y">
								<name>Venlafaxine XR</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.1927</individualPrice>
								<listingDate>2011-08-04</listingDate>
								<amountMOHLTCPays>.1927</amountMOHLTCPays>
							</drug>
							<drug id="02380099" sec3="Y">
								<name>Taro-Venlafaxine XR</name>
								<manufacturerId>SPC</manufacturerId>
								<individualPrice>.1927</individualPrice>
								<listingDate>2012-04-24</listingDate>
								<amountMOHLTCPays>.1927</amountMOHLTCPays>
							</drug>
							<drug id="02385945" sec3="Y">
								<name>Venlafaxine XR</name>
								<manufacturerId>SIV</manufacturerId>
								<individualPrice>.1927</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.1927</amountMOHLTCPays>
							</drug>
							<drug id="02452855" sec3="Y">
								<name>Auro-Venlafaxine XR</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.1927</individualPrice>
								<listingDate>2016-05-31</listingDate>
								<amountMOHLTCPays>.1927</amountMOHLTCPays>
							</drug>
							<drug id="02471302" sec3="Y">
								<name>M-Venlafaxine XR</name>
								<manufacturerId>MAT</manufacturerId>
								<individualPrice>.1927</individualPrice>
								<listingDate>2021-11-30</listingDate>
								<amountMOHLTCPays>.1927</amountMOHLTCPays>
							</drug>
							<drug id="02516551" sec3="Y">
								<name>Venlafaxine XR</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.1927</individualPrice>
								<listingDate>2022-02-28</listingDate>
								<amountMOHLTCPays>.1927</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="02142">
					<name>VORTIOXETINE HYDROBROMIDE</name>
					<pcgGroup>
						<pcg9 id="281604133">
							<itemNumber>1115</itemNumber>
							<strength>5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02432919" sec3="Y">
								<name>Trintellix</name>
								<manufacturerId>VLH</manufacturerId>
								<individualPrice>2.8824</individualPrice>
								<listingDate>2021-01-29</listingDate>
								<amountMOHLTCPays>2.8824</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604134">
							<itemNumber>1116</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02432927" sec3="Y">
								<name>Trintellix</name>
								<manufacturerId>VLH</manufacturerId>
								<individualPrice>3.0192</individualPrice>
								<listingDate>2021-01-29</listingDate>
								<amountMOHLTCPays>3.0192</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281604135">
							<itemNumber>1117</itemNumber>
							<strength>20mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02432943" sec3="Y">
								<name>Trintellix</name>
								<manufacturerId>VLH</manufacturerId>
								<individualPrice>3.2779</individualPrice>
								<listingDate>2021-01-29</listingDate>
								<amountMOHLTCPays>3.2779</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
			</pcg6>
			<pcg6 id="281608000">
				<name>PSYCHOTHERAPEUTIC AGENTS TRANQUILIZERS</name>
				<genericName id="00540">
					<name>ALPRAZOLAM</name>
					<pcgGroup>
						<pcg9 id="281608119">
							<itemNumber>1118</itemNumber>
							<strength>0.25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00548359" sec3="Y">
								<name>Xanax</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>.3237</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0633</amountMOHLTCPays>
							</drug>
							<drug id="00865397" sec3="Y">
								<name>Apo-Alpraz</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0633</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0633</amountMOHLTCPays>
							</drug>
							<drug id="01913484" sec3="Y">
								<name>Teva-Alprazolam</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.0633</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0633</amountMOHLTCPays>
							</drug>
							<drug id="02349191" dinStatus="E" sec3="Y">
								<name>Alprazolam</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.0633</individualPrice>
								<listingDate>2011-10-25</listingDate>
								<amountMOHLTCPays>.0633</amountMOHLTCPays>
							</drug>
							<drug id="02400111" sec3="Y">
								<name>Jamp-Alprazolam</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.0633</individualPrice>
								<listingDate>2013-05-31</listingDate>
								<amountMOHLTCPays>.0633</amountMOHLTCPays>
							</drug>
							<drug id="02417634" sec3="Y">
								<name>Nat-Alprazolam</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>.0633</individualPrice>
								<listingDate>2015-10-29</listingDate>
								<amountMOHLTCPays>.0633</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281608118">
							<itemNumber>1119</itemNumber>
							<strength>0.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00548367" sec3="Y">
								<name>Xanax</name>
								<manufacturerId>UJC</manufacturerId>
								<individualPrice>.3871</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0757</amountMOHLTCPays>
							</drug>
							<drug id="00865400" sec3="Y">
								<name>Apo-Alpraz</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0757</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0757</amountMOHLTCPays>
							</drug>
							<drug id="01913492" sec3="Y">
								<name>Teva-Alprazolam</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.0757</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0757</amountMOHLTCPays>
							</drug>
							<drug id="02349205" dinStatus="E" sec3="Y">
								<name>Alprazolam</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.0757</individualPrice>
								<listingDate>2011-10-25</listingDate>
								<amountMOHLTCPays>.0757</amountMOHLTCPays>
							</drug>
							<drug id="02400138" sec3="Y">
								<name>Jamp-Alprazolam</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.0757</individualPrice>
								<listingDate>2013-05-31</listingDate>
								<amountMOHLTCPays>.0757</amountMOHLTCPays>
							</drug>
							<drug id="02417642" sec3="Y">
								<name>Nat-Alprazolam</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>.0757</individualPrice>
								<listingDate>2015-10-29</listingDate>
								<amountMOHLTCPays>.0757</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281608233">
							<itemNumber>1120</itemNumber>
							<strength>1mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00723770" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Xanax</name>
								<manufacturerId>UJC</manufacturerId>
								<listingDate>2008-03-25</listingDate>
							</drug>
							<drug id="02243611" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Alpraz</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.3099</individualPrice>
								<listingDate>2008-03-25</listingDate>
							</drug>
							<drug id="02400146" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Jamp-Alprazolam</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.3099</individualPrice>
								<listingDate>2014-02-27</listingDate>
							</drug>
							<drug id="02417650" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Nat-Alprazolam</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>.3099</individualPrice>
								<listingDate>2015-10-29</listingDate>
							</drug>
							<drug id="02434636" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Jamp Alprazolam</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.3099</individualPrice>
								<listingDate>2022-03-31</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="281608234">
							<itemNumber>1121</itemNumber>
							<strength>2mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00813958" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Xanax TS</name>
								<manufacturerId>UJC</manufacturerId>
								<listingDate>2008-03-25</listingDate>
							</drug>
							<drug id="02243612" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Apo-Alpraz TS</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.5508</individualPrice>
								<listingDate>2008-03-25</listingDate>
							</drug>
							<drug id="02400154" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Jamp-Alprazolam</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.5508</individualPrice>
								<listingDate>2014-02-27</listingDate>
							</drug>
							<drug id="02417669" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Nat-Alprazolam</name>
								<manufacturerId>NAT</manufacturerId>
								<individualPrice>.5508</individualPrice>
								<listingDate>2016-11-30</listingDate>
							</drug>
							<drug id="02434644" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Jamp Alprazolam</name>
								<manufacturerId>JPC</manufacturerId>
								<individualPrice>.5508</individualPrice>
								<listingDate>2022-03-31</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01856">
					<name>ARIPIPRAZOLE</name>
					<pcgGroup>
						<pcg9 id="281608323">
							<itemNumber>1122</itemNumber>
							<strength>300mg/Vial</strength>
							<dosageForm>Prolong-Rel Inj Pd-Vial Pk</dosageForm>
							<note>For the maintenance treatment of schizophrenia in patients who are stabilized on oral aripiprazole who have:
A history of non-adherence; AND one of the following:
a) Inadequate control or significant side-effects from two or more formulary oral antipsychotic medications, including at least one atypical agent; OR
b) Inadequate control or significant side-effects from one or more conventional depot antipsychotic agents.</note>
							<drug id="02420864" sec3="Y">
								<name>Abilify Maintena</name>
								<manufacturerId>OTS</manufacturerId>
								<individualPrice>456.1800</individualPrice>
								<listingDate>2015-07-29</listingDate>
								<amountMOHLTCPays>456.1800</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281608324">
							<itemNumber>1123</itemNumber>
							<strength>400mg/Vial</strength>
							<dosageForm>Prolong-Rel Inj Pd-Vial Pk</dosageForm>
							<note>For the maintenance treatment of schizophrenia in patients who are stabilized on oral aripiprazole who have:
A history of non-adherence; AND one of the following:
a) Inadequate control or significant side-effects from two or more formulary oral antipsychotic medications, including at least one atypical agent; OR
b) Inadequate control or significant side-effects from one or more conventional depot antipsychotic agents.</note>
							<drug id="02420872" sec3="Y">
								<name>Abilify Maintena</name>
								<manufacturerId>OTS</manufacturerId>
								<individualPrice>456.1800</individualPrice>
								<listingDate>2015-07-29</listingDate>
								<amountMOHLTCPays>456.1800</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281608301">
							<itemNumber>1124</itemNumber>
							<strength>2mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>Notes: Subject to the specific drug&apos;s product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.
Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.
Prescribers should be informed and stay current with a drug&apos;s official indications in accordance with Health Canada&apos;s approved product monograph.</note>
							<drug id="02322374" sec3="Y">
								<name>Abilify</name>
								<manufacturerId>OTS</manufacturerId>
								<individualPrice>3.3143</individualPrice>
								<listingDate>2011-10-25</listingDate>
								<amountMOHLTCPays>.8092</amountMOHLTCPays>
							</drug>
							<drug id="02460025" sec3="Y">
								<name>Auro-Aripiprazole</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.8092</individualPrice>
								<listingDate>2018-09-27</listingDate>
								<amountMOHLTCPays>.8092</amountMOHLTCPays>
							</drug>
							<drug id="02464144" sec3="Y">
								<name>Teva-Aripiprazole</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.8092</individualPrice>
								<listingDate>2018-10-31</listingDate>
								<amountMOHLTCPays>.8092</amountMOHLTCPays>
							</drug>
							<drug id="02466635" sec3="Y">
								<name>PMS-Aripiprazole</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.8092</individualPrice>
								<listingDate>2018-09-27</listingDate>
								<amountMOHLTCPays>.8092</amountMOHLTCPays>
							</drug>
							<drug id="02471086" sec3="Y">
								<name>Apo-Aripiprazole</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.8092</individualPrice>
								<listingDate>2018-06-29</listingDate>
								<amountMOHLTCPays>.8092</amountMOHLTCPays>
							</drug>
							<drug id="02473658" sec3="Y">
								<name>Sandoz Aripiprazole</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.8092</individualPrice>
								<listingDate>2018-09-27</listingDate>
								<amountMOHLTCPays>.8092</amountMOHLTCPays>
							</drug>
							<drug id="02483556" sec3="Y">
								<name>Mint-Aripiprazole</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.8092</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.8092</amountMOHLTCPays>
							</drug>
							<drug id="02506688" sec3="Y">
								<name>Aripiprazole</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.8092</individualPrice>
								<listingDate>2021-06-30</listingDate>
								<amountMOHLTCPays>.8092</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281608302">
							<itemNumber>1125</itemNumber>
							<strength>5mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>Notes: Subject to the specific drug&apos;s product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.
Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.
Prescribers should be informed and stay current with a drug&apos;s official indications in accordance with Health Canada&apos;s approved product monograph.</note>
							<drug id="02322382" sec3="Y">
								<name>Abilify</name>
								<manufacturerId>OTS</manufacturerId>
								<individualPrice>3.7052</individualPrice>
								<listingDate>2011-10-25</listingDate>
								<amountMOHLTCPays>.9046</amountMOHLTCPays>
							</drug>
							<drug id="02460033" sec3="Y">
								<name>Auro-Aripiprazole</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>.9046</individualPrice>
								<listingDate>2018-09-27</listingDate>
								<amountMOHLTCPays>.9046</amountMOHLTCPays>
							</drug>
							<drug id="02464152" sec3="Y">
								<name>Teva-Aripiprazole</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.9046</individualPrice>
								<listingDate>2018-10-31</listingDate>
								<amountMOHLTCPays>.9046</amountMOHLTCPays>
							</drug>
							<drug id="02466643" sec3="Y">
								<name>PMS-Aripiprazole</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>.9046</individualPrice>
								<listingDate>2018-09-27</listingDate>
								<amountMOHLTCPays>.9046</amountMOHLTCPays>
							</drug>
							<drug id="02471094" sec3="Y">
								<name>Apo-Aripiprazole</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.9046</individualPrice>
								<listingDate>2018-06-29</listingDate>
								<amountMOHLTCPays>.9046</amountMOHLTCPays>
							</drug>
							<drug id="02473666" sec3="Y">
								<name>Sandoz Aripiprazole</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>.9046</individualPrice>
								<listingDate>2018-09-27</listingDate>
								<amountMOHLTCPays>.9046</amountMOHLTCPays>
							</drug>
							<drug id="02483564" sec3="Y">
								<name>Mint-Aripiprazole</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>.9046</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>.9046</amountMOHLTCPays>
							</drug>
							<drug id="02506718" sec3="Y">
								<name>Aripiprazole</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>.9046</individualPrice>
								<listingDate>2021-06-30</listingDate>
								<amountMOHLTCPays>.9046</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281608303">
							<itemNumber>1126</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>Notes: Subject to the specific drug&apos;s product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.
Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.
Prescribers should be informed and stay current with a drug&apos;s official indications in accordance with Health Canada&apos;s approved product monograph.</note>
							<drug id="02322390" sec3="Y">
								<name>Abilify</name>
								<manufacturerId>OTS</manufacturerId>
								<individualPrice>4.4049</individualPrice>
								<listingDate>2011-10-25</listingDate>
								<amountMOHLTCPays>1.0754</amountMOHLTCPays>
							</drug>
							<drug id="02460041" sec3="Y">
								<name>Auro-Aripiprazole</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>1.0754</individualPrice>
								<listingDate>2018-09-27</listingDate>
								<amountMOHLTCPays>1.0754</amountMOHLTCPays>
							</drug>
							<drug id="02464160" sec3="Y">
								<name>Teva-Aripiprazole</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>1.0754</individualPrice>
								<listingDate>2018-10-31</listingDate>
								<amountMOHLTCPays>1.0754</amountMOHLTCPays>
							</drug>
							<drug id="02466651" sec3="Y">
								<name>PMS-Aripiprazole</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>1.0754</individualPrice>
								<listingDate>2018-09-27</listingDate>
								<amountMOHLTCPays>1.0754</amountMOHLTCPays>
							</drug>
							<drug id="02471108" sec3="Y">
								<name>Apo-Aripiprazole</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.0754</individualPrice>
								<listingDate>2018-06-29</listingDate>
								<amountMOHLTCPays>1.0754</amountMOHLTCPays>
							</drug>
							<drug id="02473674" sec3="Y">
								<name>Sandoz Aripiprazole</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>1.0754</individualPrice>
								<listingDate>2018-09-27</listingDate>
								<amountMOHLTCPays>1.0754</amountMOHLTCPays>
							</drug>
							<drug id="02483572" sec3="Y">
								<name>Mint-Aripiprazole</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>1.0754</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>1.0754</amountMOHLTCPays>
							</drug>
							<drug id="02506726" sec3="Y">
								<name>Aripiprazole</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>1.0754</individualPrice>
								<listingDate>2021-06-30</listingDate>
								<amountMOHLTCPays>1.0754</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281608304">
							<itemNumber>1127</itemNumber>
							<strength>15mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>Notes: Subject to the specific drug&apos;s product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.
Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.
Prescribers should be informed and stay current with a drug&apos;s official indications in accordance with Health Canada&apos;s approved product monograph.</note>
							<drug id="02322404" sec3="Y">
								<name>Abilify</name>
								<manufacturerId>OTS</manufacturerId>
								<individualPrice>5.1985</individualPrice>
								<listingDate>2011-10-25</listingDate>
								<amountMOHLTCPays>1.2692</amountMOHLTCPays>
							</drug>
							<drug id="02460068" sec3="Y">
								<name>Auro-Aripiprazole</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>1.2692</individualPrice>
								<listingDate>2018-09-27</listingDate>
								<amountMOHLTCPays>1.2692</amountMOHLTCPays>
							</drug>
							<drug id="02464179" sec3="Y">
								<name>Teva-Aripiprazole</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>1.2692</individualPrice>
								<listingDate>2018-09-27</listingDate>
								<amountMOHLTCPays>1.2692</amountMOHLTCPays>
							</drug>
							<drug id="02466678" sec3="Y">
								<name>PMS-Aripiprazole</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>1.2692</individualPrice>
								<listingDate>2018-09-27</listingDate>
								<amountMOHLTCPays>1.2692</amountMOHLTCPays>
							</drug>
							<drug id="02471116" sec3="Y">
								<name>Apo-Aripiprazole</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.2692</individualPrice>
								<listingDate>2018-06-29</listingDate>
								<amountMOHLTCPays>1.2692</amountMOHLTCPays>
							</drug>
							<drug id="02473682" sec3="Y">
								<name>Sandoz Aripiprazole</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>1.2692</individualPrice>
								<listingDate>2018-09-27</listingDate>
								<amountMOHLTCPays>1.2692</amountMOHLTCPays>
							</drug>
							<drug id="02483580" sec3="Y">
								<name>Mint-Aripiprazole</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>1.2692</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>1.2692</amountMOHLTCPays>
							</drug>
							<drug id="02506734" sec3="Y">
								<name>Aripiprazole</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>1.2692</individualPrice>
								<listingDate>2021-06-30</listingDate>
								<amountMOHLTCPays>1.2692</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281608305">
							<itemNumber>1128</itemNumber>
							<strength>20mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>Notes: Subject to the specific drug&apos;s product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.
Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.
Prescribers should be informed and stay current with a drug&apos;s official indications in accordance with Health Canada&apos;s approved product monograph.</note>
							<drug id="02322412" sec3="Y">
								<name>Abilify</name>
								<manufacturerId>OTS</manufacturerId>
								<individualPrice>4.1028</individualPrice>
								<listingDate>2011-10-25</listingDate>
								<amountMOHLTCPays>1.0017</amountMOHLTCPays>
							</drug>
							<drug id="02460076" sec3="Y">
								<name>Auro-Aripiprazole</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>1.0017</individualPrice>
								<listingDate>2018-09-27</listingDate>
								<amountMOHLTCPays>1.0017</amountMOHLTCPays>
							</drug>
							<drug id="02464187" sec3="Y">
								<name>Teva-Aripiprazole</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>1.0017</individualPrice>
								<listingDate>2018-09-27</listingDate>
								<amountMOHLTCPays>1.0017</amountMOHLTCPays>
							</drug>
							<drug id="02466686" sec3="Y">
								<name>PMS-Aripiprazole</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>1.0017</individualPrice>
								<listingDate>2018-09-27</listingDate>
								<amountMOHLTCPays>1.0017</amountMOHLTCPays>
							</drug>
							<drug id="02471124" sec3="Y">
								<name>Apo-Aripiprazole</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.0017</individualPrice>
								<listingDate>2018-06-29</listingDate>
								<amountMOHLTCPays>1.0017</amountMOHLTCPays>
							</drug>
							<drug id="02473690" sec3="Y">
								<name>Sandoz Aripiprazole</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>1.0017</individualPrice>
								<listingDate>2018-09-27</listingDate>
								<amountMOHLTCPays>1.0017</amountMOHLTCPays>
							</drug>
							<drug id="02483599" sec3="Y">
								<name>Mint-Aripiprazole</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>1.0017</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>1.0017</amountMOHLTCPays>
							</drug>
							<drug id="02506750" sec3="Y">
								<name>Aripiprazole</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>1.0017</individualPrice>
								<listingDate>2021-06-30</listingDate>
								<amountMOHLTCPays>1.0017</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281608306">
							<itemNumber>1129</itemNumber>
							<strength>30mg</strength>
							<dosageForm>Tab</dosageForm>
							<note>Notes: Subject to the specific drug&apos;s product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.
Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.
Prescribers should be informed and stay current with a drug&apos;s official indications in accordance with Health Canada&apos;s approved product monograph.</note>
							<drug id="02322455" sec3="Y">
								<name>Abilify</name>
								<manufacturerId>OTS</manufacturerId>
								<individualPrice>4.1028</individualPrice>
								<listingDate>2011-10-25</listingDate>
								<amountMOHLTCPays>1.0017</amountMOHLTCPays>
							</drug>
							<drug id="02460084" sec3="Y">
								<name>Auro-Aripiprazole</name>
								<manufacturerId>AUR</manufacturerId>
								<individualPrice>1.0017</individualPrice>
								<listingDate>2018-09-27</listingDate>
								<amountMOHLTCPays>1.0017</amountMOHLTCPays>
							</drug>
							<drug id="02464195" sec3="Y">
								<name>Teva-Aripiprazole</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>1.0017</individualPrice>
								<listingDate>2018-10-31</listingDate>
								<amountMOHLTCPays>1.0017</amountMOHLTCPays>
							</drug>
							<drug id="02466694" sec3="Y">
								<name>PMS-Aripiprazole</name>
								<manufacturerId>PMS</manufacturerId>
								<individualPrice>1.0017</individualPrice>
								<listingDate>2018-09-27</listingDate>
								<amountMOHLTCPays>1.0017</amountMOHLTCPays>
							</drug>
							<drug id="02471132" sec3="Y">
								<name>Apo-Aripiprazole</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>1.0017</individualPrice>
								<listingDate>2018-06-29</listingDate>
								<amountMOHLTCPays>1.0017</amountMOHLTCPays>
							</drug>
							<drug id="02473704" sec3="Y">
								<name>Sandoz Aripiprazole</name>
								<manufacturerId>SDZ</manufacturerId>
								<individualPrice>1.0017</individualPrice>
								<listingDate>2018-09-27</listingDate>
								<amountMOHLTCPays>1.0017</amountMOHLTCPays>
							</drug>
							<drug id="02483602" sec3="Y">
								<name>Mint-Aripiprazole</name>
								<manufacturerId>MIN</manufacturerId>
								<individualPrice>1.0017</individualPrice>
								<listingDate>2020-06-30</listingDate>
								<amountMOHLTCPays>1.0017</amountMOHLTCPays>
							</drug>
							<drug id="02506785" sec3="Y">
								<name>Aripiprazole</name>
								<manufacturerId>SAI</manufacturerId>
								<individualPrice>1.0017</individualPrice>
								<listingDate>2021-06-30</listingDate>
								<amountMOHLTCPays>1.0017</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="01937">
					<name>ASENAPINE</name>
					<pcgGroup>
						<pcg9 id="281608317">
							<itemNumber>1130</itemNumber>
							<strength>5mg</strength>
							<dosageForm>SL Tab</dosageForm>
							<note>For the acute treatment of manic or mixed episodes associated with bipolar I disorder as either:
Monotherapy, after a trial of lithium or divalproex sodium has failed, and trials of less expensive atypical antipsychotic agents have failed due to intolerance or lack of response;
OR
Co-therapy with lithium or divalproex sodium, after trials of less expensive atypical antipsychotic agents have failed due to intolerance or lack of response.
</note>
							<drug id="02374803" sec3="Y">
								<name>Saphris</name>
								<manufacturerId>OCI</manufacturerId>
								<individualPrice>1.5910</individualPrice>
								<listingDate>2014-02-27</listingDate>
								<amountMOHLTCPays>1.5910</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281608318">
							<itemNumber>1131</itemNumber>
							<strength>10mg</strength>
							<dosageForm>SL Tab</dosageForm>
							<note>For the acute treatment of manic or mixed episodes associated with bipolar I disorder as either:
Monotherapy, after a trial of lithium or divalproex sodium has failed, and trials of less expensive atypical antipsychotic agents have failed due to intolerance or lack of response;
OR
Co-therapy with lithium or divalproex sodium, after trials of less expensive atypical antipsychotic agents have failed due to intolerance or lack of response.</note>
							<drug id="02374811" sec3="Y">
								<name>Saphris</name>
								<manufacturerId>OCI</manufacturerId>
								<individualPrice>1.5910</individualPrice>
								<listingDate>2014-02-27</listingDate>
								<amountMOHLTCPays>1.5910</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="02079">
					<name>BREXPIPRAZOLE</name>
					<pcgGroup>
						<pcg9 id="281608344">
							<itemNumber>1132</itemNumber>
							<strength>0.25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02461749" sec3="Y">
								<name>Rexulti</name>
								<manufacturerId>OTS</manufacturerId>
								<individualPrice>3.5000</individualPrice>
								<listingDate>2019-04-30</listingDate>
								<amountMOHLTCPays>3.5000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281608345">
							<itemNumber>1133</itemNumber>
							<strength>0.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02461757" sec3="Y">
								<name>Rexulti</name>
								<manufacturerId>OTS</manufacturerId>
								<individualPrice>3.5000</individualPrice>
								<listingDate>2019-04-30</listingDate>
								<amountMOHLTCPays>3.5000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281608346">
							<itemNumber>1134</itemNumber>
							<strength>1mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02461765" sec3="Y">
								<name>Rexulti</name>
								<manufacturerId>OTS</manufacturerId>
								<individualPrice>3.5000</individualPrice>
								<listingDate>2019-04-30</listingDate>
								<amountMOHLTCPays>3.5000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281608347">
							<itemNumber>1135</itemNumber>
							<strength>2mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02461773" sec3="Y">
								<name>Rexulti</name>
								<manufacturerId>OTS</manufacturerId>
								<individualPrice>3.5000</individualPrice>
								<listingDate>2019-04-30</listingDate>
								<amountMOHLTCPays>3.5000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281608348">
							<itemNumber>1136</itemNumber>
							<strength>3mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02461781" sec3="Y">
								<name>Rexulti</name>
								<manufacturerId>OTS</manufacturerId>
								<individualPrice>3.5000</individualPrice>
								<listingDate>2019-04-30</listingDate>
								<amountMOHLTCPays>3.5000</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281608349">
							<itemNumber>1137</itemNumber>
							<strength>4mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02461803" sec3="Y">
								<name>Rexulti</name>
								<manufacturerId>OTS</manufacturerId>
								<individualPrice>3.5000</individualPrice>
								<listingDate>2019-04-30</listingDate>
								<amountMOHLTCPays>3.5000</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00541">
					<name>BROMAZEPAM</name>
					<pcgGroup>
						<pcg9 id="281608146">
							<itemNumber>1138</itemNumber>
							<strength>1.5mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00682314" notABenefit="Y" sec3="Y">
								<name>Lectopam</name>
								<manufacturerId>HLR</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02177153" sec3="Y">
								<name>Apo-Bromazepam</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1028</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1028</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281608123">
							<itemNumber>1139</itemNumber>
							<strength>3mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00518123" notABenefit="Y" sec3="Y">
								<name>Lectopam</name>
								<manufacturerId>HLR</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02177161" sec3="Y">
								<name>Apo-Bromazepam</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.0897</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0897</amountMOHLTCPays>
							</drug>
							<drug id="02230584" sec3="Y">
								<name>Teva-Bromazepam</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.0897</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.0897</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281608122">
							<itemNumber>1140</itemNumber>
							<strength>6mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00518131" notABenefit="Y" sec3="Y">
								<name>Lectopam</name>
								<manufacturerId>HLR</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="02177188" sec3="Y">
								<name>Apo-Bromazepam</name>
								<manufacturerId>APX</manufacturerId>
								<individualPrice>.1310</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1310</amountMOHLTCPays>
							</drug>
							<drug id="02230585" sec3="Y">
								<name>Teva-Bromazepam</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.1310</individualPrice>
								<listingDate>1998-12-31</listingDate>
								<amountMOHLTCPays>.1310</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00515">
					<name>CHLORDIAZEPOXIDE</name>
					<pcgGroup>
						<pcg9 id="281608003">
							<itemNumber>1141</itemNumber>
							<strength>5mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00012629" notABenefit="Y" sec3="Y">
								<name>Librium</name>
								<manufacturerId>HLR</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00522724" sec3="Y">
								<name>Chlordiazepoxide</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.0725</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.0725</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281608002">
							<itemNumber>1142</itemNumber>
							<strength>10mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00012637" notABenefit="Y" sec3="Y">
								<name>Librium</name>
								<manufacturerId>HLR</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00522988" sec3="Y">
								<name>Chlordiazepoxide</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.1091</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1091</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281608001">
							<itemNumber>1143</itemNumber>
							<strength>25mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00012645" notABenefit="Y" sec3="Y">
								<name>Librium</name>
								<manufacturerId>HLR</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00522996" sec3="Y">
								<name>Chlordiazepoxide</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.1740</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1740</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00517">
					<name>CHLORPROMAZINE</name>
					<pcgGroup>
						<pcg9 id="281608009">
							<itemNumber>1144</itemNumber>
							<strength>25mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00232823" sec3="Y">
								<name>Teva-Chlorpromazine</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2454</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2454</amountMOHLTCPays>
							</drug>
							<drug id="01929917" notABenefit="Y" sec3="Y">
								<name>Largactil</name>
								<manufacturerId>RPP</manufacturerId>
								<listingDate>1999-07-22</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="281608008">
							<itemNumber>1145</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00232807" sec3="Y">
								<name>Teva-Chlorpromazine</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.2808</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2808</amountMOHLTCPays>
							</drug>
							<drug id="01929925" notABenefit="Y" sec3="Y">
								<name>Largactil</name>
								<manufacturerId>RPP</manufacturerId>
								<listingDate>1999-07-22</listingDate>
							</drug>
						</pcg9>
						<pcg9 id="281608007">
							<itemNumber>1146</itemNumber>
							<strength>100mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="00232831" sec3="Y">
								<name>Teva-Chlorpromazine</name>
								<manufacturerId>TEV</manufacturerId>
								<individualPrice>.7475</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.7475</amountMOHLTCPays>
							</drug>
							<drug id="01929933" notABenefit="Y" sec3="Y">
								<name>Largactil</name>
								<manufacturerId>RPP</manufacturerId>
								<listingDate>1999-07-22</listingDate>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00519">
					<name>CLORAZEPATE DIPOTASSIUM</name>
					<pcgGroup>
						<pcg9 id="281608022">
							<itemNumber>1147</itemNumber>
							<strength>3.75mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00264938" notABenefit="Y" sec3="Y">
								<name>Tranxene</name>
								<manufacturerId>ABB</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00860689" sec3="Y">
								<name>Clorazepate</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.1687</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.1687</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281608021">
							<itemNumber>1148</itemNumber>
							<strength>7.5mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00264946" notABenefit="Y" sec3="Y">
								<name>Tranxene</name>
								<manufacturerId>ABB</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00860700" sec3="Y">
								<name>Clorazepate</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.2200</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.2200</amountMOHLTCPays>
							</drug>
						</pcg9>
						<pcg9 id="281608020">
							<itemNumber>1149</itemNumber>
							<strength>15mg</strength>
							<dosageForm>Cap</dosageForm>
							<drug id="00264911" notABenefit="Y" sec3="Y">
								<name>Tranxene</name>
								<manufacturerId>ABB</manufacturerId>
								<listingDate>1996-10-01</listingDate>
							</drug>
							<drug id="00860697" sec3="Y">
								<name>Clorazepate</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>.4405</individualPrice>
								<listingDate>1996-10-01</listingDate>
								<amountMOHLTCPays>.4405</amountMOHLTCPays>
							</drug>
						</pcg9>
					</pcgGroup>
				</genericName>
				<genericName id="00544">
					<name>CLOZAPINE</name>
					<pcgGroup>
						<pcg9 id="281608351">
							<itemNumber>1150</itemNumber>
							<strength>50mg</strength>
							<dosageForm>Tab</dosageForm>
							<drug id="02458748" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>AA-Clozapine</name>
								<manufacturerId>AAP</manufacturerId>
								<individualPrice>1.3206</individualPrice>
								<listingDate>2021-12-17</listingDate>
							</drug>
							<drug id="02490668" notABenefit="Y" sec3b="Y" sec3="Y">
								<name>Clozaril</name>
								<manufacturerId>HLS</manufacturerId>
								<listingDate>2021-12-17</listingDate>
							</drug>
						</pcg9>